{"PMC7444503": [["IntroductionOn 31 December 2019, the health authorities of Wuhan city (Hubei Province, China) reported a cluster of 27 cases of pneumonia of unknown aetiology with onset of symptoms on 8 December, including 7 severe cases, with a common exposure identified in a city market [1], which was closed on January 1, 2020.", [["pneumonia", "DISEASE", 128, 137], ["pneumonia", "PROBLEM", 128, 137], ["symptoms", "PROBLEM", 173, 181], ["7 severe cases", "PROBLEM", 207, 221], ["pneumonia", "OBSERVATION", 128, 137]]], ["On 7 January 2020, the Chinese authorities identified a new Coronaviridae family virus, initially named coronavirus 2019-nCoV and later coronavirus SARS-CoV-2 as the causal agent [2].", [["coronavirus 2019-nCoV", "ORGANISM", 104, 125], ["CoV-2", "ORGANISM", 153, 158], ["coronavirus", "SPECIES", 104, 115], ["coronavirus SARS-CoV", "SPECIES", 136, 156], ["coronavirus 2019-nCoV", "SPECIES", 104, 125], ["a new Coronaviridae family virus", "PROBLEM", 54, 86], ["nCoV", "TREATMENT", 121, 125]]], ["On 30 January 2020, the World Health Organization declared the SARS-CoV-2 outbreak in China a public health emergency of international concern [4].", [["SARS", "DISEASE", 63, 67], ["the SARS", "PROBLEM", 59, 67]]], ["Subsequently, the outbreak has spread outside China, with Europe especially affected [5].IntroductionThe first positive case diagnosed in Spain was confirmed on January 31, 2020 on the island of La Gomera, while the first death occurred on February 13 in Valencia city (the date was confirmed twenty days later).", [["death", "DISEASE", 222, 227], ["spread", "OBSERVATION_MODIFIER", 31, 37], ["La Gomera", "ANATOMY", 195, 204]]], ["The first confirmed case in Barcelona was on 24 February, and from then until 29 June 2020, there have been 248,970 confirmed cases in Spain [6].IntroductionThe most common signs of infection are respiratory symptoms: fever, cough and shortness of breath.", [["respiratory", "ANATOMY", 196, 207], ["infection", "DISEASE", 182, 191], ["respiratory symptoms", "DISEASE", 196, 216], ["fever", "DISEASE", 218, 223], ["cough", "DISEASE", 225, 230], ["shortness of breath", "DISEASE", 235, 254], ["infection", "PROBLEM", 182, 191], ["respiratory symptoms", "PROBLEM", 196, 216], ["fever", "PROBLEM", 218, 223], ["cough", "PROBLEM", 225, 230], ["shortness of breath", "PROBLEM", 235, 254], ["most common", "OBSERVATION_MODIFIER", 161, 172], ["infection", "OBSERVATION", 182, 191], ["fever", "OBSERVATION", 218, 223]]], ["In more severe cases, the infection may cause pneumonia, severe acute respiratory syndrome, renal failure and death [7].", [["respiratory", "ANATOMY", 70, 81], ["renal", "ANATOMY", 92, 97], ["infection", "DISEASE", 26, 35], ["pneumonia", "DISEASE", 46, 55], ["acute respiratory syndrome", "DISEASE", 64, 90], ["renal failure", "DISEASE", 92, 105], ["death", "DISEASE", 110, 115], ["renal", "ORGAN", 92, 97], ["the infection", "PROBLEM", 22, 35], ["pneumonia", "PROBLEM", 46, 55], ["severe acute respiratory syndrome", "PROBLEM", 57, 90], ["renal failure", "PROBLEM", 92, 105], ["death", "PROBLEM", 110, 115], ["severe", "OBSERVATION_MODIFIER", 8, 14], ["cases", "OBSERVATION", 15, 20], ["infection", "OBSERVATION", 26, 35], ["may cause", "UNCERTAINTY", 36, 45], ["pneumonia", "OBSERVATION", 46, 55], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["respiratory syndrome", "OBSERVATION", 70, 90], ["renal", "ANATOMY", 92, 97], ["failure", "OBSERVATION", 98, 105]]], ["Transmission appears to be mainly person-to-person via the airway through respiratory droplets measuring > 5 microns when the patient has respiratory symptoms (cough and sneezing) and contact with fomites [8].", [["airway", "ANATOMY", 59, 65], ["respiratory droplets", "ANATOMY", 74, 94], ["respiratory", "ANATOMY", 138, 149], ["respiratory symptoms", "DISEASE", 138, 158], ["cough", "DISEASE", 160, 165], ["airway", "MULTI-TISSUE_STRUCTURE", 59, 65], ["patient", "ORGANISM", 126, 133], ["person", "SPECIES", 34, 40], ["person", "SPECIES", 44, 50], ["patient", "SPECIES", 126, 133], ["respiratory droplets", "TEST", 74, 94], ["respiratory symptoms", "PROBLEM", 138, 158], ["cough", "PROBLEM", 160, 165], ["sneezing", "PROBLEM", 170, 178], ["airway", "ANATOMY", 59, 65], ["respiratory", "ANATOMY", 138, 149]]], ["Most estimates of the incubation period of COVID-19 range from 1 to 14 days, with most around five days.", [["COVID", "TEST", 43, 48]]], ["Evidence on the transmission of the virus before symptom onset is unclear.", [["the virus", "PROBLEM", 32, 41], ["symptom", "PROBLEM", 49, 56]]], ["There is currently no specific treatment for COVID-19 infections.", [["infections", "DISEASE", 54, 64], ["specific treatment", "TREATMENT", 22, 40], ["COVID-19 infections", "PROBLEM", 45, 64], ["infections", "OBSERVATION", 54, 64]]], ["To date, the most important scientific efforts have focused on three areas: strategies to contain the spread of the disease, the initiation of clinical trials with antivirals and multiple therapies, and the design of a new vaccine, which is still unclear.", [["the disease", "PROBLEM", 112, 123], ["clinical trials", "TREATMENT", 143, 158], ["antivirals", "TREATMENT", 164, 174], ["multiple therapies", "TREATMENT", 179, 197], ["a new vaccine", "TREATMENT", 217, 230], ["disease", "OBSERVATION", 116, 123]]], ["These strategies include some of a community nature, where primary healthcare plays a central role in disease prevention and control [9].", [["disease prevention", "TREATMENT", 102, 120]]], ["Few studies have described the clinical characteristics of the disease, fewer the predictive factors, and virtually none have described the Mediterranean population compared with the rest of the world.", [["Few studies", "TEST", 0, 11], ["the disease", "PROBLEM", 59, 70], ["disease", "OBSERVATION", 63, 70]]], ["Therefore, this study aimed to describe the clinical, biological and radiological manifestations, the evolution, treatments and mortality rate of patients with COVID-19 infection in the population of Barcelona city and determine the most important predictors of a poor prognosis.Statistical analysis ::: Materials and methodsCategorical variables are presented as absolute frequencies and percentages (%) and continuous variables as means and standard deviations (SD).", [["COVID-19", "CHEMICAL", 160, 168], ["infection", "DISEASE", 169, 178], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["this study", "TEST", 11, 21], ["the clinical, biological and radiological manifestations", "PROBLEM", 40, 96], ["treatments", "TREATMENT", 113, 123], ["mortality rate", "TEST", 128, 142], ["COVID", "TEST", 160, 165], ["19 infection", "PROBLEM", 166, 178], ["absolute frequencies", "TEST", 364, 384], ["percentages", "TEST", 389, 400], ["infection", "OBSERVATION", 169, 178]]], ["Predictors of death, ICU admission and hospitalization were determined using the student\u2019s t test for continuous variables and the chi-square test for categorical variables.", [["death", "DISEASE", 14, 19], ["the chi-square test", "TEST", 127, 146], ["categorical variables", "TEST", 151, 172]]], ["Logistic multivariate regression models adjusted for age and sex were constructed to analyse independent predictive factors associated with death, ICU admission and hospitalization.", [["death", "DISEASE", 140, 145], ["Logistic multivariate regression models", "PROBLEM", 0, 39]]], ["Odds ratios (OR) and their 95% confidence intervals (95%CI) obtained in the adjusted regression analysis were calculated.", [["the adjusted regression analysis", "TEST", 72, 104]]], ["Forest plots were used to represent OR and 95%CI.", [["Forest plots", "TEST", 0, 12]]], ["Values of p<0.05 were considered statistically significant.", [["Values", "TEST", 0, 6], ["p", "TEST", 10, 11]]], ["The statistical analysis was performed using the R version 3.6.1. for Windows.Clinical characteristics and comorbidities ::: ResultsWe included 322 patients (mean age 56.7 years, 50% female, 115 (35.7%) aged \u2265 65 years).", [["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["The statistical analysis", "TEST", 0, 24], ["the R version", "TEST", 45, 58]]], ["The most frequent clinical symptoms were cough (73.9%), fever (63.8%), general malaise (43.5%), fatigue (30.7%), myalgia or arthralgia (30.1%), dyspnoea (25.5%), diarrhoea (23%), headache (20.8%), anosmia (17.4%) and dysgeusia (14.9%).", [["cough", "DISEASE", 41, 46], ["fever", "DISEASE", 56, 61], ["general malaise", "DISEASE", 71, 86], ["fatigue", "DISEASE", 96, 103], ["myalgia", "DISEASE", 113, 120], ["arthralgia", "DISEASE", 124, 134], ["dyspnoea", "DISEASE", 144, 152], ["diarrhoea", "DISEASE", 162, 171], ["headache", "DISEASE", 179, 187], ["anosmia", "DISEASE", 197, 204], ["dysgeusia", "DISEASE", 217, 226], ["The most frequent clinical symptoms", "PROBLEM", 0, 35], ["cough", "PROBLEM", 41, 46], ["fever", "PROBLEM", 56, 61], ["general malaise", "PROBLEM", 71, 86], ["fatigue", "PROBLEM", 96, 103], ["myalgia", "PROBLEM", 113, 120], ["arthralgia", "PROBLEM", 124, 134], ["dyspnoea", "PROBLEM", 144, 152], ["diarrhoea", "PROBLEM", 162, 171], ["headache", "PROBLEM", 179, 187], ["anosmia", "PROBLEM", 197, 204], ["dysgeusia", "PROBLEM", 217, 226], ["myalgia", "ANATOMY", 113, 120], ["arthralgia", "OBSERVATION", 124, 134]]], ["Physical examination in 223 (69.3%) patients showed 69.1% had auscultatory alterations, 28.7% tachypnoea and 20.5% an oxygen saturation of \u2264 92%.Clinical characteristics and comorbidities ::: ResultsICU admission and death were associated with a greater mean age (68.2 years vs 54.3 years, p < 0.001), male sex (71.4% vs 45.5%, p = 0.001), dyspnoea (39.3% vs 22.6%, p = 0.012), fever (77.4% vs 61.0%, p = 0.027), auscultatory alterations (80.8% vs 65.5%, p = 0.041) and low oxygen saturation (35.3% vs 15.6%, p = 0.005) (Table 1).", [["auscultatory alterations", "DISEASE", 62, 86], ["tachypnoea", "DISEASE", 94, 104], ["oxygen", "CHEMICAL", 118, 124], ["death", "DISEASE", 217, 222], ["dyspnoea", "DISEASE", 340, 348], ["fever", "DISEASE", 378, 383], ["auscultatory alterations", "DISEASE", 413, 437], ["oxygen", "CHEMICAL", 474, 480], ["oxygen", "CHEMICAL", 118, 124], ["oxygen", "CHEMICAL", 474, 480], ["patients", "ORGANISM", 36, 44], ["oxygen", "SIMPLE_CHEMICAL", 118, 124], ["oxygen", "SIMPLE_CHEMICAL", 474, 480], ["patients", "SPECIES", 36, 44], ["Physical examination", "TEST", 0, 20], ["auscultatory alterations", "TEST", 62, 86], ["tachypnoea", "TEST", 94, 104], ["an oxygen saturation", "TEST", 115, 135], ["dyspnoea", "PROBLEM", 340, 348], ["p", "TEST", 366, 367], ["fever", "PROBLEM", 378, 383], ["vs", "TEST", 391, 393], ["p", "TEST", 401, 402], ["auscultatory alterations", "TEST", 413, 437], ["vs", "TEST", 445, 447], ["p", "TEST", 455, 456], ["low oxygen saturation", "TEST", 470, 491], ["p", "TEST", 509, 510]]], ["Myalgia or arthralgia (12.5% vs 33.8%, p = 0.001), headache (8.9% vs 23.3%, p = 0.018), dysgeusia (5.4% vs 16.9%, p = 0.024) and anosmia (5.4% vs 19.9%, p = 0.006) were less frequent in patients admitted to the ICU or who died than the remaining patients.", [["Myalgia", "DISEASE", 0, 7], ["arthralgia", "DISEASE", 11, 21], ["headache", "DISEASE", 51, 59], ["dysgeusia", "DISEASE", 88, 97], ["anosmia", "DISEASE", 129, 136], ["patients", "ORGANISM", 186, 194], ["patients", "ORGANISM", 246, 254], ["patients", "SPECIES", 186, 194], ["patients", "SPECIES", 246, 254], ["Myalgia", "PROBLEM", 0, 7], ["arthralgia", "PROBLEM", 11, 21], ["headache", "PROBLEM", 51, 59], ["dysgeusia", "PROBLEM", 88, 97], ["p", "TEST", 114, 115], ["anosmia", "TEST", 129, 136], ["p", "TEST", 153, 154], ["arthralgia", "OBSERVATION", 11, 21]]], ["Age (OR = 1.05; 95%CI = 1.03 to 1.07) and male sex (OR = 2.94; 95%CI = 1.55 to 5.82) were independent predictors of ICU admission and death.", [["death", "DISEASE", 134, 139], ["CI", "TEST", 19, 21], ["CI", "TEST", 66, 68], ["death", "PROBLEM", 134, 139]]], ["Myalgia or arthralgia (OR = 0.31; 95%CI = 0.12 to 0.70) was the only significant protective factor against ICU admission and death after adjusting for age and sex (Fig 1).", [["Myalgia", "DISEASE", 0, 7], ["arthralgia", "DISEASE", 11, 21], ["death", "DISEASE", 125, 130], ["Myalgia", "PROBLEM", 0, 7], ["arthralgia", "PROBLEM", 11, 21], ["CI", "TEST", 37, 39], ["death", "PROBLEM", 125, 130], ["arthralgia", "OBSERVATION", 11, 21]]], ["The best clinical predictors of hospitalization were chills (OR = 5.66; 95%CI = 1.68 to 23.49), fever (OR = 3.33; 95%CI = 1.89 to 5.96) and dyspnoea (OR = 2.92; 95%CI = 1.62 to 5.42).", [["chills", "DISEASE", 53, 59], ["fever", "DISEASE", 96, 101], ["dyspnoea", "DISEASE", 140, 148], ["chills", "PROBLEM", 53, 59], ["CI", "TEST", 75, 77], ["fever", "PROBLEM", 96, 101], ["CI", "TEST", 117, 119], ["dyspnoea", "PROBLEM", 140, 148], ["CI", "TEST", 164, 166]]], ["Anosmia (OR = 0.42; 95%CI = 0.19 to 0.90) was the only significant protective factor for hospitalization after adjusting for age and sex (Table 1 and Fig 2).Clinical characteristics and comorbidities ::: ResultsComorbidities were presented by 212 (65.8%) patients: the most common were hypertension in 109 (33.9%), diabetes mellitus in 46 (14.3%), and obesity in 46 (14.3%) (Table 2).", [["Anosmia", "DISEASE", 0, 7], ["hypertension", "DISEASE", 286, 298], ["diabetes mellitus", "DISEASE", 315, 332], ["obesity", "DISEASE", 352, 359], ["patients", "ORGANISM", 255, 263], ["patients", "SPECIES", 255, 263], ["Anosmia", "TEST", 0, 7], ["CI", "TEST", 23, 25], ["hypertension", "PROBLEM", 286, 298], ["diabetes mellitus", "PROBLEM", 315, 332], ["obesity", "PROBLEM", 352, 359], ["hypertension", "OBSERVATION", 286, 298], ["obesity", "OBSERVATION", 352, 359]]], ["Heart disease (19.6% vs 5.3%, p = 0.001), autoimmune disease (16.1% vs 4.5%, p = 0.004), diabetes (32.1% vs 10.5%, p < 0.001), hypertension (60.7% vs 28.2%, p < 0.001) and chronic kidney disease (17.9% vs 7.9%, p = 0.042) were the comorbidities significantly associated with ICU admission and death (Table 2).", [["Heart", "ANATOMY", 0, 5], ["kidney", "ANATOMY", 180, 186], ["Heart disease", "DISEASE", 0, 13], ["autoimmune disease", "DISEASE", 42, 60], ["diabetes", "DISEASE", 89, 97], ["hypertension", "DISEASE", 127, 139], ["chronic kidney disease", "DISEASE", 172, 194], ["death", "DISEASE", 293, 298], ["Heart", "ORGAN", 0, 5], ["kidney", "ORGAN", 180, 186], ["Heart disease", "PROBLEM", 0, 13], ["vs", "TEST", 21, 23], ["p", "TEST", 30, 31], ["autoimmune disease", "PROBLEM", 42, 60], ["p", "TEST", 77, 78], ["diabetes", "TEST", 89, 97], ["vs", "TEST", 105, 107], ["p", "TEST", 115, 116], ["hypertension", "PROBLEM", 127, 139], ["p", "TEST", 157, 158], ["chronic kidney disease", "PROBLEM", 172, 194], ["p", "TEST", 211, 212], ["the comorbidities", "PROBLEM", 227, 244], ["disease", "OBSERVATION", 6, 13], ["hypertension", "OBSERVATION", 127, 139], ["chronic", "OBSERVATION_MODIFIER", 172, 179], ["kidney", "ANATOMY", 180, 186], ["disease", "OBSERVATION", 187, 194]]], ["Autoimmune disease was the only significant predictive comorbidity for ICU admission and death after adjusting for age and sex (OR = 2.82; 95%CI = 1.00 to 7.84) (Fig 1).", [["Autoimmune disease", "DISEASE", 0, 18], ["death", "DISEASE", 89, 94], ["Autoimmune disease", "PROBLEM", 0, 18], ["CI", "TEST", 142, 144]]], ["Depression was the best predictor of hospitalization among all comorbidities (OR = 6.06; 95%CI = 1.54 to 40.42) (Fig 2).", [["Depression", "DISEASE", 0, 10], ["Depression", "PROBLEM", 0, 10], ["CI", "TEST", 92, 94]]], ["Having \u2265 1 comorbidity was associated with ICU admission and death (OR = 3.43; 95%CI = 1.30 to 10.83) and hospitalization (OR = 2.05; 95%CI = 1.13 to 3.75) independently of age and sex.Imaging and laboratory tests ::: ResultsChest X-ray was necessary in 227 patients (70.5%) and showed lobar pulmonary infiltrates in 35 (15.4%), bilateral pulmonary infiltrates in 129 (56.8%) and an interstitial pattern in 48 (21.1%) (Table 3).", [["lobar pulmonary infiltrates", "ANATOMY", 286, 313], ["pulmonary infiltrates", "ANATOMY", 339, 360], ["interstitial", "ANATOMY", 383, 395], ["death", "DISEASE", 61, 66], ["lobar pulmonary infiltrates", "DISEASE", 286, 313], ["patients", "ORGANISM", 258, 266], ["pulmonary", "ORGAN", 292, 301], ["pulmonary", "ORGAN", 339, 348], ["patients", "SPECIES", 258, 266], ["death", "PROBLEM", 61, 66], ["CI", "TEST", 82, 84], ["CI", "TEST", 137, 139], ["Imaging", "TEST", 185, 192], ["laboratory tests", "TEST", 197, 213], ["ResultsChest X-ray", "TEST", 218, 236], ["lobar pulmonary infiltrates", "PROBLEM", 286, 313], ["bilateral pulmonary infiltrates", "PROBLEM", 329, 360], ["an interstitial pattern", "TEST", 380, 403], ["lobar", "ANATOMY_MODIFIER", 286, 291], ["pulmonary", "ANATOMY", 292, 301], ["infiltrates", "OBSERVATION", 302, 313], ["bilateral", "ANATOMY_MODIFIER", 329, 338], ["pulmonary", "ANATOMY", 339, 348], ["infiltrates", "OBSERVATION", 349, 360], ["interstitial", "ANATOMY_MODIFIER", 383, 395], ["pattern", "OBSERVATION_MODIFIER", 396, 403]]], ["Chest CT was required in 28 patients and pulmonary ultrasound in 10 (3.1%).", [["pulmonary", "ANATOMY", 41, 50], ["patients", "ORGANISM", 28, 36], ["pulmonary", "ORGAN", 41, 50], ["patients", "SPECIES", 28, 36], ["Chest CT", "TEST", 0, 8], ["pulmonary ultrasound", "TEST", 41, 61], ["pulmonary", "ANATOMY", 41, 50]]], ["Biologically, 171 (81.4%) of 210 patients had lymphopenia (< 1,000 mm3).", [["lymphopenia", "DISEASE", 46, 57], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["lymphopenia", "PROBLEM", 46, 57], ["lymphopenia", "OBSERVATION", 46, 57]]], ["Likewise, 60.8% had a lactate dehydrogenase (LDH) > 250 U/ml and liver test alterations were common: elevated AST/GOT in 41.4% and ALT/GPT in 32.4%.", [["liver", "ANATOMY", 65, 70], ["lactate", "CHEMICAL", 22, 29], ["lactate", "CHEMICAL", 22, 29], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 22, 43], ["LDH", "GENE_OR_GENE_PRODUCT", 45, 48], ["liver", "ORGAN", 65, 70], ["AST", "SIMPLE_CHEMICAL", 110, 113], ["GOT", "SIMPLE_CHEMICAL", 114, 117], ["lactate dehydrogenase", "PROTEIN", 22, 43], ["LDH", "PROTEIN", 45, 48], ["AST", "PROTEIN", 110, 113], ["GOT", "PROTEIN", 114, 117], ["ALT", "PROTEIN", 131, 134], ["a lactate dehydrogenase", "TEST", 20, 43], ["LDH", "TEST", 45, 48], ["U/ml", "TEST", 56, 60], ["liver test alterations", "TEST", 65, 87], ["elevated AST", "PROBLEM", 101, 113], ["ALT", "TEST", 131, 134], ["GPT", "TEST", 135, 138], ["liver", "ANATOMY", 65, 70]]], ["In 86 (52.1%) of 165 cases D-dimer was elevated (> 500mg/L).", [["D-dimer", "SIMPLE_CHEMICAL", 27, 34], ["cases D-dimer", "TEST", 21, 34], ["elevated", "PROBLEM", 39, 47]]], ["The most important factors for ICU admission and death were bilateral pulmonary infiltrates (OR = 2.86; 95%CI = 1.41 to 6.13), elevated lactate-dehydrogenase (OR = 2.85; 95%CI = 1.28 to 6.90), elevated D-dimer (OR = 2.85; 95%CI = 1.22 to 6.98) and elevated C-reactive protein (OR = 2.38; 95%CI = 1.22 to 4.68) (Fig 1).", [["pulmonary", "ANATOMY", 70, 79], ["death", "DISEASE", 49, 54], ["bilateral pulmonary infiltrates", "DISEASE", 60, 91], ["lactate", "CHEMICAL", 136, 143], ["lactate", "CHEMICAL", 136, 143], ["pulmonary", "ORGAN", 70, 79], ["lactate-dehydrogenase", "GENE_OR_GENE_PRODUCT", 136, 157], ["D-dimer", "SIMPLE_CHEMICAL", 202, 209], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 257, 275], ["lactate-dehydrogenase", "PROTEIN", 136, 157], ["D-dimer", "PROTEIN", 202, 209], ["elevated C-reactive protein", "PROTEIN", 248, 275], ["bilateral pulmonary infiltrates", "PROBLEM", 60, 91], ["CI", "TEST", 107, 109], ["elevated lactate", "PROBLEM", 127, 143], ["dehydrogenase", "TEST", 144, 157], ["CI", "TEST", 173, 175], ["elevated D-dimer", "PROBLEM", 193, 209], ["CI", "TEST", 225, 227], ["elevated C-reactive protein", "PROBLEM", 248, 275], ["CI", "TEST", 291, 293], ["Fig", "TEST", 311, 314], ["bilateral", "ANATOMY_MODIFIER", 60, 69], ["pulmonary", "ANATOMY", 70, 79], ["infiltrates", "OBSERVATION", 80, 91]]], ["Significant predictive factors associated with hospitalization, after adjusting for age and sex, were lymphopenia (OR = 3.48; 95%CI = 1.67 to 7.40) and elevated C-reactive protein (OR = 3.27; 95%CI = 1.59 to 7.18) (Fig 2).Treatment, complications and evolution ::: ResultsTreatment included hydroxychloroquine in 162 (50.3%) patients, azithromycin in 149 (46.3%), lopinavir/ritonavir in 132 (40.7%), glucocorticoids in 34 (10.6%) and tocilizumab in 27 (8.4%), among others (Table 4), and 49.1% of patients required hospitalization.", [["lymphopenia", "DISEASE", 102, 113], ["hydroxychloroquine", "CHEMICAL", 291, 309], ["azithromycin", "CHEMICAL", 335, 347], ["lopinavir/ritonavir", "CHEMICAL", 364, 383], ["glucocorticoids", "CHEMICAL", 400, 415], ["tocilizumab", "CHEMICAL", 434, 445], ["hydroxychloroquine", "CHEMICAL", 291, 309], ["azithromycin", "CHEMICAL", 335, 347], ["lopinavir", "CHEMICAL", 364, 373], ["ritonavir", "CHEMICAL", 374, 383], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 161, 179], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 291, 309], ["patients", "ORGANISM", 325, 333], ["azithromycin", "SIMPLE_CHEMICAL", 335, 347], ["lopinavir", "SIMPLE_CHEMICAL", 364, 373], ["ritonavir", "SIMPLE_CHEMICAL", 374, 383], ["patients", "ORGANISM", 497, 505], ["C-reactive protein", "PROTEIN", 161, 179], ["patients", "SPECIES", 325, 333], ["patients", "SPECIES", 497, 505], ["Significant predictive factors", "PROBLEM", 0, 30], ["lymphopenia", "PROBLEM", 102, 113], ["CI", "TEST", 129, 131], ["elevated C-reactive protein", "PROBLEM", 152, 179], ["CI", "TEST", 195, 197], ["Fig", "TEST", 215, 218], ["hydroxychloroquine", "TREATMENT", 291, 309], ["azithromycin", "TREATMENT", 335, 347], ["lopinavir/ritonavir", "TREATMENT", 364, 383], ["glucocorticoids", "TREATMENT", 400, 415], ["tocilizumab", "TREATMENT", 434, 445], ["lymphopenia", "OBSERVATION", 102, 113]]], ["Phone follow up was registered in 277 (86.0%) patients, 57 (17.7%) patients were monitored at home.", [["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 67, 75]]], ["161 (77.8%) of the 207 patients of working age sought work disability due to COVID-19.", [["disability", "DISEASE", 59, 69], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["COVID", "TEST", 77, 82]]], ["The ICU admission rate was 13.0%.", [["The ICU admission rate", "TEST", 0, 22]]], ["The evolution included pneumonia in 177 (55%) patients, adult respiratory distress syndrome in 37 (11.5%), severe renal failure in 8 (2.5%), pulmonary thromboembolism in 4 (1.2%) and sepsis in 3 (0.9%) patients.", [["respiratory", "ANATOMY", 62, 73], ["renal", "ANATOMY", 114, 119], ["pulmonary", "ANATOMY", 141, 150], ["pneumonia", "DISEASE", 23, 32], ["respiratory distress syndrome", "DISEASE", 62, 91], ["renal failure", "DISEASE", 114, 127], ["pulmonary thromboembolism", "DISEASE", 141, 166], ["sepsis", "DISEASE", 183, 189], ["patients", "ORGANISM", 46, 54], ["renal", "ORGAN", 114, 119], ["pulmonary", "ORGAN", 141, 150], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 202, 210], ["pneumonia", "PROBLEM", 23, 32], ["adult respiratory distress syndrome", "PROBLEM", 56, 91], ["severe renal failure", "PROBLEM", 107, 127], ["pulmonary thromboembolism", "PROBLEM", 141, 166], ["sepsis", "PROBLEM", 183, 189], ["pneumonia", "OBSERVATION", 23, 32], ["respiratory", "ANATOMY", 62, 73], ["distress syndrome", "OBSERVATION", 74, 91], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["renal", "ANATOMY", 114, 119], ["failure", "OBSERVATION", 120, 127], ["pulmonary", "ANATOMY", 141, 150], ["thromboembolism", "OBSERVATION", 151, 166], ["sepsis", "OBSERVATION", 183, 189]]], ["Occupational contact with persons with confirmed or suspected COVID-19 infection was reported by 71 (22.0%) patients, while 51 (15.8%) reported that contact occurred in the family setting.", [["infection", "DISEASE", 71, 80], ["persons", "ORGANISM", 26, 33], ["patients", "ORGANISM", 108, 116], ["persons", "SPECIES", 26, 33], ["patients", "SPECIES", 108, 116], ["COVID-19", "SPECIES", 62, 70], ["suspected COVID-19 infection", "PROBLEM", 52, 80]]], ["Occupational contact was a protective factor against hospitalization (OR = 0.41; 95%CI = 0.20 to 0.80), ICU admission and death (OR = 0.12; 95%CI = 0.01 to 0.59) after adjusting for age and sex.", [["death", "DISEASE", 122, 127], ["CI", "TEST", 84, 86], ["CI", "TEST", 143, 145]]], ["The mortality rate to date was 5.6%.DiscussionThis study summarizes the clinical, biological and radiological characteristics, evolution and prognostic factors of patients with COVID-19 disease in primary and community healthcare.", [["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["The mortality rate", "TEST", 0, 18], ["This study", "TEST", 46, 56], ["COVID-19 disease", "PROBLEM", 177, 193]]], ["The first reported data from 48 patients on ICU admissions in a region where the pandemic was reported early [10].", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40]]], ["The study by Borobia et al [11] describes the first 2226 adult patients with COVID-19 consecutively admitted to a University Hospital in Madrid.", [["COVID", "DISEASE", 77, 82], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["The study", "TEST", 0, 9]]], ["The third focuses on the differences by age-dependent categories in the clinical profile, presentation, management, and short-term outcomes [12].", [["management", "TREATMENT", 104, 114]]], ["Although there have been two systematic reviews and meta-analysis that analyse the clinical characteristics of COVID-19, they are limited to Chinese cohorts or case series [13, 14] and a large USA cohort [15] that did not analyse clinical predictors of a poor prognosis.DiscussionClinically, the same main symptoms of cough and fever are reported in all series.", [["cough", "DISEASE", 318, 323], ["fever", "DISEASE", 328, 333], ["meta-analysis", "TEST", 52, 65], ["COVID", "TEST", 111, 116], ["cough", "PROBLEM", 318, 323], ["fever", "PROBLEM", 328, 333], ["cough", "OBSERVATION", 318, 323], ["fever", "OBSERVATION", 328, 333]]], ["However, in Barcelona city, we have observed diarrhoea, anosmia and dysgeusia, which is hardly reported in the Chinese series [7] which, unlike ours comes principally from hospitals: diarrhoea occurred in 23.8% of cases, very similar to the 23% in New York [16] and clearly higher than the 3.8% reported in China.", [["diarrhoea", "DISEASE", 45, 54], ["anosmia", "DISEASE", 56, 63], ["dysgeusia", "DISEASE", 68, 77], ["diarrhoea", "DISEASE", 183, 192], ["diarrhoea", "PROBLEM", 45, 54], ["anosmia", "PROBLEM", 56, 63], ["dysgeusia", "PROBLEM", 68, 77], ["diarrhoea", "PROBLEM", 183, 192], ["dysgeusia", "OBSERVATION", 68, 77], ["higher", "OBSERVATION_MODIFIER", 274, 280]]], ["Nearly 20% of patients had anosmia and dysgeusia, similar to the results obtained in French patients [17].", [["anosmia", "DISEASE", 27, 34], ["dysgeusia", "DISEASE", 39, 48], ["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 92, 100], ["anosmia", "PROBLEM", 27, 34], ["dysgeusia", "PROBLEM", 39, 48], ["dysgeusia", "OBSERVATION", 39, 48]]], ["In contrast, expectoration was found in only 9%, compared with 33.7% in the Chinese series.DiscussionChinese patients had a mean age of 47 years, ten years lower than our series, and 35.7% of our patients were aged \u2265 65 years, compared with 15%, 29% and 31% in China, Germany and the USA respectively, but > 40% in Italy [7, 18\u201320].", [["expectoration", "DISEASE", 13, 26], ["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 196, 204], ["expectoration", "PROBLEM", 13, 26]]], ["Older age and male sex predisposed to a higher mortality rate in our and all large series [7, 15].", [["a higher mortality rate", "PROBLEM", 38, 61]]], ["In our patients, comorbidities were three times higher than in the Chinese cohort [7] and were similar to the findings of the New York study [15].", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["comorbidities", "PROBLEM", 17, 30]]], ["Any comorbidity was a risk factor for hospitalization, ICU admission and death.", [["death", "DISEASE", 73, 78], ["Any comorbidity", "PROBLEM", 0, 15], ["death", "PROBLEM", 73, 78], ["comorbidity", "OBSERVATION", 4, 15]]], ["Depression was an independent risk factor for hospitalization, which has not been observed in other cohorts studied.", [["Depression", "DISEASE", 0, 10], ["Depression", "PROBLEM", 0, 10]]], ["Depression was often accompanied by a vulnerable social situation, which may have justified hospitalization.", [["Depression", "DISEASE", 0, 10], ["Depression", "PROBLEM", 0, 10]]], ["Likewise, autoimmune diseases were independent risk factor for ICU admission and death.", [["autoimmune diseases", "DISEASE", 10, 29], ["death", "DISEASE", 81, 86], ["autoimmune diseases", "PROBLEM", 10, 29], ["death", "PROBLEM", 81, 86], ["autoimmune diseases", "OBSERVATION", 10, 29]]], ["Various hypotheses have been postulated on possible autoimmune alterations in the pathogenic evolution of the disease.", [["autoimmune alterations", "PROBLEM", 52, 74], ["the disease", "PROBLEM", 106, 117], ["possible", "UNCERTAINTY", 43, 51], ["autoimmune", "OBSERVATION_MODIFIER", 52, 62], ["disease", "OBSERVATION", 110, 117]]], ["With respect to treatment, no drug has proved effective against Covid-19 until now.", [["treatment", "TREATMENT", 16, 25], ["drug", "TREATMENT", 30, 34], ["Covid", "TEST", 64, 69]]], ["Moreover, many treatments were unavailable in the outpatient setting.", [["many treatments", "TREATMENT", 10, 25]]], ["Currently, we are only certain that treatment with tocilizumab showed better survival rates in retrospective cohorts [21], although its efficacy has not been tested in randomized clinical trials.", [["tocilizumab", "CHEMICAL", 51, 62], ["tocilizumab", "SIMPLE_CHEMICAL", 51, 62], ["treatment", "TREATMENT", 36, 45], ["tocilizumab", "TREATMENT", 51, 62]]], ["Therefore, the results on the outcomes associated with treatment should be interpreted with caution.DiscussionThe same comorbidities were identified, with hypertension and diabetes being the two most common, while in the USA and Italy, obesity seems to be higher.", [["hypertension", "DISEASE", 155, 167], ["diabetes", "DISEASE", 172, 180], ["obesity", "DISEASE", 236, 243], ["treatment", "TREATMENT", 55, 64], ["hypertension", "PROBLEM", 155, 167], ["diabetes", "PROBLEM", 172, 180], ["obesity", "PROBLEM", 236, 243], ["hypertension", "OBSERVATION", 155, 167], ["diabetes", "OBSERVATION", 172, 180], ["obesity", "OBSERVATION", 236, 243], ["higher", "OBSERVATION_MODIFIER", 256, 262]]], ["Our results show that obesity was close to being an independent risk factor for hospitalization (OR = 2.05; 95%CI = 0.99 to 4.46).DiscussionStrikingly, 38.2% of our patients were healthcare workers, compared with 3.5% in Wuhan and 5.2% in Germany [7, 18].", [["obesity", "DISEASE", 22, 29], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173], ["obesity", "PROBLEM", 22, 29], ["CI", "TEST", 111, 113], ["obesity", "OBSERVATION", 22, 29]]], ["Although these studies recognized an important degree of underreporting of cases in health workers, the difference remains important.", [["these studies", "TEST", 9, 22]]], ["There are at least two possible explanations: first, the lack of personal protective equipment in the initial phase of the epidemic, a constant revindication of health professionals, who felt undersupplied.", [["personal protective equipment", "TREATMENT", 65, 94], ["at least", "OBSERVATION_MODIFIER", 10, 18]]], ["Secondly, many cases were health professionals from primary healthcare or the reference hospital who reside in the same area where they work.DiscussionIn all reported series, bilateral pneumonia was the most common radiological finding, was present in more than half the cases [22] and was a factor of a poor prognosis and mortality.", [["pneumonia", "DISEASE", 185, 194], ["bilateral pneumonia", "PROBLEM", 175, 194], ["bilateral", "ANATOMY_MODIFIER", 175, 184], ["pneumonia", "OBSERVATION", 185, 194]]], ["In contrast, an interstitial radiological pattern did not confer an increased risk of mortality.", [["interstitial", "ANATOMY", 16, 28], ["an interstitial radiological pattern", "PROBLEM", 13, 49], ["interstitial", "ANATOMY_MODIFIER", 16, 28], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["mortality", "OBSERVATION", 86, 95]]], ["The Wuhan study reported a CAT scan use of 88.7%, compared with 8.7% in Barcelona.", [["CAT", "PROTEIN", 27, 30], ["The Wuhan study", "TEST", 0, 15], ["a CAT scan", "TEST", 25, 35]]], ["In contrast, chest X-rays were carried out in 59.1% and 70.5%, respectively: the availability of diagnostic means was higher in China.", [["chest X-rays", "TEST", 13, 25], ["diagnostic means", "TEST", 97, 113], ["chest", "ANATOMY", 13, 18]]], ["A recent international consensus states that radiological assessment is not necessary in asymptomatic patients or those with mild disease but is required in patients with moderate or severe disease, regardless of whether a definite diagnosis of COVID-19 has been made [23].", [["COVID", "DISEASE", 245, 250], ["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 157, 165], ["radiological assessment", "TEST", 45, 68], ["mild disease", "PROBLEM", 125, 137], ["moderate or severe disease", "PROBLEM", 171, 197], ["COVID", "TEST", 245, 250], ["mild", "OBSERVATION_MODIFIER", 125, 129], ["disease", "OBSERVATION", 130, 137], ["severe", "OBSERVATION_MODIFIER", 183, 189], ["disease", "OBSERVATION", 190, 197]]], ["In addition, simple chest X-rays are preferable in a resource-constrained environment with difficulties in accessing CAT scans [23].", [["CAT", "PROTEIN", 117, 120], ["simple chest X-rays", "PROBLEM", 13, 32], ["accessing CAT scans", "TEST", 107, 126], ["chest", "ANATOMY", 20, 25]]], ["The possible use of pulmonary ultrasound for the point-of-care diagnosis of COVID-19 pneumonia has not been sufficiently analysed but might be an efficient alternative due to its portability and reliability [24].", [["pulmonary", "ANATOMY", 20, 29], ["pneumonia", "DISEASE", 85, 94], ["pulmonary", "ORGAN", 20, 29], ["pulmonary ultrasound", "TEST", 20, 40], ["COVID", "TEST", 76, 81], ["pneumonia", "PROBLEM", 85, 94], ["pulmonary", "ANATOMY", 20, 29], ["pneumonia", "OBSERVATION", 85, 94]]], ["In fact, the regional Catalan government has recently acquired 90 ultrasound machines to enable family physicians to make doctors can make point-of-care (home or nursing home) diagnoses of pneumonia [25].", [["pneumonia", "DISEASE", 189, 198], ["pneumonia", "PROBLEM", 189, 198], ["pneumonia", "OBSERVATION", 189, 198]]], ["Biologically, lymphopenia and increased CRP, LDH and D-dimer were usually constant and similar in all series and were associated with an increased risk of mortality.", [["lymphopenia", "DISEASE", 14, 25], ["CRP", "GENE_OR_GENE_PRODUCT", 40, 43], ["LDH", "GENE_OR_GENE_PRODUCT", 45, 48], ["D-dimer", "GENE_OR_GENE_PRODUCT", 53, 60], ["CRP", "PROTEIN", 40, 43], ["LDH", "PROTEIN", 45, 48], ["D-dimer", "PROTEIN", 53, 60], ["lymphopenia", "PROBLEM", 14, 25], ["increased CRP", "PROBLEM", 30, 43], ["LDH", "TEST", 45, 48], ["D-dimer", "PROBLEM", 53, 60], ["an increased risk of mortality", "PROBLEM", 134, 164], ["lymphopenia", "OBSERVATION", 14, 25], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["CRP", "OBSERVATION_MODIFIER", 40, 43], ["D-dimer", "OBSERVATION_MODIFIER", 53, 60], ["constant", "OBSERVATION_MODIFIER", 74, 82], ["increased", "OBSERVATION_MODIFIER", 137, 146], ["mortality", "OBSERVATION", 155, 164]]], ["A differential variable in our series is a greater number of alterations in liver tests, which was present in 30\u201340% of patients, data similar to the USA and Italian cohorts, but different from the Chinese cohort, where it was 22% [7].", [["liver", "ANATOMY", 76, 81], ["liver", "ORGAN", 76, 81], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["our series", "TEST", 27, 37], ["liver tests", "TEST", 76, 87], ["differential", "OBSERVATION_MODIFIER", 2, 14], ["variable", "OBSERVATION_MODIFIER", 15, 23], ["greater", "OBSERVATION_MODIFIER", 43, 50], ["number", "OBSERVATION_MODIFIER", 51, 57], ["liver", "ANATOMY", 76, 81]]], ["We also found hypokalaemia in 20.5% of patients, a factor not reported in other studies.DiscussionWe found a hospitalization rate of 48.7%, compared with 20\u201331% in the USA and 93.6% in China, and an ICU admission rate of 13%, which was similar to the Chinese (15%), USA (5\u201311.5%) and German (10%) results.", [["hypokalaemia", "DISEASE", 14, 26], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["hypokalaemia", "PROBLEM", 14, 26], ["other studies", "TEST", 74, 87], ["a hospitalization rate", "TEST", 107, 129], ["an ICU admission rate", "TEST", 196, 217], ["USA", "TEST", 266, 269], ["hypokalaemia", "OBSERVATION", 14, 26], ["20.5%", "OBSERVATION_MODIFIER", 30, 35]]], ["While the protocols of action and admission are similar and depend on the level of clinical involvement, the therapeutic protocols differ between hospitals, cities, and countries.", [["the therapeutic protocols", "TREATMENT", 105, 130]]], ["There remain many unknowns in the treatment of COVID-19.", [["COVID-19", "CHEMICAL", 47, 55], ["COVID", "TEST", 47, 52], ["many", "OBSERVATION_MODIFIER", 13, 17], ["unknowns", "OBSERVATION", 18, 26]]], ["The only truth is that we do not have a vaccine, an etiological treatment or a treatment with sufficient scientific evidence to generalize its use.", [["a vaccine", "TREATMENT", 38, 47], ["an etiological treatment", "TREATMENT", 49, 73], ["a treatment", "TREATMENT", 77, 88]]], ["Currently, the systematic review of antiretroviral treatments has not offered conclusive results [26] and despite in vitro results for hydroxychloroquine, COVID-19 infections are currently intractable [27, 28].DiscussionThe mortality rate in our study was 5.6%, compared with 10.2% in New York (21% in hospitalized patients), 1.4% in China, 3.1% in Germany and 6.8% in Italy.", [["hydroxychloroquine", "CHEMICAL", 135, 153], ["COVID-19", "CHEMICAL", 155, 163], ["infections", "DISEASE", 164, 174], ["hydroxychloroquine", "CHEMICAL", 135, 153], ["COVID-19", "CHEMICAL", 155, 163], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 135, 153], ["COVID-19", "SIMPLE_CHEMICAL", 155, 163], ["patients", "ORGANISM", 315, 323], ["patients", "SPECIES", 315, 323], ["antiretroviral treatments", "TREATMENT", 36, 61], ["hydroxychloroquine", "TREATMENT", 135, 153], ["COVID", "TREATMENT", 155, 160], ["The mortality rate", "TEST", 220, 238], ["our study", "TEST", 242, 251]]], ["Different information and recording systems, the availability of diagnostic tests, and above all, the organization of national health systems may have contributed to the differences observed.DiscussionThe study had some limitations due to the observational, retrospective design.", [["recording systems", "TEST", 26, 43], ["diagnostic tests", "TEST", 65, 81], ["The study", "TEST", 201, 210]]], ["However, it is sufficiently representative of the population with confirmed COVID-19 to permit better identification of the factors of a poor prognosis of the disease from a clinical perspective.", [["COVID", "TEST", 76, 81], ["the disease", "PROBLEM", 155, 166], ["disease", "OBSERVATION", 159, 166]]], ["We cannot rule out some heterogeneity in data codification due to observers\u2019 interpretations of the medical records.", [["some heterogeneity in data codification", "PROBLEM", 19, 58], ["heterogeneity", "OBSERVATION", 24, 37]]], ["However, this bias is minimal, as most clinical factors included are clearly defined in the electronic medical record.", [["minimal", "OBSERVATION_MODIFIER", 22, 29]]], ["Another limitation of this study is the percentage of patients without laboratory parameters (more than 30%).", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["this study", "TEST", 22, 32], ["laboratory parameters", "TEST", 71, 92]]], ["Even though in real clinical practice these percentages may be expected, the results corresponding to laboratory parameters should be interpreted with caution.DiscussionFour months after the declaration of the pandemic, there is not a sufficiently reliable, available and generalizable diagnostic test that can analyse the seroprevalence of COVID-19, even in the most industrialized countries.", [["laboratory parameters", "TEST", 102, 123], ["generalizable diagnostic test", "TEST", 272, 301], ["COVID", "TEST", 341, 346]]], ["Given this lack, determining the clinical, biological and radiological characteristics of probable cases of COVID-19 infection will be key to the initiation of early treatment and isolation, and for contact tracing, especially in primary healthcare.", [["infection", "DISEASE", 117, 126], ["COVID-19", "ORGANISM", 108, 116], ["COVID-19 infection", "PROBLEM", 108, 126], ["early treatment", "TREATMENT", 160, 175], ["isolation", "TREATMENT", 180, 189], ["contact tracing", "TEST", 199, 214], ["infection", "OBSERVATION", 117, 126]]]], "PMC7094751": [["IntroductionThe spread of infectious diseases between discrete geographic regions (or cities) is a phenomenon that involves many different compartments.", [["infectious diseases", "DISEASE", 26, 45], ["infectious diseases", "PROBLEM", 26, 45], ["a phenomenon", "PROBLEM", 97, 109], ["spread", "OBSERVATION_MODIFIER", 16, 22], ["infectious", "OBSERVATION", 26, 36], ["discrete", "OBSERVATION_MODIFIER", 54, 62], ["geographic", "OBSERVATION_MODIFIER", 63, 73]]], ["To control the spread of an infectious disease, one has to understand how the growth and spread of the disease affect its outbreak.", [["infectious disease", "DISEASE", 28, 46], ["an infectious disease", "PROBLEM", 25, 46], ["the disease affect", "PROBLEM", 99, 117], ["spread", "OBSERVATION_MODIFIER", 15, 21], ["infectious", "OBSERVATION", 28, 38]]], ["There are many factors that lead to the dynamics of an infectious disease of humans.", [["humans", "ORGANISM", 77, 83], ["humans", "SPECIES", 77, 83], ["humans", "SPECIES", 77, 83], ["an infectious disease of humans", "PROBLEM", 52, 83], ["infectious", "OBSERVATION", 55, 65]]], ["They include such human behaviors as population dislocations, living styles, sexual practices and rising international travel.", [["dislocations", "DISEASE", 48, 60], ["human", "ORGANISM", 18, 23], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23], ["population dislocations", "PROBLEM", 37, 60]]], ["In current, population dispersal by human transportation plays an important role in the spread of infectious disease around the world.", [["infectious disease", "DISEASE", 98, 116], ["human", "ORGANISM", 36, 41], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["infectious disease", "PROBLEM", 98, 116], ["infectious", "OBSERVATION", 98, 108]]], ["SARS (severe acute respiratory syndrome) spread along the routes of international air travel and infection was carried to many places [33], [34].", [["SARS", "DISEASE", 0, 4], ["acute respiratory syndrome", "DISEASE", 13, 39], ["infection", "DISEASE", 97, 106], ["SARS (severe acute respiratory syndrome)", "PROBLEM", 0, 40], ["infection", "PROBLEM", 97, 106], ["severe", "OBSERVATION_MODIFIER", 6, 12], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["respiratory syndrome", "OBSERVATION", 19, 39], ["infection", "OBSERVATION", 97, 106]]], ["Khan et al. [14] pointed out a correlation between inter-regional spread of a novel influenza A (H1N1) virus and travelers.", [["influenza A (H1N1) virus", "DISEASE", 84, 108], ["influenza A (H1N1) virus", "ORGANISM", 84, 108], ["influenza A (H1N1", "SPECIES", 84, 101], ["influenza A (H1N1) virus", "SPECIES", 84, 108], ["a novel influenza A (H1N1) virus", "PROBLEM", 76, 108]]], ["From these observations a number of authors have proposed epidemic models describing disease transmission dynamics among multiple locations due to the population dispersal (see [3], [4], [10], [23], [24], [25], [26], [29], [30], [31], [32] and the references therein).", [["disease transmission dynamics", "PROBLEM", 85, 114]]], ["Recently, Cui et al. [7] have proposed a SIS epidemic model to understand the effect of transport related infection on disease spread.", [["infection", "DISEASE", 106, 115], ["a SIS epidemic model", "PROBLEM", 39, 59], ["transport related infection", "PROBLEM", 88, 115], ["disease spread", "PROBLEM", 119, 133], ["infection", "OBSERVATION", 106, 115]]], ["They found that the global stabilities of equilibria disease-free and endemic equilibriums, still required additional condition besides the condition for their existence.", [["equilibria disease", "PROBLEM", 42, 60], ["endemic equilibriums", "PROBLEM", 70, 90], ["global", "OBSERVATION_MODIFIER", 20, 26], ["stabilities", "OBSERVATION_MODIFIER", 27, 38], ["equilibria disease", "OBSERVATION", 42, 60], ["free", "OBSERVATION_MODIFIER", 61, 65], ["endemic", "OBSERVATION_MODIFIER", 70, 77]]], ["Considering entry screening and exit screening to detect infected individuals, Liu and Takeuchi [20] proposed an SIQS model to study the effect of transport-related infection and entry screening.", [["infection", "DISEASE", 165, 174], ["entry screening", "TEST", 12, 27], ["exit screening", "TEST", 32, 46], ["infected individuals", "PROBLEM", 57, 77], ["an SIQS model", "TREATMENT", 110, 123], ["related infection", "PROBLEM", 157, 174], ["entry screening", "TEST", 179, 194], ["infection", "OBSERVATION", 165, 174]]], ["Subsequently, Liu and Zhou [21] analyzed global stability of an SIRS epidemic model with transport-related infection.", [["SIRS", "DISEASE", 64, 68], ["infection", "DISEASE", 107, 116], ["an SIRS epidemic model", "PROBLEM", 61, 83], ["related infection", "PROBLEM", 99, 116], ["SIRS epidemic", "OBSERVATION", 64, 77], ["infection", "OBSERVATION", 107, 116]]], ["Their results shown transport-related infection can make the disease endemic even if both the isolated regions are disease free.", [["infection", "DISEASE", 38, 47], ["transport-related infection", "PROBLEM", 20, 47], ["the disease endemic", "PROBLEM", 57, 76], ["disease free", "PROBLEM", 115, 127], ["infection", "OBSERVATION", 38, 47], ["disease", "OBSERVATION", 115, 122]]], ["Obviously, the models in [7], [20], [27] assumed that a susceptible individual becomes infectious immediately after infected.", [["[20]", "SIMPLE_CHEMICAL", 30, 34], ["infectious", "PROBLEM", 87, 97], ["infectious", "OBSERVATION", 87, 97]]], ["However, for many diseases, a host stays in a latent period before becoming infectious after infected, Wan and Cui [29] formulated an SEIS epidemic model to describe the transmission of infectious diseases related by transports.", [["infectious diseases", "DISEASE", 186, 205], ["many diseases", "PROBLEM", 13, 26], ["infectious", "PROBLEM", 76, 86], ["infectious diseases", "PROBLEM", 186, 205], ["diseases", "OBSERVATION", 18, 26], ["infectious", "OBSERVATION", 76, 86], ["infectious", "OBSERVATION", 186, 196]]], ["When the individuals have immunity to the disease after recover, the SEIR or SEIRS models are more general than the SEI or SEIS types depending on whether the acquired immunity is permanent or otherwise.", [["individuals", "ORGANISM", 9, 20], ["the disease", "PROBLEM", 38, 49], ["SEIRS models", "PROBLEM", 77, 89]]], ["For example, Greenhalgh [11] considered an SEIR model that incorporates density dependence in the death rate.", [["death", "DISEASE", 98, 103], ["Greenhalgh", "TEST", 13, 23], ["an SEIR model", "PROBLEM", 40, 53], ["density dependence", "PROBLEM", 72, 90], ["the death rate", "TEST", 94, 108], ["density", "OBSERVATION_MODIFIER", 72, 79], ["dependence", "OBSERVATION_MODIFIER", 80, 90]]], ["Greenhalgh [12] studied Hopf bifurcations in the SEIRS type models with density dependent contact rate and death rate.", [["Greenhalgh", "CHEMICAL", 0, 10], ["death", "DISEASE", 107, 112], ["density dependent contact rate", "PROBLEM", 72, 102], ["death rate", "TEST", 107, 117], ["density dependent", "OBSERVATION", 72, 89]]], ["Li and Muldowney [16] and Li et al. [17] studied the global dynamics of the SEIR models with a non-linear incidence rate as well as standard incidence rate.", [["Li", "CHEMICAL", 0, 2], ["Li", "CHEMICAL", 0, 2], ["Li", "TEST", 0, 2], ["Muldowney", "TEST", 7, 16], ["Li et al.", "TEST", 26, 35], ["a non-linear incidence rate", "PROBLEM", 93, 120]]], ["However, those models have not applied to real data of outbreak to investigate the effect of transport-related infection when individuals travel among two cities.IntroductionThe aim of this paper is to formulate an SEIRS epidemic model to describe the transmission of infectious diseases related by transports.", [["infection", "DISEASE", 111, 120], ["infectious diseases", "DISEASE", 268, 287], ["outbreak", "PROBLEM", 55, 63], ["related infection", "PROBLEM", 103, 120], ["infectious diseases", "PROBLEM", 268, 287], ["infection", "OBSERVATION", 111, 120], ["infectious", "OBSERVATION", 268, 278]]], ["The formulated model is applied to real data of SARS outbreak in 2003 in order to investigate the transmission of disease when individuals in a population suffer from diseases and possibly become infected during the movement between two cities.IntroductionThis paper is organized as follows.", [["SARS", "DISEASE", 48, 52], ["disease", "PROBLEM", 114, 121], ["diseases", "PROBLEM", 167, 175], ["disease", "OBSERVATION", 114, 121], ["diseases", "OBSERVATION", 167, 175], ["infected", "OBSERVATION", 196, 204]]], ["An SEIRS model with transport-related infection is formulated in Section 2.", [["infection", "DISEASE", 38, 47], ["related infection", "PROBLEM", 30, 47], ["infection", "OBSERVATION", 38, 47]]], ["In Section 3, the basic reproduction number of the formulated model is derived and the local stability of the model is analyzed to verify that the equilibria of the model are locally asymptotically stable under the condition of the basic reproduction number.", [["stable", "OBSERVATION_MODIFIER", 198, 204]]], ["Simulation results are presented in Section 4 to illustrate the effect of transport-related infection on its outbreak and the final size of all individuals for the populations.", [["infection", "DISEASE", 92, 101], ["transport-related infection", "PROBLEM", 74, 101], ["infection", "OBSERVATION", 92, 101], ["size", "OBSERVATION_MODIFIER", 132, 136]]], ["The SEIRS model and SEIRS model with transport-related infection are applied to predict the SARS outbreak within a city and if there is the movement of population between two cities, respectively.Model formulationThe epidemic model for transmission of a communicable disease with population travel between two cities is based on monitoring the dynamics of the sub\u2013populations (susceptible; Si(t), exposed (latent); Ei(t), infected; Ii(t), and recovered; Ri(t), in the city i, i=1,2 at time t).", [["infection", "DISEASE", 55, 64], ["SARS", "DISEASE", 92, 96], ["communicable disease", "DISEASE", 254, 274], ["Si", "CHEMICAL", 390, 392], ["The SEIRS model", "TEST", 0, 15], ["SEIRS model", "PROBLEM", 20, 31], ["related infection", "PROBLEM", 47, 64], ["the SARS outbreak", "PROBLEM", 88, 105], ["Model formulation", "TREATMENT", 196, 213], ["a communicable disease", "PROBLEM", 252, 274], ["infection", "OBSERVATION", 55, 64], ["movement", "OBSERVATION_MODIFIER", 140, 148]]], ["Thus, the total population in city i at time t is given by Ni=Si(t)+Ei(t)+Ii(t)+Ri(t) for i=1,2.", [["Ni", "CHEMICAL", 59, 61], ["Ni", "CHEMICAL", 59, 61], ["Si", "CHEMICAL", 62, 64]]], ["It is assumed that both cities are identical, i.e. the demographic parameters are the same for each city.Model formulationThe population of susceptible individuals is increased by the recruitment of individuals which are all newborn into the population at the rate a and the loss of infection\u2013acquired immunity among recovered individuals at the rate \u03b12 and by the susceptible individuals of city j leave to city i(j\u2260i,i=1,2) at the rate \u03b11.", [["\u03b12", "GENE_OR_GENE_PRODUCT", 351, 353], ["the demographic parameters", "TEST", 51, 77], ["Model formulation", "TREATMENT", 105, 122], ["susceptible individuals", "PROBLEM", 140, 163], ["the loss of infection\u2013acquired immunity", "PROBLEM", 271, 310], ["population", "OBSERVATION_MODIFIER", 126, 136], ["susceptible", "OBSERVATION_MODIFIER", 140, 151], ["individuals", "OBSERVATION", 152, 163], ["increased", "OBSERVATION_MODIFIER", 167, 176], ["recruitment", "OBSERVATION_MODIFIER", 184, 195]]], ["In the other hand, it is decreased when the susceptible individuals in city i leave to city j at the rate \u03b11 and by natural death at the rate b.", [["death", "DISEASE", 124, 129], ["natural death", "PROBLEM", 116, 129], ["decreased", "OBSERVATION", 25, 34]]], ["It is assumed that susceptible individuals can acquire exposed individuals via effective contacts with infected individuals.", [["individuals", "ORGANISM", 31, 42], ["susceptible individuals", "PROBLEM", 19, 42], ["infected individuals", "PROBLEM", 103, 123]]], ["The disease is transmitted horizontally within and between cities according to standard the incidence rate (that is, the number of new cases of infection per unit time)\u03b2SiIiNi,fori=1,2,where \u03b2 is the transmission rate within a city.", [["infection", "DISEASE", 144, 153], ["The disease", "PROBLEM", 0, 11], ["infection", "PROBLEM", 144, 153], ["disease", "OBSERVATION", 4, 11], ["horizontally", "OBSERVATION_MODIFIER", 27, 39], ["infection", "OBSERVATION", 144, 153]]], ["This population is further decreased when the individuals in city j travel to city i, and the disease is transmitted with the incidence rate\u03b3(\u03b11Sj)(\u03b11Ij)(\u03b11Sj+\u03b11Ej+\u03b11Ij+\u03b11Ri)=\u03b3\u03b11SjIjNj,forj=1,2,where \u03b3 is the transport-related transmission rate.", [["\u03b11Ij", "PROTEIN", 148, 152], ["\u03b11Sj", "PROTEIN", 154, 158], ["1Ej", "PROTEIN", 160, 163], ["1Ij", "PROTEIN", 165, 168], ["1Ri", "PROTEIN", 170, 173], ["\u03b3\u03b11SjIjNj", "PROTEIN", 175, 184], ["the disease", "PROBLEM", 90, 101], ["the incidence rate\u03b3", "TEST", 122, 141], ["1Sj", "TEST", 155, 158], ["the transport", "TEST", 205, 218], ["transmission rate", "TEST", 227, 244], ["decreased", "OBSERVATION_MODIFIER", 27, 36], ["disease", "OBSERVATION", 94, 101]]], ["Thus, the rate of change of population of susceptible class is given by(2.1)dSidt=a-bSi-\u03b2SiIiNi+\u03b12Ri-\u03b11Si+\u03b11Sj-\u03b3\u03b11SjIjNj.The population of exposed individuals is generated by the infected of susceptible individuals at the rate \u03b2SiIiNi and at the rate \u03b3\u03b11SjIjNj when the individuals in city j travel to city i.", [["Sidt=a-bSi-\u03b2SiIiNi+\u03b12Ri-\u03b11Si+\u03b11Sj-\u03b3\u03b11SjIjNj", "CHEMICAL", 77, 120], ["Sidt=a-bSi-\u03b2SiIiNi+\u03b12Ri-\u03b11Si+\u03b11Sj-\u03b3\u03b11SjIjNj", "SIMPLE_CHEMICAL", 77, 120], ["individuals", "ORGANISM", 147, 158], ["Sidt=a-bSi-\u03b2SiIiNi+\u03b12Ri-\u03b11Si+\u03b11Sj-\u03b3\u03b11SjIjNj", "PROTEIN", 77, 120], ["\u03b2SiIiNi", "PROTEIN", 227, 234], ["\u03b3\u03b11SjIjNj", "PROTEIN", 251, 260], ["infected", "OBSERVATION_MODIFIER", 179, 187]]], ["It is reduced by progression to symptoms development at the rate c, travel to city j at the rate \u03b11 and natural death at the rate b.", [["death", "DISEASE", 112, 117], ["symptoms", "PROBLEM", 32, 40], ["natural death", "PROBLEM", 104, 117], ["reduced", "OBSERVATION_MODIFIER", 6, 13], ["progression", "OBSERVATION_MODIFIER", 17, 28]]], ["Thus(2.2)dEidt=\u03b2SiIiNi-b+c+\u03b11Ei+\u03b11Ej+\u03b3\u03b11SjIjNj.The population of infected individuals in city i is generated when exposed individuals develop symptoms at the rate c, and when infected individuals of city j leave to city i at the rate \u03b11.", [["=\u03b2", "PROTEIN", 14, 16], ["SiIiNi-b+c+\u03b11Ei+\u03b11Ej", "PROTEIN", 16, 36], ["+\u03b3\u03b11SjIjNj", "PROTEIN", 36, 46], ["Thus", "TEST", 0, 4], ["symptoms", "PROBLEM", 142, 150], ["infected", "OBSERVATION", 65, 73]]], ["It is decreased by progression to the recovered class at the rate d, natural death and disease induced mortality at the rate e, and when infected individuals of city i move to city j at the rate \u03b11.", [["death", "DISEASE", 77, 82], ["natural death", "PROBLEM", 69, 82], ["disease induced mortality", "PROBLEM", 87, 112], ["decreased", "OBSERVATION_MODIFIER", 6, 15], ["progression", "OBSERVATION_MODIFIER", 19, 30]]], ["Thus,(2.3)dIidt=cEi-e+d+\u03b11Ii+\u03b11Ii.The population of recovered individuals is generated when infected individuals recover and move to the recovered class at the rate d, and when recovered individuals of city j leave to city i.", [["(2.3)d", "CHEMICAL", 5, 11], ["individuals", "ORGANISM", 101, 112], ["1Ii", "PROTEIN", 25, 28]]], ["It is decreased by the loss of infection\u2013acquired immunity at the rate \u03b12, by natural death at the rate b, and when recovered individuals of city i move to city j at the rate \u03b11.", [["death", "DISEASE", 86, 91], ["\u03b12", "GENE_OR_GENE_PRODUCT", 71, 73], ["decreased", "OBSERVATION_MODIFIER", 6, 15], ["loss", "OBSERVATION_MODIFIER", 23, 27]]], ["Thus,(2.4)dRidt=dIi-b+\u03b11+\u03b12Ri+\u03b11Rj.It is assumed that the individuals have no infectious force in the latent period and the exposed individuals cannot recover to susceptible individuals.", [["Ridt=dIi-b+\u03b11+\u03b12Ri+\u03b11Rj", "GENE_OR_GENE_PRODUCT", 11, 34], ["individuals", "ORGANISM", 132, 143], ["Ridt=dIi-b+\u03b11+\u03b12Ri", "PROTEIN", 11, 29], ["1Rj", "PROTEIN", 31, 34], ["susceptible individuals", "PROBLEM", 162, 185], ["no", "UNCERTAINTY", 75, 77], ["infectious", "OBSERVATION_MODIFIER", 78, 88], ["force", "OBSERVATION_MODIFIER", 89, 94], ["latent", "OBSERVATION_MODIFIER", 102, 108]]], ["The individuals who are travelling do not give birth and do not take die.", [["individuals", "ORGANISM", 4, 15]]], ["Infected individuals do not recover during travel.", [["individuals", "ORGANISM", 9, 20], ["Infected individuals", "PROBLEM", 0, 20]]], ["Thus, An SEIRS with transport-related infection consists of the following system of non\u2013linear differential equations:(2.5)dS1dt=a-bS1-\u03b2S1I1N1+\u03b12R1-\u03b11S1+\u03b11S2-\u03b3\u03b11S2I2N2,dE1dt=\u03b2S1I1N1-b+c+\u03b11E1+\u03b11E2+\u03b3\u03b11S2I2N2,dI1dt=cE1-e+d+\u03b11I1+\u03b11I2,dR1dt=dI1-b+\u03b11+\u03b12R1+\u03b11R2,dS2dt=a-bS2-\u03b2S2I2N2+\u03b12R2-\u03b11S2+\u03b11S1-\u03b3\u03b11S1I1N1,dE2dt=\u03b2S2I2N2-b+c+\u03b11E2+\u03b11E1+\u03b3\u03b11S1I1N1,dI2dt=cE2-e+d+\u03b11I2+\u03b11I1,dR2dt=dI2-b+\u03b11+\u03b12R2+\u03b11R1.A flow diagram of the model is depicted in Fig. 1.", [["infection", "DISEASE", 38, 47], ["S1dt", "GENE_OR_GENE_PRODUCT", 124, 128], ["cE1-e+d+\u03b11I1+\u03b11I2", "SIMPLE_CHEMICAL", 212, 229], ["dI1-b+\u03b11+\u03b12R1+\u03b11R2", "SIMPLE_CHEMICAL", 236, 254], ["dS2dt=a-bS2-\u03b2S2I2N2+\u03b12R2-\u03b11S2+\u03b11S1-\u03b3\u03b11S1I1N1", "SIMPLE_CHEMICAL", 255, 299], ["\u03b2S2I2N2-b+c+\u03b11E2+\u03b11E1+\u03b3\u03b11S1I1N1", "SIMPLE_CHEMICAL", 306, 337], ["cE2-e+d+\u03b11I2+\u03b11I1", "SIMPLE_CHEMICAL", 344, 361], ["dI2-b+\u03b11+\u03b12R2+\u03b11R1", "SIMPLE_CHEMICAL", 368, 386], ["S1dt", "PROTEIN", 124, 128], ["bS1", "PROTEIN", 131, 134], ["\u03b2", "PROTEIN", 135, 136], ["S1I1N1", "PROTEIN", 136, 142], ["2R1", "PROTEIN", 144, 147], ["1S1", "PROTEIN", 149, 152], ["1S2", "PROTEIN", 154, 157], ["\u03b3", "PROTEIN", 158, 159], ["1S2I2N2", "PROTEIN", 160, 167], ["E1dt", "PROTEIN", 169, 173], ["\u03b2", "PROTEIN", 174, 175], ["S1I1N1", "PROTEIN", 175, 181], ["b", "PROTEIN", 182, 183], ["c", "PROTEIN", 184, 185], ["1E1", "PROTEIN", 187, 190], ["1E2", "PROTEIN", 192, 195], ["\u03b3", "PROTEIN", 196, 197], ["1S2I2N2", "PROTEIN", 198, 205], ["dI1dt", "PROTEIN", 206, 211], ["cE1", "PROTEIN", 212, 215], ["+d", "PROTEIN", 217, 219], ["1I1", "PROTEIN", 221, 224], ["\u03b11I2", "CELL_LINE", 225, 229], ["dR1dt", "PROTEIN", 230, 235], ["dI1", "PROTEIN", 236, 239], ["b+\u03b11", "CELL_LINE", 240, 244], ["\u03b12R1", "CELL_LINE", 245, 249], ["\u03b11R2", "CELL_LINE", 250, 254], ["dS2dt", "CELL_LINE", 255, 260], ["bS2", "PROTEIN", 263, 266], ["\u03b2", "PROTEIN", 267, 268], ["S2I2N2", "PROTEIN", 268, 274], ["\u03b12R2", "CELL_LINE", 275, 279], ["\u03b11S2", "CELL_LINE", 280, 284], ["\u03b11S1", "CELL_LINE", 285, 289], ["\u03b3\u03b11S1I1N1", "CELL_LINE", 290, 299], ["dE2dt", "PROTEIN", 300, 305], ["\u03b2", "PROTEIN", 306, 307], ["S2I2N2", "PROTEIN", 307, 313], ["b", "PROTEIN", 314, 315], ["c", "PROTEIN", 316, 317], ["1E2", "PROTEIN", 319, 322], ["1E1", "PROTEIN", 324, 327], ["\u03b3\u03b11S1I1N1", "CELL_LINE", 328, 337], ["dI2dt", "PROTEIN", 338, 343], ["cE2", "PROTEIN", 344, 347], ["+d", "PROTEIN", 349, 351], ["\u03b11I2", "CELL_LINE", 352, 356], ["\u03b11I1", "CELL_LINE", 357, 361], ["dR2dt", "PROTEIN", 362, 367], ["dI2", "PROTEIN", 368, 371], ["+\u03b11", "PROTEIN", 373, 376], ["\u03b12R2", "CELL_LINE", 377, 381], ["\u03b11R1", "CELL_LINE", 382, 386], ["related infection", "PROBLEM", 30, 47], ["S1dt", "TEST", 124, 128], ["bS1", "TEST", 131, 134], ["S1I1N1", "TEST", 136, 142], ["d", "TEST", 168, 169], ["E1dt", "TEST", 169, 173], ["\u03b1", "TEST", 197, 198], ["cE1", "TEST", 212, 215], ["+d", "TEST", 217, 219], ["\u03b1", "TEST", 225, 226], ["dI1", "TEST", 236, 239], ["dS2dt", "TEST", 255, 260], ["a", "TEST", 261, 262], ["bS2", "TEST", 263, 266], ["S2I2N2", "TEST", 268, 274], ["1S2", "TEST", 281, 284], ["1S1", "TEST", 286, 289], ["\u03b1", "TEST", 291, 292], ["dE2dt", "TEST", 300, 305], ["S2I2N2", "TEST", 307, 313], ["\u03b1", "TEST", 329, 330], ["1S1I1N1", "TEST", 330, 337], ["dI2dt", "TEST", 338, 343], ["cE2", "TEST", 344, 347], ["\u03b1", "TEST", 357, 358], ["1I1", "TEST", 358, 361], ["dR2dt", "TEST", 362, 367], ["dI2", "TEST", 368, 371], ["A flow diagram", "TEST", 387, 401], ["infection", "OBSERVATION", 38, 47], ["flow diagram", "OBSERVATION", 389, 401], ["Fig", "OBSERVATION_MODIFIER", 430, 433]]], ["If initial conditions are set as Si(0)\u2a7e0, Ei(0)\u2a7e0, Ii(0)\u2a7e0 and Ri(0)\u2a7e0, it is easy to check that all solutions of (2.5) are nonnegative (that is Si(0)\u2a7e0, Ei(0)\u2a7e0, Ii(0)\u2a7e0 and Ri(0)\u2a7e0 for t>0, i=1,2) under the assumption 0\u2a7d\u03b3\u22641.", [["Si(0)\u2a7e0, Ei(0)\u2a7e0, Ii(0)", "CHEMICAL", 33, 56], ["Si(0)", "CHEMICAL", 145, 150], ["Ri", "TEST", 63, 65], ["Si", "TEST", 145, 147], ["Ei", "TEST", 154, 156], ["Ii", "TEST", 163, 165], ["\u2a7e", "TEST", 168, 169], ["Ri", "TEST", 175, 177], ["t", "TEST", 187, 188], ["the assumption", "TEST", 205, 219]]], ["Note that the last two terms in the first and fifth equations of (2.5) satisfy that\u03b11Si-\u03b3\u03b11SiIiNi\u2a7e0(i=1,2),for any Si\u2a7e0, Ei\u2a7e0, Ii\u2a7e0 and Ri\u2a7e0 when 0\u2a7d\u03b3\u22641.", [["1Si-\u03b3\u03b11SiIiNi\u2a7e0", "CHEMICAL", 84, 99], ["Si\u2a7e0", "CHEMICAL", 115, 119], ["Ei\u2a7e0", "CHEMICAL", 121, 125], ["Ii\u2a7e0", "CHEMICAL", 127, 131], ["Ri\u2a7e0", "CHEMICAL", 136, 140], ["1Si-\u03b3\u03b11SiIiNi\u2a7e0", "SIMPLE_CHEMICAL", 84, 99], ["i=1,2)", "SIMPLE_CHEMICAL", 100, 106], ["Si\u2a7e0", "SIMPLE_CHEMICAL", 115, 119], ["Ei\u2a7e0", "SIMPLE_CHEMICAL", 121, 125], ["Ii\u2a7e0", "SIMPLE_CHEMICAL", 127, 131], ["Si\u2a7e0", "PROTEIN", 115, 119], ["Ei\u2a7e0", "PROTEIN", 121, 125], ["Ii\u2a7e0", "PROTEIN", 127, 131], ["Ri\u2a7e0", "PROTEIN", 136, 140], ["0\u2a7d\u03b3\u22641", "PROTEIN", 146, 151]]], ["This is reasonable from a biological point of view, since the first term \u03b11Si represents the susceptible individuals leaving city i and the second term \u03b3\u03b11SiIiNi denotes individuals in \u03b11Si becoming infected during travel from city i to j.", [["\u03b11Si", "GENE_OR_GENE_PRODUCT", 73, 77], ["\u03b3\u03b11SiIiNi", "GENE_OR_GENE_PRODUCT", 152, 161], ["\u03b11Si", "GENE_OR_GENE_PRODUCT", 185, 189], ["\u03b11Si", "PROTEIN", 73, 77], ["\u03b11Si", "CELL_LINE", 185, 189], ["infected", "OBSERVATION", 199, 207]]], ["It is supposed that 0\u2a7d\u03b3\u22641.No individual travel ::: Analysis of the modelThe movement of individuals is neglected, this case \u03b11=0, then model (2.5) reduces to the SEIRS model:(3.2)dSdt=a-\u03b2SIN-bS+\u03b12R,dEdt=\u03b2SIN-b+cE,dIdt=cE-e+dI,dRdt=dI-b+\u03b12R.From biological considerations, we study (3.2) in the closed setD={(S,E,I,R)\u2208R+4|S\u2a7e0,E\u2a7e0,I\u2a7e0,R\u2a7e0,S+E+I+R\u2a7da/b},where R+4 denotes the non\u2013negative cone of R4 including its lower dimensional faces.", [["I", "CHEMICAL", 341, 342], ["R\u2a7da", "CHEMICAL", 343, 346], ["cE-e+dI", "SIMPLE_CHEMICAL", 218, 225], ["-b+\u03b12R", "GENE_OR_GENE_PRODUCT", 233, 239], ["R+4", "GENE_OR_GENE_PRODUCT", 356, 359], ["bS", "PROTEIN", 191, 193], ["cE", "CELL_LINE", 210, 212], ["cE", "PROTEIN", 218, 220], ["+dI", "CELL_LINE", 222, 225], ["Rdt", "PROTEIN", 227, 230], ["=dI", "PROTEIN", 230, 233], ["-b", "PROTEIN", 233, 235], ["\u03b12R", "PROTEIN", 236, 239], ["I", "PROTEIN", 341, 342], ["R\u2a7da", "PROTEIN", 343, 346], ["b}", "PROTEIN", 347, 349], ["R", "PROTEIN", 356, 357], ["R4", "PROTEIN", 393, 395], ["bS", "TEST", 191, 193], ["dEdt", "TEST", 198, 202], ["cE", "TEST", 210, 212], ["Idt", "TEST", 214, 217], ["cE", "TEST", 218, 220], ["Rdt", "TEST", 227, 230], ["S", "TEST", 321, 322], ["E\u2a7e", "TEST", 325, 327], ["I\u2a7e", "TEST", 329, 331], ["R\u2a7e", "TEST", 333, 335], ["movement", "OBSERVATION_MODIFIER", 76, 84], ["R4", "ANATOMY_MODIFIER", 393, 395], ["lower", "ANATOMY_MODIFIER", 410, 415]]], ["It can be verified that D is positively invariant with respect to (3.2).No individual travel ::: Analysis of the modelThe disease-free equilibrium, obtained by setting the right\u2013hand sides of equations in (3.2) to zero, is given by(3.3)P0(S0,0,0,0)=ab,0,0,0.The linear stability of P0 can be established using the next generation method [8], [10] by writing the right hand sides of second and third equation in (3.2) in term of two matrices F and V, where F is a matrix consisting of all term with \u03b2 and V is M-matrix consisting of the remaining transition term in two equations (it should be recalled that a matrix A is an M-matrix if and only if every off-diagonal entry of A is non-positive and the diagonal entries are all non-negative).", [["right hand", "ANATOMY", 362, 372], ["D", "SIMPLE_CHEMICAL", 24, 25], ["P0", "DNA", 282, 284], ["\u03b2", "PROTEIN", 498, 499], ["The disease", "PROBLEM", 118, 129], ["the next generation method", "TREATMENT", 310, 336], ["positively", "OBSERVATION_MODIFIER", 29, 39], ["invariant", "OBSERVATION_MODIFIER", 40, 49], ["disease", "OBSERVATION", 122, 129], ["free equilibrium", "OBSERVATION", 130, 146], ["linear", "OBSERVATION_MODIFIER", 262, 268], ["stability", "OBSERVATION_MODIFIER", 269, 278], ["right", "ANATOMY_MODIFIER", 362, 367], ["remaining", "OBSERVATION_MODIFIER", 536, 545], ["transition term", "OBSERVATION", 546, 561]]], ["That is, for the model (3.2), the next generation matrices F and V are given byF=0\u03b200andV=b+c0-ce+d.Using the next generation method, the local stability of disease-free equilibrium, P0, is based on whether or not \u03c1(FV-1)<1, where \u03c1 is the spectral radius.", [["c0", "PROTEIN", 92, 94], ["byF", "TEST", 77, 80], ["andV", "TEST", 85, 89], ["the next generation method", "TREATMENT", 106, 132], ["disease", "PROBLEM", 157, 164], ["FV", "TEST", 216, 218], ["disease", "OBSERVATION", 157, 164], ["spectral", "ANATOMY_MODIFIER", 240, 248], ["radius", "ANATOMY_MODIFIER", 249, 255]]], ["If \u03c1(FV-1)<1, then all eigenvalues of the linearized model have negative real parts, so that the disease-free equilibrium is locally asymptotically stable (LAS).", [["FV", "TEST", 5, 7], ["the disease-free equilibrium", "PROBLEM", 93, 121], ["negative", "OBSERVATION", 64, 72], ["disease", "OBSERVATION", 97, 104]]], ["For \u03c1(FV-1)>1, at least one of the eigenvalues of the linearization has positive real part, thus, the disease-free equilibrium is unstable in this case.", [["\u03c1(FV", "TEST", 4, 8], ["the disease-free equilibrium", "PROBLEM", 98, 126], ["positive", "OBSERVATION_MODIFIER", 72, 80], ["disease", "OBSERVATION", 102, 109], ["unstable", "OBSERVATION_MODIFIER", 130, 138]]], ["Let R0=\u03c1(FV-1), it is easy to show that(3.4)R0=\u03b2ce+db+c.Consequently, using Theorem 2 of [28], the following results is established.Theorem 3.1The disease-free equilibrium (DFE),P0, of the system (3.2) is locally asymptotically stable (LAS) ifR0<1and unstable ifR0>1.The quantity R0 in (3.4) is called the basic reproduction number of infection [2].", [["infection", "DISEASE", 335, 344], ["Let R0", "TEST", 0, 6], ["FV", "TEST", 9, 11], ["\u03b2ce", "TEST", 47, 50], ["Theorem", "TEST", 132, 139], ["The disease", "PROBLEM", 143, 154], ["unstable ifR0", "PROBLEM", 251, 264], ["infection", "PROBLEM", 335, 344], ["disease", "OBSERVATION", 147, 154], ["stable", "OBSERVATION_MODIFIER", 228, 234], ["quantity", "OBSERVATION_MODIFIER", 271, 279], ["R0", "OBSERVATION_MODIFIER", 280, 282], ["infection", "OBSERVATION", 335, 344]]], ["It is generally known that if R0<1, then the disease-free equilibrium is locally asymptotically stable (and the disease will be eradicate from the community if the initial sizes of the four state variables are within the vicinity of P0).", [["P0", "DNA", 233, 235], ["the disease-free equilibrium", "PROBLEM", 41, 69], ["the disease", "PROBLEM", 108, 119], ["disease", "OBSERVATION", 45, 52], ["stable", "OBSERVATION_MODIFIER", 96, 102]]], ["Therefore, in the event of an epidemic, the theoretical determination of conditions that can make R0 less than unity is of great public health interest.", [["epidemic", "OBSERVATION", 30, 38]]], ["If R0>1, the system (3.2) has an endemic equilibrium P\u2217(S\u2217,E\u2217,I\u2217,R\u2217), where(3.5)S=aR0-1b+\u03b12e+d\u03a9,(3.6)I=S\u2217+E\u2217+I\u2217+R\u2217=R0S\u2217.", [["R0S", "CHEMICAL", 115, 118], ["\u03b12e+d\u03a9", "SIMPLE_CHEMICAL", 89, 95], ["E\u2217", "PROTEIN", 106, 108], ["I", "PROTEIN", 109, 110], ["R0S", "PROTEIN", 115, 118], ["R0", "TEST", 3, 5], ["the system", "TEST", 9, 19], ["an endemic equilibrium", "TEST", 30, 52], ["S\u2217", "TEST", 56, 58], ["E\u2217", "TEST", 59, 61], ["S", "TEST", 80, 81], ["aR0", "TEST", 82, 85], ["I", "TEST", 101, 102], ["S\u2217", "TEST", 103, 105], ["E\u2217", "TEST", 106, 108], ["R\u2217", "TEST", 112, 114]]]], "PMC7097747": [["The threat of a worldwide epidemic of severe acute respiratory syndrome (SARS) prompted an unprecedented global effort to identify its cause.", [["acute respiratory syndrome", "DISEASE", 45, 71], ["SARS", "DISEASE", 73, 77], ["severe acute respiratory syndrome", "PROBLEM", 38, 71], ["SARS", "PROBLEM", 73, 77], ["worldwide", "OBSERVATION_MODIFIER", 16, 25], ["epidemic", "OBSERVATION_MODIFIER", 26, 34], ["severe", "OBSERVATION_MODIFIER", 38, 44], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["respiratory syndrome", "OBSERVATION", 51, 71]]], ["Within weeks, a novel human coronavirus was identified as the root of the disease and its genome was sequenced, allowing researchers to identify crucial proteins of the SARS coronavirus (SARS-CoV) against which thousands of compounds are being screened to find new drugs.", [["root", "ANATOMY", 62, 66], ["SARS coronavirus", "DISEASE", 169, 185], ["human", "ORGANISM", 22, 27], ["coronavirus", "ORGANISM", 28, 39], ["SARS coronavirus", "ORGANISM", 169, 185], ["SARS-CoV", "ORGANISM", 187, 195], ["human", "SPECIES", 22, 27], ["coronavirus", "SPECIES", 28, 39], ["human coronavirus", "SPECIES", 22, 39], ["SARS coronavirus", "SPECIES", 169, 185], ["SARS-CoV", "SPECIES", 187, 195], ["a novel human coronavirus", "PROBLEM", 14, 39], ["the disease", "PROBLEM", 70, 81], ["the SARS coronavirus", "PROBLEM", 165, 185], ["coronavirus", "OBSERVATION", 28, 39], ["disease", "OBSERVATION", 74, 81]]]], "PMC7106269": [["IntroductionSevere acute respiratory syndrome (SARS) was the first major outbreak of a newly emergent communicable disease in the 21st century, affecting over 8000 persons on multiple continents.1 Its appearance stirred an unprecedented coordinated effort to control transmission and morbidity, motivated by fears that local outbreaks might give rise to a major pandemic within months.", [["acute respiratory syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["communicable disease", "DISEASE", 102, 122], ["persons", "SPECIES", 164, 171], ["acute respiratory syndrome", "PROBLEM", 19, 45], ["SARS", "PROBLEM", 47, 51], ["a newly emergent communicable disease", "PROBLEM", 85, 122], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45]]], ["From the onset, mathematical modeling has proven to be a very useful tool for evaluating the impact of the control measures instigated.2, 3, 4", [["2, 3, 4", "CHEMICAL", 135, 142], ["the control measures", "TREATMENT", 103, 123]]]], "cdc7a84bccdf6a66bb0e2c902a818aa09ffabfc9": [["IntroductionTanreqing injection (TRQ) is a widely used classical compound herbal recipe for several decades in China.", [["Tanreqing", "CHEMICAL", 12, 21], ["TRQ", "CHEMICAL", 33, 36], ["Tanreqing", "SIMPLE_CHEMICAL", 12, 21], ["IntroductionTanreqing injection", "TREATMENT", 0, 31], ["classical compound herbal recipe", "TREATMENT", 55, 87]]], ["It is composed of water soluble natural extractives from five crude herbal plants, namely, Radix Scutellariae Baicalensis, Fel Selenarcti, Cornu Naemorhedi, Flos Lonicerae, and Forsythiae Fructus [1] , and is a mixture of about 12 main active pharmaceutical ingredients including chlorogenic acid, caffeic acid, luteoloside, forsythiaside, forsythin, forsythigenol, baicalin, wogonoside, wogonin, salidroside, and ursodeoxycholic acid [2] .", [["chlorogenic acid", "CHEMICAL", 280, 296], ["caffeic acid", "CHEMICAL", 298, 310], ["luteoloside", "CHEMICAL", 312, 323], ["forsythiaside", "CHEMICAL", 325, 338], ["forsythin", "CHEMICAL", 340, 349], ["forsythigenol", "CHEMICAL", 351, 364], ["baicalin", "CHEMICAL", 366, 374], ["wogonoside", "CHEMICAL", 376, 386], ["wogonin", "CHEMICAL", 388, 395], ["salidroside", "CHEMICAL", 397, 408], ["ursodeoxycholic acid", "CHEMICAL", 414, 434], ["chlorogenic acid", "CHEMICAL", 280, 296], ["caffeic acid", "CHEMICAL", 298, 310], ["luteoloside", "CHEMICAL", 312, 323], ["forsythiaside", "CHEMICAL", 325, 338], ["forsythin", "CHEMICAL", 340, 349], ["forsythigenol", "CHEMICAL", 351, 364], ["baicalin", "CHEMICAL", 366, 374], ["wogonoside", "CHEMICAL", 376, 386], ["wogonin", "CHEMICAL", 388, 395], ["salidroside", "CHEMICAL", 397, 408], ["ursodeoxycholic acid", "CHEMICAL", 414, 434], ["Fel Selenarcti", "ORGANISM", 123, 137], ["Cornu Naemorhedi", "ORGANISM", 139, 155], ["Flos Lonicerae", "ORGANISM", 157, 171], ["chlorogenic acid", "SIMPLE_CHEMICAL", 280, 296], ["caffeic acid", "SIMPLE_CHEMICAL", 298, 310], ["luteoloside", "SIMPLE_CHEMICAL", 312, 323], ["forsythiaside", "SIMPLE_CHEMICAL", 325, 338], ["forsythin", "SIMPLE_CHEMICAL", 340, 349], ["forsythigenol", "SIMPLE_CHEMICAL", 351, 364], ["baicalin", "SIMPLE_CHEMICAL", 366, 374], ["wogonoside", "SIMPLE_CHEMICAL", 376, 386], ["wogonin", "SIMPLE_CHEMICAL", 388, 395], ["salidroside", "SIMPLE_CHEMICAL", 397, 408], ["ursodeoxycholic acid", "SIMPLE_CHEMICAL", 414, 434], ["Scutellariae Baicalensis", "SPECIES", 97, 121], ["Radix Scutellariae Baicalensis", "SPECIES", 91, 121], ["water soluble natural extractives", "TREATMENT", 18, 51], ["five crude herbal plants", "TREATMENT", 57, 81], ["Radix Scutellariae Baicalensis", "TREATMENT", 91, 121], ["Flos Lonicerae", "TREATMENT", 157, 171], ["Forsythiae Fructus", "PROBLEM", 177, 195], ["chlorogenic acid", "TREATMENT", 280, 296], ["caffeic acid", "TREATMENT", 298, 310], ["luteoloside", "TREATMENT", 312, 323], ["forsythiaside", "TREATMENT", 325, 338], ["forsythin", "TREATMENT", 340, 349], ["forsythigenol", "TREATMENT", 351, 364], ["baicalin", "TREATMENT", 366, 374], ["wogonoside", "TREATMENT", 376, 386], ["wogonin", "TREATMENT", 388, 395], ["salidroside", "TREATMENT", 397, 408], ["ursodeoxycholic acid", "TREATMENT", 414, 434], ["Radix Scutellariae", "ANATOMY", 91, 109], ["Fel Selenarcti", "OBSERVATION", 123, 137], ["pharmaceutical ingredients", "OBSERVATION", 243, 269]]], ["Clinical evidence has supported the minimal toxicity and side effects of TRQ [3, 4] .", [["toxicity", "DISEASE", 44, 52], ["TRQ", "CHEMICAL", 73, 76], ["TRQ", "CHEMICAL", 73, 76], ["the minimal toxicity", "PROBLEM", 32, 52], ["minimal", "OBSERVATION_MODIFIER", 36, 43], ["toxicity", "OBSERVATION", 44, 52]]], ["With its predominant antibacterial and antiviral actions being proved by modern pharmacologic studies [5, 6] , TRQ is predominately used for acute inflammatory lung diseases including acute upper respiratory tract infections [7] , pneumonia [3, 8, 9] , acute COPD [4, 10, 11] , SARS (Serious Acute Respiration Symptom) [12, 13] , A/H1N1 flu [14, 15] , A/H7N9 flu [16] , and the recently mentioned Middle East Respiratory Syndrome (National Health and Family Planning Commission of China, http://www.nhfpc.gov.cn/).IntroductionStimulation of MAPKs and IKK/I B/NF-B pathways is common phenomena in many types of inflammation response.", [["lung", "ANATOMY", 160, 164], ["upper respiratory tract", "ANATOMY", 190, 213], ["TRQ", "CHEMICAL", 111, 114], ["lung diseases", "DISEASE", 160, 173], ["upper respiratory tract infections", "DISEASE", 190, 224], ["pneumonia", "DISEASE", 231, 240], ["COPD", "DISEASE", 259, 263], ["SARS", "DISEASE", 278, 282], ["Middle East Respiratory Syndrome", "DISEASE", 397, 429], ["inflammation", "DISEASE", 610, 622], ["TRQ", "SIMPLE_CHEMICAL", 111, 114], ["lung", "ORGAN", 160, 164], ["MAPKs", "GENE_OR_GENE_PRODUCT", 541, 546], ["IKK/I B", "GENE_OR_GENE_PRODUCT", 551, 558], ["NF-B", "GENE_OR_GENE_PRODUCT", 559, 563], ["inflammation", "PATHOLOGICAL_FORMATION", 610, 622], ["MAPKs", "PROTEIN", 541, 546], ["IKK", "PROTEIN", 551, 554], ["I B", "PROTEIN", 555, 558], ["NF-B", "PROTEIN", 559, 563], ["H1N1 flu", "SPECIES", 332, 340], ["A/H1N1 flu", "SPECIES", 330, 340], ["A/H7N9 flu", "SPECIES", 352, 362], ["its predominant antibacterial", "TREATMENT", 5, 34], ["antiviral actions", "TREATMENT", 39, 56], ["modern pharmacologic studies", "TEST", 73, 101], ["TRQ", "TREATMENT", 111, 114], ["acute inflammatory lung diseases", "PROBLEM", 141, 173], ["acute upper respiratory tract infections", "PROBLEM", 184, 224], ["pneumonia", "PROBLEM", 231, 240], ["acute COPD", "PROBLEM", 253, 263], ["SARS (Serious Acute Respiration Symptom", "PROBLEM", 278, 317], ["A/H1N1 flu", "TEST", 330, 340], ["A/H7N9 flu", "TEST", 352, 362], ["Middle East Respiratory Syndrome", "PROBLEM", 397, 429], ["MAPKs", "TEST", 541, 546], ["IKK", "TEST", 551, 554], ["common phenomena", "PROBLEM", 576, 592], ["inflammation response", "PROBLEM", 610, 631], ["predominant", "OBSERVATION_MODIFIER", 9, 20], ["antibacterial", "OBSERVATION_MODIFIER", 21, 34], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["inflammatory", "OBSERVATION_MODIFIER", 147, 159], ["lung", "ANATOMY", 160, 164], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["upper", "ANATOMY_MODIFIER", 190, 195], ["respiratory tract", "ANATOMY", 196, 213], ["pneumonia", "OBSERVATION", 231, 240], ["acute", "OBSERVATION_MODIFIER", 253, 258], ["COPD", "OBSERVATION", 259, 263], ["Middle", "ANATOMY_MODIFIER", 397, 403], ["Respiratory Syndrome", "OBSERVATION", 409, 429], ["common phenomena", "OBSERVATION", 576, 592], ["inflammation", "OBSERVATION", 610, 622]]], ["Targeting the pathways has been considered as an effective therapeutic approach to mitigate progression of numbers of inflammatory disorders, such as the classical neutrophil-predominant airway inflammation induced by Lipopolysaccharide (LPS) [17] .", [["neutrophil", "ANATOMY", 164, 174], ["airway", "ANATOMY", 187, 193], ["inflammatory disorders", "DISEASE", 118, 140], ["inflammation", "DISEASE", 194, 206], ["Lipopolysaccharide", "CHEMICAL", 218, 236], ["LPS", "CHEMICAL", 238, 241], ["neutrophil", "CELL", 164, 174], ["airway", "MULTI-TISSUE_STRUCTURE", 187, 193], ["Lipopolysaccharide", "SIMPLE_CHEMICAL", 218, 236], ["LPS", "SIMPLE_CHEMICAL", 238, 241], ["an effective therapeutic approach", "TREATMENT", 46, 79], ["inflammatory disorders", "PROBLEM", 118, 140], ["the classical neutrophil", "TEST", 150, 174], ["airway inflammation", "PROBLEM", 187, 206], ["inflammatory", "OBSERVATION_MODIFIER", 118, 130], ["predominant", "OBSERVATION_MODIFIER", 175, 186], ["airway", "ANATOMY", 187, 193], ["inflammation", "OBSERVATION", 194, 206]]], ["The involvement of the ubiquitous nuclear transcription factor NF-B in the pathogenesis of the LPS-induced inflammatory response has been well recognized [18] .", [["nuclear", "ANATOMY", 34, 41], ["LPS", "CHEMICAL", 95, 98], ["nuclear", "CELLULAR_COMPONENT", 34, 41], ["NF-B", "GENE_OR_GENE_PRODUCT", 63, 67], ["LPS", "SIMPLE_CHEMICAL", 95, 98], ["ubiquitous nuclear transcription factor NF-B", "PROTEIN", 23, 67], ["the LPS", "PROBLEM", 91, 98], ["inflammatory response", "PROBLEM", 107, 128], ["inflammatory", "OBSERVATION", 107, 119]]], ["LPS liberates and activates NF-B mostly through I B kinase-(IKK-) dependent phosphorylation and 2 Evidence-Based Complementary and Alternative Medicine subsequent degradation of I B- [19] .", [["LPS", "CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["NF-B", "GENE_OR_GENE_PRODUCT", 28, 32], ["I B kinase", "GENE_OR_GENE_PRODUCT", 48, 58], ["IKK", "GENE_OR_GENE_PRODUCT", 60, 63], ["NF-B", "PROTEIN", 28, 32], ["I B kinase", "PROTEIN", 48, 58], ["IKK", "PROTEIN", 60, 63], ["I B", "PROTEIN", 178, 181], ["LPS liberates", "TEST", 0, 13], ["activates NF", "TEST", 18, 30], ["I B kinase", "TEST", 48, 58], ["IKK", "TEST", 60, 63], ["dependent phosphorylation", "PROBLEM", 66, 91]]], ["The liberated NF-B dimers are crucial for regulating transcription of diverse genes coding for cytokines including TNF-, IL-1 , IL-6, and IL-8 [20, 21] , which together contribute to the upregulation of inflammatory responses.", [["NF-B", "GENE_OR_GENE_PRODUCT", 14, 18], ["TNF", "GENE_OR_GENE_PRODUCT", 115, 118], ["IL-1", "GENE_OR_GENE_PRODUCT", 121, 125], ["IL-6", "GENE_OR_GENE_PRODUCT", 128, 132], ["IL-8", "GENE_OR_GENE_PRODUCT", 138, 142], ["20, 21", "SIMPLE_CHEMICAL", 144, 150], ["NF-B dimers", "PROTEIN", 14, 25], ["cytokines", "PROTEIN", 95, 104], ["TNF", "PROTEIN", 115, 118], ["cytokines", "TEST", 95, 104], ["TNF", "TEST", 115, 118], ["IL", "TEST", 121, 123], ["IL", "TEST", 128, 130], ["IL", "TEST", 138, 140], ["inflammatory responses", "PROBLEM", 203, 225], ["inflammatory", "OBSERVATION", 203, 215]]], ["Similar to IKK/I B-/NF-B pathway, the mitogen-activated protein kinase (MAPK) pathway is also activated during an LPS-challenged inflammatory condition [22] .", [["LPS", "CHEMICAL", 114, 117], ["IKK/I B", "GENE_OR_GENE_PRODUCT", 11, 18], ["NF-B", "GENE_OR_GENE_PRODUCT", 20, 24], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 38, 70], ["MAPK", "GENE_OR_GENE_PRODUCT", 72, 76], ["LPS", "SIMPLE_CHEMICAL", 114, 117], ["IKK", "PROTEIN", 11, 14], ["I B", "PROTEIN", 15, 18], ["NF", "PROTEIN", 20, 22], ["mitogen-activated protein kinase", "PROTEIN", 38, 70], ["MAPK", "PROTEIN", 72, 76], ["IKK", "TEST", 11, 14], ["B", "TEST", 17, 18], ["the mitogen", "TEST", 34, 45], ["activated protein kinase (MAPK) pathway", "TEST", 46, 85], ["an LPS", "TEST", 111, 117], ["challenged inflammatory condition", "PROBLEM", 118, 151], ["inflammatory", "OBSERVATION_MODIFIER", 129, 141]]], ["The three subfamilies, extracellular regulated kinases (ERK1/2), c-Jun N-terminal kinases (JNK), and p38 MAP kinases, have been implicated in the release of proinflammatory cytokines [23, 24] and the activation of NF-B [25] .IntroductionPrior studies have given consistent results on the ability of TRQ to alleviate LPS-induced inflammation through multiple actions including scavenging excessive oxygen free radicals, suppressing the activation and expression of NF-B, decreasing serum NO level, and downregulating the expression of Caspase-3 and Bcl-2/Fas gene [12, 13, [26] [27] [28] .", [["serum", "ANATOMY", 481, 486], ["TRQ", "CHEMICAL", 299, 302], ["LPS", "CHEMICAL", 316, 319], ["inflammation", "DISEASE", 328, 340], ["oxygen", "CHEMICAL", 397, 403], ["NO", "CHEMICAL", 487, 489], ["N", "CHEMICAL", 71, 72], ["oxygen", "CHEMICAL", 397, 403], ["NO", "CHEMICAL", 487, 489], ["extracellular regulated kinases", "GENE_OR_GENE_PRODUCT", 23, 54], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 56, 62], ["c-Jun N-terminal kinases", "GENE_OR_GENE_PRODUCT", 65, 89], ["JNK", "GENE_OR_GENE_PRODUCT", 91, 94], ["p38 MAP kinases", "GENE_OR_GENE_PRODUCT", 101, 116], ["NF-B", "GENE_OR_GENE_PRODUCT", 214, 218], ["TRQ", "SIMPLE_CHEMICAL", 299, 302], ["LPS", "SIMPLE_CHEMICAL", 316, 319], ["oxygen", "SIMPLE_CHEMICAL", 397, 403], ["NF-B", "GENE_OR_GENE_PRODUCT", 464, 468], ["serum", "ORGANISM_SUBSTANCE", 481, 486], ["NO", "SIMPLE_CHEMICAL", 487, 489], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 534, 543], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 548, 553], ["Fas", "GENE_OR_GENE_PRODUCT", 554, 557], ["12, 13, [26] [27] [28]", "SIMPLE_CHEMICAL", 564, 586], ["extracellular regulated kinases", "PROTEIN", 23, 54], ["ERK1", "PROTEIN", 56, 60], ["c-Jun N-terminal kinases", "PROTEIN", 65, 89], ["JNK", "PROTEIN", 91, 94], ["p38 MAP kinases", "PROTEIN", 101, 116], ["proinflammatory cytokines", "PROTEIN", 157, 182], ["NF", "PROTEIN", 214, 216], ["NF-B", "PROTEIN", 464, 468], ["Caspase-3", "PROTEIN", 534, 543], ["Fas gene", "DNA", 554, 562], ["extracellular regulated kinases", "TEST", 23, 54], ["ERK1", "TEST", 56, 60], ["c-Jun N-terminal kinases", "TEST", 65, 89], ["p38 MAP kinases", "TEST", 101, 116], ["proinflammatory cytokines", "TEST", 157, 182], ["the activation of NF", "TEST", 196, 216], ["Prior studies", "TEST", 237, 250], ["TRQ", "TREATMENT", 299, 302], ["LPS", "PROBLEM", 316, 319], ["inflammation", "PROBLEM", 328, 340], ["multiple actions", "TREATMENT", 349, 365], ["scavenging excessive oxygen free radicals", "TREATMENT", 376, 417], ["NF", "TEST", 464, 466], ["decreasing serum NO level", "PROBLEM", 470, 495], ["Caspase", "TEST", 534, 541], ["Bcl", "TEST", 548, 551], ["Fas gene", "TEST", 554, 562], ["inflammation", "OBSERVATION", 328, 340]]], ["Since MAPKs and NF-B pathway has been highlighted during the LPSinduced inflammatory disorders, we hypothesize that protective actions of TRQ are likely, at least partially, due to its regulations on the two pathways.", [["inflammatory disorders", "DISEASE", 72, 94], ["MAPKs", "GENE_OR_GENE_PRODUCT", 6, 11], ["NF-B", "GENE_OR_GENE_PRODUCT", 16, 20], ["TRQ", "GENE_OR_GENE_PRODUCT", 138, 141], ["MAPKs", "PROTEIN", 6, 11], ["NF-B", "PROTEIN", 16, 20], ["TRQ", "PROTEIN", 138, 141], ["MAPKs", "TEST", 6, 11], ["the LPSinduced inflammatory disorders", "PROBLEM", 57, 94]]], ["In the present study, we attempted to elucidate the anti-inflammatory potential of TRQ on LPS-induced airway inflammation in rat models by investigating the pivotal molecular basis involved in the two classical signaling pathways.Animals and Drugs.", [["airway", "ANATOMY", 102, 108], ["TRQ", "CHEMICAL", 83, 86], ["LPS", "CHEMICAL", 90, 93], ["airway inflammation", "DISEASE", 102, 121], ["TRQ", "SIMPLE_CHEMICAL", 83, 86], ["LPS", "SIMPLE_CHEMICAL", 90, 93], ["airway", "MULTI-TISSUE_STRUCTURE", 102, 108], ["rat", "ORGANISM", 125, 128], ["rat", "SPECIES", 125, 128], ["TRQ", "PROBLEM", 83, 86], ["LPS", "TREATMENT", 90, 93], ["airway inflammation in rat models", "PROBLEM", 102, 135], ["airway", "ANATOMY", 102, 108], ["inflammation", "OBSERVATION", 109, 121]]], ["75 male specific-pathogen-free (SPF) grade SD rats (10-12 weeks old, initially weighing 180-220 g) were raised under SPF conditions on a 12 h light/dark cycle at a temperature of 22 \u00b1 2 \u2218 C with free access to food and water.", [["rats", "ORGANISM", 46, 50], ["rats", "SPECIES", 46, 50], ["grade SD rats", "PROBLEM", 37, 50], ["a temperature", "TEST", 162, 175]]], ["SD rats used for the experiment were obtained from Jianyang Animal and Science Co., Ltd.", [["SD rats", "ORGANISM", 0, 7], ["rats", "SPECIES", 3, 7]]], ["Tanreqing injection was purchased from Shanghai Kai Bao Pharmaceutical Co., Ltd.", [["Tanreqing", "CHEMICAL", 0, 9], ["Tanreqing", "SIMPLE_CHEMICAL", 0, 9], ["Tanreqing injection", "TREATMENT", 0, 19]]], ["(Shanghai, China). reported as optimal time points to observe the anti-inflammatory activity of TRQ [28] , rats were intraperitoneally anaesthetised with 4% sodium pentobarbital (40 mg/kg) and then exsanguinated from the abdominal aorta.", [["abdominal aorta", "ANATOMY", 221, 236], ["TRQ", "CHEMICAL", 96, 99], ["sodium pentobarbital", "CHEMICAL", 157, 177], ["sodium pentobarbital", "CHEMICAL", 157, 177], ["TRQ", "SIMPLE_CHEMICAL", 96, 99], ["rats", "ORGANISM", 107, 111], ["sodium", "SIMPLE_CHEMICAL", 157, 163], ["pentobarbital", "SIMPLE_CHEMICAL", 164, 177], ["abdominal aorta", "MULTI-TISSUE_STRUCTURE", 221, 236], ["rats", "SPECIES", 107, 111], ["the anti-inflammatory activity of TRQ", "TREATMENT", 62, 99], ["4% sodium pentobarbital", "TREATMENT", 154, 177], ["abdominal aorta", "ANATOMY", 221, 236]]], ["The chest cavity was opened by a midline incision to expose and cannulate the trachea.", [["chest cavity", "ANATOMY", 4, 16], ["trachea", "ANATOMY", 78, 85], ["chest cavity", "MULTI-TISSUE_STRUCTURE", 4, 16], ["trachea", "ORGAN", 78, 85], ["a midline incision", "TREATMENT", 31, 49], ["chest cavity", "ANATOMY", 4, 16], ["midline", "OBSERVATION_MODIFIER", 33, 40], ["incision", "OBSERVATION", 41, 49], ["trachea", "ANATOMY", 78, 85]]], ["The right lobe of the lung was ligated at the hilus of the lung, and the left lung was immediately lavaged three times with 2 mL ice sterile saline through the tracheostomy tube.", [["right lobe", "ANATOMY", 4, 14], ["lung", "ANATOMY", 22, 26], ["hilus", "ANATOMY", 46, 51], ["lung", "ANATOMY", 59, 63], ["left lung", "ANATOMY", 73, 82], ["right lobe", "MULTI-TISSUE_STRUCTURE", 4, 14], ["lung", "ORGAN", 22, 26], ["lung", "ORGAN", 59, 63], ["lung", "ORGAN", 78, 82], ["tube", "TISSUE", 173, 177], ["2 mL ice sterile saline", "TREATMENT", 124, 147], ["the tracheostomy tube", "TREATMENT", 156, 177], ["right", "ANATOMY_MODIFIER", 4, 9], ["lobe", "ANATOMY_MODIFIER", 10, 14], ["lung", "ANATOMY", 22, 26], ["ligated", "OBSERVATION", 31, 38], ["hilus", "ANATOMY_MODIFIER", 46, 51], ["lung", "ANATOMY", 59, 63], ["left", "ANATOMY_MODIFIER", 73, 77], ["lung", "ANATOMY", 78, 82], ["lavaged", "OBSERVATION", 99, 106], ["tracheostomy tube", "OBSERVATION", 160, 177]]], ["Fluid recovery was always above 90% of the original volume.", [["Fluid recovery", "TEST", 0, 14], ["volume", "OBSERVATION_MODIFIER", 52, 58]]], ["Pooled BALF samples were centrifuged and the supernatants were collected and stored at \u221280 \u2218 C for cytokine ELISA.", [["BALF samples", "ANATOMY", 7, 19], ["supernatants", "ANATOMY", 45, 57], ["BALF samples", "ORGANISM_SUBSTANCE", 7, 19], ["cytokine", "PROTEIN", 99, 107], ["Pooled BALF samples", "TEST", 0, 19], ["the supernatants", "TEST", 41, 57], ["cytokine ELISA", "TEST", 99, 113]]], ["The deposited cells were resuspended for total leukocyte count and the differential leukocyte classification, counting 500 cells from each rat.", [["cells", "ANATOMY", 14, 19], ["leukocyte", "ANATOMY", 47, 56], ["leukocyte", "ANATOMY", 84, 93], ["cells", "ANATOMY", 123, 128], ["cells", "CELL", 14, 19], ["leukocyte", "CELL", 47, 56], ["leukocyte", "CELL", 84, 93], ["cells", "CELL", 123, 128], ["rat", "ORGANISM", 139, 142], ["rat", "SPECIES", 139, 142], ["rat", "SPECIES", 139, 142], ["The deposited cells", "PROBLEM", 0, 19], ["total leukocyte count", "TEST", 41, 62], ["the differential leukocyte classification", "TEST", 67, 108], ["differential", "OBSERVATION_MODIFIER", 71, 83], ["leukocyte classification", "OBSERVATION", 84, 108]]], ["An experienced investigator who was independent of experimental operations did all the enumerations based on standard morphological criteria.", [["experimental operations", "TREATMENT", 51, 74]]], ["The right middle lobe of the lung was preserved in 4% paraformaldehyde for 24 h at 4 \u2218 C for histology and histochemical studies.", [["right middle lobe", "ANATOMY", 4, 21], ["lung", "ANATOMY", 29, 33], ["paraformaldehyde", "CHEMICAL", 54, 70], ["middle lobe", "MULTI-TISSUE_STRUCTURE", 10, 21], ["lung", "ORGAN", 29, 33], ["paraformaldehyde", "SIMPLE_CHEMICAL", 54, 70], ["histology", "TEST", 93, 102], ["histochemical studies", "TEST", 107, 128], ["right middle lobe", "ANATOMY", 4, 21], ["lung", "ANATOMY", 29, 33], ["preserved", "OBSERVATION", 38, 47]]], ["The right posterior lobe of the lung was snap preserved in liquid nitrogen and stored at \u221280 \u2218 C for mRNA and protein analysis.Enzyme-Linked Immunosorbent Assay (ELISA).Quantitation of cytokines in the supernatants of undiluted BALF and lung homogenate was determined by ELISA technique, according to the manufacturer's instructions.", [["right posterior lobe", "ANATOMY", 4, 24], ["lung", "ANATOMY", 32, 36], ["supernatants", "ANATOMY", 202, 214], ["BALF", "ANATOMY", 228, 232], ["lung homogenate", "ANATOMY", 237, 252], ["nitrogen", "CHEMICAL", 66, 74], ["posterior lobe", "MULTI-TISSUE_STRUCTURE", 10, 24], ["lung", "ORGAN", 32, 36], ["BALF", "CELL", 228, 232], ["lung homogenate", "ORGANISM_SUBSTANCE", 237, 252], ["mRNA", "RNA", 101, 105], ["cytokines", "PROTEIN", 185, 194], ["BALF", "CELL_TYPE", 228, 232], ["liquid nitrogen", "TREATMENT", 59, 74], ["mRNA and protein analysis", "TEST", 101, 126], ["Enzyme", "TEST", 127, 133], ["Immunosorbent Assay", "TEST", 141, 160], ["Quantitation of cytokines", "PROBLEM", 169, 194], ["the supernatants of undiluted BALF", "TEST", 198, 232], ["lung homogenate", "TEST", 237, 252], ["ELISA technique", "TEST", 271, 286], ["right", "ANATOMY_MODIFIER", 4, 9], ["posterior", "ANATOMY_MODIFIER", 10, 19], ["lobe", "ANATOMY_MODIFIER", 20, 24], ["lung", "ANATOMY", 32, 36], ["snap preserved", "OBSERVATION", 41, 55], ["liquid nitrogen", "OBSERVATION", 59, 74], ["cytokines", "OBSERVATION", 185, 194], ["lung", "ANATOMY", 237, 241]]], ["Three replicates were carried out for each of the different treatments.", [["the different treatments", "TREATMENT", 46, 70]]], ["Rat IL-1 ELISA kit was purchased from Shanghai ExCell Biology Company (Shanghai, China) (Cat.", [["IL-1", "GENE_OR_GENE_PRODUCT", 4, 8], ["Rat", "SPECIES", 0, 3], ["Rat IL", "TEST", 0, 6]]], ["Number: ER008-96; Sensitivity: 15 pg/mL; Assay Range: 31.25\u223c2000 pg/mL).", [["ER008", "TEST", 8, 13], ["Sensitivity", "TEST", 18, 29], ["Assay Range", "TEST", 41, 52]]], ["Rat CXCL-1/CINC-1 ELISA kit (rat analogue of human IL-8) (Cat.", [["CXCL-1", "GENE_OR_GENE_PRODUCT", 4, 10], ["CINC-1", "GENE_OR_GENE_PRODUCT", 11, 17], ["rat", "ORGANISM", 29, 32], ["human", "ORGANISM", 45, 50], ["IL-8", "GENE_OR_GENE_PRODUCT", 51, 55], ["Cat", "GENE_OR_GENE_PRODUCT", 58, 61], ["Rat CXCL-1/CINC-1 ELISA kit", "PROTEIN", 0, 27], ["human IL-8", "PROTEIN", 45, 55], ["Cat", "PROTEIN", 58, 61], ["Rat", "SPECIES", 0, 3], ["rat", "SPECIES", 29, 32], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["Rat", "TEST", 0, 3], ["CXCL", "TEST", 4, 8], ["CINC", "TEST", 11, 15], ["ELISA kit", "TEST", 18, 27], ["(rat analogue of human IL", "TREATMENT", 28, 53]]], ["Number: RCN100; Sensitivity: 1.3 pg/mL; Assay Range: 7.8\u223c500 pg/mL), Rat IL-6 ELISA kit (Cat.", [["IL-6", "GENE_OR_GENE_PRODUCT", 73, 77], ["IL", "PROTEIN", 73, 75], ["Sensitivity", "TEST", 16, 27], ["Assay Range", "TEST", 40, 51], ["Rat IL", "TEST", 69, 75]]], ["Number: R6000B; Sensitivity: 0.7 pg/mL; Assay Range: 3.1\u223c700 pg/mL), and Rat TNF-ELISA kit (Cat.", [["TNF", "GENE_OR_GENE_PRODUCT", 77, 80], ["Cat", "GENE_OR_GENE_PRODUCT", 92, 95], ["TNF", "PROTEIN", 77, 80], ["Sensitivity", "TEST", 16, 27], ["Assay Range", "TEST", 40, 51], ["Rat TNF", "TEST", 73, 80]]], ["Number: RTA00; Sensitivity: 5 pg/mL; Assay Range: 12.5\u223c800 pg/mL) were purchased from USA R&D Systems (Minneapolis, MN, USA).", [["RTA00", "TEST", 8, 13], ["Sensitivity", "TEST", 15, 26], ["Assay Range", "TEST", 37, 48]]], ["Samples were applied to wells of 96-well polystyrene microtiter plates that were precoated with specific monoclonal antibodies before incubation, and then wells were washed five times, followed by incubation with the respective HRP-conjugated polyclonal antibodies.", [["Samples", "ANATOMY", 0, 7], ["polystyrene", "CHEMICAL", 41, 52], ["HRP", "GENE_OR_GENE_PRODUCT", 228, 231], ["monoclonal antibodies", "PROTEIN", 105, 126], ["HRP-conjugated polyclonal antibodies", "PROTEIN", 228, 264], ["Samples", "TEST", 0, 7], ["well polystyrene microtiter plates", "TREATMENT", 36, 70], ["specific monoclonal antibodies", "TREATMENT", 96, 126], ["the respective HRP", "TEST", 213, 231]]], ["After the repeat of aspiration and washing steps, the substrate solutions and stop solutions were added one after another.", [["aspiration", "TREATMENT", 20, 30], ["washing steps", "TREATMENT", 35, 48], ["the substrate solutions", "TREATMENT", 50, 73], ["stop solutions", "TREATMENT", 78, 92], ["aspiration", "OBSERVATION", 20, 30]]], ["The optical density of each well was determined at 450 nm using a microplate reader (Bio-Rad, Richmond, CA) within 30 minutes.Histopathology and Immunohistochemistry.Fixed specimen was rinsed in PBS, dehydrated, and embedded in paraffin according to standard procedures and serially sectioned at 4 micrometer.", [["specimen", "ANATOMY", 172, 180], ["paraffin", "CHEMICAL", 228, 236], ["a microplate", "TEST", 64, 76], ["Histopathology", "TEST", 126, 140], ["Immunohistochemistry", "TEST", 145, 165], ["Fixed specimen", "TEST", 166, 180], ["dehydrated", "PROBLEM", 200, 210], ["paraffin", "TREATMENT", 228, 236], ["standard procedures", "TEST", 250, 269], ["optical", "OBSERVATION_MODIFIER", 4, 11], ["density", "OBSERVATION", 12, 19]]], ["Then sections were stained with haematoxylin and eosin (H&E) and Alcian blue (AB)/periodic acid-Schiff (PAS) for general morphology evaluation, which were subsequently practiced by a pathologist who was blinded to group allocation under a light microscopy.", [["sections", "ANATOMY", 5, 13], ["Alcian blue", "CHEMICAL", 65, 76], ["acid-Schiff", "CHEMICAL", 91, 102], ["haematoxylin", "CHEMICAL", 32, 44], ["eosin", "CHEMICAL", 49, 54], ["Alcian blue", "CHEMICAL", 65, 76], ["acid-Schiff", "CHEMICAL", 91, 102], ["haematoxylin", "SIMPLE_CHEMICAL", 32, 44], ["eosin", "SIMPLE_CHEMICAL", 49, 54], ["H&E", "SIMPLE_CHEMICAL", 56, 59], ["Alcian blue", "SIMPLE_CHEMICAL", 65, 76], ["periodic acid-Schiff", "SIMPLE_CHEMICAL", 82, 102], ["haematoxylin", "TREATMENT", 32, 44], ["eosin", "TEST", 49, 54], ["Alcian blue", "TEST", 65, 76], ["periodic acid-Schiff (PAS", "TREATMENT", 82, 107], ["general morphology evaluation", "TEST", 113, 142], ["a light microscopy", "TEST", 237, 255]]], ["The evaluation of inflammation lesions was performed using a subjective numeric scale ranging from 0 to 10, which comprises three scoring parts including peribronchial/peribronchiolar Evidence-Based Complementary and Alternative Medicine 3 inflammation score, perivascular inflammation score, and alveolar inflammation score.", [["inflammation lesions", "ANATOMY", 18, 38], ["peribronchial", "ANATOMY", 154, 167], ["perivascular", "ANATOMY", 260, 272], ["alveolar", "ANATOMY", 297, 305], ["inflammation", "DISEASE", 18, 30], ["inflammation", "DISEASE", 240, 252], ["inflammation lesions", "CANCER", 18, 38], ["perivascular", "TISSUE", 260, 272], ["alveolar", "TISSUE", 297, 305], ["The evaluation", "TEST", 0, 14], ["inflammation lesions", "PROBLEM", 18, 38], ["a subjective numeric scale", "TEST", 59, 85], ["peribronchial/peribronchiolar Evidence", "PROBLEM", 154, 192], ["Alternative Medicine 3 inflammation score", "PROBLEM", 217, 258], ["perivascular inflammation score", "PROBLEM", 260, 291], ["alveolar inflammation score", "PROBLEM", 297, 324], ["inflammation", "OBSERVATION_MODIFIER", 18, 30], ["lesions", "OBSERVATION", 31, 38], ["peribronchial", "ANATOMY", 154, 167], ["peribronchiolar", "ANATOMY_MODIFIER", 168, 183], ["perivascular", "ANATOMY_MODIFIER", 260, 272], ["inflammation", "OBSERVATION", 273, 285], ["alveolar", "ANATOMY_MODIFIER", 297, 305], ["inflammation", "OBSERVATION", 306, 318]]], ["Peribronchial/peribronchiolar and perivascular inflammations were individually scored from 0 to 4, representing normal (score 0), mild inflammation (score 1, <25%), moderate inflammation (score 2, 25-50%), severe inflammation (score 3, 50-75%), and very severe inflammation (score 4, >75%), respectively [30] .", [["Peribronchial", "ANATOMY", 0, 13], ["peribronchiolar", "ANATOMY", 14, 29], ["perivascular", "ANATOMY", 34, 46], ["inflammations", "DISEASE", 47, 60], ["inflammation", "DISEASE", 135, 147], ["inflammation", "DISEASE", 174, 186], ["inflammation", "DISEASE", 213, 225], ["inflammation", "DISEASE", 261, 273], ["peribronchiolar", "CANCER", 14, 29], ["perivascular inflammations", "PATHOLOGICAL_FORMATION", 34, 60], ["Peribronchial/peribronchiolar and perivascular inflammations", "PROBLEM", 0, 60], ["mild inflammation", "PROBLEM", 130, 147], ["score", "TEST", 149, 154], ["moderate inflammation", "PROBLEM", 165, 186], ["score", "TEST", 188, 193], ["severe inflammation", "PROBLEM", 206, 225], ["score", "TEST", 227, 232], ["very severe inflammation", "PROBLEM", 249, 273], ["peribronchiolar", "ANATOMY_MODIFIER", 14, 29], ["perivascular", "ANATOMY_MODIFIER", 34, 46], ["inflammations", "OBSERVATION", 47, 60], ["normal", "OBSERVATION", 112, 118], ["mild", "OBSERVATION_MODIFIER", 130, 134], ["inflammation", "OBSERVATION", 135, 147], ["moderate", "OBSERVATION_MODIFIER", 165, 173], ["inflammation", "OBSERVATION", 174, 186], ["severe", "OBSERVATION_MODIFIER", 206, 212], ["inflammation", "OBSERVATION", 213, 225], ["very", "OBSERVATION_MODIFIER", 249, 253], ["severe", "OBSERVATION_MODIFIER", 254, 260], ["inflammation", "OBSERVATION", 261, 273]]], ["Alveolar inflammation was scored from 0 to 2 that represents normal (score 0), mild inflammation infiltration (score 1, few foci present), and severe inflammation infiltration (score 2, many foci present).", [["Alveolar", "ANATOMY", 0, 8], ["foci", "ANATOMY", 124, 128], ["inflammation", "DISEASE", 84, 96], ["inflammation", "DISEASE", 150, 162], ["Alveolar", "MULTI-TISSUE_STRUCTURE", 0, 8], ["Alveolar inflammation", "PROBLEM", 0, 21], ["mild inflammation infiltration", "PROBLEM", 79, 109], ["few foci", "PROBLEM", 120, 128], ["severe inflammation infiltration (score 2", "PROBLEM", 143, 184], ["inflammation", "OBSERVATION", 9, 21], ["normal", "OBSERVATION", 61, 67], ["mild", "OBSERVATION_MODIFIER", 79, 83], ["inflammation", "OBSERVATION_MODIFIER", 84, 96], ["infiltration", "OBSERVATION", 97, 109], ["few", "OBSERVATION_MODIFIER", 120, 123], ["foci", "OBSERVATION", 124, 128], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["inflammation", "OBSERVATION_MODIFIER", 150, 162], ["infiltration", "OBSERVATION", 163, 175], ["many", "OBSERVATION_MODIFIER", 186, 190], ["foci", "OBSERVATION", 191, 195]]], ["The scores were then summed to give a total inflammatory score.", [["a total inflammatory score", "PROBLEM", 36, 62]]], ["Percentage of AB/PAS positively stained areas to the total area of bronchial epithelium was measured.Histopathology and Immunohistochemistry.For p38 MAPK and NF-B immunohistochemical staining, paraffin-embedded sections were deparaffinized, rehydrated, and washed with distilled water.", [["area", "ANATOMY", 59, 63], ["bronchial epithelium", "ANATOMY", 67, 87], ["sections", "ANATOMY", 211, 219], ["paraffin", "CHEMICAL", 193, 201], ["AB", "CELL", 14, 16], ["PAS", "SIMPLE_CHEMICAL", 17, 20], ["bronchial epithelium", "TISSUE", 67, 87], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 145, 153], ["NF-B", "GENE_OR_GENE_PRODUCT", 158, 162], ["sections", "MULTI-TISSUE_STRUCTURE", 211, 219], ["p38 MAPK", "PROTEIN", 145, 153], ["NF-B", "PROTEIN", 158, 162], ["AB/PAS", "TEST", 14, 20], ["bronchial epithelium", "PROBLEM", 67, 87], ["Histopathology", "TEST", 101, 115], ["Immunohistochemistry", "TEST", 120, 140], ["p38 MAPK", "TEST", 145, 153], ["NF", "TEST", 158, 160], ["B immunohistochemical staining", "TEST", 161, 191], ["positively", "OBSERVATION_MODIFIER", 21, 31], ["stained", "OBSERVATION_MODIFIER", 32, 39], ["areas", "OBSERVATION_MODIFIER", 40, 45], ["total", "OBSERVATION_MODIFIER", 53, 58], ["area", "OBSERVATION_MODIFIER", 59, 63], ["bronchial epithelium", "ANATOMY", 67, 87]]], ["The monoclonal antibodies used were as follows: rabbit anti-p38 MAPK (1 : 400 dilution) and rabbit NF-B p65 (1 : 800 dilution).", [["rabbit", "ORGANISM", 48, 54], ["anti-p38 MAPK", "GENE_OR_GENE_PRODUCT", 55, 68], ["rabbit", "ORGANISM", 92, 98], ["NF-B p65", "GENE_OR_GENE_PRODUCT", 99, 107], ["monoclonal antibodies", "PROTEIN", 4, 25], ["rabbit anti", "PROTEIN", 48, 59], ["p38 MAPK", "PROTEIN", 60, 68], ["rabbit NF-B p65", "PROTEIN", 92, 107], ["rabbit", "SPECIES", 48, 54], ["rabbit", "SPECIES", 92, 98], ["rabbit", "SPECIES", 48, 54], ["rabbit", "SPECIES", 92, 98], ["The monoclonal antibodies", "TEST", 0, 25], ["rabbit NF", "TEST", 92, 101]]], ["Both antibodies were purchased from Cell Signaling (Danvers, MA, USA).", [["Cell", "ANATOMY", 36, 40], ["Cell", "CELL", 36, 40], ["antibodies", "PROTEIN", 5, 15], ["Both antibodies", "TEST", 0, 15]]], ["PBS was used to replace the primary antibody as a blank control.", [["primary antibody", "PROTEIN", 28, 44], ["PBS", "TREATMENT", 0, 3], ["the primary antibody", "TREATMENT", 24, 44], ["a blank control", "TREATMENT", 48, 63]]], ["The mean optical density (IOD) was calculated by measuring 10 consecutive visual fields for each sample at a magnification of 400x, using an optical microscope equipped with an Image-Pro Plus software (version 6.0, Media Cybernetics, Silver Spring, MD, USA) by a pathologist who was blinded to the identity of the groups.RNA Extraction, Reverse Transcription, and Quantitative Real-time Polymerase ChainReaction.", [["sample", "ANATOMY", 97, 103], ["an optical microscope", "TEST", 138, 159], ["an Image", "TEST", 174, 182], ["RNA Extraction", "TREATMENT", 321, 335], ["Reverse Transcription", "TREATMENT", 337, 358], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["optical", "OBSERVATION_MODIFIER", 9, 16], ["density", "OBSERVATION", 17, 24]]], ["Frozen tissue was ground to a fine powder in liquid nitrogen.", [["tissue", "ANATOMY", 7, 13], ["nitrogen", "CHEMICAL", 52, 60], ["Frozen tissue", "TISSUE", 0, 13], ["Frozen tissue", "PROBLEM", 0, 13], ["a fine powder in liquid nitrogen", "TREATMENT", 28, 60]]], ["After the samples were thawed, total RNA was isolated from 30 mg lung tissue using the E.Z.N.ATM HP total RNA kit (Omega Biotech, Norcross, GA, USA) according to specific modifications to maximize RNA extraction.", [["samples", "ANATOMY", 10, 17], ["lung tissue", "ANATOMY", 65, 76], ["lung tissue", "TISSUE", 65, 76], ["the samples", "TEST", 6, 17], ["total RNA", "TREATMENT", 31, 40], ["the E.Z.N.ATM HP total RNA kit (Omega Biotech", "TREATMENT", 83, 128], ["RNA extraction", "TREATMENT", 197, 211], ["lung", "ANATOMY", 65, 69]]], ["RNA pellets were ethanol-precipitated, washed, and resuspended in sterile ribonuclease-free water.", [["ethanol", "CHEMICAL", 17, 24], ["ethanol", "CHEMICAL", 17, 24], ["ethanol", "SIMPLE_CHEMICAL", 17, 24], ["ribonuclease", "GENE_OR_GENE_PRODUCT", 74, 86], ["ribonuclease", "PROTEIN", 74, 86], ["sterile ribonuclease", "TREATMENT", 66, 86]]], ["RNA samples were reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA) to synthesize the first-strand cDNA.", [["samples", "ANATOMY", 4, 11], ["iScript cDNA", "DNA", 47, 59], ["first-strand cDNA", "DNA", 134, 151], ["RNA samples", "TEST", 0, 11], ["Hercules", "TEST", 97, 105]]], ["Reverse transcription was then performed on 1 L RNA sample by adding iScript reagents to a final reaction volume of 20 L. The RNA samples were incubated in a Bio-Rad DNA Engine Peltier Thermal Cycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at 25 \u2218 C for 5 min and then reverse transcribed at 42 \u2218 C for 30 min and, finally, the enzyme was denatured at 85 \u2218 C for 5 min.", [["samples", "ANATOMY", 130, 137], ["iScript reagents", "TREATMENT", 69, 85], ["a final reaction volume", "TEST", 89, 112], ["The RNA samples", "TEST", 122, 137], ["a Bio", "TEST", 156, 161], ["Thermal Cycler", "TREATMENT", 185, 199], ["Hercules", "TEST", 229, 237], ["the enzyme", "TEST", 332, 342]]], ["Subsequently, the RNA concentrations were determined by measuring the absorbance at 260 and 280 nm, using a Nanodrop spectrophotometer (Montchanin, DE, USA).RNA Extraction, Reverse Transcription, and Quantitative Real-time Polymerase ChainPCR primers specific for selected target genes were predesigned and validated (Table 1) .", [["target genes", "DNA", 273, 285], ["the RNA concentrations", "TEST", 14, 36], ["the absorbance", "TEST", 66, 80], ["a Nanodrop spectrophotometer", "TREATMENT", 106, 134], ["RNA Extraction", "TREATMENT", 157, 171], ["Reverse Transcription", "TREATMENT", 173, 194], ["Quantitative Real-time Polymerase ChainPCR primers", "TREATMENT", 200, 250]]], ["Gradient PCRs were used to determine the optimal annealing temperature and primer concentration. qPCR reactions had a final volume of 10 L and contained 1 L of cDNA, 0.5 L of each primer, 5 L Sso-Fast EvaGreen supermix (Bio-Rad Laboratories, Hercules, CA, USA), and 3 L DEPC-treated sterile distilled water.", [["DEPC", "CHEMICAL", 270, 274], ["DEPC", "CHEMICAL", 270, 274], ["DEPC", "SIMPLE_CHEMICAL", 270, 274], ["cDNA", "DNA", 160, 164], ["Gradient PCRs", "TEST", 0, 13], ["primer concentration", "TREATMENT", 75, 95], ["qPCR reactions", "TEST", 97, 111], ["cDNA", "TEST", 160, 164], ["Hercules", "TEST", 242, 250], ["CA", "TEST", 252, 254], ["3 L DEPC", "TREATMENT", 266, 274], ["sterile distilled water", "TREATMENT", 283, 306]]], ["The relative expression levels of mRNA of studied cytokines were Table 1: The primer sequences.", [["mRNA", "RNA", 34, 38], ["cytokines", "PROTEIN", 50, 59], ["primer sequences", "DNA", 78, 94], ["The primer sequences", "TEST", 74, 94]]], ["TNF--forward TGCTATCTCATACCAGGAGA TNF--reverse GACTCCGCAAAGTCTAAGTA IL-6-forward TCTTGGGACTGATGTTGTTG IL-6-reverse TAAGCCTCCGACTTGTGAA ILTRQ Protects LPS-Induced Histopathological Damage ofRat Lungs.", [["Lungs", "ANATOMY", 193, 198], ["LPS", "CHEMICAL", 150, 153], ["TNF", "GENE_OR_GENE_PRODUCT", 0, 3], ["TNF", "GENE_OR_GENE_PRODUCT", 34, 37], ["LPS", "SIMPLE_CHEMICAL", 150, 153], ["Lungs", "ORGAN", 193, 198], ["TNF", "PROTEIN", 0, 3], ["TNF", "PROTEIN", 34, 37], ["TNF", "TEST", 0, 3], ["TNF", "TEST", 34, 37], ["reverse GACTCCGCAAAGTCTAAGTA IL", "TREATMENT", 39, 70], ["TCTTGGGACTGATGTTGTTG IL", "TREATMENT", 81, 104], ["reverse TAAGCCTCCGACTTGTGAA ILTRQ Protects LPS", "TREATMENT", 107, 153], ["Damage", "OBSERVATION", 180, 186], ["Rat", "ANATOMY_MODIFIER", 189, 192], ["Lungs", "ANATOMY", 193, 198]]], ["Histopathological changes in rat lungs showed major difference in gross morphology between groups treated with and without TRQ.", [["lungs", "ANATOMY", 33, 38], ["rat", "ORGANISM", 29, 32], ["lungs", "ORGAN", 33, 38], ["TRQ", "PROTEIN", 123, 126], ["rat", "SPECIES", 29, 32], ["rat", "SPECIES", 29, 32], ["Histopathological changes in rat lungs", "PROBLEM", 0, 38], ["major difference", "PROBLEM", 46, 62], ["TRQ", "TREATMENT", 123, 126], ["lungs", "ANATOMY", 33, 38], ["major", "OBSERVATION_MODIFIER", 46, 51], ["difference", "OBSERVATION_MODIFIER", 52, 62], ["gross", "OBSERVATION_MODIFIER", 66, 71], ["morphology", "OBSERVATION_MODIFIER", 72, 82]]], ["In non-LPS-exposed tissues sections, no obvious histological abnormalities were revealed (Figures 1(a)-1(c) ).", [["tissues sections", "ANATOMY", 19, 35], ["tissues sections", "MULTI-TISSUE_STRUCTURE", 19, 35], ["obvious histological abnormalities", "PROBLEM", 40, 74], ["Figures", "TEST", 90, 97], ["exposed tissues", "OBSERVATION_MODIFIER", 11, 26], ["no obvious", "UNCERTAINTY", 37, 47]]], ["In contrast, intratracheal instillation of LPS induced an acute bronchopneumonia involving the focal areas of the main bronchus and also preterminal bronchioles, presented as prominent thickening of the airway epitheliums and the alveolar septa, conspicuous peribronchial inflammatory cell infiltration, and bronchiolar lumen obstruction by mucus and cell debris.", [["intratracheal", "ANATOMY", 13, 26], ["focal areas", "ANATOMY", 95, 106], ["bronchus", "ANATOMY", 119, 127], ["preterminal bronchioles", "ANATOMY", 137, 160], ["airway epitheliums", "ANATOMY", 203, 221], ["alveolar septa", "ANATOMY", 230, 244], ["peribronchial inflammatory cell", "ANATOMY", 258, 289], ["bronchiolar lumen", "ANATOMY", 308, 325], ["mucus", "ANATOMY", 341, 346], ["cell", "ANATOMY", 351, 355], ["LPS", "CHEMICAL", 43, 46], ["bronchopneumonia", "DISEASE", 64, 80], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 26], ["LPS", "SIMPLE_CHEMICAL", 43, 46], ["bronchus", "ORGAN", 119, 127], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 149, 160], ["airway epitheliums", "PATHOLOGICAL_FORMATION", 203, 221], ["alveolar septa", "TISSUE", 230, 244], ["peribronchial inflammatory cell", "CELL", 258, 289], ["bronchiolar lumen", "TISSUE", 308, 325], ["mucus", "ORGANISM_SUBSTANCE", 341, 346], ["cell debris", "CELLULAR_COMPONENT", 351, 362], ["intratracheal instillation of LPS", "TREATMENT", 13, 46], ["an acute bronchopneumonia", "PROBLEM", 55, 80], ["preterminal bronchioles", "PROBLEM", 137, 160], ["prominent thickening of the airway epitheliums", "PROBLEM", 175, 221], ["the alveolar septa", "PROBLEM", 226, 244], ["peribronchial inflammatory cell infiltration", "PROBLEM", 258, 302], ["bronchiolar lumen obstruction", "PROBLEM", 308, 337], ["mucus and cell debris", "PROBLEM", 341, 362], ["intratracheal", "ANATOMY", 13, 26], ["LPS induced", "OBSERVATION_MODIFIER", 43, 54], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["bronchopneumonia", "OBSERVATION", 64, 80], ["focal", "OBSERVATION_MODIFIER", 95, 100], ["main bronchus", "ANATOMY", 114, 127], ["preterminal", "ANATOMY_MODIFIER", 137, 148], ["bronchioles", "ANATOMY", 149, 160], ["prominent", "OBSERVATION_MODIFIER", 175, 184], ["thickening", "OBSERVATION", 185, 195], ["airway", "ANATOMY", 203, 209], ["epitheliums", "ANATOMY_MODIFIER", 210, 221], ["alveolar septa", "ANATOMY", 230, 244], ["conspicuous", "OBSERVATION_MODIFIER", 246, 257], ["peribronchial", "ANATOMY_MODIFIER", 258, 271], ["inflammatory cell infiltration", "OBSERVATION", 272, 302], ["bronchiolar", "ANATOMY_MODIFIER", 308, 319], ["lumen", "ANATOMY_MODIFIER", 320, 325], ["obstruction", "OBSERVATION", 326, 337], ["mucus", "OBSERVATION_MODIFIER", 341, 346], ["cell debris", "OBSERVATION", 351, 362]]], ["In addition, some blood vessels in affected regions also thickened with a mixed inflammatory infiltrate of main neutrophils and less monocytes and lymphocytes (Figures 1(d) -1(f)).", [["blood vessels", "ANATOMY", 18, 31], ["neutrophils", "ANATOMY", 112, 123], ["monocytes", "ANATOMY", 133, 142], ["lymphocytes", "ANATOMY", 147, 158], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 18, 31], ["neutrophils", "CELL", 112, 123], ["monocytes", "CELL", 133, 142], ["lymphocytes", "CELL", 147, 158], ["neutrophils", "CELL_TYPE", 112, 123], ["monocytes", "CELL_TYPE", 133, 142], ["lymphocytes", "CELL_TYPE", 147, 158], ["some blood vessels in affected regions", "PROBLEM", 13, 51], ["thickened", "PROBLEM", 57, 66], ["a mixed inflammatory infiltrate of main neutrophils", "PROBLEM", 72, 123], ["monocytes", "TEST", 133, 142], ["lymphocytes", "TEST", 147, 158], ["Figures", "TEST", 160, 167], ["blood vessels", "ANATOMY", 18, 31], ["thickened", "OBSERVATION", 57, 66], ["mixed", "OBSERVATION_MODIFIER", 74, 79], ["inflammatory", "OBSERVATION_MODIFIER", 80, 92], ["infiltrate", "OBSERVATION", 93, 103], ["main neutrophils", "ANATOMY", 107, 123], ["less monocytes", "OBSERVATION_MODIFIER", 128, 142], ["lymphocytes", "ANATOMY", 147, 158]]], ["Low dose TRQ treatment failed to contribute to a remarkable alleviation of extensive inflammation with alveolar air spaces flooded with fibrinous exudate admixed with numerous neutrophils at 24 h (Figure 1(g) ); however, high dose TRQ expressed noteworthy anti-inflammation property throughout the observing period (Figures 1(j)-1(l) ).", [["alveolar", "ANATOMY", 103, 111], ["fibrinous exudate", "ANATOMY", 136, 153], ["neutrophils", "ANATOMY", 176, 187], ["TRQ", "CHEMICAL", 9, 12], ["inflammation", "DISEASE", 85, 97], ["TRQ", "CHEMICAL", 231, 234], ["TRQ", "CHEMICAL", 9, 12], ["TRQ", "SIMPLE_CHEMICAL", 9, 12], ["exudate", "ORGANISM_SUBSTANCE", 146, 153], ["neutrophils", "CELL", 176, 187], ["TRQ", "SIMPLE_CHEMICAL", 231, 234], ["neutrophils", "CELL_TYPE", 176, 187], ["Low dose TRQ treatment", "TREATMENT", 0, 22], ["extensive inflammation", "PROBLEM", 75, 97], ["alveolar air spaces", "PROBLEM", 103, 122], ["fibrinous exudate", "PROBLEM", 136, 153], ["numerous neutrophils", "TEST", 167, 187], ["Figure", "TEST", 197, 203], ["high dose TRQ", "TREATMENT", 221, 234], ["anti-inflammation property", "TREATMENT", 256, 282], ["extensive", "OBSERVATION_MODIFIER", 75, 84], ["inflammation", "OBSERVATION", 85, 97], ["alveolar", "ANATOMY_MODIFIER", 103, 111], ["air spaces", "OBSERVATION", 112, 122], ["fibrinous", "OBSERVATION_MODIFIER", 136, 145], ["exudate", "OBSERVATION_MODIFIER", 146, 153]]], ["In general, inflammatory lesion scores decreased over time and they were effectively decreased by TRQ administration in a dose-dependent way (Figure 1(m) ).", [["lesion", "ANATOMY", 25, 31], ["TRQ", "CHEMICAL", 98, 101], ["TRQ", "CHEMICAL", 98, 101], ["TRQ", "SIMPLE_CHEMICAL", 98, 101], ["inflammatory lesion scores", "PROBLEM", 12, 38], ["inflammatory", "OBSERVATION_MODIFIER", 12, 24], ["lesion", "OBSERVATION", 25, 31], ["decreased", "OBSERVATION_MODIFIER", 39, 48]]], ["Besides, a noticeable and conspicuous increase in numbers of mucous cells and amounts of mucosubstances was detected along the airway surface epithelium in LPS group (Figures 2(d) -2(f)), verifying the exact link between airway inflammation and mucus production [31] , while the goblet cell metaplasia and hyperplasia were rarely found in the main airways in control rats (Figures 2(a) -2(c)), with a faint positive AB/PAS staining area being detected.", [["mucous cells", "ANATOMY", 61, 73], ["airway surface epithelium", "ANATOMY", 127, 152], ["airway", "ANATOMY", 221, 227], ["mucus", "ANATOMY", 245, 250], ["goblet cell metaplasia", "ANATOMY", 279, 301], ["airways", "ANATOMY", 348, 355], ["LPS", "CHEMICAL", 156, 159], ["airway inflammation", "DISEASE", 221, 240], ["hyperplasia", "DISEASE", 306, 317], ["mucous cells", "CELL", 61, 73], ["mucosubstances", "GENE_OR_GENE_PRODUCT", 89, 103], ["airway surface epithelium", "TISSUE", 127, 152], ["LPS", "SIMPLE_CHEMICAL", 156, 159], ["airway", "MULTI-TISSUE_STRUCTURE", 221, 227], ["mucus", "ORGANISM_SUBSTANCE", 245, 250], ["goblet cell metaplasia", "CANCER", 279, 301], ["airways", "MULTI-TISSUE_STRUCTURE", 348, 355], ["rats", "ORGANISM", 367, 371], ["PAS", "SIMPLE_CHEMICAL", 419, 422], ["mucous cells", "CELL_TYPE", 61, 73], ["rats", "SPECIES", 367, 371], ["mucous cells", "PROBLEM", 61, 73], ["amounts of mucosubstances", "PROBLEM", 78, 103], ["Figures", "TEST", 167, 174], ["airway inflammation", "PROBLEM", 221, 240], ["mucus production", "PROBLEM", 245, 261], ["the goblet cell metaplasia", "PROBLEM", 275, 301], ["hyperplasia", "PROBLEM", 306, 317], ["Figures", "TEST", 373, 380], ["a faint positive AB/PAS staining area", "PROBLEM", 399, 436], ["noticeable", "OBSERVATION_MODIFIER", 11, 21], ["conspicuous", "OBSERVATION_MODIFIER", 26, 37], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["numbers", "OBSERVATION_MODIFIER", 50, 57], ["mucous cells", "OBSERVATION", 61, 73], ["amounts", "OBSERVATION_MODIFIER", 78, 85], ["mucosubstances", "OBSERVATION", 89, 103], ["airway", "ANATOMY", 127, 133], ["surface", "ANATOMY_MODIFIER", 134, 141], ["epithelium", "ANATOMY_MODIFIER", 142, 152], ["airway", "ANATOMY", 221, 227], ["inflammation", "OBSERVATION", 228, 240], ["goblet cell metaplasia", "OBSERVATION", 279, 301], ["hyperplasia", "OBSERVATION", 306, 317], ["main", "ANATOMY_MODIFIER", 343, 347], ["airways", "ANATOMY", 348, 355], ["faint", "OBSERVATION_MODIFIER", 401, 406], ["positive", "OBSERVATION_MODIFIER", 407, 415]]], ["TRQ treatment significantly inhibited, though not fully abrogated, the mucus hypersecretion at each time point (Figures 2(g)-2(l) ).TRQ Regulates LPS-Induced Leukocyte Accumulation in BALF.As a potent stimulus for immune cell, LPS significantly recruited more cells at 24 h, and although the total cell amount decreased over time, it was always significantly higher than that in the control group.", [["mucus", "ANATOMY", 71, 76], ["Leukocyte", "ANATOMY", 158, 167], ["BALF", "ANATOMY", 184, 188], ["immune cell", "ANATOMY", 214, 225], ["cells", "ANATOMY", 260, 265], ["cell", "ANATOMY", 298, 302], ["TRQ", "CHEMICAL", 0, 3], ["LPS", "CHEMICAL", 146, 149], ["LPS", "CHEMICAL", 227, 230], ["TRQ", "SIMPLE_CHEMICAL", 0, 3], ["mucus", "ORGANISM_SUBSTANCE", 71, 76], ["TRQ", "SIMPLE_CHEMICAL", 132, 135], ["LPS", "SIMPLE_CHEMICAL", 146, 149], ["Leukocyte", "CELL", 158, 167], ["BALF", "ORGANISM_SUBSTANCE", 184, 188], ["immune cell", "CELL", 214, 225], ["LPS", "SIMPLE_CHEMICAL", 227, 230], ["cells", "CELL", 260, 265], ["cell", "CELL", 298, 302], ["TRQ", "PROTEIN", 132, 135], ["BALF", "CELL_TYPE", 184, 188], ["TRQ treatment", "TREATMENT", 0, 13], ["the mucus hypersecretion", "PROBLEM", 67, 91], ["Figures", "TEST", 112, 119], ["LPS", "TEST", 146, 149], ["Leukocyte Accumulation in BALF", "PROBLEM", 158, 188], ["a potent stimulus", "TREATMENT", 192, 209], ["immune cell", "PROBLEM", 214, 225], ["LPS", "PROBLEM", 227, 230], ["the total cell amount", "TEST", 288, 309], ["LPS", "OBSERVATION_MODIFIER", 146, 149], ["Leukocyte Accumulation", "OBSERVATION", 158, 180], ["BALF", "ANATOMY", 184, 188], ["total cell", "OBSERVATION_MODIFIER", 292, 302], ["amount", "OBSERVATION_MODIFIER", 303, 309], ["decreased", "OBSERVATION_MODIFIER", 310, 319], ["significantly", "OBSERVATION_MODIFIER", 345, 358], ["higher", "OBSERVATION_MODIFIER", 359, 365]]], ["TRQ effectively accelerated the process of cell number decrease (Figure 3(a) ).", [["cell", "ANATOMY", 43, 47], ["TRQ", "CHEMICAL", 0, 3], ["TRQ", "SIMPLE_CHEMICAL", 0, 3], ["cell", "CELL", 43, 47], ["TRQ", "PROTEIN", 0, 3], ["cell number decrease", "PROBLEM", 43, 63], ["cell", "OBSERVATION", 43, 47], ["number", "OBSERVATION_MODIFIER", 48, 54], ["decrease", "OBSERVATION_MODIFIER", 55, 63]]], ["For the number of neutrophils, even low dose of TRQ effectively cut down the neutrophil release in BALF after LPS administration at 24 h (Figure 3(b) ).", [["neutrophils", "ANATOMY", 18, 29], ["neutrophil", "ANATOMY", 77, 87], ["BALF", "ANATOMY", 99, 103], ["TRQ", "CHEMICAL", 48, 51], ["LPS", "CHEMICAL", 110, 113], ["TRQ", "CHEMICAL", 48, 51], ["neutrophils", "CELL", 18, 29], ["TRQ", "SIMPLE_CHEMICAL", 48, 51], ["neutrophil", "CELL", 77, 87], ["BALF", "ORGANISM_SUBSTANCE", 99, 103], ["LPS", "SIMPLE_CHEMICAL", 110, 113], ["neutrophils", "CELL_TYPE", 18, 29], ["TRQ", "PROTEIN", 48, 51], ["neutrophil", "CELL_TYPE", 77, 87], ["BALF", "CELL_TYPE", 99, 103], ["neutrophils", "TEST", 18, 29], ["TRQ", "TREATMENT", 48, 51], ["the neutrophil release", "TREATMENT", 73, 95], ["LPS administration", "TREATMENT", 110, 128]]], ["The inhibitory effect of TRQ in macrophage accumulation started from 48 h, which was only in high dose group (Figure 3(c) ).", [["macrophage", "ANATOMY", 32, 42], ["TRQ", "CHEMICAL", 25, 28], ["TRQ", "SIMPLE_CHEMICAL", 25, 28], ["macrophage", "CELL", 32, 42], ["TRQ", "PROTEIN", 25, 28], ["TRQ in macrophage accumulation", "PROBLEM", 25, 55]]], ["The number of lymphocytes in BALF enhanced observably after LPS administration, which was completely reversed by high dose TRQ at 24 h (Figure 3(d) ).TRQ Attenuates LPS-Induced Proinflammatory Cytokines in BALF andLungs.", [["lymphocytes", "ANATOMY", 14, 25], ["BALF", "ANATOMY", 29, 33], ["BALF andLungs", "ANATOMY", 206, 219], ["LPS", "CHEMICAL", 60, 63], ["TRQ", "CHEMICAL", 123, 126], ["LPS", "CHEMICAL", 165, 168], ["lymphocytes", "CELL", 14, 25], ["BALF", "CELL", 29, 33], ["LPS", "SIMPLE_CHEMICAL", 60, 63], ["TRQ", "SIMPLE_CHEMICAL", 150, 153], ["LPS", "SIMPLE_CHEMICAL", 165, 168], ["BALF andLungs", "CELL", 206, 219], ["lymphocytes", "CELL_TYPE", 14, 25], ["BALF", "CELL_TYPE", 29, 33], ["TRQ", "PROTEIN", 150, 153], ["Proinflammatory Cytokines", "PROTEIN", 177, 202], ["LPS administration", "TREATMENT", 60, 78], ["high dose TRQ", "TREATMENT", 113, 126], ["LPS", "TEST", 165, 168], ["Proinflammatory Cytokines in BALF andLungs", "PROBLEM", 177, 219], ["number", "OBSERVATION_MODIFIER", 4, 10], ["lymphocytes", "OBSERVATION", 14, 25], ["BALF", "OBSERVATION_MODIFIER", 29, 33], ["enhanced", "OBSERVATION_MODIFIER", 34, 42], ["LPS", "OBSERVATION_MODIFIER", 165, 168], ["Proinflammatory Cytokines", "OBSERVATION", 177, 202], ["BALF", "ANATOMY", 206, 210]]], ["Since they have been previously reported [32] , protein release and mRNA upregulation of TNF-, IL-1 , IL-6, and CINC-1 were examined to determine the effect of TRQ.", [["TNF", "GENE_OR_GENE_PRODUCT", 89, 92], ["IL-1", "GENE_OR_GENE_PRODUCT", 95, 99], ["IL-6", "GENE_OR_GENE_PRODUCT", 102, 106], ["CINC-1", "GENE_OR_GENE_PRODUCT", 112, 118], ["TRQ", "SIMPLE_CHEMICAL", 160, 163], ["TNF", "PROTEIN", 89, 92], ["IL-6", "PROTEIN", 102, 106], ["CINC", "PROTEIN", 112, 116], ["TRQ", "PROTEIN", 160, 163], ["protein release", "TEST", 48, 63], ["mRNA upregulation", "TEST", 68, 85], ["TNF", "TEST", 89, 92], ["IL", "TEST", 95, 97], ["IL", "TEST", 102, 104], ["CINC", "TEST", 112, 116], ["TRQ", "TREATMENT", 160, 163]]], ["As expected, levels of selected cytokines were significantly elevated in BALF ( Figure 4 ) and lung homogenate ( Figure 5 ) 24 h after LPS inoculation.", [["BALF", "ANATOMY", 73, 77], ["lung homogenate", "ANATOMY", 95, 110], ["LPS", "CHEMICAL", 135, 138], ["BALF", "ORGANISM_SUBSTANCE", 73, 77], ["lung homogenate", "TISSUE", 95, 110], ["LPS", "SIMPLE_CHEMICAL", 135, 138], ["cytokines", "PROTEIN", 32, 41], ["BALF", "CELL_TYPE", 73, 77], ["selected cytokines", "TEST", 23, 41], ["significantly elevated", "PROBLEM", 47, 69], ["BALF", "TEST", 73, 77], ["lung homogenate ( Figure", "TREATMENT", 95, 119], ["LPS inoculation", "TREATMENT", 135, 150], ["BALF", "ANATOMY", 73, 77], ["lung", "ANATOMY", 95, 99]]], ["Although they were always significantly higher than those in the control groups, levels of TNF-, IL-6, and CINC-1 tended to rapidly decrease from 24 h, while levels of IL-1 continued to be high at 48 h.", [["TNF", "GENE_OR_GENE_PRODUCT", 91, 94], ["IL-6", "GENE_OR_GENE_PRODUCT", 97, 101], ["CINC-1", "GENE_OR_GENE_PRODUCT", 107, 113], ["IL-1", "GENE_OR_GENE_PRODUCT", 168, 172], ["TNF", "PROTEIN", 91, 94], ["CINC", "PROTEIN", 107, 111], ["IL", "PROTEIN", 168, 170], ["levels", "TEST", 81, 87], ["TNF", "TEST", 91, 94], ["IL", "TEST", 97, 99], ["CINC", "TEST", 107, 111], ["levels of IL", "TEST", 158, 170], ["significantly", "OBSERVATION_MODIFIER", 26, 39], ["higher", "OBSERVATION_MODIFIER", 40, 46]]], ["Amounts of TNF-, IL-6, and CINC-1 were markedly reduced starting from 24 h after LPS exposure by even low dose of TRQ.", [["LPS", "CHEMICAL", 81, 84], ["TRQ", "CHEMICAL", 114, 117], ["TNF", "GENE_OR_GENE_PRODUCT", 11, 14], ["IL-6", "GENE_OR_GENE_PRODUCT", 17, 21], ["CINC-1", "GENE_OR_GENE_PRODUCT", 27, 33], ["LPS", "SIMPLE_CHEMICAL", 81, 84], ["TRQ", "SIMPLE_CHEMICAL", 114, 117], ["TNF", "PROTEIN", 11, 14], ["CINC", "PROTEIN", 27, 31], ["TNF", "TEST", 11, 14], ["IL", "TEST", 17, 19], ["CINC", "TEST", 27, 31], ["LPS exposure", "TREATMENT", 81, 93], ["TRQ", "TREATMENT", 114, 117]]], ["Of interest, for IL-1 a reduction was observed only in high dose TRQ group at 48 h.", [["TRQ", "CHEMICAL", 65, 68], ["IL-1", "GENE_OR_GENE_PRODUCT", 17, 21], ["TRQ", "SIMPLE_CHEMICAL", 65, 68], ["IL", "PROTEIN", 17, 19], ["IL-1 a reduction", "TREATMENT", 17, 33], ["high dose TRQ group", "TREATMENT", 55, 74]]], ["At the last time point, high dosage of TRQ successfully recovered levels of all cytokines to normal.", [["TRQ", "CHEMICAL", 39, 42], ["TRQ", "CHEMICAL", 39, 42], ["TRQ", "SIMPLE_CHEMICAL", 39, 42], ["TRQ", "PROTEIN", 39, 42], ["cytokines", "PROTEIN", 80, 89], ["high dosage of TRQ", "TREATMENT", 24, 42], ["normal", "OBSERVATION", 93, 99]]], ["Taken together, TRQ exerted a more potent and earlier effect on reversing the overproduction of IL-6, which was completely repressed at 48 h.TRQ Attenuates LPS-Induced Proinflammatory Cytokines in BALF andAs for the qPCR results, CINC-1 was accumulated with mRNA levels peaking at 24 h and then declining.", [["BALF", "ANATOMY", 197, 201], ["TRQ", "CHEMICAL", 16, 19], ["LPS", "CHEMICAL", 156, 159], ["TRQ", "CHEMICAL", 16, 19], ["TRQ", "SIMPLE_CHEMICAL", 16, 19], ["IL-6", "GENE_OR_GENE_PRODUCT", 96, 100], ["LPS", "SIMPLE_CHEMICAL", 156, 159], ["BALF", "CELL", 197, 201], ["CINC-1", "GENE_OR_GENE_PRODUCT", 230, 236], ["IL-6", "PROTEIN", 96, 100], ["Proinflammatory Cytokines", "PROTEIN", 168, 193], ["BALF", "CELL_TYPE", 197, 201], ["LPS", "TEST", 156, 159], ["Proinflammatory Cytokines in BALF", "TEST", 168, 201], ["the qPCR", "TEST", 212, 220], ["CINC", "TEST", 230, 234], ["mRNA levels", "TEST", 258, 269], ["more potent", "OBSERVATION_MODIFIER", 30, 41], ["Proinflammatory Cytokines", "OBSERVATION", 168, 193]]], ["TNF-, IL-6, and IL-1 mRNA reached a plateau at 24 h and continued to escalate until the end of the 48 hour study.", [["TNF", "GENE_OR_GENE_PRODUCT", 0, 3], ["IL-6", "GENE_OR_GENE_PRODUCT", 6, 10], ["IL-1", "GENE_OR_GENE_PRODUCT", 16, 20], ["TNF-, IL-6, and IL-1 mRNA", "RNA", 0, 25], ["TNF", "TEST", 0, 3], ["IL", "TEST", 6, 8], ["the 48 hour study", "TEST", 95, 112]]], ["These data demonstrated the complex patterns of cytokine gene expression and suggest that production of early mediators may augment continued expression of TNF-, IL-6, and IL-1 mRNA.", [["TNF", "GENE_OR_GENE_PRODUCT", 156, 159], ["IL-6", "GENE_OR_GENE_PRODUCT", 162, 166], ["IL-1", "GENE_OR_GENE_PRODUCT", 172, 176], ["cytokine gene", "DNA", 48, 61], ["TNF-, IL-6, and IL-1 mRNA", "RNA", 156, 181], ["cytokine gene expression", "PROBLEM", 48, 72], ["early mediators", "PROBLEM", 104, 119], ["TNF", "TEST", 156, 159], ["IL", "TEST", 162, 164], ["cytokine gene expression", "OBSERVATION", 48, 72]]], ["The mRNA induction for each cytokine was significantly mitigated or reversed by TRQ treatment (Figure 6 ).TRQ Modulates LPS-Induced Synthesis of Signaling Proteins in Rat Lungs.", [["Lungs", "ANATOMY", 171, 176], ["TRQ", "CHEMICAL", 80, 83], ["LPS", "CHEMICAL", 120, 123], ["TRQ", "CHEMICAL", 80, 83], ["TRQ", "SIMPLE_CHEMICAL", 80, 83], ["TRQ", "SIMPLE_CHEMICAL", 106, 109], ["LPS", "SIMPLE_CHEMICAL", 120, 123], ["Lungs", "ORGAN", 171, 176], ["cytokine", "PROTEIN", 28, 36], ["TRQ", "PROTEIN", 106, 109], ["Signaling Proteins", "PROTEIN", 145, 163], ["The mRNA induction", "TREATMENT", 0, 18], ["TRQ treatment", "TREATMENT", 80, 93], ["LPS", "TEST", 120, 123], ["Signaling Proteins in Rat Lungs", "PROBLEM", 145, 176], ["LPS", "OBSERVATION_MODIFIER", 120, 123], ["Signaling Proteins", "OBSERVATION", 145, 163], ["Rat", "ANATOMY_MODIFIER", 167, 170], ["Lungs", "ANATOMY", 171, 176]]], ["Effect of TRQ on LPS-induced p38MAPK and NF-B p65 expression in rat lungs was measured by immunohistochemistry.", [["lungs", "ANATOMY", 68, 73], ["TRQ", "CHEMICAL", 10, 13], ["LPS", "CHEMICAL", 17, 20], ["TRQ", "SIMPLE_CHEMICAL", 10, 13], ["LPS", "SIMPLE_CHEMICAL", 17, 20], ["p38MAPK", "GENE_OR_GENE_PRODUCT", 29, 36], ["NF-B p65", "GENE_OR_GENE_PRODUCT", 41, 49], ["rat", "ORGANISM", 64, 67], ["lungs", "ORGAN", 68, 73], ["p38MAPK", "PROTEIN", 29, 36], ["NF-B p65", "PROTEIN", 41, 49], ["rat", "SPECIES", 64, 67], ["rat", "SPECIES", 64, 67], ["TRQ", "TEST", 10, 13], ["LPS", "TEST", 17, 20], ["p38MAPK", "TEST", 29, 36], ["NF", "TEST", 41, 43], ["immunohistochemistry", "TEST", 90, 110], ["lungs", "ANATOMY", 68, 73]]], ["Results revealed that IOD value of areas positively stained by p38 MAPK and NF-B p65 monoclonal antibody in lung sections increased markedly at 24 h after LPS exposure, which could be significantly attenuated by TRQ in a dose-dependent way (Figures 7 and 8 ).TRQ Modulates LPS-Induced Phosphorylation of Signaling Proteins in MAPKs Pathway in Rat Lungs.Western blot analysis on changes of prominent protein expressions involved in MAPKs pathway in rat lungs showed that stimulation with LPS resulted in a significant increase in the amount of phosphorylation of p38, JNK, and ERK1/2 compared with the control group at 24 h, which were markedly inhibited by an addition of TRQ (Figures 9(a) and 9(c)-9(e)).", [["lung sections", "ANATOMY", 108, 121], ["Lungs", "ANATOMY", 347, 352], ["lungs", "ANATOMY", 452, 457], ["LPS", "CHEMICAL", 155, 158], ["TRQ", "CHEMICAL", 212, 215], ["LPS", "CHEMICAL", 273, 276], ["LPS", "CHEMICAL", 487, 490], ["TRQ", "CHEMICAL", 212, 215], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 63, 71], ["NF-B p65", "GENE_OR_GENE_PRODUCT", 76, 84], ["lung sections", "MULTI-TISSUE_STRUCTURE", 108, 121], ["LPS", "SIMPLE_CHEMICAL", 155, 158], ["TRQ", "SIMPLE_CHEMICAL", 212, 215], ["TRQ", "SIMPLE_CHEMICAL", 259, 262], ["LPS", "SIMPLE_CHEMICAL", 273, 276], ["MAPKs", "GENE_OR_GENE_PRODUCT", 326, 331], ["Lungs", "ORGAN", 347, 352], ["MAPKs", "GENE_OR_GENE_PRODUCT", 431, 436], ["rat", "ORGANISM", 448, 451], ["lungs", "ORGAN", 452, 457], ["LPS", "SIMPLE_CHEMICAL", 487, 490], ["p38", "GENE_OR_GENE_PRODUCT", 562, 565], ["JNK", "GENE_OR_GENE_PRODUCT", 567, 570], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 576, 582], ["TRQ", "SIMPLE_CHEMICAL", 672, 675], ["IOD", "PROTEIN", 22, 25], ["p38 MAPK", "PROTEIN", 63, 71], ["NF-B p65 monoclonal antibody", "PROTEIN", 76, 104], ["TRQ", "PROTEIN", 259, 262], ["Signaling Proteins", "PROTEIN", 304, 322], ["MAPKs", "PROTEIN", 326, 331], ["MAPKs", "PROTEIN", 431, 436], ["p38", "PROTEIN", 562, 565], ["JNK", "PROTEIN", 567, 570], ["ERK1/2", "PROTEIN", 576, 582], ["rat", "SPECIES", 448, 451], ["rat", "SPECIES", 448, 451], ["IOD value", "TEST", 22, 31], ["p38 MAPK", "TEST", 63, 71], ["NF", "TEST", 76, 78], ["monoclonal antibody", "TEST", 85, 104], ["lung sections", "TEST", 108, 121], ["LPS exposure", "TEST", 155, 167], ["Figures", "TEST", 241, 248], ["LPS", "TEST", 273, 276], ["Signaling Proteins", "PROBLEM", 304, 322], ["Western blot analysis", "TEST", 353, 374], ["prominent protein expressions", "PROBLEM", 389, 418], ["MAPKs pathway", "TEST", 431, 444], ["LPS", "TREATMENT", 487, 490], ["a significant increase", "PROBLEM", 503, 525], ["phosphorylation of p38", "PROBLEM", 543, 565], ["JNK", "TEST", 567, 570], ["ERK1", "TEST", 576, 580], ["TRQ", "TEST", 672, 675], ["Figures", "TEST", 677, 684], ["lung", "ANATOMY", 108, 112], ["LPS", "OBSERVATION_MODIFIER", 273, 276], ["Signaling Proteins", "OBSERVATION", 304, 322], ["Rat", "ANATOMY_MODIFIER", 343, 346], ["Lungs", "ANATOMY", 347, 352], ["prominent", "OBSERVATION_MODIFIER", 389, 398], ["protein expressions", "OBSERVATION", 399, 418], ["lungs", "ANATOMY", 452, 457], ["significant", "OBSERVATION_MODIFIER", 505, 516], ["increase", "OBSERVATION_MODIFIER", 517, 525], ["amount", "OBSERVATION_MODIFIER", 533, 539]]], ["Except for phospho-JNK, a significant difference between the effects in different dosage of TRQ was observed in all indicators.TRQ Suppresses LPS-Induced Phosphorylation of Signaling Proteins in NF-B Pathway in RatLungs.", [["LPS", "CHEMICAL", 142, 145], ["phospho", "CHEMICAL", 11, 18], ["phospho-JNK", "GENE_OR_GENE_PRODUCT", 11, 22], ["TRQ", "SIMPLE_CHEMICAL", 92, 95], ["TRQ", "SIMPLE_CHEMICAL", 127, 130], ["LPS", "SIMPLE_CHEMICAL", 142, 145], ["NF-B", "GENE_OR_GENE_PRODUCT", 195, 199], ["phospho", "PROTEIN", 11, 18], ["JNK", "PROTEIN", 19, 22], ["TRQ", "PROTEIN", 92, 95], ["Signaling Proteins", "PROTEIN", 173, 191], ["NF-B", "PROTEIN", 195, 199], ["RatLungs", "CELL_LINE", 211, 219], ["phospho-JNK", "TEST", 11, 22], ["different dosage of TRQ", "TREATMENT", 72, 95], ["LPS", "TEST", 142, 145], ["Signaling Proteins in NF", "PROBLEM", 173, 197], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["difference", "OBSERVATION_MODIFIER", 38, 48]]], ["According to the results, stimulation with LPS alone for 24 h notably induced the strong signal of the immunostained band for phosphorylated p65, I B-, and IKK / in rat lungs, which were significantly decreased after TRQ treatment in a dosagedependent manner, as expected (Figures 9(b) and 9(f)-9(h)).", [["lungs", "ANATOMY", 169, 174], ["LPS", "CHEMICAL", 43, 46], ["TRQ", "CHEMICAL", 217, 220], ["TRQ", "CHEMICAL", 217, 220], ["LPS", "SIMPLE_CHEMICAL", 43, 46], ["p65", "GENE_OR_GENE_PRODUCT", 141, 144], ["I B-", "GENE_OR_GENE_PRODUCT", 146, 150], ["IKK", "GENE_OR_GENE_PRODUCT", 156, 159], ["rat", "ORGANISM", 165, 168], ["lungs", "ORGAN", 169, 174], ["TRQ", "SIMPLE_CHEMICAL", 217, 220], ["p65", "PROTEIN", 141, 144], ["I B-", "PROTEIN", 146, 150], ["IKK", "PROTEIN", 156, 159], ["rat", "SPECIES", 165, 168], ["rat", "SPECIES", 165, 168], ["LPS", "TREATMENT", 43, 46], ["phosphorylated p65", "TEST", 126, 144], ["IKK / in rat lungs", "TEST", 156, 174], ["TRQ treatment", "TREATMENT", 217, 230], ["Figures", "TEST", 273, 280], ["lungs", "ANATOMY", 169, 174], ["significantly", "OBSERVATION_MODIFIER", 187, 200], ["decreased", "OBSERVATION_MODIFIER", 201, 210]]], ["Evidence-Based Complementary and Alternative Medicine Figure 3 : Total and differential cell counts in BALF. * < 0.05 means significant difference from the control group; # < 0.05 means significant difference from the LPS group and & < 0.05 means significant difference between LPS + 2.8 mL/kg TRQ group and LPS + 5.6 mL/kg TRQ group.Evidence-Based Complementary and AlternativeMedicine 5 (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k) (l)(a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k) (l)DiscussionIn recent decades, MAPKs and IKK/I B-/NF-B p65 signaling pathways have attracted considerable attention as targets for inflammation inhibition.", [["cell", "ANATOMY", 88, 92], ["BALF", "ANATOMY", 103, 107], ["LPS", "CHEMICAL", 218, 221], ["LPS", "CHEMICAL", 278, 281], ["TRQ", "CHEMICAL", 294, 297], ["LPS", "CHEMICAL", 308, 311], ["inflammation", "DISEASE", 612, 624], ["(b) (c) (d) (e) (f) (g) (h) (i) (j) (k) (l)(a) (b) (c) (d) (e) (f)", "CHEMICAL", 393, 459], ["cell", "CELL", 88, 92], ["BALF", "ORGANISM_SUBSTANCE", 103, 107], ["LPS", "SIMPLE_CHEMICAL", 218, 221], ["LPS", "SIMPLE_CHEMICAL", 278, 281], ["TRQ", "SIMPLE_CHEMICAL", 294, 297], ["LPS", "SIMPLE_CHEMICAL", 308, 311], ["AlternativeMedicine 5 (a) (b) (c) (d) (e) (f) (g) (h) (i", "SIMPLE_CHEMICAL", 367, 423], ["MAPKs", "GENE_OR_GENE_PRODUCT", 512, 517], ["IKK/I B", "GENE_OR_GENE_PRODUCT", 522, 529], ["NF-B p65", "GENE_OR_GENE_PRODUCT", 531, 539], ["BALF", "CELL_TYPE", 103, 107], ["MAPKs", "PROTEIN", 512, 517], ["IKK", "PROTEIN", 522, 525], ["I B", "PROTEIN", 526, 529], ["NF", "PROTEIN", 531, 533], ["p65", "PROTEIN", 536, 539], ["differential cell counts", "TEST", 75, 99], ["significant difference", "PROBLEM", 186, 208], ["the LPS group", "TEST", 214, 227], ["LPS", "TEST", 278, 281], ["LPS", "TEST", 308, 311], ["MAPKs", "TEST", 512, 517], ["IKK", "TEST", 522, 525], ["B", "TEST", 528, 529], ["NF", "TEST", 531, 533], ["inflammation inhibition", "PROBLEM", 612, 635], ["cell counts", "OBSERVATION", 88, 99], ["significant", "OBSERVATION_MODIFIER", 186, 197], ["difference", "OBSERVATION_MODIFIER", 198, 208]]], ["In the present study, we focused on the two pathways to tentatively explore the pharmacological mechanisms of TRQ, which, we hope, might in turn advance the drug development.", [["TRQ", "SIMPLE_CHEMICAL", 110, 113], ["the present study", "TEST", 3, 20]]], ["Here we showed that TRQ effectively reduced the phosphorylation of pivotal factors in MAPKs and NF-B signaling pathways, which contribute to significantly less recruitment and infiltration of immune cells in BALF and subsequent suppression on toxic cytokines release, realizing a promising mitigation on LPSinduced airway inflammation.DiscussionAs prominent target cells of LPS, neutrophils and macrophages were dramatically induced in BALF after LPS stimulation.", [["immune cells", "ANATOMY", 192, 204], ["BALF", "ANATOMY", 208, 212], ["airway", "ANATOMY", 315, 321], ["cells", "ANATOMY", 365, 370], ["neutrophils", "ANATOMY", 379, 390], ["macrophages", "ANATOMY", 395, 406], ["BALF", "ANATOMY", 436, 440], ["TRQ", "CHEMICAL", 20, 23], ["airway inflammation", "DISEASE", 315, 334], ["LPS", "CHEMICAL", 447, 450], ["TRQ", "CHEMICAL", 20, 23], ["TRQ", "SIMPLE_CHEMICAL", 20, 23], ["MAPKs", "GENE_OR_GENE_PRODUCT", 86, 91], ["NF-B", "GENE_OR_GENE_PRODUCT", 96, 100], ["immune cells", "CELL", 192, 204], ["BALF", "CELL", 208, 212], ["airway", "MULTI-TISSUE_STRUCTURE", 315, 321], ["cells", "CELL", 365, 370], ["LPS", "CELL", 374, 377], ["neutrophils", "CELL", 379, 390], ["macrophages", "CELL", 395, 406], ["BALF", "ORGANISM_SUBSTANCE", 436, 440], ["LPS", "SIMPLE_CHEMICAL", 447, 450], ["MAPKs", "PROTEIN", 86, 91], ["NF-B", "PROTEIN", 96, 100], ["immune cells", "CELL_TYPE", 192, 204], ["BALF", "CELL_TYPE", 208, 212], ["cytokines", "PROTEIN", 249, 258], ["neutrophils", "CELL_TYPE", 379, 390], ["macrophages", "CELL_TYPE", 395, 406], ["BALF", "CELL_TYPE", 436, 440], ["TRQ", "PROBLEM", 20, 23], ["pivotal factors", "PROBLEM", 67, 82], ["immune cells", "PROBLEM", 192, 204], ["BALF", "PROBLEM", 208, 212], ["toxic cytokines release", "TREATMENT", 243, 266], ["LPSinduced airway inflammation", "PROBLEM", 304, 334], ["LPS", "TEST", 374, 377], ["neutrophils", "TEST", 379, 390], ["macrophages", "PROBLEM", 395, 406], ["LPS stimulation", "TREATMENT", 447, 462], ["significantly", "OBSERVATION_MODIFIER", 141, 154], ["less", "OBSERVATION_MODIFIER", 155, 159], ["recruitment", "OBSERVATION_MODIFIER", 160, 171], ["infiltration", "OBSERVATION", 176, 188], ["immune cells", "OBSERVATION", 192, 204], ["BALF", "ANATOMY", 208, 212], ["airway", "ANATOMY", 315, 321], ["inflammation", "OBSERVATION", 322, 334], ["prominent", "OBSERVATION_MODIFIER", 348, 357], ["target cells", "OBSERVATION", 358, 370], ["macrophages", "ANATOMY", 395, 406]]], ["As for the neutrophil migration, LPS induces an enhanced chemokinesis by its direct effect on cells and an increased chemotaxis by indirect effects.", [["neutrophil", "ANATOMY", 11, 21], ["cells", "ANATOMY", 94, 99], ["LPS", "CHEMICAL", 33, 36], ["neutrophil", "CELL", 11, 21], ["LPS", "SIMPLE_CHEMICAL", 33, 36], ["cells", "CELL", 94, 99], ["neutrophil", "CELL_TYPE", 11, 21], ["the neutrophil migration", "PROBLEM", 7, 31], ["LPS", "PROBLEM", 33, 36], ["an enhanced chemokinesis", "PROBLEM", 45, 69], ["its direct effect on cells", "PROBLEM", 73, 99], ["an increased chemotaxis", "PROBLEM", 104, 127], ["neutrophil migration", "OBSERVATION", 11, 31], ["enhanced", "OBSERVATION_MODIFIER", 48, 56], ["chemokinesis", "OBSERVATION", 57, 69], ["increased", "OBSERVATION_MODIFIER", 107, 116], ["chemotaxis", "OBSERVATION_MODIFIER", 117, 127]]], ["For example, LPS challenge prominently enhances the level of IL-8, an essential CXC chemokine to attract neutrophils to sites of inflammation in the lung.", [["neutrophils", "ANATOMY", 105, 116], ["sites", "ANATOMY", 120, 125], ["lung", "ANATOMY", 149, 153], ["LPS", "CHEMICAL", 13, 16], ["inflammation", "DISEASE", 129, 141], ["LPS", "SIMPLE_CHEMICAL", 13, 16], ["IL-8", "GENE_OR_GENE_PRODUCT", 61, 65], ["CXC", "GENE_OR_GENE_PRODUCT", 80, 83], ["neutrophils", "CELL", 105, 116], ["lung", "ORGAN", 149, 153], ["IL-8", "PROTEIN", 61, 65], ["CXC chemokine", "PROTEIN", 80, 93], ["neutrophils", "CELL_TYPE", 105, 116], ["LPS challenge", "TEST", 13, 26], ["an essential CXC chemokine", "TEST", 67, 93], ["inflammation in the lung", "PROBLEM", 129, 153], ["inflammation", "OBSERVATION", 129, 141], ["lung", "ANATOMY", 149, 153]]], ["Both direct and indirect effects are modulated by the coordinated action of ERK, p38 MAPK, and NF-B pathways [33] .", [["ERK", "GENE_OR_GENE_PRODUCT", 76, 79], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 81, 89], ["NF-B", "GENE_OR_GENE_PRODUCT", 95, 99], ["ERK", "PROTEIN", 76, 79], ["p38 MAPK", "PROTEIN", 81, 89], ["NF-B", "PROTEIN", 95, 99], ["ERK", "TEST", 76, 79], ["p38 MAPK", "TEST", 81, 89], ["NF", "TEST", 95, 97]]], ["The pathways also contribute to macrophage migration.", [["macrophage", "ANATOMY", 32, 42], ["macrophage", "CELL", 32, 42], ["macrophage migration", "PROBLEM", 32, 52], ["pathways also contribute to", "UNCERTAINTY", 4, 31], ["macrophage migration", "OBSERVATION", 32, 52]]], ["It has been demonstrated that LPS or TNF--induced activation of matrix metalloproteinases, key players in macrophage migration and invasion into foci inflammation, is controlled via ERK1/2, JNK, and 24 48 96Control group LPS group(h) 2.8 mL/kg TRQ group 5.6 mL/kg TRQ group * # * # * # * # * # * * * (d) Figure 4 : Levels of cytokines in lung tissues. * < 0.05 means significant difference from the control group; # < 0.05 means significant difference from the LPS group and & < 0.05 means significant difference between LPS + 2.8 mL/kg TRQ group and LPS + 5.6 mL/kg TRQ group.Control group LPS groupIKK/NF-B pathway [34, 35] .", [["macrophage", "ANATOMY", 106, 116], ["foci", "ANATOMY", 145, 149], ["lung tissues", "ANATOMY", 338, 350], ["LPS", "CHEMICAL", 30, 33], ["inflammation", "DISEASE", 150, 162], ["LPS", "CHEMICAL", 221, 224], ["LPS", "CHEMICAL", 461, 464], ["LPS", "CHEMICAL", 521, 524], ["TRQ", "CHEMICAL", 537, 540], ["LPS", "CHEMICAL", 551, 554], ["LPS", "CHEMICAL", 591, 594], ["LPS", "SIMPLE_CHEMICAL", 30, 33], ["TNF", "GENE_OR_GENE_PRODUCT", 37, 40], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 64, 89], ["macrophage", "CELL", 106, 116], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 182, 188], ["JNK", "GENE_OR_GENE_PRODUCT", 190, 193], ["LPS", "SIMPLE_CHEMICAL", 221, 224], ["lung tissues", "TISSUE", 338, 350], ["LPS", "SIMPLE_CHEMICAL", 461, 464], ["LPS", "SIMPLE_CHEMICAL", 521, 524], ["TRQ", "SIMPLE_CHEMICAL", 537, 540], ["LPS", "SIMPLE_CHEMICAL", 551, 554], ["NF-B", "GENE_OR_GENE_PRODUCT", 604, 608], ["TNF", "PROTEIN", 37, 40], ["matrix metalloproteinases", "PROTEIN", 64, 89], ["ERK1", "PROTEIN", 182, 186], ["JNK", "PROTEIN", 190, 193], ["cytokines", "PROTEIN", 325, 334], ["groupIKK", "PROTEIN", 595, 603], ["NF", "PROTEIN", 604, 606], ["LPS", "PROBLEM", 30, 33], ["TNF", "PROBLEM", 37, 40], ["matrix metalloproteinases", "PROBLEM", 64, 89], ["macrophage migration", "TREATMENT", 106, 126], ["invasion into foci inflammation", "PROBLEM", 131, 162], ["ERK1", "TEST", 182, 186], ["JNK", "TEST", 190, 193], ["TRQ", "TEST", 244, 247], ["group", "TEST", 248, 253], ["Figure", "TEST", 304, 310], ["Levels of cytokines in lung tissues", "PROBLEM", 315, 350], ["significant difference", "PROBLEM", 429, 451], ["the LPS group", "TEST", 457, 470], ["LPS", "TEST", 521, 524], ["LPS", "TEST", 551, 554], ["cytokines", "OBSERVATION", 325, 334], ["lung tissues", "ANATOMY", 338, 350], ["significant", "OBSERVATION_MODIFIER", 429, 440], ["difference", "OBSERVATION_MODIFIER", 441, 451]]], ["Besides, the expression of MCP-1, another important chemokine for monocytes/ macrophages, is stimulated by LPS via NF-B-dependent mechanism [36] .", [["monocytes", "ANATOMY", 66, 75], ["macrophages", "ANATOMY", 77, 88], ["LPS", "CHEMICAL", 107, 110], ["MCP-1", "GENE_OR_GENE_PRODUCT", 27, 32], ["monocytes", "CELL", 66, 75], ["macrophages", "CELL", 77, 88], ["LPS", "SIMPLE_CHEMICAL", 107, 110], ["NF-B", "GENE_OR_GENE_PRODUCT", 115, 119], ["MCP-1", "PROTEIN", 27, 32], ["chemokine", "PROTEIN", 52, 61], ["monocytes", "CELL_TYPE", 66, 75], ["macrophages", "CELL_TYPE", 77, 88], ["NF-B", "PROTEIN", 115, 119], ["MCP", "TEST", 27, 30], ["monocytes/ macrophages", "TREATMENT", 66, 88]]], ["In particular, the involvement of lymphocytes was also observed after LPS treatment in this study.", [["lymphocytes", "ANATOMY", 34, 45], ["LPS", "CHEMICAL", 70, 73], ["lymphocytes", "CELL", 34, 45], ["LPS", "SIMPLE_CHEMICAL", 70, 73], ["lymphocytes", "CELL_TYPE", 34, 45], ["the involvement of lymphocytes", "PROBLEM", 15, 45], ["LPS treatment", "TREATMENT", 70, 83], ["this study", "TEST", 87, 97], ["lymphocytes", "OBSERVATION", 34, 45]]], ["Previous data showed that lymphocytes present in lung played a role in immunopathology of inflammatory process in both humans and mice [37, 38] .", [["lymphocytes", "ANATOMY", 26, 37], ["lung", "ANATOMY", 49, 53], ["lymphocytes", "CELL", 26, 37], ["lung", "ORGAN", 49, 53], ["humans", "ORGANISM", 119, 125], ["mice", "ORGANISM", 130, 134], ["lymphocytes", "CELL_TYPE", 26, 37], ["humans", "SPECIES", 119, 125], ["mice", "SPECIES", 130, 134], ["humans", "SPECIES", 119, 125], ["mice", "SPECIES", 130, 134], ["Previous data", "TEST", 0, 13], ["lymphocytes", "PROBLEM", 26, 37], ["inflammatory process", "PROBLEM", 90, 110], ["lymphocytes", "OBSERVATION", 26, 37], ["lung", "ANATOMY", 49, 53], ["inflammatory", "OBSERVATION", 90, 102]]], ["More specifically, study of Dushianthan and colleagues [39] revealed a rapid infiltration of different T cells, including regulatory T cells (Tregs), NKT, and NK cells in human lungs in response to LPS, accompanied by a significant elevation of IL-17, a potent recruiter of neutrophils to inflammatory sites.", [["T cells", "ANATOMY", 103, 110], ["regulatory T cells", "ANATOMY", 122, 140], ["Tregs", "ANATOMY", 142, 147], ["NKT", "ANATOMY", 150, 153], ["NK cells", "ANATOMY", 159, 167], ["lungs", "ANATOMY", 177, 182], ["neutrophils", "ANATOMY", 274, 285], ["inflammatory sites", "ANATOMY", 289, 307], ["LPS", "CHEMICAL", 198, 201], ["T cells", "CELL", 103, 110], ["regulatory T cells", "CELL", 122, 140], ["Tregs", "CELL", 142, 147], ["NKT", "CELL", 150, 153], ["NK cells", "CELL", 159, 167], ["human", "ORGANISM", 171, 176], ["lungs", "ORGAN", 177, 182], ["LPS", "SIMPLE_CHEMICAL", 198, 201], ["IL-17", "GENE_OR_GENE_PRODUCT", 245, 250], ["neutrophils", "CELL", 274, 285], ["T cells", "CELL_TYPE", 103, 110], ["regulatory T cells", "CELL_TYPE", 122, 140], ["Tregs", "CELL_TYPE", 142, 147], ["NKT, and NK cells", "CELL_TYPE", 150, 167], ["IL-17", "PROTEIN", 245, 250], ["neutrophils", "CELL_TYPE", 274, 285], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 171, 176], ["a rapid infiltration of different T cells", "PROBLEM", 69, 110], ["regulatory T cells", "PROBLEM", 122, 140], ["NKT", "PROBLEM", 150, 153], ["NK cells in human lungs", "PROBLEM", 159, 182], ["LPS", "TEST", 198, 201], ["a significant elevation of IL", "PROBLEM", 218, 247], ["inflammatory sites", "PROBLEM", 289, 307], ["rapid", "OBSERVATION_MODIFIER", 71, 76], ["infiltration", "OBSERVATION", 77, 89], ["different T cells", "OBSERVATION", 93, 110], ["NKT", "ANATOMY", 150, 153], ["NK cells", "OBSERVATION", 159, 167], ["human", "ANATOMY_MODIFIER", 171, 176], ["lungs", "ANATOMY", 177, 182], ["significant", "OBSERVATION_MODIFIER", 220, 231], ["elevation", "OBSERVATION_MODIFIER", 232, 241], ["inflammatory", "OBSERVATION_MODIFIER", 289, 301]]], ["They demonstrated that both lymphocyte released IL-17 and Tregs modulated the recruitment of neutrophils to the lung in LPS-induced ALI.", [["lymphocyte", "ANATOMY", 28, 38], ["neutrophils", "ANATOMY", 93, 104], ["lung", "ANATOMY", 112, 116], ["LPS", "CHEMICAL", 120, 123], ["ALI", "DISEASE", 132, 135], ["lymphocyte", "CELL", 28, 38], ["IL-17", "GENE_OR_GENE_PRODUCT", 48, 53], ["Tregs", "CELL", 58, 63], ["neutrophils", "CELL", 93, 104], ["lung", "ORGAN", 112, 116], ["LPS", "SIMPLE_CHEMICAL", 120, 123], ["lymphocyte released IL-17", "PROTEIN", 28, 53], ["Tregs", "CELL_TYPE", 58, 63], ["neutrophils", "CELL_TYPE", 93, 104], ["Tregs", "TREATMENT", 58, 63], ["neutrophils", "TEST", 93, 104], ["ALI", "PROBLEM", 132, 135], ["recruitment", "OBSERVATION_MODIFIER", 78, 89], ["lung", "ANATOMY", 112, 116], ["ALI", "OBSERVATION", 132, 135]]], ["Therefore, the drastic rise of neutrophils in BALF may partly be attributed to the elevation of lymphocytes in this study.Control group LPS groupIt has been well characterized that LPS administration on rats leads to overproduction of cytokines from neutrophils and macrophages including IL-1 , IL-6, IL-8, and TNF- [40] [41] [42] for up to 48 h [43] , as a result of a series of MAPKs/NF-B signal transduction cascade.", [["neutrophils", "ANATOMY", 31, 42], ["BALF", "ANATOMY", 46, 50], ["lymphocytes", "ANATOMY", 96, 107], ["neutrophils", "ANATOMY", 250, 261], ["macrophages", "ANATOMY", 266, 277], ["LPS", "CHEMICAL", 136, 139], ["LPS", "CHEMICAL", 181, 184], ["neutrophils", "CELL", 31, 42], ["BALF", "CELL", 46, 50], ["lymphocytes", "CELL", 96, 107], ["LPS", "SIMPLE_CHEMICAL", 181, 184], ["rats", "ORGANISM", 203, 207], ["neutrophils", "CELL", 250, 261], ["macrophages", "CELL", 266, 277], ["IL-1", "GENE_OR_GENE_PRODUCT", 288, 292], ["IL-6", "GENE_OR_GENE_PRODUCT", 295, 299], ["IL-8", "GENE_OR_GENE_PRODUCT", 301, 305], ["TNF- [40] [41] [42]", "SIMPLE_CHEMICAL", 311, 330], ["MAPKs", "GENE_OR_GENE_PRODUCT", 380, 385], ["NF-B", "GENE_OR_GENE_PRODUCT", 386, 390], ["neutrophils", "CELL_TYPE", 31, 42], ["BALF", "CELL_TYPE", 46, 50], ["lymphocytes", "CELL_TYPE", 96, 107], ["cytokines", "PROTEIN", 235, 244], ["neutrophils", "CELL_TYPE", 250, 261], ["macrophages", "CELL_TYPE", 266, 277], ["TNF", "PROTEIN", 311, 314], ["MAPKs", "PROTEIN", 380, 385], ["NF-B", "PROTEIN", 386, 390], ["rats", "SPECIES", 203, 207], ["the drastic rise of neutrophils in BALF", "PROBLEM", 11, 50], ["the elevation of lymphocytes", "PROBLEM", 79, 107], ["this study", "TEST", 111, 121], ["LPS administration", "TREATMENT", 181, 199], ["overproduction of cytokines", "PROBLEM", 217, 244], ["neutrophils", "TEST", 250, 261], ["macrophages", "TEST", 266, 277], ["IL", "TEST", 288, 290], ["IL", "TEST", 295, 297], ["IL", "TEST", 301, 303], ["TNF", "TEST", 311, 314], ["MAPKs/NF", "TREATMENT", 380, 388], ["B signal transduction cascade", "TREATMENT", 389, 418], ["drastic", "OBSERVATION_MODIFIER", 15, 22], ["rise", "OBSERVATION_MODIFIER", 23, 27], ["neutrophils", "OBSERVATION", 31, 42], ["BALF", "ANATOMY", 46, 50], ["may partly be attributed to", "UNCERTAINTY", 51, 78], ["elevation", "OBSERVATION_MODIFIER", 83, 92], ["lymphocytes", "OBSERVATION", 96, 107]]], ["It has been demonstrated that pretreatment with TNF inhibitors led to a reduction in circulating IL-1, IL-6, and IL-8, suggesting an important role of TNF-in the amplification of inflammatory response [44] .", [["TNF", "GENE_OR_GENE_PRODUCT", 48, 51], ["IL-1", "GENE_OR_GENE_PRODUCT", 97, 101], ["IL-6", "GENE_OR_GENE_PRODUCT", 103, 107], ["IL-8", "GENE_OR_GENE_PRODUCT", 113, 117], ["TNF", "GENE_OR_GENE_PRODUCT", 151, 154], ["TNF", "PROTEIN", 48, 51], ["IL-8", "PROTEIN", 113, 117], ["TNF", "PROTEIN", 151, 154], ["TNF inhibitors", "TREATMENT", 48, 62], ["circulating IL", "TEST", 85, 99], ["IL", "TEST", 103, 105], ["IL", "TEST", 113, 115], ["TNF", "PROBLEM", 151, 154], ["inflammatory response", "PROBLEM", 179, 200], ["reduction", "OBSERVATION_MODIFIER", 72, 81]]], ["TNF helps neutrophils, monocytes, and lymphocytes recruitment and infiltration by inducing vasodilation and loss of vascular permeability [45] and triggering the secretion of chemokines [46] and cell adhesion molecules [47] .", [["neutrophils", "ANATOMY", 10, 21], ["monocytes", "ANATOMY", 23, 32], ["lymphocytes", "ANATOMY", 38, 49], ["vascular", "ANATOMY", 116, 124], ["cell", "ANATOMY", 195, 199], ["TNF", "GENE_OR_GENE_PRODUCT", 0, 3], ["neutrophils", "CELL", 10, 21], ["monocytes", "CELL", 23, 32], ["lymphocytes", "CELL", 38, 49], ["vascular", "MULTI-TISSUE_STRUCTURE", 116, 124], ["cell", "CELL", 195, 199], ["TNF", "PROTEIN", 0, 3], ["neutrophils", "CELL_TYPE", 10, 21], ["monocytes", "CELL_TYPE", 23, 32], ["lymphocytes", "CELL_TYPE", 38, 49], ["chemokines", "PROTEIN", 175, 185], ["cell adhesion molecules", "PROTEIN", 195, 218], ["TNF", "TEST", 0, 3], ["neutrophils", "TEST", 10, 21], ["monocytes", "TEST", 23, 32], ["lymphocytes recruitment", "PROBLEM", 38, 61], ["infiltration", "PROBLEM", 66, 78], ["loss of vascular permeability", "PROBLEM", 108, 137], ["chemokines", "TEST", 175, 185], ["cell adhesion molecules", "TEST", 195, 218], ["neutrophils", "OBSERVATION", 10, 21], ["monocytes", "ANATOMY", 23, 32], ["lymphocytes recruitment", "OBSERVATION", 38, 61], ["infiltration", "OBSERVATION", 66, 78], ["vascular", "ANATOMY", 116, 124]]], ["Similarly to TNF, IL-1 is also mainly produced and 24 48 96Control group LPS group(h) 2.8 mL/kg TRQ group 5.6 mL/kg TRQ group * # * # * # * # * # * * * (d) Figure 5 : Levels of cytokines in BALF. * < 0.05 means significant difference from the control group; # < 0.05 means significant difference from the LPS group and & < 0.05 means significant difference between LPS + 2.8 mL/kg TRQ group and LPS + 5.6 mL/kg TRQ group. released from monocytes/macrophages in the initiation of inflammatory process after endotoxin exposure.", [["BALF", "ANATOMY", 190, 194], ["monocytes", "ANATOMY", 436, 445], ["macrophages", "ANATOMY", 446, 457], ["LPS", "CHEMICAL", 73, 76], ["LPS", "CHEMICAL", 305, 308], ["LPS", "CHEMICAL", 365, 368], ["TRQ", "CHEMICAL", 381, 384], ["LPS", "CHEMICAL", 395, 398], ["endotoxin", "CHEMICAL", 506, 515], ["TNF", "GENE_OR_GENE_PRODUCT", 13, 16], ["IL-1", "GENE_OR_GENE_PRODUCT", 18, 22], ["LPS", "SIMPLE_CHEMICAL", 73, 76], ["BALF", "CELL", 190, 194], ["LPS", "SIMPLE_CHEMICAL", 305, 308], ["LPS", "SIMPLE_CHEMICAL", 365, 368], ["TRQ", "SIMPLE_CHEMICAL", 381, 384], ["LPS", "SIMPLE_CHEMICAL", 395, 398], ["monocytes", "CELL", 436, 445], ["macrophages", "CELL", 446, 457], ["endotoxin", "SIMPLE_CHEMICAL", 506, 515], ["TNF", "PROTEIN", 13, 16], ["IL-1", "PROTEIN", 18, 22], ["cytokines", "PROTEIN", 177, 186], ["BALF", "CELL_TYPE", 190, 194], ["monocytes", "CELL_TYPE", 436, 445], ["macrophages", "CELL_TYPE", 446, 457], ["TNF", "TEST", 13, 16], ["IL", "TEST", 18, 20], ["TRQ", "TEST", 96, 99], ["Figure", "TEST", 156, 162], ["Levels", "TEST", 167, 173], ["cytokines in BALF", "TEST", 177, 194], ["significant difference", "PROBLEM", 273, 295], ["the LPS group", "TEST", 301, 314], ["LPS", "TEST", 365, 368], ["LPS", "TEST", 395, 398], ["macrophages", "PROBLEM", 446, 457], ["inflammatory process", "PROBLEM", 479, 499], ["endotoxin exposure", "TREATMENT", 506, 524], ["TNF", "ANATOMY", 13, 16], ["BALF", "ANATOMY", 190, 194], ["significant", "OBSERVATION_MODIFIER", 273, 284], ["difference", "OBSERVATION_MODIFIER", 285, 295], ["monocytes", "OBSERVATION", 436, 445], ["macrophages", "OBSERVATION", 446, 457], ["inflammatory", "OBSERVATION_MODIFIER", 479, 491], ["endotoxin exposure", "OBSERVATION", 506, 524]]], ["Released IL-1 subsequently triggers further production of IL-1 and other cytokines/chemokines by infiltrating cells and accounts for the perpetuation of inflammation.", [["infiltrating cells", "ANATOMY", 97, 115], ["inflammation", "DISEASE", 153, 165], ["IL-1", "GENE_OR_GENE_PRODUCT", 9, 13], ["IL-1", "GENE_OR_GENE_PRODUCT", 58, 62], ["infiltrating cells", "CELL", 97, 115], ["IL-1", "PROTEIN", 9, 13], ["IL-1", "PROTEIN", 58, 62], ["cytokines", "PROTEIN", 73, 82], ["chemokines", "PROTEIN", 83, 93], ["infiltrating cells", "CELL_TYPE", 97, 115], ["further production of IL", "TREATMENT", 36, 60], ["other cytokines/chemokines", "TREATMENT", 67, 93], ["infiltrating cells", "PROBLEM", 97, 115], ["inflammation", "PROBLEM", 153, 165], ["infiltrating cells", "OBSERVATION", 97, 115], ["inflammation", "OBSERVATION", 153, 165]]], ["This may partially explain why IL-1 keeps at high levels at 48 h after LPS instillation in our results.", [["LPS", "CHEMICAL", 71, 74], ["IL-1", "GENE_OR_GENE_PRODUCT", 31, 35], ["LPS", "SIMPLE_CHEMICAL", 71, 74], ["IL", "PROTEIN", 31, 33], ["IL", "TEST", 31, 33], ["LPS instillation", "TREATMENT", 71, 87]]], ["As a pleiotropic cytokine that possesses both pro-and anti-inflammation properties, IL-6 plays a key role in acute-phase of lung injury by affecting the release and functions of neutrophils and macrophages [48] .", [["lung", "ANATOMY", 124, 128], ["neutrophils", "ANATOMY", 178, 189], ["macrophages", "ANATOMY", 194, 205], ["lung injury", "DISEASE", 124, 135], ["IL-6", "GENE_OR_GENE_PRODUCT", 84, 88], ["lung", "ORGAN", 124, 128], ["neutrophils", "CELL", 178, 189], ["macrophages", "CELL", 194, 205], ["pleiotropic cytokine", "PROTEIN", 5, 25], ["IL-6", "PROTEIN", 84, 88], ["neutrophils", "CELL_TYPE", 178, 189], ["macrophages", "CELL_TYPE", 194, 205], ["a pleiotropic cytokine", "TREATMENT", 3, 25], ["both pro-and anti-inflammation properties", "TREATMENT", 41, 82], ["lung injury", "PROBLEM", 124, 135], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["lung", "ANATOMY", 124, 128], ["injury", "OBSERVATION", 129, 135]]], ["Time-course studies showed that induction of mRNA for IL-1 and TNF-occurred rapidly preceding that of IL-6 mRNA after LPS exposure [49] .", [["LPS", "CHEMICAL", 118, 121], ["IL-1", "GENE_OR_GENE_PRODUCT", 54, 58], ["TNF", "GENE_OR_GENE_PRODUCT", 63, 66], ["IL-6", "GENE_OR_GENE_PRODUCT", 102, 106], ["LPS", "SIMPLE_CHEMICAL", 118, 121], ["mRNA", "RNA", 45, 49], ["IL", "PROTEIN", 54, 56], ["TNF", "PROTEIN", 63, 66], ["IL-6 mRNA", "RNA", 102, 111], ["IL", "TEST", 54, 56], ["TNF", "TEST", 63, 66], ["IL", "TEST", 102, 104], ["LPS exposure", "TEST", 118, 130]]], ["Subsequently, depending on p38 MAPK and NF-B pathways, early produced IL-1 and TNF-induced IL-6 mRNA expression and more IL-6 production.", [["p38 MAPK", "GENE_OR_GENE_PRODUCT", 27, 35], ["NF-B", "GENE_OR_GENE_PRODUCT", 40, 44], ["IL-1", "GENE_OR_GENE_PRODUCT", 70, 74], ["TNF", "GENE_OR_GENE_PRODUCT", 79, 82], ["IL-6", "GENE_OR_GENE_PRODUCT", 91, 95], ["IL-6", "GENE_OR_GENE_PRODUCT", 121, 125], ["p38 MAPK", "PROTEIN", 27, 35], ["NF-B", "PROTEIN", 40, 44], ["p38 MAPK", "TEST", 27, 35], ["NF", "TEST", 40, 42], ["IL", "TEST", 70, 72], ["TNF", "TEST", 79, 82], ["IL", "TEST", 91, 93]]], ["This may explain the continued rise in IL-6 mRNA level till 48 h.", [["IL-6", "GENE_OR_GENE_PRODUCT", 39, 43], ["IL-6 mRNA", "RNA", 39, 48], ["the continued rise in IL", "PROBLEM", 17, 41], ["continued", "OBSERVATION_MODIFIER", 21, 30], ["rise", "OBSERVATION_MODIFIER", 31, 35]]], ["Therefore, it is noteworthy that a large proportion of LPS-stimulated IL-6 is actually indirectly induced by TNF-and/or IL-1 [50] .", [["LPS", "CHEMICAL", 55, 58], ["LPS", "SIMPLE_CHEMICAL", 55, 58], ["IL-6", "GENE_OR_GENE_PRODUCT", 70, 74], ["TNF", "GENE_OR_GENE_PRODUCT", 109, 112], ["IL-1", "GENE_OR_GENE_PRODUCT", 120, 124], ["IL-6", "PROTEIN", 70, 74], ["TNF", "PROTEIN", 109, 112], ["LPS-stimulated IL", "TREATMENT", 55, 72], ["TNF", "TEST", 109, 112], ["large", "OBSERVATION_MODIFIER", 35, 40]]], ["Inversely, endotoxininduced IL-6 functions to downregulate its own inducers, TNF-and IL-1 on mRNA and protein levels [51, 52] , with a negative feedback mechanism.", [["IL-6", "GENE_OR_GENE_PRODUCT", 28, 32], ["TNF", "GENE_OR_GENE_PRODUCT", 77, 80], ["IL-1", "GENE_OR_GENE_PRODUCT", 85, 89], ["endotoxininduced IL-6", "PROTEIN", 11, 32], ["TNF", "PROTEIN", 77, 80], ["endotoxininduced IL", "TREATMENT", 11, 30], ["TNF", "TEST", 77, 80], ["IL", "TEST", 85, 87], ["mRNA", "TEST", 93, 97], ["protein levels", "TEST", 102, 116]]], ["As a result, the acute neutrophil and macrophage exudation would be diminished [53] , realizing the protective role of IL-6 on endotoxininduced inflammation [54] .", [["neutrophil", "ANATOMY", 23, 33], ["macrophage", "ANATOMY", 38, 48], ["inflammation", "DISEASE", 144, 156], ["neutrophil", "CELL", 23, 33], ["macrophage", "CELL", 38, 48], ["IL-6", "GENE_OR_GENE_PRODUCT", 119, 123], ["acute neutrophil", "CELL_TYPE", 17, 33], ["IL-6", "PROTEIN", 119, 123], ["the acute neutrophil", "PROBLEM", 13, 33], ["macrophage exudation", "PROBLEM", 38, 58], ["diminished", "PROBLEM", 68, 78], ["endotoxininduced inflammation", "PROBLEM", 127, 156], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["neutrophil", "OBSERVATION", 23, 33], ["macrophage exudation", "OBSERVATION", 38, 58]]], ["Although nonnegligible amount of IL-6 is induced by TNF-and IL-1 in this condition, TNF-and IL-1 are both produced in a very rapid burst in response to LPS; therefore, the decrease of IL-6 levels here was likely not due to a secondary effect exerted by decline of TNFand IL-1 levels, which should be ascribed to the effect from Control group LPS group 24 48 96Control group LPS group(h) 2.8 mL/kg TRQ group 5.6 mL/kg TRQ group * * * * * * (d) Figure 6 : Changes in relative mRNA levels of cytokines in lung tissues. * < 0.05 means significant difference from the control group; # < 0.05 means significant difference from the LPS group and & < 0.05 means significant difference between LPS + 2.8 mL/kg TRQ group and LPS + 5.6 mL/kg TRQ group.Control group LPS groupTRQ.", [["lung tissues", "ANATOMY", 502, 514], ["LPS", "CHEMICAL", 152, 155], ["LPS", "CHEMICAL", 342, 345], ["LPS", "CHEMICAL", 374, 377], ["LPS", "CHEMICAL", 625, 628], ["LPS", "CHEMICAL", 685, 688], ["TRQ", "CHEMICAL", 701, 704], ["LPS", "CHEMICAL", 715, 718], ["LPS", "CHEMICAL", 755, 758], ["IL-6", "GENE_OR_GENE_PRODUCT", 33, 37], ["TNF", "GENE_OR_GENE_PRODUCT", 52, 55], ["IL-1", "GENE_OR_GENE_PRODUCT", 60, 64], ["TNF", "GENE_OR_GENE_PRODUCT", 84, 87], ["IL-1", "GENE_OR_GENE_PRODUCT", 92, 96], ["LPS", "SIMPLE_CHEMICAL", 152, 155], ["IL-6", "GENE_OR_GENE_PRODUCT", 184, 188], ["TNFand", "GENE_OR_GENE_PRODUCT", 264, 270], ["IL-1", "GENE_OR_GENE_PRODUCT", 271, 275], ["LPS", "SIMPLE_CHEMICAL", 374, 377], ["lung tissues", "TISSUE", 502, 514], ["LPS", "SIMPLE_CHEMICAL", 625, 628], ["LPS", "SIMPLE_CHEMICAL", 685, 688], ["TRQ", "SIMPLE_CHEMICAL", 701, 704], ["LPS", "SIMPLE_CHEMICAL", 715, 718], ["IL-6", "PROTEIN", 33, 37], ["TNF", "PROTEIN", 52, 55], ["IL-1", "PROTEIN", 60, 64], ["TNF", "PROTEIN", 84, 87], ["IL-1", "PROTEIN", 92, 96], ["IL-6", "PROTEIN", 184, 188], ["IL", "PROTEIN", 271, 273], ["cytokines", "PROTEIN", 489, 498], ["TNF", "TEST", 52, 55], ["IL", "TEST", 60, 62], ["TNF", "TEST", 84, 87], ["a very rapid burst", "PROBLEM", 118, 136], ["LPS", "TREATMENT", 152, 155], ["the decrease of IL", "TREATMENT", 168, 186], ["a secondary effect", "PROBLEM", 223, 241], ["TNFand IL", "TREATMENT", 264, 273], ["Control group LPS group", "TREATMENT", 328, 351], ["Changes in relative mRNA levels of cytokines in lung tissues", "PROBLEM", 454, 514], ["significant difference", "PROBLEM", 593, 615], ["the LPS group", "TEST", 621, 634], ["LPS", "TEST", 685, 688], ["LPS", "TEST", 715, 718], ["Control group LPS groupTRQ", "TREATMENT", 741, 767], ["amount", "OBSERVATION_MODIFIER", 23, 29], ["mRNA", "OBSERVATION_MODIFIER", 474, 478], ["levels", "OBSERVATION_MODIFIER", 479, 485], ["cytokines", "OBSERVATION", 489, 498], ["lung tissues", "ANATOMY", 502, 514], ["significant", "OBSERVATION_MODIFIER", 593, 604], ["difference", "OBSERVATION_MODIFIER", 605, 615]]], ["Clinical trials demonstrated that TRQ administration showed a potent effect on lowering the levels of IL-1 , IL-6, IL-8, TNF-, and IL-17 in plasma of patients under acute pulmonary conditions [11, 55, 56] , which was promisingly consistent with our results obtained from rat models.Control group LPS groupTo our knowledge, it is the first attempt to discover the underlying mechanism involving signaling pathways for the effect of TRQ.", [["plasma", "ANATOMY", 140, 146], ["pulmonary", "ANATOMY", 171, 180], ["TRQ", "CHEMICAL", 34, 37], ["LPS", "CHEMICAL", 296, 299], ["TRQ", "CHEMICAL", 34, 37], ["TRQ", "SIMPLE_CHEMICAL", 34, 37], ["IL-1", "GENE_OR_GENE_PRODUCT", 102, 106], ["IL-6", "GENE_OR_GENE_PRODUCT", 109, 113], ["IL-8", "GENE_OR_GENE_PRODUCT", 115, 119], ["TNF", "GENE_OR_GENE_PRODUCT", 121, 124], ["IL-17", "GENE_OR_GENE_PRODUCT", 131, 136], ["plasma", "ORGANISM_SUBSTANCE", 140, 146], ["patients", "ORGANISM", 150, 158], ["pulmonary", "ORGAN", 171, 180], ["rat", "ORGANISM", 271, 274], ["TRQ", "GENE_OR_GENE_PRODUCT", 431, 434], ["TNF", "PROTEIN", 121, 124], ["IL-17", "PROTEIN", 131, 136], ["TRQ", "PROTEIN", 431, 434], ["patients", "SPECIES", 150, 158], ["rat", "SPECIES", 271, 274], ["Clinical trials", "TEST", 0, 15], ["TRQ administration", "TREATMENT", 34, 52], ["a potent effect", "PROBLEM", 60, 75], ["IL", "TEST", 102, 104], ["IL", "TEST", 109, 111], ["IL", "TEST", 115, 117], ["TNF", "TEST", 121, 124], ["IL", "TEST", 131, 133], ["acute pulmonary conditions", "PROBLEM", 165, 191], ["TRQ", "TREATMENT", 431, 434], ["acute", "OBSERVATION_MODIFIER", 165, 170], ["pulmonary", "ANATOMY", 171, 180]]], ["This present study had some limitations.", [["This present study", "TEST", 0, 18]]], ["Although pathogenesis of LPS-induced airway inflammation generally involves multiple signaling pathways, we only investigated MAPKs/NF-B pathways and only discussed its role in LPS-stimulated inflammations in vivo.", [["airway", "ANATOMY", 37, 43], ["LPS", "CHEMICAL", 25, 28], ["airway inflammation", "DISEASE", 37, 56], ["LPS", "CHEMICAL", 177, 180], ["inflammations", "DISEASE", 192, 205], ["LPS", "SIMPLE_CHEMICAL", 25, 28], ["airway", "MULTI-TISSUE_STRUCTURE", 37, 43], ["MAPKs", "GENE_OR_GENE_PRODUCT", 126, 131], ["NF-B", "GENE_OR_GENE_PRODUCT", 132, 136], ["LPS", "SIMPLE_CHEMICAL", 177, 180], ["MAPKs", "PROTEIN", 126, 131], ["NF-B", "PROTEIN", 132, 136], ["LPS", "PROBLEM", 25, 28], ["airway inflammation", "PROBLEM", 37, 56], ["MAPKs", "TEST", 126, 131], ["stimulated inflammations", "PROBLEM", 181, 205], ["LPS", "OBSERVATION_MODIFIER", 25, 28], ["airway", "ANATOMY", 37, 43], ["inflammation", "OBSERVATION", 44, 56]]], ["If necessary, we will conduct more comprehensive work in the future to systematically evaluate its function in vitro and multiple pathways and also other pathogen-induced inflammation models.ConclusionIn summary, this work demonstrated that TRQ dose-dependently attenuated LPS-induced neutrophils, macrophages, and lymphocytes infiltration and inhibited proinflammatory cytokines including TNF-, IL-1 , IL-6, and IL-8 on both mRNA transcription and protein synthesis levels, which were very beneficial to the resolution of inflammation.", [["neutrophils", "ANATOMY", 285, 296], ["macrophages", "ANATOMY", 298, 309], ["lymphocytes", "ANATOMY", 315, 326], ["inflammation", "DISEASE", 171, 183], ["TRQ", "CHEMICAL", 241, 244], ["LPS", "CHEMICAL", 273, 276], ["inflammation", "DISEASE", 523, 535], ["TRQ", "CHEMICAL", 241, 244], ["TRQ", "SIMPLE_CHEMICAL", 241, 244], ["LPS", "SIMPLE_CHEMICAL", 273, 276], ["neutrophils", "CELL", 285, 296], ["macrophages", "CELL", 298, 309], ["lymphocytes", "CELL", 315, 326], ["TNF", "GENE_OR_GENE_PRODUCT", 390, 393], ["IL-1", "GENE_OR_GENE_PRODUCT", 396, 400], ["IL-6", "GENE_OR_GENE_PRODUCT", 403, 407], ["IL-8", "GENE_OR_GENE_PRODUCT", 413, 417], ["neutrophils", "CELL_TYPE", 285, 296], ["macrophages", "CELL_TYPE", 298, 309], ["lymphocytes", "CELL_TYPE", 315, 326], ["proinflammatory cytokines", "PROTEIN", 354, 379], ["TNF", "PROTEIN", 390, 393], ["IL-8", "PROTEIN", 413, 417], ["induced inflammation models", "PROBLEM", 163, 190], ["TRQ dose", "TEST", 241, 249], ["dependently attenuated LPS", "PROBLEM", 250, 276], ["neutrophils", "PROBLEM", 285, 296], ["macrophages", "PROBLEM", 298, 309], ["lymphocytes infiltration", "PROBLEM", 315, 339], ["proinflammatory cytokines", "TEST", 354, 379], ["TNF", "TEST", 390, 393], ["IL", "TEST", 396, 398], ["IL", "TEST", 403, 405], ["IL", "TEST", 413, 415], ["both mRNA transcription", "TEST", 421, 444], ["protein synthesis levels", "TEST", 449, 473], ["inflammation", "PROBLEM", 523, 535], ["inflammation", "OBSERVATION", 171, 183], ["neutrophils", "ANATOMY", 285, 296], ["macrophages", "ANATOMY", 298, 309], ["lymphocytes infiltration", "OBSERVATION", 315, 339], ["inflammation", "OBSERVATION", 523, 535]]], ["The therapeutic action of TRQ, in some degree, benefited from its inhibitory effect on the expressions of p38 MAPK and NF-B p65 in lungs by reducing phosphorylation of p38 MAPK, ERK1/2, IKK / , I B-, and NF-B p65.", [["lungs", "ANATOMY", 131, 136], ["TRQ", "CHEMICAL", 26, 29], ["TRQ", "SIMPLE_CHEMICAL", 26, 29], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 106, 114], ["NF-B p65", "GENE_OR_GENE_PRODUCT", 119, 127], ["lungs", "ORGAN", 131, 136], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 168, 176], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 178, 184], ["IKK", "GENE_OR_GENE_PRODUCT", 186, 189], ["I B-", "GENE_OR_GENE_PRODUCT", 194, 198], ["NF-B p65", "GENE_OR_GENE_PRODUCT", 204, 212], ["p38 MAPK", "PROTEIN", 106, 114], ["NF-B p65", "PROTEIN", 119, 127], ["p38 MAPK", "PROTEIN", 168, 176], ["ERK1/2", "PROTEIN", 178, 184], ["IKK", "PROTEIN", 186, 189], ["I B-", "PROTEIN", 194, 198], ["NF-B p65", "PROTEIN", 204, 212], ["TRQ", "TREATMENT", 26, 29], ["p38 MAPK", "TEST", 106, 114], ["NF", "TEST", 119, 121], ["p38 MAPK", "TEST", 168, 176], ["ERK1", "TEST", 178, 182], ["IKK", "TEST", 186, 189], ["NF", "TEST", 204, 206], ["some degree", "OBSERVATION_MODIFIER", 34, 45], ["lungs", "ANATOMY", 131, 136]]], ["All the present findings specified that the underlying mechanisms of the suppressive actions of TRQ on LPS-induced airway inflammation and mucus overproduction might be due to, at least in part, the suppression on MAPKs and NF-B signaling pathways.", [["airway", "ANATOMY", 115, 121], ["mucus", "ANATOMY", 139, 144], ["TRQ", "CHEMICAL", 96, 99], ["LPS", "CHEMICAL", 103, 106], ["airway inflammation", "DISEASE", 115, 134], ["TRQ", "SIMPLE_CHEMICAL", 96, 99], ["LPS", "SIMPLE_CHEMICAL", 103, 106], ["airway", "MULTI-TISSUE_STRUCTURE", 115, 121], ["mucus", "MULTI-TISSUE_STRUCTURE", 139, 144], ["MAPKs", "GENE_OR_GENE_PRODUCT", 214, 219], ["NF-B", "GENE_OR_GENE_PRODUCT", 224, 228], ["MAPKs", "PROTEIN", 214, 219], ["NF-B", "PROTEIN", 224, 228], ["TRQ", "TREATMENT", 96, 99], ["LPS", "TREATMENT", 103, 106], ["airway inflammation", "PROBLEM", 115, 134], ["mucus overproduction", "PROBLEM", 139, 159], ["MAPKs", "TEST", 214, 219], ["NF", "TEST", 224, 226], ["airway", "ANATOMY", 115, 121], ["inflammation", "OBSERVATION", 122, 134], ["mucus overproduction", "OBSERVATION", 139, 159]]], ["Values are expressed as mean \u00b1 SD. * < 0.05 means significant difference from the control group; # < 0.05 means significant difference from the LPS group and & < 0.05 means significant difference between LPS + 2.8 mL/kg TRQ group and LPS + 5.6 mL/kg TRQ group.", [["LPS", "CHEMICAL", 144, 147], ["LPS", "CHEMICAL", 204, 207], ["TRQ", "CHEMICAL", 220, 223], ["LPS", "CHEMICAL", 234, 237], ["LPS", "SIMPLE_CHEMICAL", 144, 147], ["LPS", "SIMPLE_CHEMICAL", 204, 207], ["TRQ", "SIMPLE_CHEMICAL", 220, 223], ["LPS", "SIMPLE_CHEMICAL", 234, 237], ["Values", "TEST", 0, 6], ["significant difference", "PROBLEM", 112, 134], ["the LPS group", "TEST", 140, 153], ["LPS", "TEST", 204, 207], ["LPS", "TEST", 234, 237], ["significant", "OBSERVATION_MODIFIER", 112, 123], ["difference", "OBSERVATION_MODIFIER", 124, 134]]], ["Figure 9 : Changes in protein levels in lung tissues. * < 0.05 means significant difference from the control group; # < 0.05 means significant difference from the LPS group and & < 0.05 means significant difference between LPS + 2.8 mL/kg TRQ group and LPS + 5.6 mL/kg TRQ group.", [["lung tissues", "ANATOMY", 40, 52], ["LPS", "CHEMICAL", 163, 166], ["LPS", "CHEMICAL", 223, 226], ["TRQ", "CHEMICAL", 239, 242], ["LPS", "CHEMICAL", 253, 256], ["lung tissues", "TISSUE", 40, 52], ["LPS", "SIMPLE_CHEMICAL", 163, 166], ["LPS", "SIMPLE_CHEMICAL", 223, 226], ["TRQ", "SIMPLE_CHEMICAL", 239, 242], ["LPS", "SIMPLE_CHEMICAL", 253, 256], ["Changes in protein levels in lung tissues", "PROBLEM", 11, 52], ["significant difference", "PROBLEM", 131, 153], ["the LPS group", "TEST", 159, 172], ["LPS", "TEST", 223, 226], ["LPS", "TEST", 253, 256], ["lung tissues", "ANATOMY", 40, 52], ["significant", "OBSERVATION_MODIFIER", 131, 142], ["difference", "OBSERVATION_MODIFIER", 143, 153]]]], "PMC7104997": [], "03aa008cb34bd2e4d31ce08d893366b3a24277db": [["logistics are well positioned to serve on critical care resuscitation/delivery teams under such conditions.", [["critical care resuscitation", "TREATMENT", 42, 69], ["delivery teams", "TREATMENT", 70, 84]]], ["The Coronavirus Disease-Activated Emergency Scaling of Anesthesiology Responsibilities in the Intensive Care Unit (CAESAR-ICU) program is a joint initiative of American Society of Anesthesiologists (ASA), Society of Critical Care Medicine (SCCM), Anesthesia Patient Safety Foundation (APSF), and Society of Critical Care Anesthesiologists (SOCCA) and is intended to create a \"survival\" guide for the practicing anesthesiologist who may be called on to provide early management and stabilization of COVID-19 patients.", [["patients", "ORGANISM", 507, 515], ["patients", "SPECIES", 507, 515], ["The Coronavirus Disease", "PROBLEM", 0, 23], ["Anesthesiologists (ASA", "TREATMENT", 180, 202], ["early management", "TREATMENT", 460, 476], ["COVID", "TEST", 498, 503], ["Coronavirus Disease", "OBSERVATION", 4, 23], ["joint", "ANATOMY", 140, 145]]], ["This narrative review of COVID-19 is based on study done by the CAESAR-ICU group and provides basic critical care management principles for the anesthesiologist with an emphasis on relevant organ system effects impacted by COVID-19.COVID-19 PATHOPHYSIOLOGY AND THE ANGIOTENSIN-CONVERTING ENZYME-2 RECEPTORCOVID-19 is the systemic manifestation of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) virus.", [["organ", "ANATOMY", 190, 195], ["acute respiratory syndrome coronavirus", "DISEASE", 358, 396], ["COVID-19", "CHEMICAL", 223, 231], ["organ", "ORGAN", 190, 195], ["SARS-COV-2) virus", "ORGANISM", 400, 417], ["severe acute respiratory syndrome coronavirus", "SPECIES", 351, 396], ["SARS-COV-2) virus", "SPECIES", 400, 417], ["COVID", "TEST", 25, 30], ["study", "TEST", 46, 51], ["basic critical care management", "TREATMENT", 94, 124], ["the anesthesiologist", "TREATMENT", 140, 160], ["COVID", "TEST", 223, 228], ["COVID", "TEST", 232, 237], ["THE ANGIOTENSIN-CONVERTING ENZYME", "TEST", 261, 294], ["RECEPTORCOVID", "TEST", 297, 310], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 347, 396], ["SARS", "TEST", 400, 404], ["COV", "TEST", 405, 408], ["virus", "PROBLEM", 412, 417], ["severe", "OBSERVATION_MODIFIER", 351, 357], ["acute", "OBSERVATION_MODIFIER", 358, 363], ["respiratory syndrome", "OBSERVATION", 364, 384]]], ["SARS-COV-2 enters human cells via the angiotensin-converting enzyme-2 (ACE-2) receptor.", [["cells", "ANATOMY", 24, 29], ["SARS", "DISEASE", 0, 4], ["angiotensin", "CHEMICAL", 38, 49], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["human", "ORGANISM", 18, 23], ["cells", "CELL", 24, 29], ["angiotensin-converting enzyme-2", "GENE_OR_GENE_PRODUCT", 38, 69], ["ACE-2", "GENE_OR_GENE_PRODUCT", 71, 76], ["SARS-COV-2", "DNA", 0, 10], ["human cells", "CELL_TYPE", 18, 29], ["angiotensin-converting enzyme-2 (ACE-2) receptor", "PROTEIN", 38, 86], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23], ["SARS", "TEST", 0, 4], ["COV", "TEST", 5, 8], ["the angiotensin", "TREATMENT", 34, 49], ["converting enzyme-2 (ACE-2) receptor", "TREATMENT", 50, 86]]], ["It has a binding affinity 10-15 times greater than the SARS virus responsible for a smaller outbreak in 2003.", [["SARS", "DISEASE", 55, 59], ["SARS virus", "SPECIES", 55, 65], ["a binding affinity", "PROBLEM", 7, 25], ["the SARS virus", "PROBLEM", 51, 65], ["smaller", "OBSERVATION_MODIFIER", 84, 91]]], ["1 The ACE-2 receptor is a cell membrane-associated protein that can be found in epithelial (cardiac and renal) cells, endothelial (pulmonary and vascular) cells, and cells of the oral mucosa and nasopharynx ( Figure 1 ).", [["cell membrane", "ANATOMY", 26, 39], ["epithelial", "ANATOMY", 80, 90], ["cardiac", "ANATOMY", 92, 99], ["renal) cells", "ANATOMY", 104, 116], ["endothelial", "ANATOMY", 118, 129], ["pulmonary", "ANATOMY", 131, 140], ["vascular) cells", "ANATOMY", 145, 160], ["cells", "ANATOMY", 166, 171], ["oral mucosa", "ANATOMY", 179, 190], ["nasopharynx", "ANATOMY", 195, 206], ["ACE-2 receptor", "GENE_OR_GENE_PRODUCT", 6, 20], ["cell membrane", "CELLULAR_COMPONENT", 26, 39], ["epithelial", "CELL", 80, 90], ["cardiac", "CELL", 92, 99], ["renal) cells", "CELL", 104, 116], ["endothelial", "CELL", 118, 129], ["pulmonary", "CELL", 131, 140], ["vascular) cells", "CELL", 145, 160], ["cells", "CELL", 166, 171], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 179, 190], ["nasopharynx", "ORGAN", 195, 206], ["ACE-2 receptor", "PROTEIN", 6, 20], ["cell membrane-associated protein", "PROTEIN", 26, 58], ["epithelial (cardiac and renal) cells", "CELL_TYPE", 80, 116], ["endothelial (pulmonary and vascular) cells", "CELL_TYPE", 118, 160], ["a cell membrane", "TEST", 24, 39], ["associated protein", "PROBLEM", 40, 58], ["epithelial (cardiac and renal) cells", "PROBLEM", 80, 116], ["endothelial (pulmonary and vascular) cells", "PROBLEM", 118, 160], ["cells of the oral mucosa and nasopharynx", "PROBLEM", 166, 206], ["epithelial", "ANATOMY_MODIFIER", 80, 90], ["cardiac", "ANATOMY", 92, 99], ["renal", "ANATOMY", 104, 109], ["endothelial", "ANATOMY", 118, 129], ["pulmonary", "ANATOMY", 131, 140], ["vascular", "ANATOMY", 145, 153], ["oral mucosa", "ANATOMY", 179, 190], ["nasopharynx", "ANATOMY", 195, 206]]], ["When SARS-COV-2 binds to the ACE-2 receptor, it reduces intracellular ACE-2 protein activity.", [["intracellular", "ANATOMY", 56, 69], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 5, 15], ["ACE-2 receptor", "GENE_OR_GENE_PRODUCT", 29, 43], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 69], ["ACE-2", "GENE_OR_GENE_PRODUCT", 70, 75], ["SARS-COV-2", "DNA", 5, 15], ["ACE-2 receptor", "PROTEIN", 29, 43], ["ACE", "PROTEIN", 70, 73], ["SARS", "TEST", 5, 9], ["COV", "TEST", 10, 13], ["the ACE", "TEST", 25, 32], ["intracellular ACE", "TEST", 56, 73]]], ["2, 3 In the heart, ACE-2 is involved in endothelial regulation, vasoconstriction, and cardiac function.", [["heart", "ANATOMY", 12, 17], ["endothelial", "ANATOMY", 40, 51], ["cardiac", "ANATOMY", 86, 93], ["heart", "ORGAN", 12, 17], ["ACE-2", "GENE_OR_GENE_PRODUCT", 19, 24], ["endothelial", "CELL", 40, 51], ["cardiac", "ORGAN", 86, 93], ["ACE", "TEST", 19, 22], ["vasoconstriction", "PROBLEM", 64, 80], ["heart", "ANATOMY", 12, 17], ["endothelial", "ANATOMY", 40, 51], ["vasoconstriction", "OBSERVATION", 64, 80], ["cardiac", "ANATOMY", 86, 93]]], ["In the renal system, ACE-2 impairment has been implicated in oxidative stress, inflammation, and fibrosis of the renal tissue.", [["renal system", "ANATOMY", 7, 19], ["renal tissue", "ANATOMY", 113, 125], ["inflammation", "DISEASE", 79, 91], ["fibrosis", "DISEASE", 97, 105], ["renal", "ORGAN", 7, 12], ["ACE-2", "GENE_OR_GENE_PRODUCT", 21, 26], ["renal tissue", "TISSUE", 113, 125], ["ACE", "PROTEIN", 21, 24], ["ACE-2 impairment", "PROBLEM", 21, 37], ["oxidative stress", "PROBLEM", 61, 77], ["inflammation", "PROBLEM", 79, 91], ["fibrosis of the renal tissue", "PROBLEM", 97, 125], ["renal system", "ANATOMY", 7, 19], ["oxidative stress", "OBSERVATION", 61, 77], ["inflammation", "OBSERVATION", 79, 91], ["fibrosis", "OBSERVATION", 97, 105], ["renal tissue", "ANATOMY", 113, 125]]], ["4 The role of ACE-2 in the lung is incompletely understood, but increased activity may possibly reduce lung injury in the adult respiratory distress syndrome (ARDS).", [["lung", "ANATOMY", 27, 31], ["lung", "ANATOMY", 103, 107], ["respiratory", "ANATOMY", 128, 139], ["lung injury", "DISEASE", 103, 114], ["respiratory distress syndrome", "DISEASE", 128, 157], ["ARDS", "DISEASE", 159, 163], ["ACE-2", "GENE_OR_GENE_PRODUCT", 14, 19], ["lung", "ORGAN", 27, 31], ["lung", "ORGAN", 103, 107], ["ACE-2", "PROTEIN", 14, 19], ["ACE-2", "TREATMENT", 14, 19], ["lung injury", "PROBLEM", 103, 114], ["the adult respiratory distress syndrome", "PROBLEM", 118, 157], ["ARDS", "PROBLEM", 159, 163], ["lung", "ANATOMY", 27, 31], ["lung", "ANATOMY", 103, 107], ["injury", "OBSERVATION", 108, 114], ["adult", "OBSERVATION_MODIFIER", 122, 127], ["respiratory distress", "OBSERVATION", 128, 148], ["ARDS", "OBSERVATION", 159, 163]]], ["5PULMONARY CONSIDERATIONS Hypoxia and HypercarbiaAlthough COVID-19 may have diverse presentations, respiratory failure is the presentation most relevant to critical care management.", [["respiratory", "ANATOMY", 99, 110], ["respiratory failure", "DISEASE", 99, 118], ["Hypoxia", "PROBLEM", 26, 33], ["HypercarbiaAlthough COVID", "PROBLEM", 38, 63], ["respiratory failure", "PROBLEM", 99, 118], ["critical care management", "TREATMENT", 156, 180], ["PULMONARY", "ANATOMY", 1, 10], ["respiratory failure", "OBSERVATION", 99, 118]]], ["Patients often present with a dry cough, fever, tachypnea, and dyspnea 6 ; oxygen saturations <90% are common; and patients are surprisingly asymptomatic for their degree of desaturation.", [["dry cough", "DISEASE", 30, 39], ["fever", "DISEASE", 41, 46], ["tachypnea", "DISEASE", 48, 57], ["dyspnea", "DISEASE", 63, 70], ["oxygen", "CHEMICAL", 75, 81], ["desaturation", "DISEASE", 174, 186], ["oxygen", "CHEMICAL", 75, 81], ["Patients", "ORGANISM", 0, 8], ["oxygen", "SIMPLE_CHEMICAL", 75, 81], ["patients", "ORGANISM", 115, 123], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 115, 123], ["a dry cough", "PROBLEM", 28, 39], ["fever", "PROBLEM", 41, 46], ["tachypnea", "PROBLEM", 48, 57], ["dyspnea", "PROBLEM", 63, 70], ["oxygen saturations", "TEST", 75, 93], ["desaturation", "PROBLEM", 174, 186], ["cough", "OBSERVATION", 34, 39], ["tachypnea", "OBSERVATION", 48, 57]]], ["7, 8 Alternative diagnoses include pneumonia, congestive heart failure (CHF), iatrogenic volume overload, or pulmonary embolism; however, these should not rule out COVID-19 without testing.", [["heart", "ANATOMY", 57, 62], ["pulmonary", "ANATOMY", 109, 118], ["pneumonia", "DISEASE", 35, 44], ["congestive heart failure", "DISEASE", 46, 70], ["CHF", "DISEASE", 72, 75], ["volume overload", "DISEASE", 89, 104], ["pulmonary embolism", "DISEASE", 109, 127], ["heart", "ORGAN", 57, 62], ["pulmonary", "ORGAN", 109, 118], ["pneumonia", "PROBLEM", 35, 44], ["congestive heart failure", "PROBLEM", 46, 70], ["CHF)", "PROBLEM", 72, 76], ["iatrogenic volume overload", "PROBLEM", 78, 104], ["pulmonary embolism", "PROBLEM", 109, 127], ["COVID", "TEST", 164, 169], ["testing", "TEST", 181, 188], ["pneumonia", "OBSERVATION", 35, 44], ["congestive", "OBSERVATION_MODIFIER", 46, 56], ["heart", "ANATOMY", 57, 62], ["failure", "OBSERVATION", 63, 70], ["CHF", "OBSERVATION", 72, 75], ["iatrogenic", "OBSERVATION_MODIFIER", 78, 88], ["volume overload", "OBSERVATION", 89, 104], ["pulmonary", "ANATOMY", 109, 118], ["embolism", "OBSERVATION", 119, 127]]], ["Pulmonary embolism occurs commonly in conjunction with COVID-19, 9 even in patients receiving prophylactic or therapeutic anticoagulation, suggesting an underlying hypercoagulable state.", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary embolism", "DISEASE", 0, 18], ["Pulmonary", "ORGAN", 0, 9], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["Pulmonary embolism", "PROBLEM", 0, 18], ["COVID", "TEST", 55, 60], ["prophylactic", "TREATMENT", 94, 106], ["therapeutic anticoagulation", "TREATMENT", 110, 137], ["an underlying hypercoagulable state", "PROBLEM", 150, 185], ["embolism", "OBSERVATION", 10, 18], ["hypercoagulable state", "OBSERVATION", 164, 185]]], ["The role of ACE-2.", [["ACE-2", "GENE_OR_GENE_PRODUCT", 12, 17], ["ACE", "PROTEIN", 12, 15]]], ["This figure illustrates the conversion of angiotensin I and II into angiotensin (1-7) which has organ-protective effects by ACE-2 cleavage.", [["organ", "ANATOMY", 96, 101], ["angiotensin I and II", "CHEMICAL", 42, 62], ["angiotensin (1-7)", "CHEMICAL", 68, 85], ["angiotensin I", "GENE_OR_GENE_PRODUCT", 42, 55], ["angiotensin", "SIMPLE_CHEMICAL", 68, 79], ["1-7", "SIMPLE_CHEMICAL", 81, 84], ["organ", "ORGAN", 96, 101], ["ACE-2", "GENE_OR_GENE_PRODUCT", 124, 129], ["angiotensin I and II", "PROTEIN", 42, 62], ["ACE", "PROTEIN", 124, 127], ["angiotensin I and II into angiotensin", "TREATMENT", 42, 79], ["ACE-2 cleavage", "TREATMENT", 124, 138]]], ["Angiotensin II in the absence of ACE-2 demonstrates increased cytokine release and could lead to end-organ injury.", [["organ", "ANATOMY", 101, 106], ["Angiotensin II", "CHEMICAL", 0, 14], ["end-organ injury", "DISEASE", 97, 113], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 0, 14], ["ACE-2", "GENE_OR_GENE_PRODUCT", 33, 38], ["organ", "ORGAN", 101, 106], ["Angiotensin II", "PROTEIN", 0, 14], ["ACE", "PROTEIN", 33, 36], ["cytokine", "PROTEIN", 62, 70], ["Angiotensin II", "PROBLEM", 0, 14], ["ACE", "TEST", 33, 36], ["increased cytokine release", "PROBLEM", 52, 78], ["end-organ injury", "PROBLEM", 97, 113], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["cytokine release", "OBSERVATION", 62, 78], ["organ", "ANATOMY", 101, 106], ["injury", "OBSERVATION", 107, 113]]], ["ACE-2 indicates angiotensin-converting enzyme-2.PULMONARY CONSIDERATIONS Hypoxia and HypercarbiaIn a suspected COVID-19 patient, personal protective equipment (PPE) should include precautions against contact, droplet, and, in the case of aerosolizing procedures (eg, transesophageal echocardiogram examinations, endoscopy, extubation, tracheostomy, chest compressions, and nebulizer treatments), 11 airborne spread.", [["chest", "ANATOMY", 349, 354], ["angiotensin", "CHEMICAL", 16, 27], ["HypercarbiaIn", "CHEMICAL", 85, 98], ["ACE-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["angiotensin-converting enzyme-2", "GENE_OR_GENE_PRODUCT", 16, 47], ["patient", "ORGANISM", 120, 127], ["patient", "SPECIES", 120, 127], ["ACE", "TEST", 0, 3], ["angiotensin", "TREATMENT", 16, 27], ["Hypoxia", "PROBLEM", 73, 80], ["personal protective equipment", "TREATMENT", 129, 158], ["aerosolizing procedures", "TREATMENT", 238, 261], ["transesophageal echocardiogram examinations", "TEST", 267, 310], ["endoscopy", "TEST", 312, 321], ["extubation", "TREATMENT", 323, 333], ["tracheostomy", "TREATMENT", 335, 347], ["chest compressions", "TREATMENT", 349, 367], ["nebulizer treatments", "TREATMENT", 373, 393], ["chest", "ANATOMY", 349, 354]]], ["Avoiding bronchoscopies and sputum cultures will reduce aerosolization.Injured Lungs and ARDSAlthough COVID-19 lung injury clinically resembles bilateral pneumonia, the specific pathophysiology remains controversial.", [["sputum cultures", "ANATOMY", 28, 43], ["Lungs", "ANATOMY", 79, 84], ["lung", "ANATOMY", 111, 115], ["lung injury", "DISEASE", 111, 122], ["pneumonia", "DISEASE", 154, 163], ["Lungs", "ORGAN", 79, 84], ["lung", "ORGAN", 111, 115], ["bronchoscopies", "TEST", 9, 23], ["sputum cultures", "TEST", 28, 43], ["aerosolization", "PROBLEM", 56, 70], ["COVID", "TEST", 102, 107], ["lung injury", "PROBLEM", 111, 122], ["bilateral pneumonia", "PROBLEM", 144, 163], ["Lungs", "ANATOMY", 79, 84], ["lung", "ANATOMY", 111, 115], ["injury", "OBSERVATION", 116, 122], ["bilateral", "ANATOMY_MODIFIER", 144, 153], ["pneumonia", "OBSERVATION", 154, 163]]], ["12, 13 In some patients, lung compliance is low, leading to lower tidal volumes for the same inspiratory airway pressure.", [["lung", "ANATOMY", 25, 29], ["inspiratory airway", "ANATOMY", 93, 111], ["patients", "ORGANISM", 15, 23], ["lung", "ORGAN", 25, 29], ["tidal", "ORGANISM_SUBDIVISION", 66, 71], ["airway", "MULTI-TISSUE_STRUCTURE", 105, 111], ["patients", "SPECIES", 15, 23], ["lower tidal volumes", "PROBLEM", 60, 79], ["the same inspiratory airway pressure", "TEST", 84, 120], ["lung", "ANATOMY", 25, 29], ["compliance", "OBSERVATION", 30, 40], ["low", "OBSERVATION_MODIFIER", 44, 47], ["lower", "ANATOMY_MODIFIER", 60, 65], ["tidal volumes", "OBSERVATION", 66, 79], ["airway pressure", "OBSERVATION", 105, 120]]], ["14 This reduced compliance is likely due to alveolar exudates that reduce the number of viable alveoli.", [["alveolar", "ANATOMY", 44, 52], ["alveoli", "ANATOMY", 95, 102], ["alveolar exudates", "TISSUE", 44, 61], ["alveoli", "MULTI-TISSUE_STRUCTURE", 95, 102], ["alveolar exudates", "PROBLEM", 44, 61], ["likely due to", "UNCERTAINTY", 30, 43], ["alveolar", "ANATOMY_MODIFIER", 44, 52], ["exudates", "OBSERVATION", 53, 61], ["number", "OBSERVATION_MODIFIER", 78, 84], ["viable", "OBSERVATION_MODIFIER", 88, 94], ["alveoli", "OBSERVATION", 95, 102]]], ["Such a presentation resembles the ARDS and can be stratified based on Pao 2 /Fio 2 ratio of <300 = mild disease and <100 = severe.", [["ARDS", "DISEASE", 34, 38], ["the ARDS", "PROBLEM", 30, 38], ["Pao", "TEST", 70, 73], ["Fio 2 ratio", "TEST", 77, 88], ["mild disease", "PROBLEM", 99, 111], ["ARDS", "OBSERVATION", 34, 38], ["mild", "OBSERVATION_MODIFIER", 99, 103], ["disease", "OBSERVATION", 104, 111], ["severe", "OBSERVATION_MODIFIER", 123, 129]]], ["[14] [15] [16] In some patients with COVID-19, lung compliance can be normal.", [["lung", "ANATOMY", 47, 51], ["[14] [15] [16", "SIMPLE_CHEMICAL", 0, 13], ["patients", "ORGANISM", 23, 31], ["lung", "ORGAN", 47, 51], ["patients", "SPECIES", 23, 31], ["COVID", "TEST", 37, 42], ["lung", "ANATOMY", 47, 51], ["compliance", "OBSERVATION", 52, 62], ["normal", "OBSERVATION", 70, 76]]], ["17, 18 Ventilation Strategies Many patients with COVID-19 respiratory failure do not require immediate intubation.", [["respiratory", "ANATOMY", 58, 69], ["respiratory failure", "DISEASE", 58, 77], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["Ventilation Strategies", "TREATMENT", 7, 29], ["COVID", "TEST", 49, 54], ["respiratory failure", "PROBLEM", 58, 77], ["immediate intubation", "TREATMENT", 93, 113], ["respiratory failure", "OBSERVATION", 58, 77]]], ["Efforts to avoid intubation and mechanical ventilation should be balanced against the risk of nosocomial transmission.", [["intubation", "TREATMENT", 17, 27], ["mechanical ventilation", "TREATMENT", 32, 54], ["nosocomial transmission", "PROBLEM", 94, 117], ["nosocomial", "OBSERVATION", 94, 104]]], ["The use of high-flow nasal cannula (HFNC) carries a poorly quantified but likely higher risk of aerosol generation than lower-flow forms of oxygen supplementation 19 ; its risk compared to noninvasive positive pressure ventilation (NIPPV), 20 or intubation and mechanical ventilation, are also unknown.", [["nasal", "ANATOMY", 21, 26], ["oxygen", "CHEMICAL", 140, 146], ["oxygen", "CHEMICAL", 140, 146], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 21, 34], ["oxygen", "SIMPLE_CHEMICAL", 140, 146], ["high-flow nasal cannula (HFNC", "TREATMENT", 11, 40], ["aerosol generation", "TREATMENT", 96, 114], ["oxygen supplementation", "TREATMENT", 140, 162], ["noninvasive positive pressure ventilation", "TREATMENT", 189, 230], ["NIPPV", "TREATMENT", 232, 237], ["intubation", "TREATMENT", 246, 256], ["mechanical ventilation", "TREATMENT", 261, 283], ["aerosol generation", "OBSERVATION", 96, 114], ["pressure ventilation", "OBSERVATION", 210, 230], ["mechanical ventilation", "OBSERVATION", 261, 283]]], ["Some health care organizations have recommended against noninvasive ventilation due to the risk of COVID transmission [21] [22] [23] [24] given these same risks.", [["COVID", "DISEASE", 99, 104], ["COVID", "SIMPLE_CHEMICAL", 99, 104], ["noninvasive ventilation", "TREATMENT", 56, 79], ["COVID transmission", "PROBLEM", 99, 117]]], ["Self-proning of awake patients receiving oxygen by nasal cannula or HFNC, while minimally described in the literature, 25 is low risk and may improve oxygenation.", [["nasal", "ANATOMY", 51, 56], ["oxygen", "CHEMICAL", 41, 47], ["oxygen", "CHEMICAL", 41, 47], ["patients", "ORGANISM", 22, 30], ["oxygen", "SIMPLE_CHEMICAL", 41, 47], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 51, 64], ["patients", "SPECIES", 22, 30], ["oxygen", "TREATMENT", 41, 47], ["nasal cannula", "TREATMENT", 51, 64], ["HFNC", "TREATMENT", 68, 72], ["low risk", "OBSERVATION_MODIFIER", 125, 133]]], ["26 A core principle of ARDS management is control of fluid balance to reduce the contribution of pulmonary edema to gas exchange abnormalities in the injured lung.", [["fluid", "ANATOMY", 53, 58], ["pulmonary", "ANATOMY", 97, 106], ["lung", "ANATOMY", 158, 162], ["ARDS", "DISEASE", 23, 27], ["pulmonary edema", "DISEASE", 97, 112], ["fluid", "ORGANISM_SUBSTANCE", 53, 58], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 97, 112], ["lung", "ORGAN", 158, 162], ["ARDS management", "TREATMENT", 23, 38], ["fluid balance", "PROBLEM", 53, 66], ["pulmonary edema", "PROBLEM", 97, 112], ["gas exchange abnormalities in the injured lung", "PROBLEM", 116, 162], ["ARDS", "OBSERVATION", 23, 27], ["fluid balance", "OBSERVATION", 53, 66], ["pulmonary", "ANATOMY", 97, 106], ["edema", "OBSERVATION", 107, 112], ["gas exchange", "OBSERVATION", 116, 128], ["injured", "ANATOMY_MODIFIER", 150, 157], ["lung", "ANATOMY", 158, 162]]], ["Although data in COVID-19 are lacking, limiting fluids has improved outcomes in other forms of ARDS 27 and is used in COVID-19 management to improve gas exchange.", [["ARDS", "DISEASE", 95, 99], ["COVID", "TEST", 17, 22], ["ARDS", "PROBLEM", 95, 99], ["ARDS", "OBSERVATION", 95, 99], ["gas exchange", "OBSERVATION", 149, 161]]], ["Under such conditions, monitoring for adequacy of oxygen delivery and end-organ damage due to hypovolemia is needed.Injured Lungs and ARDSConsiderable variability currently exists among centers with respect to when patients with COVID-19 respiratory failure should be intubated.", [["organ", "ANATOMY", 74, 79], ["Lungs", "ANATOMY", 124, 129], ["oxygen", "CHEMICAL", 50, 56], ["end-organ damage", "DISEASE", 70, 86], ["hypovolemia", "DISEASE", 94, 105], ["respiratory failure", "DISEASE", 238, 257], ["oxygen", "CHEMICAL", 50, 56], ["oxygen", "SIMPLE_CHEMICAL", 50, 56], ["organ", "ORGAN", 74, 79], ["Lungs", "MULTI-TISSUE_STRUCTURE", 124, 129], ["patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 215, 223], ["oxygen delivery", "TREATMENT", 50, 65], ["end-organ damage", "PROBLEM", 70, 86], ["hypovolemia", "PROBLEM", 94, 105], ["Injured Lungs and ARDSConsiderable variability", "PROBLEM", 116, 162], ["COVID", "TEST", 229, 234], ["respiratory failure", "PROBLEM", 238, 257], ["intubated", "TREATMENT", 268, 277], ["organ", "ANATOMY", 74, 79], ["damage", "OBSERVATION", 80, 86], ["hypovolemia", "OBSERVATION", 94, 105], ["Lungs", "ANATOMY", 124, 129], ["variability", "OBSERVATION_MODIFIER", 151, 162], ["respiratory failure", "OBSERVATION", 238, 257]]], ["Factors to consider include the time required to don PPE and the rapidity of deterioration in gas exchange.", [["don PPE", "TREATMENT", 49, 56], ["deterioration in gas exchange", "PROBLEM", 77, 106], ["gas exchange", "OBSERVATION", 94, 106]]], ["For COVID-19 intubations, video laryngoscopy with appropriate PPE (contact, droplet, and airborne), ideally in a negative pressure environment and with the most experienced personnel performing the laryngoscopy, may reduce the likelihood of health care infection ( Figure 2 ).", [["infection", "DISEASE", 253, 262], ["COVID", "TEST", 4, 9], ["intubations", "TREATMENT", 13, 24], ["video laryngoscopy", "TEST", 26, 44], ["appropriate PPE", "TREATMENT", 50, 65], ["the laryngoscopy", "TEST", 194, 210], ["health care infection", "PROBLEM", 241, 262]]], ["Bag mask ventilation may also increase the risk of aerosolization.", [["Bag mask ventilation", "TREATMENT", 0, 20], ["aerosolization", "PROBLEM", 51, 65], ["mask ventilation", "OBSERVATION", 4, 20], ["aerosolization", "OBSERVATION", 51, 65]]], ["In many centers, central line and arterial line insertion are performed in the same encounter to reduce donning/doffing episodes for clinicians and radiology staff.", [["central line", "ANATOMY", 17, 29], ["arterial line", "ANATOMY", 34, 47], ["central line", "CELL", 17, 29], ["arterial line", "CELL", 34, 47], ["central line", "TREATMENT", 17, 29], ["arterial line insertion", "TREATMENT", 34, 57], ["central line", "OBSERVATION", 17, 29], ["arterial", "ANATOMY", 34, 42], ["line insertion", "OBSERVATION", 43, 57]]], ["Once intubated, lungprotective ventilation is the cornerstone of ARDS management, and ARDSNet-based principles of ventilation should be followed.Injured Lungs and ARDSKey priorities are as follows:Injured Lungs and ARDS\u2022 Volume control modes of ventilation are easiest to manage clinically as they deliver a prespecified tidal volume rather than an inspiratory flow and do not allow the patient to increase tidal volumes.", [["Lungs", "ANATOMY", 153, 158], ["Lungs", "ANATOMY", 205, 210], ["ARDS", "DISEASE", 65, 69], ["ARDS", "DISEASE", 215, 219], ["ARDSNet", "SIMPLE_CHEMICAL", 86, 93], ["Lungs", "MULTI-TISSUE_STRUCTURE", 153, 158], ["Lungs", "ORGAN", 205, 210], ["patient", "ORGANISM", 387, 394], ["patient", "SPECIES", 387, 394], ["intubated", "TREATMENT", 5, 14], ["lungprotective ventilation", "TREATMENT", 16, 42], ["ARDS management", "TREATMENT", 65, 80], ["ARDSNet", "TREATMENT", 86, 93], ["ventilation", "TREATMENT", 114, 125], ["ARDS", "PROBLEM", 215, 219], ["Volume control modes of ventilation", "TREATMENT", 221, 256], ["a prespecified tidal volume", "TEST", 306, 333], ["an inspiratory flow", "TEST", 346, 365], ["tidal volumes", "TEST", 407, 420], ["ARDS", "OBSERVATION", 65, 69], ["Lungs", "ANATOMY", 153, 158], ["Lungs", "ANATOMY", 205, 210], ["ARDS", "OBSERVATION", 215, 219], ["inspiratory flow", "OBSERVATION", 349, 365], ["tidal volumes", "OBSERVATION", 407, 420]]], ["Small tidal volumes combined with high PEEP and hypercarbia may contribute to air-hunger and deep sedation may be required (see Neurologic Considerations section for drug choices and strategies).", [["hypercarbia", "DISEASE", 48, 59], ["Small tidal volumes", "PROBLEM", 0, 19], ["high PEEP", "TREATMENT", 34, 43], ["hypercarbia", "PROBLEM", 48, 59], ["air-hunger", "PROBLEM", 78, 88], ["deep sedation", "TREATMENT", 93, 106], ["drug choices", "TREATMENT", 166, 178], ["tidal volumes", "OBSERVATION", 6, 19], ["high PEEP", "OBSERVATION", 34, 43]]], ["Auto-PEEP can cause severe reductions in cardiac output and may do so when expiratory gas flow does not reach 0 L/s before the next breath.", [["cardiac", "ANATOMY", 41, 48], ["reductions in cardiac output", "DISEASE", 27, 55], ["cardiac", "ORGAN", 41, 48], ["PEEP", "TREATMENT", 5, 9], ["severe reductions in cardiac output", "PROBLEM", 20, 55], ["expiratory gas flow", "TEST", 75, 94], ["the next breath", "PROBLEM", 123, 138], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["reductions", "OBSERVATION_MODIFIER", 27, 37], ["cardiac", "ANATOMY", 41, 48], ["output", "OBSERVATION", 49, 55]]], ["In such patients, disconnecting the ventilator can prevent cardiac arrest.", [["cardiac", "ANATOMY", 59, 66], ["cardiac arrest", "DISEASE", 59, 73], ["patients", "ORGANISM", 8, 16], ["cardiac", "ORGAN", 59, 66], ["patients", "SPECIES", 8, 16], ["disconnecting the ventilator", "TREATMENT", 18, 46], ["cardiac arrest", "PROBLEM", 59, 73], ["cardiac", "ANATOMY", 59, 66], ["arrest", "OBSERVATION", 67, 73]]], ["If the ventilator must be disconnected for a COVID-19 patient, caregivers should be careful to limit aerosolization as much as is possible (ie, disconnecting from the circuit in a way that leaves any filtering device in place on the endotracheal tube).", [["endotracheal tube", "ANATOMY", 233, 250], ["patient", "ORGANISM", 54, 61], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 233, 250], ["patient", "SPECIES", 54, 61], ["the ventilator", "TREATMENT", 3, 17], ["caregivers", "TREATMENT", 63, 73], ["aerosolization", "TREATMENT", 101, 115], ["any filtering device", "TREATMENT", 196, 216], ["the endotracheal tube", "TREATMENT", 229, 250], ["endotracheal tube", "OBSERVATION", 233, 250]]], ["Instead, if clinically appropriate, shortening inspiratory time, treating bronchospasm if present, and increasing sedation may resolve the issue.Rescue StrategiesOther than lung-protective ventilation and maintaining a negative fluid balance, 27 few therapies have been successful in managing ARDS.", [["lung", "ANATOMY", 173, 177], ["fluid", "ANATOMY", 228, 233], ["bronchospasm", "DISEASE", 74, 86], ["ARDS", "DISEASE", 293, 297], ["lung", "ORGAN", 173, 177], ["shortening inspiratory time", "PROBLEM", 36, 63], ["bronchospasm", "PROBLEM", 74, 86], ["increasing sedation", "TREATMENT", 103, 122], ["Rescue Strategies", "TREATMENT", 145, 162], ["lung-protective ventilation", "TREATMENT", 173, 200], ["ARDS", "PROBLEM", 293, 297], ["lung", "ANATOMY", 173, 177], ["protective ventilation", "OBSERVATION", 178, 200], ["ARDS", "OBSERVATION", 293, 297]]], ["15 Prone positioning may improve outcomes 28 care during mechanical ventilation includes stress ulcer prophylaxis, spontaneous awakening trials coupled with spontaneous breathing trials (SAT/SBT) where safe, and the use of bundled care to prevent ventilator-associated pneumonia (VAP) and sepsis.", [["stress ulcer", "ANATOMY", 89, 101], ["ulcer", "DISEASE", 96, 101], ["ventilator-associated pneumonia", "DISEASE", 247, 278], ["VAP", "DISEASE", 280, 283], ["sepsis", "DISEASE", 289, 295], ["outcomes 28 care", "TREATMENT", 33, 49], ["mechanical ventilation", "TREATMENT", 57, 79], ["stress ulcer prophylaxis", "TREATMENT", 89, 113], ["spontaneous awakening trials", "TREATMENT", 115, 143], ["spontaneous breathing trials", "TREATMENT", 157, 185], ["SAT/SBT", "TREATMENT", 187, 194], ["bundled care", "TREATMENT", 223, 235], ["ventilator-associated pneumonia", "PROBLEM", 247, 278], ["VAP", "PROBLEM", 280, 283], ["sepsis", "PROBLEM", 289, 295], ["ulcer prophylaxis", "OBSERVATION", 96, 113], ["pneumonia", "OBSERVATION", 269, 278], ["sepsis", "OBSERVATION", 289, 295]]], ["The importance of deep venous thrombosis (DVT) prophylaxis deserves emphasis, given the reported hypercoagulable state 10 and high rate of DVT 9 in patients with COVID-19.", [["deep venous", "ANATOMY", 18, 29], ["deep venous thrombosis", "DISEASE", 18, 40], ["DVT", "DISEASE", 42, 45], ["DVT", "DISEASE", 139, 142], ["COVID-19", "CHEMICAL", 162, 170], ["deep venous", "MULTI-TISSUE_STRUCTURE", 18, 29], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["deep venous thrombosis", "PROBLEM", 18, 40], ["DVT) prophylaxis", "TREATMENT", 42, 58], ["the reported hypercoagulable state", "PROBLEM", 84, 118], ["high rate of DVT", "PROBLEM", 126, 142], ["COVID", "TEST", 162, 167], ["deep", "ANATOMY_MODIFIER", 18, 22], ["venous", "ANATOMY", 23, 29], ["thrombosis", "OBSERVATION", 30, 40], ["DVT", "OBSERVATION", 42, 45], ["hypercoagulable", "OBSERVATION", 97, 112], ["DVT", "OBSERVATION", 139, 142]]], ["There is some evidence that elevated D-dimer levels may be associated with poor prognosis.", [["D-dimer", "GENE_OR_GENE_PRODUCT", 37, 44], ["elevated D-dimer levels", "PROBLEM", 28, 51], ["elevated", "OBSERVATION_MODIFIER", 28, 36], ["D-dimer", "OBSERVATION_MODIFIER", 37, 44]]], ["31 It is believed that SARS-COV-2 may facilitate both endothelial activation of von Willebrand factor and factor VIII as well as complement-mediated microvascular injury and thrombosis.", [["endothelial", "ANATOMY", 54, 65], ["microvascular", "ANATOMY", 149, 162], ["microvascular injury", "DISEASE", 149, 169], ["thrombosis", "DISEASE", 174, 184], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 23, 33], ["endothelial", "CELL", 54, 65], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 80, 101], ["factor VIII", "GENE_OR_GENE_PRODUCT", 106, 117], ["microvascular", "TISSUE", 149, 162], ["von Willebrand factor", "PROTEIN", 80, 101], ["factor VIII", "PROTEIN", 106, 117], ["SARS", "PROBLEM", 23, 27], ["von Willebrand factor", "PROBLEM", 80, 101], ["factor VIII", "TREATMENT", 106, 117], ["microvascular injury", "PROBLEM", 149, 169], ["thrombosis", "PROBLEM", 174, 184], ["endothelial", "ANATOMY", 54, 65], ["microvascular", "ANATOMY", 149, 162], ["injury", "OBSERVATION", 163, 169], ["thrombosis", "OBSERVATION", 174, 184]]], ["32 Both pathways would contribute to a hypercoagulable state.", [["a hypercoagulable state", "PROBLEM", 37, 60], ["hypercoagulable", "OBSERVATION", 39, 54]]], ["Because of the reduced mortality associated with anticoagulation in severe COVID-19 cases, some authors have recommended therapeutic doses of anticoagulation.", [["COVID", "DISEASE", 75, 80], ["the reduced mortality", "PROBLEM", 11, 32], ["anticoagulation", "TREATMENT", 49, 64], ["anticoagulation", "TREATMENT", 142, 157], ["reduced", "OBSERVATION_MODIFIER", 15, 22], ["mortality", "OBSERVATION", 23, 32]]], ["33, 34 In the absence of shock, fluid therapy should be managed conservatively to minimize the contribution of pulmonary edema to gas exchange and lung compliance.", [["pulmonary", "ANATOMY", 111, 120], ["lung", "ANATOMY", 147, 151], ["shock", "DISEASE", 25, 30], ["pulmonary edema", "DISEASE", 111, 126], ["fluid", "ORGANISM_SUBSTANCE", 32, 37], ["pulmonary", "ORGAN", 111, 120], ["edema", "PATHOLOGICAL_FORMATION", 121, 126], ["lung", "ORGAN", 147, 151], ["shock", "PROBLEM", 25, 30], ["fluid therapy", "TREATMENT", 32, 45], ["pulmonary edema", "PROBLEM", 111, 126], ["gas exchange", "TREATMENT", 130, 142], ["lung compliance", "TREATMENT", 147, 162], ["shock", "OBSERVATION", 25, 30], ["fluid therapy", "OBSERVATION", 32, 45], ["pulmonary", "ANATOMY", 111, 120], ["edema", "OBSERVATION", 121, 126], ["gas exchange", "OBSERVATION", 130, 142], ["lung", "ANATOMY", 147, 151]]], ["35 The inhaled pulmonary vasodilator (ie, nitric oxide) can be trialed to reduce V/Q mismatch and shunt but can worsen hypotension or hypoxemia.", [["pulmonary", "ANATOMY", 15, 24], ["nitric oxide", "CHEMICAL", 42, 54], ["hypotension", "DISEASE", 119, 130], ["hypoxemia", "DISEASE", 134, 143], ["nitric oxide", "CHEMICAL", 42, 54], ["pulmonary", "ORGAN", 15, 24], ["nitric oxide", "SIMPLE_CHEMICAL", 42, 54], ["The inhaled pulmonary vasodilator", "TREATMENT", 3, 36], ["nitric oxide)", "TREATMENT", 42, 55], ["V/Q mismatch", "TREATMENT", 81, 93], ["shunt", "TREATMENT", 98, 103], ["hypotension", "PROBLEM", 119, 130], ["hypoxemia", "PROBLEM", 134, 143], ["pulmonary", "ANATOMY", 15, 24], ["shunt", "OBSERVATION", 98, 103], ["hypoxemia", "OBSERVATION", 134, 143]]], ["36 Use of methylprednisone for ARDS, in general, and for COVID-19, specifically, remains controversial.", [["methylprednisone", "CHEMICAL", 10, 26], ["ARDS", "DISEASE", 31, 35], ["methylprednisone", "CHEMICAL", 10, 26], ["methylprednisone", "SIMPLE_CHEMICAL", 10, 26], ["methylprednisone", "TREATMENT", 10, 26], ["ARDS", "PROBLEM", 31, 35], ["COVID", "TEST", 57, 62], ["ARDS", "OBSERVATION", 31, 35]]], ["[37] [38] [39] In cases of refractory hypoxemia and hypercarbia, extracorporeal membrane oxygenation (ECMO) can be considered (see Extracorporeal Life Support Considerations section).", [["extracorporeal membrane", "ANATOMY", 65, 88], ["hypoxemia", "DISEASE", 38, 47], ["hypercarbia", "DISEASE", 52, 63], ["refractory hypoxemia", "PROBLEM", 27, 47], ["hypercarbia", "PROBLEM", 52, 63], ["extracorporeal membrane oxygenation", "TREATMENT", 65, 100], ["ECMO", "TREATMENT", 102, 106], ["refractory", "OBSERVATION_MODIFIER", 27, 37], ["hypoxemia", "OBSERVATION", 38, 47], ["hypercarbia", "OBSERVATION", 52, 63], ["extracorporeal", "OBSERVATION_MODIFIER", 65, 79], ["membrane oxygenation", "OBSERVATION", 80, 100]]], ["40 In light of increased mortality in elderly patients and those who require intubation, end-of-life care issues should be addressed.Rescue StrategiesWhen the respiratory status improves, the most common approach to ventilator weaning is daily SAT/SBT to assess readiness for extubation.", [["respiratory", "ANATOMY", 159, 170], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["intubation", "TREATMENT", 77, 87], ["end-of-life care issues", "TREATMENT", 89, 112], ["Rescue Strategies", "TREATMENT", 133, 150], ["ventilator weaning", "TREATMENT", 216, 234], ["SBT", "TREATMENT", 248, 251], ["extubation", "TREATMENT", 276, 286], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["mortality", "OBSERVATION", 25, 34]]], ["Patients with COVID-19 often require prolonged ventilation and extubation failure can worsen outcomes.", [["extubation failure", "DISEASE", 63, 81], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 14, 19], ["prolonged ventilation", "TREATMENT", 37, 58], ["extubation failure", "PROBLEM", 63, 81]]], ["41 A daily SBT is usually coupled with an SAT and should last for 30-60 minutes with institution-specific pressure support settings (usually 5/5 cm H 2 O).", [["H 2 O", "CHEMICAL", 148, 153], ["SAT", "TISSUE", 42, 45], ["A daily SBT", "TREATMENT", 3, 14], ["an SAT", "TEST", 39, 45], ["specific pressure support settings", "TREATMENT", 97, 131]]], ["Patients with COVID-19 should be extubated with the same PPE required for intubation.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 14, 19], ["intubation", "TREATMENT", 74, 84]]], ["42 Although data are lacking in patients with COVID-19, extubating to HFNC can decrease reintubation and should be considered if resources are sufficient.", [["HFNC", "DISEASE", 70, 74], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["COVID", "TEST", 46, 51], ["HFNC", "TREATMENT", 70, 74], ["reintubation", "TREATMENT", 88, 100]]], ["43, 44 The same PPE required for intubation should be utilized by health care workers during extubation.INFECTIOUS DISEASE CONSIDERATIONSThe dramatic spread of COVID-19 has galvanized research institutions to find effective solutions to minimize the societal impacts of this disease.", [["COVID-19", "CHEMICAL", 160, 168], ["intubation", "TREATMENT", 33, 43], ["COVID", "TEST", 160, 165], ["effective solutions", "TREATMENT", 214, 233], ["this disease", "PROBLEM", 270, 282], ["dramatic", "OBSERVATION_MODIFIER", 141, 149], ["spread", "OBSERVATION_MODIFIER", 150, 156]]], ["The Surviving Sepsis Campaign COVID-19 panel composed guidelines based on an extensive review of the literature.", [["Sepsis", "DISEASE", 14, 20], ["an extensive review", "TEST", 74, 93], ["Sepsis", "OBSERVATION", 14, 20]]], ["45 47 Without proper infection control, those providing treatment can clearly become transmitters of the disease itself.", [["infection", "DISEASE", 21, 30], ["proper infection control", "TREATMENT", 14, 38], ["treatment", "TREATMENT", 56, 65], ["the disease itself", "PROBLEM", 101, 119], ["infection", "OBSERVATION", 21, 30], ["disease", "OBSERVATION", 105, 112]]], ["Laboratory diagnosis and specimen retrieval enable confirmation of the suspected diagnosis as well as appropriate de-escalation of treatment and resources like broad-spectrum antibiotics, airborne precautions, and negative pressure isolation.", [["specimen", "ANATOMY", 25, 33], ["Laboratory diagnosis", "TEST", 0, 20], ["specimen retrieval", "TEST", 25, 43], ["treatment", "TREATMENT", 131, 140], ["broad-spectrum antibiotics", "TREATMENT", 160, 186], ["airborne precautions", "TREATMENT", 188, 208], ["negative pressure isolation", "TREATMENT", 214, 241], ["pressure isolation", "OBSERVATION", 223, 241]]], ["Typical specimen samples will include nasal swab if the patient is not intubated and tracheal aspirate if intubated.", [["specimen samples", "ANATOMY", 8, 24], ["nasal swab", "ANATOMY", 38, 48], ["tracheal aspirate", "ANATOMY", 85, 102], ["specimen samples", "CANCER", 8, 24], ["nasal swab", "ORGANISM_SUBSTANCE", 38, 48], ["patient", "ORGANISM", 56, 63], ["tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 85, 102], ["patient", "SPECIES", 56, 63], ["Typical specimen samples", "TEST", 0, 24], ["nasal swab", "TEST", 38, 48], ["intubated", "TREATMENT", 71, 80], ["tracheal aspirate", "TEST", 85, 102], ["intubated", "TREATMENT", 106, 115], ["tracheal", "ANATOMY", 85, 93]]], ["45 The last of the principles-supportive careencompasses a range of issues in patients with COVID-19.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["COVID", "TEST", 92, 97]]], ["With regard to systemic steroids, the panel reserved administration for ventilated patients with severe ARDS, but on a case-by-case basis.", [["steroids", "CHEMICAL", 24, 32], ["ARDS", "DISEASE", 104, 108], ["steroids", "CHEMICAL", 24, 32], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["systemic steroids", "TREATMENT", 15, 32], ["the panel", "TEST", 34, 43], ["severe ARDS", "PROBLEM", 97, 108], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["ARDS", "OBSERVATION", 104, 108]]], ["Empiric antibiotics were recommended because bacterial coinfection may be difficult to recognize and diagnose (Table) .", [["bacterial coinfection", "DISEASE", 45, 66], ["Empiric antibiotics", "TREATMENT", 0, 19], ["bacterial coinfection", "PROBLEM", 45, 66]]], ["Daily assessment for de-escalation, duration, and antibiotic spectrum was recommended based on microbiology specimens.", [["specimens", "ANATOMY", 108, 117], ["Daily assessment", "TEST", 0, 16], ["de-escalation", "TREATMENT", 21, 34], ["antibiotic spectrum", "TREATMENT", 50, 69], ["microbiology specimens", "TEST", 95, 117]]], ["In regard to fever management, acetaminophen was viewed as a patient comfort strategy.", [["fever", "DISEASE", 13, 18], ["acetaminophen", "CHEMICAL", 31, 44], ["acetaminophen", "CHEMICAL", 31, 44], ["acetaminophen", "SIMPLE_CHEMICAL", 31, 44], ["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68], ["fever management", "TREATMENT", 13, 29], ["acetaminophen", "TREATMENT", 31, 44], ["a patient comfort strategy", "TREATMENT", 59, 85]]], ["For the patient presenting in high output septic shock, conservative and judicious resuscitation with crystalloids was preferred over liberal fluid resuscitation due to lung injury associated with a concomitant capillary leak syndrome and poor outcomes with higher cumulative fluid balances in ARDS.", [["fluid", "ANATOMY", 142, 147], ["lung", "ANATOMY", 169, 173], ["capillary", "ANATOMY", 211, 220], ["fluid", "ANATOMY", 276, 281], ["septic shock", "DISEASE", 42, 54], ["lung injury", "DISEASE", 169, 180], ["ARDS", "DISEASE", 294, 298], ["patient", "ORGANISM", 8, 15], ["lung", "ORGAN", 169, 173], ["capillary", "TISSUE", 211, 220], ["fluid", "ORGANISM_SUBSTANCE", 276, 281], ["patient", "SPECIES", 8, 15], ["high output septic shock", "PROBLEM", 30, 54], ["judicious resuscitation", "TREATMENT", 73, 96], ["crystalloids", "TREATMENT", 102, 114], ["liberal fluid resuscitation", "TREATMENT", 134, 161], ["lung injury", "PROBLEM", 169, 180], ["a concomitant capillary leak syndrome", "PROBLEM", 197, 234], ["poor outcomes", "PROBLEM", 239, 252], ["higher cumulative fluid balances", "PROBLEM", 258, 290], ["ARDS", "PROBLEM", 294, 298], ["high output", "OBSERVATION_MODIFIER", 30, 41], ["septic shock", "OBSERVATION", 42, 54], ["lung", "ANATOMY", 169, 173], ["injury", "OBSERVATION", 174, 180], ["concomitant", "OBSERVATION_MODIFIER", 199, 210], ["capillary leak", "OBSERVATION", 211, 225], ["syndrome", "OBSERVATION", 226, 234], ["fluid balances", "OBSERVATION", 276, 290], ["ARDS", "OBSERVATION", 294, 298]]], ["If a vasoactive agent was needed, the panel recommended norepinephrine as the preferred first-line vasoactive agent.", [["norepinephrine", "CHEMICAL", 56, 70], ["norepinephrine", "CHEMICAL", 56, 70], ["norepinephrine", "SIMPLE_CHEMICAL", 56, 70], ["a vasoactive agent", "TREATMENT", 3, 21], ["norepinephrine", "TREATMENT", 56, 70], ["first-line vasoactive agent", "TREATMENT", 88, 115]]], ["Vasopressin was the second-line agent if norepinephrine alone did not reach the targeted mean arterial pressure goal of 65 mm Hg.", [["arterial", "ANATOMY", 94, 102], ["Vasopressin", "CHEMICAL", 0, 11], ["norepinephrine", "CHEMICAL", 41, 55], ["Vasopressin", "CHEMICAL", 0, 11], ["norepinephrine", "CHEMICAL", 41, 55], ["Hg", "CHEMICAL", 126, 128], ["Vasopressin", "GENE_OR_GENE_PRODUCT", 0, 11], ["norepinephrine", "SIMPLE_CHEMICAL", 41, 55], ["arterial", "MULTI-TISSUE_STRUCTURE", 94, 102], ["Vasopressin", "TREATMENT", 0, 11], ["the second-line agent", "TREATMENT", 16, 37], ["norepinephrine", "TREATMENT", 41, 55]]], ["Dobutamine was the recommended inotropic agent when cardiac dysfunction was present.", [["cardiac", "ANATOMY", 52, 59], ["Dobutamine", "CHEMICAL", 0, 10], ["cardiac dysfunction", "DISEASE", 52, 71], ["Dobutamine", "CHEMICAL", 0, 10], ["Dobutamine", "SIMPLE_CHEMICAL", 0, 10], ["cardiac", "ORGAN", 52, 59], ["Dobutamine", "TREATMENT", 0, 10], ["inotropic agent", "TREATMENT", 31, 46], ["cardiac dysfunction", "PROBLEM", 52, 71], ["dysfunction", "OBSERVATION", 60, 71]]], ["Hydrocortisone at 200 mg/d was recommended in refractory shock.", [["Hydrocortisone", "CHEMICAL", 0, 14], ["shock", "DISEASE", 57, 62], ["Hydrocortisone", "CHEMICAL", 0, 14], ["Hydrocortisone", "SIMPLE_CHEMICAL", 0, 14], ["Hydrocortisone", "TREATMENT", 0, 14], ["refractory shock", "TREATMENT", 46, 62]]], ["45 Angiotensin II, though not recommended by the SCCM guidelines, may have a potential therapeutic role beyond supporting the MAP based on the speculative hypothesis of downregulation of ACE-2 receptors, saturation of and competitive inhibition of ACE-2 enzyme activity.", [["Angiotensin II", "CHEMICAL", 3, 17], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 3, 17], ["ACE-2", "GENE_OR_GENE_PRODUCT", 187, 192], ["ACE-2", "GENE_OR_GENE_PRODUCT", 248, 253], ["ACE-2 receptors", "PROTEIN", 187, 202], ["ACE-2 enzyme", "PROTEIN", 248, 260], ["the MAP", "TEST", 122, 129], ["ACE", "TEST", 187, 190], ["ACE", "TEST", 248, 251]]], ["48, 49 Insufficient data exist to strongly support any single approach to antiviral therapy.", [["any single approach", "TREATMENT", 51, 70], ["antiviral therapy", "TREATMENT", 74, 91], ["antiviral therapy", "OBSERVATION", 74, 91]]], ["The panel did not recommend IVIG without adequate titers of neutralizing antibodies.", [["IVIG", "SIMPLE_CHEMICAL", 28, 32], ["neutralizing antibodies", "PROTEIN", 60, 83], ["The panel", "TEST", 0, 9], ["IVIG", "TREATMENT", 28, 32], ["neutralizing antibodies", "PROBLEM", 60, 83], ["neutralizing antibodies", "OBSERVATION", 60, 83]]], ["Recombinant interferon-beta (INF-beta) inhibits SARS-COV-2 in cell cultures, and studies by the World Health Organization (WHO) are ongoing.", [["cell cultures", "ANATOMY", 62, 75], ["interferon-beta", "GENE_OR_GENE_PRODUCT", 12, 27], ["INF-beta", "GENE_OR_GENE_PRODUCT", 29, 37], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 48, 58], ["cell cultures", "CELL", 62, 75], ["Recombinant interferon-beta (INF-beta", "PROTEIN", 0, 37], ["SARS-COV-2", "DNA", 48, 58], ["cell cultures", "CELL_LINE", 62, 75], ["Recombinant interferon", "TREATMENT", 0, 22], ["beta (INF-beta)", "TEST", 23, 38], ["SARS", "PROBLEM", 48, 52], ["COV", "TEST", 53, 56], ["cell cultures", "TEST", 62, 75], ["interferon", "OBSERVATION", 12, 22]]], ["Currently, trials of convalescent plasma are also underway.", [["plasma", "ANATOMY", 34, 40], ["plasma", "ORGANISM_SUBSTANCE", 34, 40], ["convalescent plasma", "TREATMENT", 21, 40]]], ["Lopinavir/ritonavir is still being investigated by the WHO.", [["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 10, 19], ["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 10, 19], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["ritonavir", "SIMPLE_CHEMICAL", 10, 19], ["Lopinavir", "TREATMENT", 0, 9], ["ritonavir", "TREATMENT", 10, 19]]], ["Remdesivir-a prodrug analog of adenosine-results in premature RNA chain termination, and trials in mild, moderate, and severe COVID-19 patients are ongoing.", [["Remdesivir", "CHEMICAL", 0, 10], ["adenosine", "CHEMICAL", 31, 40], ["Remdesivir", "CHEMICAL", 0, 10], ["adenosine", "CHEMICAL", 31, 40], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["adenosine", "SIMPLE_CHEMICAL", 31, 40], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["Remdesivir", "TREATMENT", 0, 10], ["a prodrug analog of adenosine", "TREATMENT", 11, 40], ["premature RNA chain termination", "PROBLEM", 52, 83], ["mild, moderate, and severe COVID", "PROBLEM", 99, 131], ["mild", "OBSERVATION_MODIFIER", 99, 103], ["moderate", "OBSERVATION_MODIFIER", 105, 113], ["severe", "OBSERVATION_MODIFIER", 119, 125]]], ["Hydroxychloroquine has received attention in the lay-press and may be a more potent inhibitor of SARS-COV-2 in vitro compared to chloroquine.", [["Hydroxychloroquine", "CHEMICAL", 0, 18], ["chloroquine", "CHEMICAL", 129, 140], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["chloroquine", "CHEMICAL", 129, 140], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 97, 107], ["chloroquine", "SIMPLE_CHEMICAL", 129, 140], ["Hydroxychloroquine", "TREATMENT", 0, 18], ["SARS", "PROBLEM", 97, 101], ["COV", "TEST", 102, 105], ["vitro", "TREATMENT", 111, 116], ["chloroquine", "TREATMENT", 129, 140]]], ["Although randomized trial data are lacking, dosing regimens of 400 mg BID loading followed by 200 mg BID for 4 days.", [["BID", "CHEMICAL", 70, 73], ["BID", "CHEMICAL", 101, 104], ["BID", "SIMPLE_CHEMICAL", 70, 73], ["randomized trial data", "TREATMENT", 9, 30], ["dosing regimens", "TREATMENT", 44, 59]]], ["Tocilizumab is an anti-interleukin-6 (IL-6) immunoglobulin.", [["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "SIMPLE_CHEMICAL", 0, 11], ["anti-interleukin-6", "GENE_OR_GENE_PRODUCT", 18, 36], ["IL-6", "GENE_OR_GENE_PRODUCT", 38, 42], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 44, 58], ["anti-interleukin-6 (IL-6) immunoglobulin", "PROTEIN", 18, 58], ["Tocilizumab", "TREATMENT", 0, 11], ["an anti-interleukin-6 (IL", "TREATMENT", 15, 40], ["immunoglobulin", "TREATMENT", 44, 58]]], ["This drug was originally used in both rheumatology and oncology for its effects on hemophagocytic syndrome.", [["hemophagocytic syndrome", "DISEASE", 83, 106], ["hemophagocytic syndrome", "PROBLEM", 83, 106], ["hemophagocytic syndrome", "OBSERVATION", 83, 106]]], ["Its effects on reducing cytokine concentrations and acute phase reactants has prompted its consideration in severe COVID-19 where a hyperinflammatory state (cytokine release syndrome) is known to be a prominent feature.", [["cytokine", "PROTEIN", 24, 32], ["cytokine", "PROTEIN", 157, 165], ["reducing cytokine concentrations", "PROBLEM", 15, 47], ["acute phase reactants", "PROBLEM", 52, 73], ["severe COVID", "PROBLEM", 108, 120], ["a hyperinflammatory state (cytokine release syndrome", "PROBLEM", 130, 182], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["phase", "OBSERVATION_MODIFIER", 58, 63], ["prominent", "OBSERVATION_MODIFIER", 201, 210]]], ["50CARDIOVASCULAR CONSIDERATIONSAs previously mentioned, SARS-COV-2 virus entry target is the ACE-2 receptor.", [["SARS-COV-2 virus", "ORGANISM", 56, 72], ["ACE-2 receptor", "GENE_OR_GENE_PRODUCT", 93, 107], ["SARS-COV-2 virus entry target", "DNA", 56, 85], ["ACE-2 receptor", "PROTEIN", 93, 107], ["SARS", "PROBLEM", 56, 60], ["COV", "TEST", 61, 64]]], ["The presence of this receptor in cardiac epithelial cells facilitates myocardial damage by the virus via inhibition of the intracellular activity of the ACE-2 protein.", [["cardiac epithelial cells", "ANATOMY", 33, 57], ["myocardial", "ANATOMY", 70, 80], ["intracellular", "ANATOMY", 123, 136], ["myocardial damage", "DISEASE", 70, 87], ["cardiac epithelial cells", "CELL", 33, 57], ["myocardial", "MULTI-TISSUE_STRUCTURE", 70, 80], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 123, 136], ["ACE-2", "GENE_OR_GENE_PRODUCT", 153, 158], ["cardiac epithelial cells", "CELL_TYPE", 33, 57], ["ACE-2 protein", "PROTEIN", 153, 166], ["this receptor in cardiac epithelial cells", "PROBLEM", 16, 57], ["myocardial damage", "PROBLEM", 70, 87], ["the virus", "PROBLEM", 91, 100], ["the ACE", "TEST", 149, 156], ["cardiac", "ANATOMY", 33, 40], ["epithelial cells", "OBSERVATION", 41, 57], ["myocardial", "ANATOMY", 70, 80], ["damage", "OBSERVATION", 81, 87]]], ["48, 51, 52 In the setting of COVID-19, a 7.2% incidence of acute cardiac injury and 16.7% incidence of arrhythmias have been reported.", [["cardiac", "ANATOMY", 65, 72], ["cardiac injury", "DISEASE", 65, 79], ["arrhythmias", "DISEASE", 103, 114], ["cardiac", "ORGAN", 65, 72], ["COVID", "TEST", 29, 34], ["acute cardiac injury", "PROBLEM", 59, 79], ["arrhythmias", "PROBLEM", 103, 114], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["cardiac", "ANATOMY", 65, 72], ["injury", "OBSERVATION", 73, 79], ["arrhythmias", "OBSERVATION", 103, 114]]], ["1 The presentation of myocardial injury in COVID-19 includes elevated troponin and C-reactive protein, ST changes, T-wave inversion, arrhythmia, heart failure, reduced ejection fraction, angina, and cardiomegaly on chest X-ray.", [["myocardial", "ANATOMY", 22, 32], ["heart", "ANATOMY", 145, 150], ["myocardial injury", "DISEASE", 22, 39], ["arrhythmia", "DISEASE", 133, 143], ["heart failure", "DISEASE", 145, 158], ["reduced ejection fraction", "DISEASE", 160, 185], ["angina", "DISEASE", 187, 193], ["cardiomegaly", "DISEASE", 199, 211], ["myocardial", "MULTI-TISSUE_STRUCTURE", 22, 32], ["troponin", "GENE_OR_GENE_PRODUCT", 70, 78], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 83, 101], ["heart", "ORGAN", 145, 150], ["troponin", "PROTEIN", 70, 78], ["C-reactive protein", "PROTEIN", 83, 101], ["myocardial injury", "PROBLEM", 22, 39], ["COVID", "TEST", 43, 48], ["elevated troponin", "PROBLEM", 61, 78], ["C-reactive protein", "PROBLEM", 83, 101], ["ST changes", "PROBLEM", 103, 113], ["T-wave inversion", "PROBLEM", 115, 131], ["arrhythmia", "PROBLEM", 133, 143], ["heart failure", "PROBLEM", 145, 158], ["reduced ejection fraction", "PROBLEM", 160, 185], ["angina", "PROBLEM", 187, 193], ["cardiomegaly", "PROBLEM", 199, 211], ["chest X-ray", "TEST", 215, 226], ["myocardial", "ANATOMY", 22, 32], ["injury", "OBSERVATION", 33, 39], ["reactive protein", "OBSERVATION", 85, 101], ["arrhythmia", "OBSERVATION", 133, 143], ["heart", "ANATOMY", 145, 150], ["failure", "OBSERVATION", 151, 158], ["reduced", "OBSERVATION_MODIFIER", 160, 167], ["ejection fraction", "OBSERVATION", 168, 185], ["angina", "OBSERVATION", 187, 193], ["cardiomegaly", "OBSERVATION", 199, 211], ["chest", "ANATOMY", 215, 220]]], ["Trending these markers helps plot an overall cardiac course.", [["cardiac", "ANATOMY", 45, 52], ["cardiac", "ORGAN", 45, 52], ["these markers", "TEST", 9, 22], ["cardiac", "ANATOMY", 45, 52], ["course", "OBSERVATION_MODIFIER", 53, 59]]], ["Additionally, IL-6 levels are used as an indicator of systemic dysregulation of proinflammatory mediators (cytokines, oxygen-free radical, and coagulation factors).", [["oxygen", "CHEMICAL", 118, 124], ["oxygen", "CHEMICAL", 118, 124], ["IL-6", "GENE_OR_GENE_PRODUCT", 14, 18], ["oxygen", "SIMPLE_CHEMICAL", 118, 124], ["IL-6", "PROTEIN", 14, 18], ["proinflammatory mediators", "PROTEIN", 80, 105], ["cytokines", "PROTEIN", 107, 116], ["coagulation factors", "PROTEIN", 143, 162], ["IL-6 levels", "TREATMENT", 14, 25], ["systemic dysregulation of proinflammatory mediators", "PROBLEM", 54, 105], ["cytokines", "TREATMENT", 107, 116], ["oxygen", "TREATMENT", 118, 124], ["free radical", "TREATMENT", 125, 137], ["coagulation factors", "TEST", 143, 162], ["systemic dysregulation", "OBSERVATION", 54, 76]]], ["In COVID-19, early detection and mitigation of such a cytokine \"storm\" may reduce end-organ damage (a clinical trial is ongoing).", [["organ", "ANATOMY", 86, 91], ["end-organ damage", "DISEASE", 82, 98], ["organ", "ORGAN", 86, 91], ["cytokine", "PROTEIN", 54, 62], ["early detection", "TEST", 13, 28], ["a cytokine \"storm", "TREATMENT", 52, 69], ["end-organ damage", "PROBLEM", 82, 98], ["organ", "ANATOMY", 86, 91], ["damage", "OBSERVATION", 92, 98]]], ["52 In the absence of rapid IL-6 levels, clinicians have also used the H score to assess excessive immune reactivity.", [["IL-6", "GENE_OR_GENE_PRODUCT", 27, 31], ["IL", "PROTEIN", 27, 29], ["excessive immune reactivity", "PROBLEM", 88, 115]]], ["53, 54 If elevated, tocilizumab may be used.", [["tocilizumab", "CHEMICAL", 20, 31], ["tocilizumab", "SIMPLE_CHEMICAL", 20, 31], ["elevated", "PROBLEM", 10, 18], ["tocilizumab", "TREATMENT", 20, 31], ["elevated", "OBSERVATION_MODIFIER", 10, 18]]], ["54, 55 Electrocardiography not only helps monitor arrhythmias and ST changes but can also help detect drug-related prolongation of QTc.", [["arrhythmias", "DISEASE", 50, 61], ["Electrocardiography", "TEST", 7, 26], ["arrhythmias", "PROBLEM", 50, 61], ["ST changes", "PROBLEM", 66, 76], ["drug-related prolongation of QTc", "PROBLEM", 102, 134]]], ["55 Hydroxychloroquine/chloroquine and azithromycin are commonly used treatments for COVID-19.", [["Hydroxychloroquine", "CHEMICAL", 3, 21], ["chloroquine", "CHEMICAL", 22, 33], ["azithromycin", "CHEMICAL", 38, 50], ["Hydroxychloroquine", "CHEMICAL", 3, 21], ["chloroquine", "CHEMICAL", 22, 33], ["azithromycin", "CHEMICAL", 38, 50], ["COVID-19", "CHEMICAL", 84, 92], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 3, 21], ["chloroquine", "SIMPLE_CHEMICAL", 22, 33], ["azithromycin", "SIMPLE_CHEMICAL", 38, 50], ["Hydroxychloroquine", "TREATMENT", 3, 21], ["chloroquine", "TREATMENT", 22, 33], ["azithromycin", "TREATMENT", 38, 50], ["COVID", "TEST", 84, 89]]], ["Both agents cause prolongation of QTc.", [["prolongation of QTc", "PROBLEM", 18, 37]]], ["56, 57 When the QTc is greater than 500, the risk of Torsade de Pointes (polymorphic ventricular tachycardia) is higher, which can be avoided if the medications are either stopped or the doses reduced.CARDIOVASCULAR CONSIDERATIONSEchocardiography may also distinguish between COVID-19-related acute coronary syndrome (ACS) and myocarditis.", [["ventricular", "ANATOMY", 85, 96], ["coronary", "ANATOMY", 299, 307], ["Torsade de Pointes", "DISEASE", 53, 71], ["ventricular tachycardia", "DISEASE", 85, 108], ["COVID-19", "CHEMICAL", 276, 284], ["acute coronary syndrome", "DISEASE", 293, 316], ["ACS", "DISEASE", 318, 321], ["myocarditis", "DISEASE", 327, 338], ["ventricular", "ORGAN", 85, 96], ["coronary", "MULTI-TISSUE_STRUCTURE", 299, 307], ["the QTc", "TEST", 12, 19], ["Torsade de Pointes", "PROBLEM", 53, 71], ["polymorphic ventricular tachycardia", "PROBLEM", 73, 108], ["the medications", "TREATMENT", 145, 160], ["CARDIOVASCULAR CONSIDERATIONSEchocardiography", "TEST", 201, 246], ["COVID", "TEST", 276, 281], ["acute coronary syndrome", "PROBLEM", 293, 316], ["ACS", "PROBLEM", 318, 321], ["myocarditis", "PROBLEM", 327, 338], ["acute", "OBSERVATION_MODIFIER", 293, 298], ["coronary", "ANATOMY", 299, 307], ["syndrome", "OBSERVATION", 308, 316], ["myocarditis", "OBSERVATION", 327, 338]]], ["The hypoxia of ARDS, increased metabolic demand, and end-organ hypoperfusion can cause myocardial ischemia, which presents on echo as regional hypokinesis.", [["organ", "ANATOMY", 57, 62], ["myocardial", "ANATOMY", 87, 97], ["hypoxia", "DISEASE", 4, 11], ["ARDS", "DISEASE", 15, 19], ["hypoperfusion", "DISEASE", 63, 76], ["myocardial ischemia", "DISEASE", 87, 106], ["hypokinesis", "DISEASE", 143, 154], ["organ", "ORGAN", 57, 62], ["myocardial", "MULTI-TISSUE_STRUCTURE", 87, 97], ["The hypoxia", "PROBLEM", 0, 11], ["ARDS", "PROBLEM", 15, 19], ["increased metabolic demand", "PROBLEM", 21, 47], ["end-organ hypoperfusion", "PROBLEM", 53, 76], ["myocardial ischemia", "PROBLEM", 87, 106], ["echo", "TEST", 126, 130], ["regional hypokinesis", "PROBLEM", 134, 154], ["hypoxia", "OBSERVATION", 4, 11], ["ARDS", "OBSERVATION", 15, 19], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["metabolic demand", "OBSERVATION", 31, 47], ["organ", "ANATOMY", 57, 62], ["hypoperfusion", "OBSERVATION", 63, 76], ["myocardial", "ANATOMY", 87, 97], ["ischemia", "OBSERVATION", 98, 106], ["regional", "OBSERVATION_MODIFIER", 134, 142], ["hypokinesis", "OBSERVATION", 143, 154]]], ["If severe, overall ejection fraction may be depressed, and echo may reveal isolated left ventricular or right ventricular dilation.", [["left ventricular", "ANATOMY", 84, 100], ["right ventricular", "ANATOMY", 104, 121], ["depressed", "DISEASE", 44, 53], ["ventricular", "MULTI-TISSUE_STRUCTURE", 89, 100], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 104, 121], ["overall ejection fraction", "TEST", 11, 36], ["depressed", "PROBLEM", 44, 53], ["echo", "TEST", 59, 63], ["isolated left ventricular or right ventricular dilation", "PROBLEM", 75, 130], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["ejection fraction", "OBSERVATION", 19, 36], ["left ventricular", "ANATOMY", 84, 100], ["right ventricular", "ANATOMY", 104, 121], ["dilation", "OBSERVATION", 122, 130]]], ["The typical ACS management protocol should be followed with the caveat that the effect of beta-blockers (eg, metoprolol) may be enhanced by concomitant use of either hydroxychloroquine and chloroquine due to inhibition of CYP2D6.CARDIOVASCULAR CONSIDERATIONSIn contrast to the regional hypokinesis of myocardial ischemia, hypokinesis due to COVID-19-induced myocarditis is global.", [["myocardial", "ANATOMY", 301, 311], ["ACS", "DISEASE", 12, 15], ["beta-blockers", "CHEMICAL", 90, 103], ["metoprolol", "CHEMICAL", 109, 119], ["hydroxychloroquine", "CHEMICAL", 166, 184], ["chloroquine", "CHEMICAL", 189, 200], ["hypokinesis", "DISEASE", 286, 297], ["myocardial ischemia", "DISEASE", 301, 320], ["hypokinesis", "DISEASE", 322, 333], ["COVID-19", "CHEMICAL", 341, 349], ["myocarditis", "DISEASE", 358, 369], ["metoprolol", "CHEMICAL", 109, 119], ["hydroxychloroquine", "CHEMICAL", 166, 184], ["chloroquine", "CHEMICAL", 189, 200], ["COVID-19", "CHEMICAL", 341, 349], ["beta-blockers", "SIMPLE_CHEMICAL", 90, 103], ["metoprolol", "SIMPLE_CHEMICAL", 109, 119], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 166, 184], ["chloroquine", "SIMPLE_CHEMICAL", 189, 200], ["CYP2D6", "GENE_OR_GENE_PRODUCT", 222, 228], ["myocardial", "MULTI-TISSUE_STRUCTURE", 301, 311], ["COVID-19", "GENE_OR_GENE_PRODUCT", 341, 349], ["CYP2D6", "PROTEIN", 222, 228], ["The typical ACS management protocol", "TREATMENT", 0, 35], ["beta-blockers (eg", "TREATMENT", 90, 107], ["metoprolol", "TREATMENT", 109, 119], ["hydroxychloroquine", "TREATMENT", 166, 184], ["chloroquine", "TREATMENT", 189, 200], ["inhibition of CYP2D6", "PROBLEM", 208, 228], ["the regional hypokinesis", "PROBLEM", 273, 297], ["myocardial ischemia", "PROBLEM", 301, 320], ["hypokinesis", "PROBLEM", 322, 333], ["COVID", "TEST", 341, 346], ["myocarditis", "PROBLEM", 358, 369], ["regional", "ANATOMY_MODIFIER", 277, 285], ["hypokinesis", "OBSERVATION", 286, 297], ["myocardial", "ANATOMY", 301, 311], ["ischemia", "OBSERVATION", 312, 320], ["hypokinesis", "OBSERVATION", 322, 333], ["myocarditis", "OBSERVATION", 358, 369], ["global", "OBSERVATION_MODIFIER", 373, 379]]], ["Both ventricles are dilated and contractility is reduced (Figure 3 ).", [["ventricles", "ANATOMY", 5, 15], ["ventricles", "MULTI-TISSUE_STRUCTURE", 5, 15], ["dilated", "PROBLEM", 20, 27], ["ventricles", "ANATOMY", 5, 15], ["dilated", "OBSERVATION", 20, 27], ["contractility", "OBSERVATION_MODIFIER", 32, 45], ["reduced", "OBSERVATION_MODIFIER", 49, 56]]], ["On echocardiography, the ventricles will appear round in the 4-chamber view instead of the typical oval shape that tapers at the apex.", [["ventricles", "ANATOMY", 25, 35], ["ventricles", "MULTI-TISSUE_STRUCTURE", 25, 35], ["echocardiography", "TEST", 3, 19], ["the typical oval shape", "PROBLEM", 87, 109], ["ventricles", "ANATOMY", 25, 35], ["round", "OBSERVATION_MODIFIER", 48, 53], ["typical", "OBSERVATION_MODIFIER", 91, 98], ["oval", "OBSERVATION_MODIFIER", 99, 103], ["shape", "OBSERVATION_MODIFIER", 104, 109], ["tapers", "OBSERVATION_MODIFIER", 115, 121], ["apex", "ANATOMY_MODIFIER", 129, 133]]], ["In the presence of COVID-19, this finding is highly suggestive of myocarditis.", [["myocarditis", "DISEASE", 66, 77], ["COVID-19", "CHEMICAL", 19, 27], ["COVID", "TEST", 19, 24], ["myocarditis", "PROBLEM", 66, 77], ["highly suggestive of", "UNCERTAINTY", 45, 65], ["myocarditis", "OBSERVATION", 66, 77]]], ["56, 58, 59 If the left ventricular ejection fraction falls below 20%, anticoagulation should be considered to prevent spontaneous left ventricular thrombus formation.", [["left ventricular", "ANATOMY", 18, 34], ["left ventricular thrombus", "ANATOMY", 130, 155], ["left ventricular thrombus", "DISEASE", 130, 155], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 18, 34], ["ventricular thrombus", "PATHOLOGICAL_FORMATION", 135, 155], ["the left ventricular ejection fraction", "TEST", 14, 52], ["anticoagulation", "TREATMENT", 70, 85], ["spontaneous left ventricular thrombus formation", "PROBLEM", 118, 165], ["left ventricular", "ANATOMY", 18, 34], ["ejection fraction", "OBSERVATION", 35, 52], ["left ventricular", "ANATOMY", 130, 146], ["thrombus", "OBSERVATION", 147, 155]]], ["Steroids and nonsteroidal anti-inflammatory drugs (NSAIDs) are not recommended for COVID-19 patients, in general, 60 and particularly those with impending or ongoing myocardial injury and may worsen heart failure.", [["nonsteroidal", "ANATOMY", 13, 25], ["myocardial", "ANATOMY", 166, 176], ["heart", "ANATOMY", 199, 204], ["myocardial injury", "DISEASE", 166, 183], ["heart failure", "DISEASE", 199, 212], ["Steroids", "CHEMICAL", 0, 8], ["nonsteroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 13, 49], ["NSAIDs", "SIMPLE_CHEMICAL", 51, 57], ["patients", "ORGANISM", 92, 100], ["myocardial", "MULTI-TISSUE_STRUCTURE", 166, 176], ["heart", "ORGAN", 199, 204], ["patients", "SPECIES", 92, 100], ["Steroids", "TREATMENT", 0, 8], ["nonsteroidal anti-inflammatory drugs", "TREATMENT", 13, 49], ["NSAIDs", "TREATMENT", 51, 57], ["ongoing myocardial injury", "PROBLEM", 158, 183], ["heart failure", "PROBLEM", 199, 212], ["myocardial", "ANATOMY", 166, 176], ["injury", "OBSERVATION", 177, 183], ["heart", "ANATOMY", 199, 204], ["failure", "OBSERVATION", 205, 212]]], ["61, 62 Data are insufficient to support stoppage of ACE inhibitors and ACE receptor blockers.", [["ACE", "GENE_OR_GENE_PRODUCT", 52, 55], ["ACE receptor blockers", "GENE_OR_GENE_PRODUCT", 71, 92], ["ACE inhibitors", "TREATMENT", 52, 66], ["ACE receptor blockers", "TREATMENT", 71, 92]]], ["63 If the H score or C-reactive protein level is significantly elevated, an IL-6 inhibitor should be considered.EXTRACORPOREAL LIFE SUPPORT CONSIDERATIONSInitiating ECMO is an option for some COVID-19 patients, depending on institutional expertise and resource availability.", [["C-reactive protein", "GENE_OR_GENE_PRODUCT", 21, 39], ["IL-6", "GENE_OR_GENE_PRODUCT", 76, 80], ["patients", "ORGANISM", 201, 209], ["C-reactive protein", "PROTEIN", 21, 39], ["patients", "SPECIES", 201, 209], ["the H score", "TEST", 6, 17], ["C-reactive protein level", "TEST", 21, 45], ["significantly elevated", "PROBLEM", 49, 71], ["an IL-6 inhibitor", "TREATMENT", 73, 90], ["ECMO", "TREATMENT", 165, 169], ["some COVID", "TREATMENT", 187, 197]]], ["In the 2018 ECMO to Rescue Lung Injury in Severe ARDS (EOLIA) trial, 64 60-day mortality was not significantly lower with patients randomized to receive ECMO, but the trial was limited by a high rate of crossover from the control to the ECMO group.", [["Lung", "ANATOMY", 27, 31], ["Lung Injury", "DISEASE", 27, 38], ["ARDS", "DISEASE", 49, 53], ["Lung", "ORGAN", 27, 31], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["Rescue Lung Injury", "PROBLEM", 20, 38], ["Severe ARDS", "PROBLEM", 42, 53], ["ECMO", "TREATMENT", 153, 157], ["Lung", "ANATOMY", 27, 31], ["Injury", "OBSERVATION", 32, 38], ["Severe", "OBSERVATION_MODIFIER", 42, 48], ["ARDS", "OBSERVATION", 49, 53]]], ["40, 64 A recently published pooled analysis of 17 COVID-19 patients treated with ECMO reported a high mortality (94.1%), 65 although in other emerging reports, survivors have been reported.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["pooled analysis", "TEST", 28, 43], ["ECMO", "TREATMENT", 81, 85], ["a high mortality", "PROBLEM", 95, 111]]], ["66 Given the overwhelming presentation of patients during the COVID-19 pandemic, starting new ECMO centers is not advised and decisions to initiate ECMO must be subject to considerable thought and judgment 66 and each patient should be considered individually with respect to risks, benefits, and available resources.", [["patients", "ORGANISM", 42, 50], ["patient", "ORGANISM", 218, 225], ["patients", "SPECIES", 42, 50], ["patient", "SPECIES", 218, 225], ["the COVID", "TEST", 58, 67], ["new ECMO centers", "TREATMENT", 90, 106], ["ECMO", "TREATMENT", 148, 152]]], ["For both venovenous (VV) and venoarterial (VA) approaches, current guidelines 67,68 endorse use of ECMO for patients with severe disease and high predicted mortality.", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["VV", "SPECIES", 21, 23], ["venoarterial (VA) approaches", "TREATMENT", 29, 57], ["ECMO", "TREATMENT", 99, 103], ["severe disease", "PROBLEM", 122, 136], ["high predicted mortality", "PROBLEM", 141, 165], ["venovenous", "OBSERVATION", 9, 19], ["venoarterial", "ANATOMY", 29, 41]]], ["Experience with non-COVID use of ECMO suggests that younger patients with minor or no-comorbidities should remain the highest priority for ECMO.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["ECMO", "TREATMENT", 33, 37], ["minor or no-comorbidities", "PROBLEM", 74, 99], ["ECMO", "TREATMENT", 139, 143]]], ["66, 69 Use of ECMO in COVID-19 patients with a combination of advanced age (>60 years old), multiple comorbidities, or multiple organ failures should be rare.", [["organ", "ANATOMY", 128, 133], ["patients", "ORGANISM", 31, 39], ["organ", "ORGAN", 128, 133], ["patients", "SPECIES", 31, 39], ["ECMO", "TREATMENT", 14, 18], ["multiple comorbidities", "PROBLEM", 92, 114], ["multiple organ failures", "PROBLEM", 119, 142], ["multiple", "OBSERVATION_MODIFIER", 92, 100], ["comorbidities", "OBSERVATION", 101, 114], ["organ", "ANATOMY", 128, 133], ["failures", "OBSERVATION", 134, 142]]], ["Readers are encouraged to review ECMO management materials available at the ASA CAESAR resource library (https://www.asahq.org/in-the-spotlight/coronavirus-covid-19-information/caesar) and the Extracorporeal Life Support Organization (https:// www.elso.org/Resources/Guidelines.aspx).NEUROLOGIC CONSIDERATIONSMany patients in the ICU with COVID-19 will require mechanical ventilation, which typically obligates them to sedation.", [["patients", "ORGANISM", 314, 322], ["patients", "SPECIES", 314, 322], ["ECMO management materials", "TREATMENT", 33, 58], ["the Extracorporeal Life Support", "TREATMENT", 189, 220], ["COVID", "TEST", 339, 344], ["mechanical ventilation", "TREATMENT", 361, 383], ["sedation", "TREATMENT", 419, 427], ["Extracorporeal", "ANATOMY", 193, 207], ["mechanical ventilation", "OBSERVATION", 361, 383]]], ["The ABCDEF Bundle is helpful to determine sedation needs and is implemented in the following fashion: Assess, Prevent, and Manage Pain, Both SAT and SBT, Choice of analgesia and sedation, Delirium: Assess, Prevent, and Manage, Early mobility and Exercise, and Family engagement and empowerment.", [["Pain", "DISEASE", 130, 134], ["Delirium", "DISEASE", 188, 196], ["Pain", "PROBLEM", 130, 134], ["SBT", "TREATMENT", 149, 152], ["analgesia", "TREATMENT", 164, 173], ["sedation", "TREATMENT", 178, 186], ["Delirium", "PROBLEM", 188, 196]]], ["70 Delirium screening should be performed daily in patients who are able to participate, as delirium increases mortality and should be prevented.", [["Delirium", "DISEASE", 3, 11], ["delirium", "DISEASE", 92, 100], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["Delirium screening", "TEST", 3, 21], ["delirium", "PROBLEM", 92, 100]]], ["71 The Confusion Assessment Method for the ICU (CAM-ICU) is commonly used to screen patients for delirium and is validated for patients receiving sedation and on mechanical ventilation.", [["Confusion", "DISEASE", 7, 16], ["delirium", "DISEASE", 97, 105], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 127, 135], ["delirium", "PROBLEM", 97, 105], ["sedation", "TREATMENT", 146, 154], ["mechanical ventilation", "TREATMENT", 162, 184]]], ["72 Sedation should be titrated using a clinical scale such as the Richmond Agitation and Sedation Scale (RASS) score ranges from +4 (combative), 0 (awake and calm), to \u22125 (comatose), and a reasonable goal would be a range of 0 to \u22122.", [["Agitation", "DISEASE", 75, 84], ["comatose", "DISEASE", 172, 180], ["Sedation", "TREATMENT", 3, 11], ["a clinical scale", "TREATMENT", 37, 53], ["the Richmond Agitation", "TREATMENT", 62, 84], ["Sedation Scale", "TREATMENT", 89, 103], ["RASS) score ranges", "TEST", 105, 123]]], ["73 Such scales are preferred over EEG monitoring.", [["EEG monitoring", "TEST", 34, 48]]], ["74 Deeper sedation is often required to tolerate high PEEP ventilator settings and for patients who will require paralysis.", [["paralysis", "DISEASE", 113, 122], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["Deeper sedation", "TREATMENT", 3, 18], ["high PEEP ventilator settings", "TREATMENT", 49, 78], ["paralysis", "PROBLEM", 113, 122], ["paralysis", "OBSERVATION", 113, 122]]], ["Strict ventilator synchrony (eg, not overbreathing or \"double-stacking\") is important to avoid increased oxygen consumption and barotrauma.", [["oxygen", "CHEMICAL", 105, 111], ["barotrauma", "DISEASE", 128, 138], ["oxygen", "CHEMICAL", 105, 111], ["oxygen", "SIMPLE_CHEMICAL", 105, 111], ["increased oxygen consumption", "TREATMENT", 95, 123], ["barotrauma", "PROBLEM", 128, 138], ["ventilator synchrony", "OBSERVATION", 7, 27], ["oxygen consumption", "OBSERVATION", 105, 123], ["barotrauma", "OBSERVATION", 128, 138]]], ["Dexmedetomidine should not be used without other amnestic medication in patients requiring neuromuscular blockade, and bispectral index (BIS) monitor might be suited to such patients.", [["neuromuscular", "ANATOMY", 91, 104], ["Dexmedetomidine", "CHEMICAL", 0, 15], ["Dexmedetomidine", "CHEMICAL", 0, 15], ["Dexmedetomidine", "SIMPLE_CHEMICAL", 0, 15], ["patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 174, 182], ["Dexmedetomidine", "TREATMENT", 0, 15], ["other amnestic medication", "TREATMENT", 43, 68], ["neuromuscular blockade", "TREATMENT", 91, 113], ["bispectral index (BIS", "TREATMENT", 119, 140]]], ["74 Of note, sevoflurane and propofol interact with chloroquine and hydroxychloroquine to increase the likelihood of QTc prolongation.", [["sevoflurane", "CHEMICAL", 12, 23], ["propofol", "CHEMICAL", 28, 36], ["chloroquine", "CHEMICAL", 51, 62], ["hydroxychloroquine", "CHEMICAL", 67, 85], ["sevoflurane", "CHEMICAL", 12, 23], ["propofol", "CHEMICAL", 28, 36], ["chloroquine", "CHEMICAL", 51, 62], ["hydroxychloroquine", "CHEMICAL", 67, 85], ["sevoflurane", "SIMPLE_CHEMICAL", 12, 23], ["propofol", "SIMPLE_CHEMICAL", 28, 36], ["chloroquine", "SIMPLE_CHEMICAL", 51, 62], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 67, 85], ["QTc", "SIMPLE_CHEMICAL", 116, 119], ["sevoflurane", "TREATMENT", 12, 23], ["propofol", "TREATMENT", 28, 36], ["chloroquine", "TREATMENT", 51, 62], ["hydroxychloroquine", "TREATMENT", 67, 85], ["QTc prolongation", "PROBLEM", 116, 132]]], ["Remdesivir does not have known interactions with any major anesthesia drugs.", [["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["any major anesthesia drugs", "TREATMENT", 49, 75]]], ["Propofol infusion syndrome should always be considered if sudden acidosis occurs after prolonged infusion, particularly in younger patients.", [["Propofol", "CHEMICAL", 0, 8], ["acidosis", "DISEASE", 65, 73], ["Propofol", "CHEMICAL", 0, 8], ["Propofol", "SIMPLE_CHEMICAL", 0, 8], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["Propofol infusion syndrome", "TREATMENT", 0, 26], ["sudden acidosis", "PROBLEM", 58, 73], ["prolonged infusion", "TREATMENT", 87, 105], ["acidosis", "OBSERVATION", 65, 73]]], ["75 Furthermore, pain control with IV infusions and enteral regimens are both acceptable.", [["pain", "DISEASE", 16, 20], ["pain control", "TREATMENT", 16, 28], ["IV infusions", "TREATMENT", 34, 46], ["enteral regimens", "TREATMENT", 51, 67]]], ["Half of ICU patients will have pain, and multimodal regimens can be used even when patients are mechanically ventilated (eg, acetaminophen, gabapentinoids, transdermal lidocaine, tramadol, muscle relaxants [methocarbamol, etc], and opioids).", [["muscle", "ANATOMY", 189, 195], ["pain", "DISEASE", 31, 35], ["acetaminophen", "CHEMICAL", 125, 138], ["gabapentinoids", "CHEMICAL", 140, 154], ["lidocaine", "CHEMICAL", 168, 177], ["tramadol", "CHEMICAL", 179, 187], ["methocarbamol", "CHEMICAL", 207, 220], ["acetaminophen", "CHEMICAL", 125, 138], ["gabapentinoids", "CHEMICAL", 140, 154], ["lidocaine", "CHEMICAL", 168, 177], ["tramadol", "CHEMICAL", 179, 187], ["methocarbamol", "CHEMICAL", 207, 220], ["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 83, 91], ["acetaminophen", "SIMPLE_CHEMICAL", 125, 138], ["gabapentinoids", "SIMPLE_CHEMICAL", 140, 154], ["transdermal", "SIMPLE_CHEMICAL", 156, 167], ["lidocaine", "SIMPLE_CHEMICAL", 168, 177], ["tramadol", "SIMPLE_CHEMICAL", 179, 187], ["muscle", "ORGAN", 189, 195], ["methocarbamol", "SIMPLE_CHEMICAL", 207, 220], ["opioids", "SIMPLE_CHEMICAL", 232, 239], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 83, 91], ["pain", "PROBLEM", 31, 35], ["multimodal regimens", "TREATMENT", 41, 60], ["mechanically ventilated", "TREATMENT", 96, 119], ["acetaminophen", "TREATMENT", 125, 138], ["gabapentinoids", "TREATMENT", 140, 154], ["transdermal lidocaine", "TREATMENT", 156, 177], ["tramadol", "TREATMENT", 179, 187], ["muscle relaxants", "TREATMENT", 189, 205], ["methocarbamol", "TREATMENT", 207, 220], ["opioids", "TREATMENT", 232, 239], ["muscle", "ANATOMY", 189, 195]]], ["76 Although epidemiologic data are lacking, and given noted concerns about hypercoagulability, stroke may be a relatively common complication of COVID-19.", [["hypercoagulability", "DISEASE", 75, 93], ["stroke", "DISEASE", 95, 101], ["COVID-19", "CHEMICAL", 145, 153], ["epidemiologic data", "TEST", 12, 30], ["hypercoagulability", "PROBLEM", 75, 93], ["stroke", "PROBLEM", 95, 101], ["COVID", "TEST", 145, 150]]], ["77 A sudden change in mental status or acute onset of focal neurologic changes not explained by drugs should trigger a differential diagnosis that includes stroke and hemorrhage.", [["neurologic", "ANATOMY", 60, 70], ["stroke", "DISEASE", 156, 162], ["hemorrhage", "DISEASE", 167, 177], ["A sudden change in mental status", "PROBLEM", 3, 35], ["focal neurologic changes", "PROBLEM", 54, 78], ["stroke", "PROBLEM", 156, 162], ["hemorrhage", "PROBLEM", 167, 177], ["sudden", "OBSERVATION_MODIFIER", 5, 11], ["change", "OBSERVATION_MODIFIER", 12, 18], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["focal", "OBSERVATION_MODIFIER", 54, 59], ["stroke", "OBSERVATION", 156, 162], ["hemorrhage", "OBSERVATION", 167, 177]]], ["The National Institute of Health Stroke Scale (NIHSS) is performed for all patients suspected of stroke, and a head CT should be ordered when a stroke is suspected.", [["head", "ANATOMY", 111, 115], ["Stroke", "DISEASE", 33, 39], ["stroke", "DISEASE", 97, 103], ["stroke", "DISEASE", 144, 150], ["patients", "ORGANISM", 75, 83], ["head", "ORGANISM_SUBDIVISION", 111, 115], ["patients", "SPECIES", 75, 83], ["stroke", "PROBLEM", 97, 103], ["a head CT", "TEST", 109, 118], ["a stroke", "PROBLEM", 142, 150], ["stroke", "OBSERVATION", 97, 103], ["stroke", "OBSERVATION", 144, 150]]], ["78 In many institutions, a \"CODE STROKE\" pathway is present which mobilizes the neurology team and makes the patient a top priority for a rapid, definitive diagnostic evaluation.", [["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116], ["definitive diagnostic evaluation", "TEST", 145, 177]]], ["79 Ischemic strokes and subarachnoid hemorrhage (after clipping/coiling) may require a higher blood pressure for several days to prevent permanent loss of function while hemorrhagic strokes require tighter blood pressure control, commonly with an infusion.", [["subarachnoid", "ANATOMY", 24, 36], ["blood", "ANATOMY", 94, 99], ["blood", "ANATOMY", 206, 211], ["Ischemic strokes", "DISEASE", 3, 19], ["subarachnoid hemorrhage", "DISEASE", 24, 47], ["hemorrhagic strokes", "DISEASE", 170, 189], ["blood", "ORGANISM_SUBSTANCE", 94, 99], ["blood", "ORGANISM_SUBSTANCE", 206, 211], ["Ischemic strokes", "PROBLEM", 3, 19], ["subarachnoid hemorrhage", "PROBLEM", 24, 47], ["clipping/coiling", "TREATMENT", 55, 71], ["a higher blood pressure", "TREATMENT", 85, 108], ["permanent loss of function", "PROBLEM", 137, 163], ["hemorrhagic strokes", "PROBLEM", 170, 189], ["tighter blood pressure control", "TREATMENT", 198, 228], ["an infusion", "TREATMENT", 244, 255], ["Ischemic", "OBSERVATION_MODIFIER", 3, 11], ["strokes", "OBSERVATION", 12, 19], ["subarachnoid", "OBSERVATION_MODIFIER", 24, 36], ["hemorrhage", "OBSERVATION", 37, 47]]], ["Special care should be given to patients with status epilepticus, spinal cord injuries, and TBI, and hyperventilation cannot be used for anything beyond short-term, emergent control of catastrophic elevations in intracranial pressure (ie, during active herniation).RENAL CONSIDERATIONSAcute kidney injury (AKI) is common in critically ill adults with an incidence of 57.3% in 1 large, international epidemiologic study.", [["spinal cord", "ANATOMY", 66, 77], ["intracranial", "ANATOMY", 212, 224], ["kidney", "ANATOMY", 291, 297], ["status epilepticus", "DISEASE", 46, 64], ["cord injuries", "DISEASE", 73, 86], ["TBI", "DISEASE", 92, 95], ["hyperventilation", "DISEASE", 101, 117], ["herniation", "DISEASE", 253, 263], ["kidney injury", "DISEASE", 291, 304], ["AKI", "DISEASE", 306, 309], ["critically ill", "DISEASE", 324, 338], ["patients", "ORGANISM", 32, 40], ["spinal cord", "ORGAN", 66, 77], ["intracranial", "IMMATERIAL_ANATOMICAL_ENTITY", 212, 224], ["kidney", "ORGAN", 291, 297], ["patients", "SPECIES", 32, 40], ["Special care", "TREATMENT", 0, 12], ["status epilepticus", "PROBLEM", 46, 64], ["spinal cord injuries", "PROBLEM", 66, 86], ["TBI", "PROBLEM", 92, 95], ["hyperventilation", "PROBLEM", 101, 117], ["catastrophic elevations in intracranial pressure", "PROBLEM", 185, 233], ["active herniation", "PROBLEM", 246, 263], ["RENAL CONSIDERATIONSAcute kidney injury", "PROBLEM", 265, 304], ["AKI", "PROBLEM", 306, 309], ["international epidemiologic study", "TEST", 385, 418], ["spinal cord", "ANATOMY", 66, 77], ["injuries", "OBSERVATION", 78, 86], ["catastrophic", "OBSERVATION_MODIFIER", 185, 197], ["elevations", "OBSERVATION", 198, 208], ["intracranial pressure", "ANATOMY", 212, 233], ["active", "OBSERVATION_MODIFIER", 246, 252], ["herniation", "OBSERVATION", 253, 263], ["kidney", "ANATOMY", 291, 297], ["injury", "OBSERVATION", 298, 304], ["AKI", "OBSERVATION", 306, 309]]], ["80 AKI and the duration thereof are independently associated with poor clinical outcomes.", [["AKI", "DISEASE", 3, 6], ["AKI", "PROBLEM", 3, 6], ["AKI", "OBSERVATION", 3, 6]]], ["81, 82 Early published COVID-19 data suggest that AKI develops in approximately 15% of inpatients and 50% of nonsurvivors.", [["AKI", "DISEASE", 50, 53], ["Early published COVID", "TEST", 7, 28], ["AKI", "PROBLEM", 50, 53], ["AKI", "OBSERVATION", 50, 53]]], ["83 In another study examining critically ill adults, 29% had AKI.", [["critically ill", "DISEASE", 30, 44], ["AKI", "DISEASE", 61, 64], ["another study", "TEST", 6, 19], ["AKI", "PROBLEM", 61, 64], ["AKI", "OBSERVATION", 61, 64]]], ["84 AKI has likewise been associated with adverse outcomes in patients with COVID-19.", [["AKI", "DISEASE", 3, 6], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["AKI", "PROBLEM", 3, 6], ["COVID", "TEST", 75, 80], ["AKI", "OBSERVATION", 3, 6]]], ["85, 86 In 1 small series of critically ill adults from Washington state, 4 of 21 patients developed acute kidney failure.", [["kidney", "ANATOMY", 106, 112], ["critically ill", "DISEASE", 28, 42], ["acute kidney failure", "DISEASE", 100, 120], ["patients", "ORGANISM", 81, 89], ["kidney", "ORGAN", 106, 112], ["patients", "SPECIES", 81, 89], ["acute kidney failure", "PROBLEM", 100, 120], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["kidney", "ANATOMY", 106, 112], ["failure", "OBSERVATION", 113, 120]]], ["87 Anecdotally, the authors have personally found that approximately 20%-30% of mechanically ventilated COVID-19 patients require renal replacement therapy (RRT) in their institutions.RENAL CONSIDERATIONSThe pathophysiology of AKI in COVID- 19 is not yet definitively established.", [["renal", "ANATOMY", 130, 135], ["AKI", "DISEASE", 227, 230], ["patients", "ORGANISM", 113, 121], ["renal", "ORGAN", 130, 135], ["patients", "SPECIES", 113, 121], ["mechanically ventilated COVID", "TREATMENT", 80, 109], ["renal replacement therapy", "TREATMENT", 130, 155], ["RRT", "TREATMENT", 157, 160], ["AKI", "PROBLEM", 227, 230], ["COVID", "TEST", 234, 239], ["renal", "ANATOMY", 130, 135], ["replacement", "OBSERVATION", 136, 147], ["AKI", "OBSERVATION", 227, 230]]], ["SARS-CoV-2 binds with ACE-2 receptors, which are expressed in the kidneys.", [["kidneys", "ANATOMY", 66, 73], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["ACE-2 receptors", "GENE_OR_GENE_PRODUCT", 22, 37], ["kidneys", "ORGAN", 66, 73], ["ACE-2 receptors", "PROTEIN", 22, 37], ["SARS", "TEST", 0, 4], ["ACE-2 receptors", "TREATMENT", 22, 37], ["kidneys", "ANATOMY", 66, 73]]], ["Both podocytes and proximal straight tubule cells have been identified as viral hosts, 88 possibly explaining the high incidence of observed proteinuria.", [["podocytes", "ANATOMY", 5, 14], ["straight tubule cells", "ANATOMY", 28, 49], ["proteinuria", "DISEASE", 141, 152], ["podocytes", "CELL", 5, 14], ["proximal straight tubule cells", "CELL", 19, 49], ["podocytes", "CELL_TYPE", 5, 14], ["proximal straight tubule cells", "CELL_TYPE", 19, 49], ["proximal straight tubule cells", "PROBLEM", 19, 49], ["viral hosts", "TEST", 74, 85], ["observed proteinuria", "PROBLEM", 132, 152], ["podocytes", "OBSERVATION", 5, 14], ["proximal", "ANATOMY_MODIFIER", 19, 27], ["straight tubule cells", "OBSERVATION", 28, 49], ["viral hosts", "OBSERVATION", 74, 85], ["proteinuria", "OBSERVATION", 141, 152]]], ["85 Pathologic findings have been consistent with acute tubular necrosis (ATN).", [["tubular", "ANATOMY", 55, 62], ["acute tubular necrosis", "DISEASE", 49, 71], ["ATN", "DISEASE", 73, 76], ["tubular", "PATHOLOGICAL_FORMATION", 55, 62], ["acute tubular necrosis", "PROBLEM", 49, 71], ["ATN", "PROBLEM", 73, 76], ["consistent with", "UNCERTAINTY", 33, 48], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["tubular", "ANATOMY_MODIFIER", 55, 62], ["necrosis", "OBSERVATION", 63, 71], ["ATN", "OBSERVATION", 73, 76]]], ["89 Aside from direct cytopathic effects, ARDS and shock may also contribute to ATN in severely ill patients.", [["ARDS", "DISEASE", 41, 45], ["shock", "DISEASE", 50, 55], ["ATN", "DISEASE", 79, 82], ["ill", "DISEASE", 95, 98], ["ATN", "SIMPLE_CHEMICAL", 79, 82], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["direct cytopathic effects", "PROBLEM", 14, 39], ["ARDS", "PROBLEM", 41, 45], ["shock", "PROBLEM", 50, 55], ["ATN in severely ill patients", "PROBLEM", 79, 107], ["cytopathic", "OBSERVATION_MODIFIER", 21, 31], ["ARDS", "OBSERVATION", 41, 45]]], ["Prerenal etiologies should be considered early in the disease course in patients who have had anorexia or severe GI manifestations.RENAL CONSIDERATIONSFor critically ill adults with COVID-19, the authors recommend that the routine diagnostic workup include urine analysis, spot urine studies for electrolytes, protein, and microalbumin-to-creatinine ratio in addition to routine serum chemistries.", [["GI", "ANATOMY", 113, 115], ["urine", "ANATOMY", 257, 262], ["urine", "ANATOMY", 278, 283], ["serum", "ANATOMY", 379, 384], ["anorexia", "DISEASE", 94, 102], ["critically ill", "DISEASE", 155, 169], ["creatinine", "CHEMICAL", 339, 349], ["creatinine", "CHEMICAL", 339, 349], ["patients", "ORGANISM", 72, 80], ["urine", "ORGANISM_SUBSTANCE", 257, 262], ["urine", "ORGANISM_SUBSTANCE", 278, 283], ["electrolytes", "SIMPLE_CHEMICAL", 296, 308], ["microalbumin", "SIMPLE_CHEMICAL", 323, 335], ["creatinine", "SIMPLE_CHEMICAL", 339, 349], ["serum", "ORGANISM_SUBSTANCE", 379, 384], ["patients", "SPECIES", 72, 80], ["Prerenal etiologies", "PROBLEM", 0, 19], ["anorexia", "PROBLEM", 94, 102], ["severe GI manifestations", "PROBLEM", 106, 130], ["COVID", "TEST", 182, 187], ["the routine diagnostic workup", "TEST", 219, 248], ["urine analysis", "TEST", 257, 271], ["spot urine studies", "TEST", 273, 291], ["electrolytes", "TEST", 296, 308], ["protein", "TEST", 310, 317], ["microalbumin", "TEST", 323, 335], ["creatinine ratio", "TEST", 339, 355], ["routine serum chemistries", "TEST", 371, 396], ["should be considered", "UNCERTAINTY", 20, 40], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["GI", "ANATOMY", 113, 115], ["manifestations", "OBSERVATION", 116, 130]]], ["For patients with AKI, urine microscopy may be helpful, and the diagnostic workup should parallel that of AKI in critically ill adults.", [["urine", "ANATOMY", 23, 28], ["AKI", "DISEASE", 18, 21], ["AKI", "DISEASE", 106, 109], ["critically ill", "DISEASE", 113, 127], ["patients", "ORGANISM", 4, 12], ["urine", "ORGANISM_SUBSTANCE", 23, 28], ["patients", "SPECIES", 4, 12], ["AKI", "PROBLEM", 18, 21], ["urine microscopy", "TEST", 23, 39], ["the diagnostic workup", "TEST", 60, 81], ["AKI", "PROBLEM", 106, 109], ["AKI", "OBSERVATION", 106, 109]]], ["Similarly, the care of COVID-19 patients with perturbations in renal function should center around foundational supportive care: avoidance of renal insults (ie, nephrotoxins and hypotension), resuscitation or diuresis to euvolemia, correction of electrolyte and acid-base perturbations, and nutritional optimization.", [["renal", "ANATOMY", 63, 68], ["renal", "ANATOMY", 142, 147], ["renal insults", "DISEASE", 142, 155], ["hypotension", "DISEASE", 178, 189], ["euvolemia", "DISEASE", 221, 230], ["patients", "ORGANISM", 32, 40], ["renal", "ORGAN", 63, 68], ["renal", "ORGAN", 142, 147], ["patients", "SPECIES", 32, 40], ["COVID", "TEST", 23, 28], ["perturbations in renal function", "PROBLEM", 46, 77], ["renal insults", "PROBLEM", 142, 155], ["nephrotoxins", "TREATMENT", 161, 173], ["hypotension", "PROBLEM", 178, 189], ["resuscitation", "TREATMENT", 192, 205], ["diuresis", "TREATMENT", 209, 217], ["euvolemia", "TREATMENT", 221, 230], ["electrolyte and acid-base perturbations", "TREATMENT", 246, 285], ["nutritional optimization", "TREATMENT", 291, 315], ["renal", "ANATOMY", 63, 68], ["renal", "ANATOMY", 142, 147], ["insults", "OBSERVATION", 148, 155]]], ["90 Patients with COVID-19 demonstrate hypercoagulability 10 which may increase the risk of clotting of continuous renal replacement therapy (CRRT) filters.", [["renal", "ANATOMY", 114, 119], ["hypercoagulability", "DISEASE", 38, 56], ["Patients", "ORGANISM", 3, 11], ["renal", "ORGAN", 114, 119], ["Patients", "SPECIES", 3, 11], ["COVID", "TEST", 17, 22], ["hypercoagulability", "PROBLEM", 38, 56], ["continuous renal replacement therapy", "TREATMENT", 103, 139], ["CRRT) filters", "TREATMENT", 141, 154], ["hypercoagulability", "OBSERVATION", 38, 56], ["clotting", "OBSERVATION", 91, 99], ["renal", "ANATOMY", 114, 119], ["replacement", "OBSERVATION", 120, 131]]], ["Appropriate temporary dialysis catheter placement and position are important from an access quality standpoint, and optimization of the dialysis prescription (eg, high blood flows and predilution replacement fluid) may help to extend filter life.", [["blood", "ANATOMY", 168, 173], ["blood", "ORGANISM_SUBSTANCE", 168, 173], ["Appropriate temporary dialysis catheter placement", "TREATMENT", 0, 49], ["the dialysis prescription", "TREATMENT", 132, 157], ["high blood flows and predilution replacement fluid)", "TREATMENT", 163, 214], ["temporary", "OBSERVATION_MODIFIER", 12, 21], ["dialysis catheter", "OBSERVATION", 22, 39]]], ["One potential solution is staged anticoagulation for patients on CRRT: regional citrate anticoagulation, followed by escalation to prefilter heparin administration with serum monitoring of heparin levels per local protocol, and then finally consideration of alternative systemic anticoagulants (ie, direct thrombin inhibitors).", [["serum", "ANATOMY", 169, 174], ["citrate", "CHEMICAL", 80, 87], ["heparin", "CHEMICAL", 141, 148], ["heparin", "CHEMICAL", 189, 196], ["citrate", "CHEMICAL", 80, 87], ["patients", "ORGANISM", 53, 61], ["citrate", "SIMPLE_CHEMICAL", 80, 87], ["heparin", "SIMPLE_CHEMICAL", 141, 148], ["serum", "ORGANISM_SUBSTANCE", 169, 174], ["heparin", "SIMPLE_CHEMICAL", 189, 196], ["thrombin", "GENE_OR_GENE_PRODUCT", 306, 314], ["thrombin", "PROTEIN", 306, 314], ["patients", "SPECIES", 53, 61], ["staged anticoagulation", "TREATMENT", 26, 48], ["CRRT", "TREATMENT", 65, 69], ["regional citrate anticoagulation", "TREATMENT", 71, 103], ["prefilter heparin administration", "TREATMENT", 131, 163], ["serum monitoring", "TEST", 169, 185], ["heparin levels", "TREATMENT", 189, 203], ["alternative systemic anticoagulants", "TREATMENT", 258, 293], ["direct thrombin inhibitors", "TREATMENT", 299, 325]]], ["Potential local or national shortages of citrate, calcium, and/ or systemic anticoagulants may influence the optimal approach.", [["citrate", "CHEMICAL", 41, 48], ["calcium", "CHEMICAL", 50, 57], ["citrate", "CHEMICAL", 41, 48], ["calcium", "CHEMICAL", 50, 57], ["citrate", "SIMPLE_CHEMICAL", 41, 48], ["calcium", "SIMPLE_CHEMICAL", 50, 57], ["citrate", "TREATMENT", 41, 48], ["calcium", "TREATMENT", 50, 57], ["systemic anticoagulants", "TREATMENT", 67, 90]]], ["Hospitals should also develop staged RRT surge plans, which might include mixed CRRT durations with machine redeployment, various prolonged intermittent RRT approaches, and/or acute peritoneal dialysis.", [["peritoneal", "ANATOMY", 182, 192], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 182, 192], ["staged RRT surge", "TREATMENT", 30, 46], ["mixed CRRT durations", "TREATMENT", 74, 94], ["machine redeployment", "TREATMENT", 100, 120], ["various prolonged intermittent RRT approaches", "TREATMENT", 122, 167], ["acute peritoneal dialysis", "TREATMENT", 176, 201], ["acute", "OBSERVATION_MODIFIER", 176, 181], ["peritoneal", "ANATOMY", 182, 192], ["dialysis", "OBSERVATION", 193, 201]]], ["91ENDOCRINE CONSIDERATIONS Glycemic ControlLike other critically ill patients, those with COVID-19 are at risk of dysregulated glucose.", [["critically ill", "DISEASE", 54, 68], ["glucose", "CHEMICAL", 127, 134], ["glucose", "CHEMICAL", 127, 134], ["patients", "ORGANISM", 69, 77], ["glucose", "SIMPLE_CHEMICAL", 127, 134], ["patients", "SPECIES", 69, 77], ["COVID", "TEST", 90, 95], ["dysregulated glucose", "PROBLEM", 114, 134], ["dysregulated glucose", "OBSERVATION", 114, 134]]], ["Targeting blood glucose levels <180 mg/dL utilizing subcutaneous or intravenous insulin and avoiding oral hypoglycemics are reasonable.", [["blood", "ANATOMY", 10, 15], ["subcutaneous", "ANATOMY", 52, 64], ["intravenous", "ANATOMY", 68, 79], ["oral", "ANATOMY", 101, 105], ["glucose", "CHEMICAL", 16, 23], ["glucose", "CHEMICAL", 16, 23], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["glucose", "SIMPLE_CHEMICAL", 16, 23], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 68, 79], ["insulin", "GENE_OR_GENE_PRODUCT", 80, 87], ["oral", "ORGANISM_SUBDIVISION", 101, 105], ["blood glucose levels", "TEST", 10, 30], ["intravenous insulin", "TREATMENT", 68, 87], ["oral hypoglycemics", "TREATMENT", 101, 119]]], ["92, 93 Aggressive treatment of hypoglycemia with 50% dextrose or continuous infusion of dextrose-containing crystalloids will avoid complications of hypoglycemia.ENDOCRINE CONSIDERATIONS Glycemic ControlSevere hyperglycemia may be associated with diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome.", [["hypoglycemia", "DISEASE", 31, 43], ["dextrose", "CHEMICAL", 53, 61], ["dextrose", "CHEMICAL", 88, 96], ["hypoglycemia", "DISEASE", 149, 161], ["hyperglycemia", "DISEASE", 210, 223], ["diabetic ketoacidosis", "DISEASE", 247, 268], ["hyperosmolar hyperglycemic syndrome", "DISEASE", 272, 307], ["dextrose", "CHEMICAL", 53, 61], ["dextrose", "CHEMICAL", 88, 96], ["dextrose", "SIMPLE_CHEMICAL", 53, 61], ["dextrose", "SIMPLE_CHEMICAL", 88, 96], ["crystalloids", "ORGANISM_SUBSTANCE", 108, 120], ["hypoglycemia", "PROBLEM", 31, 43], ["50% dextrose", "TREATMENT", 49, 61], ["continuous infusion of dextrose", "TREATMENT", 65, 96], ["crystalloids", "TREATMENT", 108, 120], ["hypoglycemia", "PROBLEM", 149, 161], ["Glycemic ControlSevere hyperglycemia", "PROBLEM", 187, 223], ["diabetic ketoacidosis", "PROBLEM", 247, 268], ["hyperosmolar hyperglycemic syndrome", "PROBLEM", 272, 307], ["may be associated with", "UNCERTAINTY", 224, 246], ["hyperosmolar", "OBSERVATION", 272, 284], ["hyperglycemic syndrome", "OBSERVATION", 285, 307]]], ["Both processes result in osmotic diuresis and electrolyte wasting, and therefore require volume resuscitation and vigilant correction of electrolyte imbalances, along with administration of insulin.", [["wasting", "DISEASE", 58, 65], ["insulin", "GENE_OR_GENE_PRODUCT", 190, 197], ["insulin", "PROTEIN", 190, 197], ["osmotic diuresis", "TREATMENT", 25, 41], ["electrolyte wasting", "PROBLEM", 46, 65], ["volume resuscitation", "TREATMENT", 89, 109], ["electrolyte imbalances", "PROBLEM", 137, 159], ["insulin", "TREATMENT", 190, 197], ["osmotic diuresis", "OBSERVATION", 25, 41], ["electrolyte wasting", "OBSERVATION", 46, 65], ["electrolyte imbalances", "OBSERVATION", 137, 159]]], ["94 Measured sodium values may be falsely low in the presence of hyperglycemia and require corrected calculation.", [["sodium", "CHEMICAL", 12, 18], ["hyperglycemia", "DISEASE", 64, 77], ["sodium", "CHEMICAL", 12, 18], ["sodium", "SIMPLE_CHEMICAL", 12, 18], ["Measured sodium values", "TEST", 3, 25], ["hyperglycemia", "PROBLEM", 64, 77], ["corrected calculation", "TEST", 90, 111], ["falsely low", "OBSERVATION_MODIFIER", 33, 44], ["hyperglycemia", "OBSERVATION", 64, 77]]], ["Insulin infusions require hourly glucose checks and are resource demanding, so subcutaneous regimens should be used if possible.", [["subcutaneous", "ANATOMY", 79, 91], ["glucose", "CHEMICAL", 33, 40], ["Insulin", "GENE_OR_GENE_PRODUCT", 0, 7], ["glucose", "SIMPLE_CHEMICAL", 33, 40], ["Insulin infusions", "TREATMENT", 0, 17], ["hourly glucose checks", "TEST", 26, 47], ["resource demanding", "TREATMENT", 56, 74], ["subcutaneous regimens", "TREATMENT", 79, 100]]], ["Nutritional considerations are critical to the management of patients with ARDS, in general, and a detailed resource can be found on the CAESAR-ICU website https://bit. ly/2VpcGmI.Thyroid FunctionCritically ill patients may have abnormal thyroid function tests (eg, decreased T3) in the absence of true thyroid dysfunction (ie, euthyroid sick syndrome), and thyroid hormone supplementation is not warranted.", [["Thyroid", "ANATOMY", 180, 187], ["thyroid", "ANATOMY", 238, 245], ["thyroid", "ANATOMY", 303, 310], ["ARDS", "DISEASE", 75, 79], ["Thyroid FunctionCritically ill", "DISEASE", 180, 210], ["abnormal thyroid function", "DISEASE", 229, 254], ["thyroid dysfunction", "DISEASE", 303, 322], ["euthyroid sick syndrome", "DISEASE", 328, 351], ["patients", "ORGANISM", 61, 69], ["2VpcGmI", "GENE_OR_GENE_PRODUCT", 172, 179], ["Thyroid", "ORGAN", 180, 187], ["patients", "ORGANISM", 211, 219], ["thyroid", "ORGAN", 238, 245], ["thyroid", "ORGAN", 303, 310], ["thyroid", "ORGAN", 358, 365], ["2VpcGmI", "PROTEIN", 172, 179], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 211, 219], ["ARDS", "PROBLEM", 75, 79], ["abnormal thyroid function tests", "PROBLEM", 229, 260], ["decreased T3)", "PROBLEM", 266, 279], ["true thyroid dysfunction", "PROBLEM", 298, 322], ["euthyroid sick syndrome", "PROBLEM", 328, 351], ["thyroid hormone supplementation", "TREATMENT", 358, 389], ["ARDS", "OBSERVATION", 75, 79], ["thyroid", "ANATOMY", 238, 245], ["thyroid", "ANATOMY", 303, 310], ["dysfunction", "OBSERVATION", 311, 322], ["thyroid", "ANATOMY", 358, 365]]], ["95, 96 Patients with chronic hypo-or hyperthyroidism should continue their home thyroid medication regimens with minimal interruptions.", [["thyroid", "ANATOMY", 80, 87], ["hyperthyroidism", "DISEASE", 37, 52], ["Patients", "ORGANISM", 7, 15], ["thyroid", "ORGAN", 80, 87], ["Patients", "SPECIES", 7, 15], ["chronic hypo-or hyperthyroidism", "PROBLEM", 21, 52], ["their home thyroid medication regimens", "TREATMENT", 69, 107], ["hyperthyroidism", "OBSERVATION", 37, 52], ["thyroid", "ANATOMY", 80, 87]]], ["Rarely, patients with untreated thyroid dysfunction may develop life-threatening thyroid disorders (eg, myxedema coma, thyroid storm), which warrant immediate consultation with an endocrinologist.Steroid Use and Adrenal InsufficiencyPatients with primary or secondary (eg, chronic prednisone use) adrenal insufficiency are at significant risk for adrenal crisis.", [["thyroid", "ANATOMY", 32, 39], ["thyroid", "ANATOMY", 81, 88], ["thyroid", "ANATOMY", 119, 126], ["Adrenal", "ANATOMY", 212, 219], ["adrenal", "ANATOMY", 297, 304], ["adrenal", "ANATOMY", 347, 354], ["thyroid dysfunction", "DISEASE", 32, 51], ["thyroid disorders", "DISEASE", 81, 98], ["myxedema", "DISEASE", 104, 112], ["coma", "DISEASE", 113, 117], ["thyroid storm", "DISEASE", 119, 132], ["prednisone", "CHEMICAL", 281, 291], ["adrenal insufficiency", "DISEASE", 297, 318], ["adrenal crisis", "DISEASE", 347, 361], ["Steroid", "CHEMICAL", 196, 203], ["prednisone", "CHEMICAL", 281, 291], ["patients", "ORGANISM", 8, 16], ["thyroid", "ORGAN", 32, 39], ["thyroid", "ORGAN", 81, 88], ["thyroid", "ORGAN", 119, 126], ["Steroid", "SIMPLE_CHEMICAL", 196, 203], ["Adrenal", "ORGAN", 212, 219], ["prednisone", "SIMPLE_CHEMICAL", 281, 291], ["adrenal", "ORGAN", 297, 304], ["adrenal", "ORGAN", 347, 354], ["patients", "SPECIES", 8, 16], ["untreated thyroid dysfunction", "PROBLEM", 22, 51], ["life-threatening thyroid disorders", "PROBLEM", 64, 98], ["myxedema coma", "PROBLEM", 104, 117], ["Steroid Use", "TREATMENT", 196, 207], ["Adrenal InsufficiencyPatients", "TREATMENT", 212, 241], ["secondary (eg, chronic prednisone use", "TREATMENT", 258, 295], ["adrenal insufficiency", "PROBLEM", 297, 318], ["adrenal crisis", "PROBLEM", 347, 361], ["thyroid", "ANATOMY", 32, 39], ["dysfunction", "OBSERVATION", 40, 51], ["thyroid", "ANATOMY", 81, 88], ["thyroid", "ANATOMY", 119, 126], ["Adrenal", "ANATOMY", 212, 219], ["adrenal", "ANATOMY", 297, 304], ["insufficiency", "OBSERVATION", 305, 318], ["adrenal", "ANATOMY", 347, 354], ["crisis", "OBSERVATION", 355, 361]]], ["Empiric stress dose steroid replacement (eg, hydrocortisone 50 mg every 6 hours) should be considered in these patients for the duration of their critical illness.", [["steroid", "CHEMICAL", 20, 27], ["hydrocortisone", "CHEMICAL", 45, 59], ["steroid", "CHEMICAL", 20, 27], ["hydrocortisone", "CHEMICAL", 45, 59], ["steroid", "SIMPLE_CHEMICAL", 20, 27], ["hydrocortisone", "SIMPLE_CHEMICAL", 45, 59], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["Empiric stress dose steroid replacement", "TREATMENT", 0, 39], ["hydrocortisone", "TREATMENT", 45, 59]]], ["97 Patients without known adrenal insufficiency may develop relative adrenal insufficiency during critical illness, which presents commonly as refractory hypotension unexplained by sepsis or cardiac dysfunction.", [["adrenal", "ANATOMY", 26, 33], ["adrenal", "ANATOMY", 69, 76], ["cardiac", "ANATOMY", 191, 198], ["adrenal insufficiency", "DISEASE", 26, 47], ["adrenal insufficiency", "DISEASE", 69, 90], ["critical illness", "DISEASE", 98, 114], ["hypotension", "DISEASE", 154, 165], ["sepsis", "DISEASE", 181, 187], ["cardiac dysfunction", "DISEASE", 191, 210], ["Patients", "ORGANISM", 3, 11], ["adrenal", "ORGAN", 26, 33], ["adrenal", "ORGAN", 69, 76], ["cardiac", "ORGAN", 191, 198], ["Patients", "SPECIES", 3, 11], ["known adrenal insufficiency", "PROBLEM", 20, 47], ["relative adrenal insufficiency", "PROBLEM", 60, 90], ["critical illness", "PROBLEM", 98, 114], ["refractory hypotension", "PROBLEM", 143, 165], ["sepsis", "PROBLEM", 181, 187], ["cardiac dysfunction", "PROBLEM", 191, 210], ["adrenal", "ANATOMY", 26, 33], ["insufficiency", "OBSERVATION", 34, 47], ["adrenal", "ANATOMY", 69, 76], ["insufficiency", "OBSERVATION", 77, 90], ["sepsis", "OBSERVATION", 181, 187], ["cardiac", "ANATOMY", 191, 198], ["dysfunction", "OBSERVATION", 199, 210]]], ["Random cortisol levels and ACTH stimulation testing are not routinely recommended; rather empiric use of stress dose hydrocortisone (as above) should be considered in patients with profound distributive shock and inadequate response to vasoactive medications.", [["cortisol", "CHEMICAL", 7, 15], ["hydrocortisone", "CHEMICAL", 117, 131], ["shock", "DISEASE", 203, 208], ["cortisol", "CHEMICAL", 7, 15], ["hydrocortisone", "CHEMICAL", 117, 131], ["cortisol", "GENE_OR_GENE_PRODUCT", 7, 15], ["ACTH", "SIMPLE_CHEMICAL", 27, 31], ["hydrocortisone", "SIMPLE_CHEMICAL", 117, 131], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["Random cortisol levels", "TEST", 0, 22], ["ACTH stimulation testing", "TEST", 27, 51], ["stress dose hydrocortisone", "TREATMENT", 105, 131], ["profound distributive shock", "PROBLEM", 181, 208], ["vasoactive medications", "TREATMENT", 236, 258], ["distributive shock", "OBSERVATION", 190, 208]]], ["[97] [98] [99] Steroids are not recommended for the treatment of hypoxia and ARDS precipitated by viral pneumonia, as they may prolong viral clearance and increase mortality.", [["hypoxia", "DISEASE", 65, 72], ["ARDS", "DISEASE", 77, 81], ["viral pneumonia", "DISEASE", 98, 113], ["[97] [98] [99] Steroids", "CHEMICAL", 0, 23], ["[97] [98] [99] Steroids", "SIMPLE_CHEMICAL", 0, 23], ["Steroids", "TREATMENT", 15, 23], ["hypoxia", "PROBLEM", 65, 72], ["ARDS", "PROBLEM", 77, 81], ["viral pneumonia", "PROBLEM", 98, 113], ["increase mortality", "PROBLEM", 155, 173], ["hypoxia", "OBSERVATION", 65, 72], ["ARDS", "OBSERVATION", 77, 81], ["viral", "OBSERVATION_MODIFIER", 98, 103], ["pneumonia", "OBSERVATION", 104, 113]]], ["100 Steroids can be considered for patients with COVID-19 who develop refractory shock or have underlying adrenal insufficiency.ETHICAL CONSIDERATIONSUnder normal nonpandemic circumstances, the general principles of medical ethics apply, as described by Beauchamp and Childress.", [["adrenal", "ANATOMY", 106, 113], ["shock", "DISEASE", 81, 86], ["adrenal insufficiency", "DISEASE", 106, 127], ["Steroids", "CHEMICAL", 4, 12], ["patients", "ORGANISM", 35, 43], ["adrenal", "ORGAN", 106, 113], ["patients", "SPECIES", 35, 43], ["Steroids", "TREATMENT", 4, 12], ["COVID", "TEST", 49, 54], ["refractory shock", "PROBLEM", 70, 86], ["underlying adrenal insufficiency", "PROBLEM", 95, 127], ["medical ethics", "TREATMENT", 216, 230], ["refractory", "OBSERVATION_MODIFIER", 70, 80], ["shock", "OBSERVATION", 81, 86], ["adrenal", "ANATOMY", 106, 113], ["insufficiency", "OBSERVATION", 114, 127], ["nonpandemic circumstances", "OBSERVATION", 163, 188]]], ["101 These include patient autonomy, beneficence, nonmaleficence, and justice.", [["nonmaleficence", "DISEASE", 49, 63], ["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25]]], ["However, under resource-limited circumstances such as in the COVID-19 pandemic, the Utilitarian philosophy of social justice (the most good for the greatest number of people) becomes important.", [["people", "ORGANISM", 167, 173], ["people", "SPECIES", 167, 173]]], ["Ethical issues may occur when allocating ICU beds, ventilating patients, withdrawing life-supportive treatment, starting experimental treatments, or resuscitating patients suffering from cardiac arrest.", [["cardiac", "ANATOMY", 187, 194], ["cardiac arrest", "DISEASE", 187, 201], ["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 163, 171], ["cardiac", "ORGAN", 187, 194], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 163, 171], ["Ethical issues", "PROBLEM", 0, 14], ["ventilating patients", "TREATMENT", 51, 71], ["withdrawing life", "TREATMENT", 73, 89], ["supportive treatment", "TREATMENT", 90, 110], ["experimental treatments", "TREATMENT", 121, 144], ["cardiac arrest", "PROBLEM", 187, 201], ["cardiac", "ANATOMY", 187, 194], ["arrest", "OBSERVATION", 195, 201]]], ["102 Such decisions should consider (a) the age and premorbid status of the patient, (b) the severity and prognosis of the disease, (c) the severity of the shortage of resources (supply/demand proportion), and (d) the stage of the pandemic (whether the overburdened phase has been reached).", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["the disease", "PROBLEM", 118, 129], ["the pandemic", "PROBLEM", 226, 238]]], ["103 Ways of moving forward should include the following: 105 Other specific strategies may ease the impact of these complex decisions on caregivers and families, but all stem from the underlying recognition that the patients are someone's loved one who may be denied some aspect of care (eg, an ICU bed or ventilator).", [["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["an ICU bed", "TREATMENT", 292, 302], ["ventilator", "TREATMENT", 306, 316]]], ["The sharing of empathy and compassion and having conversations early in the clinical course may be helpful, particularly for patients who are elderly or at high risk.", [["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["empathy", "OBSERVATION", 15, 22]]], ["Emphasizing comfort care measures may allay concerns that caregivers are abandoning patients who are not being offered other critical care measures, and palliative care teams can be invaluable in this setting.", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["comfort care measures", "TREATMENT", 12, 33]]], ["It is also critical for clinicians to make use of available support system resources, as complex end-of-life issues will take a psychological toll on caregivers.CONCLUSIONSThe current Coronavirus pandemic is unprecedented in the modern medical era and COVID-19 is an entirely new disease.", [["COVID", "TEST", 252, 257], ["an entirely new disease", "PROBLEM", 264, 287], ["Coronavirus", "OBSERVATION", 184, 195], ["new", "OBSERVATION_MODIFIER", 276, 279], ["disease", "OBSERVATION", 280, 287]]], ["COVID-19 is remarkably transmissible and can render patients critically ill in a very short period of time.", [["critically ill", "DISEASE", 61, 75], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60]]], ["The COVID-19 pandemic may require health care systems to adapt to volumes of critically ill patients that exceed their capacity, and nonintensivist anesthesiologists are rapidly being deployed in their critical care management.", [["critically ill", "DISEASE", 77, 91], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["The COVID", "TEST", 0, 9], ["health care systems", "TREATMENT", 34, 53]]], ["The respiratory care of these patients should closely mimic the care for ARDS patients without COVID-19, with the caveat that some patients may not have the typical poor compliance of ARDS, and that many patients require extended ventilatory support.", [["respiratory", "ANATOMY", 4, 15], ["ARDS", "DISEASE", 73, 77], ["ARDS", "DISEASE", 184, 188], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 204, 212], ["ARDS", "PROBLEM", 73, 77], ["COVID", "TEST", 95, 100], ["ARDS", "PROBLEM", 184, 188], ["extended ventilatory support", "TREATMENT", 221, 249], ["ARDS", "OBSERVATION", 184, 188], ["ventilatory support", "OBSERVATION", 230, 249]]], ["Because COVID-19 may affect the heart and affected patients may be hypercoagulable, myocardial injury has been reported and can be severe.", [["heart", "ANATOMY", 32, 37], ["myocardial", "ANATOMY", 84, 94], ["COVID-19", "CHEMICAL", 8, 16], ["hypercoagulable", "DISEASE", 67, 82], ["myocardial injury", "DISEASE", 84, 101], ["COVID-19", "GENE_OR_GENE_PRODUCT", 8, 16], ["heart", "ORGAN", 32, 37], ["patients", "ORGANISM", 51, 59], ["myocardial", "MULTI-TISSUE_STRUCTURE", 84, 94], ["COVID-19", "DNA", 8, 16], ["patients", "SPECIES", 51, 59], ["COVID", "TEST", 8, 13], ["hypercoagulable", "PROBLEM", 67, 82], ["myocardial injury", "PROBLEM", 84, 101], ["heart", "ANATOMY", 32, 37], ["hypercoagulable", "OBSERVATION", 67, 82], ["myocardial", "ANATOMY", 84, 94], ["injury", "OBSERVATION", 95, 101], ["severe", "OBSERVATION_MODIFIER", 131, 137]]], ["In addition to antiviral protocols, the use of broad-spectrum antibiotics to cover coinfection should be considered, particularly for patients in shock.", [["coinfection", "DISEASE", 83, 94], ["shock", "DISEASE", 146, 151], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["antiviral protocols", "TREATMENT", 15, 34], ["broad-spectrum antibiotics", "TREATMENT", 47, 73], ["coinfection", "PROBLEM", 83, 94], ["shock", "PROBLEM", 146, 151], ["shock", "OBSERVATION", 146, 151]]], ["Many critically ill patients with COVID-19 will require sedation for mechanical ventilation, and the 2018 SCCM guidelines are appropriate for the care of these patients.", [["critically ill", "DISEASE", 5, 19], ["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 160, 168], ["COVID", "TEST", 34, 39], ["sedation", "TREATMENT", 56, 64], ["mechanical ventilation", "TREATMENT", 69, 91], ["the 2018 SCCM guidelines", "TREATMENT", 97, 121], ["critically", "OBSERVATION_MODIFIER", 5, 15], ["ill", "OBSERVATION", 16, 19]]], ["Most importantly, sedation should be targeted to a desired effect, including ventilator synchrony, with interruptions daily if possible, and patients will often require deep sedation if they are severely hypoxemic or require neuromuscular blockade.", [["neuromuscular", "ANATOMY", 225, 238], ["hypoxemic", "DISEASE", 204, 213], ["neuromuscular blockade", "DISEASE", 225, 247], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["sedation", "TREATMENT", 18, 26], ["ventilator synchrony", "TREATMENT", 77, 97], ["deep sedation", "TREATMENT", 169, 182], ["severely hypoxemic", "PROBLEM", 195, 213], ["neuromuscular blockade", "TREATMENT", 225, 247]]], ["AKI is a common consequence of COVID-19, either due to ATN or hypotension.", [["AKI", "DISEASE", 0, 3], ["ATN", "DISEASE", 55, 58], ["hypotension", "DISEASE", 62, 73], ["COVID-19", "CHEMICAL", 31, 39], ["AKI", "PROBLEM", 0, 3], ["COVID", "TEST", 31, 36], ["ATN", "PROBLEM", 55, 58], ["hypotension", "PROBLEM", 62, 73], ["ATN", "OBSERVATION", 55, 58], ["hypotension", "OBSERVATION", 62, 73]]], ["The hypercoagulability of COVID-19 patients may lead to increased clotting of CRRT filters but the nature of this hypercoagulability is not defined.", [["hypercoagulability", "DISEASE", 4, 22], ["hypercoagulability", "DISEASE", 114, 132], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["COVID", "TEST", 26, 31], ["increased clotting of CRRT filters", "TREATMENT", 56, 90], ["this hypercoagulability", "PROBLEM", 109, 132], ["hypercoagulability", "OBSERVATION", 4, 22], ["increased", "OBSERVATION_MODIFIER", 56, 65], ["clotting", "OBSERVATION", 66, 74], ["CRRT filters", "OBSERVATION", 78, 90], ["hypercoagulability", "OBSERVATION", 114, 132]]], ["The need for glycemic control is not unique to patients with COVID-19, but because of the need to limit room entry, patients who might otherwise be managed with an insulin infusion should be first trialed on a subcutaneous regimen.", [["subcutaneous", "ANATOMY", 210, 222], ["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 116, 124], ["insulin", "GENE_OR_GENE_PRODUCT", 164, 171], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 116, 124], ["glycemic control", "TREATMENT", 13, 29], ["COVID", "TEST", 61, 66], ["an insulin infusion", "TREATMENT", 161, 180], ["a subcutaneous regimen", "TREATMENT", 208, 230]]], ["The role of steroids has been raised for both lung injury and hemodynamic aspects of care of COVID-19 patients, but the best evidence for steroids is for the treatment of septic shock refractory to pressors and for adrenal insufficiency.", [["lung", "ANATOMY", 46, 50], ["adrenal", "ANATOMY", 215, 222], ["steroids", "CHEMICAL", 12, 20], ["lung injury", "DISEASE", 46, 57], ["steroids", "CHEMICAL", 138, 146], ["septic shock", "DISEASE", 171, 183], ["adrenal insufficiency", "DISEASE", 215, 236], ["steroids", "CHEMICAL", 12, 20], ["steroids", "CHEMICAL", 138, 146], ["steroids", "SIMPLE_CHEMICAL", 12, 20], ["lung", "ORGAN", 46, 50], ["patients", "ORGANISM", 102, 110], ["steroids", "SIMPLE_CHEMICAL", 138, 146], ["adrenal", "ORGAN", 215, 222], ["patients", "SPECIES", 102, 110], ["steroids", "TREATMENT", 12, 20], ["both lung injury", "PROBLEM", 41, 57], ["COVID", "TEST", 93, 98], ["steroids", "TREATMENT", 138, 146], ["septic shock", "PROBLEM", 171, 183], ["pressors", "TREATMENT", 198, 206], ["adrenal insufficiency", "PROBLEM", 215, 236], ["lung", "ANATOMY", 46, 50], ["injury", "OBSERVATION", 51, 57], ["septic", "OBSERVATION", 171, 177], ["adrenal", "ANATOMY", 215, 222], ["insufficiency", "OBSERVATION", 223, 236]]], ["Finally, because of the expected high mortality of critically ill patients, and the possibility that the number of patients will exceed the resources available, ethical considerations must be a part of health care systems' response plans.", [["critically ill", "DISEASE", 51, 65], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 115, 123]]], ["Systems, not individual clinicians, should develop plans for how to triage and ration care requiring limited resources (eg, ventilators, ICU beds, blood products), and, perhaps more important than many of the medical strategies described above, clinicians must address the end-of-life concerns of patients who have a high likelihood of dying of this disease.", [["blood", "ANATOMY", 147, 152], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["patients", "ORGANISM", 297, 305], ["patients", "SPECIES", 297, 305], ["ventilators", "TREATMENT", 124, 135], ["ICU beds", "TREATMENT", 137, 145], ["blood products", "TREATMENT", 147, 161], ["this disease", "PROBLEM", 345, 357]]], ["E", [["E", "SPECIES", 0, 1]]]], "0887d72928848c7c8dfea2b737af6ad098fd5bbb": [["IntroductionThe innate immune system is a key component of antiviral defense [1, 2] .", [["The innate immune system", "TREATMENT", 12, 36], ["antiviral defense", "OBSERVATION", 59, 76]]], ["Danger associated molecular patterns (DAMPs), or alarmins [3] [4] [5] plays an important role in innate immunity.", [["alarmins [3] [4] [5]", "CHEMICAL", 49, 69], ["alarmins", "CHEMICAL", 49, 57], ["alarmins [3] [4] [5]", "SIMPLE_CHEMICAL", 49, 69]]], ["DAMPs are intracellular molecules that primarily regulate cell homeostasis, but also act as extracellularly when secreted by activated or damaged cells.", [["intracellular", "ANATOMY", 10, 23], ["cell", "ANATOMY", 58, 62], ["cells", "ANATOMY", 146, 151], ["DAMPs", "GENE_OR_GENE_PRODUCT", 0, 5], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 10, 23], ["cell", "CELL", 58, 62], ["cells", "CELL", 146, 151], ["DAMPs", "PROTEIN", 0, 5], ["activated or damaged cells", "CELL_TYPE", 125, 151], ["DAMPs", "PROBLEM", 0, 5], ["intracellular molecules", "PROBLEM", 10, 33], ["intracellular molecules", "OBSERVATION", 10, 33], ["regulate cell homeostasis", "OBSERVATION", 49, 74]]], ["The DAMPs interact with Pattern recognition receptors (PRRs) and initiate the production of cytokines and chemokines, which further amplify the inflammation [6] [7] [8] [9] .", [["inflammation", "DISEASE", 144, 156], ["DAMPs", "GENE_OR_GENE_PRODUCT", 4, 9], ["Pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 24, 53], ["PRRs", "GENE_OR_GENE_PRODUCT", 55, 59], ["DAMPs", "PROTEIN", 4, 9], ["Pattern recognition receptors", "PROTEIN", 24, 53], ["PRRs", "PROTEIN", 55, 59], ["cytokines", "PROTEIN", 92, 101], ["chemokines", "PROTEIN", 106, 116], ["cytokines and chemokines", "TREATMENT", 92, 116], ["the inflammation", "PROBLEM", 140, 156], ["DAMPs", "OBSERVATION", 4, 9]]], ["However, there is very little known about the role of DAMPs in inflammation or immunity during virus infection.", [["inflammation", "DISEASE", 63, 75], ["infection", "DISEASE", 101, 110], ["DAMPs", "GENE_OR_GENE_PRODUCT", 54, 59], ["DAMPs", "PROTEIN", 54, 59], ["DAMPs", "PROBLEM", 54, 59], ["inflammation", "PROBLEM", 63, 75], ["immunity during virus infection", "PROBLEM", 79, 110], ["DAMPs", "OBSERVATION", 54, 59], ["inflammation", "OBSERVATION", 63, 75]]], ["A one protein family of DAMPs, known as S100 (i.e., S100A7, S100A15 [6] , S100A12, S100A8, and S100A9) [7] [8] [9] have shown a direct effect on the innate immune system.", [["DAMPs", "GENE_OR_GENE_PRODUCT", 24, 29], ["S100", "GENE_OR_GENE_PRODUCT", 40, 44], ["S100A7", "GENE_OR_GENE_PRODUCT", 52, 58], ["S100A15 [6]", "GENE_OR_GENE_PRODUCT", 60, 71], ["S100A12", "GENE_OR_GENE_PRODUCT", 74, 81], ["S100A8", "GENE_OR_GENE_PRODUCT", 83, 89], ["S100A9) [7] [8] [9]", "SIMPLE_CHEMICAL", 95, 114], ["DAMPs", "PROTEIN", 24, 29], ["S100", "PROTEIN", 40, 44], ["S100A7", "PROTEIN", 52, 58], ["S100A15", "PROTEIN", 60, 67], ["S100A12", "PROTEIN", 74, 81], ["S100A8", "PROTEIN", 83, 89], ["S100A9", "PROTEIN", 95, 101], ["S100A7", "TEST", 52, 58], ["S100A12", "TEST", 74, 81], ["S100A8", "TEST", 83, 89]]], ["The protein S100A9 initiates the immune response through the TLR4/MyD88 pathway [10] .", [["S100A9", "GENE_OR_GENE_PRODUCT", 12, 18], ["TLR4", "GENE_OR_GENE_PRODUCT", 61, 65], ["MyD88", "GENE_OR_GENE_PRODUCT", 66, 71], ["S100A9", "PROTEIN", 12, 18], ["TLR4", "PROTEIN", 61, 65], ["MyD88", "PROTEIN", 66, 71], ["The protein S100A9", "TEST", 0, 18]]], ["S100A9 is expressed by a variety of cell types including neutrophils, dendritic cells, monocytes and endothelial cells [10] [11] [12] [13] .", [["cell", "ANATOMY", 36, 40], ["neutrophils", "ANATOMY", 57, 68], ["dendritic cells", "ANATOMY", 70, 85], ["monocytes", "ANATOMY", 87, 96], ["endothelial cells", "ANATOMY", 101, 118], ["S100A9", "GENE_OR_GENE_PRODUCT", 0, 6], ["cell types", "CELL", 36, 46], ["neutrophils", "CELL", 57, 68], ["dendritic cells", "CELL", 70, 85], ["monocytes", "CELL", 87, 96], ["endothelial cells", "CELL", 101, 118], ["S100A9", "PROTEIN", 0, 6], ["neutrophils", "CELL_TYPE", 57, 68], ["dendritic cells", "CELL_TYPE", 70, 85], ["monocytes", "CELL_TYPE", 87, 96], ["endothelial cells", "CELL_TYPE", 101, 118], ["neutrophils", "TEST", 57, 68], ["monocytes", "TEST", 87, 96], ["endothelial cells", "TEST", 101, 118], ["dendritic cells", "OBSERVATION", 70, 85], ["endothelial", "ANATOMY", 101, 112]]], ["Activation of TLR4/MyD88 pathway by S100A9 triggers the downstream signaling cascade, leading to the activation of nuclear factor-\u043aB (NF-\u043aB), and subsequently activates type 1 interferon (IFN-\u03b1/\u03b2) [7, 9] .IntroductionBVDV belongs to the Pestivirus genus of the Flaviviridae family.", [["IntroductionBVDV", "CHEMICAL", 205, 221], ["TLR4", "GENE_OR_GENE_PRODUCT", 14, 18], ["MyD88", "GENE_OR_GENE_PRODUCT", 19, 24], ["S100A9", "GENE_OR_GENE_PRODUCT", 36, 42], ["nuclear factor-\u043aB", "GENE_OR_GENE_PRODUCT", 115, 132], ["NF-\u043aB", "GENE_OR_GENE_PRODUCT", 134, 139], ["type 1 interferon", "GENE_OR_GENE_PRODUCT", 169, 186], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 188, 193], ["\u03b2", "GENE_OR_GENE_PRODUCT", 194, 195], ["Pestivirus genus", "ORGANISM", 237, 253], ["Flaviviridae", "ORGANISM", 261, 273], ["TLR4", "PROTEIN", 14, 18], ["MyD88", "PROTEIN", 19, 24], ["S100A9", "PROTEIN", 36, 42], ["nuclear factor-\u043aB", "PROTEIN", 115, 132], ["NF-\u043aB", "PROTEIN", 134, 139], ["type 1 interferon", "PROTEIN", 169, 186], ["IFN", "PROTEIN", 188, 191], ["\u03b1", "PROTEIN", 192, 193], ["\u03b2", "PROTEIN", 194, 195], ["TLR4/MyD88 pathway", "TREATMENT", 14, 32], ["the downstream signaling cascade", "PROBLEM", 52, 84], ["nuclear factor", "TEST", 115, 129]]], ["It an immunosuppressive virus and one of the major threats to the cattle industry worldwide [14] [15] [16] [17] [18] .", [["[14] [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 92, 116], ["cattle", "SPECIES", 66, 72], ["an immunosuppressive virus", "TREATMENT", 3, 29], ["immunosuppressive virus", "OBSERVATION", 6, 29]]], ["BVDV has a positive sense single stranded RNA genome with the size of 12.3 Kb [19] .", [["BVDV", "ORGANISM", 0, 4], ["positive sense single stranded RNA genome", "DNA", 11, 52], ["BVDV", "SPECIES", 0, 4], ["BVDV", "SPECIES", 0, 4], ["BVDV", "PROBLEM", 0, 4], ["a positive sense single stranded RNA genome", "PROBLEM", 9, 52], ["the size", "TEST", 58, 66], ["positive", "OBSERVATION_MODIFIER", 11, 19], ["stranded", "OBSERVATION_MODIFIER", 33, 41], ["RNA genome", "OBSERVATION", 42, 52], ["size", "OBSERVATION_MODIFIER", 62, 66], ["12.3 Kb", "OBSERVATION_MODIFIER", 70, 77]]], ["The genome is translated into a single open reading frame (ORF) that encodes approximately 4000 codons comprising 10 to 11 posttranslational cleaved proteins [17, 19] .", [["open reading frame", "DNA", 39, 57], ["ORF", "DNA", 59, 62], ["posttranslational cleaved proteins", "PROTEIN", 123, 157], ["posttranslational cleaved proteins", "TEST", 123, 157]]], ["The polyprotein is cleaved into 4 structural proteins [e.g. Erns, envelope proteins E1, E2, and capsid protein (C)] and 7 to 8 nonstructural proteins (e.g. Npro, p7, NS2-3 or NS2 and NS3, NS4A NS4B, NS5A and NS5B) by viral or/and host cell proteases [17, 19, 20] .", [["cell", "ANATOMY", 235, 239], ["Erns", "GENE_OR_GENE_PRODUCT", 60, 64], ["E1", "GENE_OR_GENE_PRODUCT", 84, 86], ["E2", "GENE_OR_GENE_PRODUCT", 88, 90], ["capsid protein (C)", "GENE_OR_GENE_PRODUCT", 96, 114], ["Npro", "GENE_OR_GENE_PRODUCT", 156, 160], ["p7", "GENE_OR_GENE_PRODUCT", 162, 164], ["NS2-3", "GENE_OR_GENE_PRODUCT", 166, 171], ["NS2", "GENE_OR_GENE_PRODUCT", 175, 178], ["NS3", "GENE_OR_GENE_PRODUCT", 183, 186], ["NS5A", "GENE_OR_GENE_PRODUCT", 199, 203], ["NS5B", "GENE_OR_GENE_PRODUCT", 208, 212], ["4 structural proteins", "PROTEIN", 32, 53], ["Erns", "PROTEIN", 60, 64], ["envelope proteins", "PROTEIN", 66, 83], ["E1", "PROTEIN", 84, 86], ["E2", "PROTEIN", 88, 90], ["capsid protein", "PROTEIN", 96, 110], ["C", "PROTEIN", 112, 113], ["nonstructural proteins", "PROTEIN", 127, 149], ["Npro", "PROTEIN", 156, 160], ["p7", "PROTEIN", 162, 164], ["NS2", "PROTEIN", 166, 169], ["3", "PROTEIN", 170, 171], ["NS2", "PROTEIN", 175, 178], ["NS3", "PROTEIN", 183, 186], ["NS4A", "PROTEIN", 188, 192], ["NS4B", "PROTEIN", 193, 197], ["NS5A", "PROTEIN", 199, 203], ["NS5B", "PROTEIN", 208, 212], ["viral or/and host cell proteases", "PROTEIN", 217, 249], ["The polyprotein", "TREATMENT", 0, 15], ["e.g. Erns", "TEST", 55, 64], ["envelope proteins E1", "TEST", 66, 86], ["E2", "TEST", 88, 90], ["capsid protein", "TEST", 96, 110], ["nonstructural proteins", "TEST", 127, 149], ["Npro", "TEST", 156, 160], ["p7", "TEST", 162, 164], ["NS2", "TEST", 166, 169], ["NS2", "TEST", 175, 178], ["NS3", "TEST", 183, 186], ["NS4A", "TEST", 188, 192], ["NS4B", "TEST", 193, 197], ["NS5A", "TEST", 199, 203], ["NS5B", "TEST", 208, 212], ["viral", "TEST", 217, 222], ["host cell proteases", "TEST", 230, 249], ["host cell", "OBSERVATION", 230, 239]]], ["The Flaviviridae family also includes Flavivirus and Hepacivirus genus.", [["Flaviviridae", "ORGANISM", 4, 16], ["Hepacivirus genus", "ORGANISM", 53, 70], ["Flavivirus", "PROBLEM", 38, 48]]], ["The Flavivirus genus has viruses with zoonotic importance, such as West Nile virus and dengue virus while Hepacivirus genus comprised solely of the hepatitis C virus (HCV) [21, 22] .", [["Flavivirus genus", "DISEASE", 4, 20], ["dengue virus", "DISEASE", 87, 99], ["hepatitis C", "DISEASE", 148, 159], ["West Nile virus", "ORGANISM", 67, 82], ["dengue virus", "ORGANISM", 87, 99], ["Hepacivirus genus", "ORGANISM", 106, 123], ["hepatitis C virus", "ORGANISM", 148, 165], ["HCV", "ORGANISM", 167, 170], ["West Nile virus", "SPECIES", 67, 82], ["dengue virus", "SPECIES", 87, 99], ["hepatitis C virus", "SPECIES", 148, 165], ["West Nile virus", "SPECIES", 67, 82], ["dengue virus", "SPECIES", 87, 99], ["hepatitis C virus", "SPECIES", 148, 165], ["HCV", "SPECIES", 167, 170], ["viruses", "PROBLEM", 25, 32], ["West Nile virus", "PROBLEM", 67, 82], ["dengue virus", "PROBLEM", 87, 99], ["the hepatitis C virus", "PROBLEM", 144, 165], ["Flavivirus genus", "OBSERVATION", 4, 20], ["hepatitis", "OBSERVATION", 148, 157]]], ["Of the three Flaviviridae genuses, the Pestivirus genome is unique because it encodes two proteins (e.g. Npro and Erns) that are not present in the other genus in Flaviviridae family [23] .", [["Flaviviridae", "ORGANISM", 13, 25], ["Pestivirus", "GENE_OR_GENE_PRODUCT", 39, 49], ["Npro", "GENE_OR_GENE_PRODUCT", 105, 109], ["Erns", "GENE_OR_GENE_PRODUCT", 114, 118], ["Pestivirus genome", "DNA", 39, 56], ["Npro", "PROTEIN", 105, 109], ["Erns", "PROTEIN", 114, 118], ["the three Flaviviridae genuses", "PROBLEM", 3, 33], ["the Pestivirus genome", "PROBLEM", 35, 56], ["Flaviviridae genuses", "OBSERVATION", 13, 33], ["Pestivirus genome", "OBSERVATION", 39, 56]]], ["Npro is the first protein coded in the ORF, which has protease activity, but is not necessary for viral replication [24, 25] .", [["Npro", "GENE_OR_GENE_PRODUCT", 0, 4], ["Npro", "PROTEIN", 0, 4], ["ORF", "DNA", 39, 42], ["protease", "PROTEIN", 54, 62], ["viral replication", "TREATMENT", 98, 115]]], ["Npro interferes with the innate immune mechanisms through inhibiting type one interferon (e.g. interferon alpha and beta: FN-\u03b1/\u03b2) in cell culture [23, 26, 27] .", [["cell", "ANATOMY", 133, 137], ["Npro", "CHEMICAL", 0, 4], ["Npro", "GENE_OR_GENE_PRODUCT", 0, 4], ["type one interferon", "GENE_OR_GENE_PRODUCT", 69, 88], ["interferon alpha", "GENE_OR_GENE_PRODUCT", 95, 111], ["beta: FN-\u03b1", "GENE_OR_GENE_PRODUCT", 116, 126], ["\u03b2", "GENE_OR_GENE_PRODUCT", 127, 128], ["cell", "CELL", 133, 137], ["Npro", "PROTEIN", 0, 4], ["interferon", "PROTEIN", 78, 88], ["interferon alpha", "PROTEIN", 95, 111], ["beta", "PROTEIN", 116, 120], ["FN", "PROTEIN", 122, 124], ["\u03b1", "PROTEIN", 125, 126], ["\u03b2", "PROTEIN", 127, 128], ["the innate immune mechanisms", "TREATMENT", 21, 49], ["type one interferon", "TREATMENT", 69, 88], ["interferon alpha", "TREATMENT", 95, 111], ["FN", "TEST", 122, 124], ["cell culture", "TEST", 133, 145]]], ["This inhibition is potentially associated with the immunotolerance and development of persistent infection (PI) in BVDV infection [25] .IntroductionStudies with Npro deleted classical swine fever virus demonstrated that Npro is not required for viral replication in cell culture [25] while deletion facilitated the induction of type one IFN [26, 27] .", [["cell culture", "ANATOMY", 266, 278], ["infection", "DISEASE", 97, 106], ["BVDV infection", "DISEASE", 115, 129], ["swine fever", "DISEASE", 184, 195], ["BVDV", "ORGANISM", 115, 119], ["Npro deleted classical swine fever virus", "ORGANISM", 161, 201], ["Npro", "GENE_OR_GENE_PRODUCT", 220, 224], ["cell", "CELL", 266, 270], ["Npro", "PROTEIN", 220, 224], ["IFN", "PROTEIN", 337, 340], ["swine fever virus", "SPECIES", 184, 201], ["BVDV", "SPECIES", 115, 119], ["swine fever virus", "SPECIES", 184, 201], ["the immunotolerance", "PROBLEM", 47, 66], ["persistent infection (PI)", "PROBLEM", 86, 111], ["BVDV infection", "PROBLEM", 115, 129], ["Npro deleted classical swine fever virus", "PROBLEM", 161, 201], ["viral replication", "TREATMENT", 245, 262], ["cell culture", "TEST", 266, 278], ["potentially associated with", "UNCERTAINTY", 19, 46], ["persistent", "OBSERVATION_MODIFIER", 86, 96], ["infection", "OBSERVATION", 97, 106], ["BVDV", "OBSERVATION_MODIFIER", 115, 119], ["infection", "OBSERVATION", 120, 129]]], ["Vaccination with Npro deleted virus induced a strong antibody response with significantly increased protection against highly virulent CSFV [25, 28] .", [["Npro", "CHEMICAL", 17, 21], ["Npro", "GENE_OR_GENE_PRODUCT", 17, 21], ["CSFV", "ORGANISM", 135, 139], ["Npro", "PROTEIN", 17, 21], ["CSFV", "SPECIES", 135, 139], ["Vaccination", "TREATMENT", 0, 11], ["Npro deleted virus", "PROBLEM", 17, 35], ["a strong antibody response", "PROBLEM", 44, 70], ["highly virulent CSFV", "PROBLEM", 119, 139], ["virulent", "OBSERVATION_MODIFIER", 126, 134], ["CSFV", "OBSERVATION", 135, 139]]], ["Similarly, a BVDV virus with mutations in both the Npro protease coding sequence as well as the Erns RNase region, failed to induce PI in calves [29] .", [["BVDV virus", "ORGANISM", 13, 23], ["Npro protease", "GENE_OR_GENE_PRODUCT", 51, 64], ["Erns RNase", "GENE_OR_GENE_PRODUCT", 96, 106], ["Npro protease coding sequence", "DNA", 51, 80], ["Erns RNase region", "DNA", 96, 113], ["calves", "SPECIES", 138, 144], ["BVDV virus", "SPECIES", 13, 23], ["a BVDV virus", "PROBLEM", 11, 23], ["mutations", "PROBLEM", 29, 38], ["the Npro protease coding sequence", "TREATMENT", 47, 80], ["the Erns RNase region", "TREATMENT", 92, 113], ["BVDV virus", "OBSERVATION", 13, 23]]], ["The Npro potentially reduces type I IFN by decreasing interferon regulatory factor-3 (IRF-3).", [["Npro", "CHEMICAL", 4, 8], ["Npro", "SIMPLE_CHEMICAL", 4, 8], ["type I IFN", "GENE_OR_GENE_PRODUCT", 29, 39], ["interferon regulatory factor-3", "GENE_OR_GENE_PRODUCT", 54, 84], ["IRF-3", "GENE_OR_GENE_PRODUCT", 86, 91], ["Npro", "PROTEIN", 4, 8], ["type I IFN", "PROTEIN", 29, 39], ["interferon regulatory factor-3", "PROTEIN", 54, 84], ["IRF-3", "PROTEIN", 86, 91], ["type I IFN", "PROBLEM", 29, 39], ["decreasing interferon regulatory factor", "PROBLEM", 43, 82], ["decreasing", "OBSERVATION_MODIFIER", 43, 53], ["interferon", "OBSERVATION", 54, 64]]], ["The phosphorylation of IRF-3 resulted in its conformational change with increased binding ability to DNA.", [["IRF-3", "GENE_OR_GENE_PRODUCT", 23, 28], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["IRF-3", "PROTEIN", 23, 28], ["The phosphorylation of IRF", "PROBLEM", 0, 26], ["its conformational change", "PROBLEM", 41, 66], ["increased binding ability to DNA", "PROBLEM", 72, 104], ["IRF", "OBSERVATION", 23, 26]]], ["Phosphorylated IRF-3 binding to DNA up-regulated the IRF-3 transcriptional as well as interferon (IFN)-responsive genes to produce type I IFN [30, 31] .", [["IRF-3", "GENE_OR_GENE_PRODUCT", 15, 20], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["IRF-3", "GENE_OR_GENE_PRODUCT", 53, 58], ["interferon", "GENE_OR_GENE_PRODUCT", 86, 96], ["IFN", "GENE_OR_GENE_PRODUCT", 98, 101], ["type I IFN", "GENE_OR_GENE_PRODUCT", 131, 141], ["Phosphorylated IRF-3", "PROTEIN", 0, 20], ["IRF-3", "DNA", 53, 58], ["interferon (IFN)-responsive genes", "DNA", 86, 119], ["type I IFN", "PROTEIN", 131, 141], ["Phosphorylated IRF", "TEST", 0, 18], ["DNA", "TEST", 32, 35], ["interferon (IFN)", "TREATMENT", 86, 102], ["responsive genes", "PROBLEM", 103, 119]]], ["While, BVDV Npro decreased the IRF-3 level via proteasomal degradation, leading to decreased expression of type I IFN [32, 33] .IntroductionThe current study showed a strong association of BVDV Npro with cellular S100A9 protein.", [["cellular", "ANATOMY", 204, 212], ["BVDV", "ORGANISM", 7, 11], ["Npro", "GENE_OR_GENE_PRODUCT", 12, 16], ["IRF-3", "GENE_OR_GENE_PRODUCT", 31, 36], ["type I IFN", "GENE_OR_GENE_PRODUCT", 107, 117], ["BVDV", "ORGANISM", 189, 193], ["Npro", "GENE_OR_GENE_PRODUCT", 194, 198], ["cellular", "CELL", 204, 212], ["S100A9", "GENE_OR_GENE_PRODUCT", 213, 219], ["BVDV Npro", "PROTEIN", 7, 16], ["IRF-3", "PROTEIN", 31, 36], ["type I IFN", "PROTEIN", 107, 117], ["BVDV Npro", "PROTEIN", 189, 198], ["cellular S100A9 protein", "PROTEIN", 204, 227], ["BVDV", "SPECIES", 7, 11], ["BVDV", "SPECIES", 189, 193], ["BVDV", "PROBLEM", 7, 11], ["proteasomal degradation", "PROBLEM", 47, 70], ["decreased expression of type I IFN", "PROBLEM", 83, 117], ["The current study", "TEST", 140, 157], ["decreased", "OBSERVATION_MODIFIER", 17, 26], ["IRF", "OBSERVATION_MODIFIER", 31, 34], ["proteasomal degradation", "OBSERVATION", 47, 70], ["decreased", "OBSERVATION_MODIFIER", 83, 92]]], ["Inhibition of S100A9 protein expression by small interfering RNA (siRNA) enhanced the virus replication in infected cells.", [["cells", "ANATOMY", 116, 121], ["S100A9", "GENE_OR_GENE_PRODUCT", 14, 20], ["cells", "CELL", 116, 121], ["S100A9", "PROTEIN", 14, 20], ["small interfering RNA", "RNA", 43, 64], ["infected cells", "CELL_TYPE", 107, 121], ["S100A9 protein expression", "TEST", 14, 39], ["small interfering RNA (siRNA)", "PROBLEM", 43, 72], ["the virus replication", "TREATMENT", 82, 103], ["infected cells", "PROBLEM", 107, 121], ["small", "OBSERVATION_MODIFIER", 43, 48], ["interfering RNA", "OBSERVATION", 49, 64], ["virus replication", "OBSERVATION", 86, 103], ["infected cells", "OBSERVATION", 107, 121]]], ["Overexpression of bovine S100A9 enhanced the ncpBVDV2a 1373 mediated Type-I interferon production.", [["bovine", "ORGANISM", 18, 24], ["S100A9", "GENE_OR_GENE_PRODUCT", 25, 31], ["Type-I interferon", "GENE_OR_GENE_PRODUCT", 69, 86], ["bovine S100A9", "PROTEIN", 18, 31], ["Type-I interferon", "PROTEIN", 69, 86], ["bovine", "SPECIES", 18, 24], ["bovine", "SPECIES", 18, 24], ["Type-I interferon production", "PROBLEM", 69, 97]]], ["These results indicated that BVDV Npro reduced the S100A9 protein availability/ activity in infected cells resulting in reduced Type-I interferon production.", [["cells", "ANATOMY", 101, 106], ["Npro", "CHEMICAL", 34, 38], ["BVDV", "ORGANISM", 29, 33], ["Npro", "GENE_OR_GENE_PRODUCT", 34, 38], ["S100A9", "GENE_OR_GENE_PRODUCT", 51, 57], ["cells", "CELL", 101, 106], ["Type-I interferon", "GENE_OR_GENE_PRODUCT", 128, 145], ["BVDV Npro", "PROTEIN", 29, 38], ["S100A9", "PROTEIN", 51, 57], ["infected cells", "CELL_TYPE", 92, 106], ["Type-I interferon", "PROTEIN", 128, 145], ["BVDV", "SPECIES", 29, 33], ["BVDV", "PROBLEM", 29, 33], ["infected cells", "PROBLEM", 92, 106], ["reduced Type-I interferon production", "PROBLEM", 120, 156], ["infected cells", "OBSERVATION", 92, 106], ["reduced", "OBSERVATION_MODIFIER", 120, 127]]], ["The non-cytopathic (ncp) BVDV2a-1373 was propagated and titrated in MDBK cells.", [["MDBK cells", "ANATOMY", 68, 78], ["BVDV2a-1373", "CHEMICAL", 25, 36], ["BVDV2a-1373", "CHEMICAL", 25, 36], ["MDBK cells", "CELL", 68, 78], ["non-cytopathic (ncp) BVDV2a-1373", "DNA", 4, 36], ["MDBK cells", "CELL_LINE", 68, 78], ["MDBK", "SPECIES", 68, 72], ["BVDV2a", "TEST", 25, 31], ["MDBK cells", "OBSERVATION", 68, 78]]], ["Titrated virus was aliquoted and stored at \u221280\u00b0C until use.", [["Titrated virus", "TREATMENT", 0, 14]]], ["The p3XFLAG-CMV-10 (Sigma-Aldrich, St. Louis, MO) or pEGFP C1 (Clontech Laboratories Inc., Mountain View, CA) plasmid was transformed and amplified in DH5\u03b1 strain of Escherichia coli (E coli) (Life Technologies, Grand Island NY).", [["CMV", "ORGANISM", 12, 15], ["Sigma-Aldrich", "ORGANISM", 20, 33], ["St. Louis", "ORGANISM", 35, 44], ["MO", "ORGANISM", 46, 48], ["pEGFP C1", "GENE_OR_GENE_PRODUCT", 53, 61], ["Mountain View, CA", "GENE_OR_GENE_PRODUCT", 91, 108], ["Escherichia coli", "ORGANISM", 166, 182], ["E coli", "ORGANISM", 184, 190], ["p3XFLAG-CMV-10", "DNA", 4, 18], ["pEGFP C1", "DNA", 53, 61], ["Clontech Laboratories Inc., Mountain View, CA) plasmid", "DNA", 63, 117], ["Escherichia coli", "SPECIES", 166, 182], ["E coli", "SPECIES", 184, 190], ["Escherichia coli", "SPECIES", 166, 182], ["E coli", "SPECIES", 184, 190], ["The p3XFLAG", "TEST", 0, 11], ["CMV", "TEST", 12, 15], ["Mountain View", "TEST", 91, 104], ["CA) plasmid", "TREATMENT", 106, 117], ["Escherichia coli (E coli", "PROBLEM", 166, 190], ["CMV", "OBSERVATION", 12, 15], ["Escherichia coli", "OBSERVATION", 166, 182]]], ["After amplification, plasmids were extracted through QIAGEN Plasmid Mini Kit (QIAGEN, Germantown, MD) and stored at \u221280\u00b0C until use.p3XFLAG-Npro ConstructionWe chose to clone the Npro gene from ncp BVDV2a-1373 as BVDV suppresses type 1 IFN production in vitro [35] and the ncp BVDV2a-1373 is one of the high pathogenic BVDV strains [36] .", [["plasmids", "ANATOMY", 21, 29], ["BVDV2a-1373", "CHEMICAL", 198, 209], ["BVDV2a-1373", "CHEMICAL", 277, 288], ["Npro", "GENE_OR_GENE_PRODUCT", 179, 183], ["BVDV", "ORGANISM", 213, 217], ["type 1 IFN", "GENE_OR_GENE_PRODUCT", 229, 239], ["BVDV", "ORGANISM", 319, 323], ["plasmids", "DNA", 21, 29], ["Npro gene", "DNA", 179, 188], ["IFN", "PROTEIN", 236, 239], ["BVDV", "SPECIES", 213, 217], ["BVDV2a-1373", "SPECIES", 277, 288], ["BVDV", "SPECIES", 319, 323], ["plasmids", "TREATMENT", 21, 29], ["the ncp BVDV2a", "TEST", 269, 283], ["the high pathogenic BVDV strains", "PROBLEM", 299, 331]]], ["To construct the Npro plasmid, total RNA extracted from ncp BVDV2a-1373 using QIAamp viral RNA mini-kit (QIAGEN, Germantown MD) was used as a template.", [["BVDV2a-1373", "CHEMICAL", 60, 71], ["Npro", "GENE_OR_GENE_PRODUCT", 17, 21], ["Npro plasmid", "DNA", 17, 29], ["ncp BVDV2a-1373", "DNA", 56, 71], ["ncp BVDV2a-1373", "SPECIES", 56, 71], ["the Npro plasmid", "TREATMENT", 13, 29], ["total RNA", "TREATMENT", 31, 40], ["ncp BVDV2a", "TEST", 56, 66], ["QIAamp viral RNA mini-kit (QIAGEN, Germantown MD)", "TREATMENT", 78, 127]]], ["The obtained RNA was used as a template to create Npro complementary DNA (cDNA).", [["Npro", "GENE_OR_GENE_PRODUCT", 50, 54], ["DNA", "CELLULAR_COMPONENT", 69, 72], ["cDNA", "CELLULAR_COMPONENT", 74, 78], ["Npro complementary DNA", "DNA", 50, 72], ["cDNA", "DNA", 74, 78], ["a template", "TREATMENT", 29, 39]]], ["The BVDV Npro cDNA was made through reverse transcription-polymerase chain reaction (RT-PCR) using the OneStep RT-PCR kit (QIAGEN, Germantown MD).", [["BVDV", "ORGANISM", 4, 8], ["Npro", "GENE_OR_GENE_PRODUCT", 9, 13], ["BVDV Npro cDNA", "DNA", 4, 18], ["BVDV", "SPECIES", 4, 8], ["BVDV", "SPECIES", 4, 8], ["The BVDV Npro cDNA", "TEST", 0, 18], ["polymerase chain reaction", "PROBLEM", 58, 83], ["RT-PCR", "TEST", 85, 91], ["the OneStep RT", "TREATMENT", 99, 113]]], ["Npro-forward and -reverse primers such as 5\u2032CGGAATTCTGCTGGAGTGAATACTGAAGAG ATAGT 3\u2032 and 5\u2032CGGGATCCATTAATCGTGGCGAAAATAATTACAA 3\u2032 were designed respectively to amplify the segment encoding Npro protein from nucleotide 389 to 892, according to the sequence of ncp BVDV2a-1373 from the GenBank (Accession No., AF145967) (Fig. 1A) .", [["nucleotide", "CHEMICAL", 205, 215], ["BVDV2a-1373", "CHEMICAL", 261, 272], ["nucleotide", "CHEMICAL", 205, 215], ["Npro", "GENE_OR_GENE_PRODUCT", 187, 191], ["Npro-forward and -reverse primers", "DNA", 0, 33], ["Npro protein", "PROTEIN", 187, 199], ["ncp BVDV2a-1373", "DNA", 257, 272], ["Npro-forward and -reverse primers", "TREATMENT", 0, 33], ["CGGGATCCATTAATCGTGGCGAAAATAATTACAA", "TEST", 90, 124], ["ncp BVDV2a", "TEST", 257, 267], ["segment", "ANATOMY_MODIFIER", 170, 177]]], ["Amplification of cDNA was performed using a temperature profile of 50\u00b0C for 30 min, 95\u00b0C for 15 min, followed by 30 cycles of (95\u00b0C for 10 s, 52\u00b0C for 30 s and 72\u00b0C for 30 s) respectively.", [["cDNA", "DNA", 17, 21], ["a temperature profile", "TEST", 42, 63]]], ["Upon completion of the 30 cycles, the resultant was prolonged for 7 min at 72\u00b0C. The PCR product was analyzed on 1% agarose gel.", [["agarose", "SIMPLE_CHEMICAL", 116, 123], ["the 30 cycles", "TREATMENT", 19, 32], ["The PCR product", "TREATMENT", 81, 96], ["1% agarose gel", "TREATMENT", 113, 127]]], ["The amplified DNA as well as p3XFLAG-CMV-10 (6.4 Kb) plasmid were double digested by EcoRI, Fig. 1 . p3XFLAG-Npro and p3XFLAG-S100A9 construction and knock down of S100A9 protein through siRNA.", [["DNA", "CELLULAR_COMPONENT", 14, 17], ["p3XFLAG", "GENE_OR_GENE_PRODUCT", 29, 36], ["EcoRI", "GENE_OR_GENE_PRODUCT", 85, 90], ["p3XFLAG-Npro", "GENE_OR_GENE_PRODUCT", 101, 113], ["p3XFLAG-S100A9", "GENE_OR_GENE_PRODUCT", 118, 132], ["S100A9", "GENE_OR_GENE_PRODUCT", 164, 170], ["amplified DNA", "DNA", 4, 17], ["p3XFLAG-CMV-10 (6.4 Kb) plasmid", "DNA", 29, 60], ["EcoRI", "DNA", 85, 90], ["p3XFLAG", "PROTEIN", 101, 108], ["p3XFLAG", "PROTEIN", 118, 125], ["S100A9", "PROTEIN", 126, 132], ["S100A9 protein", "PROTEIN", 164, 178], ["The amplified DNA", "PROBLEM", 0, 17], ["p3XFLAG", "TEST", 29, 36], ["CMV", "TEST", 37, 40], ["plasmid", "TREATMENT", 53, 60], ["p3XFLAG", "TEST", 101, 108], ["Npro", "TEST", 109, 113], ["p3XFLAG", "TEST", 118, 125], ["siRNA", "PROBLEM", 187, 192], ["DNA", "OBSERVATION", 14, 17], ["siRNA", "ANATOMY", 187, 192]]], ["The BVDV Npro cDNA was made through RT-PCR targeting Npro protein from nucleotide 389 to 892 (A).", [["nucleotide", "CHEMICAL", 71, 81], ["nucleotide", "CHEMICAL", 71, 81], ["BVDV", "ORGANISM", 4, 8], ["Npro", "GENE_OR_GENE_PRODUCT", 9, 13], ["Npro", "GENE_OR_GENE_PRODUCT", 53, 57], ["BVDV Npro cDNA", "DNA", 4, 18], ["Npro protein", "PROTEIN", 53, 65], ["BVDV", "SPECIES", 4, 8], ["BVDV", "SPECIES", 4, 8], ["The BVDV Npro cDNA", "TEST", 0, 18], ["RT-PCR", "TEST", 36, 42], ["nucleotide", "TEST", 71, 81], ["BVDV", "OBSERVATION", 4, 8]]], ["The p3XFLAG-Npro or p3XFLAG-S100A9 vector were constructed and transfected in to 293T cells.", [["293T cells", "ANATOMY", 81, 91], ["p3XFLAG-Npro", "GENE_OR_GENE_PRODUCT", 4, 16], ["p3XFLAG-S100A9", "GENE_OR_GENE_PRODUCT", 20, 34], ["293T cells", "CELL", 81, 91], ["p3XFLAG-Npro or p3XFLAG-S100A9 vector", "DNA", 4, 41], ["293T cells", "CELL_LINE", 81, 91], ["The p3XFLAG", "TEST", 0, 11], ["p3XFLAG-S100A9 vector", "TREATMENT", 20, 41]]], ["After 24 h post transfection, cells were harvested and conformed for Npro-FLAG (B) or S100A9-FLAG (C) expression by western blot. and BamH1 (Sigma, St. Louis, MO) for 2 h.", [["cells", "ANATOMY", 30, 35], ["cells", "CELL", 30, 35], ["Npro-FLAG", "GENE_OR_GENE_PRODUCT", 69, 78], ["B", "GENE_OR_GENE_PRODUCT", 80, 81], ["S100A9-FLAG (C", "GENE_OR_GENE_PRODUCT", 86, 100], ["BamH1", "GENE_OR_GENE_PRODUCT", 134, 139], ["St. Louis, MO", "ORGANISM", 148, 161], ["Npro-FLAG", "PROTEIN", 69, 78], ["B", "PROTEIN", 80, 81], ["S100A9", "PROTEIN", 86, 92], ["FLAG (C)", "PROTEIN", 93, 101], ["Npro-FLAG", "TEST", 69, 78], ["S100A9", "TEST", 86, 92]]], ["The Npro cDNA was then ligated into the p3XFLAG-CMV-10 vector using T4 ligase (Sigma, St. Louis, MO), to get p3XFLAG -Npro vector.", [["Npro", "GENE_OR_GENE_PRODUCT", 4, 8], ["p3XFLAG", "GENE_OR_GENE_PRODUCT", 40, 47], ["CMV", "ORGANISM", 48, 51], ["T4 ligase", "GENE_OR_GENE_PRODUCT", 68, 77], ["St. Louis", "ORGANISM", 86, 95], ["MO", "GENE_OR_GENE_PRODUCT", 97, 99], ["p3XFLAG", "GENE_OR_GENE_PRODUCT", 109, 116], ["Npro cDNA", "DNA", 4, 13], ["p3XFLAG-CMV-10 vector", "DNA", 40, 61], ["T4 ligase", "PROTEIN", 68, 77], ["MO", "PROTEIN", 97, 99], ["p3XFLAG", "PROTEIN", 109, 116], ["Npro vector", "DNA", 118, 129], ["The Npro cDNA", "TEST", 0, 13], ["the p3XFLAG", "TEST", 36, 47], ["CMV", "TEST", 48, 51]]], ["The p3XFLAG -Npro was then transformed into E. coli-DH5\u03b1 competent cells (Life Technologies, Grand Island, NY) for amplification.", [["cells", "ANATOMY", 67, 72], ["p3XFLAG -Npro", "GENE_OR_GENE_PRODUCT", 4, 17], ["cells", "CELL", 67, 72], ["p3XFLAG", "PROTEIN", 4, 11], ["Npro", "PROTEIN", 13, 17], ["E. coli-DH5\u03b1 competent cells", "CELL_LINE", 44, 72], ["The p3XFLAG", "TEST", 0, 11]]], ["After amplification, the insertion of Npro to p3XFLAG-CMV in p3XFLAG -Npro vector was confirmed through restriction enzyme reaction digestion as well as by DNA sequencing.", [["Npro", "GENE_OR_GENE_PRODUCT", 38, 42], ["p3XFLAG", "GENE_OR_GENE_PRODUCT", 46, 53], ["CMV", "ORGANISM", 54, 57], ["p3XFLAG -Npro", "GENE_OR_GENE_PRODUCT", 61, 74], ["DNA", "CELLULAR_COMPONENT", 156, 159], ["Npro", "DNA", 38, 42], ["p3XFLAG", "DNA", 46, 53], ["p3XFLAG", "DNA", 61, 68], ["Npro vector", "DNA", 70, 81], ["the insertion of Npro", "TREATMENT", 21, 42], ["p3XFLAG", "TEST", 46, 53], ["CMV in p3XFLAG", "TREATMENT", 54, 68], ["Npro vector", "TREATMENT", 70, 81], ["restriction enzyme reaction digestion", "PROBLEM", 104, 141], ["CMV", "OBSERVATION", 54, 57]]], ["The restriction enzyme digestion of p3XFLAG -Npro vector with EcoRI, and BamH1 (Sigma, St. Louis, MO) gave 503 base pairs (bp) Npro and 6.4 Kb p3XFLAG-CMV vector portion.pEGFP C1-Npro Vector constructionThe pEGFP-C1 plasmid was kindly provided by Dr. Adam Hoppe, Department of Chemistry and Biochemistry, South Dakota State University, Brookings, SD.", [["p3XFLAG -Npro", "GENE_OR_GENE_PRODUCT", 36, 49], ["EcoRI", "GENE_OR_GENE_PRODUCT", 62, 67], ["BamH1", "GENE_OR_GENE_PRODUCT", 73, 78], ["pEGFP", "GENE_OR_GENE_PRODUCT", 170, 175], ["pEGFP-C1", "GENE_OR_GENE_PRODUCT", 207, 215], ["p3XFLAG", "PROTEIN", 36, 43], ["Npro vector", "DNA", 45, 56], ["EcoRI", "DNA", 62, 67], ["BamH1", "DNA", 73, 78], ["MO", "DNA", 98, 100], ["503 base pairs", "DNA", 107, 121], ["6.4 Kb p3XFLAG-CMV vector portion", "DNA", 136, 169], ["pEGFP C1", "PROTEIN", 170, 178], ["pEGFP-C1 plasmid", "DNA", 207, 223], ["The restriction enzyme digestion", "TEST", 0, 32], ["p3XFLAG", "TEST", 36, 43], ["EcoRI", "TEST", 62, 67], ["base pairs", "TEST", 111, 121], ["bp", "TEST", 123, 125], ["Npro", "TEST", 127, 131], ["Kb p3XFLAG", "TEST", 140, 150], ["C1-Npro Vector construction", "TREATMENT", 176, 203], ["The pEGFP-C1 plasmid", "TREATMENT", 203, 223], ["CMV vector", "OBSERVATION", 151, 161]]], ["The pEGFP-C1 plasmid was utilized to construct pEGFP C1-Npro Vector by inserting Npro gene at EcoRI and Bam HI restriction site as described above in p3XFLAG-Npro Construction.", [["pEGFP-C1", "GENE_OR_GENE_PRODUCT", 4, 12], ["pEGFP", "GENE_OR_GENE_PRODUCT", 47, 52], ["Npro Vector", "GENE_OR_GENE_PRODUCT", 56, 67], ["Npro", "GENE_OR_GENE_PRODUCT", 81, 85], ["EcoRI", "GENE_OR_GENE_PRODUCT", 94, 99], ["Bam HI", "GENE_OR_GENE_PRODUCT", 104, 110], ["pEGFP-C1 plasmid", "DNA", 4, 20], ["pEGFP C1", "PROTEIN", 47, 55], ["Npro Vector", "DNA", 56, 67], ["Npro gene", "DNA", 81, 90], ["EcoRI", "DNA", 94, 99], ["Bam HI restriction site", "DNA", 104, 127], ["p3XFLAG", "DNA", 150, 157], ["The pEGFP-C1 plasmid", "TREATMENT", 0, 20], ["Npro Vector", "TREATMENT", 56, 67], ["EcoRI and Bam HI restriction site", "TREATMENT", 94, 127]]], ["The insertion of Npro gene was then confirmed by restriction digestion using EcoRI and Bam HI enzymes, which yield 503 bp Npro and 4.7 Kb pEGFP vector as well as by nucleotide sequencing of Npro.p3XFLAG-S100A9 vector constructionThe S100A9 gene was cloned into the p3XFLAG-CMV-10 plasmid for co-precipitation experiments.", [["plasmid", "ANATOMY", 280, 287], ["nucleotide", "CHEMICAL", 165, 175], ["nucleotide", "CHEMICAL", 165, 175], ["Npro", "GENE_OR_GENE_PRODUCT", 17, 21], ["EcoRI", "GENE_OR_GENE_PRODUCT", 77, 82], ["Bam HI enzymes", "GENE_OR_GENE_PRODUCT", 87, 101], ["pEGFP", "GENE_OR_GENE_PRODUCT", 138, 143], ["Npro.p3XFLAG-S100A9", "GENE_OR_GENE_PRODUCT", 190, 209], ["S100A9", "GENE_OR_GENE_PRODUCT", 233, 239], ["p3XFLAG", "GENE_OR_GENE_PRODUCT", 265, 272], ["CMV", "ORGANISM", 273, 276], ["Npro gene", "DNA", 17, 26], ["EcoRI and Bam HI enzymes", "DNA", 77, 101], ["503 bp Npro and 4.7 Kb pEGFP vector", "DNA", 115, 150], ["S100A9", "PROTEIN", 203, 209], ["S100A9 gene", "DNA", 233, 244], ["p3XFLAG-CMV-10 plasmid", "DNA", 265, 287], ["The insertion of Npro gene", "TREATMENT", 0, 26], ["Bam HI enzymes", "TEST", 87, 101], ["bp Npro", "TEST", 119, 126], ["Kb pEGFP vector", "TREATMENT", 135, 150], ["nucleotide sequencing", "TEST", 165, 186], ["Npro.p3XFLAG", "TEST", 190, 202]]], ["The total RNA was extracted from MDBK cells using TRIzol reagent (Invitrogen, Grand Island NY).", [["MDBK cells", "ANATOMY", 33, 43], ["MDBK cells", "CELL", 33, 43], ["MDBK cells", "CELL_LINE", 33, 43], ["MDBK", "SPECIES", 33, 37], ["The total RNA", "TEST", 0, 13], ["MDBK cells", "TREATMENT", 33, 43], ["TRIzol reagent", "TREATMENT", 50, 64], ["total RNA", "OBSERVATION_MODIFIER", 4, 13], ["MDBK cells", "OBSERVATION", 33, 43]]], ["The total RNA extracted from MDBK cells was used as template to generate to synthesize S100A9 cDNA using One step RT PCR kit (QIAGEN).", [["MDBK cells", "ANATOMY", 29, 39], ["MDBK cells", "CELL", 29, 39], ["S100A9", "GENE_OR_GENE_PRODUCT", 87, 93], ["MDBK cells", "CELL_LINE", 29, 39], ["S100A9 cDNA", "DNA", 87, 98], ["MDBK", "SPECIES", 29, 33], ["The total RNA", "TREATMENT", 0, 13], ["MDBK cells", "TREATMENT", 29, 39], ["One step RT PCR kit", "TREATMENT", 105, 124], ["total RNA", "OBSERVATION_MODIFIER", 4, 13], ["MDBK cells", "OBSERVATION", 29, 39]]], ["The S100A9 forward:5\u2032 GAAGATCTGATGACTTGCAAAATGTCGCAGCT3\u00b4; and S100A9 reverse: 5\u2032CGGGATCCTTAGGGGGTGCCCTCCCC3 primers were designed to clone S100A9 gene from 108th nucleotide to 400th as described by the bovine S100A9 cDNA sequence published in GenBank (Accession Number: XM_005203730).", [["S100A9", "GENE_OR_GENE_PRODUCT", 4, 10], ["S100A9", "GENE_OR_GENE_PRODUCT", 62, 68], ["CGGGATCCTTAGGGGGTGCCCTCCCC3", "GENE_OR_GENE_PRODUCT", 80, 107], ["S100A9", "GENE_OR_GENE_PRODUCT", 139, 145], ["bovine", "ORGANISM", 202, 208], ["S100A9", "GENE_OR_GENE_PRODUCT", 209, 215], ["S100A9", "PROTEIN", 4, 10], ["S100A9", "PROTEIN", 62, 68], ["clone S100A9 gene", "DNA", 133, 150], ["bovine S100A9 cDNA sequence", "DNA", 202, 229], ["bovine", "SPECIES", 202, 208], ["GAAGATCTGATGACTTGCAAAATGTCGCAGCT3", "TEST", 22, 55], ["CGGGATCCTTAGGGGGTGCCCTCCCC3 primers", "TREATMENT", 80, 115]]], ["The forward and reverse primers contained Bgl\u0399\u0399 and BamH1 restriction sites, respectively.", [["Bgl\u0399\u0399", "GENE_OR_GENE_PRODUCT", 42, 47], ["BamH1", "GENE_OR_GENE_PRODUCT", 52, 57], ["forward and reverse primers", "DNA", 4, 31], ["Bgl\u0399\u0399 and BamH1 restriction sites", "DNA", 42, 75], ["reverse primers", "TREATMENT", 16, 31], ["Bgl\u0399\u0399 and BamH1 restriction sites", "TREATMENT", 42, 75], ["reverse primers", "OBSERVATION", 16, 31], ["Bgl\u0399\u0399", "OBSERVATION_MODIFIER", 42, 47], ["BamH1 restriction", "OBSERVATION", 52, 69], ["sites", "OBSERVATION_MODIFIER", 70, 75]]], ["Amplification of S100A9 cDNA was performed using a temperature profile of 50\u00b0C for 30 min, 95\u00b0C for 15 min, followed by 30 cycles of (95\u00b0C for 10 s, 52\u00b0C for 30 s and 72\u00b0C for 30 s) respectively.", [["S100A9", "GENE_OR_GENE_PRODUCT", 17, 23], ["S100A9 cDNA", "DNA", 17, 28], ["a temperature profile", "TEST", 49, 70]]], ["Upon completion of the 30 cycles, the reaction was prolonged for 7 min at 72\u00b0C. The obtained S100A9 cDNA was then inserted into p3XFLAG vector using Bgl\u0399\u0399 and Bam H1 restriction sites to get p3XFLAG-S100A9 plasmid.", [["S100A9", "GENE_OR_GENE_PRODUCT", 93, 99], ["p3XFLAG", "GENE_OR_GENE_PRODUCT", 128, 135], ["Bgl\u0399\u0399", "GENE_OR_GENE_PRODUCT", 149, 154], ["Bam H1", "GENE_OR_GENE_PRODUCT", 159, 165], ["p3XFLAG-S100A9", "GENE_OR_GENE_PRODUCT", 191, 205], ["S100A9 cDNA", "DNA", 93, 104], ["p3XFLAG vector", "DNA", 128, 142], ["Bgl\u0399\u0399 and Bam H1 restriction sites", "DNA", 149, 183], ["p3XFLAG", "DNA", 191, 198], ["S100A9 plasmid", "DNA", 199, 213], ["the 30 cycles", "TREATMENT", 19, 32], ["the reaction", "PROBLEM", 34, 46], ["S100A9 cDNA", "TREATMENT", 93, 104], ["p3XFLAG vector", "TREATMENT", 128, 142], ["Bgl\u0399\u0399", "TREATMENT", 149, 154], ["Bam H1 restriction sites", "TREATMENT", 159, 183], ["p3XFLAG", "TEST", 191, 198], ["S100A9 plasmid", "TREATMENT", 199, 213]]], ["The insertion of S100A9 was then confirmed using Bgl\u0399\u0399 and Bam H1 restriction digestion as well as nucleotide sequencing.", [["nucleotide", "CHEMICAL", 99, 109], ["nucleotide", "CHEMICAL", 99, 109], ["S100A9", "GENE_OR_GENE_PRODUCT", 17, 23], ["Bam H1", "GENE_OR_GENE_PRODUCT", 59, 65], ["S100A9", "PROTEIN", 17, 23], ["The insertion of S100A9", "TREATMENT", 0, 23], ["Bgl\u0399\u0399", "TREATMENT", 49, 54], ["Bam H1 restriction digestion", "TREATMENT", 59, 87], ["nucleotide sequencing", "TREATMENT", 99, 120]]], ["The restriction digestion yielded 292 bp S100A9 and 6.4 Kb p3XFLAG-CMV.TransfectionsThe 293T cells have a higher transfection efficiency as compared to MDBK cells, therefore 293T cells were used to express the BVDV or bovine gene in those cells as per the practice used earlier [37, 38] .", [["293T cells", "ANATOMY", 88, 98], ["MDBK cells", "ANATOMY", 152, 162], ["293T cells", "ANATOMY", 174, 184], ["cells", "ANATOMY", 239, 244], ["S100A9", "GENE_OR_GENE_PRODUCT", 41, 47], ["293T cells", "CELL", 88, 98], ["MDBK cells", "CELL", 152, 162], ["293T cells", "CELL", 174, 184], ["BVDV", "ORGANISM", 210, 214], ["bovine", "ORGANISM", 218, 224], ["cells", "CELL", 239, 244], ["S100A9", "PROTEIN", 41, 47], ["293T cells", "CELL_LINE", 88, 98], ["MDBK cells", "CELL_LINE", 152, 162], ["293T cells", "CELL_LINE", 174, 184], ["BVDV or bovine gene", "DNA", 210, 229], ["bovine", "SPECIES", 218, 224], ["MDBK", "SPECIES", 152, 156], ["BVDV", "SPECIES", 210, 214], ["The restriction digestion", "TEST", 0, 25], ["bp S100A9", "TEST", 38, 47], ["Kb p3XFLAG", "TEST", 56, 66], ["CMV", "TEST", 67, 70], ["a higher transfection efficiency", "PROBLEM", 104, 136], ["MDBK cells", "TEST", 152, 162], ["293T cells", "TREATMENT", 174, 184], ["the BVDV", "PROBLEM", 206, 214], ["bovine gene in those cells", "TREATMENT", 218, 244], ["CMV", "OBSERVATION", 67, 70], ["293T cells", "OBSERVATION", 88, 98], ["higher", "OBSERVATION_MODIFIER", 106, 112], ["transfection efficiency", "OBSERVATION", 113, 136]]], ["293T cells were transfected with p3XFLAG-S100A9, pEGFP C1-Npro or p3XFLAG-Npro plasmids carrying bovine S100A9 or BVDV Npro gene respectively.", [["293T cells", "ANATOMY", 0, 10], ["293T cells", "CELL", 0, 10], ["p3XFLAG-S100A9", "GENE_OR_GENE_PRODUCT", 33, 47], ["pEGFP C1-Npro", "GENE_OR_GENE_PRODUCT", 49, 62], ["p3XFLAG-Npro", "GENE_OR_GENE_PRODUCT", 66, 78], ["bovine", "ORGANISM", 97, 103], ["S100A9", "GENE_OR_GENE_PRODUCT", 104, 110], ["BVDV", "ORGANISM", 114, 118], ["Npro", "GENE_OR_GENE_PRODUCT", 119, 123], ["293T cells", "CELL_LINE", 0, 10], ["p3XFLAG-S100A9, pEGFP C1-Npro or p3XFLAG-Npro plasmids", "DNA", 33, 87], ["bovine S100A9 or BVDV Npro gene", "DNA", 97, 128], ["bovine", "SPECIES", 97, 103], ["BVDV", "SPECIES", 114, 118], ["p3XFLAG", "TEST", 33, 40], ["pEGFP", "TEST", 49, 54], ["p3XFLAG", "TREATMENT", 66, 73], ["Npro plasmids", "TREATMENT", 74, 87]]], ["The 293T cells were transfected using X-tremeGENE HP DNA Transfection Reagent (Roche Applied Science, Indianapolis, IN), according to the manufacturer's protocol.", [["293T cells", "ANATOMY", 4, 14], ["293T cells", "CELL", 4, 14], ["293T cells", "CELL_LINE", 4, 14], ["The 293T cells", "TREATMENT", 0, 14], ["X-tremeGENE HP DNA Transfection Reagent", "TREATMENT", 38, 77], ["the manufacturer's protocol", "TREATMENT", 134, 161], ["293T cells", "OBSERVATION", 4, 14]]], ["Briefly, 293T cells were plated for 18 h before transfection at a concentration of 7.5 \u00d7 10 5 cells/ well in six-well culture plates and were 85-95% confluent at the time of transfection.", [["293T cells", "ANATOMY", 9, 19], ["cells", "ANATOMY", 94, 99], ["293T cells", "CELL", 9, 19], ["cells", "CELL", 94, 99], ["293T cells", "CELL_LINE", 9, 19], ["transfection", "TREATMENT", 48, 60], ["culture plates", "TEST", 118, 132], ["confluent", "OBSERVATION_MODIFIER", 149, 158]]], ["During transfection, the growth media was replaced with 500 \u03bcl of serum-free Opti-MEM (Life Technologies).", [["serum", "ANATOMY", 66, 71], ["serum", "ORGANISM_SUBSTANCE", 66, 71], ["the growth media", "TREATMENT", 21, 37], ["serum-free Opti-MEM", "TREATMENT", 66, 85]]], ["The plasmid DNA was diluted in Opti-MEM to get a final concentration of 1 \u03bcg plasmid DNA/100 \u03bcl medium (0.01 \u03bcg/\u03bcl).", [["plasmid", "ANATOMY", 4, 11], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["DNA", "CELLULAR_COMPONENT", 85, 88], ["plasmid DNA", "DNA", 4, 15], ["The plasmid DNA", "TREATMENT", 0, 15], ["1 \u03bcg plasmid DNA", "TREATMENT", 72, 88]]], ["Then 4 \u03bcl of the transfection reagent was added to the DNA-Opti-MEM mixture and mixed gently.", [["DNA", "CELLULAR_COMPONENT", 55, 58], ["the transfection reagent", "TREATMENT", 13, 37], ["the DNA-Opti-MEM mixture", "TREATMENT", 51, 75]]], ["The obtained transfection reagent-DNA-Opti-MEM mixture was added to 293T cells drop by drop.", [["293T cells", "ANATOMY", 68, 78], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["293T cells", "CELL", 68, 78], ["293T cells", "CELL_LINE", 68, 78], ["The obtained transfection reagent", "TREATMENT", 0, 33], ["DNA", "PROBLEM", 34, 37], ["Opti-MEM mixture", "TREATMENT", 38, 54]]], ["Then the cells were incubated at 37\u00b0C for 6 h.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14]]], ["After 6 h, an additional 2.4 ml of pre-warmed growth media [MEM, supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin solution (100 \u03bcg/ml)] was added to each well and the plates were reincubated at 37\u00b0C with 5% CO 2 for 24 h.", [["MEM", "CHEMICAL", 60, 63], ["FBS", "CHEMICAL", 87, 90], ["penicillin", "CHEMICAL", 92, 102], ["streptomycin", "CHEMICAL", 118, 130], ["penicillin", "CHEMICAL", 92, 102], ["streptomycin", "CHEMICAL", 118, 130], ["CO 2", "CHEMICAL", 224, 228], ["FBS", "ORGANISM_SUBSTANCE", 87, 90], ["penicillin", "SIMPLE_CHEMICAL", 92, 102], ["streptomycin", "SIMPLE_CHEMICAL", 118, 130], ["pre-warmed growth media", "TREATMENT", 35, 58], ["penicillin", "TREATMENT", 92, 102], ["streptomycin solution", "TREATMENT", 118, 139]]], ["The cells were then harvested for western blot analysis to confirm the protein expressions ( Fig. 1 B and C) as per the method described below in section 2.6.Western blot analysisThe protein expression of Npro-FLAG, Npro-GFP and, S100-FLAG in 293T transfected cells were confirmed by Western blot analysis.", [["cells", "ANATOMY", 4, 9], ["293T", "ANATOMY", 243, 247], ["cells", "ANATOMY", 260, 265], ["cells", "CELL", 4, 9], ["Npro-FLAG", "GENE_OR_GENE_PRODUCT", 205, 214], ["Npro-GFP", "GENE_OR_GENE_PRODUCT", 216, 224], ["S100-FLAG", "GENE_OR_GENE_PRODUCT", 230, 239], ["293T", "CELL", 243, 247], ["cells", "CELL", 260, 265], ["Npro-FLAG", "PROTEIN", 205, 214], ["Npro-GFP", "PROTEIN", 216, 224], ["S100", "PROTEIN", 230, 234], ["FLAG", "PROTEIN", 235, 239], ["293T transfected cells", "CELL_LINE", 243, 265], ["western blot analysis", "TEST", 34, 55], ["the protein expressions", "TEST", 67, 90], ["blot analysis", "TEST", 166, 179], ["Npro-FLAG", "TEST", 205, 214], ["Npro-GFP", "TEST", 216, 224], ["S100", "TEST", 230, 234], ["blot analysis", "TEST", 292, 305]]], ["A total 5 \u00d7 10 6 transfected cells were cultured in 6-well plates for 48 h.", [["cells", "ANATOMY", 29, 34], ["cells", "CELL", 29, 34], ["transfected cells", "CELL_LINE", 17, 34], ["A total 5 \u00d7 10 6 transfected cells", "TREATMENT", 0, 34]]], ["The cells were washed once with PBS, then lysed with 0,5 ml ice-cold radioimmunoprecipitation assay (RIPA) buffer/well containing proteinase inhibitor (Sigma, St. Louis, MO) for 30 min.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["The cells", "TREATMENT", 0, 9], ["PBS", "TREATMENT", 32, 35], ["cold radioimmunoprecipitation assay", "TREATMENT", 64, 99], ["proteinase inhibitor", "TREATMENT", 130, 150]]], ["The cell lysate was transferred to 1.5 ml tube and centrifuged at 500 \u00d7 g for 20 min.", [["cell lysate", "ANATOMY", 4, 15], ["cell lysate", "CELL", 4, 15], ["tube", "TISSUE", 42, 46], ["The cell lysate", "TREATMENT", 0, 15], ["cell lysate", "OBSERVATION", 4, 15]]], ["Supernatants were collected and total protein concentration was estimated using Lowry method [39] .", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "CELL", 0, 12], ["Supernatants", "TEST", 0, 12], ["total protein concentration", "TEST", 32, 59], ["Lowry method", "TEST", 80, 92]]], ["A total 30 \u03bcg protein was loaded in each well of 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for separation followed by blotting onto a nitrocellulose membrane (Invitrogen, Grand Island, NY).", [["membrane", "ANATOMY", 182, 190], ["sodium dodecyl sulfate", "CHEMICAL", 55, 77], ["SDS-PAGE", "CHEMICAL", 114, 122], ["sodium dodecyl sulfate", "CHEMICAL", 55, 77], ["polyacrylamide", "CHEMICAL", 78, 92], ["nitrocellulose", "CHEMICAL", 167, 181], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 55, 77], ["membrane", "CELLULAR_COMPONENT", 182, 190], ["\u03bcg protein", "PROTEIN", 11, 21], ["A total 30 \u03bcg protein", "TREATMENT", 0, 21], ["12.5% sodium dodecyl sulfate", "TREATMENT", 49, 77], ["polyacrylamide gel electrophoresis", "TREATMENT", 78, 112], ["a nitrocellulose membrane", "TREATMENT", 165, 190]]], ["Membrane was blocked overnight at 4\u00b0C with 3% nonfat milk in Tris Buffered Saline (TBS) (Sigma, St. Louis, MO).", [["Membrane", "ANATOMY", 0, 8], ["nonfat milk", "ANATOMY", 46, 57], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["milk", "ORGANISM_SUBSTANCE", 53, 57], ["Tris Buffered Saline", "SIMPLE_CHEMICAL", 61, 81], ["3% nonfat milk in Tris Buffered Saline (TBS", "TREATMENT", 43, 86]]], ["The membrane was then incubated overnight at 4\u00b0C with either mouse anti-FLAG monoclonal antibody (Sigma-Aldrich) or rabbit anti-GFP polyclonal antibody (Abcam, Cambridge, MA) with 1:5000 dilution in 3% nonfat milk -TBS (pH of 8.0).", [["membrane", "ANATOMY", 4, 12], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["mouse", "ORGANISM", 61, 66], ["anti-FLAG", "GENE_OR_GENE_PRODUCT", 67, 76], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 98, 111], ["rabbit", "ORGANISM", 116, 122], ["milk", "ORGANISM_SUBSTANCE", 209, 213], ["mouse anti-FLAG monoclonal antibody", "PROTEIN", 61, 96], ["Sigma-Aldrich) or rabbit anti-GFP polyclonal antibody", "PROTEIN", 98, 151], ["Abcam", "PROTEIN", 153, 158], ["mouse", "SPECIES", 61, 66], ["rabbit", "SPECIES", 116, 122], ["mouse", "SPECIES", 61, 66], ["rabbit", "SPECIES", 116, 122], ["rabbit anti-GFP polyclonal antibody", "TEST", 116, 151], ["TBS", "TEST", 215, 218], ["pH", "TEST", 220, 222]]], ["The membrane was then washed three times with TBS and incubated with secondary goat anti-mouse antibody (IRDye \u00ae 800CW Goat, LI-COR, Lincoln NE) or goat anti-rabbit antibody (IRDye \u00ae 680RD, LI-COR) at a dilution of 1:5000 in 3% nonfat milk in TBS for 1 h at room temperature.", [["membrane", "ANATOMY", 4, 12], ["milk", "ANATOMY", 235, 239], ["NE", "CHEMICAL", 141, 143], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["goat", "ORGANISM", 79, 83], ["IRDye", "SIMPLE_CHEMICAL", 105, 110], ["Lincoln NE", "SIMPLE_CHEMICAL", 133, 143], ["goat", "ORGANISM", 148, 152], ["IRDye \u00ae", "SIMPLE_CHEMICAL", 175, 182], ["milk", "ORGANISM_SUBSTANCE", 235, 239], ["secondary goat anti-mouse antibody", "PROTEIN", 69, 103], ["IRDye \u00ae 800CW Goat", "PROTEIN", 105, 123], ["LI", "PROTEIN", 125, 127], ["COR", "PROTEIN", 128, 131], ["Lincoln NE", "PROTEIN", 133, 143], ["goat anti-rabbit antibody", "PROTEIN", 148, 173], ["COR", "PROTEIN", 193, 196], ["goat", "SPECIES", 79, 83], ["anti-mouse", "SPECIES", 84, 94], ["Goat", "SPECIES", 119, 123], ["goat", "SPECIES", 148, 152], ["anti-rabbit", "SPECIES", 153, 164], ["goat", "SPECIES", 79, 83], ["goat", "SPECIES", 148, 152], ["anti-rabbit", "SPECIES", 153, 164], ["TBS", "TEST", 46, 49], ["secondary goat anti-mouse antibody", "TEST", 69, 103], ["IRDye", "TEST", 105, 110], ["LI", "TEST", 125, 127], ["Lincoln NE", "TEST", 133, 143], ["goat anti-rabbit antibody", "TEST", 148, 173], ["IRDye", "TEST", 175, 180]]], ["Finally, the blot was analyzed using Odyssey fluorescent imaging instrument (LI-COR Biosciences, Lincoln, NE, USA) ( Fig. 1B and C).", [["the blot", "TEST", 9, 17], ["Odyssey fluorescent imaging instrument", "TEST", 37, 75]]], ["Immunoprecipitation procedures were performed as previously described by Free et al. [40] .", [["Immunoprecipitation procedures", "TEST", 0, 30]]], ["Briefly, 293T cells were plated in six, 6-well plates for 24 h before transfection.", [["293T cells", "ANATOMY", 9, 19], ["293T cells", "CELL", 9, 19], ["293T cells", "CELL_LINE", 9, 19]]], ["The plates were then divided into two groups with three plates each for three replicates.", [["The plates", "TREATMENT", 0, 10], ["three plates", "TREATMENT", 50, 62], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["One group was transfected with p3XFLAG-Npro, while the other group was transfected with empty p3XFLAG, as described above.", [["p3XFLAG-Npro", "GENE_OR_GENE_PRODUCT", 31, 43], ["p3XFLAG", "GENE_OR_GENE_PRODUCT", 94, 101], ["p3XFLAG", "PROTEIN", 31, 38], ["Npro", "PROTEIN", 39, 43], ["empty p3XFLAG", "DNA", 88, 101], ["p3XFLAG", "TREATMENT", 31, 38], ["empty p3XFLAG", "TREATMENT", 88, 101], ["empty p3XFLAG", "OBSERVATION", 88, 101]]], ["Twenty-four hr after transfection, cells were harvested and lysed using in 1 ml of ice-cold in-house solubilization/lysis buffer (50 mM [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid: HEPES], 1 mM EDTA, 10% glycerol, 1% Triton X-100, 150 mM NaCl, 50 mM NaF, and 40 mM Na 4 P 2 O 7 ) with pH of 7.4 containing protease inhibitor cocktail (Sigma, St. Louis, MO), for 1 h at 4\u00b0C. The cell lysates were then centrifuged at 20,000 \u00d7 g at 4\u00b0C for 5 min.", [["cells", "ANATOMY", 35, 40], ["cell lysates", "ANATOMY", 386, 398], ["4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid", "CHEMICAL", 137, 187], ["glycerol", "CHEMICAL", 212, 220], ["Triton X-100", "CHEMICAL", 225, 237], ["NaCl", "CHEMICAL", 246, 250], ["NaF", "CHEMICAL", 258, 261], ["Na", "CHEMICAL", 273, 275], ["[4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid", "CHEMICAL", 136, 187], ["HEPES", "CHEMICAL", 189, 194], ["EDTA", "CHEMICAL", 202, 206], ["glycerol", "CHEMICAL", 212, 220], ["NaCl", "CHEMICAL", 246, 250], ["NaF", "CHEMICAL", 258, 261], ["Na 4 P 2 O 7", "CHEMICAL", 273, 285], ["cells", "CELL", 35, 40], ["[4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid", "SIMPLE_CHEMICAL", 136, 187], ["EDTA", "SIMPLE_CHEMICAL", 202, 206], ["glycerol", "SIMPLE_CHEMICAL", 212, 220], ["Triton X-100", "SIMPLE_CHEMICAL", 225, 237], ["NaF", "SIMPLE_CHEMICAL", 258, 261], ["cell lysates", "CELL", 386, 398], ["ice", "TREATMENT", 83, 86], ["lysis buffer", "TREATMENT", 116, 128], ["hydroxyethyl)", "TREATMENT", 142, 155], ["HEPES", "TREATMENT", 189, 194], ["1 mM EDTA", "TREATMENT", 197, 206], ["glycerol", "TREATMENT", 212, 220], ["40 mM Na", "TREATMENT", 267, 275], ["pH", "TEST", 293, 295], ["protease inhibitor cocktail", "TREATMENT", 314, 341], ["The cell lysates", "TREATMENT", 382, 398], ["cell lysates", "OBSERVATION", 386, 398]]], ["The supernatant was collected and pre-cleared using protein G magnetic beads (Dynabeads \u00ae Protein G., Life Technologies) by incubation for 10 min at room temperature.", [["supernatant", "ANATOMY", 4, 15], ["The supernatant", "TREATMENT", 0, 15], ["protein G magnetic beads", "TREATMENT", 52, 76]]], ["The protein G magnetic beads were removed by centrifugation for 5 min at 1000-2500 \u00d7 g and the supernatant was collected.", [["supernatant", "ANATOMY", 95, 106], ["The protein G magnetic beads", "TREATMENT", 0, 28]]], ["The supernatants were then transferred into clean tubes with 100 \u03bcl of murine anti-FLAG IgG1 mAb-agarose slurrybeads (Sigma-Aldrich, Louis, MO).", [["supernatants", "ANATOMY", 4, 16], ["murine", "ORGANISM", 71, 77], ["anti-FLAG", "ORGANISM_SUBSTANCE", 78, 87], ["IgG1", "GENE_OR_GENE_PRODUCT", 88, 92], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 118, 131], ["murine anti-FLAG IgG1 mAb", "PROTEIN", 71, 96], ["murine", "SPECIES", 71, 77], ["The supernatants", "TREATMENT", 0, 16], ["clean tubes", "TREATMENT", 44, 55], ["murine anti-FLAG IgG1 mAb", "TREATMENT", 71, 96]]], ["The mixture was incubated on a rocking platform overnight at 4\u00b0C. The next day, the beads were washed three times with 1 ml ice-cold solubilization/lysis buffer.", [["beads", "ANATOMY", 84, 89], ["a rocking platform", "TREATMENT", 29, 47], ["the beads", "TREATMENT", 80, 89], ["cold solubilization/lysis buffer", "TREATMENT", 128, 160]]], ["Finally, the proteins were eluted from the samples and the control beads by adding 5 packed gel volumes of 0.1 M glycine HCl buffer, pH 3.0.", [["samples", "ANATOMY", 43, 50], ["glycine HCl", "CHEMICAL", 113, 124], ["glycine", "CHEMICAL", 113, 120], ["HCl", "CHEMICAL", 121, 124], ["the control beads", "TREATMENT", 55, 72], ["5 packed gel volumes", "TREATMENT", 83, 103], ["M glycine HCl buffer", "TREATMENT", 111, 131], ["pH", "TEST", 133, 135]]], ["The collected proteins were stored at \u221220\u00b0C for further use.Mass spectrometry analysis: protein precipitation after immunoprecipitationA total of 340 \u03bcl of 100% trichloro acetic acid (TCA) (Sigma, St. Louis, MO) was added for every 1 ml of eluate for protein precipitation in on ice for 3 h.", [["trichloro acetic acid", "CHEMICAL", 161, 182], ["TCA", "CHEMICAL", 184, 187], ["trichloro acetic acid", "CHEMICAL", 161, 182], ["TCA", "CHEMICAL", 184, 187], ["C", "SIMPLE_CHEMICAL", 42, 43], ["trichloro acetic acid", "SIMPLE_CHEMICAL", 161, 182], ["TCA", "SIMPLE_CHEMICAL", 184, 187], ["The collected proteins", "TEST", 0, 22], ["Mass spectrometry analysis", "TEST", 60, 86], ["protein precipitation", "PROBLEM", 88, 109], ["immunoprecipitationA", "TEST", 116, 136], ["protein precipitation", "TREATMENT", 251, 272]]], ["The eluate-TCA mixture was then centrifuged at 11,000 \u00d7 g at 4\u00b0C for 30 min to obtain protein pellet.", [["TCA", "CHEMICAL", 11, 14], ["TCA", "SIMPLE_CHEMICAL", 11, 14], ["The eluate-TCA mixture", "TREATMENT", 0, 22]]], ["The obtained protein pellets were dissolved in one ml of cold 98% acetone-0.05 N HCl solution and the tube was centrifuged again for 5 min at 16000 \u00d7 g at 4\u00b0C. The supernatant was removed carefully and the pellet was washed with one ml cold of acetone by centrifuging at 16000 \u00d7 g for 5 min at 4\u00b0C. The pellets were stored dry at \u221280\u00b0C until mass spectroscopy analysis.Mass spectrometry analysis and bioinformaticsThe mass spectroscopic analysis was performed by Dr. Eduardo Callegari at the University of South Dakota Mass Spectrometry and Proteomics Core Facility, Vermillion, SD using nano ESI-Q-Tof micro mass spectrometer (Micromass, Manchester, UK) while data was analyzed with MassLynx software 4.1 (Micromass).Co-immunoprecipitationTo confirm the interaction between the Npro and bovine S100A9, a co-immunoprecipitation experiment was performed.", [["tube", "ANATOMY", 102, 106], ["supernatant", "ANATOMY", 164, 175], ["pellet", "ANATOMY", 206, 212], ["acetone-0.05 N HCl", "CHEMICAL", 66, 84], ["acetone", "CHEMICAL", 244, 251], ["acetone", "CHEMICAL", 66, 73], ["HCl", "CHEMICAL", 81, 84], ["acetone", "CHEMICAL", 244, 251], ["acetone", "SIMPLE_CHEMICAL", 66, 73], ["tube", "TISSUE", 102, 106], ["acetone", "SIMPLE_CHEMICAL", 244, 251], ["Npro", "GENE_OR_GENE_PRODUCT", 779, 783], ["bovine", "ORGANISM", 788, 794], ["S100A9", "GENE_OR_GENE_PRODUCT", 795, 801], ["Npro", "PROTEIN", 779, 783], ["bovine S100A9", "PROTEIN", 788, 801], ["bovine", "SPECIES", 788, 794], ["The obtained protein pellets", "TEST", 0, 28], ["cold 98% acetone", "TREATMENT", 57, 73], ["N HCl solution", "TREATMENT", 79, 93], ["the tube", "TREATMENT", 98, 106], ["The supernatant", "TREATMENT", 160, 175], ["acetone", "TREATMENT", 244, 251], ["mass spectroscopy analysis", "TEST", 342, 368], ["Mass spectrometry analysis", "TEST", 369, 395], ["bioinformatics", "TEST", 400, 414], ["The mass spectroscopic analysis", "TEST", 414, 445], ["Vermillion", "TEST", 567, 577], ["nano ESI", "TEST", 588, 596], ["MassLynx software", "TEST", 684, 701], ["a co-immunoprecipitation experiment", "TEST", 803, 838], ["tube", "OBSERVATION", 102, 106], ["mass", "OBSERVATION", 418, 422]]], ["The 293T cells were seeded in six, 6-well plates with the concentration of 7.5 \u00d7 10 5 cells/well for 18 h before transfection.", [["293T cells", "ANATOMY", 4, 14], ["cells", "ANATOMY", 86, 91], ["293T cells", "CELL", 4, 14], ["cells", "CELL", 86, 91], ["293T cells", "CELL_LINE", 4, 14], ["The 293T cells", "TREATMENT", 0, 14], ["the concentration", "TREATMENT", 54, 71], ["293T cells", "OBSERVATION", 4, 14]]], ["Plates were then divided into two groups with three plates each for three replicates.", [["Plates", "TEST", 0, 6], ["three plates", "TREATMENT", 46, 58]]], ["One group was co-transfected with (p3XFLAG empty plasmid and pEGFP-C1-Npro) together, while the other group was co-transfected with (p3XFLAG -S100A9 and pEGFP-C1-Npro) together.", [["pEGFP-C1-Npro", "GENE_OR_GENE_PRODUCT", 61, 74], ["p3XFLAG -S100A9", "GENE_OR_GENE_PRODUCT", 133, 148], ["pEGFP-C1-Npro", "GENE_OR_GENE_PRODUCT", 153, 166], ["p3XFLAG empty plasmid", "DNA", 35, 56], ["pEGFP", "DNA", 61, 66], ["C1", "DNA", 67, 69], ["Npro", "DNA", 70, 74], ["p3XFLAG", "PROTEIN", 133, 140], ["S100A9", "PROTEIN", 142, 148], ["pEGFP", "PROTEIN", 153, 158], ["C1", "DNA", 159, 161], ["Npro", "DNA", 162, 166], ["p3XFLAG empty plasmid", "TREATMENT", 35, 56], ["pEGFP", "TREATMENT", 61, 66], ["p3XFLAG", "TEST", 133, 140], ["pEGFP", "TEST", 153, 158]]], ["The plasmids were co-transfected as described above using 1 \u03bcg of each plasmid/well of transfection reaction.", [["plasmids", "ANATOMY", 4, 12], ["plasmid", "ANATOMY", 71, 78], ["plasmids", "DNA", 4, 12], ["plasmid", "DNA", 71, 78], ["The plasmids", "TREATMENT", 0, 12], ["each plasmid", "TREATMENT", 66, 78], ["transfection reaction", "PROBLEM", 87, 108], ["plasmids", "OBSERVATION", 4, 12]]], ["The plates were incubated for 24 h at 37\u00b0C with 5% CO 2 and the cells were lysed by 150 \u03bcl of lysis buffer (20 mM Tris HCl pH 8.0, 137 mM NaCl, 1% Triton X-100, and 2 mM EDTA) to perform the immunoprecipitation.Co-immunoprecipitationTo confirm the interaction between Npro and S100A9, the protein was immunoprecipitated (isolated) using anti-FLAG beads in both the groups and analyzed for presence of FLAG as well as GFP (e.g. GFP-Nrop) through western blot.", [["cells", "ANATOMY", 64, 69], ["Tris HCl", "CHEMICAL", 114, 122], ["NaCl", "CHEMICAL", 138, 142], ["Triton X-100", "CHEMICAL", 147, 159], ["CO 2", "CHEMICAL", 51, 55], ["HCl", "CHEMICAL", 119, 122], ["NaCl", "CHEMICAL", 138, 142], ["EDTA", "CHEMICAL", 170, 174], ["cells", "CELL", 64, 69], ["Triton X-100", "SIMPLE_CHEMICAL", 147, 159], ["EDTA", "SIMPLE_CHEMICAL", 170, 174], ["Npro", "GENE_OR_GENE_PRODUCT", 268, 272], ["S100A9", "GENE_OR_GENE_PRODUCT", 277, 283], ["anti-FLAG", "GENE_OR_GENE_PRODUCT", 337, 346], ["FLAG", "GENE_OR_GENE_PRODUCT", 401, 405], ["GFP", "GENE_OR_GENE_PRODUCT", 417, 420], ["GFP", "GENE_OR_GENE_PRODUCT", 427, 430], ["Npro", "PROTEIN", 268, 272], ["S100A9", "PROTEIN", 277, 283], ["anti-FLAG beads", "PROTEIN", 337, 352], ["FLAG", "PROTEIN", 401, 405], ["GFP", "PROTEIN", 417, 420], ["GFP", "PROTEIN", 427, 430], ["Nrop", "PROTEIN", 431, 435], ["lysis buffer", "TREATMENT", 94, 106], ["pH", "TEST", 123, 125], ["NaCl", "TEST", 138, 142], ["the immunoprecipitation", "TEST", 187, 210], ["the protein", "TEST", 285, 296], ["anti-FLAG beads", "TREATMENT", 337, 352], ["FLAG", "TEST", 401, 405], ["GFP", "TEST", 417, 420], ["GFP", "TEST", 427, 430]]], ["The western blot was performed using a mixture of both mouse anti-FLAG monoclonal antibody (Sigma, St. Louis, MO) or rabbit anti-GFP polyclonal antibody (Abcam, Cambridge MA) followed by goat anti-mouse antibody (IRDye \u00ae 800CW Goat, LI-COR, Lincoln NE) or goat anti-rabbit antibody (IRDye \u00ae 680RD, LI-COR) and finally blot was analyzed using Odyssey fluorescent imaging instrument (LI-COR Biosciences, Lincoln, NE, USA).S100A9 knockdown and study of virus growthTo determine if S100A9 has any effect on BVDV or IFN\u03b1/\u03b2 production, the MDBK cells or bovine endothelial cells were knock out for S100A9 gene using anti-S100A9 Small interfering RNA (siRNA) (DNA Technology, Iowa City, IA).", [["MDBK cells", "ANATOMY", 534, 544], ["endothelial cells", "ANATOMY", 555, 572], ["mouse", "ORGANISM", 55, 60], ["anti-FLAG", "GENE_OR_GENE_PRODUCT", 61, 70], ["St. Louis", "ORGANISM", 99, 108], ["MO", "ORGANISM", 110, 112], ["rabbit", "ORGANISM", 117, 123], ["Abcam", "GENE_OR_GENE_PRODUCT", 154, 159], ["goat", "ORGANISM", 187, 191], ["IRDye", "SIMPLE_CHEMICAL", 213, 218], ["Lincoln NE", "SIMPLE_CHEMICAL", 241, 251], ["goat", "ORGANISM", 256, 260], ["IRDye", "SIMPLE_CHEMICAL", 283, 288], ["S100A9", "GENE_OR_GENE_PRODUCT", 420, 426], ["S100A9", "GENE_OR_GENE_PRODUCT", 478, 484], ["BVDV", "ORGANISM", 503, 507], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 511, 515], ["\u03b2", "GENE_OR_GENE_PRODUCT", 516, 517], ["MDBK cells", "CELL", 534, 544], ["bovine", "ORGANISM", 548, 554], ["endothelial cells", "CELL", 555, 572], ["S100A9", "GENE_OR_GENE_PRODUCT", 592, 598], ["anti-S100A9", "GENE_OR_GENE_PRODUCT", 610, 621], ["DNA", "CELLULAR_COMPONENT", 653, 656], ["mouse anti-FLAG monoclonal antibody", "PROTEIN", 55, 90], ["Sigma, St. Louis, MO) or rabbit anti-GFP polyclonal antibody", "PROTEIN", 92, 152], ["Abcam", "PROTEIN", 154, 159], ["Cambridge MA", "PROTEIN", 161, 173], ["goat anti-mouse antibody", "PROTEIN", 187, 211], ["IRDye \u00ae 800CW Goat", "PROTEIN", 213, 231], ["LI", "PROTEIN", 233, 235], ["COR", "PROTEIN", 236, 239], ["Lincoln NE", "PROTEIN", 241, 251], ["goat anti-rabbit antibody", "PROTEIN", 256, 281], ["IRDye \u00ae 680RD", "PROTEIN", 283, 296], ["LI", "PROTEIN", 298, 300], ["COR", "PROTEIN", 301, 304], ["S100A9", "PROTEIN", 420, 426], ["S100A9", "PROTEIN", 478, 484], ["IFN\u03b1", "PROTEIN", 511, 515], ["\u03b2", "PROTEIN", 516, 517], ["MDBK cells", "CELL_LINE", 534, 544], ["bovine endothelial cells", "CELL_TYPE", 548, 572], ["S100A9 gene", "DNA", 592, 603], ["S100A9", "PROTEIN", 615, 621], ["mouse", "SPECIES", 55, 60], ["rabbit", "SPECIES", 117, 123], ["goat", "SPECIES", 187, 191], ["anti-mouse", "SPECIES", 192, 202], ["Goat", "SPECIES", 227, 231], ["goat", "SPECIES", 256, 260], ["anti-rabbit", "SPECIES", 261, 272], ["bovine", "SPECIES", 548, 554], ["mouse", "SPECIES", 55, 60], ["rabbit", "SPECIES", 117, 123], ["goat", "SPECIES", 187, 191], ["goat", "SPECIES", 256, 260], ["anti-rabbit", "SPECIES", 261, 272], ["BVDV", "SPECIES", 503, 507], ["MDBK", "SPECIES", 534, 538], ["bovine", "SPECIES", 548, 554], ["The western blot", "TEST", 0, 16], ["rabbit anti-GFP polyclonal antibody", "TEST", 117, 152], ["goat anti-mouse antibody", "TEST", 187, 211], ["IRDye", "TEST", 213, 218], ["LI", "TEST", 233, 235], ["Lincoln NE", "TEST", 241, 251], ["goat anti-rabbit antibody", "TEST", 256, 281], ["IRDye", "TEST", 283, 288], ["Odyssey fluorescent imaging instrument", "TEST", 342, 380], ["S100A9 knockdown", "TEST", 420, 436], ["virus growth", "PROBLEM", 450, 462], ["BVDV", "PROBLEM", 503, 507], ["IFN\u03b1/\u03b2 production", "PROBLEM", 511, 528], ["the MDBK cells", "PROBLEM", 530, 544], ["bovine endothelial cells", "TEST", 548, 572], ["S100A9 gene", "TEST", 592, 603], ["anti", "TEST", 610, 614], ["bovine endothelial cells", "OBSERVATION", 548, 572], ["Small", "OBSERVATION_MODIFIER", 622, 627], ["interfering", "OBSERVATION", 628, 639]]], ["Briefly, cells were cultured for 3 days to obtain 80-90% confluency.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14]]], ["The cells were harvested by trypsinization and then were washed with culture media.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["culture media", "TREATMENT", 69, 82]]], ["The cells were centrifuged and adjusted to final concentration as 1 \u00d7 106 cells/100 \u03bcl of Nucleofector \u00ae solution (LONZA, Basel, Switzerland) per sample.", [["cells", "ANATOMY", 4, 9], ["cells", "ANATOMY", 74, 79], ["cells", "CELL", 4, 9], ["cells", "CELL", 74, 79], ["Nucleofector \u00ae solution", "TREATMENT", 90, 113]]], ["Thirty pmol of either S100A9 siRNA or control scrambled siRNA (siRNA of the reverse sequences of the bovine S100A9 siRNA) were added to the 100 \u03bcl cell suspension.", [["cell", "ANATOMY", 147, 151], ["S100A9", "GENE_OR_GENE_PRODUCT", 22, 28], ["bovine", "ORGANISM", 101, 107], ["S100A9", "GENE_OR_GENE_PRODUCT", 108, 114], ["cell", "CELL", 147, 151], ["S100A9", "PROTEIN", 22, 28], ["reverse sequences", "DNA", 76, 93], ["bovine S100A9 siRNA", "DNA", 101, 120], ["bovine", "SPECIES", 101, 107], ["S100A9 siRNA", "TREATMENT", 22, 34], ["control scrambled siRNA", "TREATMENT", 38, 61], ["the bovine S100A9 siRNA", "TREATMENT", 97, 120]]], ["The siRNA-cell suspension was then introduced into an Amaxa (LONZA) certified cuvette and the Nucleofector \u00ae Program X-001 was performed using the Nucleofactor \u00ae 2 device, (LONZA) according to manufacturer's instructions.", [["cell", "ANATOMY", 10, 14], ["X-001", "CHEMICAL", 117, 122], ["cell", "CELL", 10, 14], ["The siRNA-cell suspension", "TREATMENT", 0, 25], ["an Amaxa (LONZA) certified cuvette", "TREATMENT", 51, 85], ["the Nucleofector \u00ae Program", "TREATMENT", 90, 116], ["the Nucleofactor \u00ae 2 device", "TREATMENT", 143, 170], ["cell suspension", "OBSERVATION", 10, 25]]], ["Upon completion of the transfection, the cuvette was removed from the device and the samples were further incubated for 10 min at room temperature.", [["samples", "ANATOMY", 85, 92], ["the transfection", "TREATMENT", 19, 35], ["the cuvette", "TREATMENT", 37, 48], ["the device", "TREATMENT", 66, 76], ["the samples", "TEST", 81, 92]]], ["Following incubation, cells were transferred to 6-well plates and media [MEM media containing 10% BVDV, penicillin (100 U/ml) and streptomycin solution (100 \u03bcg/ml)] volume was brought to 1.5 ml/well.", [["cells", "ANATOMY", 22, 27], ["penicillin", "CHEMICAL", 104, 114], ["streptomycin", "CHEMICAL", 130, 142], ["penicillin", "CHEMICAL", 104, 114], ["streptomycin", "CHEMICAL", 130, 142], ["cells", "CELL", 22, 27], ["BVDV", "ORGANISM", 98, 102], ["penicillin", "SIMPLE_CHEMICAL", 104, 114], ["streptomycin", "SIMPLE_CHEMICAL", 130, 142], ["BVDV", "SPECIES", 98, 102], ["cells", "TREATMENT", 22, 27], ["media [MEM media", "TREATMENT", 66, 82], ["penicillin", "TREATMENT", 104, 114], ["streptomycin solution", "TREATMENT", 130, 151], ["volume", "TREATMENT", 165, 171]]], ["The cells were cultured for 24 h and determined for S100A9 siRNA-mediated knockdown through western blot (Fig. 2) .S100A9 knockdown and study of virus growthThe S1009 knock out (transfected with S100A9 siRNA) or control .", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["S100A9", "GENE_OR_GENE_PRODUCT", 52, 58], ["S100A9", "GENE_OR_GENE_PRODUCT", 115, 121], ["S100A9", "GENE_OR_GENE_PRODUCT", 195, 201], ["S100A9", "PROTEIN", 52, 58], ["S100A9", "PROTEIN", 115, 121], ["S100A9", "PROTEIN", 195, 201], ["S100A9 siRNA", "TEST", 52, 64], ["S100A9 knockdown", "TEST", 115, 131], ["virus growth", "PROBLEM", 145, 157], ["S100A9 siRNA)", "TREATMENT", 195, 208]]], ["The highest dilution with staining was used as an end point to calculate the TCID50 according to method, as previously described [41] .", [["highest", "OBSERVATION_MODIFIER", 4, 11]]], ["The experiment to measure the BVDV production in S1009 knock out cells were repeated three times in three different sets of experiments for its repeatability and the data was analyzed using a paired t-test at 95% level of significance.IFN-\u03b1/\u03b2 assayThe IFN\u03b1/\u03b2 production in BVDV-infected bovine endothelial cells was determined as per the method described by Rubinstein et al. with some modifications [42] .", [["cells", "ANATOMY", 65, 70], ["endothelial cells", "ANATOMY", 294, 311], ["BVDV", "ORGANISM", 30, 34], ["cells", "CELL", 65, 70], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 235, 240], ["\u03b2", "GENE_OR_GENE_PRODUCT", 241, 242], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 252, 256], ["\u03b2", "GENE_OR_GENE_PRODUCT", 257, 258], ["BVDV", "ORGANISM", 273, 277], ["bovine", "ORGANISM", 287, 293], ["endothelial cells", "CELL", 294, 311], ["S1009 knock out cells", "CELL_LINE", 49, 70], ["IFN", "PROTEIN", 235, 238], ["\u03b1", "PROTEIN", 239, 240], ["\u03b2", "PROTEIN", 241, 242], ["IFN\u03b1", "PROTEIN", 252, 256], ["\u03b2", "PROTEIN", 257, 258], ["BVDV-infected bovine endothelial cells", "CELL_LINE", 273, 311], ["BVDV", "SPECIES", 273, 277], ["bovine", "SPECIES", 287, 293], ["BVDV", "SPECIES", 30, 34], ["BVDV", "SPECIES", 273, 277], ["bovine", "SPECIES", 287, 293], ["the BVDV production", "TEST", 26, 45], ["the data", "TEST", 162, 170], ["a paired t-test", "TEST", 190, 205], ["IFN", "TEST", 235, 238], ["assay", "TEST", 243, 248], ["production", "PROBLEM", 259, 269], ["BVDV", "PROBLEM", 273, 277], ["infected bovine endothelial cells", "TREATMENT", 278, 311], ["infected bovine endothelial cells", "OBSERVATION", 278, 311]]], ["The p3XFLAG S100A9 transfected or S100A9 knock out bovine endothelial cells were infected with ncp BVDV2a-1373 at MOI of 5.", [["endothelial cells", "ANATOMY", 58, 75], ["BVDV2a-1373", "CHEMICAL", 99, 110], ["p3XFLAG S100A9", "GENE_OR_GENE_PRODUCT", 4, 18], ["S100A9", "GENE_OR_GENE_PRODUCT", 34, 40], ["bovine", "ORGANISM", 51, 57], ["endothelial cells", "CELL", 58, 75], ["p3XFLAG S100A9", "PROTEIN", 4, 18], ["S100A9", "PROTEIN", 34, 40], ["bovine endothelial cells", "CELL_TYPE", 51, 75], ["bovine", "SPECIES", 51, 57], ["The p3XFLAG S100A9", "TEST", 0, 18], ["bovine endothelial cells", "PROBLEM", 51, 75], ["ncp BVDV2a", "TEST", 95, 105], ["bovine endothelial cells", "OBSERVATION", 51, 75]]], ["The bovine endothelial cells treated with poly I:C at a concentration 1 \u03bcg/ml were used as a positive control for the assay while mock infected cells were used as negative control.", [["endothelial cells", "ANATOMY", 11, 28], ["cells", "ANATOMY", 144, 149], ["poly I:C", "CHEMICAL", 42, 50], ["bovine", "ORGANISM", 4, 10], ["endothelial cells", "CELL", 11, 28], ["poly I:C", "SIMPLE_CHEMICAL", 42, 50], ["cells", "CELL", 144, 149], ["bovine endothelial cells", "CELL_TYPE", 4, 28], ["mock infected cells", "CELL_LINE", 130, 149], ["bovine", "SPECIES", 4, 10], ["bovine", "SPECIES", 4, 10], ["The bovine endothelial cells", "TREATMENT", 0, 28], ["a concentration", "TREATMENT", 54, 69], ["a positive control", "TREATMENT", 91, 109], ["the assay", "TEST", 114, 123], ["mock infected cells", "TREATMENT", 130, 149], ["bovine endothelial cells", "OBSERVATION", 4, 28]]], ["After 24 h post infection, cell supernatant was collected and stored at 4\u00b0C for IFN assay after BVDV inactivation.", [["cell supernatant", "ANATOMY", 27, 43], ["cell", "CELL", 27, 31], ["BVDV", "ORGANISM", 96, 100], ["IFN", "PROTEIN", 80, 83], ["BVDV", "SPECIES", 96, 100], ["infection", "PROBLEM", 16, 25], ["cell supernatant", "PROBLEM", 27, 43], ["IFN assay", "TEST", 80, 89], ["BVDV inactivation", "PROBLEM", 96, 113], ["infection", "OBSERVATION", 16, 25]]], ["The data was analyzed using a paired t-test at 95% level of significance.IFN reporter gene assayThe IFN -\u03b1/\u03b2 activity was measured by using the NCL-1-ISRE-Luc-Hygro cells, (kindly provided by Dr. Clayton Kelling, University of Nebraska, Lincoln, NE).", [["Luc-Hygro cells", "ANATOMY", 155, 170], ["IFN", "GENE_OR_GENE_PRODUCT", 73, 76], ["IFN -\u03b1", "GENE_OR_GENE_PRODUCT", 100, 106], ["\u03b2", "GENE_OR_GENE_PRODUCT", 107, 108], ["NCL-1", "GENE_OR_GENE_PRODUCT", 144, 149], ["IFN reporter gene", "DNA", 73, 90], ["IFN", "PROTEIN", 100, 103], ["\u03b2", "PROTEIN", 107, 108], ["NCL-1-ISRE-Luc", "DNA", 144, 158], ["Hygro cells", "CELL_LINE", 159, 170], ["The data", "TEST", 0, 8], ["a paired t-test", "TEST", 28, 43], ["IFN reporter gene assay", "TEST", 73, 96], ["The IFN", "TEST", 96, 103], ["the NCL", "TEST", 140, 147]]], ["Briefly, 1.5 \u00d7 10 5 cells were seeded into a 12-well plate and incubated at 37\u00b0C with 5% CO 2 for 12 h.", [["cells", "ANATOMY", 20, 25], ["CO 2", "CHEMICAL", 89, 93], ["cells", "CELL", 20, 25], ["5% CO", "TREATMENT", 86, 91]]], ["After 12 h incubation, the medium was replaced with 0.5 ml of the test supernatants and reincubated for another 8 h.", [["supernatants", "ANATOMY", 71, 83], ["the test supernatants", "TEST", 62, 83]]], ["The cells were harvested and lysed with 100 \u03bcl passive lysis buffer (Promega, WI), and the firefly luciferase activity in cell lysate was measured by luciferase reporter assay kit (Promega, WI) according to manufacturer's Fig. 2 .", [["cells", "ANATOMY", 4, 9], ["cell lysate", "ANATOMY", 122, 133], ["cells", "CELL", 4, 9], ["luciferase", "GENE_OR_GENE_PRODUCT", 99, 109], ["cell", "CELL", 122, 126], ["luciferase", "GENE_OR_GENE_PRODUCT", 150, 160], ["luciferase", "PROTEIN", 99, 109], ["luciferase", "PROTEIN", 150, 160], ["100 \u03bcl passive lysis buffer", "TREATMENT", 40, 67], ["Promega, WI)", "TREATMENT", 69, 81], ["the firefly luciferase activity in cell lysate", "TREATMENT", 87, 133]]], ["The knockout of S100A9 gene in MDBK cells or bovine endothelial cells.", [["MDBK cells", "ANATOMY", 31, 41], ["endothelial cells", "ANATOMY", 52, 69], ["S100A9", "GENE_OR_GENE_PRODUCT", 16, 22], ["MDBK cells", "CELL", 31, 41], ["bovine", "ORGANISM", 45, 51], ["endothelial cells", "CELL", 52, 69], ["S100A9 gene", "DNA", 16, 27], ["MDBK cells", "CELL_LINE", 31, 41], ["bovine endothelial cells", "CELL_TYPE", 45, 69], ["bovine", "SPECIES", 45, 51], ["MDBK", "SPECIES", 31, 35], ["bovine", "SPECIES", 45, 51], ["MDBK cells", "TREATMENT", 31, 41], ["bovine endothelial cells", "PROBLEM", 45, 69], ["MDBK cells", "OBSERVATION", 31, 41], ["bovine endothelial cells", "OBSERVATION", 45, 69]]], ["The S100A9 gene was knocked down using anti-S100A9 siRNA while scrambled siRNA (reverse sequences of the bovine S100A9) was used as negative control.", [["S100A9", "GENE_OR_GENE_PRODUCT", 4, 10], ["bovine", "ORGANISM", 105, 111], ["S100A9", "GENE_OR_GENE_PRODUCT", 112, 118], ["S100A9 gene", "DNA", 4, 15], ["anti-S100A9 siRNA", "DNA", 39, 56], ["reverse sequences", "DNA", 80, 97], ["bovine S100A9", "PROTEIN", 105, 118], ["bovine", "SPECIES", 105, 111], ["anti-S100A9 siRNA", "TREATMENT", 39, 56], ["scrambled siRNA", "TREATMENT", 63, 78], ["the bovine S100A9)", "TREATMENT", 101, 119]]], ["The knock down of S100A9 gene was confirmed by western blot.", [["S100A9", "GENE_OR_GENE_PRODUCT", 18, 24], ["S100A9 gene", "DNA", 18, 29]]], ["The S100A9 knocked down cells did not show and protein band for S1009A on western blot analysis (A), while it was present in the Scramble control cell (B).IFN reporter gene assayinstructions.", [["cells", "ANATOMY", 24, 29], ["Scramble control cell", "ANATOMY", 129, 150], ["S100A9", "GENE_OR_GENE_PRODUCT", 4, 10], ["cells", "CELL", 24, 29], ["cell", "CELL", 146, 150], ["B", "CELL", 152, 153], ["IFN", "GENE_OR_GENE_PRODUCT", 155, 158], ["S100A9", "PROTEIN", 4, 10], ["S1009A", "PROTEIN", 64, 70], ["Scramble control cell", "CELL_LINE", 129, 150], ["IFN reporter gene assayinstructions", "DNA", 155, 190], ["The S100A9 knocked down cells", "TEST", 0, 29], ["protein band", "TEST", 47, 59], ["western blot analysis", "TEST", 74, 95]]], ["Briefly, 20 \u03bcl of cell lysate was added to each well of an opaque 96-well plate.", [["cell lysate", "ANATOMY", 18, 29], ["cell lysate", "CELL", 18, 29], ["cell lysate", "TREATMENT", 18, 29]]], ["A100\u03bcl of Luciferase Assay Reagent (Promega, WI) was added one well at a time, and each well was read immediately.", [["Luciferase Assay Reagent", "TREATMENT", 10, 34]]], ["The light produced for a period of 10 s was measured using a Microplate Reader (BioTek Synergy 2 Multi-detection, Winooski, VT).", [["a Microplate Reader (BioTek Synergy", "TREATMENT", 59, 94]]], ["The experiment to measure IFN -\u03b1/\u03b2 activity in S100A9 knock out or in S100A9 overexpressed cells was done in three replicates and reproduced three times.", [["cells", "ANATOMY", 91, 96], ["IFN -\u03b1", "GENE_OR_GENE_PRODUCT", 26, 32], ["\u03b2", "GENE_OR_GENE_PRODUCT", 33, 34], ["S100A9", "GENE_OR_GENE_PRODUCT", 47, 53], ["S100A9", "GENE_OR_GENE_PRODUCT", 70, 76], ["cells", "CELL", 91, 96], ["IFN", "PROTEIN", 26, 29], ["\u03b2", "PROTEIN", 33, 34], ["S100A9", "PROTEIN", 47, 53], ["S100A9 overexpressed cells", "CELL_LINE", 70, 96], ["IFN", "TEST", 26, 29], ["S100A9 overexpressed cells", "PROBLEM", 70, 96]]], ["The data was analyzed using paired t-test at 95% level of significance.Identification of cellular protein interaction with BVDV2a 1373 Npro protein through mass spectrometryCellular protein interactions with ncp BVDV2a 1373 Npro were identified in p3XFLAG-Npro transfected 293T cells using co-immunoprecipitation technique.", [["cellular", "ANATOMY", 89, 97], ["Cellular", "ANATOMY", 173, 181], ["293T cells", "ANATOMY", 273, 283], ["cellular", "CELL", 89, 97], ["BVDV2a 1373 Npro", "GENE_OR_GENE_PRODUCT", 123, 139], ["ncp BVDV2a 1373 Npro", "GENE_OR_GENE_PRODUCT", 208, 228], ["p3XFLAG-Npro", "CELL", 248, 260], ["293T cells", "CELL", 273, 283], ["BVDV2a 1373 Npro protein", "PROTEIN", 123, 147], ["ncp BVDV2a 1373 Npro", "DNA", 208, 228], ["p3XFLAG-Npro transfected 293T cells", "CELL_LINE", 248, 283], ["The data", "TEST", 0, 8], ["paired t-test", "TEST", 28, 41], ["cellular protein interaction", "PROBLEM", 89, 117], ["BVDV2a", "TEST", 123, 129], ["mass spectrometry", "PROBLEM", 156, 173], ["Cellular protein interactions", "PROBLEM", 173, 202], ["ncp BVDV2a", "TEST", 208, 218], ["p3XFLAG", "TEST", 248, 255], ["co-immunoprecipitation technique", "TREATMENT", 290, 322], ["cellular protein interaction", "OBSERVATION", 89, 117], ["protein interactions", "OBSERVATION", 182, 202]]], ["The proteins in cell lysate of p3XFLAG-Npro or p3XFLAG transfected 293T was pulled down (isolated) using anti-FLAG antibody and examined through mass spectrometry.", [["cell lysate", "ANATOMY", 16, 27], ["293T", "ANATOMY", 67, 71], ["cell", "CELL", 16, 20], ["p3XFLAG-Npro", "GENE_OR_GENE_PRODUCT", 31, 43], ["293T", "CELL", 67, 71], ["p3XFLAG", "PROTEIN", 31, 38], ["Npro", "PROTEIN", 39, 43], ["p3XFLAG transfected 293T", "CELL_LINE", 47, 71], ["anti-FLAG antibody", "PROTEIN", 105, 123], ["The proteins", "TEST", 0, 12], ["p3XFLAG", "TEST", 31, 38], ["Npro", "TREATMENT", 39, 43], ["p3XFLAG", "TREATMENT", 47, 54], ["anti-FLAG antibody", "TEST", 105, 123], ["mass spectrometry", "PROBLEM", 145, 162], ["cell lysate", "OBSERVATION", 16, 27]]], ["A total 30 most abundant proteins were identified in p3XFLAG as well as in p3XFLAG-Npro transfected cells lysate which mainly included keratin protein for cytoskeletal, ATP synthase, chain B of Immunoglobulin and protein S100A9.", [["cells lysate", "ANATOMY", 100, 112], ["cytoskeletal", "ANATOMY", 155, 167], ["ATP", "CHEMICAL", 169, 172], ["ATP", "CHEMICAL", 169, 172], ["p3XFLAG", "GENE_OR_GENE_PRODUCT", 53, 60], ["p3XFLAG-Npro", "GENE_OR_GENE_PRODUCT", 75, 87], ["cells", "CELL", 100, 105], ["keratin protein", "GENE_OR_GENE_PRODUCT", 135, 150], ["cytoskeletal", "CELLULAR_COMPONENT", 155, 167], ["ATP synthase", "GENE_OR_GENE_PRODUCT", 169, 181], ["chain B", "GENE_OR_GENE_PRODUCT", 183, 190], ["Immunoglobulin", "GENE_OR_GENE_PRODUCT", 194, 208], ["S100A9", "GENE_OR_GENE_PRODUCT", 221, 227], ["p3XFLAG", "PROTEIN", 53, 60], ["p3XFLAG", "PROTEIN", 75, 82], ["Npro transfected cells", "CELL_LINE", 83, 105], ["keratin protein", "PROTEIN", 135, 150], ["cytoskeletal, ATP synthase", "PROTEIN", 155, 181], ["chain B", "PROTEIN", 183, 190], ["Immunoglobulin", "PROTEIN", 194, 208], ["protein S100A9", "PROTEIN", 213, 227], ["p3XFLAG", "TEST", 75, 82], ["lysate", "TEST", 106, 112], ["keratin protein", "TEST", 135, 150], ["cytoskeletal", "TEST", 155, 167], ["ATP synthase", "TEST", 169, 181], ["chain B of Immunoglobulin and protein S100A9", "TEST", 183, 227]]], ["In comparing these two groups, a total of sixteen proteins were identified which were present in p3XFLAG-Npro transfected cells that were absent in p3XFLAG transfected cells (Table 1) .", [["cells", "ANATOMY", 122, 127], ["cells", "ANATOMY", 168, 173], ["p3XFLAG", "GENE_OR_GENE_PRODUCT", 97, 104], ["cells", "CELL", 122, 127], ["cells", "CELL", 168, 173], ["p3XFLAG", "PROTEIN", 97, 104], ["Npro transfected cells", "CELL_LINE", 105, 127], ["p3XFLAG transfected cells", "CELL_LINE", 148, 173], ["sixteen proteins", "TEST", 42, 58], ["p3XFLAG", "TEST", 97, 104], ["transfected cells", "OBSERVATION", 110, 127], ["transfected cells", "OBSERVATION", 156, 173]]], ["Among these proteins, S100A9 had the highest mass spectrometry score (i.e., 295) indicating a strong association between BVDV Npro and cellular S100A9 ( Table 1 ).", [["cellular", "ANATOMY", 135, 143], ["S100A9", "GENE_OR_GENE_PRODUCT", 22, 28], ["BVDV", "ORGANISM", 121, 125], ["Npro", "GENE_OR_GENE_PRODUCT", 126, 130], ["cellular S100A9", "GENE_OR_GENE_PRODUCT", 135, 150], ["S100A9", "PROTEIN", 22, 28], ["BVDV Npro", "PROTEIN", 121, 130], ["cellular S100A9", "PROTEIN", 135, 150], ["Table 1", "PROTEIN", 153, 160], ["BVDV", "SPECIES", 121, 125], ["these proteins", "TEST", 6, 20], ["the highest mass spectrometry score", "PROBLEM", 33, 68]]], ["The further analysis of S100A9 protein using MassLynx software 4.1 (Micromass) revealed 7 peptide fragments ( Table 2) .Co-immunoprecipitation confirms the interaction of BVDV2a 1373 Npro and S100A9 cellular proteinTo further confirm the interaction between the BVDV2a 1373 Npro and cellular S100A9, the 293T cells were co-transfected with pEGFP-C1-Npro and p3XFLAG -S100A9 plasmid or pEGFP-C1-Npro and p3XFLAG (empty FLAG plasmid without S100A9).", [["cellular", "ANATOMY", 199, 207], ["cellular", "ANATOMY", 283, 291], ["293T cells", "ANATOMY", 304, 314], ["S100A9", "GENE_OR_GENE_PRODUCT", 24, 30], ["BVDV2a 1373 Npro", "GENE_OR_GENE_PRODUCT", 171, 187], ["S100A9", "GENE_OR_GENE_PRODUCT", 192, 198], ["BVDV2a 1373 Npro", "GENE_OR_GENE_PRODUCT", 262, 278], ["cellular S100A9", "GENE_OR_GENE_PRODUCT", 283, 298], ["293T cells", "CELL", 304, 314], ["pEGFP-C1-Npro", "GENE_OR_GENE_PRODUCT", 340, 353], ["p3XFLAG -S100A9", "GENE_OR_GENE_PRODUCT", 358, 373], ["pEGFP-C1-Npro", "GENE_OR_GENE_PRODUCT", 385, 398], ["p3XFLAG", "GENE_OR_GENE_PRODUCT", 403, 410], ["S100A9", "GENE_OR_GENE_PRODUCT", 439, 445], ["S100A9 protein", "PROTEIN", 24, 38], ["BVDV2a 1373 Npro", "PROTEIN", 171, 187], ["S100A9 cellular proteinTo", "PROTEIN", 192, 217], ["BVDV2a 1373 Npro", "PROTEIN", 262, 278], ["cellular S100A9", "PROTEIN", 283, 298], ["293T cells", "CELL_LINE", 304, 314], ["pEGFP-C1-Npro and p3XFLAG -S100A9 plasmid", "DNA", 340, 381], ["pEGFP", "DNA", 385, 390], ["C1", "DNA", 391, 393], ["Npro", "DNA", 394, 398], ["p3XFLAG", "DNA", 403, 410], ["empty FLAG plasmid", "DNA", 412, 430], ["S100A9", "PROTEIN", 439, 445], ["The further analysis", "TEST", 0, 20], ["S100A9 protein", "TEST", 24, 38], ["MassLynx software", "TEST", 45, 62], ["Micromass", "TEST", 68, 77], ["7 peptide fragments", "PROBLEM", 88, 107], ["BVDV2a", "TEST", 171, 177], ["the BVDV2a", "TEST", 258, 268], ["pEGFP", "TEST", 340, 345], ["C1", "TEST", 346, 348], ["Npro", "TEST", 349, 353], ["p3XFLAG", "TEST", 358, 365], ["pEGFP", "TEST", 385, 390], ["C1", "TEST", 391, 393], ["p3XFLAG", "TREATMENT", 403, 410], ["empty FLAG plasmid", "TREATMENT", 412, 430]]], ["The transfected cells were lysed and proteins were isolated using the anti-FLAG beads.", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["anti-FLAG", "GENE_OR_GENE_PRODUCT", 70, 79], ["transfected cells", "CELL_LINE", 4, 21], ["anti-FLAG beads", "PROTEIN", 70, 85], ["The transfected cells", "PROBLEM", 0, 21], ["proteins", "TEST", 37, 45], ["the anti-FLAG beads", "TREATMENT", 66, 85], ["transfected cells", "OBSERVATION", 4, 21]]], ["Proteins isolated by anti-FLAG beads were analyzed for presence of GFP (e.g GFP-Npro) as well as FLAG using western blot.", [["anti-FLAG", "GENE_OR_GENE_PRODUCT", 21, 30], ["GFP", "GENE_OR_GENE_PRODUCT", 67, 70], ["GFP-Npro", "GENE_OR_GENE_PRODUCT", 76, 84], ["FLAG", "GENE_OR_GENE_PRODUCT", 97, 101], ["anti-FLAG beads", "PROTEIN", 21, 36], ["GFP", "PROTEIN", 67, 70], ["GFP", "PROTEIN", 76, 79], ["Npro", "PROTEIN", 80, 84], ["FLAG", "PROTEIN", 97, 101], ["Proteins", "TEST", 0, 8], ["anti-FLAG beads", "TREATMENT", 21, 36], ["GFP", "TEST", 67, 70], ["GFP", "TEST", 76, 79]]], ["The mock transfected 293T cells were used as negative control while cells transfected with pEGFP-C1-Npro plasmid were used as GFP-Npro positive control.Co-immunoprecipitation confirms the interaction of BVDV2a 1373 Npro and S100A9 cellular proteinCells co-transfected with p3XFLAG (without S100A9) with pEGFP C1-Npro did not show the presence of Npro while the cells co-transfected with p3XFLAG S100A9 along with pEGFP C1-Npro presence of both S100A9 as well as Npro proteins (Fig. 3) .", [["293T cells", "ANATOMY", 21, 31], ["cells", "ANATOMY", 68, 73], ["cellular", "ANATOMY", 231, 239], ["cells", "ANATOMY", 361, 366], ["293T cells", "CELL", 21, 31], ["cells", "CELL", 68, 73], ["pEGFP-C1", "GENE_OR_GENE_PRODUCT", 91, 99], ["GFP", "GENE_OR_GENE_PRODUCT", 126, 129], ["BVDV2a 1373 Npro", "GENE_OR_GENE_PRODUCT", 203, 219], ["S100A9", "GENE_OR_GENE_PRODUCT", 224, 230], ["p3XFLAG", "GENE_OR_GENE_PRODUCT", 273, 280], ["S100A9", "GENE_OR_GENE_PRODUCT", 290, 296], ["pEGFP", "GENE_OR_GENE_PRODUCT", 303, 308], ["Npro", "GENE_OR_GENE_PRODUCT", 346, 350], ["cells", "CELL", 361, 366], ["p3XFLAG S100A9", "GENE_OR_GENE_PRODUCT", 387, 401], ["pEGFP", "GENE_OR_GENE_PRODUCT", 413, 418], ["S100A9", "GENE_OR_GENE_PRODUCT", 444, 450], ["Npro proteins", "GENE_OR_GENE_PRODUCT", 462, 475], ["mock transfected 293T cells", "CELL_LINE", 4, 31], ["pEGFP-C1-Npro plasmid", "DNA", 91, 112], ["GFP", "PROTEIN", 126, 129], ["BVDV2a 1373 Npro", "PROTEIN", 203, 219], ["S100A9 cellular proteinCells", "PROTEIN", 224, 252], ["p3XFLAG", "PROTEIN", 273, 280], ["S100A9", "PROTEIN", 290, 296], ["pEGFP C1", "PROTEIN", 303, 311], ["Npro", "PROTEIN", 312, 316], ["Npro", "PROTEIN", 346, 350], ["p3XFLAG S100A9", "PROTEIN", 387, 401], ["pEGFP C1", "PROTEIN", 413, 421], ["S100A9", "PROTEIN", 444, 450], ["Npro proteins", "PROTEIN", 462, 475], ["The mock transfected 293T cells", "TREATMENT", 0, 31], ["pEGFP", "TEST", 91, 96], ["Npro plasmid", "TREATMENT", 100, 112], ["GFP", "TEST", 126, 129], ["Co-immunoprecipitation", "TEST", 152, 174], ["BVDV2a", "TEST", 203, 209], ["p3XFLAG", "TEST", 273, 280], ["pEGFP C1", "TEST", 303, 311], ["p3XFLAG S100A9", "TEST", 387, 401]]], ["These resulted further confirmed a strong association of cellular S100A9 and BVDV Npro proteins.Inhibition of bovine S100A9 by small interfering RNA (siRNA)enhanced virus replicationThe activity of S100A9 on BVDV replication was measured in S100A9 knock out MDBK cells.", [["cellular", "ANATOMY", 57, 65], ["MDBK cells", "ANATOMY", 258, 268], ["cellular", "CELL", 57, 65], ["S100A9", "GENE_OR_GENE_PRODUCT", 66, 72], ["BVDV Npro proteins", "GENE_OR_GENE_PRODUCT", 77, 95], ["bovine", "ORGANISM", 110, 116], ["S100A9", "GENE_OR_GENE_PRODUCT", 117, 123], ["S100A9", "GENE_OR_GENE_PRODUCT", 198, 204], ["BVDV", "ORGANISM", 208, 212], ["S100A9", "GENE_OR_GENE_PRODUCT", 241, 247], ["MDBK cells", "CELL", 258, 268], ["S100A9", "PROTEIN", 66, 72], ["BVDV Npro proteins", "PROTEIN", 77, 95], ["bovine S100A9", "PROTEIN", 110, 123], ["small interfering RNA", "RNA", 127, 148], ["S100A9", "PROTEIN", 198, 204], ["S100A9", "PROTEIN", 241, 247], ["MDBK cells", "CELL_LINE", 258, 268], ["bovine", "SPECIES", 110, 116], ["BVDV", "SPECIES", 77, 81], ["bovine", "SPECIES", 110, 116], ["BVDV", "SPECIES", 208, 212], ["cellular S100A9", "PROBLEM", 57, 72], ["Inhibition of bovine S100A9", "TREATMENT", 96, 123], ["small interfering RNA (siRNA)enhanced virus replication", "TREATMENT", 127, 182], ["BVDV replication", "TEST", 208, 224], ["MDBK cells", "PROBLEM", 258, 268], ["small", "OBSERVATION_MODIFIER", 127, 132], ["interfering RNA", "OBSERVATION", 133, 148], ["activity", "OBSERVATION_MODIFIER", 186, 194], ["MDBK cells", "OBSERVATION", 258, 268]]], ["The S100 A9 knock out or control MDBK cells were infected with ncpBVDV2a 1373 with MOI of 1.", [["MDBK cells", "ANATOMY", 33, 43], ["S100 A9", "GENE_OR_GENE_PRODUCT", 4, 11], ["MDBK cells", "CELL", 33, 43], ["MDBK cells", "CELL_LINE", 33, 43], ["MDBK", "SPECIES", 33, 37], ["control MDBK cells", "PROBLEM", 25, 43], ["ncpBVDV2a", "TEST", 63, 72], ["MOI", "TEST", 83, 86]]], ["The supernatant was collected at 12 h, 24 h, 36 h and 60 h post infection and analyzed for BVDV viral titer.", [["supernatant", "ANATOMY", 4, 15], ["BVDV", "ORGANISM", 91, 95], ["BVDV", "SPECIES", 91, 95], ["infection", "PROBLEM", 64, 73], ["BVDV viral titer", "PROBLEM", 91, 107], ["infection", "OBSERVATION", 64, 73], ["viral titer", "OBSERVATION", 96, 107]]], ["The results showed an increase in viral production by 1.5 log10 at 24 h (p < 0.05) and 0.5 log10 at 36 h in S100A9 knock out cells, as compared to scrambled siRNA-transfected cells (Fig. 4) .", [["cells", "ANATOMY", 125, 130], ["cells", "ANATOMY", 175, 180], ["S100A9", "GENE_OR_GENE_PRODUCT", 108, 114], ["cells", "CELL", 125, 130], ["cells", "CELL", 175, 180], ["S100A9", "PROTEIN", 108, 114], ["scrambled siRNA-transfected cells", "CELL_LINE", 147, 180], ["an increase in viral production", "PROBLEM", 19, 50], ["S100A9 knock out cells", "PROBLEM", 108, 130], ["scrambled siRNA", "PROBLEM", 147, 162], ["increase", "OBSERVATION_MODIFIER", 22, 30], ["viral production", "OBSERVATION", 34, 50], ["transfected cells", "OBSERVATION", 163, 180]]], ["BVDV infected S100A9 gene knock out cells had virus production of 2.5 \u00b1 0.75 log10/ml, 5.0 \u00b1 0.75 log10/ml, 6 \u00b1 0.75 log10/ml, 6.25 \u00b1 0.75 log10/ml, 5.5 \u00b1 0.75 log10/ml at 12 h, 24 h, 36 h, 48 h and 60 h post infection respectively.", [["cells", "ANATOMY", 36, 41], ["infection", "DISEASE", 209, 218], ["BVDV", "ORGANISM", 0, 4], ["S100A9", "GENE_OR_GENE_PRODUCT", 14, 20], ["cells", "CELL", 36, 41], ["BVDV", "SPECIES", 0, 4], ["BVDV", "SPECIES", 0, 4], ["BVDV", "PROBLEM", 0, 4], ["virus production", "TEST", 46, 62], ["infection", "PROBLEM", 209, 218], ["infection", "OBSERVATION", 209, 218]]], ["In comparison, the scrambled siRNA-transfected cells had virus production of 3.25 \u00b1 0.75 log10/ml, 3.5 \u00b1 0.75 log10/ml, 5.5 \u00b1 0.75 log10/ml, 6.5 \u00b1 0.75 log10/ml and 5.5 \u00b1 0.75 log10/ml 12 h, 24 h, 36 h and 60 h post infection respectively.Overexpression of bovine S100A9 counteracted the interferon Type-I inhibition induced by ncp BVDV2a 1373To determine whether the interaction of BVDV Npro with S100A9 affected the ability of Npro to inhibit type 1 (\u03b1/\u03b2) IFN, an interferon reporter assay was performed in S100A9 over expressed or S100A9 knock out cells [23] .", [["cells", "ANATOMY", 47, 52], ["cells", "ANATOMY", 551, 556], ["infection", "DISEASE", 216, 225], ["Npro", "CHEMICAL", 429, 433], ["cells", "CELL", 47, 52], ["bovine", "ORGANISM", 257, 263], ["S100A9", "GENE_OR_GENE_PRODUCT", 264, 270], ["interferon Type-I", "GENE_OR_GENE_PRODUCT", 288, 305], ["ncp BVDV2a 1373To", "SIMPLE_CHEMICAL", 328, 345], ["BVDV", "ORGANISM", 383, 387], ["Npro", "GENE_OR_GENE_PRODUCT", 388, 392], ["S100A9", "GENE_OR_GENE_PRODUCT", 398, 404], ["Npro", "SIMPLE_CHEMICAL", 429, 433], ["type 1", "GENE_OR_GENE_PRODUCT", 445, 451], ["\u03b1/\u03b2) IFN", "GENE_OR_GENE_PRODUCT", 453, 461], ["S100A9", "GENE_OR_GENE_PRODUCT", 509, 515], ["S100A9", "GENE_OR_GENE_PRODUCT", 534, 540], ["transfected cells", "CELL_LINE", 35, 52], ["bovine S100A9", "PROTEIN", 257, 270], ["interferon Type-I", "PROTEIN", 288, 305], ["BVDV Npro", "PROTEIN", 383, 392], ["S100A9", "PROTEIN", 398, 404], ["Npro", "PROTEIN", 429, 433], ["type 1 (\u03b1/\u03b2) IFN", "PROTEIN", 445, 461], ["S100A9", "PROTEIN", 509, 515], ["S100A9", "PROTEIN", 534, 540], ["bovine", "SPECIES", 257, 263], ["bovine", "SPECIES", 257, 263], ["BVDV", "SPECIES", 383, 387], ["the scrambled siRNA", "TEST", 15, 34], ["transfected cells", "PROBLEM", 35, 52], ["virus production", "TEST", 57, 73], ["infection", "PROBLEM", 216, 225], ["Overexpression of bovine S100A9", "TREATMENT", 239, 270], ["the interferon Type-I inhibition", "TREATMENT", 284, 316], ["BVDV", "PROBLEM", 383, 387], ["IFN", "PROBLEM", 458, 461], ["an interferon reporter assay", "TEST", 463, 491], ["infection", "OBSERVATION", 216, 225]]], ["The S100A9 over expressed or S100A9 knock out cells were infected with ncp BVDV2a-1373 for 24 h.", [["cells", "ANATOMY", 46, 51], ["BVDV2a-1373", "CHEMICAL", 75, 86], ["BVDV2a-1373", "CHEMICAL", 75, 86], ["S100A9", "GENE_OR_GENE_PRODUCT", 4, 10], ["S100A9", "GENE_OR_GENE_PRODUCT", 29, 35], ["cells", "CELL", 46, 51], ["S100A9", "PROTEIN", 4, 10], ["S100A9", "PROTEIN", 29, 35], ["ncp BVDV2a-1373", "SPECIES", 71, 86], ["S100A9 knock out cells", "PROBLEM", 29, 51], ["ncp BVDV2a", "TEST", 71, 81]]], ["After 24 h infection, the supernatant was collected and examined for type 1 interferon expression through firefly luciferase activity in NCL-1-ISRE-Luc-Hygro cells.", [["supernatant", "ANATOMY", 26, 37], ["NCL-1-ISRE-Luc-Hygro cells", "ANATOMY", 137, 163], ["infection", "DISEASE", 11, 20], ["type 1 interferon", "GENE_OR_GENE_PRODUCT", 69, 86], ["luciferase", "GENE_OR_GENE_PRODUCT", 114, 124], ["NCL-1", "GENE_OR_GENE_PRODUCT", 137, 142], ["Luc-Hygro cells", "CELL", 148, 163], ["interferon", "PROTEIN", 76, 86], ["luciferase", "PROTEIN", 114, 124], ["NCL-1-ISRE-Luc-Hygro cells", "CELL_LINE", 137, 163], ["24 h infection", "PROBLEM", 6, 20], ["the supernatant", "TREATMENT", 22, 37], ["type 1 interferon expression", "TREATMENT", 69, 97], ["firefly luciferase activity", "TEST", 106, 133], ["NCL", "TEST", 137, 140], ["infection", "OBSERVATION", 11, 20], ["Hygro cells", "OBSERVATION", 152, 163]]], ["There was significantly higher type 1 interferon expression in S100A9 overexpressed cells as compared to S100A9 knockout or poly I:C treated cells (p < 0.05) (Fig. 5) or BVDV2a 1373 infected normal cells without any.", [["cells", "ANATOMY", 84, 89], ["cells", "ANATOMY", 141, 146], ["cells", "ANATOMY", 198, 203], ["poly I:C", "CHEMICAL", 124, 132], ["type 1 interferon", "GENE_OR_GENE_PRODUCT", 31, 48], ["S100A9", "GENE_OR_GENE_PRODUCT", 63, 69], ["cells", "CELL", 84, 89], ["S100A9", "GENE_OR_GENE_PRODUCT", 105, 111], ["poly I:C", "GENE_OR_GENE_PRODUCT", 124, 132], ["cells", "CELL", 141, 146], ["BVDV2a 1373", "CELL", 170, 181], ["cells", "CELL", 198, 203], ["interferon", "PROTEIN", 38, 48], ["S100A9", "PROTEIN", 63, 69], ["S100A9", "PROTEIN", 105, 111], ["poly I:C treated cells", "CELL_LINE", 124, 146], ["normal cells", "CELL_TYPE", 191, 203], ["significantly higher type 1 interferon expression in S100A9 overexpressed cells", "PROBLEM", 10, 89], ["S100A9 knockout", "TEST", 105, 120], ["poly I:C treated cells", "PROBLEM", 124, 146], ["BVDV2a", "TEST", 170, 176], ["significantly", "OBSERVATION_MODIFIER", 10, 23], ["higher", "OBSERVATION_MODIFIER", 24, 30], ["type 1", "OBSERVATION_MODIFIER", 31, 37], ["interferon expression", "OBSERVATION", 38, 59], ["normal cells", "OBSERVATION", 191, 203]]], ["S100A9 overexpressed cells infected with ncpBVDV2a 1373 showed the luciferase activity reading as 230 \u00b1 5.0 as compared to 148.0 \u00b1 10.0 or 182.0 \u00b1 2.0 in S100A9 knockout infected with ncpBVDV2a 1373 or cell treated with poly I:C respectively (Fig. 5 ).DiscussionIn this study, immunoprecipitation coupled with mass spectrometry demonstrated the interaction of viral ncp BVDV2a 1373 Npro protein with the cellular S100A9 protein.", [["cells", "ANATOMY", 21, 26], ["cell", "ANATOMY", 202, 206], ["cellular", "ANATOMY", 404, 412], ["ncpBVDV2a 1373", "CHEMICAL", 41, 55], ["S100A9", "GENE_OR_GENE_PRODUCT", 0, 6], ["cells", "CELL", 21, 26], ["luciferase", "GENE_OR_GENE_PRODUCT", 67, 77], ["S100A9", "GENE_OR_GENE_PRODUCT", 154, 160], ["cell", "CELL", 202, 206], ["poly I:C", "SIMPLE_CHEMICAL", 220, 228], ["Npro", "GENE_OR_GENE_PRODUCT", 382, 386], ["cellular S100A9", "GENE_OR_GENE_PRODUCT", 404, 419], ["S100A9", "PROTEIN", 0, 6], ["ncpBVDV2a 1373", "DNA", 41, 55], ["luciferase", "PROTEIN", 67, 77], ["S100A9", "PROTEIN", 154, 160], ["ncpBVDV2a 1373", "PROTEIN", 184, 198], ["viral ncp BVDV2a 1373 Npro protein", "PROTEIN", 360, 394], ["cellular S100A9 protein", "PROTEIN", 404, 427], ["S100A9 overexpressed cells infected", "PROBLEM", 0, 35], ["ncpBVDV2a", "TEST", 41, 50], ["the luciferase activity", "TEST", 63, 86], ["ncpBVDV2a", "TEST", 184, 193], ["this study", "TEST", 265, 275], ["immunoprecipitation", "TEST", 277, 296], ["mass spectrometry", "TEST", 310, 327]]], ["The interaction was confirmed first by a co-immunoprecipitation-mass spectrometry experiment targeting BVDV Npro protein, which showed the co-presence of cellular S1009A.", [["cellular", "ANATOMY", 154, 162], ["BVDV", "ORGANISM", 103, 107], ["Npro", "GENE_OR_GENE_PRODUCT", 108, 112], ["cellular", "CELL", 154, 162], ["BVDV Npro protein", "PROTEIN", 103, 120], ["cellular S1009A", "PROTEIN", 154, 169], ["BVDV", "SPECIES", 103, 107], ["a co-immunoprecipitation", "TEST", 39, 63], ["BVDV Npro protein", "TEST", 103, 120], ["cellular S1009A", "OBSERVATION", 154, 169]]], ["It was reconfirmed by western blot analysis demonstrated cellular S1009A protein interaction with BVDV Npro protein.", [["cellular", "ANATOMY", 57, 65], ["cellular", "CELL", 57, 65], ["BVDV", "ORGANISM", 98, 102], ["Npro", "GENE_OR_GENE_PRODUCT", 103, 107], ["S1009A protein", "PROTEIN", 66, 80], ["BVDV Npro protein", "PROTEIN", 98, 115], ["BVDV", "SPECIES", 98, 102], ["western blot analysis", "TEST", 22, 43]]], ["Additionally, Table 1 Cellular protein interactions with ncp BVDV2 1373 Npro protein.", [["ncp BVDV2 1373 Npro protein", "PROTEIN", 57, 84], ["BVDV2", "TEST", 61, 66]]], ["A total 30 proteins were co-immunoprecipitated in the cells transfected with p3XFLAG (control) or p3XFLAG-Npro plasmid, using anti-FLAG antibody.", [["cells", "ANATOMY", 54, 59], ["cells", "CELL", 54, 59], ["p3XFLAG", "GENE_OR_GENE_PRODUCT", 77, 84], ["p3XFLAG-Npro", "GENE_OR_GENE_PRODUCT", 98, 110], ["anti-FLAG", "GENE_OR_GENE_PRODUCT", 126, 135], ["p3XFLAG (control) or p3XFLAG-Npro plasmid", "DNA", 77, 118], ["anti-FLAG antibody", "PROTEIN", 126, 144], ["A total 30 proteins", "TREATMENT", 0, 19], ["p3XFLAG (control", "TREATMENT", 77, 93], ["p3XFLAG", "TREATMENT", 98, 105], ["Npro plasmid", "TREATMENT", 106, 118], ["anti-FLAG antibody", "TREATMENT", 126, 144]]], ["The comparison between these two groups revealed a total of sixteen proteins which were present in p3XFLAG-Npro transfected cells that were absent in p3XFLAG transfected cells.", [["cells", "ANATOMY", 124, 129], ["cells", "ANATOMY", 170, 175], ["p3XFLAG", "GENE_OR_GENE_PRODUCT", 99, 106], ["cells", "CELL", 124, 129], ["cells", "CELL", 170, 175], ["p3XFLAG", "PROTEIN", 99, 106], ["Npro transfected cells", "CELL_LINE", 107, 129], ["p3XFLAG transfected cells", "CELL_LINE", 150, 175], ["a total of sixteen proteins", "PROBLEM", 49, 76], ["p3XFLAG", "TEST", 99, 106], ["Npro transfected cells", "PROBLEM", 107, 129], ["transfected cells", "OBSERVATION", 112, 129], ["transfected cells", "OBSERVATION", 158, 175]]], ["The proteins are ranked according to mass spectrometry score e.g. highest to lowest in the SiRNA-knockdown experiments showed a significant increase in BVDV titers (p < 0.05) by more than one log in S100A9 knock down cells at 24 h post infection while overexpression of S100A9 enhanced type 1 interferon production, indicating a functional relationship between BVDV pathogenesis and cellular S100A9 protein.DiscussionCurrently there is very little is known about the role of S100A9 in viral infections.", [["cells", "ANATOMY", 217, 222], ["cellular", "ANATOMY", 383, 391], ["infection", "DISEASE", 236, 245], ["viral infections", "DISEASE", 485, 501], ["SiRNA", "GENE_OR_GENE_PRODUCT", 91, 96], ["BVDV", "ORGANISM", 152, 156], ["S100A9", "GENE_OR_GENE_PRODUCT", 199, 205], ["cells", "CELL", 217, 222], ["S100A9", "GENE_OR_GENE_PRODUCT", 270, 276], ["type 1 interferon", "GENE_OR_GENE_PRODUCT", 286, 303], ["BVDV", "ORGANISM", 361, 365], ["cellular", "CELL", 383, 391], ["S100A9", "GENE_OR_GENE_PRODUCT", 392, 398], ["S100A9", "GENE_OR_GENE_PRODUCT", 475, 481], ["SiRNA", "PROTEIN", 91, 96], ["S100A9", "PROTEIN", 199, 205], ["S100A9", "PROTEIN", 270, 276], ["interferon", "PROTEIN", 293, 303], ["cellular S100A9 protein", "PROTEIN", 383, 406], ["S100A9", "PROTEIN", 475, 481], ["BVDV", "SPECIES", 152, 156], ["BVDV", "SPECIES", 361, 365], ["mass spectrometry score", "TEST", 37, 60], ["the SiRNA", "TEST", 87, 96], ["a significant increase in BVDV titers", "PROBLEM", 126, 163], ["infection", "PROBLEM", 236, 245], ["S100A9 enhanced type 1 interferon production", "PROBLEM", 270, 314], ["BVDV pathogenesis", "PROBLEM", 361, 378], ["viral infections", "PROBLEM", 485, 501], ["significant", "OBSERVATION_MODIFIER", 128, 139], ["increase", "OBSERVATION_MODIFIER", 140, 148], ["BVDV titers", "OBSERVATION", 152, 163], ["infection", "OBSERVATION", 236, 245], ["viral infections", "OBSERVATION", 485, 501]]], ["A previous study showed that S100A9 was upregulated in response to poly I:C, a synthetic analog of viral double-stranded RNA (dsRNA) with increase type 1 IFN [43] .", [["poly I:C", "CHEMICAL", 67, 75], ["poly I:C", "CHEMICAL", 67, 75], ["S100A9", "GENE_OR_GENE_PRODUCT", 29, 35], ["poly I:C", "SIMPLE_CHEMICAL", 67, 75], ["S100A9", "PROTEIN", 29, 35], ["viral double-stranded RNA", "RNA", 99, 124], ["IFN", "PROTEIN", 154, 157], ["A previous study", "TEST", 0, 16], ["S100A9", "PROBLEM", 29, 35], ["a synthetic analog", "TREATMENT", 77, 95], ["viral double-stranded RNA (dsRNA", "TREATMENT", 99, 131], ["stranded RNA", "OBSERVATION", 112, 124]]], ["The human papillomavirus infection also increased systemic levels of S100A8 and S100A9 [44] .", [["human papillomavirus infection", "DISEASE", 4, 34], ["human", "ORGANISM", 4, 9], ["papillomavirus", "ORGANISM", 10, 24], ["S100A8", "GENE_OR_GENE_PRODUCT", 69, 75], ["S100A9", "GENE_OR_GENE_PRODUCT", 80, 86], ["S100A8", "PROTEIN", 69, 75], ["S100A9", "PROTEIN", 80, 86], ["human", "SPECIES", 4, 9], ["human papillomavirus", "SPECIES", 4, 24], ["The human papillomavirus infection", "PROBLEM", 0, 34], ["systemic levels", "TEST", 50, 65], ["S100A8", "TEST", 69, 75], ["S100A9", "TEST", 80, 86], ["papillomavirus", "OBSERVATION_MODIFIER", 10, 24], ["infection", "OBSERVATION", 25, 34]]], ["Likewise, S100A9 increased 60-fold in patients with coronavirus induced severe acute respiratory syndrome [45] .", [["coronavirus", "DISEASE", 52, 63], ["acute respiratory syndrome", "DISEASE", 79, 105], ["S100A9", "GENE_OR_GENE_PRODUCT", 10, 16], ["patients", "ORGANISM", 38, 46], ["S100A9", "PROTEIN", 10, 16], ["patients", "SPECIES", 38, 46], ["coronavirus", "SPECIES", 52, 63], ["S100A9", "TEST", 10, 16], ["coronavirus induced severe acute respiratory syndrome", "PROBLEM", 52, 105], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["respiratory syndrome", "OBSERVATION", 85, 105]]], ["S100A9 exhibits its effect through two well characterized PRRs:DiscussionTLR4 and receptor advanced glycation end products (RAGE) [10, 46] .", [["S100A9", "GENE_OR_GENE_PRODUCT", 0, 6], ["DiscussionTLR4", "SIMPLE_CHEMICAL", 63, 77], ["receptor advanced glycation end products", "GENE_OR_GENE_PRODUCT", 82, 122], ["RAGE", "GENE_OR_GENE_PRODUCT", 124, 128], ["S100A9", "PROTEIN", 0, 6], ["PRRs", "PROTEIN", 58, 62], ["DiscussionTLR4", "PROTEIN", 63, 77], ["receptor advanced glycation end products", "PROTEIN", 82, 122], ["RAGE", "PROTEIN", 124, 128], ["DiscussionTLR4 and receptor advanced glycation end products", "TREATMENT", 63, 122]]], ["Both PRRs use independent downstream pathways [13] .", [["PRRs", "GENE_OR_GENE_PRODUCT", 5, 9], ["PRRs", "PROTEIN", 5, 9]]], ["When TLRs are stimulated by alarmins (i.e., PAMPs and DAMPs), they recruit one or more adapter proteins, such as MyD88 (a downstream signaling protein).", [["TLRs", "GENE_OR_GENE_PRODUCT", 5, 9], ["alarmins", "GENE_OR_GENE_PRODUCT", 28, 36], ["PAMPs", "GENE_OR_GENE_PRODUCT", 44, 49], ["DAMPs", "GENE_OR_GENE_PRODUCT", 54, 59], ["MyD88", "GENE_OR_GENE_PRODUCT", 113, 118], ["TLRs", "PROTEIN", 5, 9], ["alarmins", "PROTEIN", 28, 36], ["PAMPs", "PROTEIN", 44, 49], ["DAMPs", "PROTEIN", 54, 59], ["adapter proteins", "PROTEIN", 87, 103], ["MyD88", "PROTEIN", 113, 118], ["downstream signaling protein", "PROTEIN", 122, 150]]], ["Activated MyD88 further activates signaling molecules, including phosphatidylinositol-3-kinase (PI3K), mitogen-activated protein kinases (MAPK) (i.e., c-Jun NH2-terminal kinase [JNK] , p38, and extracellular signal-regulated kinase (ERKs), v-akt murine thymoma viral oncogene homolog (Akt), interferon regulatory factor (IRF), \u03b2-catenin [47] , as well as nuclear factor-\u043aB (NF-\u043aB) [48] .", [["phosphatidylinositol", "CHEMICAL", 65, 85], ["NH2", "CHEMICAL", 157, 160], ["MyD88", "GENE_OR_GENE_PRODUCT", 10, 15], ["phosphatidylinositol-3-kinase", "GENE_OR_GENE_PRODUCT", 65, 94], ["PI3K", "GENE_OR_GENE_PRODUCT", 96, 100], ["mitogen-activated protein kinases", "GENE_OR_GENE_PRODUCT", 103, 136], ["MAPK", "GENE_OR_GENE_PRODUCT", 138, 142], ["c-Jun NH2-terminal kinase", "GENE_OR_GENE_PRODUCT", 151, 176], ["JNK", "GENE_OR_GENE_PRODUCT", 178, 181], ["p38", "GENE_OR_GENE_PRODUCT", 185, 188], ["extracellular signal-regulated kinase", "GENE_OR_GENE_PRODUCT", 194, 231], ["ERKs", "GENE_OR_GENE_PRODUCT", 233, 237], ["v-akt murine thymoma viral oncogene homolog", "GENE_OR_GENE_PRODUCT", 240, 283], ["Akt", "GENE_OR_GENE_PRODUCT", 285, 288], ["interferon regulatory factor", "GENE_OR_GENE_PRODUCT", 291, 319], ["IRF", "GENE_OR_GENE_PRODUCT", 321, 324], ["\u03b2-catenin [47]", "GENE_OR_GENE_PRODUCT", 327, 341], ["nuclear factor-\u043aB", "GENE_OR_GENE_PRODUCT", 355, 372], ["NF-\u043aB", "GENE_OR_GENE_PRODUCT", 374, 379], ["MyD88", "PROTEIN", 10, 15], ["signaling molecules", "PROTEIN", 34, 53], ["phosphatidylinositol-3-kinase", "PROTEIN", 65, 94], ["PI3K", "PROTEIN", 96, 100], ["mitogen-activated protein kinases", "PROTEIN", 103, 136], ["MAPK", "PROTEIN", 138, 142], ["Jun NH2-terminal kinase", "PROTEIN", 153, 176], ["JNK", "PROTEIN", 178, 181], ["p38", "PROTEIN", 185, 188], ["extracellular signal-regulated kinase", "PROTEIN", 194, 231], ["ERKs", "PROTEIN", 233, 237], ["v-akt murine thymoma viral oncogene homolog", "PROTEIN", 240, 283], ["Akt", "PROTEIN", 285, 288], ["interferon regulatory factor", "PROTEIN", 291, 319], ["IRF", "PROTEIN", 321, 324], ["\u03b2-catenin", "PROTEIN", 327, 336], ["nuclear factor-\u043aB (NF-\u043aB", "PROTEIN", 355, 379], ["murine", "SPECIES", 246, 252], ["signaling molecules", "TEST", 34, 53], ["phosphatidylinositol", "TEST", 65, 85], ["PI3K", "TEST", 96, 100], ["mitogen", "TEST", 103, 110], ["activated protein kinases", "TEST", 111, 136], ["MAPK", "TEST", 138, 142], ["c-Jun NH2", "TEST", 151, 160], ["terminal kinase", "TEST", 161, 176], ["JNK", "TEST", 178, 181], ["p38", "TEST", 185, 188], ["extracellular signal", "TEST", 194, 214], ["kinase", "TEST", 225, 231], ["ERKs", "TEST", 233, 237], ["v-akt", "TEST", 240, 245], ["interferon regulatory factor", "PROBLEM", 291, 319], ["\u03b2-catenin", "TEST", 327, 336], ["nuclear factor", "TEST", 355, 369]]], ["Increased NF-\u043aB expression increased the pro-inflammatory cytokines including chemokine ligand 2(CCL2), interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin-8 (IL-80, monocyte-chemo Table 2 The peptide fragments present in S100A9 protein.", [["tumor necrosis", "DISEASE", 152, 166], ["NF-\u043aB", "GENE_OR_GENE_PRODUCT", 10, 15], ["chemokine ligand 2", "GENE_OR_GENE_PRODUCT", 78, 96], ["CCL2", "GENE_OR_GENE_PRODUCT", 97, 101], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 104, 117], ["IL-1", "GENE_OR_GENE_PRODUCT", 119, 123], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 126, 139], ["IL-6", "GENE_OR_GENE_PRODUCT", 141, 145], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 152, 175], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 177, 182], ["interleukin-8", "GENE_OR_GENE_PRODUCT", 185, 198], ["IL-80", "GENE_OR_GENE_PRODUCT", 200, 205], ["monocyte-chemo Table 2", "GENE_OR_GENE_PRODUCT", 207, 229], ["S100A9", "GENE_OR_GENE_PRODUCT", 263, 269], ["NF-\u043aB", "PROTEIN", 10, 15], ["pro-inflammatory cytokines", "PROTEIN", 41, 67], ["chemokine ligand 2", "PROTEIN", 78, 96], ["CCL2", "PROTEIN", 97, 101], ["interleukin-1 (IL-1", "PROTEIN", 104, 123], ["interleukin-6", "PROTEIN", 126, 139], ["TNF", "PROTEIN", 177, 180], ["interleukin-8", "PROTEIN", 185, 198], ["S100A9 protein", "PROTEIN", 263, 277], ["Increased NF", "PROBLEM", 0, 12], ["the pro-inflammatory cytokines", "TEST", 37, 67], ["chemokine ligand", "TEST", 78, 94], ["CCL2", "TEST", 97, 101], ["interleukin", "TEST", 104, 115], ["IL", "TEST", 119, 121], ["interleukin", "TEST", 126, 137], ["IL", "TEST", 141, 143], ["tumor necrosis factor", "PROBLEM", 152, 173], ["TNF", "TEST", 177, 180], ["interleukin", "TEST", 185, 196], ["IL", "TEST", 200, 202], ["monocyte-chemo Table", "TREATMENT", 207, 227], ["The peptide fragments", "TREATMENT", 230, 251], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["pro-inflammatory cytokines", "OBSERVATION", 41, 67], ["tumor", "OBSERVATION_MODIFIER", 152, 157], ["necrosis", "OBSERVATION", 158, 166], ["monocyte", "ANATOMY", 207, 215]]], ["The cellular S100A9 protein was analyzed through nano ESI-Q-Tof micro mass spectrometer (Micromass, Manchester, UK) using MassLynx software 4.1 (Micromass).", [["cellular", "ANATOMY", 4, 12], ["cellular", "CELL", 4, 12], ["S100A9", "GENE_OR_GENE_PRODUCT", 13, 19], ["cellular S100A9 protein", "PROTEIN", 4, 27], ["The cellular S100A9 protein", "TEST", 0, 27], ["nano ESI", "TEST", 49, 57], ["MassLynx software", "TEST", 122, 139], ["S100A9 protein", "OBSERVATION", 13, 27]]], ["Software revealed seven peptide fragments in S100A9 protein.DiscussionProtein S100-A9 Fig. 3 .", [["S100A9", "GENE_OR_GENE_PRODUCT", 45, 51], ["S100A9 protein", "PROTEIN", 45, 59], ["S100", "PROTEIN", 78, 82], ["A9 Fig. 3", "PROTEIN", 83, 92], ["seven peptide fragments in S100A9 protein", "PROBLEM", 18, 59], ["seven peptide fragments", "OBSERVATION", 18, 41]]], ["Interaction of BVDV2a 1373 Npro and S100A9 cellular protein.", [["cellular", "ANATOMY", 43, 51], ["BVDV2a 1373 Npro", "GENE_OR_GENE_PRODUCT", 15, 31], ["S100A9 cellular protein", "GENE_OR_GENE_PRODUCT", 36, 59], ["BVDV2a 1373", "PROTEIN", 15, 26], ["Npro", "PROTEIN", 27, 31], ["S100A9 cellular protein", "PROTEIN", 36, 59], ["BVDV2a", "TEST", 15, 21]]], ["The interaction of BVDV Npro with S100A9 protein in cells were confirmed by co immunoprecipitation assays.", [["cells", "ANATOMY", 52, 57], ["BVDV", "ORGANISM", 19, 23], ["Npro", "GENE_OR_GENE_PRODUCT", 24, 28], ["S100A9", "GENE_OR_GENE_PRODUCT", 34, 40], ["cells", "CELL", 52, 57], ["BVDV Npro", "PROTEIN", 19, 28], ["S100A9 protein", "PROTEIN", 34, 48], ["BVDV", "SPECIES", 19, 23], ["BVDV", "PROBLEM", 19, 23], ["S100A9 protein in cells", "PROBLEM", 34, 57], ["co immunoprecipitation assays", "TEST", 76, 105]]], ["The 293T cells were co-transfected with pEGFP-C1-Npro and p3XFLAG -S100A9 plasmid or pEGFP-C1-Npro and p3XFLAG.", [["293T cells", "ANATOMY", 4, 14], ["293T cells", "CELL", 4, 14], ["pEGFP-C1-Npro", "GENE_OR_GENE_PRODUCT", 40, 53], ["p3XFLAG -S100A9", "GENE_OR_GENE_PRODUCT", 58, 73], ["pEGFP-C1-Npro", "GENE_OR_GENE_PRODUCT", 85, 98], ["p3XFLAG", "GENE_OR_GENE_PRODUCT", 103, 110], ["293T cells", "CELL_LINE", 4, 14], ["pEGFP-C1-Npro and p3XFLAG -S100A9 plasmid", "DNA", 40, 81], ["pEGFP", "DNA", 85, 90], ["C1", "DNA", 91, 93], ["Npro", "DNA", 94, 98], ["p3XFLAG", "DNA", 103, 110], ["The 293T cells", "TREATMENT", 0, 14], ["pEGFP", "TEST", 40, 45], ["C1", "TEST", 46, 48], ["Npro", "TEST", 49, 53], ["p3XFLAG", "TEST", 58, 65], ["pEGFP", "TEST", 85, 90], ["p3XFLAG", "TREATMENT", 103, 110], ["293T cells", "OBSERVATION", 4, 14], ["C1", "ANATOMY", 91, 93]]], ["At 24 h post transfection, cells were lysed and the proteins were isolated (by co-immunoprecipitation) using the anti-FLAG beads.", [["cells", "ANATOMY", 27, 32], ["cells", "CELL", 27, 32], ["anti-FLAG", "GENE_OR_GENE_PRODUCT", 113, 122], ["anti-FLAG beads", "PROTEIN", 113, 128], ["the proteins", "TEST", 48, 60], ["the anti-FLAG beads", "TREATMENT", 109, 128]]], ["Isolated proteins were analyzed for presence of GFP (e.g GFP-Npro) as well as FLAG using western blot using anti-GPF or anti-FLAG antibodies.", [["GFP", "GENE_OR_GENE_PRODUCT", 48, 51], ["e.g GFP-Npro", "GENE_OR_GENE_PRODUCT", 53, 65], ["FLAG", "GENE_OR_GENE_PRODUCT", 78, 82], ["anti-GPF", "GENE_OR_GENE_PRODUCT", 108, 116], ["anti-FLAG", "GENE_OR_GENE_PRODUCT", 120, 129], ["GFP", "PROTEIN", 48, 51], ["GFP", "PROTEIN", 57, 60], ["Npro", "PROTEIN", 61, 65], ["FLAG", "PROTEIN", 78, 82], ["anti-GPF", "PROTEIN", 108, 116], ["anti-FLAG antibodies", "PROTEIN", 120, 140], ["Isolated proteins", "TEST", 0, 17], ["GFP", "TEST", 48, 51], ["GFP", "TEST", 57, 60], ["anti-GPF", "TREATMENT", 108, 116], ["anti-FLAG antibodies", "TREATMENT", 120, 140]]], ["The mock transfected 293T cells were used as negative control while cells transfected with pEGFP-C1-Npro plasmid were used as GFP-Npro positive control.", [["293T cells", "ANATOMY", 21, 31], ["cells", "ANATOMY", 68, 73], ["293T cells", "CELL", 21, 31], ["cells", "CELL", 68, 73], ["pEGFP-C1", "GENE_OR_GENE_PRODUCT", 91, 99], ["GFP", "GENE_OR_GENE_PRODUCT", 126, 129], ["mock transfected 293T cells", "CELL_LINE", 4, 31], ["pEGFP-C1-Npro plasmid", "DNA", 91, 112], ["GFP", "PROTEIN", 126, 129], ["The mock transfected 293T cells", "TREATMENT", 0, 31], ["pEGFP", "TEST", 91, 96], ["Npro plasmid", "TREATMENT", 100, 112], ["GFP", "TEST", 126, 129]]], ["Lane (1) The 293T cells without co-transfection did not show the presence of GFP-Npro or FLAG-S100A9, Lane (2) cells transfected with pEGFP-C1-Npro alone and showed the presence of GFP-Npro, Lane (3) cells transfected with p3XFLAG -S100A9 and showed the presence of S100A9, Lane (4) cells were co transfected with empty p3XFLAG along with pEGFP C1-Npro and did not show the presence of Npro (the FLAG size was 8 aa and was seen at very lower side of the gel).", [["293T cells", "ANATOMY", 13, 23], ["Lane (2) cells", "ANATOMY", 102, 116], ["Lane (3) cells", "ANATOMY", 191, 205], ["Lane (4) cells", "ANATOMY", 274, 288], ["pEGFP-C1-Npro", "CHEMICAL", 134, 147], ["293T cells", "CELL", 13, 23], ["GFP-Npro", "GENE_OR_GENE_PRODUCT", 77, 85], ["FLAG-S100A9", "GENE_OR_GENE_PRODUCT", 89, 100], ["cells", "CELL", 111, 116], ["pEGFP-C1-Npro", "GENE_OR_GENE_PRODUCT", 134, 147], ["GFP", "GENE_OR_GENE_PRODUCT", 181, 184], ["Lane (3) cells", "CELL", 191, 205], ["p3XFLAG -S100A9", "GENE_OR_GENE_PRODUCT", 223, 238], ["S100A9", "GENE_OR_GENE_PRODUCT", 266, 272], ["Lane (4) cells", "CELL", 274, 288], ["p3XFLAG", "GENE_OR_GENE_PRODUCT", 320, 327], ["pEGFP", "GENE_OR_GENE_PRODUCT", 339, 344], ["Npro", "GENE_OR_GENE_PRODUCT", 386, 390], ["FLAG", "GENE_OR_GENE_PRODUCT", 396, 400], ["293T cells", "CELL_LINE", 13, 23], ["GFP", "PROTEIN", 77, 80], ["Npro", "PROTEIN", 81, 85], ["FLAG", "PROTEIN", 89, 93], ["S100A9", "PROTEIN", 94, 100], ["Lane (2) cells", "CELL_LINE", 102, 116], ["pEGFP", "PROTEIN", 134, 139], ["C1", "PROTEIN", 140, 142], ["Npro", "PROTEIN", 143, 147], ["GFP", "PROTEIN", 181, 184], ["Npro, Lane (3) cells", "CELL_LINE", 185, 205], ["p3XFLAG", "PROTEIN", 223, 230], ["S100A9", "PROTEIN", 232, 238], ["S100A9", "PROTEIN", 266, 272], ["Lane (4) cells", "CELL_LINE", 274, 288], ["p3XFLAG", "PROTEIN", 320, 327], ["pEGFP C1", "PROTEIN", 339, 347], ["Npro", "PROTEIN", 348, 352], ["Npro", "PROTEIN", 386, 390], ["FLAG", "PROTEIN", 396, 400], ["GFP", "TEST", 77, 80], ["FLAG", "TEST", 89, 93], ["pEGFP", "TEST", 134, 139], ["GFP", "TEST", 181, 184], ["p3XFLAG", "TEST", 223, 230], ["empty p3XFLAG", "TREATMENT", 314, 327], ["the FLAG size", "TEST", 392, 405], ["S100A9", "OBSERVATION", 266, 272], ["size", "OBSERVATION_MODIFIER", 401, 405]]], ["Lane (5) Cell lysates from cells cotransfected with p3XFLAG S100A9 along with pEGFP C1-Npro which showed the presence of S100A9 as well as Npro.", [["Cell lysates", "ANATOMY", 9, 21], ["cells", "ANATOMY", 27, 32], ["Cell lysates", "CELL", 9, 21], ["cells", "CELL", 27, 32], ["p3XFLAG S100A9", "GENE_OR_GENE_PRODUCT", 52, 66], ["pEGFP", "GENE_OR_GENE_PRODUCT", 78, 83], ["S100A9", "GENE_OR_GENE_PRODUCT", 121, 127], ["Npro", "GENE_OR_GENE_PRODUCT", 139, 143], ["p3XFLAG S100A9", "PROTEIN", 52, 66], ["pEGFP C1", "PROTEIN", 78, 86], ["Npro", "PROTEIN", 87, 91], ["S100A9", "PROTEIN", 121, 127], ["Npro", "PROTEIN", 139, 143], ["Cell lysates from cells cotransfected", "TREATMENT", 9, 46], ["p3XFLAG S100A9", "TEST", 52, 66], ["S100A9", "OBSERVATION", 121, 127]]], ["Inhibition of bovine S100A9 by small interfering RNA (siRNA)-enhanced virus replication.", [["bovine", "ORGANISM", 14, 20], ["S100A9", "GENE_OR_GENE_PRODUCT", 21, 27], ["small interfering RNA", "GENE_OR_GENE_PRODUCT", 31, 52], ["bovine S100A9", "PROTEIN", 14, 27], ["bovine", "SPECIES", 14, 20], ["bovine", "SPECIES", 14, 20], ["Inhibition of bovine S100A9", "TEST", 0, 27], ["small interfering RNA", "PROBLEM", 31, 52], ["enhanced virus replication", "TREATMENT", 61, 87], ["small", "OBSERVATION_MODIFIER", 31, 36], ["interfering RNA", "OBSERVATION", 37, 52]]], ["The S100 A9 knock down or control MDBK cells were infected with ncpBVDV2a 1373 with MOI of 1.", [["MDBK cells", "ANATOMY", 34, 44], ["S100 A9", "GENE_OR_GENE_PRODUCT", 4, 11], ["MDBK cells", "CELL", 34, 44], ["MDBK cells", "CELL_LINE", 34, 44], ["MDBK", "SPECIES", 34, 38], ["The S100", "TEST", 0, 8], ["MDBK cells", "PROBLEM", 34, 44], ["ncpBVDV2a", "TEST", 64, 73], ["MOI", "TEST", 84, 87]]], ["The supernatant was collected at 12 h, 24 h, 36 h or 60 h post infection and analyzed for BVDV viral titer.", [["supernatant", "ANATOMY", 4, 15], ["BVDV", "ORGANISM", 90, 94], ["BVDV", "SPECIES", 90, 94], ["infection", "PROBLEM", 63, 72], ["BVDV viral titer", "PROBLEM", 90, 106], ["infection", "OBSERVATION", 63, 72], ["viral titer", "OBSERVATION", 95, 106]]], ["There was a significant increase in viral production by 1.5 log10 at 24 h (p < 0.05) in S100A9 knocked out cells while at 36 h in S100A9 knock out cells also increased (0.5 log 10 ) virus production compared to scrambled siRNA-transfected cells.", [["cells", "ANATOMY", 107, 112], ["cells", "ANATOMY", 147, 152], ["cells", "ANATOMY", 239, 244], ["S100A9", "GENE_OR_GENE_PRODUCT", 88, 94], ["cells", "CELL", 107, 112], ["S100A9", "GENE_OR_GENE_PRODUCT", 130, 136], ["cells", "CELL", 147, 152], ["cells", "CELL", 239, 244], ["S100A9", "PROTEIN", 88, 94], ["S100A9", "PROTEIN", 130, 136], ["scrambled siRNA-transfected cells", "CELL_LINE", 211, 244], ["a significant increase in viral production", "PROBLEM", 10, 52], ["S100A9 knock out cells", "TEST", 130, 152], ["virus production", "PROBLEM", 182, 198], ["scrambled siRNA", "PROBLEM", 211, 226], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["increase", "OBSERVATION_MODIFIER", 24, 32], ["viral production", "OBSERVATION", 36, 52], ["increased", "OBSERVATION_MODIFIER", 158, 167], ["transfected cells", "OBSERVATION", 227, 244]]], ["Error bars are SEM. attractant protein-1, chemokine ligand 1 (CXCL1 or GRO-\u03b1), type 1 IFN [49] [50] [51] ; vascular endothelial growth factor (VEGF), granulocyte-macrophage colony-stimulating factor (GMCSF) and matrix metalloproteinases (MMP2 and MMP9) [52] with upregulated adhesion molecules and antiapoptotic proteins such as B-cell CLL/lymphoma-2, Bcl-XL [53] .DiscussionSince S100A9 is integral to so many important immune pathways, it is a \"logical\" target for viral protein interference with cell defense mechanisms [54] .", [["B-cell CLL", "ANATOMY", 329, 339], ["cell", "ANATOMY", 499, 503], ["attractant protein-1", "GENE_OR_GENE_PRODUCT", 20, 40], ["chemokine ligand 1", "GENE_OR_GENE_PRODUCT", 42, 60], ["CXCL1", "GENE_OR_GENE_PRODUCT", 62, 67], ["GRO-\u03b1", "GENE_OR_GENE_PRODUCT", 71, 76], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 107, 141], ["VEGF", "GENE_OR_GENE_PRODUCT", 143, 147], ["granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 150, 198], ["GMCSF", "GENE_OR_GENE_PRODUCT", 200, 205], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 211, 236], ["MMP2", "GENE_OR_GENE_PRODUCT", 238, 242], ["MMP9", "GENE_OR_GENE_PRODUCT", 247, 251], ["B-cell CLL", "CANCER", 329, 339], ["lymphoma-2", "GENE_OR_GENE_PRODUCT", 340, 350], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 352, 358], ["S100A9", "GENE_OR_GENE_PRODUCT", 381, 387], ["cell", "CELL", 499, 503], ["attractant protein-1", "PROTEIN", 20, 40], ["chemokine ligand 1", "PROTEIN", 42, 60], ["CXCL1", "PROTEIN", 62, 67], ["GRO-\u03b1", "PROTEIN", 71, 76], ["vascular endothelial growth factor", "PROTEIN", 107, 141], ["VEGF", "PROTEIN", 143, 147], ["granulocyte-macrophage colony-stimulating factor", "PROTEIN", 150, 198], ["GMCSF", "PROTEIN", 200, 205], ["matrix metalloproteinases", "PROTEIN", 211, 236], ["MMP2", "PROTEIN", 238, 242], ["MMP9", "PROTEIN", 247, 251], ["adhesion molecules", "PROTEIN", 275, 293], ["antiapoptotic proteins", "PROTEIN", 298, 320], ["Bcl-XL", "PROTEIN", 352, 358], ["S100A9", "PROTEIN", 381, 387], ["viral protein", "PROTEIN", 467, 480], ["attractant protein", "TEST", 20, 38], ["chemokine ligand", "TEST", 42, 58], ["CXCL1", "TEST", 62, 67], ["GRO-\u03b1", "TEST", 71, 76], ["vascular endothelial growth factor", "TEST", 107, 141], ["VEGF", "TEST", 143, 147], ["granulocyte", "TEST", 150, 161], ["macrophage colony", "TEST", 162, 179], ["stimulating factor", "PROBLEM", 180, 198], ["GMCSF", "TEST", 200, 205], ["matrix metalloproteinases", "TEST", 211, 236], ["MMP2", "TEST", 238, 242], ["MMP9", "TEST", 247, 251], ["upregulated adhesion molecules", "PROBLEM", 263, 293], ["antiapoptotic proteins", "PROBLEM", 298, 320], ["B-cell CLL/lymphoma", "PROBLEM", 329, 348], ["Bcl-XL", "TEST", 352, 358], ["viral protein interference", "PROBLEM", 467, 493], ["SEM", "OBSERVATION", 15, 18], ["vascular endothelial", "ANATOMY", 107, 127], ["granulocyte", "ANATOMY", 150, 161], ["macrophage colony", "OBSERVATION", 162, 179], ["cell CLL", "OBSERVATION", 331, 339], ["lymphoma", "OBSERVATION", 340, 348]]], ["In this study, virus titer increased by one log in the absence of S100A9; whereas, overexpression of S100A9 in cells infected with ncp BVDV2a-1373 overcame the interferon inhibition.", [["cells", "ANATOMY", 111, 116], ["BVDV2a-1373", "CHEMICAL", 135, 146], ["BVDV2a-1373", "CHEMICAL", 135, 146], ["S100A9", "GENE_OR_GENE_PRODUCT", 66, 72], ["S100A9", "GENE_OR_GENE_PRODUCT", 101, 107], ["cells", "CELL", 111, 116], ["interferon", "GENE_OR_GENE_PRODUCT", 160, 170], ["S100A9", "PROTEIN", 66, 72], ["S100A9", "PROTEIN", 101, 107], ["interferon", "PROTEIN", 160, 170], ["this study", "TEST", 3, 13], ["virus titer", "PROBLEM", 15, 26], ["ncp BVDV2a", "TEST", 131, 141], ["the interferon inhibition", "TREATMENT", 156, 181]]], ["This is consistent with Npro inhibition of IFN-1 through a dual mechanism that includes degradation of IRF-3 in the proteasome [33] .DiscussionThe results of this study indicated that S100A9 interacted with ncp BVDV2a-1373 Npro.", [["BVDV2a-1373 Npro", "CHEMICAL", 211, 227], ["Npro", "SIMPLE_CHEMICAL", 24, 28], ["IFN-1", "GENE_OR_GENE_PRODUCT", 43, 48], ["IRF-3", "GENE_OR_GENE_PRODUCT", 103, 108], ["S100A9", "GENE_OR_GENE_PRODUCT", 184, 190], ["IFN-1", "PROTEIN", 43, 48], ["IRF-3", "PROTEIN", 103, 108], ["proteasome", "PROTEIN", 116, 126], ["S100A9", "PROTEIN", 184, 190], ["ncp BVDV2a", "PROTEIN", 207, 217], ["1373 Npro", "PROTEIN", 218, 227], ["Npro inhibition of IFN", "PROBLEM", 24, 46], ["a dual mechanism", "PROBLEM", 57, 73], ["degradation of IRF", "PROBLEM", 88, 106], ["this study", "TEST", 158, 168], ["ncp BVDV2a", "TEST", 207, 217], ["consistent with", "UNCERTAINTY", 8, 23], ["IRF", "OBSERVATION", 103, 106]]], ["The interaction of BVDV2a-1373 Npro with cellular S100A9, potentially reduced the availability of S100A9 and therefore reduced the type 1 interferon production.", [["cellular", "ANATOMY", 41, 49], ["BVDV2a-1373", "CHEMICAL", 19, 30], ["BVDV2a-1373", "CHEMICAL", 19, 30], ["BVDV2a-1373 Npro", "GENE_OR_GENE_PRODUCT", 19, 35], ["cellular S100A9", "GENE_OR_GENE_PRODUCT", 41, 56], ["S100A9", "GENE_OR_GENE_PRODUCT", 98, 104], ["type 1 interferon", "GENE_OR_GENE_PRODUCT", 131, 148], ["BVDV2a", "PROTEIN", 19, 25], ["1373 Npro", "PROTEIN", 26, 35], ["cellular S100A9", "PROTEIN", 41, 56], ["S100A9", "PROTEIN", 98, 104], ["interferon", "PROTEIN", 138, 148], ["BVDV2a", "TEST", 19, 25], ["the type 1 interferon production", "PROBLEM", 127, 159], ["reduced", "OBSERVATION_MODIFIER", 70, 77]]], ["Hilton et al., 2006 [55] and Chen et al., 2007 [56] found that NPro blocks IRF-3 from binding to DNA.", [["NPro", "CHEMICAL", 63, 67], ["NPro", "SIMPLE_CHEMICAL", 63, 67], ["IRF-3", "GENE_OR_GENE_PRODUCT", 75, 80], ["DNA", "CELLULAR_COMPONENT", 97, 100], ["IRF-3", "PROTEIN", 75, 80], ["NPro blocks IRF", "PROBLEM", 63, 78], ["IRF", "OBSERVATION", 75, 78]]], ["Additionally, NPro has the property of targeting IRF-3 for polyubiquitination and subsequent destruction by cellular multicatalytic proteasomes, indicating that Npro induces immune suppression through multiple pathways that need to be further explored.DiscussionIt has been suggested that BVDV infection, in persistently infected (PI) animals, may lead to immunosuppression through neutrophil dysfunction [57] .", [["cellular", "ANATOMY", 108, 116], ["neutrophil", "ANATOMY", 382, 392], ["NPro", "CHEMICAL", 14, 18], ["Npro", "CHEMICAL", 161, 165], ["BVDV infection", "DISEASE", 289, 303], ["neutrophil dysfunction", "DISEASE", 382, 404], ["NPro", "SIMPLE_CHEMICAL", 14, 18], ["IRF-3", "GENE_OR_GENE_PRODUCT", 49, 54], ["cellular", "CELL", 108, 116], ["Npro", "GENE_OR_GENE_PRODUCT", 161, 165], ["BVDV", "ORGANISM", 289, 293], ["neutrophil", "CELL", 382, 392], ["NPro", "PROTEIN", 14, 18], ["IRF-3", "PROTEIN", 49, 54], ["cellular multicatalytic proteasomes", "PROTEIN", 108, 143], ["Npro", "PROTEIN", 161, 165], ["BVDV", "SPECIES", 289, 293], ["targeting IRF", "PROBLEM", 39, 52], ["polyubiquitination", "PROBLEM", 59, 77], ["subsequent destruction", "PROBLEM", 82, 104], ["cellular multicatalytic proteasomes", "PROBLEM", 108, 143], ["immune suppression", "PROBLEM", 174, 192], ["BVDV infection", "PROBLEM", 289, 303], ["immunosuppression", "TREATMENT", 356, 373], ["neutrophil dysfunction", "PROBLEM", 382, 404], ["IRF", "OBSERVATION", 49, 52], ["destruction", "OBSERVATION", 93, 104], ["multicatalytic proteasomes", "OBSERVATION", 117, 143], ["BVDV", "OBSERVATION_MODIFIER", 289, 293], ["infection", "OBSERVATION", 294, 303]]], ["Modified live BVDV cp strains caused a decrease in circulating lymphocytes and neutrophils and also suppressed neutrophil functions [58, 59] .", [["lymphocytes", "ANATOMY", 63, 74], ["neutrophils", "ANATOMY", 79, 90], ["neutrophil", "ANATOMY", 111, 121], ["BVDV cp", "ORGANISM", 14, 21], ["lymphocytes", "CELL", 63, 74], ["neutrophils", "CELL", 79, 90], ["neutrophil", "CELL", 111, 121], ["circulating lymphocytes", "CELL_TYPE", 51, 74], ["neutrophils", "CELL_TYPE", 79, 90], ["BVDV cp", "SPECIES", 14, 21], ["Modified live BVDV cp strains", "PROBLEM", 0, 29], ["a decrease in circulating lymphocytes", "PROBLEM", 37, 74], ["neutrophils", "TEST", 79, 90], ["neutrophil functions", "TEST", 111, 131], ["decrease", "OBSERVATION_MODIFIER", 39, 47], ["circulating lymphocytes", "OBSERVATION", 51, 74], ["neutrophil functions", "OBSERVATION", 111, 131]]], ["These effects could be explained by the interaction of S100A9 with the virus Npro, as S100A9 has a major role in the migration of phagocytes [60, 61] and neutrophil oxidative burst [62] .", [["phagocytes", "ANATOMY", 130, 140], ["neutrophil", "ANATOMY", 154, 164], ["S100A9", "GENE_OR_GENE_PRODUCT", 55, 61], ["Npro", "GENE_OR_GENE_PRODUCT", 77, 81], ["S100A9", "GENE_OR_GENE_PRODUCT", 86, 92], ["phagocytes", "CELL", 130, 140], ["neutrophil", "CELL", 154, 164], ["S100A9", "PROTEIN", 55, 61], ["virus Npro", "PROTEIN", 71, 81], ["S100A9", "PROTEIN", 86, 92], ["phagocytes", "CELL_TYPE", 130, 140], ["neutrophil", "CELL_TYPE", 154, 164], ["neutrophil oxidative burst", "TEST", 154, 180], ["migration", "OBSERVATION_MODIFIER", 117, 126]]], ["Additionally, an important sequela of BVDV infection is the increase in secondary bacterial infection [63] .", [["BVDV infection", "DISEASE", 38, 52], ["bacterial infection", "DISEASE", 82, 101], ["BVDV", "ORGANISM", 38, 42], ["BVDV", "SPECIES", 38, 42], ["BVDV infection", "PROBLEM", 38, 52], ["secondary bacterial infection", "PROBLEM", 72, 101], ["important", "OBSERVATION_MODIFIER", 17, 26], ["sequela", "OBSERVATION_MODIFIER", 27, 34], ["BVDV", "OBSERVATION_MODIFIER", 38, 42], ["infection", "OBSERVATION", 43, 52], ["increase", "OBSERVATION_MODIFIER", 60, 68], ["secondary", "OBSERVATION_MODIFIER", 72, 81], ["bacterial", "OBSERVATION_MODIFIER", 82, 91], ["infection", "OBSERVATION", 92, 101]]], ["Interaction of Npro with S100A9 protein could have potent antimicrobial and chemotactic effects that could increase the incidence of secondary infections [60] .", [["infections", "DISEASE", 143, 153], ["Npro", "GENE_OR_GENE_PRODUCT", 15, 19], ["S100A9", "GENE_OR_GENE_PRODUCT", 25, 31], ["Npro", "PROTEIN", 15, 19], ["S100A9 protein", "PROTEIN", 25, 39], ["S100A9 protein", "TREATMENT", 25, 39], ["potent antimicrobial", "TREATMENT", 51, 71], ["chemotactic effects", "TREATMENT", 76, 95], ["secondary infections", "PROBLEM", 133, 153], ["secondary", "OBSERVATION_MODIFIER", 133, 142], ["infections", "OBSERVATION", 143, 153]]], ["S100A8/S100A9 functions as an endogenous TLR4 ligand that is essential to the amplification of lipopolysaccharide (LPS) effects on phagocytes upstream of TNF-\u03b1 [64] .", [["phagocytes", "ANATOMY", 131, 141], ["lipopolysaccharide", "CHEMICAL", 95, 113], ["LPS", "CHEMICAL", 115, 118], ["S100A8", "GENE_OR_GENE_PRODUCT", 0, 6], ["S100A9", "GENE_OR_GENE_PRODUCT", 7, 13], ["TLR4", "GENE_OR_GENE_PRODUCT", 41, 45], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 95, 113], ["LPS", "SIMPLE_CHEMICAL", 115, 118], ["phagocytes", "CELL", 131, 141], ["TNF", "GENE_OR_GENE_PRODUCT", 154, 157], ["S100A8", "PROTEIN", 0, 6], ["S100A9", "PROTEIN", 7, 13], ["TLR4 ligand", "PROTEIN", 41, 52], ["phagocytes", "CELL_TYPE", 131, 141], ["TNF", "PROTEIN", 154, 157], ["S100A8", "TEST", 0, 6], ["an endogenous TLR4 ligand", "PROBLEM", 27, 52], ["lipopolysaccharide (LPS", "TREATMENT", 95, 118], ["phagocytes upstream", "TEST", 131, 150], ["TNF", "TEST", 154, 157]]], ["One study showed a decline in S100A8/S100A9 levels in patients that survived sepsis, whereas nonsurvivors had increased serum levels of S100A8/S100A9 [65] .", [["serum", "ANATOMY", 120, 125], ["sepsis", "DISEASE", 77, 83], ["S100A8", "GENE_OR_GENE_PRODUCT", 30, 36], ["S100A9", "GENE_OR_GENE_PRODUCT", 37, 43], ["patients", "ORGANISM", 54, 62], ["serum", "ORGANISM_SUBSTANCE", 120, 125], ["S100A8", "GENE_OR_GENE_PRODUCT", 136, 142], ["S100A9", "GENE_OR_GENE_PRODUCT", 143, 149], ["S100A8", "PROTEIN", 30, 36], ["S100A9", "PROTEIN", 37, 43], ["S100A8", "PROTEIN", 136, 142], ["S100A9", "PROTEIN", 143, 149], ["patients", "SPECIES", 54, 62], ["One study", "TEST", 0, 9], ["a decline in S100A8/S100A9 levels", "PROBLEM", 17, 50], ["sepsis", "PROBLEM", 77, 83], ["serum levels", "TEST", 120, 132], ["S100A8", "TEST", 136, 142], ["S100A9", "TEST", 143, 149], ["decline", "OBSERVATION_MODIFIER", 19, 26], ["sepsis", "OBSERVATION", 77, 83]]], ["This higher mortality with BVDV mucosal disease where sudden death often occurs could also be due to an increase level of S100A9 that amplifies the inflammatory response, thus increasing the chance of endotoxic shock.", [["mucosal", "ANATOMY", 32, 39], ["BVDV mucosal disease", "DISEASE", 27, 47], ["sudden death", "DISEASE", 54, 66], ["endotoxic shock", "DISEASE", 201, 216], ["BVDV", "ORGANISM", 27, 31], ["mucosal", "ORGAN", 32, 39], ["S100A9", "GENE_OR_GENE_PRODUCT", 122, 128], ["S100A9", "PROTEIN", 122, 128], ["BVDV", "SPECIES", 27, 31], ["BVDV mucosal disease", "PROBLEM", 27, 47], ["sudden death", "PROBLEM", 54, 66], ["an increase level of S100A9", "PROBLEM", 101, 128], ["the inflammatory response", "PROBLEM", 144, 169], ["endotoxic shock", "PROBLEM", 201, 216], ["BVDV mucosal disease", "OBSERVATION", 27, 47], ["could also be due to", "UNCERTAINTY", 80, 100], ["increase", "OBSERVATION_MODIFIER", 104, 112], ["inflammatory", "OBSERVATION_MODIFIER", 148, 160], ["endotoxic shock", "OBSERVATION", 201, 216]]], ["The interaction of BVDV Npro with S100A9 found in this study creates several questions that need to be answered regarding BVDV pathogenesis and role of DAMPs in viral infection.ConclusionBovine viral diarrhea virus (BVDV) is an immunosuppressive virus.ConclusionThere are a number of studies which demonstrated that the nonstructural protein Npro, is responsible for its immunosuppressive effect.", [["viral infection", "DISEASE", 161, 176], ["ConclusionBovine viral diarrhea", "DISEASE", 177, 208], ["BVDV", "ORGANISM", 19, 23], ["Npro", "GENE_OR_GENE_PRODUCT", 24, 28], ["S100A9", "GENE_OR_GENE_PRODUCT", 34, 40], ["BVDV", "ORGANISM", 122, 126], ["DAMPs", "GENE_OR_GENE_PRODUCT", 152, 157], ["ConclusionBovine viral diarrhea virus", "ORGANISM", 177, 214], ["BVDV", "ORGANISM", 216, 220], ["Npro", "GENE_OR_GENE_PRODUCT", 342, 346], ["BVDV Npro", "PROTEIN", 19, 28], ["S100A9", "PROTEIN", 34, 40], ["DAMPs", "PROTEIN", 152, 157], ["nonstructural protein Npro", "PROTEIN", 320, 346], ["ConclusionBovine viral diarrhea virus", "SPECIES", 177, 214], ["BVDV", "SPECIES", 216, 220], ["BVDV", "SPECIES", 19, 23], ["BVDV", "SPECIES", 122, 126], ["ConclusionBovine viral diarrhea virus", "SPECIES", 177, 214], ["BVDV", "SPECIES", 216, 220], ["this study", "TEST", 50, 60], ["BVDV pathogenesis", "PROBLEM", 122, 139], ["DAMPs", "PROBLEM", 152, 157], ["viral infection", "PROBLEM", 161, 176], ["ConclusionBovine viral diarrhea virus", "PROBLEM", 177, 214], ["BVDV", "PROBLEM", 216, 220], ["an immunosuppressive virus", "PROBLEM", 225, 251], ["studies", "TEST", 284, 291], ["the nonstructural protein Npro", "PROBLEM", 316, 346], ["its immunosuppressive effect", "PROBLEM", 367, 395], ["viral infection", "OBSERVATION", 161, 176], ["diarrhea virus", "OBSERVATION", 200, 214], ["immunosuppressive virus", "OBSERVATION", 228, 251], ["responsible for", "UNCERTAINTY", 351, 366], ["immunosuppressive effect", "OBSERVATION", 371, 395]]], ["However, very little is known of the mechanism of how Npro protein induces immunosuppression.", [["Npro", "GENE_OR_GENE_PRODUCT", 54, 58], ["Npro protein", "PROTEIN", 54, 66], ["immunosuppression", "TREATMENT", 75, 92]]], ["The current study demonstrated that Npro interacts with the cellular S100A9 protein.", [["cellular", "ANATOMY", 60, 68], ["Npro", "GENE_OR_GENE_PRODUCT", 36, 40], ["cellular", "CELL", 60, 68], ["S100A9", "GENE_OR_GENE_PRODUCT", 69, 75], ["Npro", "PROTEIN", 36, 40], ["cellular S100A9 protein", "PROTEIN", 60, 83], ["The current study", "TEST", 0, 17]]], ["S100A9 is a member of the danger associated molecular patterns (DAMPs) and play an important role in innate immune response.", [["S100A9", "GENE_OR_GENE_PRODUCT", 0, 6], ["danger associated molecular patterns", "GENE_OR_GENE_PRODUCT", 26, 62], ["DAMPs", "GENE_OR_GENE_PRODUCT", 64, 69], ["S100A9", "PROTEIN", 0, 6], ["danger associated molecular patterns", "PROTEIN", 26, 62], ["DAMPs", "PROTEIN", 64, 69]]], ["Interaction of BVDV Npro with cellular S100A9 protein, potentially reduced its availability/activity in virus infected cells leading to reduced type 1 interferon production and higher virus production.", [["cellular", "ANATOMY", 30, 38], ["cells", "ANATOMY", 119, 124], ["BVDV", "ORGANISM", 15, 19], ["Npro", "GENE_OR_GENE_PRODUCT", 20, 24], ["cellular S100A9", "GENE_OR_GENE_PRODUCT", 30, 45], ["cells", "CELL", 119, 124], ["type 1 interferon", "GENE_OR_GENE_PRODUCT", 144, 161], ["BVDV Npro", "PROTEIN", 15, 24], ["cellular S100A9 protein", "PROTEIN", 30, 53], ["virus infected cells", "CELL_TYPE", 104, 124], ["interferon", "PROTEIN", 151, 161], ["BVDV", "SPECIES", 15, 19], ["BVDV", "PROBLEM", 15, 19], ["cellular S100A9 protein", "TEST", 30, 53], ["virus infected cells", "PROBLEM", 104, 124], ["reduced type 1 interferon production", "PROBLEM", 136, 172], ["higher virus production", "PROBLEM", 177, 200], ["reduced", "OBSERVATION_MODIFIER", 67, 74]]], ["Overexpression of bovine S100A9 counteract the interferon Type-I interferon (IFN \u03b1/\u03b2) inhibition induced by ncp BVDV2a 1373.", [["ncp BVDV2a 1373", "CHEMICAL", 108, 123], ["bovine", "ORGANISM", 18, 24], ["S100A9", "GENE_OR_GENE_PRODUCT", 25, 31], ["Type-I interferon", "GENE_OR_GENE_PRODUCT", 58, 75], ["IFN \u03b1", "GENE_OR_GENE_PRODUCT", 77, 82], ["\u03b2", "GENE_OR_GENE_PRODUCT", 83, 84], ["bovine S100A9", "PROTEIN", 18, 31], ["interferon Type-I interferon", "PROTEIN", 47, 75], ["IFN \u03b1/\u03b2", "PROTEIN", 77, 84], ["bovine", "SPECIES", 18, 24], ["Overexpression of bovine S100A9", "TREATMENT", 0, 31], ["the interferon Type-I interferon (IFN \u03b1/\u03b2) inhibition", "TREATMENT", 43, 96]]], ["The S100A9 over expressed or S100A9 knock out cells were infected with ncp BVDV2a-1373 with MOI of 5 for 24 h while control cells were mock treated or treated with poly I:C. After 24 h infection/treatment, supernatant was collected and examined for type 1 interferon expression through firefly luciferase activity in NCL-1-ISRE-Luc-Hygro cells.", [["cells", "ANATOMY", 46, 51], ["cells", "ANATOMY", 124, 129], ["supernatant", "ANATOMY", 206, 217], ["NCL-1-ISRE-Luc-Hygro cells", "ANATOMY", 317, 343], ["BVDV2a-1373", "CHEMICAL", 75, 86], ["infection", "DISEASE", 185, 194], ["BVDV2a-1373", "CHEMICAL", 75, 86], ["S100A9", "GENE_OR_GENE_PRODUCT", 4, 10], ["S100A9", "GENE_OR_GENE_PRODUCT", 29, 35], ["cells", "CELL", 46, 51], ["cells", "CELL", 124, 129], ["type 1 interferon", "GENE_OR_GENE_PRODUCT", 249, 266], ["luciferase", "GENE_OR_GENE_PRODUCT", 294, 304], ["NCL-1", "GENE_OR_GENE_PRODUCT", 317, 322], ["Luc-Hygro cells", "CELL", 328, 343], ["S100A9", "PROTEIN", 4, 10], ["S100A9", "PROTEIN", 29, 35], ["interferon", "PROTEIN", 256, 266], ["luciferase", "PROTEIN", 294, 304], ["NCL-1-ISRE-Luc-Hygro cells", "CELL_LINE", 317, 343], ["S100A9 knock out cells", "PROBLEM", 29, 51], ["ncp BVDV2a", "TEST", 71, 81], ["MOI", "TEST", 92, 95], ["24 h infection", "PROBLEM", 180, 194], ["treatment", "TREATMENT", 195, 204], ["supernatant", "TREATMENT", 206, 217], ["type 1 interferon expression", "TREATMENT", 249, 277], ["firefly luciferase activity", "TEST", 286, 313], ["NCL", "TEST", 317, 320], ["infection", "OBSERVATION", 185, 194], ["Hygro cells", "OBSERVATION", 332, 343]]], ["The control cell treated with poly I:C, S100A9 over expressed or S100A9 knock out cells infected with ncp BVDV2a-1373 showed significantly higher IFN \u03b1/\u03b2 as compare to mock-infected/treated control cell {*}, p < 0.05.", [["cell", "ANATOMY", 12, 16], ["cells", "ANATOMY", 82, 87], ["cell", "ANATOMY", 198, 202], ["BVDV2a-1373", "CHEMICAL", 106, 117], ["BVDV2a-1373", "CHEMICAL", 106, 117], ["cell", "CELL", 12, 16], ["poly I:C", "SIMPLE_CHEMICAL", 30, 38], ["S100A9", "GENE_OR_GENE_PRODUCT", 40, 46], ["S100A9", "GENE_OR_GENE_PRODUCT", 65, 71], ["cells", "CELL", 82, 87], ["IFN \u03b1", "GENE_OR_GENE_PRODUCT", 146, 151], ["\u03b2", "GENE_OR_GENE_PRODUCT", 152, 153], ["cell {*}", "CELL", 198, 206], ["S100A9", "PROTEIN", 40, 46], ["S100A9", "PROTEIN", 65, 71], ["IFN \u03b1", "PROTEIN", 146, 151], ["\u03b2", "PROTEIN", 152, 153], ["ncp BVDV2a", "TEST", 102, 112], ["significantly higher IFN \u03b1/\u03b2", "PROBLEM", 125, 153], ["mock", "TEST", 168, 172]]], ["While S100A9 overexpressed cells infected with ncp BVDV2a-1373 had significantly higher IFN \u03b1/\u03b2 as compared to S100A9 knock out cells infected with ncp BVDV2a-1373 or cells treated with poly I:C {**}, p < 0.05.", [["cells", "ANATOMY", 27, 32], ["cells", "ANATOMY", 128, 133], ["ncp BVDV2a-1373", "ANATOMY", 148, 163], ["cells", "ANATOMY", 167, 172], ["BVDV2a-1373", "CHEMICAL", 51, 62], ["BVDV2a-1373", "CHEMICAL", 152, 163], ["BVDV2a-1373", "CHEMICAL", 51, 62], ["S100A9", "GENE_OR_GENE_PRODUCT", 6, 12], ["cells", "CELL", 27, 32], ["IFN \u03b1", "GENE_OR_GENE_PRODUCT", 88, 93], ["\u03b2", "GENE_OR_GENE_PRODUCT", 94, 95], ["S100A9", "GENE_OR_GENE_PRODUCT", 111, 117], ["cells", "CELL", 128, 133], ["ncp BVDV2a-1373", "CELL", 148, 163], ["cells", "CELL", 167, 172], ["S100A9", "PROTEIN", 6, 12], ["IFN \u03b1", "PROTEIN", 88, 93], ["\u03b2", "PROTEIN", 94, 95], ["S100A9", "PROTEIN", 111, 117], ["BVDV2a", "PROTEIN", 152, 158], ["ncp BVDV2a-1373", "SPECIES", 47, 62], ["ncp BVDV2a", "TEST", 47, 57], ["significantly higher IFN \u03b1/\u03b2", "PROBLEM", 67, 95], ["cells infected", "PROBLEM", 128, 142], ["ncp BVDV2a", "TEST", 148, 158], ["p", "TEST", 201, 202]]]], "229c14218c264e64c209ba8022c636d52fe8f279": [["(Continued from previous page)Conclusions: Cytokine pre-activation enhanced the capacity of cryopreserved, XF-hMSCs to promote injury resolution following VILI, potentially via a KGF-dependent mechanism.(Continued from previous page)Keywords: Acute respiratory distress syndrome, Ventilation-induced lung injury, Injury resolution and repair, Mesenchymal stem/stromal cells, Cryopreservation, Cell activation Background Mechanical ventilation is a potentially life-saving manoeuvre in patients with acute respiratory distress syndrome (ARDS) [1, 2] , but it can also exacerbate lung damage-this is termed ventilation-induced lung injury (VILI) [3] .", [["XF-hMSCs", "ANATOMY", 107, 115], ["respiratory", "ANATOMY", 249, 260], ["lung", "ANATOMY", 300, 304], ["Mesenchymal stem/stromal cells", "ANATOMY", 343, 373], ["Cell", "ANATOMY", 393, 397], ["respiratory", "ANATOMY", 505, 516], ["lung", "ANATOMY", 578, 582], ["lung", "ANATOMY", 625, 629], ["respiratory distress syndrome", "DISEASE", 249, 278], ["lung injury", "DISEASE", 300, 311], ["Injury", "DISEASE", 313, 319], ["acute respiratory distress syndrome", "DISEASE", 499, 534], ["ARDS", "DISEASE", 536, 540], ["lung damage", "DISEASE", 578, 589], ["lung injury", "DISEASE", 625, 636], ["VILI", "DISEASE", 638, 642], ["Cytokine", "GENE_OR_GENE_PRODUCT", 43, 51], ["XF-hMSCs", "CELL", 107, 115], ["KGF", "GENE_OR_GENE_PRODUCT", 179, 182], ["lung", "ORGAN", 300, 304], ["Mesenchymal stem/stromal cells", "CELL", 343, 373], ["Cell", "CELL", 393, 397], ["patients", "ORGANISM", 485, 493], ["lung", "ORGAN", 578, 582], ["lung", "ORGAN", 625, 629], ["Cytokine", "PROTEIN", 43, 51], ["cryopreserved, XF-hMSCs", "CELL_LINE", 92, 115], ["KGF", "PROTEIN", 179, 182], ["Mesenchymal stem/stromal cells", "CELL_TYPE", 343, 373], ["patients", "SPECIES", 485, 493], ["XF-hMSCs", "TREATMENT", 107, 115], ["VILI", "PROBLEM", 155, 159], ["a KGF-dependent mechanism", "TREATMENT", 177, 202], ["Acute respiratory distress syndrome", "PROBLEM", 243, 278], ["Ventilation", "TREATMENT", 280, 291], ["lung injury", "PROBLEM", 300, 311], ["Injury resolution", "TREATMENT", 313, 330], ["repair", "TREATMENT", 335, 341], ["Mesenchymal stem/stromal cells", "TREATMENT", 343, 373], ["Cryopreservation", "TREATMENT", 375, 391], ["Cell activation", "TREATMENT", 393, 408], ["Mechanical ventilation", "TREATMENT", 420, 442], ["saving manoeuvre", "TREATMENT", 465, 481], ["acute respiratory distress syndrome", "PROBLEM", 499, 534], ["ARDS)", "PROBLEM", 536, 541], ["lung damage", "PROBLEM", 578, 589], ["lung injury", "PROBLEM", 625, 636], ["injury", "OBSERVATION", 127, 133], ["Acute", "OBSERVATION_MODIFIER", 243, 248], ["respiratory distress", "OBSERVATION", 249, 269], ["lung", "ANATOMY", 300, 304], ["injury", "OBSERVATION", 305, 311], ["Mesenchymal stem", "ANATOMY", 343, 359], ["stromal cells", "OBSERVATION", 360, 373], ["acute", "OBSERVATION_MODIFIER", 499, 504], ["respiratory", "ANATOMY", 505, 516], ["distress", "OBSERVATION", 517, 525], ["lung", "ANATOMY", 578, 582], ["damage", "OBSERVATION", 583, 589], ["ventilation", "OBSERVATION", 605, 616], ["lung", "ANATOMY", 625, 629], ["injury", "OBSERVATION", 630, 636]]], ["Mesenchymal stem/stromal cells (MSCs) demonstrate beneficial effects in diverse pre-clinical lung injury models including pulmonary [4] [5] [6] and abdominal sepsis [7] [8] [9] , bleomycin-induced acute lung injury [10] and fibrosis [11, 12] .", [["Mesenchymal stem/stromal cells", "ANATOMY", 0, 30], ["MSCs", "ANATOMY", 32, 36], ["lung", "ANATOMY", 93, 97], ["pulmonary", "ANATOMY", 122, 131], ["abdominal", "ANATOMY", 148, 157], ["lung", "ANATOMY", 203, 207], ["lung injury", "DISEASE", 93, 104], ["abdominal sepsis", "DISEASE", 148, 164], ["bleomycin", "CHEMICAL", 179, 188], ["acute lung injury", "DISEASE", 197, 214], ["fibrosis", "DISEASE", 224, 232], ["bleomycin", "CHEMICAL", 179, 188], ["Mesenchymal stem/stromal cells", "CELL", 0, 30], ["MSCs", "CELL", 32, 36], ["lung", "ORGAN", 93, 97], ["pulmonary", "ORGAN", 122, 131], ["5] [6]", "SIMPLE_CHEMICAL", 137, 143], ["abdominal", "ORGAN", 148, 157], ["[7] [8] [9]", "SIMPLE_CHEMICAL", 165, 176], ["bleomycin", "SIMPLE_CHEMICAL", 179, 188], ["lung", "ORGAN", 203, 207], ["Mesenchymal stem/stromal cells", "CELL_TYPE", 0, 30], ["MSCs", "CELL_TYPE", 32, 36], ["Mesenchymal stem/stromal cells (MSCs", "TREATMENT", 0, 36], ["beneficial effects", "PROBLEM", 50, 68], ["diverse pre-clinical lung injury models", "PROBLEM", 72, 111], ["abdominal sepsis", "PROBLEM", 148, 164], ["bleomycin", "TREATMENT", 179, 188], ["acute lung injury", "PROBLEM", 197, 214], ["fibrosis", "PROBLEM", 224, 232], ["stem", "ANATOMY", 12, 16], ["stromal cells", "OBSERVATION", 17, 30], ["diverse", "OBSERVATION_MODIFIER", 72, 79], ["lung", "ANATOMY", 93, 97], ["injury", "OBSERVATION", 98, 104], ["pulmonary", "ANATOMY", 122, 131], ["abdominal", "ANATOMY", 148, 157], ["sepsis", "OBSERVATION", 158, 164], ["acute", "OBSERVATION_MODIFIER", 197, 202], ["lung", "ANATOMY", 203, 207], ["injury", "OBSERVATION", 208, 214], ["fibrosis", "OBSERVATION", 224, 232]]], ["Human-derived MSCs (hMSCs) enhance injury resolution following established VILI [13, 14] , enhance recovery of human lungs ex vivo [15] and reduce the severity of Escherichia coli pneumonia [16] .", [["MSCs", "ANATOMY", 14, 18], ["hMSCs", "ANATOMY", 20, 25], ["lungs", "ANATOMY", 117, 122], ["Escherichia coli pneumonia", "DISEASE", 163, 189], ["Human", "ORGANISM", 0, 5], ["MSCs", "CELL", 14, 18], ["hMSCs", "CELL", 20, 25], ["human", "ORGANISM", 111, 116], ["lungs", "ORGAN", 117, 122], ["Escherichia coli", "ORGANISM", 163, 179], ["Human-derived MSCs", "CELL_TYPE", 0, 18], ["hMSCs", "CELL_TYPE", 20, 25], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 111, 116], ["Escherichia coli", "SPECIES", 163, 179], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 111, 116], ["Escherichia coli", "SPECIES", 163, 179], ["Human-derived MSCs (hMSCs)", "TREATMENT", 0, 26], ["Escherichia coli pneumonia", "PROBLEM", 163, 189], ["lungs", "ANATOMY", 117, 122], ["Escherichia coli pneumonia", "OBSERVATION", 163, 189]]], ["Finally, recent phase 1-2 studies suggest that allogeneic bone marrow-derived hMSCs (BM-hMSCs) can be safely administered to patients with moderate to severe ARDS [17, 18] .(Continued from previous page)In regard to clinical translation of hMSC therapies, concern exists that the cryopreservation and thawing processes may reduce the efficacy of hMSCs and its secretome [19] .", [["bone marrow", "ANATOMY", 58, 69], ["hMSCs", "ANATOMY", 78, 83], ["BM-hMSCs", "ANATOMY", 85, 93], ["hMSC", "ANATOMY", 240, 244], ["hMSCs", "ANATOMY", 346, 351], ["ARDS", "DISEASE", 158, 162], ["bone marrow-derived hMSCs", "CELL", 58, 83], ["BM-hMSCs", "CELL", 85, 93], ["patients", "ORGANISM", 125, 133], ["hMSC", "CELL", 240, 244], ["hMSCs", "CELL", 346, 351], ["allogeneic bone marrow-derived hMSCs", "CELL_LINE", 47, 83], ["BM", "CELL_TYPE", 85, 87], ["hMSCs", "CELL_TYPE", 88, 93], ["hMSCs", "CELL_TYPE", 346, 351], ["patients", "SPECIES", 125, 133], ["allogeneic bone marrow-derived hMSCs (BM-hMSCs)", "TREATMENT", 47, 94], ["moderate to severe ARDS", "PROBLEM", 139, 162], ["hMSC therapies", "TREATMENT", 240, 254], ["the cryopreservation", "TREATMENT", 276, 296], ["the efficacy of hMSCs", "PROBLEM", 330, 351], ["allogeneic", "OBSERVATION", 47, 57], ["bone marrow", "ANATOMY", 58, 69], ["severe", "OBSERVATION_MODIFIER", 151, 157], ["ARDS", "OBSERVATION", 158, 162]]], ["The use of xenogeneic products, particularly foetal bovine serum (FBS)based media for passage of MSCs [20] , has generated important safety concerns [21] , including the risk of virus and prion contamination, and concerns regarding immunogenicity [22] [23] [24] [25] .", [["foetal bovine serum", "ANATOMY", 45, 64], ["FBS", "ANATOMY", 66, 69], ["MSCs", "ANATOMY", 97, 101], ["prion contamination", "DISEASE", 188, 207], ["bovine", "ORGANISM", 52, 58], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["FBS", "ORGANISM_SUBSTANCE", 66, 69], ["MSCs", "CELL", 97, 101], ["MSCs", "CELL_TYPE", 97, 101], ["bovine", "SPECIES", 52, 58], ["bovine", "SPECIES", 52, 58], ["xenogeneic products", "TREATMENT", 11, 30], ["particularly foetal bovine serum (FBS)", "TREATMENT", 32, 70], ["virus", "PROBLEM", 178, 183], ["prion contamination", "PROBLEM", 188, 207], ["virus", "OBSERVATION", 178, 183]]], ["Xenogeneic culture-free (XF) supplements such as the recently patented XF supplement (WO2015121471 A1) have been developed that preserve the differentiation, proliferation and low immunogenicity properties of MSCs [26] .", [["MSCs", "ANATOMY", 209, 213], ["XF", "CHEMICAL", 71, 73], ["WO2015121471 A1", "CHEMICAL", 86, 101], ["WO2015121471 A1", "CHEMICAL", 86, 101], ["XF", "SIMPLE_CHEMICAL", 71, 73], ["MSCs", "CELL", 209, 213], ["MSCs", "CELL_TYPE", 209, 213], ["Xenogeneic culture", "TEST", 0, 18], ["free (XF) supplements", "TREATMENT", 19, 40], ["low immunogenicity properties of MSCs", "PROBLEM", 176, 213], ["low immunogenicity", "OBSERVATION_MODIFIER", 176, 194]]], ["Finally, demonstrating true 'therapeutic' potential of MSC therapies, i.e. showing efficacy at later points (delayed administration) in the injury and/or repair process, is necessary to better mimic the clinical scenario.(Continued from previous page)Cytokine activation of hMSCs may enhance their function by simulating the inflammatory/injury microenvironment [27] [28] [29] , potentially minimizing any impact of cryopreservation, XF culture conditions or loss of therapeutic efficacy with delayed delivery following disease onset.", [["MSC", "ANATOMY", 55, 58], ["hMSCs", "ANATOMY", 274, 279], ["MSC", "CELL", 55, 58], ["Cytokine", "GENE_OR_GENE_PRODUCT", 251, 259], ["hMSCs", "CELL", 274, 279], ["Cytokine", "PROTEIN", 251, 259], ["hMSCs", "CELL_TYPE", 274, 279], ["MSC therapies", "TREATMENT", 55, 68], ["the injury", "PROBLEM", 136, 146], ["repair process", "TREATMENT", 154, 168], ["Cytokine activation of hMSCs", "TREATMENT", 251, 279], ["the inflammatory/injury microenvironment", "PROBLEM", 321, 361], ["cryopreservation", "TREATMENT", 416, 432], ["XF culture conditions", "TEST", 434, 455], ["delayed delivery", "TREATMENT", 493, 509], ["disease onset", "PROBLEM", 520, 533], ["injury", "OBSERVATION", 140, 146], ["repair", "OBSERVATION", 154, 160], ["inflammatory", "OBSERVATION_MODIFIER", 325, 337]]], ["We wished to test the hypothesis that pre-activation of cryopreserved, XF-hMSCs would enhance their efficacy after delayed administration in a relevant preclinical model of VILI injury and repair and to investigate the mechanisms underlying these effects.", [["XF-hMSCs", "ANATOMY", 71, 79], ["VILI injury", "DISEASE", 173, 184], ["XF-hMSCs", "CELL", 71, 79], ["cryopreserved, XF-hMSCs", "CELL_LINE", 56, 79], ["delayed administration", "TREATMENT", 115, 137], ["VILI injury", "PROBLEM", 173, 184], ["repair", "TREATMENT", 189, 195]]], ["In vitro studies examined the potential for naive and cytokine pre-activated XF-hMSC-conditioned medium (CM) to attenuate pulmonary epithelial stretch-induced injury.", [["hMSC", "ANATOMY", 80, 84], ["CM", "ANATOMY", 105, 107], ["pulmonary epithelial", "ANATOMY", 122, 142], ["XF-hMSC", "CELL", 77, 84], ["CM", "CELL", 105, 107], ["pulmonary epithelial", "TISSUE", 122, 142], ["cytokine", "PROTEIN", 54, 62], ["XF-hMSC", "CELL_LINE", 77, 84], ["vitro studies", "TEST", 3, 16], ["naive and cytokine pre-activated XF", "TREATMENT", 44, 79], ["pulmonary epithelial stretch", "PROBLEM", 122, 150], ["induced injury", "PROBLEM", 151, 165], ["pulmonary", "ANATOMY", 122, 131], ["epithelial stretch", "OBSERVATION", 132, 150], ["injury", "OBSERVATION", 159, 165]]], ["In vivo experiments examined the potential for cytokine preactivation to enhance the efficacy of (fresh and cryopreserved) XF-hMSCs to enhance resolution when administered at therapeutically relevant time points following the development of VILI.", [["XF-hMSCs", "ANATOMY", 123, 131], ["VILI", "DISEASE", 241, 245], ["XF-hMSCs", "CELL", 123, 131], ["cytokine", "PROTEIN", 47, 55], ["hMSCs", "CELL_TYPE", 126, 131], ["cytokine preactivation", "PROBLEM", 47, 69], ["fresh and cryopreserved) XF-hMSCs", "TREATMENT", 98, 131], ["VILI", "PROBLEM", 241, 245], ["VILI", "OBSERVATION", 241, 245]]], ["Subsequent mechanistic experiments examined the potential for the pulmonary epithelial reparative effects of XF-hMSCs to be mediated in part via KGF present in the MSC secretome.Materials and methodshMSC isolation, culture and expansion hMSCs were isolated from healthy donor bone marrow as previously described [30] and used at passages 2-3 for all experiments.", [["pulmonary epithelial", "ANATOMY", 66, 86], ["XF-hMSCs", "ANATOMY", 109, 117], ["MSC secretome", "ANATOMY", 164, 177], ["hMSCs", "ANATOMY", 237, 242], ["bone marrow", "ANATOMY", 276, 287], ["pulmonary epithelial", "TISSUE", 66, 86], ["XF-hMSCs", "CELL", 109, 117], ["KGF", "GENE_OR_GENE_PRODUCT", 145, 148], ["MSC", "CELL", 164, 167], ["hMSCs", "CELL", 237, 242], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 276, 287], ["KGF", "PROTEIN", 145, 148], ["hMSCs", "CELL_TYPE", 237, 242], ["the pulmonary epithelial reparative effects of XF", "PROBLEM", 62, 111], ["hMSCs", "PROBLEM", 112, 117], ["methodshMSC isolation", "TREATMENT", 192, 213], ["culture", "TEST", 215, 222], ["expansion hMSCs", "TEST", 227, 242], ["healthy donor bone marrow", "TREATMENT", 262, 287], ["pulmonary", "ANATOMY", 66, 75], ["epithelial", "ANATOMY_MODIFIER", 76, 86], ["reparative", "OBSERVATION", 87, 97], ["KGF", "OBSERVATION", 145, 148], ["MSC secretome", "OBSERVATION", 164, 177], ["bone marrow", "ANATOMY", 276, 287]]], ["MSCs were cultured in Alpha Minimum Essential Eagle Medium (MEM-\u03b1) with GlutaMAX (GIBCO\u00ae) supplemented with 10% FBS, penicillin G (100 U/mL), streptomycin (100 \u03bcg/mL) and FGF-1 (10 ng/mL) (Pepro-Tech EC Ltd., London, UK). hMSCs were maintained in 95% humidity, 5% CO 2 and hypoxia (2% O 2 ) at 37\u00b0C; sub-cultured with 0.025% trypsin-0.05 mM EDTA; and cryopreserved in CryoStor cell preservation medium (Sigma-Aldrich) at a density of 5 \u00d7 10 6 /mL.", [["MSCs", "ANATOMY", 0, 4], ["FBS", "ANATOMY", 112, 115], ["hMSCs", "ANATOMY", 222, 227], ["cell", "ANATOMY", 377, 381], ["MEM-\u03b1", "CHEMICAL", 60, 65], ["GlutaMAX", "CHEMICAL", 72, 80], ["penicillin", "CHEMICAL", 117, 127], ["streptomycin", "CHEMICAL", 142, 154], ["hypoxia", "DISEASE", 273, 280], ["penicillin G", "CHEMICAL", 117, 129], ["streptomycin", "CHEMICAL", 142, 154], ["CO 2", "CHEMICAL", 264, 268], ["EDTA", "CHEMICAL", 341, 345], ["MSCs", "CELL", 0, 4], ["MEM-\u03b1", "SIMPLE_CHEMICAL", 60, 65], ["GlutaMAX", "SIMPLE_CHEMICAL", 72, 80], ["GIBCO", "ORGANISM", 82, 87], ["FBS", "ORGANISM_SUBSTANCE", 112, 115], ["penicillin G", "SIMPLE_CHEMICAL", 117, 129], ["streptomycin", "SIMPLE_CHEMICAL", 142, 154], ["FGF-1", "GENE_OR_GENE_PRODUCT", 171, 176], ["hMSCs", "CELL", 222, 227], ["trypsin", "SIMPLE_CHEMICAL", 325, 332], ["EDTA", "SIMPLE_CHEMICAL", 341, 345], ["CryoStor cell", "CELL", 368, 381], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 403, 416], ["MSCs", "CELL_TYPE", 0, 4], ["FGF", "PROTEIN", 171, 174], ["hMSCs", "CELL_TYPE", 222, 227], ["trypsin", "PROTEIN", 325, 332], ["MSCs", "TEST", 0, 4], ["Alpha", "TEST", 22, 27], ["GlutaMAX (GIBCO\u00ae)", "TREATMENT", 72, 89], ["penicillin G", "TREATMENT", 117, 129], ["streptomycin", "TREATMENT", 142, 154], ["FGF", "TEST", 171, 174], ["hMSCs", "TEST", 222, 227], ["hypoxia", "PROBLEM", 273, 280], ["0.025% trypsin", "TREATMENT", 318, 332], ["cryopreserved in CryoStor cell preservation medium", "TREATMENT", 351, 401]]], ["XF-hMSCs were isolated as above but expanded using an FBS-free medium containing a patented XF (WO2015121471 A1) growth supplement [26] .", [["XF-hMSCs", "ANATOMY", 0, 8], ["WO2015121471 A1", "CHEMICAL", 96, 111], ["XF-hMSCs", "CELL", 0, 8], ["FBS", "ORGANISM_SUBSTANCE", 54, 57], ["XF", "SIMPLE_CHEMICAL", 92, 94], ["XF-hMSCs", "CELL_LINE", 0, 8], ["an FBS", "TEST", 51, 57]]], ["Following expansion, hMSCs were pre-activated with cytokine cocktail consisting of interleukin (IL)-1\u03b2 (10 ng/mL), tumour necrosis factor (TNF)-\u03b1 (50 ng/mL) and interferon (IFN)-\u03b3 (50 ng/mL) for 24 h, and either delivered freshly harvested or cryopreserved and stored for later delivery.", [["hMSCs", "ANATOMY", 21, 26], ["necrosis", "DISEASE", 122, 130], ["hMSCs", "CELL", 21, 26], ["interleukin (IL)-1\u03b2", "GENE_OR_GENE_PRODUCT", 83, 102], ["tumour necrosis factor (TNF)-\u03b1", "GENE_OR_GENE_PRODUCT", 115, 145], ["interferon (IFN)-\u03b3", "GENE_OR_GENE_PRODUCT", 161, 179], ["hMSCs", "CELL_TYPE", 21, 26], ["cytokine", "PROTEIN", 51, 59], ["interleukin (IL)-1\u03b2", "PROTEIN", 83, 102], ["tumour necrosis factor (TNF)-\u03b1", "PROTEIN", 115, 145], ["interferon (IFN)-\u03b3", "PROTEIN", 161, 179], ["hMSCs", "TEST", 21, 26], ["cytokine cocktail", "TREATMENT", 51, 68], ["interleukin (IL)", "TREATMENT", 83, 99], ["tumour necrosis factor", "PROBLEM", 115, 137], ["TNF", "TEST", 139, 142], ["interferon (IFN)", "TREATMENT", 161, 177], ["necrosis", "OBSERVATION", 122, 130], ["harvested", "OBSERVATION", 230, 239]]], ["IL-8 secretion from naive or pre-activated hMSCs, before and after freezing (24 and 48 h post-cryopreservation), was determined using an IL-8 sandwich ELISA DuoSet kit (R&D Systems Inc., Minneapolis, MN, USA) to confirm the responsive state persisted post-thaw (Additional file 1: Figure S1 ).", [["hMSCs", "ANATOMY", 43, 48], ["IL-8", "GENE_OR_GENE_PRODUCT", 0, 4], ["hMSCs", "CELL", 43, 48], ["IL-8", "GENE_OR_GENE_PRODUCT", 137, 141], ["IL-8", "PROTEIN", 0, 4], ["naive or pre-activated hMSCs", "CELL_TYPE", 20, 48], ["IL", "TEST", 0, 2], ["pre-activated hMSCs", "PROBLEM", 29, 48], ["an IL", "TREATMENT", 134, 139], ["the responsive state", "PROBLEM", 220, 240]]], ["For in vivo experiments, cryopreserved XF-hMSCs were stored for up to 2 months and cell viability after thaw was between 95 and 97% as determined by trypan blue exclusion.Materials and methodshMSC-conditioned medium hMSCs were seeded at 1 \u00d7 10 4 cells/cm 2 in a 175-cm 2 culture flask and left to reach confluence for 48 h.", [["XF-hMSCs", "ANATOMY", 39, 47], ["cell", "ANATOMY", 83, 87], ["hMSCs", "ANATOMY", 216, 221], ["cells", "ANATOMY", 246, 251], ["trypan blue", "CHEMICAL", 149, 160], ["trypan blue", "CHEMICAL", 149, 160], ["XF-hMSCs", "CELL", 39, 47], ["cell", "CELL", 83, 87], ["trypan blue", "SIMPLE_CHEMICAL", 149, 160], ["methodshMSC", "CELL", 185, 196], ["hMSCs", "CELL", 216, 221], ["cryopreserved XF-hMSCs", "CELL_LINE", 25, 47], ["methodshMSC-conditioned medium hMSCs", "CELL_LINE", 185, 221], ["cell viability", "TEST", 83, 97], ["methodshMSC-conditioned medium hMSCs", "TREATMENT", 185, 221], ["culture flask", "TEST", 271, 284], ["left", "ANATOMY_MODIFIER", 289, 293]]], ["The cells were then re-fed with complete FBS medium or XF medium with or without cytokine cocktail for 24 h.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["FBS", "ORGANISM_SUBSTANCE", 41, 44], ["cytokine", "PROTEIN", 81, 89], ["cytokine cocktail", "TREATMENT", 81, 98]]], ["For naive CM, phosphate-buffered saline (PBS) vehicle was added for 24 h.", [["CM", "ANATOMY", 10, 12], ["CM", "DISEASE", 10, 12], ["phosphate", "CHEMICAL", 14, 23], ["phosphate", "CHEMICAL", 14, 23], ["CM", "CELL", 10, 12], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 14, 39], ["naive CM", "TREATMENT", 4, 12], ["phosphate-buffered saline (PBS) vehicle", "TREATMENT", 14, 53]]], ["All cells were washed with PBS three times and re-fed with serum-free medium, to remove pre-activating cytokines.", [["cells", "ANATOMY", 4, 9], ["serum", "ANATOMY", 59, 64], ["cells", "CELL", 4, 9], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["pre-activating cytokines", "PROTEIN", 88, 112], ["All cells", "TREATMENT", 0, 9], ["PBS", "TREATMENT", 27, 30], ["serum", "TEST", 59, 64]]], ["This CM was harvested 24 h later.", [["CM", "ANATOMY", 5, 7], ["CM", "DISEASE", 5, 7]]], ["Serum-free MEM-\u03b1 medium was used for the control treatment groups in experiments.", [["Serum", "ANATOMY", 0, 5], ["MEM-\u03b1", "CHEMICAL", 11, 16], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum", "TEST", 0, 5], ["the control treatment groups", "TREATMENT", 37, 65]]], ["Multiple donors and multiple batches were used in all experiments.Materials and methodsPulmonary epithelial stretch injury model A549/NF-\u03baB-luc cells were seeded to laminin-coated 6-well BioFlex plates (Flexcell International, Burlington, NC, USA) at 1 \u00d7 10 5 cells/cm 2 and incubated for 48 h.", [["Pulmonary epithelial", "ANATOMY", 87, 107], ["A549/NF-\u03baB-luc cells", "ANATOMY", 129, 149], ["cells", "ANATOMY", 260, 265], ["donors", "ORGANISM", 9, 15], ["Pulmonary epithelial", "TISSUE", 87, 107], ["laminin", "GENE_OR_GENE_PRODUCT", 165, 172], ["A549/NF-\u03baB-luc cells", "CELL_LINE", 129, 149], ["laminin", "PROTEIN", 165, 172], ["Multiple donors", "TREATMENT", 0, 15], ["multiple batches", "TREATMENT", 20, 36], ["Pulmonary epithelial stretch injury", "PROBLEM", 87, 122], ["A549", "TEST", 129, 133], ["NF", "TEST", 134, 136], ["B-luc cells", "PROBLEM", 138, 149], ["laminin", "TEST", 165, 172], ["well BioFlex plates", "TREATMENT", 182, 201], ["donors", "OBSERVATION", 9, 15], ["multiple", "OBSERVATION_MODIFIER", 20, 28], ["batches", "OBSERVATION", 29, 36], ["epithelial", "ANATOMY_MODIFIER", 97, 107], ["stretch injury", "OBSERVATION", 108, 122], ["NC", "ANATOMY", 239, 241]]], ["They were then pre-conditioned in their respective hMSC CM treatment or control (MEM-\u03b1 medium) conditions for 1 h before they were mounted onto the Flexcell FX-4000 T\u00ae Tension Plus\u00ae baseplate (Flexcell International) and subjected to 22% equibiaxial stretch at a frequency of 0.1 Hz for 120 h.", [["hMSC", "ANATOMY", 51, 55], ["hMSC", "CELL", 51, 55], ["hMSC CM", "CELL_LINE", 51, 58], ["their respective hMSC CM treatment", "TREATMENT", 34, 68], ["the Flexcell FX", "TEST", 144, 159]]], ["Non-stretched cells were used as control [31] .", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["Non-stretched cells", "CELL_TYPE", 0, 19], ["Non-stretched cells", "TREATMENT", 0, 19]]], ["Cells and medium were then harvested for analysis.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["analysis", "TEST", 41, 49]]], ["Cells were scraped into 1 mL of PBS, centrifuged at 400\u00d7g for 5 min and reconstituted in 1 mL of PBS.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["PBS", "TREATMENT", 32, 35]]], ["50 \u03bcL was taken for the viability assay and the remainder then pelleted again for the luciferase assay.Injury assessmentIL-8, an NF-\u03baB-dependent cytokine, was measured in the medium using an IL-8 sandwich ELISA DuoSet kit (R&D Systems).", [["luciferase", "GENE_OR_GENE_PRODUCT", 86, 96], ["assessmentIL-8", "GENE_OR_GENE_PRODUCT", 110, 124], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 129, 134], ["IL-8", "GENE_OR_GENE_PRODUCT", 191, 195], ["luciferase", "PROTEIN", 86, 96], ["NF-\u03baB", "PROTEIN", 129, 134], ["cytokine", "PROTEIN", 145, 153], ["the viability assay", "TEST", 20, 39], ["the luciferase assay", "TEST", 82, 102], ["Injury assessmentIL", "TEST", 103, 122], ["an NF", "TEST", 126, 131], ["dependent cytokine", "PROBLEM", 135, 153], ["an IL", "TREATMENT", 188, 193]]], ["Lactate dehydrogenase (LDH) was measured to assess cell membrane integrity using the CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit (Promega Corporation, Fitchburg, WI, USA), as per the manufacturer's instructions.", [["cell membrane", "ANATOMY", 51, 64], ["Lactate", "CHEMICAL", 0, 7], ["Lactate", "CHEMICAL", 0, 7], ["Lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 0, 21], ["LDH", "GENE_OR_GENE_PRODUCT", 23, 26], ["cell membrane", "CELLULAR_COMPONENT", 51, 64], ["Lactate dehydrogenase", "PROTEIN", 0, 21], ["LDH", "PROTEIN", 23, 26], ["Lactate dehydrogenase (LDH)", "TEST", 0, 27], ["cell membrane integrity", "TEST", 51, 74], ["the CytoTox", "TEST", 81, 92], ["Non-Radioactive Cytotoxicity", "TEST", 96, 124]]], ["Cellular NF-\u03baB activity was measured by mixing cell pellets with 50 \u03bcL of SolarGlow SuperBright (Molecutools, Dublin, Ireland), agitating for 5 min and assessing luminescence using a VICTOR\u2122 X plate reader (Perkin Elmer, Waltham, MA, USA).", [["Cellular", "ANATOMY", 0, 8], ["cell", "ANATOMY", 47, 51], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 9, 14], ["cell", "CELL", 47, 51], ["NF-\u03baB", "PROTEIN", 9, 14], ["Cellular NF", "TEST", 0, 11]]], ["An MTT (Sigma-Aldrich) assay was performed to assess cell viability as previously described [32] .Ventilator-induced lung injuryAs previously described [33] [34] [35] , rats were anaesthetised with isoflurane and intravenous access was obtained via the tail vein.", [["cell", "ANATOMY", 53, 57], ["lung", "ANATOMY", 117, 121], ["intravenous", "ANATOMY", 213, 224], ["tail vein", "ANATOMY", 253, 262], ["lung injury", "DISEASE", 117, 128], ["isoflurane", "CHEMICAL", 198, 208], ["MTT", "CHEMICAL", 3, 6], ["isoflurane", "CHEMICAL", 198, 208], ["cell", "CELL", 53, 57], ["lung", "ORGAN", 117, 121], ["[33] [34] [35]", "SIMPLE_CHEMICAL", 152, 166], ["rats", "ORGANISM", 169, 173], ["isoflurane", "SIMPLE_CHEMICAL", 198, 208], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 213, 224], ["tail vein", "MULTI-TISSUE_STRUCTURE", 253, 262], ["rats", "SPECIES", 169, 173], ["An MTT (Sigma-Aldrich) assay", "TEST", 0, 28], ["cell viability", "PROBLEM", 53, 67], ["Ventilator", "TREATMENT", 98, 108], ["lung injury", "PROBLEM", 117, 128], ["isoflurane", "TREATMENT", 198, 208], ["intravenous access", "TREATMENT", 213, 231], ["lung", "ANATOMY", 117, 121], ["injury", "OBSERVATION", 122, 128], ["tail vein", "ANATOMY", 253, 262]]], ["Laryngoscopy was performed, and a 14-G catheter (BD Insyte\u00ae; Becton Dickinson Ltd., Oxford, UK) was used to intubate the animal for ventilation using a small animal ventilator (CWE SAR 830 AP; CWE Inc., Ardmore, PA, USA).", [["Laryngoscopy", "TEST", 0, 12], ["a 14-G catheter", "TREATMENT", 32, 47], ["ventilation", "TREATMENT", 132, 143], ["a small animal ventilator", "TREATMENT", 150, 175], ["CWE SAR", "TEST", 177, 184], ["AP", "TEST", 189, 191], ["CWE", "TEST", 193, 196]]], ["Anaesthesia was maintained with repeated boli of Alfaxan\u00ae (Alfaxadone 0.9% (w/v) and alfadolone acetate 0.3% (w/v); V\u00e9toquinol S A, Lure Cedex, France) and paralysis with cisatracurium besylate 0.5 mg. kg \u22121 (GlaxoSmithKline, Dublin, Ireland).", [["Alfaxan\u00ae", "CHEMICAL", 49, 57], ["Alfaxadone", "CHEMICAL", 59, 69], ["alfadolone acetate", "CHEMICAL", 85, 103], ["paralysis", "DISEASE", 156, 165], ["cisatracurium", "CHEMICAL", 171, 184], ["Alfaxan\u00ae", "CHEMICAL", 49, 57], ["Alfaxadone", "CHEMICAL", 59, 69], ["alfadolone acetate", "CHEMICAL", 85, 103], ["V\u00e9toquinol S A", "CHEMICAL", 116, 130], ["cisatracurium", "CHEMICAL", 171, 184], ["Alfaxan\u00ae", "SIMPLE_CHEMICAL", 49, 57], ["Alfaxadone", "SIMPLE_CHEMICAL", 59, 69], ["alfadolone acetate", "SIMPLE_CHEMICAL", 85, 103], ["V\u00e9toquinol S A", "SIMPLE_CHEMICAL", 116, 130], ["Anaesthesia", "TREATMENT", 0, 11], ["repeated boli of Alfaxan\u00ae", "TREATMENT", 32, 57], ["Alfaxadone", "TREATMENT", 59, 69], ["alfadolone acetate", "TREATMENT", 85, 103], ["V\u00e9toquinol S A", "TREATMENT", 116, 130], ["paralysis", "PROBLEM", 156, 165], ["cisatracurium besylate", "TREATMENT", 171, 193]]], ["Following baseline ventilation, static compliance was measured and VILI was induced using the following ventilator settings: Fi O2 of 0.3, P insp 35 cmH 2 O, respiratory rate 18 min \u22121 and PEEP 0 cmH 2 O. Following the development of severe VILI, as evidenced by a 50% decrease in respiratory static compliance, injurious ventilation was discontinued, and the animals allowed to recover from anaesthesia [34] .Experimental designSix hours following cessation of injurious ventilation, animals were randomized to receive, by intravenous administration, either (i) vehicle (1 mL PBS) or 1 \u00d7 10 7 XF-hMSCs/kg that were (ii) fresh naive hMSCs, (iii) cryopreserved naive hMSCs, (iv) fresh pre-activated hMSCs and (v) cryopreserved pre-activated hMSCs.", [["intravenous", "ANATOMY", 524, 535], ["hMSCs", "ANATOMY", 597, 602], ["hMSCs", "ANATOMY", 633, 638], ["hMSCs", "ANATOMY", 666, 671], ["hMSCs", "ANATOMY", 698, 703], ["hMSCs", "ANATOMY", 740, 745], ["VILI", "DISEASE", 241, 245], ["O2", "CHEMICAL", 128, 130], ["Fi O2", "SIMPLE_CHEMICAL", 125, 130], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 524, 535], ["hMSCs", "CELL", 633, 638], ["hMSCs", "CELL", 666, 671], ["hMSCs", "CELL", 698, 703], ["hMSCs", "CELL", 740, 745], ["naive hMSCs", "CELL_TYPE", 627, 638], ["cryopreserved naive hMSCs", "CELL_TYPE", 646, 671], ["pre-activated hMSCs", "CELL_LINE", 684, 703], ["cryopreserved pre-activated hMSCs", "CELL_TYPE", 712, 745], ["baseline ventilation", "TREATMENT", 10, 30], ["Fi O2", "TEST", 125, 130], ["respiratory rate", "TEST", 158, 174], ["PEEP", "TREATMENT", 189, 193], ["severe VILI", "PROBLEM", 234, 245], ["a 50% decrease in respiratory static compliance", "PROBLEM", 263, 310], ["injurious ventilation", "TREATMENT", 312, 333], ["injurious ventilation", "TREATMENT", 462, 483], ["XF-hMSCs/kg", "TEST", 594, 605], ["cryopreserved naive hMSCs", "TREATMENT", 646, 671], ["fresh pre-activated hMSCs and (v) cryopreserved pre-activated hMSCs", "TREATMENT", 678, 745], ["severe", "OBSERVATION_MODIFIER", 234, 240], ["VILI", "OBSERVATION", 241, 245], ["decrease", "OBSERVATION_MODIFIER", 269, 277], ["respiratory static", "OBSERVATION", 281, 299], ["injurious ventilation", "OBSERVATION", 312, 333], ["injurious ventilation", "OBSERVATION", 462, 483]]], ["The extent of inflammation and injury resolution was measured at 24 h (i.e. 18 h post-intervention delivery).In vivo assessment of lung injury and recoveryTwenty-four hours post-cessation of injurious ventilation, animals were reanaesthetised as described above, intravenous access was obtained via tail vein and a tracheostomy tube was inserted [34] .", [["lung", "ANATOMY", 131, 135], ["intravenous", "ANATOMY", 263, 274], ["tail vein", "ANATOMY", 299, 308], ["inflammation", "DISEASE", 14, 26], ["lung injury", "DISEASE", 131, 142], ["lung", "ORGAN", 131, 135], ["animals", "ORGANISM", 214, 221], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 263, 274], ["tail vein", "MULTI-TISSUE_STRUCTURE", 299, 308], ["tube", "TISSUE", 328, 332], ["inflammation", "PROBLEM", 14, 26], ["injury resolution", "PROBLEM", 31, 48], ["intervention delivery", "TREATMENT", 86, 107], ["vivo assessment", "TEST", 112, 127], ["lung injury", "PROBLEM", 131, 142], ["injurious ventilation", "TREATMENT", 191, 212], ["intravenous access", "TREATMENT", 263, 281], ["a tracheostomy tube", "TREATMENT", 313, 332], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["inflammation", "OBSERVATION", 14, 26], ["injury", "OBSERVATION_MODIFIER", 31, 37], ["resolution", "OBSERVATION_MODIFIER", 38, 48], ["lung", "ANATOMY", 131, 135], ["injury", "OBSERVATION", 136, 142], ["injurious ventilation", "OBSERVATION", 191, 212], ["tail vein", "ANATOMY", 299, 308], ["tracheostomy tube", "OBSERVATION", 315, 332]]], ["Following the commencement of ventilation, intra-arterial access was gained and anaesthesia was maintained with Saffan\u00ae and paralysis with cisatracurium besylate.", [["intra-arterial", "ANATOMY", 43, 57], ["Saffan\u00ae", "CHEMICAL", 112, 119], ["paralysis", "DISEASE", 124, 133], ["cisatracurium", "CHEMICAL", 139, 152], ["Saffan\u00ae", "CHEMICAL", 112, 119], ["cisatracurium", "CHEMICAL", 139, 152], ["intra-arterial", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 57], ["Saffan\u00ae", "SIMPLE_CHEMICAL", 112, 119], ["ventilation", "TREATMENT", 30, 41], ["intra-arterial access", "TREATMENT", 43, 64], ["anaesthesia", "TREATMENT", 80, 91], ["Saffan\u00ae", "TREATMENT", 112, 119], ["paralysis", "TREATMENT", 124, 133], ["cisatracurium besylate", "TREATMENT", 139, 161]]], ["Arterial blood pressure, airway pressure, lung static compliance and arterial blood gas analyses were performed as previously described [36, 37] .Ex vivo analyses of lung inflammation and repairFollowing exsanguination under anaesthesia, bronchoalveolar lavage (BAL) was collected, and BAL fluid differential leukocyte counts were completed.", [["Arterial", "ANATOMY", 0, 8], ["blood", "ANATOMY", 9, 14], ["airway", "ANATOMY", 25, 31], ["lung", "ANATOMY", 42, 46], ["arterial blood", "ANATOMY", 69, 83], ["lung", "ANATOMY", 166, 170], ["bronchoalveolar lavage", "ANATOMY", 238, 260], ["BAL", "ANATOMY", 262, 265], ["BAL fluid", "ANATOMY", 286, 295], ["leukocyte", "ANATOMY", 309, 318], ["lung inflammation", "DISEASE", 166, 183], ["Arterial blood", "MULTI-TISSUE_STRUCTURE", 0, 14], ["airway", "MULTI-TISSUE_STRUCTURE", 25, 31], ["lung", "ORGAN", 42, 46], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 69, 83], ["lung", "ORGAN", 166, 170], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 238, 260], ["leukocyte", "CELL", 309, 318], ["Arterial blood pressure", "TEST", 0, 23], ["airway pressure", "TEST", 25, 40], ["lung static compliance", "TEST", 42, 64], ["arterial blood gas analyses", "TEST", 69, 96], ["lung inflammation", "PROBLEM", 166, 183], ["repairFollowing exsanguination", "TREATMENT", 188, 218], ["anaesthesia", "TREATMENT", 225, 236], ["bronchoalveolar lavage (BAL)", "TEST", 238, 266], ["BAL fluid differential leukocyte counts", "TEST", 286, 325], ["pressure", "OBSERVATION_MODIFIER", 15, 23], ["airway", "ANATOMY", 25, 31], ["pressure", "OBSERVATION_MODIFIER", 32, 40], ["lung", "ANATOMY", 42, 46], ["lung", "ANATOMY", 166, 170], ["inflammation", "OBSERVATION", 171, 183], ["bronchoalveolar lavage", "OBSERVATION", 238, 260]]], ["BAL concentrations of CINC-1, IL-6, IL-10, KGF and PGE 2 were determined using ELISA (R&D Systems), and BAL protein was also measured (Micro BCA; Pierce, Rockford, IL, USA).", [["BAL", "ANATOMY", 0, 3], ["BAL", "ORGANISM_SUBSTANCE", 0, 3], ["CINC-1", "GENE_OR_GENE_PRODUCT", 22, 28], ["IL-6", "GENE_OR_GENE_PRODUCT", 30, 34], ["IL-10", "GENE_OR_GENE_PRODUCT", 36, 41], ["KGF", "GENE_OR_GENE_PRODUCT", 43, 46], ["PGE 2", "GENE_OR_GENE_PRODUCT", 51, 56], ["CINC", "PROTEIN", 22, 26], ["IL", "PROTEIN", 36, 38], ["KGF", "PROTEIN", 43, 46], ["PGE 2", "PROTEIN", 51, 56], ["BAL protein", "PROTEIN", 104, 115], ["BAL concentrations", "TEST", 0, 18], ["CINC", "TEST", 22, 26], ["IL", "TEST", 30, 32], ["IL", "TEST", 36, 38], ["KGF and PGE 2", "TEST", 43, 56], ["ELISA (R&D Systems", "TEST", 79, 97], ["BAL protein", "TEST", 104, 115]]], ["The left lung was isolated and fixed, and structural lung damage determined using stereological techniques [38] , a quantitative, robust and reproducible approach to histological assessment [39] .", [["left lung", "ANATOMY", 4, 13], ["lung", "ANATOMY", 53, 57], ["lung damage", "DISEASE", 53, 64], ["lung", "ORGAN", 9, 13], ["lung", "ORGAN", 53, 57], ["structural lung damage", "PROBLEM", 42, 64], ["stereological techniques", "TEST", 82, 106], ["histological assessment", "TEST", 166, 189], ["left", "ANATOMY_MODIFIER", 4, 8], ["lung", "ANATOMY", 9, 13], ["isolated", "OBSERVATION", 18, 26], ["fixed", "OBSERVATION_MODIFIER", 31, 36], ["lung", "ANATOMY", 53, 57], ["damage", "OBSERVATION", 58, 64]]], ["All ex vivo analyses were performed by blinded investigators.Ex vivo analyses of lung inflammation and repairPulmonary epithelial wound injury A549/NF-\u03baB-luc cells were seeded at 1 \u00d7 10 5 cells/cm 2 in a 24-well plate (Sarstedt) and left to reach confluence for 48 h.", [["lung", "ANATOMY", 81, 85], ["repairPulmonary epithelial wound", "ANATOMY", 103, 135], ["A549/NF-\u03baB-luc cells", "ANATOMY", 143, 163], ["cells", "ANATOMY", 188, 193], ["lung inflammation", "DISEASE", 81, 98], ["lung", "ORGAN", 81, 85], ["repairPulmonary epithelial wound", "PATHOLOGICAL_FORMATION", 103, 135], ["repairPulmonary epithelial wound injury A549/NF-\u03baB-luc cells", "CELL_LINE", 103, 163], ["All ex vivo analyses", "TEST", 0, 20], ["Ex vivo analyses", "TEST", 61, 77], ["lung inflammation", "PROBLEM", 81, 98], ["repairPulmonary epithelial wound injury", "PROBLEM", 103, 142], ["A549", "TEST", 143, 147], ["NF", "TEST", 148, 150], ["B-luc cells", "PROBLEM", 152, 163], ["lung", "ANATOMY", 81, 85], ["inflammation", "OBSERVATION", 86, 98], ["epithelial", "ANATOMY_MODIFIER", 119, 129], ["wound", "ANATOMY", 130, 135], ["injury", "OBSERVATION", 136, 142], ["left", "ANATOMY_MODIFIER", 233, 237]]], ["Single scratch wounds were generated with a 1-mL pipette tip (Sarstedt).", [["wounds", "ANATOMY", 15, 21], ["wounds", "PATHOLOGICAL_FORMATION", 15, 21], ["Single scratch wounds", "PROBLEM", 0, 21], ["a 1-mL pipette tip", "TREATMENT", 42, 60], ["scratch", "OBSERVATION_MODIFIER", 7, 14], ["wounds", "OBSERVATION", 15, 21]]], ["The cells were washed with PBS, and their respective treatments were added.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["PBS", "TREATMENT", 27, 30], ["their respective treatments", "TREATMENT", 36, 63]]], ["Ten per cent serum was also added.", [["serum", "ANATOMY", 13, 18], ["serum", "ORGANISM_SUBSTANCE", 13, 18]]], ["Cell treatments were MEM-\u03b1 medium, naive FBS-or XF-MSC CM, or pre-activated FBS-or XF-MSC CM +/\u2212, a KGF neutralization antibody (0.5 \u03bcg/mL) (R&D Systems).", [["Cell", "ANATOMY", 0, 4], ["FBS", "ANATOMY", 41, 44], ["XF-MSC CM", "ANATOMY", 48, 57], ["FBS", "ANATOMY", 76, 79], ["XF-MSC", "ANATOMY", 83, 89], ["MEM-\u03b1", "CHEMICAL", 21, 26], ["Cell", "CELL", 0, 4], ["MEM-\u03b1", "SIMPLE_CHEMICAL", 21, 26], ["FBS", "ORGANISM_SUBSTANCE", 41, 44], ["XF-MSC CM", "CELL", 48, 57], ["FBS", "ORGANISM_SUBSTANCE", 76, 79], ["XF-MSC CM", "CELL", 83, 92], ["KGF", "GENE_OR_GENE_PRODUCT", 100, 103], ["KGF neutralization antibody", "PROTEIN", 100, 127], ["Cell treatments", "TREATMENT", 0, 15], ["MEM", "TEST", 21, 24], ["naive FBS", "TEST", 35, 44], ["MSC CM", "PROBLEM", 51, 57], ["pre-activated FBS", "TEST", 62, 79], ["XF", "TEST", 83, 85], ["MSC CM", "TEST", 86, 92], ["a KGF neutralization antibody", "TEST", 98, 127], ["MSC", "ANATOMY", 51, 54], ["MSC", "ANATOMY", 86, 89]]], ["Wound restitution was assessed over 48 h using light microscopy imaging.Statistical analysisThe distribution of all data was tested for normality using Kolmogorov-Smirnov tests.", [["Wound", "ANATOMY", 0, 5], ["Wound", "PATHOLOGICAL_FORMATION", 0, 5], ["Wound restitution", "TREATMENT", 0, 17], ["light microscopy imaging", "TEST", 47, 71], ["Statistical analysis", "TEST", 72, 92], ["all data", "TEST", 112, 120], ["Kolmogorov-Smirnov tests", "TEST", 152, 176], ["restitution", "OBSERVATION_MODIFIER", 6, 17]]], ["A two-tailed P value of < 0.05 was considered statistically significant.Pulmonary epithelial cell stretch-induced injuryCyclic mechanical stretch-induced NF-\u03baB activation was attenuated by both FBS-and XF-cultured hMSC-CM as compared to the control (MEM-\u03b1) group (Fig. 1a) .", [["Pulmonary epithelial cell", "ANATOMY", 72, 97], ["hMSC-CM", "ANATOMY", 214, 221], ["MEM-\u03b1", "CHEMICAL", 250, 255], ["Pulmonary epithelial cell", "CELL", 72, 97], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 154, 159], ["FBS", "ORGANISM_SUBSTANCE", 194, 197], ["XF", "SIMPLE_CHEMICAL", 202, 204], ["hMSC-CM", "CELL", 214, 221], ["MEM-\u03b1", "SIMPLE_CHEMICAL", 250, 255], ["NF-\u03baB", "PROTEIN", 154, 159], ["XF-cultured hMSC-CM", "CELL_LINE", 202, 221], ["A two-tailed P value", "TEST", 0, 20], ["Pulmonary epithelial cell stretch", "PROBLEM", 72, 105], ["injuryCyclic mechanical stretch", "PROBLEM", 114, 145], ["NF", "PROBLEM", 154, 156], ["B activation", "PROBLEM", 158, 170], ["FBS", "TEST", 194, 197], ["XF", "TEST", 202, 204], ["hMSC", "TEST", 214, 218], ["epithelial cell stretch", "OBSERVATION", 82, 105]]], ["Cytokine pre-activation of both FBS-and XF-cultured MSCs enhanced the efficacy of hMSC-CM in attenuating NF-\u03baB activation.", [["FBS", "ANATOMY", 32, 35], ["MSCs", "ANATOMY", 52, 56], ["hMSC-CM", "ANATOMY", 82, 89], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["FBS", "ORGANISM_SUBSTANCE", 32, 35], ["XF", "CELL", 40, 42], ["MSCs", "CELL", 52, 56], ["hMSC-CM", "CELL", 82, 89], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 105, 110], ["Cytokine", "PROTEIN", 0, 8], ["FBS-and XF-cultured MSCs", "CELL_LINE", 32, 56], ["hMSC", "CELL_TYPE", 82, 86], ["NF-\u03baB", "PROTEIN", 105, 110], ["both FBS", "TEST", 27, 35], ["hMSC", "TEST", 82, 86]]], ["Cyclic mechanical stretch-induced IL-8 release was attenuated by FBS-and XF-cultured MSC-CM (Fig. 1b) .", [["MSC-CM", "ANATOMY", 85, 91], ["IL-8", "GENE_OR_GENE_PRODUCT", 34, 38], ["FBS", "ORGANISM_SUBSTANCE", 65, 68], ["XF", "SIMPLE_CHEMICAL", 73, 75], ["MSC-CM", "CELL", 85, 91], ["IL-8", "PROTEIN", 34, 38], ["Cyclic mechanical stretch-induced IL", "TREATMENT", 0, 36], ["FBS", "TEST", 65, 68], ["XF", "TEST", 73, 75], ["mechanical stretch", "OBSERVATION", 7, 25]]], ["Cytokine pre-activation of XFcultured-but not FBS-cultured-MSCs enhanced the efficacy of hMSC-CM in attenuating stretch-induced IL-8 release.", [["FBS", "ANATOMY", 46, 49], ["MSCs", "ANATOMY", 59, 63], ["hMSC-CM", "ANATOMY", 89, 96], ["CM", "DISEASE", 94, 96], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["XFcultured", "SIMPLE_CHEMICAL", 27, 37], ["FBS", "ORGANISM_SUBSTANCE", 46, 49], ["-cultured-MSCs", "CELL", 49, 63], ["hMSC-CM", "CELL", 89, 96], ["IL-8", "GENE_OR_GENE_PRODUCT", 128, 132], ["Cytokine", "PROTEIN", 0, 8], ["XFcultured-but not FBS-cultured-MSCs", "CELL_LINE", 27, 63], ["hMSC", "CELL_TYPE", 89, 93], ["IL-8", "PROTEIN", 128, 132], ["Cytokine pre-activation", "TEST", 0, 23], ["XFcultured", "TEST", 27, 37], ["FBS", "TEST", 46, 49], ["attenuating stretch-induced IL", "TREATMENT", 100, 130]]], ["Cyclic mechanical stretch caused pulmonary epithelial cell membrane injury, as evidenced by LDH release (Fig. 1c ).", [["pulmonary epithelial cell membrane", "ANATOMY", 33, 67], ["pulmonary epithelial cell membrane", "TISSUE", 33, 67], ["LDH", "SIMPLE_CHEMICAL", 92, 95], ["LDH", "PROTEIN", 92, 95], ["Cyclic mechanical stretch", "PROBLEM", 0, 25], ["pulmonary epithelial cell membrane injury", "PROBLEM", 33, 74], ["LDH release", "TEST", 92, 103], ["mechanical stretch", "OBSERVATION", 7, 25], ["pulmonary", "ANATOMY", 33, 42], ["epithelial cell membrane injury", "OBSERVATION", 43, 74]]], ["This pulmonary epithelial injury was attenuated by hMSC-CM from both FBS-and XF-cultured MSCs.", [["pulmonary epithelial", "ANATOMY", 5, 25], ["hMSC-CM", "ANATOMY", 51, 58], ["FBS", "ANATOMY", 69, 72], ["MSCs", "ANATOMY", 89, 93], ["pulmonary epithelial", "TISSUE", 5, 25], ["hMSC-CM", "CELL", 51, 58], ["FBS", "ORGANISM_SUBSTANCE", 69, 72], ["XF", "CELL", 77, 79], ["MSCs", "CELL", 89, 93], ["hMSC", "CELL_TYPE", 51, 55], ["FBS-and XF-cultured MSCs", "CELL_LINE", 69, 93], ["This pulmonary epithelial injury", "PROBLEM", 0, 32], ["hMSC", "TEST", 51, 55], ["FBS", "TEST", 69, 72], ["XF", "TEST", 77, 79], ["MSCs", "PROBLEM", 89, 93], ["pulmonary", "ANATOMY", 5, 14], ["epithelial", "ANATOMY_MODIFIER", 15, 25], ["injury", "OBSERVATION", 26, 32]]], ["Cytokine pre-activation of FBS-cultured-but not XF-cultured-MSCs enhanced the efficacy of hMSC-CM in attenuating epithelial injury (Fig. 1c) .", [["FBS", "ANATOMY", 27, 30], ["MSCs", "ANATOMY", 60, 64], ["hMSC-CM", "ANATOMY", 90, 97], ["epithelial", "ANATOMY", 113, 123], ["CM", "DISEASE", 95, 97], ["epithelial injury", "DISEASE", 113, 130], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["FBS", "ORGANISM_SUBSTANCE", 27, 30], ["XF-cultured-MSCs", "CELL", 48, 64], ["hMSC-CM", "CELL", 90, 97], ["epithelial", "TISSUE", 113, 123], ["Cytokine", "PROTEIN", 0, 8], ["FBS-cultured-but not XF-cultured-MSCs", "CELL_LINE", 27, 64], ["hMSC", "CELL_TYPE", 90, 94], ["FBS", "TEST", 27, 30], ["attenuating epithelial injury", "PROBLEM", 101, 130], ["epithelial", "ANATOMY_MODIFIER", 113, 123], ["injury", "OBSERVATION", 124, 130]]], ["Cyclic mechanical stretch decreased pulmonary epithelial cell viability, and this decrement in cell viability was abrogated by hMSC-CM from both FBS-and XF-cultured MSCs (Fig. 1d) .", [["pulmonary epithelial cell", "ANATOMY", 36, 61], ["cell", "ANATOMY", 95, 99], ["hMSC-CM", "ANATOMY", 127, 134], ["FBS", "ANATOMY", 145, 148], ["MSCs", "ANATOMY", 165, 169], ["pulmonary epithelial cell", "CELL", 36, 61], ["cell", "CELL", 95, 99], ["hMSC-CM", "CELL", 127, 134], ["FBS", "ORGANISM_SUBSTANCE", 145, 148], ["XF", "CELL", 153, 155], ["MSCs", "CELL", 165, 169], ["pulmonary epithelial cell", "CELL_TYPE", 36, 61], ["hMSC", "CELL_TYPE", 127, 131], ["FBS-and XF-cultured MSCs", "CELL_LINE", 145, 169], ["Cyclic mechanical stretch decreased pulmonary epithelial cell viability", "PROBLEM", 0, 71], ["this decrement in cell viability", "PROBLEM", 77, 109], ["hMSC", "TEST", 127, 131], ["FBS", "TEST", 145, 148], ["XF", "TEST", 153, 155], ["mechanical", "OBSERVATION_MODIFIER", 7, 17], ["stretch", "OBSERVATION_MODIFIER", 18, 25], ["decreased", "OBSERVATION_MODIFIER", 26, 35], ["pulmonary", "ANATOMY", 36, 45], ["epithelial cell viability", "OBSERVATION", 46, 71], ["cell viability", "OBSERVATION", 95, 109]]], ["Pre-activation of XF-cultured-but not FBS-cultured-MSCs further enhanced the efficacy of its CM in maintaining epithelial cell viability.Recovery of lung functionVILI resulted in a significant decrement in oxygenation and lung compliance and a significant increase in lung permeability compared to protective ventilation (Fig. 2) .", [["FBS", "ANATOMY", 38, 41], ["MSCs", "ANATOMY", 51, 55], ["epithelial cell", "ANATOMY", 111, 126], ["lung", "ANATOMY", 149, 153], ["lung", "ANATOMY", 222, 226], ["lung", "ANATOMY", 268, 272], ["XF", "GENE_OR_GENE_PRODUCT", 18, 20], ["FBS-cultured-MSCs", "CELL", 38, 55], ["CM", "CELL", 93, 95], ["epithelial cell", "CELL", 111, 126], ["lung", "ORGAN", 149, 153], ["lung", "ORGAN", 222, 226], ["lung", "ORGAN", 268, 272], ["XF-cultured-but not FBS-cultured-MSCs", "CELL_LINE", 18, 55], ["FBS", "TEST", 38, 41], ["MSCs", "PROBLEM", 51, 55], ["lung functionVILI", "TEST", 149, 166], ["a significant decrement in oxygenation", "PROBLEM", 179, 217], ["lung compliance", "TREATMENT", 222, 237], ["a significant increase in lung permeability", "PROBLEM", 242, 285], ["protective ventilation", "TREATMENT", 298, 320], ["epithelial cell viability", "OBSERVATION", 111, 136], ["lung", "ANATOMY", 149, 153], ["functionVILI", "OBSERVATION", 154, 166], ["significant", "OBSERVATION_MODIFIER", 181, 192], ["decrement", "OBSERVATION", 193, 202], ["oxygenation", "OBSERVATION_MODIFIER", 206, 217], ["lung", "ANATOMY", 222, 226], ["compliance", "OBSERVATION", 227, 237], ["significant", "OBSERVATION_MODIFIER", 244, 255], ["increase", "OBSERVATION_MODIFIER", 256, 264], ["lung", "ANATOMY", 268, 272], ["permeability", "OBSERVATION", 273, 285]]], ["Both fresh and cryopreserved XF-hMSCs restored arterial oxygenation (Fig. 2a) when compared to the vehicle (PBS) control group.", [["XF-hMSCs", "ANATOMY", 29, 37], ["arterial", "ANATOMY", 47, 55], ["XF-hMSCs", "CELL", 29, 37], ["arterial", "MULTI-TISSUE_STRUCTURE", 47, 55], ["cryopreserved XF-hMSCs", "CELL_LINE", 15, 37], ["cryopreserved XF", "OBSERVATION", 15, 31], ["arterial", "ANATOMY", 47, 55]]], ["Cytokine pre-activation of cryopreservedbut not fresh-XF-hMSCs further enhanced restoration of arterial oxygenation (Fig. 2a) .", [["hMSCs", "ANATOMY", 57, 62], ["arterial", "ANATOMY", 95, 103], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["cryopreservedbut", "SIMPLE_CHEMICAL", 27, 43], ["hMSCs", "CELL", 57, 62], ["arterial", "MULTI-TISSUE_STRUCTURE", 95, 103], ["Cytokine", "PROTEIN", 0, 8], ["cryopreservedbut not fresh-XF-hMSCs", "CELL_LINE", 27, 62], ["Cytokine pre-activation", "TREATMENT", 0, 23], ["arterial oxygenation", "TEST", 95, 115], ["arterial", "ANATOMY", 95, 103]]], ["Cytokine pre-activated-but not naive-fresh and cryopreserved XF-hMSCs restored lung compliance (Fig. 2b) .", [["XF-hMSCs", "ANATOMY", 61, 69], ["lung", "ANATOMY", 79, 83], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["XF-hMSCs", "CELL", 61, 69], ["lung", "ORGAN", 79, 83], ["Cytokine pre-activated-but not naive-fresh and cryopreserved XF-hMSCs", "CELL_LINE", 0, 69], ["lung", "ANATOMY", 79, 83]]], ["Both naive and cytokine pre-activated fresh and cryopreserved XF-hMSCs enhanced resolution of lung oedema (Fig. 2c) .", [["XF-hMSCs", "ANATOMY", 62, 70], ["lung", "ANATOMY", 94, 98], ["lung oedema", "DISEASE", 94, 105], ["XF-hMSCs", "CELL", 62, 70], ["lung", "ORGAN", 94, 98], ["cytokine", "PROTEIN", 15, 23], ["cryopreserved XF-hMSCs", "CELL_LINE", 48, 70], ["cytokine pre-activated fresh and cryopreserved XF", "TREATMENT", 15, 64], ["lung oedema", "PROBLEM", 94, 105], ["naive", "OBSERVATION", 5, 10], ["lung", "ANATOMY", 94, 98], ["oedema", "OBSERVATION", 99, 105]]], ["Cytokine preactivated-but not naive-fresh and cryopreserved XF-hMSCs restored alveolar barrier permeability, as evidenced by decreased BAL protein concentrations (Fig. 2d) .Modulation of the inflammatory responseFresh, but not cryopreserved, XF-hMSCs decreased alveolar infiltrating cell counts, while cytokine pre-activation restored the efficacy of cryopreserved hMSCs in reducing alveolar cell counts (Additional file 2: Figure S2 ).", [["XF-hMSCs", "ANATOMY", 60, 68], ["alveolar barrier", "ANATOMY", 78, 94], ["XF-hMSCs", "ANATOMY", 242, 250], ["alveolar infiltrating cell", "ANATOMY", 261, 287], ["hMSCs", "ANATOMY", 365, 370], ["alveolar cell", "ANATOMY", 383, 396], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["XF-hMSCs", "CELL", 60, 68], ["alveolar barrier", "TISSUE", 78, 94], ["XF-hMSCs", "CELL", 242, 250], ["alveolar infiltrating cell", "CELL", 261, 287], ["hMSCs", "CELL", 365, 370], ["alveolar cell", "CELL", 383, 396], ["Cytokine preactivated-but not naive-fresh and cryopreserved XF-hMSCs", "CELL_LINE", 0, 68], ["BAL protein", "PROTEIN", 135, 146], ["inflammatory responseFresh, but not cryopreserved, XF-hMSCs", "CELL_LINE", 191, 250], ["cytokine", "PROTEIN", 302, 310], ["cryopreserved hMSCs", "CELL_TYPE", 351, 370], ["Cytokine preactivated", "PROBLEM", 0, 21], ["alveolar barrier permeability", "PROBLEM", 78, 107], ["decreased BAL protein concentrations", "PROBLEM", 125, 161], ["the inflammatory responseFresh", "PROBLEM", 187, 217], ["alveolar infiltrating cell counts", "PROBLEM", 261, 294], ["cytokine pre-activation", "TREATMENT", 302, 325], ["cryopreserved hMSCs", "PROBLEM", 351, 370], ["alveolar cell counts", "TEST", 383, 403], ["alveolar", "ANATOMY_MODIFIER", 78, 86], ["barrier permeability", "OBSERVATION", 87, 107], ["inflammatory", "OBSERVATION_MODIFIER", 191, 203], ["not", "UNCERTAINTY", 223, 226], ["cryopreserved", "OBSERVATION_MODIFIER", 227, 240], ["decreased", "OBSERVATION_MODIFIER", 251, 260], ["alveolar", "ANATOMY_MODIFIER", 261, 269], ["infiltrating cell counts", "OBSERVATION", 270, 294], ["cryopreserved hMSCs", "OBSERVATION", 351, 370], ["alveolar cell counts", "OBSERVATION", 383, 403]]], ["Both fresh and cryopreserved XF-hMSCs decreased alveolar neutrophil counts (Fig. 3a) .", [["XF-hMSCs", "ANATOMY", 29, 37], ["alveolar neutrophil", "ANATOMY", 48, 67], ["XF-hMSCs", "CELL", 29, 37], ["alveolar neutrophil", "CELL", 48, 67], ["cryopreserved XF-hMSCs", "CELL_LINE", 15, 37], ["alveolar neutrophil", "CELL_TYPE", 48, 67], ["alveolar neutrophil counts", "TEST", 48, 74], ["fresh", "OBSERVATION_MODIFIER", 5, 10], ["cryopreserved XF", "OBSERVATION", 15, 31], ["decreased", "OBSERVATION_MODIFIER", 38, 47], ["alveolar neutrophil counts", "OBSERVATION", 48, 74]]], ["These effects were not significantly enhanced by cytokine pre-activation of either fresh or cryopreserved hMSCs (Fig. 3a) .", [["hMSCs", "ANATOMY", 106, 111], ["hMSCs", "CELL", 106, 111], ["cytokine", "PROTEIN", 49, 57], ["cryopreserved hMSCs", "CELL_TYPE", 92, 111], ["fresh or cryopreserved hMSCs", "TREATMENT", 83, 111], ["significantly enhanced", "OBSERVATION_MODIFIER", 23, 45]]], ["Fresh and cryopreserved hMSCs-whether naive or pre-activated-significantly attenuated the increase in alveolar CINC-1 (Fig. 3b) and IL-6 ( Fig. 3c) concentrations.", [["Fresh", "ANATOMY", 0, 5], ["hMSCs", "ANATOMY", 24, 29], ["alveolar", "ANATOMY", 102, 110], ["hMSCs", "CELL", 24, 29], ["CINC-1", "GENE_OR_GENE_PRODUCT", 111, 117], ["Fig. 3b", "GENE_OR_GENE_PRODUCT", 119, 126], ["IL-6", "GENE_OR_GENE_PRODUCT", 132, 136], ["Fig. 3c)", "SIMPLE_CHEMICAL", 139, 147], ["hMSCs", "CELL_TYPE", 24, 29], ["Fresh and cryopreserved hMSCs", "PROBLEM", 0, 29], ["alveolar CINC", "TEST", 102, 115], ["IL", "TEST", 132, 134], ["cryopreserved hMSCs", "OBSERVATION", 10, 29], ["increase", "OBSERVATION_MODIFIER", 90, 98], ["alveolar", "ANATOMY", 102, 110]]], ["Pre-activated, but not naive, fresh XF-hMSCs significantly increased alveolar concentrations of anti-inflammatory IL-10 ( Fig. 3d) , pro-repair KGF (Fig. 3e ) and immunomodulatory PGE 2 (Fig. 3f) .", [["XF-hMSCs", "ANATOMY", 36, 44], ["alveolar", "ANATOMY", 69, 77], ["PGE 2", "CHEMICAL", 180, 185], ["XF-hMSCs", "CELL", 36, 44], ["alveolar", "MULTI-TISSUE_STRUCTURE", 69, 77], ["IL-10", "GENE_OR_GENE_PRODUCT", 114, 119], ["KGF", "GENE_OR_GENE_PRODUCT", 144, 147], ["PGE 2", "GENE_OR_GENE_PRODUCT", 180, 185], ["XF-hMSCs", "CELL_LINE", 36, 44], ["anti-inflammatory IL-10", "PROTEIN", 96, 119], ["pro-repair KGF", "PROTEIN", 133, 147], ["anti-inflammatory IL", "TREATMENT", 96, 116], ["immunomodulatory PGE", "TREATMENT", 163, 183], ["alveolar", "ANATOMY", 69, 77], ["anti-inflammatory", "OBSERVATION_MODIFIER", 96, 113]]], ["Cryopreserved XF-hMSCs, both naive and pre-activated, did not modulate IL-10, KGF or PGE 2 concentrations (Fig. 3) .Restoration of lung structureTreatment with fresh or cryopreserved hMSCs-both naive or pre-activated-fully restored lung histologic structure post-VILI as assessed by percentage airspace (Fig. 4a ) and the resolution of interstitial and alveolar inflammatory infiltrates (Fig. 4b) .Mechanisms of action-hMSC secretomeEpithelial wound healing hMSC CM, whether from FBS-or XF-cultured cells, significantly improved pulmonary epithelial wound repair, an effect which was further enhanced with cytokine preactivation (Fig. 5a) .", [["XF-hMSCs", "ANATOMY", 14, 22], ["lung", "ANATOMY", 131, 135], ["hMSCs", "ANATOMY", 183, 188], ["lung", "ANATOMY", 232, 236], ["airspace", "ANATOMY", 294, 302], ["interstitial", "ANATOMY", 336, 348], ["alveolar", "ANATOMY", 353, 361], ["hMSC", "ANATOMY", 419, 423], ["wound", "ANATOMY", 444, 449], ["hMSC CM", "ANATOMY", 458, 465], ["FBS", "ANATOMY", 480, 483], ["cells", "ANATOMY", 499, 504], ["pulmonary epithelial wound", "ANATOMY", 529, 555], ["CM", "DISEASE", 463, 465], ["PGE 2", "CHEMICAL", 85, 90], ["XF-hMSCs", "CELL", 14, 22], ["IL-10", "GENE_OR_GENE_PRODUCT", 71, 76], ["KGF", "GENE_OR_GENE_PRODUCT", 78, 81], ["PGE 2", "GENE_OR_GENE_PRODUCT", 85, 90], ["lung", "ORGAN", 131, 135], ["hMSCs", "CELL", 183, 188], ["lung", "ORGAN", 232, 236], ["airspace", "MULTI-TISSUE_STRUCTURE", 294, 302], ["interstitial", "MULTI-TISSUE_STRUCTURE", 336, 348], ["hMSC", "CELL", 419, 423], ["wound", "PATHOLOGICAL_FORMATION", 444, 449], ["hMSC CM", "CELL", 458, 465], ["FBS", "ORGANISM_SUBSTANCE", 480, 483], ["XF-cultured cells", "CELL", 487, 504], ["pulmonary epithelial wound", "PATHOLOGICAL_FORMATION", 529, 555], ["Cryopreserved XF-hMSCs", "CELL_LINE", 0, 22], ["IL", "PROTEIN", 71, 73], ["KGF", "PROTEIN", 78, 81], ["cryopreserved hMSCs", "CELL_LINE", 169, 188], ["hMSC secretomeEpithelial wound healing hMSC CM", "CELL_LINE", 419, 465], ["FBS-or XF-cultured cells", "CELL_LINE", 480, 504], ["cytokine", "PROTEIN", 606, 614], ["Restoration of lung structure", "PROBLEM", 116, 145], ["fresh or cryopreserved hMSCs", "TREATMENT", 160, 188], ["interstitial and alveolar inflammatory infiltrates", "PROBLEM", 336, 386], ["hMSC secretomeEpithelial wound healing hMSC CM", "PROBLEM", 419, 465], ["FBS", "TEST", 480, 483], ["XF", "TEST", 487, 489], ["cultured cells", "PROBLEM", 490, 504], ["pulmonary epithelial wound repair", "TREATMENT", 529, 562], ["cytokine preactivation", "TREATMENT", 606, 628], ["lung", "ANATOMY", 131, 135], ["structure", "OBSERVATION", 136, 145], ["lung", "ANATOMY", 232, 236], ["histologic", "OBSERVATION", 237, 247], ["VILI", "OBSERVATION", 263, 267], ["airspace", "ANATOMY_MODIFIER", 294, 302], ["resolution", "OBSERVATION_MODIFIER", 322, 332], ["interstitial", "ANATOMY_MODIFIER", 336, 348], ["alveolar", "ANATOMY_MODIFIER", 353, 361], ["inflammatory", "OBSERVATION_MODIFIER", 362, 374], ["infiltrates", "OBSERVATION", 375, 386], ["healing", "OBSERVATION_MODIFIER", 450, 457], ["hMSC CM", "OBSERVATION_MODIFIER", 458, 465], ["significantly", "OBSERVATION_MODIFIER", 506, 519], ["improved", "OBSERVATION_MODIFIER", 520, 528], ["pulmonary", "ANATOMY", 529, 538], ["epithelial", "ANATOMY_MODIFIER", 539, 549], ["wound repair", "OBSERVATION", 550, 562]]], ["The effect of cytokine pre-activation was blocked by the addition of a KGF-neutralizing antibody (Fig. 5b, c) .DiscussionIn this paper, we present several important findings, each of translational significance.", [["KGF", "GENE_OR_GENE_PRODUCT", 71, 74], ["cytokine", "PROTEIN", 14, 22], ["KGF", "PROTEIN", 71, 74], ["neutralizing antibody", "PROTEIN", 75, 96], ["Fig. 5b, c)", "PROTEIN", 98, 109], ["cytokine pre-activation", "TREATMENT", 14, 37], ["a KGF", "TEST", 69, 74], ["neutralizing antibody", "TEST", 75, 96]]], ["First, we demonstrate that the efficacy of MSCs was preserved when cultured in the xenogeneic material-free medium compared to the standard medium containing xenogeneic (bovine) products, an important advance.", [["MSCs", "ANATOMY", 43, 47], ["MSCs", "CELL", 43, 47], ["bovine", "ORGANISM", 170, 176], ["MSCs", "CELL_TYPE", 43, 47], ["bovine", "SPECIES", 170, 176], ["MSCs", "PROBLEM", 43, 47], ["the standard medium containing xenogeneic (bovine) products", "TREATMENT", 127, 186], ["MSCs", "OBSERVATION", 43, 47]]], ["Second, we demonstrate that MSCs subjected to cryopreservation and thawing maintained efficacy compared to fresh MSCs in a relevant preclinical model of VILI.", [["MSCs", "ANATOMY", 28, 32], ["MSCs", "ANATOMY", 113, 117], ["VILI", "DISEASE", 153, 157], ["MSCs", "CELL", 28, 32], ["MSCs", "CELL", 113, 117], ["MSCs", "CELL_TYPE", 28, 32], ["MSCs", "CELL_TYPE", 113, 117], ["MSCs", "PROBLEM", 28, 32], ["cryopreservation", "TREATMENT", 46, 62], ["fresh MSCs", "PROBLEM", 107, 117], ["MSCs", "OBSERVATION", 28, 32], ["VILI", "OBSERVATION", 153, 157]]], ["Third, we demonstrate the potential for Fig. 2 Pre-activated, cryopreserved, XF-hMSCs restore lung function after VILI.", [["XF-hMSCs", "ANATOMY", 77, 85], ["lung", "ANATOMY", 94, 98], ["XF-hMSCs", "CELL", 77, 85], ["lung", "ORGAN", 94, 98], ["Pre-activated, cryopreserved, XF-hMSCs", "CELL_LINE", 47, 85], ["Fig", "PROBLEM", 40, 43], ["lung", "ANATOMY", 94, 98]]], ["All MSC treatments significantly restored arterial PO 2 , with pre-activated cryopreserved cells statistically better than their naive alternatives (a).", [["MSC", "ANATOMY", 4, 7], ["arterial", "ANATOMY", 42, 50], ["cells", "ANATOMY", 91, 96], ["MSC", "CELL", 4, 7], ["cells", "CELL", 91, 96], ["pre-activated cryopreserved cells", "CELL_LINE", 63, 96], ["All MSC treatments", "TREATMENT", 0, 18], ["arterial PO", "TREATMENT", 42, 53], ["pre-activated cryopreserved cells", "TREATMENT", 63, 96]]], ["For static lung compliance, only activated fresh and activated frozen delivery showed significant restoration and were statistically different to their naive counterparts (b).", [["lung", "ANATOMY", 11, 15], ["lung", "ORGAN", 11, 15], ["activated frozen delivery", "TREATMENT", 53, 78], ["lung", "ANATOMY", 11, 15], ["compliance", "OBSERVATION", 16, 26], ["significant", "OBSERVATION_MODIFIER", 86, 97], ["restoration", "OBSERVATION", 98, 109]]], ["All treatment groups restored the lung wet to dry ratio (c), but only pre-activated MSCs modulated BAL protein content (d).", [["lung", "ANATOMY", 34, 38], ["MSCs", "ANATOMY", 84, 88], ["BAL", "ANATOMY", 99, 102], ["lung", "ORGAN", 34, 38], ["MSCs", "CELL", 84, 88], ["BAL", "ORGANISM_SUBSTANCE", 99, 102], ["pre-activated MSCs", "CELL_TYPE", 70, 88], ["BAL protein", "PROTEIN", 99, 110], ["All treatment groups", "TREATMENT", 0, 20], ["BAL protein content", "TEST", 99, 118], ["lung", "ANATOMY", 34, 38], ["wet", "OBSERVATION", 39, 42]]], ["P < 0.05, 0.01 and 0.001, respectively, versus PBS control groups; $ P < 0.05 versus corresponding naive groups.", [["P", "TEST", 0, 1], ["PBS control groups", "TREATMENT", 47, 65]]], ["Sham, n = 5-6; PBS control, n = 7-8; fresh, n = 7-8; fresh pre-activated, n = 6-8; cryopreserved, n = 5-6; cryopreserved pre-activated, n = 6-7 cytokine pre-activation to enhance the efficacy of MSCs and specifically their potential to enhance the efficacy of cryopreserved xeno-free MSCs.", [["MSCs", "ANATOMY", 195, 199], ["MSCs", "ANATOMY", 284, 288], ["MSCs", "CELL", 195, 199], ["MSCs", "CELL", 284, 288], ["cytokine", "PROTEIN", 144, 152], ["MSCs", "CELL_TYPE", 195, 199], ["cryopreserved xeno-free MSCs", "CELL_LINE", 260, 288], ["Sham", "TEST", 0, 4], ["PBS control", "TEST", 15, 26], ["cryopreserved", "TEST", 83, 96], ["cytokine pre-activation", "TREATMENT", 144, 167], ["MSCs", "PROBLEM", 195, 199], ["cryopreserved xeno-free MSCs", "TREATMENT", 260, 288], ["free MSCs", "OBSERVATION", 279, 288]]], ["Fourth, we illustrate the potential role of KGF in mediating some of the protective effects of these cryopreserved xeno-free MSCs in a relevant pulmonary epithelial repair model.", [["MSCs", "ANATOMY", 125, 129], ["pulmonary epithelial", "ANATOMY", 144, 164], ["KGF", "GENE_OR_GENE_PRODUCT", 44, 47], ["MSCs", "CELL", 125, 129], ["pulmonary epithelial", "TISSUE", 144, 164], ["KGF", "PROTEIN", 44, 47], ["cryopreserved xeno-free MSCs", "CELL_LINE", 101, 129], ["these cryopreserved xeno", "TREATMENT", 95, 119], ["free MSCs", "TREATMENT", 120, 129], ["a relevant pulmonary epithelial repair model", "TREATMENT", 133, 177], ["free MSCs", "OBSERVATION", 120, 129], ["pulmonary", "ANATOMY", 144, 153], ["epithelial repair", "OBSERVATION", 154, 171]]], ["Taken together, these findings address important translational concerns and significantly advances these cells towards clinical testing for patients with ARDS.Cryopreservation of hMSCsCryopreservation and storage of hMSCs would enable banking of hMSC batches that could then be thawed and administered in a timely fashion to patients with acute conditions such as ARDS.", [["cells", "ANATOMY", 105, 110], ["hMSCs", "ANATOMY", 216, 221], ["hMSC", "ANATOMY", 246, 250], ["ARDS", "DISEASE", 154, 158], ["ARDS", "DISEASE", 364, 368], ["cells", "CELL", 105, 110], ["patients", "ORGANISM", 140, 148], ["hMSCs", "CELL", 216, 221], ["hMSC", "CELL", 246, 250], ["patients", "ORGANISM", 325, 333], ["hMSCs", "CELL_TYPE", 216, 221], ["patients", "SPECIES", 140, 148], ["patients", "SPECIES", 325, 333], ["clinical testing", "TEST", 119, 135], ["ARDS", "PROBLEM", 154, 158], ["Cryopreservation", "TREATMENT", 159, 175], ["hMSCsCryopreservation", "TREATMENT", 179, 200], ["storage of hMSCs", "TREATMENT", 205, 221], ["hMSC batches", "TREATMENT", 246, 258], ["acute conditions", "PROBLEM", 339, 355], ["ARDS", "PROBLEM", 364, 368], ["ARDS", "OBSERVATION", 154, 158], ["ARDS", "OBSERVATION", 364, 368]]], ["The alternative, namely provision of freshly cultured hMSC, would require that hMSCs are continuously available for harvest, in facilities adjacent to the clinical settings, which presents substantial logistical and economic challenges.", [["hMSC", "ANATOMY", 54, 58], ["hMSCs", "ANATOMY", 79, 84], ["hMSC", "CELL", 54, 58], ["hMSCs", "CELL", 79, 84], ["freshly cultured hMSC", "CELL_LINE", 37, 58], ["hMSCs", "CELL_TYPE", 79, 84], ["freshly cultured hMSC", "TREATMENT", 37, 58], ["hMSCs", "TREATMENT", 79, 84], ["harvest", "TREATMENT", 116, 123]]], ["Other challenges include the risk of increased cell batch variability and the potential for contamination of batches.", [["cell", "ANATOMY", 47, 51], ["cell", "CELL", 47, 51], ["increased cell batch variability", "PROBLEM", 37, 69], ["contamination of batches", "TREATMENT", 92, 116], ["increased cell batch variability", "OBSERVATION", 37, 69]]], ["However, several studies demonstrate that the cryopreservation and thawing processes may significantly reduce the efficacy of hMSCs [19, 40] .", [["hMSCs", "ANATOMY", 126, 131], ["hMSCs", "CELL", 126, 131], ["hMSCs", "CELL_TYPE", 126, 131], ["several studies", "TEST", 9, 24], ["the cryopreservation", "TREATMENT", 42, 62], ["thawing processes", "TREATMENT", 67, 84]]], ["Our finding that cryopreserved XF-hMSCs can enhance the resolution of VILI when administered at therapeutically relevant time points in our rodent model supports recent findings in other models, including pneumonia-induced ARDS [41] , and are important demonstrations of the feasibility of cryopreservation of hMSCs.", [["XF-hMSCs", "ANATOMY", 31, 39], ["hMSCs", "ANATOMY", 310, 315], ["VILI", "DISEASE", 70, 74], ["pneumonia", "DISEASE", 205, 214], ["ARDS", "DISEASE", 223, 227], ["XF-hMSCs", "CELL", 31, 39], ["hMSCs", "CELL", 310, 315], ["cryopreserved XF-hMSCs", "CELL_LINE", 17, 39], ["hMSCs", "CELL_TYPE", 310, 315], ["VILI", "PROBLEM", 70, 74], ["recent findings in other models", "PROBLEM", 162, 193], ["pneumonia", "PROBLEM", 205, 214], ["ARDS", "PROBLEM", 223, 227], ["cryopreservation of hMSCs", "TREATMENT", 290, 315], ["pneumonia", "OBSERVATION", 205, 214], ["ARDS", "OBSERVATION", 223, 227]]], ["This insight is further supported by the observation that the secretory profile of hMSCs in regard to IL-8 release, whether the hMSCs were pre-activated or not, remained the same pre-and post-cryopreservation.Xenogeneic-free hMSCsConventional culture and passage of MSCs requires the use of xenogeneic supplements to aid cell growth and replication, which includes the use of FBS that contains large amounts of growth factors [42] .", [["hMSCs", "ANATOMY", 83, 88], ["hMSCs", "ANATOMY", 128, 133], ["MSCs", "ANATOMY", 266, 270], ["cell", "ANATOMY", 321, 325], ["FBS", "ANATOMY", 376, 379], ["hMSCs", "CELL", 83, 88], ["IL-8", "GENE_OR_GENE_PRODUCT", 102, 106], ["hMSCs", "CELL", 128, 133], ["MSCs", "CELL", 266, 270], ["cell", "CELL", 321, 325], ["FBS", "ORGANISM_SUBSTANCE", 376, 379], ["hMSCs", "CELL_TYPE", 83, 88], ["IL-8", "PROTEIN", 102, 106], ["hMSCs", "CELL_TYPE", 128, 133], ["Xenogeneic-free hMSCsConventional culture", "CELL_LINE", 209, 250], ["MSCs", "CELL_TYPE", 266, 270], ["growth factors", "PROTEIN", 411, 425], ["IL", "TREATMENT", 102, 104], ["the hMSCs", "TEST", 124, 133], ["Xenogeneic", "TREATMENT", 209, 219], ["free hMSCsConventional culture", "TEST", 220, 250], ["passage of MSCs", "PROBLEM", 255, 270], ["xenogeneic supplements", "TREATMENT", 291, 313], ["FBS", "TREATMENT", 376, 379], ["growth factors", "PROBLEM", 411, 425], ["large", "OBSERVATION_MODIFIER", 394, 399], ["amounts", "OBSERVATION_MODIFIER", 400, 407]]], ["However, the risks posed by the use of animal products in the culture medium of hMSCs intended ultimately for use in humans have been highlighted by the European Medicines Agency and US Food and Drug Administration [21] .", [["hMSCs", "ANATOMY", 80, 85], ["hMSCs", "CELL", 80, 85], ["humans", "ORGANISM", 117, 123], ["hMSCs", "CELL_TYPE", 80, 85], ["humans", "SPECIES", 117, 123], ["humans", "SPECIES", 117, 123], ["animal products", "TREATMENT", 39, 54], ["the culture medium of hMSCs", "TREATMENT", 58, 85]]], ["Concerns include the risk of contamination or immunogenicity [22] [23] [24] [25] .", [["contamination", "PROBLEM", 29, 42], ["immunogenicity", "PROBLEM", 46, 60]]], ["XF culture supplements would resolve these concerns.", [["XF culture supplements", "TREATMENT", 0, 22]]], ["It has proven challenging to identify alternatives to FBS that maintain comparable growth conditions for MSCs and that do not adversely alter cell efficacy [42] .", [["FBS", "ANATOMY", 54, 57], ["MSCs", "ANATOMY", 105, 109], ["cell", "ANATOMY", 142, 146], ["FBS", "ORGANISM_SUBSTANCE", 54, 57], ["MSCs", "CELL", 105, 109], ["cell", "CELL", 142, 146], ["MSCs", "CELL_TYPE", 105, 109], ["FBS", "TEST", 54, 57], ["MSCs", "PROBLEM", 105, 109]]], ["The recently patented XF supplement (WO2015121471 A1) has been demonstrated to preserve the differentiation, proliferation and low immunogenicity properties of MSCs [26] .", [["MSCs", "ANATOMY", 160, 164], ["XF", "CHEMICAL", 22, 24], ["WO2015121471 A1", "CHEMICAL", 37, 52], ["WO2015121471 A1", "CHEMICAL", 37, 52], ["XF", "SIMPLE_CHEMICAL", 22, 24], ["MSCs", "CELL", 160, 164], ["MSCs", "CELL_TYPE", 160, 164], ["The recently patented XF supplement", "TREATMENT", 0, 35], ["low immunogenicity properties of MSCs", "PROBLEM", 127, 164], ["low immunogenicity", "OBSERVATION_MODIFIER", 127, 145]]], ["Our finding that hMSCs cultured in this XF supplement retain the capacity to enhance the resolution of injury in our preclinical model of rodent VILI and maintain the secretome efficacy in attenuating pulmonary epithelial injury induced by cyclic stretch, and promoting wound healing in vitro, are important demonstrations of the therapeutic potential of XF-cultured hMSCs.hMSC secretomeMSCs release soluble anti-inflammatory and pro-repair molecules [43] [44] [45] , a mechanism of action that has raised interest in the use of the MSC secretome as an alternative to MSC cell therapy.", [["hMSCs", "ANATOMY", 17, 22], ["secretome", "ANATOMY", 167, 176], ["pulmonary epithelial", "ANATOMY", 201, 221], ["wound", "ANATOMY", 270, 275], ["hMSCs", "ANATOMY", 367, 372], ["hMSC", "ANATOMY", 373, 377], ["MSC", "ANATOMY", 533, 536], ["MSC cell", "ANATOMY", 568, 576], ["pulmonary epithelial injury", "DISEASE", 201, 228], ["[43] [44] [45]", "CHEMICAL", 451, 465], ["hMSCs", "CELL", 17, 22], ["XF", "SIMPLE_CHEMICAL", 40, 42], ["pulmonary epithelial", "TISSUE", 201, 221], ["wound", "PATHOLOGICAL_FORMATION", 270, 275], ["XF", "SIMPLE_CHEMICAL", 355, 357], ["hMSCs", "CELL", 367, 372], ["hMSC secretomeMSCs", "CELL", 373, 391], ["[43] [44] [45]", "SIMPLE_CHEMICAL", 451, 465], ["MSC", "CELL", 533, 536], ["MSC cell", "CELL", 568, 576], ["hMSCs", "CELL_TYPE", 17, 22], ["XF-cultured hMSCs", "CELL_LINE", 355, 372], ["hMSC", "CELL_TYPE", 373, 377], ["secretomeMSCs", "CELL_TYPE", 378, 391], ["rodent", "SPECIES", 138, 144], ["this XF supplement", "TREATMENT", 35, 53], ["the capacity", "PROBLEM", 61, 73], ["injury", "PROBLEM", 103, 109], ["attenuating pulmonary epithelial injury", "PROBLEM", 189, 228], ["cyclic stretch", "PROBLEM", 240, 254], ["promoting wound healing", "PROBLEM", 260, 283], ["XF-cultured hMSCs", "TREATMENT", 355, 372], ["hMSC secretomeMSCs release soluble anti-inflammatory and pro-repair molecules", "TREATMENT", 373, 450], ["the MSC secretome", "TREATMENT", 529, 546], ["MSC cell therapy", "TREATMENT", 568, 584], ["injury", "OBSERVATION", 103, 109], ["pulmonary", "ANATOMY", 201, 210], ["epithelial", "ANATOMY_MODIFIER", 211, 221], ["injury", "OBSERVATION", 222, 228], ["cyclic stretch", "OBSERVATION", 240, 254], ["wound", "OBSERVATION_MODIFIER", 270, 275], ["healing", "OBSERVATION_MODIFIER", 276, 283], ["MSC cell therapy", "OBSERVATION", 568, 584]]], ["This study demonstrated that the secretome of XF-hMSCs protected the pulmonary alveolar epithelium from injurious cyclic stretch and also demonstrates that pre-activation with inflammatory cytokines enhanced secretome efficacy (Additional file 1: Figure S1 and Additional file 2: Figure S2 ).", [["XF-hMSCs", "ANATOMY", 46, 54], ["pulmonary alveolar epithelium", "ANATOMY", 69, 98], ["XF-hMSCs", "CELL", 46, 54], ["pulmonary alveolar epithelium", "TISSUE", 69, 98], ["XF-hMSCs", "CELL_LINE", 46, 54], ["inflammatory cytokines", "PROTEIN", 176, 198], ["This study", "TEST", 0, 10], ["the pulmonary alveolar epithelium", "PROBLEM", 65, 98], ["injurious cyclic stretch", "PROBLEM", 104, 128], ["inflammatory cytokines enhanced secretome efficacy", "PROBLEM", 176, 226], ["pulmonary", "ANATOMY", 69, 78], ["alveolar", "ANATOMY_MODIFIER", 79, 87], ["epithelium", "ANATOMY_MODIFIER", 88, 98], ["injurious cyclic stretch", "OBSERVATION", 104, 128], ["inflammatory", "OBSERVATION_MODIFIER", 176, 188]]], ["These findings were also true for the enhancement of wound healing.", [["wound", "ANATOMY", 53, 58], ["wound", "PATHOLOGICAL_FORMATION", 53, 58], ["wound healing", "PROBLEM", 53, 66], ["wound", "OBSERVATION", 53, 58], ["healing", "OBSERVATION_MODIFIER", 59, 66]]], ["We further went on to show that KGF neutralization can negate the enhancement observed as a result of cytokine preactivation.", [["KGF", "GENE_OR_GENE_PRODUCT", 32, 35], ["KGF", "PROTEIN", 32, 35], ["cytokine", "PROTEIN", 102, 110], ["KGF neutralization", "PROBLEM", 32, 50], ["the enhancement", "PROBLEM", 62, 77], ["cytokine preactivation", "PROBLEM", 102, 124], ["cytokine preactivation", "OBSERVATION", 102, 124]]], ["These outcomes extend findings from previous in vitro and in vivo studies showing that the MSC secretome resolved the inflammatory response and promoted repair and recovery post-VILI [13, 33] and thus strengthens the justification for the use of the secretome as a viable alternative therapy against VILI.", [["MSC", "ANATOMY", 91, 94], ["VILI", "DISEASE", 300, 304], ["MSC", "CELL", 91, 94], ["vivo studies", "TEST", 61, 73], ["the MSC secretome", "PROBLEM", 87, 104], ["the inflammatory response", "PROBLEM", 114, 139], ["promoted repair", "TREATMENT", 144, 159], ["VILI", "TEST", 178, 182], ["the secretome", "TREATMENT", 246, 259], ["a viable alternative therapy", "TREATMENT", 263, 291], ["VILI", "PROBLEM", 300, 304], ["inflammatory response", "OBSERVATION", 118, 139], ["repair", "OBSERVATION", 153, 159]]], ["However, it should be noted that the secretome may be less effective compared to hMSCs, especially in the early phases of the injury resolution process [46] .Activation of hMSCsMSCs are responsive to their microenvironment [44, 47] potentially providing a means of enhancing their efficacy via pre-activation strategies prior to their delivery.", [["hMSCs", "ANATOMY", 81, 86], ["hMSCsMSCs", "ANATOMY", 172, 181], ["hMSCs", "CELL", 81, 86], ["hMSCsMSCs", "GENE_OR_GENE_PRODUCT", 172, 181], ["hMSCs", "CELL_TYPE", 81, 86], ["hMSCsMSCs", "CELL_TYPE", 172, 181], ["the secretome", "PROBLEM", 33, 46], ["hMSCs", "TEST", 81, 86], ["the injury resolution process", "PROBLEM", 122, 151], ["Activation of hMSCsMSCs", "PROBLEM", 158, 181], ["pre-activation strategies", "TREATMENT", 294, 319], ["their delivery", "TREATMENT", 329, 343], ["secretome", "OBSERVATION", 37, 46], ["may be", "UNCERTAINTY", 47, 53], ["less effective", "OBSERVATION_MODIFIER", 54, 68]]], ["Recent studies have shown that MSCs pre-activated with inflammatory cytokines possess enhanced therapeutic properties [48] .", [["MSCs", "ANATOMY", 31, 35], ["MSCs", "CELL", 31, 35], ["MSCs", "CELL_TYPE", 31, 35], ["inflammatory cytokines", "PROTEIN", 55, 77], ["Recent studies", "TEST", 0, 14], ["MSCs", "PROBLEM", 31, 35], ["inflammatory cytokines", "TEST", 55, 77]]], ["Several other promising MSC activation strategies have been elucidated, including IL-10 overexpression [49] and interferon-\u03b3 priming [50] .", [["MSC", "ANATOMY", 24, 27], ["MSC", "CELL", 24, 27], ["IL-10", "GENE_OR_GENE_PRODUCT", 82, 87], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 112, 124], ["IL", "PROTEIN", 82, 84], ["interferon", "PROTEIN", 112, 122], ["\u03b3", "PROTEIN", 123, 124], ["Several other promising MSC activation strategies", "PROBLEM", 0, 49], ["interferon", "TREATMENT", 112, 122], ["promising", "OBSERVATION_MODIFIER", 14, 23], ["MSC activation", "OBSERVATION", 24, 38]]], ["Our studies advance our understanding of the therapeutic potential of priming by demonstrating that cytokine pre-activation can restore and/or enhance the function of cryopreserved XF-cultured hMSCs.Activation of hMSCsOne aim in pre-activating cryopreserved MSCs with cytomix was to restore any therapeutic potency that might have been lost during cryopreservation.", [["hMSCs", "ANATOMY", 193, 198], ["MSCs", "ANATOMY", 258, 262], ["XF", "CELL", 181, 183], ["hMSCs", "CELL", 193, 198], ["hMSCsOne", "GENE_OR_GENE_PRODUCT", 213, 221], ["MSCs", "CELL", 258, 262], ["cytomix", "SIMPLE_CHEMICAL", 268, 275], ["cytokine", "PROTEIN", 100, 108], ["cryopreserved XF-cultured hMSCs", "CELL_LINE", 167, 198], ["pre-activating cryopreserved MSCs", "CELL_LINE", 229, 262], ["Our studies", "TEST", 0, 11], ["cytokine pre-activation", "TREATMENT", 100, 123], ["cryopreserved XF", "TREATMENT", 167, 183], ["Activation of hMSCsOne aim", "TREATMENT", 199, 225], ["pre-activating cryopreserved MSCs", "TREATMENT", 229, 262], ["cytomix", "TREATMENT", 268, 275], ["cryopreservation", "TREATMENT", 348, 364]]], ["In regard to oxygenation, where cryopreserved MSCs only partially restored oxygenation, preactivation did further enhance restoration of oxygenation.", [["MSCs", "ANATOMY", 46, 50], ["MSCs", "CELL", 46, 50], ["cryopreserved MSCs", "CELL_TYPE", 32, 50], ["cryopreserved MSCs", "PROBLEM", 32, 50], ["oxygenation", "OBSERVATION", 13, 24], ["oxygenation", "OBSERVATION_MODIFIER", 137, 148]]], ["The second aim was to enhance MSC capacity to restore function post-VILI.", [["MSC", "ANATOMY", 30, 33], ["MSC", "CELL", 30, 33], ["VILI", "OBSERVATION", 68, 72]]], ["In regard to lung compliance, where the effect of even fresh MSCs was limited, pre-activation enhanced both the cryopreserved and the fresh MSCs in restoring lung compliance.Activation of hMSCsImportantly, cytokine activation prior to cryopreservation enhanced the hMSC efficacy following storage and subsequent thawing and administration to the animals following VILI at a later and more clinically relevant time point.", [["lung", "ANATOMY", 13, 17], ["MSCs", "ANATOMY", 61, 65], ["MSCs", "ANATOMY", 140, 144], ["lung", "ANATOMY", 158, 162], ["hMSC", "ANATOMY", 265, 269], ["lung", "ORGAN", 13, 17], ["MSCs", "CELL", 61, 65], ["MSCs", "CELL", 140, 144], ["lung", "ORGAN", 158, 162], ["hMSCsImportantly", "GENE_OR_GENE_PRODUCT", 188, 204], ["hMSC", "CELL", 265, 269], ["MSCs", "CELL_TYPE", 61, 65], ["MSCs", "CELL_TYPE", 140, 144], ["hMSCsImportantly", "PROTEIN", 188, 204], ["cytokine", "PROTEIN", 206, 214], ["even fresh MSCs", "PROBLEM", 50, 65], ["the fresh MSCs", "TREATMENT", 130, 144], ["Activation of hMSCsImportantly", "TREATMENT", 174, 204], ["cytokine activation", "TREATMENT", 206, 225], ["cryopreservation", "TREATMENT", 235, 251], ["administration", "TREATMENT", 324, 338], ["VILI", "TREATMENT", 364, 368], ["lung", "ANATOMY", 13, 17], ["compliance", "OBSERVATION", 18, 28], ["fresh MSCs", "OBSERVATION", 134, 144], ["lung", "ANATOMY", 158, 162], ["compliance", "OBSERVATION", 163, 173]]], ["This provides an important finding with regard to other pre-activation or enhancement strategies for hMSC therapy applications, and it suggests such modifications are compatible with cryopreservation protocols.LimitationsThere are a number of limitations to these studies.", [["hMSC", "ANATOMY", 101, 105], ["hMSC", "CELL", 101, 105], ["enhancement strategies", "TREATMENT", 74, 96], ["hMSC therapy applications", "TREATMENT", 101, 126], ["cryopreservation protocols", "TREATMENT", 183, 209], ["these studies", "TEST", 258, 271]]], ["First, while we provide data to demonstrate that pre-activation of cryopreserved XF hMSCs enhances their ability to promote injury resolution following VILI and the ability of their secretome to reduce stretch injury and promote pulmonary epithelial wound repair, these studies were carried out in a rodent model and in vitro, and caution must be exercised in extrapolating to the clinical situation.", [["XF hMSCs", "ANATOMY", 81, 89], ["pulmonary epithelial wound", "ANATOMY", 229, 255], ["XF hMSCs", "CELL", 81, 89], ["pulmonary epithelial wound", "PATHOLOGICAL_FORMATION", 229, 255], ["cryopreserved XF hMSCs", "CELL_LINE", 67, 89], ["cryopreserved XF hMSCs", "TREATMENT", 67, 89], ["VILI", "TREATMENT", 152, 156], ["stretch injury", "PROBLEM", 202, 216], ["pulmonary epithelial wound repair", "TREATMENT", 229, 262], ["these studies", "TEST", 264, 277], ["pulmonary", "ANATOMY", 229, 238], ["epithelial", "ANATOMY_MODIFIER", 239, 249], ["wound repair", "OBSERVATION", 250, 262]]], ["However, we have used a clinically relevant injury resolution VILI model and utilized human MSCs.", [["MSCs", "ANATOMY", 92, 96], ["human", "ORGANISM", 86, 91], ["MSCs", "CELL", 92, 96], ["human MSCs", "CELL_TYPE", 86, 96], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["human MSCs", "TREATMENT", 86, 96]]], ["Thus, these findings strongly suggest that the therapeutic potential of cryopreserved XF-hMSCs for human ARDS may be enhanced by pre-activation measures.", [["XF-hMSCs", "ANATOMY", 86, 94], ["ARDS", "DISEASE", 105, 109], ["XF-hMSCs", "CELL", 86, 94], ["human", "ORGANISM", 99, 104], ["cryopreserved XF-hMSCs", "CELL_LINE", 72, 94], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["cryopreserved XF", "PROBLEM", 72, 88], ["human ARDS", "PROBLEM", 99, 109], ["pre-activation measures", "TREATMENT", 129, 152], ["ARDS", "OBSERVATION", 105, 109]]], ["Second, we did not use a control non-stem cell group, such as a fibroblast group.", [["non-stem cell", "ANATOMY", 33, 46], ["fibroblast", "ANATOMY", 64, 74], ["non-stem cell", "CELL", 33, 46], ["fibroblast", "CELL", 64, 74], ["non-stem cell group", "CELL_LINE", 33, 52], ["a control non-stem cell group", "TREATMENT", 23, 52], ["a fibroblast group", "TREATMENT", 62, 80], ["fibroblast group", "OBSERVATION", 64, 80]]], ["In our previous experiments, rodent fibroblasts had no beneficial effect [35] , while in experiments using human fibroblasts in rodents, some parameters indicative of injury were worsened [51] .", [["fibroblasts", "ANATOMY", 36, 47], ["fibroblasts", "ANATOMY", 113, 124], ["rodent", "ORGANISM", 29, 35], ["fibroblasts", "CELL", 36, 47], ["human", "ORGANISM", 107, 112], ["fibroblasts", "CELL", 113, 124], ["rodent fibroblasts", "CELL_TYPE", 29, 47], ["human fibroblasts", "CELL_TYPE", 107, 124], ["rodent", "SPECIES", 29, 35], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["rodent fibroblasts", "PROBLEM", 29, 47], ["beneficial effect", "PROBLEM", 55, 72], ["human fibroblasts in rodents", "TREATMENT", 107, 135], ["injury", "PROBLEM", 167, 173], ["injury", "OBSERVATION", 167, 173], ["worsened", "OBSERVATION_MODIFIER", 179, 187]]], ["Therefore, we believe that a fibroblast control is not justifiable for these studies.", [["fibroblast", "ANATOMY", 29, 39], ["fibroblast", "CELL", 29, 39], ["a fibroblast control", "TREATMENT", 27, 47], ["these studies", "TEST", 71, 84]]], ["Our in vitro studies used A549 cells, an adenocarcinoma human alveolar basal cell line.", [["A549 cells", "ANATOMY", 26, 36], ["adenocarcinoma", "ANATOMY", 41, 55], ["alveolar basal cell line", "ANATOMY", 62, 86], ["adenocarcinoma", "DISEASE", 41, 55], ["A549 cells", "CELL", 26, 36], ["human", "ORGANISM", 56, 61], ["alveolar basal cell line", "CELL", 62, 86], ["A549 cells", "CELL_LINE", 26, 36], ["adenocarcinoma human alveolar basal cell line", "CELL_LINE", 41, 86], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["A549 cells", "TREATMENT", 26, 36], ["an adenocarcinoma human alveolar basal cell line", "PROBLEM", 38, 86], ["A549 cells", "OBSERVATION", 26, 36], ["adenocarcinoma", "OBSERVATION", 41, 55], ["alveolar", "ANATOMY_MODIFIER", 62, 70], ["basal cell line", "OBSERVATION", 71, 86]]], ["These cells did have the advantage of being a widely used cell line, and they had an integrated NF-\u03baB reporter.", [["cells", "ANATOMY", 6, 11], ["cell line", "ANATOMY", 58, 67], ["cells", "CELL", 6, 11], ["cell line", "CELL", 58, 67], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 96, 101], ["NF-\u03baB reporter", "DNA", 96, 110], ["a widely used cell line", "TREATMENT", 44, 67], ["cell line", "OBSERVATION", 58, 67]]], ["Finally, we do not provide data on a single overall mechanism of action of MSCs.", [["MSCs", "ANATOMY", 75, 79], ["MSCs", "CELL", 75, 79], ["MSCs", "CELL_TYPE", 75, 79], ["MSCs", "PROBLEM", 75, 79]]], ["Our studies to date [33, 35, 51, 52] , and those of other groups [15, 53, 54] , indicate that the effects of MSCs on, for example, innate and adaptive immunity, including antimicrobial effects, are varied, context dependent and not encapsulated by a single secreted mediator or group of mediators.", [["MSCs", "ANATOMY", 109, 113], ["MSCs", "CELL", 109, 113], ["MSCs", "CELL_TYPE", 109, 113], ["Our studies", "TEST", 0, 11], ["MSCs", "PROBLEM", 109, 113], ["antimicrobial effects", "TREATMENT", 171, 192]]], ["Nonetheless, we show that the mechanisms of MSC therapy via their secretome as a whole is enhanced with pre-activation and is partly mediated through KGF.ConclusionIn conclusion, we demonstrate that hMSCs cultured in xenogeneic material-free medium enhance the recovery and resolution of VILI when administered at clinically relevant time points following the establishment of injury.", [["MSC", "ANATOMY", 44, 47], ["hMSCs", "ANATOMY", 199, 204], ["VILI", "DISEASE", 288, 292], ["MSC", "CELL", 44, 47], ["KGF", "GENE_OR_GENE_PRODUCT", 150, 153], ["hMSCs", "CELL", 199, 204], ["MSC", "CELL_TYPE", 44, 47], ["KGF", "PROTEIN", 150, 153], ["hMSCs", "CELL_TYPE", 199, 204], ["MSC therapy", "TREATMENT", 44, 55], ["pre-activation", "TREATMENT", 104, 118], ["hMSCs", "TEST", 199, 204], ["xenogeneic material", "TEST", 217, 236], ["VILI", "PROBLEM", 288, 292], ["injury", "PROBLEM", 377, 383], ["MSC therapy", "OBSERVATION", 44, 55], ["injury", "OBSERVATION", 377, 383]]], ["These xenogeneic hMSCs were similarly effective following cryopreservation and thawing to fresh MSCs.", [["hMSCs", "ANATOMY", 17, 22], ["MSCs", "ANATOMY", 96, 100], ["hMSCs", "CELL", 17, 22], ["MSCs", "CELL", 96, 100], ["xenogeneic hMSCs", "CELL_LINE", 6, 22], ["MSCs", "CELL_TYPE", 96, 100], ["These xenogeneic hMSCs", "TREATMENT", 0, 22], ["cryopreservation", "TREATMENT", 58, 74], ["fresh MSCs", "PROBLEM", 90, 100]]], ["Cytokine pre-activation further enhanced the efficacy of cryopreserved xeno-free MSCs.", [["MSCs", "ANATOMY", 81, 85], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["MSCs", "CELL", 81, 85], ["Cytokine", "PROTEIN", 0, 8], ["cryopreserved xeno-free MSCs", "CELL_TYPE", 57, 85], ["Cytokine pre-activation", "TREATMENT", 0, 23], ["cryopreserved xeno-free MSCs", "PROBLEM", 57, 85], ["free MSCs", "OBSERVATION", 76, 85]]], ["KGF may mediate some of the protective effects of these cryopreserved xeno-free MSCs.", [["MSCs", "ANATOMY", 80, 84], ["KGF", "GENE_OR_GENE_PRODUCT", 0, 3], ["MSCs", "CELL", 80, 84], ["KGF", "PROTEIN", 0, 3], ["cryopreserved xeno-free MSCs", "CELL_LINE", 56, 84], ["these cryopreserved xeno-free MSCs", "TREATMENT", 50, 84], ["free MSCs", "OBSERVATION", 75, 84]]], ["Taken together, these findings address important translational concerns and significantly advances cryopreserved xeno-free hMSCs towards clinical testing for patients with ARDS.Supplementary informationSupplementary information accompanies this paper at https://doi.org/10.1186/s40635-020-0295-5.Supplementary informationAdditional file 1: Figure S1 . hMSCs retain their secretary profile pre-and post-cryopreservation.", [["hMSCs", "ANATOMY", 123, 128], ["hMSCs", "ANATOMY", 352, 357], ["ARDS", "DISEASE", 172, 176], ["hMSCs", "CELL", 123, 128], ["patients", "ORGANISM", 158, 166], ["hMSCs", "CELL", 352, 357], ["cryopreserved xeno-free hMSCs", "CELL_LINE", 99, 128], ["hMSCs", "CELL_TYPE", 352, 357], ["patients", "SPECIES", 158, 166], ["advances cryopreserved xeno-free hMSCs", "TREATMENT", 90, 128], ["clinical testing", "TEST", 137, 153], ["ARDS", "PROBLEM", 172, 176], ["ARDS", "OBSERVATION", 172, 176]]], ["IL-8 release by fresh naive hMSCs or fresh activated hMSCs is unaffected 24 h and 48 h post-thaw after cryopreservation. n = 3 for all groups.Supplementary informationAdditional file 2: Figure S2 .", [["hMSCs", "ANATOMY", 28, 33], ["hMSCs", "ANATOMY", 53, 58], ["IL-8", "GENE_OR_GENE_PRODUCT", 0, 4], ["hMSCs", "CELL", 28, 33], ["hMSCs", "CELL", 53, 58], ["IL-8", "PROTEIN", 0, 4], ["naive hMSCs", "CELL_TYPE", 22, 33], ["hMSCs", "CELL_TYPE", 53, 58], ["IL", "TREATMENT", 0, 2], ["fresh activated hMSCs", "PROBLEM", 37, 58], ["cryopreservation", "TREATMENT", 103, 119]]], ["Pre-activated, cryopreserved, XF-hMSCs enhance the resolution of alveolar cell counts.", [["XF-hMSCs", "ANATOMY", 30, 38], ["alveolar cell", "ANATOMY", 65, 78], ["XF-hMSCs", "CELL", 30, 38], ["alveolar cell", "CELL", 65, 78], ["Pre-activated, cryopreserved, XF-hMSCs", "CELL_LINE", 0, 38], ["alveolar cell counts", "TEST", 65, 85], ["alveolar cell counts", "OBSERVATION", 65, 85]]], ["Fresh, but not cryopreserved, XF-hMSCs decreased alveolar cell counts, while cytokine pre-activation restored the efficacy of cryopreserved hMSCs in reducing alveolar cell counts. ** and ***P < 0.01 and 0.001, respectively, versus PBS control; $$ P < 0.01 versus naive cryopreserved group.", [["XF-hMSCs", "ANATOMY", 30, 38], ["alveolar cell", "ANATOMY", 49, 62], ["hMSCs", "ANATOMY", 140, 145], ["alveolar cell", "ANATOMY", 158, 171], ["XF-hMSCs", "CELL", 30, 38], ["alveolar cell", "CELL", 49, 62], ["hMSCs", "CELL", 140, 145], ["alveolar cell", "CELL", 158, 171], ["XF-hMSCs", "CELL_LINE", 30, 38], ["cytokine", "PROTEIN", 77, 85], ["cryopreserved hMSCs", "CELL_TYPE", 126, 145], ["XF", "TEST", 30, 32], ["alveolar cell counts", "TEST", 49, 69], ["cytokine pre-activation", "TREATMENT", 77, 100], ["cryopreserved hMSCs", "PROBLEM", 126, 145], ["alveolar cell counts", "TEST", 158, 178], ["naive cryopreserved group", "TREATMENT", 263, 288], ["not", "UNCERTAINTY", 11, 14], ["cryopreserved", "OBSERVATION", 15, 28], ["decreased", "OBSERVATION_MODIFIER", 39, 48], ["alveolar cell counts", "OBSERVATION", 49, 69], ["cryopreserved hMSCs", "OBSERVATION", 126, 145], ["alveolar cell counts", "OBSERVATION", 158, 178]]], ["Sham, n = ; PBS control, n = 8; fresh, n = 8; fresh pre-activated, n = 7; cryopreserved, n = 5; cryopreserved pre-activated, n = 7.", [["PBS control", "TEST", 12, 23]]]], "0865aaa85391ecf5ead0c5be59c431bfdd895097": [["IntroductionIntroduction of foreign DNA into the murine genome by microinjection and the generation of transgenic offspring were first reported by Gordon et al. (1980) and Gordon and Ruddle (1981) .", [["DNA", "CELLULAR_COMPONENT", 36, 39], ["murine", "ORGANISM", 49, 55], ["foreign DNA", "DNA", 28, 39], ["murine genome", "DNA", 49, 62], ["murine", "SPECIES", 49, 55], ["IntroductionIntroduction", "TREATMENT", 0, 24], ["foreign DNA", "TREATMENT", 28, 39], ["the murine genome", "TREATMENT", 45, 62], ["foreign DNA", "OBSERVATION", 28, 39], ["murine genome", "OBSERVATION", 49, 62]]], ["This technique has been applied to the production of transgenic livestock.", [["This technique", "TREATMENT", 0, 14], ["transgenic livestock", "OBSERVATION", 53, 73]]], ["Using mammary gland-specific promoters, a wide range of proteins of biopharmaceutical interest have been expressed in rodents, pigs, and dairy animals.", [["mammary gland", "ANATOMY", 6, 19], ["mammary gland", "MULTI-TISSUE_STRUCTURE", 6, 19], ["pigs", "ORGANISM", 127, 131], ["pigs", "SPECIES", 127, 131], ["pigs", "SPECIES", 127, 131], ["mammary gland", "ANATOMY", 6, 19]]], ["An expression vector, comprising a gene encoding the target protein of interest fused to a milk promoter gene, is introduced by microinjection into the pronucleus of a one-cell embryo.", [["pronucleus", "ANATOMY", 152, 162], ["cell embryo", "ANATOMY", 172, 183], ["pronucleus", "CELLULAR_COMPONENT", 152, 162], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 177, 183], ["expression vector", "DNA", 3, 20], ["milk promoter gene", "DNA", 91, 109], ["An expression vector", "TREATMENT", 0, 20], ["a milk promoter gene", "TREATMENT", 89, 109], ["cell embryo", "OBSERVATION", 172, 183]]], ["Upon germ line integration and expression, the transgene becomes a dominant Mendelian genetic characteristic that is inherited by the progeny of the founder animal.", [["germ line", "ANATOMY", 5, 14], ["germ line", "CELL", 5, 14], ["germ line integration", "TREATMENT", 5, 26], ["germ line", "OBSERVATION", 5, 14]]], ["The transgenic offspring may express the target protein in gram per liter quantities, most frequently as a soluble whey protein.", [["target protein", "PROTEIN", 41, 55], ["soluble whey protein", "PROTEIN", 107, 127], ["a soluble whey protein", "TREATMENT", 105, 127]]], ["Mammalian mammary epithelial cells have the capacity to carry out complex protein synthesis with a variety of posttranslational modifications and proper folding.", [["mammary epithelial cells", "ANATOMY", 10, 34], ["mammary epithelial cells", "CELL", 10, 34], ["Mammalian mammary epithelial cells", "CELL_TYPE", 0, 34], ["Mammalian mammary epithelial cells", "PROBLEM", 0, 34], ["the capacity", "PROBLEM", 40, 52], ["complex protein synthesis", "PROBLEM", 66, 91], ["posttranslational modifications", "PROBLEM", 110, 141], ["mammary", "ANATOMY", 10, 17], ["epithelial cells", "OBSERVATION", 18, 34], ["protein synthesis", "OBSERVATION", 74, 91], ["variety", "OBSERVATION_MODIFIER", 99, 106], ["posttranslational modifications", "OBSERVATION", 110, 141], ["proper folding", "OBSERVATION", 146, 160]]], ["Coexpression of modifying enzymes in the epithelial cell Golgi apparatus may allow the heterologous protein to be engineered to confer specific or desired pharmacokinetic characteristics.", [["epithelial cell Golgi", "ANATOMY", 41, 62], ["epithelial cell", "CELL", 41, 56], ["modifying enzymes", "PROTEIN", 16, 33], ["heterologous protein", "PROTEIN", 87, 107], ["modifying enzymes", "TEST", 16, 33], ["the heterologous protein", "TREATMENT", 83, 107], ["epithelial cell", "OBSERVATION", 41, 56]]], ["The milk of transgenic livestock presents an excellent starting material from which human diagnostic or pharmaceutically active, therapeutic proteins may be purified using established technologies of the dairy and biopharmaceutical industries.IntroductionTo date (1997) , probably more than 50 proteins have been expressed in the milk of transgenic mice, rats, rabbits, goats, sheep, pigs, and dairy cows.", [["milk", "ANATOMY", 4, 8], ["milk", "ANATOMY", 330, 334], ["milk", "ORGANISM_SUBSTANCE", 4, 8], ["human", "ORGANISM", 84, 89], ["milk", "ORGANISM_SUBSTANCE", 330, 334], ["mice", "ORGANISM", 349, 353], ["rats", "ORGANISM", 355, 359], ["rabbits", "ORGANISM", 361, 368], ["goats", "ORGANISM", 370, 375], ["sheep", "ORGANISM", 377, 382], ["pigs", "ORGANISM", 384, 388], ["cows", "ORGANISM", 400, 404], ["human", "SPECIES", 84, 89], ["mice", "SPECIES", 349, 353], ["rats", "SPECIES", 355, 359], ["rabbits", "SPECIES", 361, 368], ["goats", "SPECIES", 370, 375], ["sheep", "SPECIES", 377, 382], ["pigs", "SPECIES", 384, 388], ["cows", "SPECIES", 400, 404], ["human", "SPECIES", 84, 89], ["mice", "SPECIES", 349, 353], ["rabbits", "SPECIES", 361, 368], ["goats", "SPECIES", 370, 375], ["sheep", "SPECIES", 377, 382], ["pigs", "SPECIES", 384, 388], ["therapeutic proteins", "TREATMENT", 129, 149]]], ["Phase I clinical trials with antithrombin III produced in transgenic goats were completed successfully in 1996, and phase II clinical trials are currently being performed in the United States. ~l-Antitrypsin produced in transgenic sheep is currently in phase I clinical trials in the United Kingdom.", [["~l-Antitrypsin", "CHEMICAL", 193, 207], ["antithrombin III", "GENE_OR_GENE_PRODUCT", 29, 45], ["goats", "ORGANISM", 69, 74], ["~l-Antitrypsin", "GENE_OR_GENE_PRODUCT", 193, 207], ["sheep", "ORGANISM", 231, 236], ["antithrombin III", "PROTEIN", 29, 45], ["~l-Antitrypsin", "PROTEIN", 193, 207], ["goats", "SPECIES", 69, 74], ["sheep", "SPECIES", 231, 236], ["goats", "SPECIES", 69, 74], ["sheep", "SPECIES", 231, 236], ["antithrombin III", "TREATMENT", 29, 45], ["transgenic goats", "TREATMENT", 58, 74], ["~l-Antitrypsin", "TREATMENT", 193, 207]]], ["In addition, human lactoferrin and fibrinogen expressed in the milk of transgenic cows and sheep, respectively, are in the late stages of development or preclinical evaluation.IntroductionThe field of transgenic research has been reviewed periodically since 1990.", [["milk", "ANATOMY", 63, 67], ["human", "ORGANISM", 13, 18], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 19, 30], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 35, 45], ["milk", "ORGANISM_SUBSTANCE", 63, 67], ["cows", "ORGANISM", 82, 86], ["sheep", "ORGANISM", 91, 96], ["human lactoferrin", "PROTEIN", 13, 30], ["fibrinogen", "PROTEIN", 35, 45], ["human", "SPECIES", 13, 18], ["cows", "SPECIES", 82, 86], ["sheep", "SPECIES", 91, 96], ["human", "SPECIES", 13, 18], ["cows", "SPECIES", 82, 86], ["sheep", "SPECIES", 91, 96], ["human lactoferrin", "TREATMENT", 13, 30], ["fibrinogen", "TREATMENT", 35, 45], ["preclinical evaluation", "TEST", 153, 175], ["late stages", "OBSERVATION_MODIFIER", 123, 134]]], ["The reader will find the following articles, which trace the development of transgenic technology applied to dairy animals, of interest: Henninghausen (1990) , Henninghausen et al. (1990) , Bialy (1991) , Wilmut et al. (1991) , Wall et al. (1992) , J~inne et al. (1992, 1994) , Logan (1993) , Ebert and Schindler (1993) , Lee and de Boer (1994) , Houdebine (1994 Houdebine ( , 1995 , and Echelard (1996) .IntroductionThis chapter discusses the expression of therapeutically useful proteins in mammalian milk with a focus on dairy animals as the production systems of choice and reviews expression constructs, milk-specific transgenes, transgene insertion, transgenic animal production, protein biosynthesis and secretion, lactation, milk, protein purification, and quality and regulatory issues.Expression of Heterologous Proteins in MilkLaboratory mice have served as a model expression system for foreign proteins since the inception of animal transgenesis and are used frequently for feasibility studies concomitant with or prior to the generation of larger, founder transgenic animals.", [["milk", "ANATOMY", 503, 507], ["milk", "ANATOMY", 609, 613], ["milk", "ANATOMY", 733, 737], ["milk", "ORGANISM_SUBSTANCE", 503, 507], ["milk", "ORGANISM_SUBDIVISION", 609, 613], ["milk", "ORGANISM_SUBSTANCE", 733, 737], ["MilkLaboratory mice", "ORGANISM", 834, 853], ["expression constructs", "DNA", 586, 607], ["milk-specific transgenes", "DNA", 609, 633], ["Heterologous Proteins", "PROTEIN", 809, 830], ["foreign proteins", "PROTEIN", 899, 915], ["mice", "SPECIES", 849, 853], ["mice", "SPECIES", 849, 853], ["transgenic technology", "TREATMENT", 76, 97], ["specific transgenes", "TREATMENT", 614, 633], ["transgene insertion", "TREATMENT", 635, 654], ["transgenic animal production", "TREATMENT", 656, 684], ["protein biosynthesis", "TREATMENT", 686, 706], ["protein purification", "TREATMENT", 739, 759], ["Heterologous Proteins in MilkLaboratory mice", "PROBLEM", 809, 853], ["foreign proteins", "PROBLEM", 899, 915], ["animal transgenesis", "TREATMENT", 939, 958], ["feasibility studies", "TEST", 987, 1006], ["larger", "OBSERVATION_MODIFIER", 1054, 1060]]], ["Many recombinant proteins of interest in human therapy are, by their very nature, biologically active in most mammals.", [["human", "ORGANISM", 41, 46], ["recombinant proteins", "PROTEIN", 5, 25], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["human therapy", "TREATMENT", 41, 54], ["human therapy", "OBSERVATION", 41, 54], ["active", "OBSERVATION_MODIFIER", 95, 101]]], ["The murine model is useful in determining, at an early stage of research, the transgene expression characteristics and potential effects on animal health.", [["murine", "ORGANISM", 4, 10], ["murine", "SPECIES", 4, 10]]], ["Transgenic mice are generally predictive of what will be observed in larger animals.", [["mice", "ORGANISM", 11, 15], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15]]], ["Many transgenic proteins have been expressed in the milk of transgenic livestock.", [["milk", "ANATOMY", 52, 56], ["milk", "ORGANISM_SUBSTANCE", 52, 56], ["transgenic proteins", "PROTEIN", 5, 24], ["Many transgenic proteins", "PROBLEM", 0, 24], ["transgenic", "OBSERVATION_MODIFIER", 5, 15], ["proteins", "OBSERVATION", 16, 24]]], ["Several of these proteins have been expressed at high levels, demonstrating the usefulness of the production system.", [["proteins", "OBSERVATION", 17, 25], ["high levels", "OBSERVATION_MODIFIER", 49, 60]]], ["Examination of a great number of transgenic lines has shown that mammary gland-specific expression of a target protein is associated with increased plasma levels of this protein, even in the absence of ectopic expression.", [["mammary gland", "ANATOMY", 65, 78], ["plasma", "ANATOMY", 148, 154], ["transgenic lines", "CELL", 33, 49], ["mammary gland", "ORGAN", 65, 78], ["plasma", "ORGANISM_SUBSTANCE", 148, 154], ["transgenic lines", "CELL_LINE", 33, 49], ["target protein", "PROTEIN", 104, 118], ["Examination", "TEST", 0, 11], ["transgenic lines", "TREATMENT", 33, 49], ["a target protein", "PROBLEM", 102, 118], ["increased plasma levels", "PROBLEM", 138, 161], ["this protein", "PROBLEM", 165, 177], ["ectopic expression", "PROBLEM", 202, 220], ["transgenic lines", "OBSERVATION", 33, 49], ["mammary gland", "ANATOMY", 65, 78], ["ectopic expression", "OBSERVATION", 202, 220]]], ["The most likely explanation is leakage of the protein from the milk into the circulation through the junctional complexes of the mammary epithelial cells.", [["milk", "ANATOMY", 63, 67], ["junctional complexes", "ANATOMY", 101, 121], ["mammary epithelial cells", "ANATOMY", 129, 153], ["milk", "ORGANISM_SUBSTANCE", 63, 67], ["mammary epithelial cells", "CELL", 129, 153], ["mammary epithelial cells", "CELL_TYPE", 129, 153], ["leakage of the protein", "PROBLEM", 31, 53], ["most likely explanation", "UNCERTAINTY", 4, 27], ["leakage", "OBSERVATION", 31, 38], ["junctional complexes", "OBSERVATION", 101, 121], ["mammary", "ANATOMY", 129, 136], ["epithelial cells", "OBSERVATION", 137, 153]]], ["Therefore, certain proteins and peptides, such as highly active hormones and cytokines, cannot be expressed in the mammary system as their secretion into the blood may have severe detrimental effects on the host.", [["mammary system", "ANATOMY", 115, 129], ["blood", "ANATOMY", 158, 163], ["mammary system", "ANATOMICAL_SYSTEM", 115, 129], ["blood", "ORGANISM_SUBSTANCE", 158, 163], ["cytokines", "PROTEIN", 77, 86], ["certain proteins and peptides", "PROBLEM", 11, 40], ["cytokines", "TREATMENT", 77, 86], ["severe detrimental effects on the host", "PROBLEM", 173, 211], ["mammary", "ANATOMY", 115, 122], ["severe", "OBSERVATION_MODIFIER", 173, 179]]], ["Lonnerdal and Iyer (1995) aGene insertion via teat canal using retroviral vectors GaLV and MoMLV. bData from Genzyme Transgenics Corp. (1996) .Milk-Specific TransgenesTransgenes containing sequences of several milk protein genes, reviewed by Maga and Murray (1995) and Echelard (1996) , have been used to direct the expression of exogenous proteins to the lactating mammary gland.", [["teat canal", "ANATOMY", 46, 56], ["mammary gland", "ANATOMY", 366, 379], ["teat canal", "MULTI-TISSUE_STRUCTURE", 46, 56], ["retroviral", "ORGANISM", 63, 73], ["GaLV", "GENE_OR_GENE_PRODUCT", 82, 86], ["MoMLV", "GENE_OR_GENE_PRODUCT", 91, 96], ["Milk", "ORGANISM_SUBSTANCE", 143, 147], ["mammary gland", "ORGAN", 366, 379], ["retroviral vectors", "DNA", 63, 81], ["GaLV", "DNA", 82, 86], ["MoMLV", "DNA", 91, 96], ["milk protein genes", "DNA", 210, 228], ["exogenous proteins", "PROTEIN", 330, 348], ["Lonnerdal and Iyer (1995) aGene insertion via teat canal", "TREATMENT", 0, 56], ["retroviral vectors GaLV", "TREATMENT", 63, 86], ["teat canal", "ANATOMY", 46, 56], ["mammary gland", "ANATOMY", 366, 379]]], ["These transgenes are usually chimeric, being derived from the fusion of a target protein gene and mammaryspecific regulatory sequences.", [["target protein gene", "DNA", 74, 93], ["mammaryspecific regulatory sequences", "DNA", 98, 134]]], ["Although both genomic DNAs and cDNAs coding for target proteins have been used for expression, higher levels are normally obtained with genomic DNAs.", [["DNAs", "CELLULAR_COMPONENT", 22, 26], ["DNAs", "CELLULAR_COMPONENT", 144, 148], ["genomic DNAs", "DNA", 14, 26], ["cDNAs", "DNA", 31, 36], ["genomic DNAs", "DNA", 136, 148], ["both genomic DNAs and cDNAs coding", "PROBLEM", 9, 43], ["target proteins", "PROBLEM", 48, 63], ["genomic DNAs", "PROBLEM", 136, 148], ["genomic DNAs", "OBSERVATION", 14, 26]]], ["The incorporation of untranslated exons and introns may contribute to increased expression of the transgene .", [["untranslated exons", "DNA", 21, 39], ["introns", "DNA", 44, 51], ["untranslated exons", "TREATMENT", 21, 39], ["introns", "TREATMENT", 44, 51], ["untranslated exons", "OBSERVATION", 21, 39]]], ["Addition of a signal sequence is necessary if the exogenous protein is not normally secreted.", [["exogenous protein", "PROTEIN", 50, 67], ["a signal sequence", "TEST", 12, 29], ["the exogenous protein", "TEST", 46, 67]]], ["This will cause the protein to be secreted out of the mammary tissue into the milk.Milk-Specific TransgenesRegulatory sequences from several milk-specific genes have been isolated and tested in transgenic animals: ovine ~-lactoglobulin; murine, rat, and rabbit whey acidic protein (WAP); bovine ~-sl casein; rat, rabbit, and goat f~-casein; and guinea pig, ovine, caprine, and bovine ~-lactalbumin.", [["mammary tissue", "ANATOMY", 54, 68], ["milk", "ANATOMY", 78, 82], ["milk", "ANATOMY", 141, 145], ["mammary tissue", "TISSUE", 54, 68], ["milk", "ORGANISM_SUBSTANCE", 78, 82], ["Milk", "ORGANISM_SUBSTANCE", 83, 87], ["milk", "ORGANISM_SUBSTANCE", 141, 145], ["ovine", "ORGANISM", 214, 219], ["~-lactoglobulin", "ORGANISM", 220, 235], ["murine", "ORGANISM", 237, 243], ["rat", "ORGANISM", 245, 248], ["rabbit", "ORGANISM", 254, 260], ["whey acidic protein", "GENE_OR_GENE_PRODUCT", 261, 280], ["WAP", "GENE_OR_GENE_PRODUCT", 282, 285], ["bovine", "ORGANISM", 288, 294], ["~-sl casein", "ORGANISM", 295, 306], ["rat", "ORGANISM", 308, 311], ["rabbit", "ORGANISM", 313, 319], ["goat", "ORGANISM", 325, 329], ["casein", "GENE_OR_GENE_PRODUCT", 333, 339], ["guinea pig", "ORGANISM", 345, 355], ["ovine", "ORGANISM", 357, 362], ["caprine", "ORGANISM", 364, 371], ["bovine", "ORGANISM", 377, 383], ["~-lactalbumin", "SIMPLE_CHEMICAL", 384, 397], ["Milk-Specific TransgenesRegulatory sequences", "DNA", 83, 127], ["milk-specific genes", "DNA", 141, 160], ["ovine ~-lactoglobulin; murine, rat, and rabbit whey acidic protein", "PROTEIN", 214, 280], ["WAP", "PROTEIN", 282, 285], ["ovine", "SPECIES", 214, 219], ["murine", "SPECIES", 237, 243], ["rat", "SPECIES", 245, 248], ["rabbit", "SPECIES", 254, 260], ["bovine", "SPECIES", 288, 294], ["rat", "SPECIES", 308, 311], ["rabbit", "SPECIES", 313, 319], ["goat", "SPECIES", 325, 329], ["guinea pig", "SPECIES", 345, 355], ["ovine", "SPECIES", 357, 362], ["caprine", "SPECIES", 364, 371], ["bovine", "SPECIES", 377, 383], ["ovine", "SPECIES", 214, 219], ["rat", "SPECIES", 245, 248], ["rabbit", "SPECIES", 254, 260], ["rat", "SPECIES", 308, 311], ["rabbit", "SPECIES", 313, 319], ["goat", "SPECIES", 325, 329], ["pig", "SPECIES", 352, 355], ["ovine", "SPECIES", 357, 362], ["caprine", "SPECIES", 364, 371], ["bovine", "SPECIES", 377, 383], ["the protein", "PROBLEM", 16, 27], ["Milk", "TREATMENT", 83, 87], ["rabbit whey acidic protein", "TEST", 254, 280], ["bovine ~-sl casein", "TREATMENT", 288, 306], ["goat f~-casein", "TREATMENT", 325, 339], ["guinea pig", "TREATMENT", 345, 355], ["caprine", "TREATMENT", 364, 371], ["bovine ~-lactalbumin", "TREATMENT", 377, 397], ["mammary tissue", "ANATOMY", 54, 68], ["milk", "ANATOMY", 78, 82]]], ["Of these promoters, several have permitted grams per liter expression of target proteins in the milk of transgenic offspring, sometimes in large dairy animals; some of this work is summarized next.Milk-Specific TransgenesThe ovine f~-lactoglobulin gene contains seven exons and six introns spanning a 4.2-kb region (Harris et al., 1988) .", [["milk", "ANATOMY", 96, 100], ["milk", "ORGANISM_SUBSTANCE", 96, 100], ["Milk", "ORGANISM_SUBSTANCE", 197, 201], ["ovine", "ORGANISM", 225, 230], ["f~-lactoglobulin", "GENE_OR_GENE_PRODUCT", 231, 247], ["promoters", "DNA", 9, 18], ["target proteins", "PROTEIN", 73, 88], ["Milk-Specific Transgenes", "DNA", 197, 221], ["ovine f~-lactoglobulin gene", "DNA", 225, 252], ["exons", "DNA", 268, 273], ["introns", "DNA", 282, 289], ["4.2-kb region", "DNA", 301, 314], ["Milk", "TREATMENT", 197, 201], ["The ovine f~-lactoglobulin gene", "TREATMENT", 221, 252], ["large", "OBSERVATION_MODIFIER", 139, 144]]], ["The first reported ovine ~-lactoglobulin chimeric transgenes (Archibald et al., 1990) were composed of 4 kb of 5' flanking fused to the c~l-antitrypsin genomic sequences.", [["ovine", "ORGANISM", 19, 24], ["~-lactoglobulin", "GENE_OR_GENE_PRODUCT", 25, 40], ["c~l-antitrypsin", "GENE_OR_GENE_PRODUCT", 136, 151], ["ovine ~-lactoglobulin chimeric transgenes", "DNA", 19, 60], ["5' flanking", "DNA", 111, 122], ["c~l-antitrypsin genomic sequences", "DNA", 136, 169], ["ovine ~-lactoglobulin chimeric transgenes", "TREATMENT", 19, 60]]], ["Other configurations using variable amounts of 5'-and 3'-flanking sequences have also been used (Whitelaw et al., 1992) and reviewed by Maga and Murray (1995) .", [["5'-and 3'-flanking sequences", "DNA", 47, 75], ["3'-flanking sequences", "TREATMENT", 54, 75]]], ["With the ovine ~-lactoglobulin gene, high-level expression (g/liter) of ~l-antitrypsin, fibrinogen, and HSA have been reported (Wright et al., 1991 , Shani et al., 1992 Prunkard et al., 1996) .", [["ovine", "ORGANISM", 9, 14], ["~-lactoglobulin", "GENE_OR_GENE_PRODUCT", 15, 30], ["~l-antitrypsin", "GENE_OR_GENE_PRODUCT", 72, 86], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 88, 98], ["HSA", "GENE_OR_GENE_PRODUCT", 104, 107], ["ovine ~-lactoglobulin gene", "DNA", 9, 35], ["l-antitrypsin", "PROTEIN", 73, 86], ["fibrinogen", "PROTEIN", 88, 98], ["HSA", "PROTEIN", 104, 107], ["the ovine ~-lactoglobulin gene", "TREATMENT", 5, 35], ["~l-antitrypsin", "PROBLEM", 72, 86], ["fibrinogen", "TEST", 88, 98]]], ["However, similar results have not been observed with transgenes containing cDNA sequences (Clark et al., 1989 , Shani et al., 1992 , Hansson et al., 1994 , Yull et al., 1995 .Milk-Specific TransgenesRodent WAP genes consist of four exons and three introns: the middle two exons encode the two cysteine-rich regions, which probably form separate protein domains (Campbell et al., 1984) .", [["cysteine", "CHEMICAL", 293, 301], ["cDNA sequences", "DNA", 75, 89], ["Milk-Specific TransgenesRodent WAP genes", "DNA", 175, 215], ["exons", "DNA", 232, 237], ["introns", "DNA", 248, 255], ["exons", "DNA", 272, 277], ["protein domains", "PROTEIN", 345, 360], ["Milk", "TEST", 175, 179], ["Specific TransgenesRodent WAP genes", "TREATMENT", 180, 215], ["middle", "ANATOMY_MODIFIER", 261, 267]]], ["WAP is present in the milk of mouse, rat, rabbit, and camel, but is absent from the milk of cow, sheep, pig, goat, and human.", [["milk", "ANATOMY", 22, 26], ["milk", "ANATOMY", 84, 88], ["WAP", "GENE_OR_GENE_PRODUCT", 0, 3], ["milk", "ORGANISM_SUBSTANCE", 22, 26], ["mouse", "ORGANISM", 30, 35], ["rat", "ORGANISM", 37, 40], ["rabbit", "ORGANISM", 42, 48], ["camel", "ORGANISM", 54, 59], ["milk", "ORGANISM_SUBSTANCE", 84, 88], ["cow", "ORGANISM_SUBDIVISION", 92, 95], ["sheep", "ORGANISM", 97, 102], ["pig", "ORGANISM", 104, 107], ["goat", "ORGANISM", 109, 113], ["human", "ORGANISM", 119, 124], ["WAP", "PROTEIN", 0, 3], ["mouse", "SPECIES", 30, 35], ["rat", "SPECIES", 37, 40], ["rabbit", "SPECIES", 42, 48], ["camel", "SPECIES", 54, 59], ["cow", "SPECIES", 92, 95], ["sheep", "SPECIES", 97, 102], ["pig", "SPECIES", 104, 107], ["goat", "SPECIES", 109, 113], ["human", "SPECIES", 119, 124], ["mouse", "SPECIES", 30, 35], ["rat", "SPECIES", 37, 40], ["rabbit", "SPECIES", 42, 48], ["camel", "SPECIES", 54, 59], ["cow", "SPECIES", 92, 95], ["sheep", "SPECIES", 97, 102], ["pig", "SPECIES", 104, 107], ["goat", "SPECIES", 109, 113], ["human", "SPECIES", 119, 124]]], ["No recognizable WAP gene homologues have been isolated from these species.", [["WAP", "GENE_OR_GENE_PRODUCT", 16, 19], ["WAP gene homologues", "DNA", 16, 35], ["recognizable WAP gene homologues", "PROBLEM", 3, 35]]], ["Rat (Wei et al., 1995 , Yarus et al., 1997 , mouse (Gordon et al., 1987; Ebert et al., 1991 , Reddy et al., 1991 Velander et al., 1992; Drohan et al., 1994; Hansson et al., 1994; Limonta et al., 1995) , and rabbit (Bischoff et al., 1992; Devinoy et al., 1994; Th4pot et al., 1995) WAP regulatory sequences have been used to direct expression of exogenous proteins to the mammary gland.", [["mammary gland", "ANATOMY", 371, 384], ["mouse", "ORGANISM", 45, 50], ["rabbit", "ORGANISM", 207, 213], ["mammary gland", "ORGAN", 371, 384], ["WAP regulatory sequences", "DNA", 281, 305], ["exogenous proteins", "PROTEIN", 345, 363], ["Rat", "SPECIES", 0, 3], ["mouse", "SPECIES", 45, 50], ["rabbit", "SPECIES", 207, 213], ["WAP regulatory sequences", "TEST", 281, 305], ["mammary gland", "ANATOMY", 371, 384]]], ["High-level expression of the target protein was observed with mouse and rabbit WAP transgenes.", [["mouse", "ORGANISM", 62, 67], ["rabbit", "ORGANISM", 72, 78], ["WAP", "GENE_OR_GENE_PRODUCT", 79, 82], ["mouse and rabbit WAP transgenes", "DNA", 62, 93], ["mouse", "SPECIES", 62, 67], ["rabbit", "SPECIES", 72, 78], ["mouse", "SPECIES", 62, 67], ["rabbit", "SPECIES", 72, 78], ["the target protein", "PROBLEM", 25, 43], ["mouse and rabbit WAP transgenes", "TREATMENT", 62, 93]]], ["Surprisingly, relatively high expression levels (up to 1 g/liter)were observed in transgenic pigs with a construct containing 2.6 kb of 5' and 1.3 kb of 3' mouse WAP sequences linked to a human protein C cDNA (Velander et al., 1992) .", [["pigs", "ORGANISM", 93, 97], ["mouse", "ORGANISM", 156, 161], ["WAP", "GENE_OR_GENE_PRODUCT", 162, 165], ["human", "ORGANISM", 188, 193], ["3' mouse WAP sequences", "DNA", 153, 175], ["human protein C cDNA", "DNA", 188, 208], ["pigs", "SPECIES", 93, 97], ["mouse", "SPECIES", 156, 161], ["human", "SPECIES", 188, 193], ["pigs", "SPECIES", 93, 97], ["mouse", "SPECIES", 156, 161], ["human", "SPECIES", 188, 193], ["relatively high expression levels", "PROBLEM", 14, 47], ["mouse WAP sequences", "TEST", 156, 175], ["a human protein C cDNA", "TEST", 186, 208], ["high", "OBSERVATION_MODIFIER", 25, 29]]], ["This result seems to indicate that mWAP regulatory sequences can function efficiently in species that do not have an endogenous WAP gene.Milk-Specific TransgenesThe bovine asl-casein gene contains 9 exons and spans 17.5 kb (Koczan et al., 1991) .", [["mWAP", "GENE_OR_GENE_PRODUCT", 35, 39], ["WAP", "GENE_OR_GENE_PRODUCT", 128, 131], ["Milk", "ORGANISM_SUBSTANCE", 137, 141], ["bovine", "ORGANISM", 165, 171], ["asl-casein", "GENE_OR_GENE_PRODUCT", 172, 182], ["mWAP regulatory sequences", "DNA", 35, 60], ["endogenous WAP gene", "DNA", 117, 136], ["Milk-Specific Transgenes", "DNA", 137, 161], ["bovine asl-casein gene", "DNA", 165, 187], ["exons", "DNA", 199, 204], ["bovine", "SPECIES", 165, 171], ["mWAP regulatory sequences", "PROBLEM", 35, 60], ["an endogenous WAP gene", "PROBLEM", 114, 136], ["Milk", "TREATMENT", 137, 141], ["The bovine asl-casein gene", "TREATMENT", 161, 187], ["endogenous WAP", "OBSERVATION", 117, 131]]], ["Originally (Meade et al., 1990) , a transgene containing 21 kb of 5' and 2 kb of 3' flanking sequence fused to the genomic sequences of human urokinase was shown to direct high milk expression levels (1-2 mg/ml) in mice.", [["milk", "ANATOMY", 177, 181], ["3' flanking sequence", "CELLULAR_COMPONENT", 81, 101], ["human", "ORGANISM", 136, 141], ["urokinase", "GENE_OR_GENE_PRODUCT", 142, 151], ["milk", "ORGANISM_SUBSTANCE", 177, 181], ["mice", "ORGANISM", 215, 219], ["5' and 2 kb of 3' flanking sequence", "DNA", 66, 101], ["genomic sequences", "DNA", 115, 132], ["human urokinase", "PROTEIN", 136, 151], ["human", "SPECIES", 136, 141], ["mice", "SPECIES", 215, 219], ["human", "SPECIES", 136, 141], ["mice", "SPECIES", 215, 219], ["a transgene containing 21 kb", "TREATMENT", 34, 62], ["3' flanking sequence", "TEST", 81, 101], ["human urokinase", "TREATMENT", 136, 151]]], ["Promising results were also obtained in transgenic rabbits with a construct containing the human IGF-1 cDNA (Brem et al., 1994) , in mice with the human lysozyme cDNA (Maga et al., 1994) , and in human lactoferrin and human granulocyte-macrophage colony-stimulating factor genomic constructs (Nuijens et al., 1995; Uusi-Oukari et al., 1997) .", [["rabbits", "ORGANISM", 51, 58], ["human", "ORGANISM", 91, 96], ["IGF-1", "GENE_OR_GENE_PRODUCT", 97, 102], ["mice", "ORGANISM", 133, 137], ["human", "ORGANISM", 147, 152], ["lysozyme", "GENE_OR_GENE_PRODUCT", 153, 161], ["human", "ORGANISM", 196, 201], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 202, 213], ["human", "ORGANISM", 218, 223], ["granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 224, 272], ["human IGF-1 cDNA", "DNA", 91, 107], ["human lysozyme cDNA", "DNA", 147, 166], ["human lactoferrin and human granulocyte-macrophage colony-stimulating factor genomic constructs", "DNA", 196, 291], ["rabbits", "SPECIES", 51, 58], ["human", "SPECIES", 91, 96], ["mice", "SPECIES", 133, 137], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 196, 201], ["human", "SPECIES", 218, 223], ["rabbits", "SPECIES", 51, 58], ["human", "SPECIES", 91, 96], ["mice", "SPECIES", 133, 137], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 196, 201], ["human", "SPECIES", 218, 223], ["human lactoferrin", "TREATMENT", 196, 213], ["human granulocyte", "TREATMENT", 218, 235], ["macrophage colony", "TREATMENT", 236, 253], ["granulocyte", "ANATOMY", 224, 235], ["macrophage colony", "OBSERVATION", 236, 253]]], ["Conversely, a bovine ~sl-casein-human lactoferrin cDNA construct only permitted low-level expression in milk of transgenic mice (Platenburg et al., 1994) , as was the case with a human tPA cDNA construct fused to 1.6 kb of bovine ~-sl casein 5'-flanking sequences (Riego et al., 1993) .Milk-Specific TransgenesThe bovine ~-lactalbumin gene contains four exons and three introns.", [["milk", "ANATOMY", 104, 108], ["bovine", "ORGANISM", 14, 20], ["sl-casein", "GENE_OR_GENE_PRODUCT", 22, 31], ["human", "ORGANISM", 32, 37], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 38, 49], ["milk", "ORGANISM_SUBSTANCE", 104, 108], ["mice", "ORGANISM", 123, 127], ["human", "ORGANISM", 179, 184], ["tPA", "GENE_OR_GENE_PRODUCT", 185, 188], ["bovine", "ORGANISM", 223, 229], ["~-sl casein", "GENE_OR_GENE_PRODUCT", 230, 241], ["Milk", "ORGANISM_SUBSTANCE", 286, 290], ["bovine", "ORGANISM", 314, 320], ["~-lactalbumin", "GENE_OR_GENE_PRODUCT", 321, 334], ["bovine ~sl-casein-human lactoferrin cDNA construct", "DNA", 14, 64], ["human tPA cDNA construct", "DNA", 179, 203], ["bovine ~-sl casein 5'-flanking sequences", "DNA", 223, 263], ["bovine ~-lactalbumin gene", "DNA", 314, 339], ["exons", "DNA", 354, 359], ["introns", "DNA", 370, 377], ["bovine", "SPECIES", 14, 20], ["human", "SPECIES", 32, 37], ["mice", "SPECIES", 123, 127], ["human", "SPECIES", 179, 184], ["bovine", "SPECIES", 223, 229], ["bovine", "SPECIES", 314, 320], ["human", "SPECIES", 32, 37], ["mice", "SPECIES", 123, 127], ["human", "SPECIES", 179, 184], ["a bovine ~sl-casein-human lactoferrin cDNA construct", "TREATMENT", 12, 64], ["a human tPA cDNA construct", "TREATMENT", 177, 203], ["bovine ~-sl casein", "TREATMENT", 223, 241], ["The bovine ~-lactalbumin gene", "TREATMENT", 310, 339], ["bovine ~-lactalbumin", "OBSERVATION", 314, 334], ["four exons", "OBSERVATION", 349, 359]]], ["Early reports (Vilotte et al., 1989; Stinnakre et al., 1991) indicated that a construct containing 750 bp of 5' and 336 bp of 3' flanking region was sufficient to direct intermediate expression levels in transgenic mouse milk when fused to bovine ~-lactalbumin or ovine trophoblastin cDNAs.", [["milk", "ANATOMY", 221, 225], ["3' flanking region", "CELLULAR_COMPONENT", 126, 144], ["mouse", "ORGANISM", 215, 220], ["milk", "ORGANISM_SUBSTANCE", 221, 225], ["bovine", "ORGANISM", 240, 246], ["~-lactalbumin", "GENE_OR_GENE_PRODUCT", 247, 260], ["ovine", "ORGANISM", 264, 269], ["trophoblastin", "GENE_OR_GENE_PRODUCT", 270, 283], ["3' flanking region", "DNA", 126, 144], ["bovine ~-lactalbumin or ovine trophoblastin cDNAs", "DNA", 240, 289], ["mouse", "SPECIES", 215, 220], ["milk", "SPECIES", 221, 225], ["bovine", "SPECIES", 240, 246], ["mouse", "SPECIES", 215, 220], ["ovine", "SPECIES", 264, 269], ["bp", "TEST", 103, 105], ["bp", "TEST", 120, 122], ["transgenic mouse milk", "TREATMENT", 204, 225], ["bovine ~-lactalbumin", "TREATMENT", 240, 260], ["ovine trophoblastin cDNAs", "TREATMENT", 264, 289]]], ["By using a construct containing the same amount of 5'-flanking sequence linked to hGH genomic sequences, higher levels of the target protein (up to 4.3 mg/ml) were obtained in the milk of transgenic rats (Ninomiya et al., 1994) .", [["milk", "ANATOMY", 180, 184], ["hGH", "GENE_OR_GENE_PRODUCT", 82, 85], ["milk", "ORGANISM_SUBSTANCE", 180, 184], ["rats", "ORGANISM", 199, 203], ["5'-flanking sequence", "DNA", 51, 71], ["hGH genomic sequences", "DNA", 82, 103], ["target protein", "PROTEIN", 126, 140], ["rats", "SPECIES", 199, 203], ["5'-flanking sequence", "TREATMENT", 51, 71], ["hGH genomic sequences", "TEST", 82, 103]]], ["However, at this point, results obtained with ~-lactalbumin-driven transgenes in large animals have not been reported.Milk-Specific TransgenesThe caprine ~-casein gene (CSN2) has been cloned and sequenced (Roberts et al., 1992; Persuy et al., 1992) .", [["~-lactalbumin", "CHEMICAL", 46, 59], ["~-lactalbumin", "CHEMICAL", 46, 59], ["~-lactalbumin", "SIMPLE_CHEMICAL", 46, 59], ["Milk", "ORGANISM_SUBSTANCE", 118, 122], ["caprine", "ORGANISM", 146, 153], ["~-casein", "GENE_OR_GENE_PRODUCT", 154, 162], ["CSN2", "GENE_OR_GENE_PRODUCT", 169, 173], ["~-lactalbumin-driven transgenes", "DNA", 46, 77], ["Milk-Specific Transgenes", "PROTEIN", 118, 142], ["caprine ~-casein gene", "DNA", 146, 167], ["CSN2", "DNA", 169, 173], ["caprine", "SPECIES", 146, 153], ["caprine", "SPECIES", 146, 153], ["~-lactalbumin", "TEST", 46, 59], ["large", "OBSERVATION_MODIFIER", 81, 86]]], ["The intron/exon organization of the 9-kb goat gene is similar to that of other CSN2 genes and its expression is limited principally to the mammary gland during lactation.", [["mammary gland", "ANATOMY", 139, 152], ["goat", "GENE_OR_GENE_PRODUCT", 41, 45], ["CSN2", "GENE_OR_GENE_PRODUCT", 79, 83], ["mammary gland", "ORGAN", 139, 152], ["9-kb goat gene", "DNA", 36, 50], ["CSN2 genes", "DNA", 79, 89], ["goat", "SPECIES", 41, 45], ["The intron/exon organization", "TREATMENT", 0, 28], ["mammary gland", "ANATOMY", 139, 152]]], ["High-level expression was observed in goats transgenic for a construct containing 6.2 kb of 5' and 7.1 kb of 3' goat ~casein flanking noncoding sequence fused to a variant of the human tPA cDNA .", [["goats", "ORGANISM", 38, 43], ["human", "ORGANISM", 179, 184], ["tPA", "GENE_OR_GENE_PRODUCT", 185, 188], ["casein flanking noncoding sequence", "DNA", 118, 152], ["human tPA cDNA", "DNA", 179, 193], ["goats", "SPECIES", 38, 43], ["goat", "SPECIES", 112, 116], ["human", "SPECIES", 179, 184], ["goats", "SPECIES", 38, 43], ["human", "SPECIES", 179, 184], ["High-level expression", "PROBLEM", 0, 21], ["the human tPA cDNA", "TREATMENT", 175, 193]]], ["High-level expression with caprine f~-casein-containing transgenes has also been observed, in mouse milk, with bovine K-casein (Persuy et al., 1995; Gutierrez et al., 1996) , antithrombin III (cDNA and genomic, mice and goats), HSA (cDNA and genomic), ~l-antitrypsin (genomic, mice and goats), and both heavy and light chains of several humanized antibodies (H. Meade et al., unpublished data) .Insertion of the Transgene into the Germ LineTransgenic animals may be generated by direct microinjection of the foreign gene into the pronuclei of one-cell stage embryos.", [["milk", "ANATOMY", 100, 104], ["pronuclei", "ANATOMY", 530, 539], ["cell", "ANATOMY", 547, 551], ["embryos", "ANATOMY", 558, 565], ["caprine", "ORGANISM", 27, 34], ["casein", "GENE_OR_GENE_PRODUCT", 38, 44], ["mouse", "ORGANISM", 94, 99], ["milk", "ORGANISM_SUBSTANCE", 100, 104], ["bovine", "ORGANISM", 111, 117], ["K-casein", "GENE_OR_GENE_PRODUCT", 118, 126], ["antithrombin III", "GENE_OR_GENE_PRODUCT", 175, 191], ["mice", "ORGANISM", 211, 215], ["goats", "ORGANISM", 220, 225], ["HSA", "GENE_OR_GENE_PRODUCT", 228, 231], ["l-antitrypsin", "GENE_OR_GENE_PRODUCT", 253, 266], ["mice", "ORGANISM", 277, 281], ["goats", "ORGANISM", 286, 291], ["Transgene", "GENE_OR_GENE_PRODUCT", 412, 421], ["pronuclei", "CELLULAR_COMPONENT", 530, 539], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 558, 565], ["caprine f~-casein-containing transgenes", "DNA", 27, 66], ["antithrombin III", "PROTEIN", 175, 191], ["cDNA", "DNA", 193, 197], ["HSA", "PROTEIN", 228, 231], ["cDNA", "DNA", 233, 237], ["~l-antitrypsin", "DNA", 252, 266], ["humanized antibodies", "PROTEIN", 337, 357], ["Transgene", "DNA", 412, 421], ["foreign gene", "DNA", 508, 520], ["mouse", "SPECIES", 94, 99], ["milk", "SPECIES", 100, 104], ["bovine", "SPECIES", 111, 117], ["mice", "SPECIES", 211, 215], ["goats", "SPECIES", 220, 225], ["mice", "SPECIES", 277, 281], ["goats", "SPECIES", 286, 291], ["caprine", "SPECIES", 27, 34], ["mouse", "SPECIES", 94, 99], ["mice", "SPECIES", 211, 215], ["goats", "SPECIES", 220, 225], ["mice", "SPECIES", 277, 281], ["goats", "SPECIES", 286, 291], ["caprine f~-casein", "TREATMENT", 27, 44], ["antithrombin III (cDNA", "TREATMENT", 175, 197], ["genomic, mice and goats", "TREATMENT", 202, 225], ["HSA (cDNA", "TREATMENT", 228, 237], ["~l-antitrypsin (genomic, mice and goats", "TREATMENT", 252, 291], ["several humanized antibodies", "TREATMENT", 329, 357], ["the Transgene into the Germ LineTransgenic animals", "TREATMENT", 408, 458], ["cell stage embryos", "OBSERVATION", 547, 565]]], ["Microinjection techniques have been reviewed exhaustively by Hogan et al. (1986) and Pinkert (1994) , among others.", [["Microinjection techniques", "TREATMENT", 0, 25]]], ["Techniques initially developed for gene insertion into murine pronuclei (Gordon et al., 1980; Gordon and Ruddle, 1981; Brinster et al., 1985; Palmiter and Brinster, 1986) have been adapted to gene transfer into the pronuclei of ruminants and pigs (Hammer et al., 1985; Pinkert, 1994) .", [["pronuclei", "ANATOMY", 62, 71], ["pronuclei", "ANATOMY", 215, 224], ["murine", "ORGANISM", 55, 61], ["pronuclei", "DEVELOPING_ANATOMICAL_STRUCTURE", 62, 71], ["pronuclei", "CELLULAR_COMPONENT", 215, 224], ["ruminants", "ORGANISM", 228, 237], ["pigs", "ORGANISM", 242, 246], ["murine", "SPECIES", 55, 61], ["pigs", "SPECIES", 242, 246], ["pigs", "SPECIES", 242, 246], ["gene insertion into murine pronuclei", "TREATMENT", 35, 71]]], ["If the microinjected DNA integrates into the genome of the recipient before the first cell division occurs, a heterozygous founder can be created.", [["cell", "ANATOMY", 86, 90], ["DNA", "CELLULAR_COMPONENT", 21, 24], ["genome", "CELLULAR_COMPONENT", 45, 51], ["cell", "CELL", 86, 90], ["microinjected DNA", "DNA", 7, 24], ["the microinjected DNA", "TEST", 3, 24], ["a heterozygous founder", "PROBLEM", 108, 130]]], ["Later integration leads to genetic mosaics consisting of normal cells with a normal genome and cells with transgenomes.Insertion of the Transgene into the Germ LineGenerally, fertilized eggs are flushed from the oviduct of a superovulated female donor, microinjected with a few hundred copies of the transgene, transferred to the oviduct or uterus of a pseudopregnant recipient animal, and developed to term.", [["cells", "ANATOMY", 64, 69], ["cells", "ANATOMY", 95, 100], ["eggs", "ANATOMY", 186, 190], ["oviduct", "ANATOMY", 212, 219], ["oviduct", "ANATOMY", 330, 337], ["uterus", "ANATOMY", 341, 347], ["cells", "CELL", 64, 69], ["cells", "CELL", 95, 100], ["Transgene", "GENE_OR_GENE_PRODUCT", 136, 145], ["Germ LineGenerally", "CELL", 155, 173], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 186, 190], ["oviduct", "ORGAN", 212, 219], ["oviduct", "ORGAN", 330, 337], ["uterus", "ORGAN", 341, 347], ["normal cells", "CELL_TYPE", 57, 69], ["Transgene", "DNA", 136, 145], ["transgenomes", "PROBLEM", 106, 118], ["the Transgene into the Germ LineGenerally", "TREATMENT", 132, 173], ["fertilized eggs", "TREATMENT", 175, 190], ["a superovulated female donor", "TREATMENT", 223, 251], ["the transgene", "TREATMENT", 296, 309], ["a pseudopregnant recipient", "TREATMENT", 351, 377], ["normal cells", "OBSERVATION", 57, 69], ["normal genome", "OBSERVATION", 77, 90], ["oviduct", "ANATOMY", 330, 337], ["uterus", "ANATOMY", 341, 347], ["pseudopregnant", "OBSERVATION", 353, 367]]], ["The first transgenic offspring, or founder animals, are at best hemizygous as the transgene is not integrated into both copies of a pair of homologous chromosomes.", [["chromosomes", "ANATOMY", 151, 162], ["chromosomes", "CELLULAR_COMPONENT", 151, 162], ["homologous chromosomes", "DNA", 140, 162]]], ["In the case of mosaic founders, germ line transmission is not always observed.", [["germ line", "ANATOMY", 32, 41], ["germ line", "CELL", 32, 41], ["germ line transmission", "TREATMENT", 32, 54], ["mosaic founders", "OBSERVATION", 15, 30], ["germ line", "OBSERVATION", 32, 41], ["not always observed", "UNCERTAINTY", 58, 77]]], ["In addition, multiple transgene integration sites have been detected in 10-20% of transgenic founders.Insertion of the Transgene into the Germ LineTo optimize the collection and transfer of microinjectable goat embryos, Selgrath et al. (1990) established regimens for superovulation/synchronization and timing of pronuclear embryo collection.", [["embryos", "ANATOMY", 211, 218], ["embryo", "ANATOMY", 324, 330], ["Transgene", "GENE_OR_GENE_PRODUCT", 119, 128], ["goat", "ORGANISM", 206, 210], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 211, 218], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 324, 330], ["multiple transgene integration sites", "DNA", 13, 49], ["Transgene", "DNA", 119, 128], ["goat", "SPECIES", 206, 210], ["goat", "SPECIES", 206, 210], ["multiple transgene integration sites", "PROBLEM", 13, 49], ["the Germ LineTo", "TREATMENT", 134, 149], ["microinjectable goat embryos", "TREATMENT", 190, 218], ["established regimens", "TREATMENT", 243, 263], ["superovulation/synchronization", "TREATMENT", 268, 298], ["pronuclear embryo collection", "PROBLEM", 313, 341], ["multiple", "OBSERVATION_MODIFIER", 13, 21], ["transgene", "OBSERVATION", 22, 31], ["collection", "OBSERVATION", 163, 173], ["pronuclear embryo collection", "OBSERVATION", 313, 341]]], ["Does were synchronized with Norgestomet ear implants and superovulation was induced with pregnant mare serum gonadotropin (PMSG) or follicle-stimulating hormone (FSH-P).", [["ear", "ANATOMY", 40, 43], ["serum", "ANATOMY", 103, 108], ["PMSG", "CHEMICAL", 123, 127], ["ear", "ORGAN", 40, 43], ["mare", "ORGANISM", 98, 102], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["gonadotropin", "GENE_OR_GENE_PRODUCT", 109, 121], ["PMSG", "SIMPLE_CHEMICAL", 123, 127], ["follicle-stimulating hormone", "GENE_OR_GENE_PRODUCT", 132, 160], ["FSH", "GENE_OR_GENE_PRODUCT", 162, 165], ["Norgestomet ear implants", "TREATMENT", 28, 52], ["superovulation", "TREATMENT", 57, 71], ["pregnant mare serum gonadotropin", "TEST", 89, 121], ["follicle-stimulating hormone", "TEST", 132, 160], ["implants", "OBSERVATION", 44, 52]]], ["Does were hand mated with the average female being mated six to eight times by two different males over a 24-to 36-hr period.", [["hand", "ANATOMY", 10, 14]]], ["Embryos were recovered surgically and pronuclei could be visualized without centrifugation.", [["Embryos", "ANATOMY", 0, 7], ["pronuclei", "ANATOMY", 38, 47], ["Embryos", "CELL", 0, 7], ["Embryos", "PROBLEM", 0, 7]]], ["After microinjection the embryos were transferred to the reproductive tracts of recipient females using a surgical procedure similar to that used for the embryo collection.", [["embryos", "ANATOMY", 25, 32], ["embryo", "ANATOMY", 154, 160], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 25, 32], ["reproductive tracts", "MULTI-TISSUE_STRUCTURE", 57, 76], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 154, 160], ["microinjection the embryos", "TREATMENT", 6, 32], ["a surgical procedure", "TREATMENT", 104, 124], ["the embryo collection", "PROBLEM", 150, 171], ["embryo", "ANATOMY", 154, 160], ["collection", "OBSERVATION", 161, 171]]], ["Ewes may be similarly synchronized and superovulated during the breeding season using Progestin (30 mg fluorogestone acetate) pessaries and FSH injection (Rexroad and Wall, 1987) .", [["Ewes", "ANATOMY", 0, 4], ["Progestin", "CHEMICAL", 86, 95], ["fluorogestone acetate", "CHEMICAL", 103, 124], ["FSH", "CHEMICAL", 140, 143], ["Progestin", "CHEMICAL", 86, 95], ["fluorogestone acetate", "CHEMICAL", 103, 124], ["Progestin", "SIMPLE_CHEMICAL", 86, 95], ["fluorogestone", "SIMPLE_CHEMICAL", 103, 116], ["acetate", "SIMPLE_CHEMICAL", 117, 124], ["FSH", "SIMPLE_CHEMICAL", 140, 143], ["Progestin (30 mg fluorogestone acetate) pessaries", "TREATMENT", 86, 135], ["FSH injection", "TREATMENT", 140, 153], ["Wall", "ANATOMY_MODIFIER", 167, 171]]], ["Fertilized sheep oocytes are semiopaque and not readily visible.", [["oocytes", "ANATOMY", 17, 24], ["sheep", "ORGANISM", 11, 16], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 17, 24], ["sheep", "SPECIES", 11, 16], ["sheep", "SPECIES", 11, 16], ["Fertilized sheep oocytes", "PROBLEM", 0, 24], ["sheep oocytes", "OBSERVATION", 11, 24], ["not readily", "UNCERTAINTY", 44, 55], ["visible", "OBSERVATION_MODIFIER", 56, 63]]], ["However, differential interference contrast microscopy allows visualization, and successful microinjection may be determined by the swelling of the pronucleus, which occurs on injection of DNA (Simons et al., 1988) .", [["pronucleus", "ANATOMY", 148, 158], ["pronucleus", "CELLULAR_COMPONENT", 148, 158], ["DNA", "CELLULAR_COMPONENT", 189, 192], ["differential interference contrast microscopy", "TEST", 9, 54], ["visualization", "TEST", 62, 75], ["successful microinjection", "TREATMENT", 81, 106], ["the swelling of the pronucleus", "PROBLEM", 128, 158], ["swelling", "OBSERVATION", 132, 140], ["pronucleus", "ANATOMY", 148, 158]]], ["Microinjected embryos are then transferred to recipient ewes.Insertion of the Transgene into the Germ LineBovine oocytes are generally collected from slaughtered heifers or obtained from cows superovulated with PMSG or prostaglandin.", [["embryos", "ANATOMY", 14, 21], ["Germ LineBovine oocytes", "ANATOMY", 97, 120], ["PMSG", "CHEMICAL", 211, 215], ["prostaglandin", "CHEMICAL", 219, 232], ["PMSG", "CHEMICAL", 211, 215], ["prostaglandin", "CHEMICAL", 219, 232], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 14, 21], ["ewes", "ORGANISM", 56, 60], ["Transgene", "GENE_OR_GENE_PRODUCT", 78, 87], ["heifers", "ORGANISM_SUBDIVISION", 162, 169], ["cows", "ORGANISM", 187, 191], ["PMSG", "SIMPLE_CHEMICAL", 211, 215], ["prostaglandin", "SIMPLE_CHEMICAL", 219, 232], ["Transgene", "DNA", 78, 87], ["Germ LineBovine oocytes", "CELL_LINE", 97, 120], ["cows", "SPECIES", 187, 191], ["the Transgene into the Germ LineBovine oocytes", "TREATMENT", 74, 120], ["cows superovulated", "TREATMENT", 187, 205], ["PMSG", "TREATMENT", 211, 215], ["prostaglandin", "TREATMENT", 219, 232]]], ["To circumvent surgical procedures and in vivo fertilization, Krimpenfort et al. ( 1991 ) have used an/n vitro fertilization and embryo production procedure.", [["embryo", "ANATOMY", 128, 134], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 128, 134], ["surgical procedures", "TREATMENT", 14, 33], ["vivo fertilization", "TREATMENT", 41, 59], ["an/n vitro fertilization", "TREATMENT", 99, 123], ["embryo production procedure", "TREATMENT", 128, 155]]], ["The technique for DNA microinjection is similar to those described earlier: centrifugation, e.g., at 12,000 \u2022 g for 10 min, is necessary to visualize pronuclei.", [["pronuclei", "ANATOMY", 150, 159], ["DNA", "CELLULAR_COMPONENT", 18, 21], ["pronuclei", "CELLULAR_COMPONENT", 150, 159], ["The technique", "TREATMENT", 0, 13], ["DNA microinjection", "TREATMENT", 18, 36]]], ["Microinjected cow embryos are usually cultured/n vitro to the morula-blastocyst age at which time they are transferred nonsurgically to suitable recipients.", [["embryos", "ANATOMY", 18, 25], ["morula", "ANATOMY", 62, 68], ["blastocyst", "ANATOMY", 69, 79], ["cow", "ORGANISM", 14, 17], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 18, 25], ["morula", "DEVELOPING_ANATOMICAL_STRUCTURE", 62, 68], ["blastocyst", "DEVELOPING_ANATOMICAL_STRUCTURE", 69, 79], ["recipients", "ORGANISM", 145, 155], ["cow", "SPECIES", 14, 17], ["cow", "SPECIES", 14, 17], ["Microinjected cow embryos", "PROBLEM", 0, 25]]], ["The techniques and efficiency of gene transfer in cows have been described by Roschlau et al. (1989) and McEvoy and Sreenan (1990) .Insertion of the Transgene into the Germ LineSynchronization of sows is accomplished with hormonal treatment and superovulation induced with PMSG or human chorionic gonadotropin.", [["Germ", "ANATOMY", 168, 172], ["PMSG", "CHEMICAL", 273, 277], ["PMSG", "CHEMICAL", 273, 277], ["cows", "ORGANISM", 50, 54], ["Transgene", "GENE_OR_GENE_PRODUCT", 149, 158], ["sows", "ORGANISM", 196, 200], ["PMSG", "SIMPLE_CHEMICAL", 273, 277], ["human", "ORGANISM", 281, 286], ["chorionic gonadotropin", "GENE_OR_GENE_PRODUCT", 287, 309], ["Transgene", "DNA", 149, 158], ["human", "SPECIES", 281, 286], ["human", "SPECIES", 281, 286], ["the Germ LineSynchronization", "TREATMENT", 164, 192], ["hormonal treatment", "TREATMENT", 222, 240], ["superovulation", "TREATMENT", 245, 259], ["PMSG", "TREATMENT", 273, 277], ["human chorionic gonadotropin", "TREATMENT", 281, 309]]], ["Pig ova are opaque and no nuclear structures can be seen, even using interference contrast microscopy.", [["ova", "ANATOMY", 4, 7], ["nuclear structures", "ANATOMY", 26, 44], ["Pig", "ORGANISM", 0, 3], ["ova", "ORGANISM_SUBSTANCE", 4, 7], ["Pig", "SPECIES", 0, 3], ["Pig ova", "TREATMENT", 0, 7], ["nuclear structures", "PROBLEM", 26, 44], ["interference contrast microscopy", "TEST", 69, 101], ["opaque", "OBSERVATION", 12, 18], ["no", "UNCERTAINTY", 23, 25], ["nuclear structures", "OBSERVATION", 26, 44]]], ["Centrifugation at 15,000 \u2022 g for 5 min leaves pronuclei visible in the equatorial segment of the cytoplasm (Brem et al., 1985; Hammer et al., 1985) .", [["pronuclei", "ANATOMY", 46, 55], ["cytoplasm", "ANATOMY", 97, 106], ["cytoplasm", "ORGANISM_SUBSTANCE", 97, 106], ["Centrifugation", "TREATMENT", 0, 14], ["pronuclei visible", "OBSERVATION", 46, 63], ["equatorial", "ANATOMY_MODIFIER", 71, 81], ["segment", "ANATOMY_MODIFIER", 82, 89], ["cytoplasm", "ANATOMY_MODIFIER", 97, 106]]], ["Microinjected embryos are then transferred to recipient pigs.Insertion of the Transgene into the Germ LineFactors affecting the success of microinjection as a gene insertion technique have been reviewed by Rexroad et al. (1990) .", [["embryos", "ANATOMY", 14, 21], ["Germ LineFactors", "ANATOMY", 97, 113], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 14, 21], ["pigs", "ORGANISM", 56, 60], ["Transgene", "GENE_OR_GENE_PRODUCT", 78, 87], ["Transgene", "DNA", 78, 87], ["Germ LineFactors", "DNA", 97, 113], ["pigs", "SPECIES", 56, 60], ["Microinjected embryos", "PROBLEM", 0, 21], ["the Transgene into the Germ LineFactors", "TREATMENT", 74, 113], ["microinjection", "TREATMENT", 139, 153], ["a gene insertion technique", "TREATMENT", 157, 183], ["Germ LineFactors", "OBSERVATION", 97, 113]]], ["Experience in microinjection is an important factor as well as DNA concentration and the gene construct.", [["DNA", "CELLULAR_COMPONENT", 63, 66], ["DNA concentration", "TREATMENT", 63, 80]]], ["The stage of egg development and the quality of eggs may affect the efficiency of producing transgenic animals.", [["egg", "ANATOMY", 13, 16], ["eggs", "ANATOMY", 48, 52], ["egg", "DEVELOPING_ANATOMICAL_STRUCTURE", 13, 16], ["egg development", "PROBLEM", 13, 28], ["egg", "OBSERVATION", 13, 16]]], ["Three factors contribute to problems of microinjection of livestock embryos compared to mice.", [["embryos", "ANATOMY", 68, 75], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 68, 75], ["mice", "ORGANISM", 88, 92], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 88, 92], ["livestock embryos", "PROBLEM", 58, 75]]], ["Cytoplasmic vesicles may obscure the view of pronuclei, fewer embryos are available for microinjection, and there is considerable variability in the stage of embryo development at the time of embryo collection.", [["Cytoplasmic vesicles", "ANATOMY", 0, 20], ["pronuclei", "ANATOMY", 45, 54], ["embryos", "ANATOMY", 62, 69], ["embryo", "ANATOMY", 158, 164], ["embryo", "ANATOMY", 192, 198], ["Cytoplasmic vesicles", "CELLULAR_COMPONENT", 0, 20], ["pronuclei", "CELLULAR_COMPONENT", 45, 54], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 62, 69], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 158, 164], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 192, 198], ["Cytoplasmic vesicles", "PROBLEM", 0, 20], ["microinjection", "TREATMENT", 88, 102], ["considerable variability", "PROBLEM", 117, 141], ["embryo development", "PROBLEM", 158, 176], ["embryo collection", "PROBLEM", 192, 209], ["vesicles", "OBSERVATION", 12, 20], ["considerable", "OBSERVATION_MODIFIER", 117, 129], ["variability", "OBSERVATION_MODIFIER", 130, 141], ["embryo", "OBSERVATION", 158, 164], ["embryo", "ANATOMY", 192, 198], ["collection", "OBSERVATION", 199, 209]]], ["Despite these challenges, there has been considerable success in developing transgenic goats, sheep, pigs, and cows.", [["goats", "ORGANISM", 87, 92], ["sheep", "ORGANISM", 94, 99], ["pigs", "ORGANISM", 101, 105], ["cows", "ORGANISM", 111, 115], ["goats", "SPECIES", 87, 92], ["sheep", "SPECIES", 94, 99], ["pigs", "SPECIES", 101, 105], ["cows", "SPECIES", 111, 115], ["goats", "SPECIES", 87, 92], ["sheep", "SPECIES", 94, 99], ["pigs", "SPECIES", 101, 105], ["considerable", "OBSERVATION_MODIFIER", 41, 53], ["success", "OBSERVATION_MODIFIER", 54, 61], ["transgenic goats", "OBSERVATION", 76, 92]]], ["Key reproduction parameters and the success rate of transgenesis are summarized in Table 2 .Insertion of the Transgene into the Germ LineIn summary, oocytes may be fertilized in vivo or in vitro.", [["oocytes", "ANATOMY", 149, 156], ["Transgene", "GENE_OR_GENE_PRODUCT", 109, 118], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 149, 156], ["Transgene", "DNA", 109, 118], ["the success rate of transgenesis", "TREATMENT", 32, 64]]], ["In vivo fertilization may be controlled by artificial insemination of a superovulated animal at the stage where the oocyte has matured in the ovary.", [["oocyte", "ANATOMY", 116, 122], ["ovary", "ANATOMY", 142, 147], ["oocyte", "DEVELOPING_ANATOMICAL_STRUCTURE", 116, 122], ["ovary", "ORGAN", 142, 147], ["artificial insemination", "TREATMENT", 43, 66], ["a superovulated animal", "TREATMENT", 70, 92], ["may be", "UNCERTAINTY", 22, 28], ["oocyte", "ANATOMY", 116, 122], ["ovary", "ANATOMY", 142, 147]]], ["An alternative pathway is to isolate follicular oocytes from the ovary of the donor animal and proceed to in vitro maturation and fertilization prior to microinjection and implantation in the recipient female.", [["follicular oocytes", "ANATOMY", 37, 55], ["ovary", "ANATOMY", 65, 70], ["follicular oocytes", "MULTI-TISSUE_STRUCTURE", 37, 55], ["ovary", "ORGAN", 65, 70], ["vitro maturation", "TREATMENT", 109, 125], ["fertilization", "TREATMENT", 130, 143], ["microinjection", "TREATMENT", 153, 167], ["implantation", "TREATMENT", 172, 184], ["ovary", "ANATOMY", 65, 70]]], ["In goats, sheep, and cows the rate of transgenic births is 5-10%.Insertion of the Transgene into the Germ LineEmbryonic stem (ES) cells may offer an alternative to pronuclear microinjection for achieving transgenesis.", [["Germ LineEmbryonic stem (ES) cells", "ANATOMY", 101, 135], ["pronuclear", "ANATOMY", 164, 174], ["goats", "ORGANISM", 3, 8], ["sheep", "ORGANISM", 10, 15], ["cows", "ORGANISM", 21, 25], ["Transgene", "GENE_OR_GENE_PRODUCT", 82, 91], ["Germ LineEmbryonic stem (ES) cells", "CELL", 101, 135], ["Transgene", "DNA", 82, 91], ["Germ LineEmbryonic stem (ES) cells", "CELL_LINE", 101, 135], ["goats", "SPECIES", 3, 8], ["sheep", "SPECIES", 10, 15], ["cows", "SPECIES", 21, 25], ["goats", "SPECIES", 3, 8], ["sheep", "SPECIES", 10, 15], ["the Transgene into the Germ LineEmbryonic stem (ES) cells", "TREATMENT", 78, 135], ["an alternative to pronuclear microinjection", "TREATMENT", 146, 189], ["LineEmbryonic stem", "ANATOMY", 106, 124]]], ["However, pluripotent ES cells able to contribute to the germ line have only been described in mice.", [["ES cells", "ANATOMY", 21, 29], ["germ line", "ANATOMY", 56, 65], ["pluripotent ES cells", "CELL", 9, 29], ["germ line", "CELL", 56, 65], ["mice", "ORGANISM", 94, 98], ["pluripotent ES cells", "CELL_TYPE", 9, 29], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 94, 98], ["pluripotent ES cells", "PROBLEM", 9, 29], ["the germ line", "PROBLEM", 52, 65], ["germ line", "OBSERVATION", 56, 65]]], ["There have been descriptions of chimeric animals generated with rat, pig, and cow ES cells (Iannaconne et al., 1994; Wheeler, 1994; Stice et al., 1996) , but in the case of rats and pigs no evidence of germ line transmission from these cells has been reported.", [["ES cells", "ANATOMY", 82, 90], ["germ line", "ANATOMY", 202, 211], ["cells", "ANATOMY", 236, 241], ["rat", "ORGANISM", 64, 67], ["pig", "ORGANISM", 69, 72], ["cow", "ORGANISM", 78, 81], ["ES cells", "CELL", 82, 90], ["rats", "ORGANISM", 173, 177], ["pigs", "ORGANISM", 182, 186], ["germ line", "CELL", 202, 211], ["cells", "CELL", 236, 241], ["rat, pig, and cow ES cells", "CELL_TYPE", 64, 90], ["rat", "SPECIES", 64, 67], ["pig", "SPECIES", 69, 72], ["cow", "SPECIES", 78, 81], ["rats", "SPECIES", 173, 177], ["pigs", "SPECIES", 182, 186], ["rat", "SPECIES", 64, 67], ["pig", "SPECIES", 69, 72], ["cow", "SPECIES", 78, 81], ["pigs", "SPECIES", 182, 186], ["germ line transmission from these cells", "PROBLEM", 202, 241], ["no evidence of", "UNCERTAINTY", 187, 201], ["germ line", "OBSERVATION", 202, 211]]], ["Cow fetuses obtained following nuclear transfer of ES cell-derived nuclei in recipient oocytes died in utero, exhibiting major defects in placental development (Stice et al., 1996) .", [["fetuses", "ANATOMY", 4, 11], ["nuclear", "ANATOMY", 31, 38], ["ES cell", "ANATOMY", 51, 58], ["nuclei", "ANATOMY", 67, 73], ["oocytes", "ANATOMY", 87, 94], ["placental", "ANATOMY", 138, 147], ["Cow", "ORGANISM", 0, 3], ["fetuses", "ORGANISM", 4, 11], ["nuclear", "CELLULAR_COMPONENT", 31, 38], ["ES cell", "CELL", 51, 58], ["nuclei", "CELL", 67, 73], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 87, 94], ["utero", "ORGAN", 103, 108], ["placental", "ORGAN", 138, 147], ["ES cell", "CELL_TYPE", 51, 58], ["Cow fetuses", "PROBLEM", 0, 11], ["major defects in placental development", "PROBLEM", 121, 159], ["recipient oocytes", "OBSERVATION", 77, 94], ["major", "OBSERVATION_MODIFIER", 121, 126], ["defects", "OBSERVATION", 127, 134], ["placental", "ANATOMY", 138, 147]]], ["In sheep, the first large animals derived from cultured cells were described in 1996 by Campbell et al. Two healthy phenotypicaly female lambs were born from embryos generated by transferring nuclei isolated from embryo-derived cells into enucleated oocytes.", [["cells", "ANATOMY", 56, 61], ["embryos", "ANATOMY", 158, 165], ["nuclei", "ANATOMY", 192, 198], ["embryo-derived cells", "ANATOMY", 213, 233], ["oocytes", "ANATOMY", 250, 257], ["sheep", "ORGANISM", 3, 8], ["animals", "ORGANISM", 26, 33], ["cells", "CELL", 56, 61], ["lambs", "ORGANISM", 137, 142], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 158, 165], ["nuclei", "CELL", 192, 198], ["embryo-derived cells", "CELL", 213, 233], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 250, 257], ["cultured cells", "CELL_LINE", 47, 61], ["embryo-derived cells", "CELL_TYPE", 213, 233], ["sheep", "SPECIES", 3, 8], ["lambs", "SPECIES", 137, 142], ["sheep", "SPECIES", 3, 8], ["enucleated oocytes", "OBSERVATION", 239, 257]]], ["DNA analysis demonstrated that all the nuclear transfer lambs and fetuses were derived from the cell line.", [["nuclear", "ANATOMY", 39, 46], ["lambs", "ANATOMY", 56, 61], ["fetuses", "ANATOMY", 66, 73], ["cell line", "ANATOMY", 96, 105], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["nuclear", "CELLULAR_COMPONENT", 39, 46], ["lambs", "ORGANISM", 56, 61], ["fetuses", "ORGAN", 66, 73], ["cell line", "CELL", 96, 105], ["DNA analysis", "TEST", 0, 12], ["cell line", "OBSERVATION", 96, 105]]], ["It is not yet clear whether foreign DNA can be introduced in this type of cell line, and there are questions about the health and reproductive fitness of the recovered offspring.", [["cell line", "ANATOMY", 74, 83], ["DNA", "CELLULAR_COMPONENT", 36, 39], ["cell line", "CELL", 74, 83], ["foreign DNA", "PROBLEM", 28, 39], ["foreign DNA", "OBSERVATION", 28, 39], ["cell line", "OBSERVATION", 74, 83]]], ["Nevertheless, this experiment is certainly a step toward the possibility of replacing pronuclear microinjection as the method of choice for the generation of transgenic large animals.Insertion of the Transgene into the Germ LineAnother potential alternative to the pronuclear microinjection of the transgene is the use of replication-defective retrovirus vectors.", [["pronuclear", "ANATOMY", 86, 96], ["pronuclear", "ANATOMY", 265, 275], ["Transgene", "GENE_OR_GENE_PRODUCT", 200, 209], ["pronuclear", "CELLULAR_COMPONENT", 265, 275], ["retrovirus", "ORGANISM", 344, 354], ["Transgene", "DNA", 200, 209], ["replication-defective retrovirus vectors", "DNA", 322, 362], ["replacing pronuclear microinjection", "TREATMENT", 76, 111], ["transgenic large animals", "PROBLEM", 158, 182], ["the pronuclear microinjection", "TREATMENT", 261, 290], ["replication-defective retrovirus vectors", "TREATMENT", 322, 362], ["large", "OBSERVATION_MODIFIER", 169, 174], ["defective retrovirus vectors", "OBSERVATION", 334, 362]]], ["Archer et al. (1994) have described a procedure in which the construct is infused directly into the mammary gland, via the teat canal, during a period of hormone-induced mammogenesis.", [["mammary gland", "ANATOMY", 100, 113], ["teat canal", "ANATOMY", 123, 133], ["mammogenesis", "DISEASE", 170, 182], ["mammary gland", "ORGAN", 100, 113], ["teat canal", "MULTI-TISSUE_STRUCTURE", 123, 133], ["a procedure", "TREATMENT", 36, 47], ["hormone-induced mammogenesis", "TREATMENT", 154, 182], ["mammary gland", "ANATOMY", 100, 113], ["teat canal", "ANATOMY", 123, 133]]], ["A gibbon ape leukemia virus was used to deliver the structural gene encoding for human growth hormone resulting in expression of the hormone in goat mammary epithelial cells.", [["mammary epithelial cells", "ANATOMY", 149, 173], ["leukemia virus", "DISEASE", 13, 27], ["gibbon ape leukemia virus", "ORGANISM", 2, 27], ["human", "ORGANISM", 81, 86], ["goat", "ORGANISM", 144, 148], ["mammary epithelial cells", "CELL", 149, 173], ["structural gene", "DNA", 52, 67], ["goat mammary epithelial cells", "CELL_TYPE", 144, 173], ["gibbon ape leukemia virus", "SPECIES", 2, 27], ["human", "SPECIES", 81, 86], ["goat", "SPECIES", 144, 148], ["gibbon ape leukemia virus", "SPECIES", 2, 27], ["human", "SPECIES", 81, 86], ["goat", "SPECIES", 144, 148], ["A gibbon ape leukemia virus", "TREATMENT", 0, 27], ["human growth hormone", "PROBLEM", 81, 101], ["the hormone in goat mammary epithelial cells", "PROBLEM", 129, 173], ["gibbon ape", "OBSERVATION", 2, 12], ["leukemia virus", "OBSERVATION", 13, 27], ["goat mammary", "ANATOMY", 144, 156], ["epithelial cells", "OBSERVATION", 157, 173]]], ["The advantage of this method is that expression of the recombinant protein is obtained quickly, without the delay caused by the generation interval required to generate a producing transgenic animal (18 months for goats).", [["goats", "ORGANISM", 214, 219], ["recombinant protein", "PROTEIN", 55, 74], ["goats", "SPECIES", 214, 219], ["goats", "SPECIES", 214, 219], ["the recombinant protein", "TEST", 51, 74]]], ["However, reported production levels (Archer et al., 1994) are very low (see Table 1 ) and at this point in time can only be used for analytical purposes.Transgenic Animal ProductionTransgenic animals for the production of therapeutic and diagnostic proteins are produced by transferring fertilized, transgene-carrying embryos to recipient animals.", [["embryos", "ANATOMY", 318, 325], ["Transgenic animals", "ORGANISM", 181, 199], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 318, 325], ["therapeutic and diagnostic proteins", "TREATMENT", 222, 257]]], ["Following natural gestation and birth, offspring are subject to tissue biopsy and blood sampling: usually ear tissue and blood are screened by polymerase chain reaction and/or Southern analysis for the presence of the transgene.", [["tissue biopsy", "ANATOMY", 64, 77], ["blood", "ANATOMY", 82, 87], ["ear tissue", "ANATOMY", 106, 116], ["blood", "ANATOMY", 121, 126], ["tissue biopsy", "MULTI-TISSUE_STRUCTURE", 64, 77], ["blood", "ORGANISM_SUBSTANCE", 82, 87], ["ear tissue", "TISSUE", 106, 116], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["tissue biopsy", "TEST", 64, 77], ["blood sampling", "TEST", 82, 96], ["usually ear tissue", "PROBLEM", 98, 116], ["Southern analysis", "TEST", 176, 193], ["ear tissue", "ANATOMY", 106, 116]]], ["Animals identified as being transgenic are mated with nontransgenic animals: transgenic founder females will produce the protein for which the DNA codes in their blood or milk depending on the tissue-specific, regulatory promoter sequence of the transgene.", [["blood", "ANATOMY", 162, 167], ["milk", "ANATOMY", 171, 175], ["tissue", "ANATOMY", 193, 199], ["Animals", "ORGANISM", 0, 7], ["transgenic founder females", "ORGANISM", 77, 103], ["DNA", "CELLULAR_COMPONENT", 143, 146], ["blood", "ORGANISM_SUBSTANCE", 162, 167], ["milk", "ORGANISM_SUBSTANCE", 171, 175], ["tissue", "TISSUE", 193, 199], ["regulatory promoter sequence", "DNA", 210, 238], ["the DNA codes", "PROBLEM", 139, 152]]], ["Subsequently, transgenic female progeny derived from breeding founder females and males will also express the transgenic protein.Transgenic Animal ProductionIn goats, 16-18 months are required before the first milk is obtained from a natural lactation of a female transgenic animal.", [["milk", "ANATOMY", 210, 214], ["males", "ORGANISM", 82, 87], ["Animal ProductionIn goats", "ORGANISM", 140, 165], ["milk", "ORGANISM_SUBSTANCE", 210, 214], ["transgenic female progeny", "CELL_LINE", 14, 39], ["transgenic protein", "PROTEIN", 110, 128], ["goats", "SPECIES", 160, 165], ["goats", "SPECIES", 160, 165]]], ["However, milk samples can be obtained from founder transgenic females, as well as approximately 30% of male transgenic animals by hormonally induced lactation at about 13 months after microinjection.", [["milk samples", "ANATOMY", 9, 21], ["milk samples", "ORGANISM_SUBSTANCE", 9, 21], ["animals", "ORGANISM", 119, 126], ["milk samples", "TEST", 9, 21], ["microinjection", "TREATMENT", 184, 198]]], ["Induced lactation is useful in checking the expression level and integrity of the heterologous protein.Biosynthesis of Milk ProteinsThe original precursors of most of the milk constituents are cellulose, starch, protein, fat, minerals, and vitamins of the plant materials of the ruminant diet.", [["milk", "ANATOMY", 171, 175], ["cellulose, starch, protein, fat, minerals, and vitamins", "CHEMICAL", 193, 248], ["milk", "ORGANISM", 171, 175], ["cellulose", "SIMPLE_CHEMICAL", 193, 202], ["starch", "SIMPLE_CHEMICAL", 204, 210], ["fat", "SIMPLE_CHEMICAL", 221, 224], ["minerals", "SIMPLE_CHEMICAL", 226, 234], ["vitamins", "SIMPLE_CHEMICAL", 240, 248], ["heterologous protein", "PROTEIN", 82, 102], ["Milk Proteins", "PROTEIN", 119, 132], ["Biosynthesis of Milk Proteins", "TREATMENT", 103, 132], ["protein, fat, minerals", "TREATMENT", 212, 234], ["vitamins", "TREATMENT", 240, 248], ["the plant materials", "TREATMENT", 252, 271], ["ruminant diet", "OBSERVATION", 279, 292]]], ["Water is also a prerequisite, and dairy cows require 3-4 liters of water per liter of milk produced.", [["milk", "ORGANISM_SUBSTANCE", 86, 90], ["cows", "SPECIES", 40, 44]]], ["Rumen microorganisms synthesize amino acids, which are adsorbed into the bloodstream.", [["bloodstream", "ANATOMY", 73, 84], ["amino acids", "CHEMICAL", 32, 43], ["amino acids", "CHEMICAL", 32, 43], ["amino acids", "AMINO_ACID", 32, 43], ["Rumen microorganisms synthesize amino acids", "PROBLEM", 0, 43], ["amino acids", "OBSERVATION", 32, 43], ["bloodstream", "ANATOMY", 73, 84]]], ["The milk protein precursor amino acids are adsorbed from the bloodstream via the extracellular fluid between the capillaries and the epithelial cells, across the basement membrane of the mammary epithelial cells.", [["milk", "ANATOMY", 4, 8], ["bloodstream", "ANATOMY", 61, 72], ["extracellular fluid", "ANATOMY", 81, 100], ["capillaries", "ANATOMY", 113, 124], ["epithelial cells", "ANATOMY", 133, 149], ["basement membrane", "ANATOMY", 162, 179], ["mammary epithelial cells", "ANATOMY", 187, 211], ["amino acids", "CHEMICAL", 27, 38], ["amino acids", "CHEMICAL", 27, 38], ["milk", "ORGANISM_SUBSTANCE", 4, 8], ["amino acids", "AMINO_ACID", 27, 38], ["extracellular fluid", "IMMATERIAL_ANATOMICAL_ENTITY", 81, 100], ["capillaries", "TISSUE", 113, 124], ["epithelial cells", "CELL", 133, 149], ["basement membrane", "CELLULAR_COMPONENT", 162, 179], ["mammary epithelial cells", "CELL", 187, 211], ["epithelial cells", "CELL_TYPE", 133, 149], ["mammary epithelial cells", "CELL_TYPE", 187, 211], ["The milk protein precursor amino acids", "TEST", 0, 38], ["the extracellular fluid", "TEST", 77, 100], ["amino acids", "OBSERVATION", 27, 38], ["fluid", "OBSERVATION", 95, 100], ["capillaries", "ANATOMY", 113, 124], ["epithelial cells", "OBSERVATION", 133, 149], ["basement", "ANATOMY_MODIFIER", 162, 170], ["membrane", "ANATOMY_MODIFIER", 171, 179], ["mammary", "ANATOMY", 187, 194], ["epithelial cells", "OBSERVATION", 195, 211]]], ["Protein biosynthesis is carried out in epithelial cells, and milk proteins are discharged into the lumen of the alveolus by exocytosis and then into the ducts.", [["epithelial cells", "ANATOMY", 39, 55], ["milk", "ANATOMY", 61, 65], ["lumen", "ANATOMY", 99, 104], ["alveolus", "ANATOMY", 112, 120], ["ducts", "ANATOMY", 153, 158], ["epithelial cells", "CELL", 39, 55], ["milk", "ORGANISM_SUBSTANCE", 61, 65], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 99, 104], ["alveolus", "ORGAN", 112, 120], ["ducts", "MULTI-TISSUE_STRUCTURE", 153, 158], ["epithelial cells", "CELL_TYPE", 39, 55], ["milk proteins", "PROTEIN", 61, 74], ["Protein biosynthesis", "TEST", 0, 20], ["milk proteins", "TREATMENT", 61, 74], ["epithelial cells", "OBSERVATION", 39, 55], ["lumen", "ANATOMY_MODIFIER", 99, 104], ["alveolus", "ANATOMY", 112, 120], ["ducts", "ANATOMY", 153, 158]]], ["In ruminants, the ducts empty into a single, primary duct or cistern, which provides extra milk storage capacity.", [["ducts", "ANATOMY", 18, 23], ["primary duct", "ANATOMY", 45, 57], ["cistern", "ANATOMY", 61, 68], ["milk", "ANATOMY", 91, 95], ["ducts", "MULTI-TISSUE_STRUCTURE", 18, 23], ["duct", "MULTI-TISSUE_STRUCTURE", 53, 57], ["milk", "ORGANISM_SUBSTANCE", 91, 95], ["a single, primary duct or cistern", "PROBLEM", 35, 68], ["extra milk storage capacity", "TREATMENT", 85, 112], ["ruminants", "OBSERVATION_MODIFIER", 3, 12], ["ducts", "ANATOMY", 18, 23], ["empty", "OBSERVATION", 24, 29], ["single", "OBSERVATION_MODIFIER", 37, 43], ["primary duct", "ANATOMY", 45, 57], ["cistern", "ANATOMY_MODIFIER", 61, 68]]], ["Up to 30% of the milk in the udder is held in the cistern.Biosynthesis of Milk ProteinsAs measured by the concentration difference in arteriovenous blood, the mammary gland is particularly efficient at extracting amino acids: 80% of the arterial methionine; 70% of the phenylalanine, leucine, and threonine; 60% of the lysine, arginine, and isoleucine; 55% of the histidine; and 50% of valine are adsorbed.", [["milk", "ANATOMY", 17, 21], ["udder", "ANATOMY", 29, 34], ["arteriovenous blood", "ANATOMY", 134, 153], ["mammary gland", "ANATOMY", 159, 172], ["arterial", "ANATOMY", 237, 245], ["amino acids", "CHEMICAL", 213, 224], ["methionine", "CHEMICAL", 246, 256], ["phenylalanine", "CHEMICAL", 269, 282], ["leucine", "CHEMICAL", 284, 291], ["threonine", "CHEMICAL", 297, 306], ["lysine", "CHEMICAL", 319, 325], ["arginine", "CHEMICAL", 327, 335], ["isoleucine", "CHEMICAL", 341, 351], ["histidine", "CHEMICAL", 364, 373], ["valine", "CHEMICAL", 386, 392], ["amino acids", "CHEMICAL", 213, 224], ["methionine", "CHEMICAL", 246, 256], ["phenylalanine", "CHEMICAL", 269, 282], ["leucine", "CHEMICAL", 284, 291], ["threonine", "CHEMICAL", 297, 306], ["lysine", "CHEMICAL", 319, 325], ["arginine", "CHEMICAL", 327, 335], ["isoleucine", "CHEMICAL", 341, 351], ["histidine", "CHEMICAL", 364, 373], ["valine", "CHEMICAL", 386, 392], ["milk", "ORGANISM_SUBSTANCE", 17, 21], ["udder", "ORGAN", 29, 34], ["arteriovenous blood", "ORGANISM_SUBSTANCE", 134, 153], ["mammary gland", "ORGAN", 159, 172], ["amino acids", "AMINO_ACID", 213, 224], ["arterial", "MULTI-TISSUE_STRUCTURE", 237, 245], ["methionine", "AMINO_ACID", 246, 256], ["phenylalanine", "AMINO_ACID", 269, 282], ["leucine", "AMINO_ACID", 284, 291], ["threonine", "AMINO_ACID", 297, 306], ["lysine", "AMINO_ACID", 319, 325], ["arginine", "AMINO_ACID", 327, 335], ["isoleucine", "AMINO_ACID", 341, 351], ["histidine", "AMINO_ACID", 364, 373], ["valine", "AMINO_ACID", 386, 392], ["Milk Proteins", "PROTEIN", 74, 87], ["Biosynthesis of Milk Proteins", "TREATMENT", 58, 87], ["the concentration difference in arteriovenous blood, the mammary gland", "PROBLEM", 102, 172], ["amino acids", "TEST", 213, 224], ["the arterial methionine", "TREATMENT", 233, 256], ["the phenylalanine", "TREATMENT", 265, 282], ["leucine", "TREATMENT", 284, 291], ["threonine", "TREATMENT", 297, 306], ["the lysine", "TREATMENT", 315, 325], ["arginine", "TREATMENT", 327, 335], ["isoleucine", "TREATMENT", 341, 351], ["the histidine", "TREATMENT", 360, 373], ["valine", "TREATMENT", 386, 392], ["cistern", "ANATOMY", 50, 57], ["arteriovenous blood", "ANATOMY", 134, 153], ["mammary gland", "ANATOMY", 159, 172], ["arterial", "ANATOMY", 237, 245]]], ["More than 25 % of the arterial blood glucose is removed during passage through the mammary gland and is used to power protein synthesis, fat, and lactose production.", [["arterial blood", "ANATOMY", 22, 36], ["mammary gland", "ANATOMY", 83, 96], ["fat", "ANATOMY", 137, 140], ["glucose", "CHEMICAL", 37, 44], ["lactose", "CHEMICAL", 146, 153], ["glucose", "CHEMICAL", 37, 44], ["lactose", "CHEMICAL", 146, 153], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 22, 36], ["glucose", "SIMPLE_CHEMICAL", 37, 44], ["mammary gland", "ORGAN", 83, 96], ["fat", "TISSUE", 137, 140], ["lactose", "SIMPLE_CHEMICAL", 146, 153], ["the arterial blood glucose", "TEST", 18, 44], ["arterial", "ANATOMY", 22, 30], ["mammary gland", "ANATOMY", 83, 96], ["lactose production", "OBSERVATION", 146, 164]]], ["Intermediates required for protein synthesis are produced in the cytosol and mitochondria.", [["cytosol", "ANATOMY", 65, 72], ["mitochondria", "ANATOMY", 77, 89], ["cytosol", "CELLULAR_COMPONENT", 65, 72], ["mitochondria", "CELLULAR_COMPONENT", 77, 89], ["protein synthesis", "TREATMENT", 27, 44]]], ["Protein is synthesized at polyribosomes in the rough endoplasmic reticulum where removal of signal peptides occurs.", [["polyribosomes", "ANATOMY", 26, 39], ["endoplasmic reticulum", "ANATOMY", 53, 74], ["polyribosomes", "CELLULAR_COMPONENT", 26, 39], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 53, 74], ["Protein", "TEST", 0, 7], ["signal peptides", "PROBLEM", 92, 107], ["polyribosomes", "OBSERVATION_MODIFIER", 26, 39], ["rough", "ANATOMY_MODIFIER", 47, 52], ["endoplasmic reticulum", "OBSERVATION", 53, 74], ["removal", "OBSERVATION_MODIFIER", 81, 88], ["signal peptides", "OBSERVATION", 92, 107]]], ["Glycosylation is carried out in the endoplasmic reticulum and the Golgi apparatus where phosphorylation, other posttranslational modifications, and the assembly of casein micelles are carried out.", [["endoplasmic reticulum", "ANATOMY", 36, 57], ["Golgi apparatus", "ANATOMY", 66, 81], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 36, 57], ["Golgi apparatus", "CELLULAR_COMPONENT", 66, 81], ["casein micelles", "SIMPLE_CHEMICAL", 164, 179], ["Glycosylation", "TREATMENT", 0, 13], ["other posttranslational modifications", "TREATMENT", 105, 142], ["casein micelles", "TREATMENT", 164, 179], ["endoplasmic reticulum", "ANATOMY", 36, 57], ["posttranslational modifications", "OBSERVATION", 111, 142]]], ["Studies with radiolabeled amino acids indicate that proteins are synthesized in 3-15 min.", [["amino acids", "CHEMICAL", 26, 37], ["amino acids", "CHEMICAL", 26, 37], ["amino acids", "AMINO_ACID", 26, 37], ["radiolabeled amino acids", "TEST", 13, 37]]], ["Radioactivity is seen in the Golgi apparatus after 15-30 min, and the label concentration in the lumen increases after a further 30-60 min.", [["Golgi apparatus", "ANATOMY", 29, 44], ["lumen", "ANATOMY", 97, 102], ["Golgi", "CELLULAR_COMPONENT", 29, 34], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 97, 102], ["Golgi", "ANATOMY_MODIFIER", 29, 34], ["concentration", "OBSERVATION_MODIFIER", 76, 89], ["lumen", "ANATOMY_MODIFIER", 97, 102], ["increases", "OBSERVATION_MODIFIER", 103, 112]]], ["Immunoglobulins and albumin present in milk are not synthesized in the mammary gland but by plasma cells and hepatocytes, respectively, and enter the milk by active transport or filtration.", [["milk", "ANATOMY", 39, 43], ["mammary gland", "ANATOMY", 71, 84], ["plasma cells", "ANATOMY", 92, 104], ["hepatocytes", "ANATOMY", 109, 120], ["milk", "ANATOMY", 150, 154], ["Immunoglobulins", "GENE_OR_GENE_PRODUCT", 0, 15], ["albumin", "GENE_OR_GENE_PRODUCT", 20, 27], ["milk", "ORGANISM_SUBSTANCE", 39, 43], ["mammary gland", "ORGAN", 71, 84], ["plasma cells", "CELL", 92, 104], ["hepatocytes", "CELL", 109, 120], ["milk", "ORGANISM_SUBSTANCE", 150, 154], ["Immunoglobulins", "PROTEIN", 0, 15], ["albumin", "PROTEIN", 20, 27], ["plasma cells", "CELL_TYPE", 92, 104], ["hepatocytes", "CELL_TYPE", 109, 120], ["Immunoglobulins", "TREATMENT", 0, 15], ["albumin", "TREATMENT", 20, 27], ["mammary gland", "ANATOMY", 71, 84], ["plasma cells", "OBSERVATION", 92, 104], ["hepatocytes", "ANATOMY", 109, 120]]], ["During lactation, B lymphocytes migrate to the mammary gland where they become plasma cells.", [["B lymphocytes", "ANATOMY", 18, 31], ["mammary gland", "ANATOMY", 47, 60], ["plasma cells", "ANATOMY", 79, 91], ["B lymphocytes", "CELL", 18, 31], ["mammary gland", "ORGAN", 47, 60], ["plasma cells", "CELL", 79, 91], ["B lymphocytes", "CELL_TYPE", 18, 31], ["plasma cells", "CELL_TYPE", 79, 91], ["plasma cells", "PROBLEM", 79, 91], ["mammary gland", "ANATOMY", 47, 60], ["plasma cells", "OBSERVATION", 79, 91]]], ["Plasma cells lodged in the interstitial space may contribute to the high IgG concentration present in the colostrum of early lactation.Biosynthesis of Milk ProteinsIn the cow, approximately 500 liters of blood is required to provide the precursors for 1 liter of bovine milk: the blood flow in the udder is ca.", [["Plasma cells", "ANATOMY", 0, 12], ["interstitial space", "ANATOMY", 27, 45], ["colostrum", "ANATOMY", 106, 115], ["blood", "ANATOMY", 204, 209], ["milk", "ANATOMY", 270, 274], ["blood", "ANATOMY", 280, 285], ["udder", "ANATOMY", 298, 303], ["Plasma cells", "CELL", 0, 12], ["interstitial space", "MULTI-TISSUE_STRUCTURE", 27, 45], ["IgG", "GENE_OR_GENE_PRODUCT", 73, 76], ["colostrum", "ORGANISM_SUBSTANCE", 106, 115], ["cow", "ORGANISM", 171, 174], ["blood", "ORGANISM_SUBSTANCE", 204, 209], ["bovine", "ORGANISM", 263, 269], ["milk", "ORGANISM_SUBSTANCE", 270, 274], ["blood", "ORGANISM_SUBSTANCE", 280, 285], ["udder", "ORGANISM_SUBDIVISION", 298, 303], ["Plasma cells", "CELL_TYPE", 0, 12], ["IgG", "PROTEIN", 73, 76], ["Milk Proteins", "PROTEIN", 151, 164], ["cow", "SPECIES", 171, 174], ["bovine", "SPECIES", 263, 269], ["cow", "SPECIES", 171, 174], ["bovine", "SPECIES", 263, 269], ["Plasma cells", "TEST", 0, 12], ["the high IgG concentration", "PROBLEM", 64, 90], ["Biosynthesis of Milk Proteins", "TREATMENT", 135, 164], ["the precursors", "TREATMENT", 233, 247], ["bovine milk", "TREATMENT", 263, 274], ["the blood flow", "TEST", 276, 290], ["cells lodged", "OBSERVATION", 7, 19], ["interstitial", "ANATOMY_MODIFIER", 27, 39], ["high", "OBSERVATION_MODIFIER", 68, 72], ["IgG concentration", "OBSERVATION", 73, 90], ["ca", "OBSERVATION", 307, 309]]], ["The goat uses about 400 liters of blood to produce 1 liter of milk: the blood flow in the udder is ca.", [["blood", "ANATOMY", 34, 39], ["milk", "ANATOMY", 62, 66], ["blood", "ANATOMY", 72, 77], ["udder", "ANATOMY", 90, 95], ["goat", "ORGANISM", 4, 8], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["milk", "ORGANISM_SUBSTANCE", 62, 66], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["udder", "ORGANISM_SUBDIVISION", 90, 95], ["goat", "SPECIES", 4, 8], ["the blood flow", "TEST", 68, 82], ["ca", "OBSERVATION", 99, 101]]], ["The mammary gland is able to secrete about 2 g of milk, containing approximately 18 mg of whey protein, per gram of tissue per day.", [["mammary gland", "ANATOMY", 4, 17], ["milk", "ANATOMY", 50, 54], ["tissue", "ANATOMY", 116, 122], ["mammary gland", "ORGAN", 4, 17], ["milk", "ORGANISM_SUBSTANCE", 50, 54], ["tissue", "TISSUE", 116, 122], ["whey protein", "PROTEIN", 90, 102], ["mammary gland", "ANATOMY", 4, 17]]], ["A gram of tissue contains about 2 x 108 cells and the milk output is therefore of the order of 10 -8 g per cell per day.", [["tissue", "ANATOMY", 10, 16], ["cells", "ANATOMY", 40, 45], ["milk", "ANATOMY", 54, 58], ["cell", "ANATOMY", 107, 111], ["tissue", "TISSUE", 10, 16], ["cells", "CELL", 40, 45], ["milk", "ORGANISM_SUBSTANCE", 54, 58], ["cell", "CELL", 107, 111], ["A gram of tissue", "PROBLEM", 0, 16], ["the milk output", "TEST", 50, 65], ["gram of tissue", "OBSERVATION_MODIFIER", 2, 16], ["about 2 x 108 cells", "OBSERVATION_MODIFIER", 26, 45]]], ["Lymph drains from the udder of the cow at the rate of 1300 ml per hour and in the goat at the rate of 6.5-35 ml per hour.", [["Lymph drains", "ANATOMY", 0, 12], ["udder", "ANATOMY", 22, 27], ["Lymph drains", "MULTI-TISSUE_STRUCTURE", 0, 12], ["udder", "ORGANISM_SUBDIVISION", 22, 27], ["cow", "ORGANISM_SUBDIVISION", 35, 38], ["goat", "ORGANISM", 82, 86], ["goat", "SPECIES", 82, 86], ["cow", "SPECIES", 35, 38], ["goat", "SPECIES", 82, 86], ["Lymph drains", "TREATMENT", 0, 12], ["drains", "OBSERVATION", 6, 12]]], ["Leukocytes, which account for the major part of the somatic cells found in milk, are derived from lymph.", [["Leukocytes", "ANATOMY", 0, 10], ["somatic cells", "ANATOMY", 52, 65], ["milk", "ANATOMY", 75, 79], ["lymph", "ANATOMY", 98, 103], ["Leukocytes", "CELL", 0, 10], ["somatic cells", "CELL", 52, 65], ["milk", "ORGANISM_SUBSTANCE", 75, 79], ["lymph", "ORGAN", 98, 103], ["Leukocytes", "CELL_TYPE", 0, 10], ["somatic cells", "CELL_TYPE", 52, 65], ["Leukocytes", "TEST", 0, 10], ["the somatic cells", "PROBLEM", 48, 65], ["somatic cells", "OBSERVATION", 52, 65], ["lymph", "ANATOMY", 98, 103]]], ["Morc61 et al. (1994) have calculated the synthesis rate of human recombinant protein C in transgenic swine expressing the protein at 0.1-1 mg/ml milk to be approximately 14 mg per gram of mammary cell per day or about 14 pg/cell/day.", [["mammary cell", "ANATOMY", 188, 200], ["cell", "ANATOMY", 224, 228], ["human", "ORGANISM", 59, 64], ["recombinant protein C", "GENE_OR_GENE_PRODUCT", 65, 86], ["transgenic swine", "ORGANISM", 90, 106], ["milk", "ORGANISM_SUBSTANCE", 145, 149], ["mammary cell", "CELL", 188, 200], ["human recombinant protein C", "PROTEIN", 59, 86], ["human", "SPECIES", 59, 64], ["swine", "SPECIES", 101, 106], ["human", "SPECIES", 59, 64], ["swine", "SPECIES", 101, 106], ["the synthesis rate", "TEST", 37, 55], ["human recombinant protein C in transgenic swine expressing the protein", "TREATMENT", 59, 129]]], ["In contrast, the rate of normal synthesis in hepatocytes was calculated to be 0.02 mg protein C per gram cells per day.Biosynthesis of Milk ProteinsIt has been suggested that mammalian species phylogenetically close to humans may be expected to have more elements of the glycosylation machinery in common (Jenkins et al., 1996) .", [["hepatocytes", "ANATOMY", 45, 56], ["cells", "ANATOMY", 105, 110], ["hepatocytes", "CELL", 45, 56], ["cells", "CELL", 105, 110], ["humans", "ORGANISM", 219, 225], ["hepatocytes", "CELL_TYPE", 45, 56], ["Milk Proteins", "PROTEIN", 135, 148], ["humans", "SPECIES", 219, 225], ["humans", "SPECIES", 219, 225], ["Biosynthesis of Milk Proteins", "TREATMENT", 119, 148], ["mammalian species", "PROBLEM", 175, 192], ["the glycosylation machinery", "TREATMENT", 267, 294], ["normal", "OBSERVATION", 25, 31], ["hepatocytes", "ANATOMY", 45, 56]]], ["Initial reports indicate that human glycoproteins expressed in the mammary gland of transgenic animals contain glycosylation patterns that differ from those found on human plasma-derived proteins.", [["mammary gland", "ANATOMY", 67, 80], ["plasma", "ANATOMY", 172, 178], ["human", "ORGANISM", 30, 35], ["mammary gland", "ORGAN", 67, 80], ["human", "ORGANISM", 166, 171], ["plasma", "ORGANISM_SUBSTANCE", 172, 178], ["human glycoproteins", "PROTEIN", 30, 49], ["human plasma-derived proteins", "PROTEIN", 166, 195], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 166, 171], ["human glycoproteins", "PROBLEM", 30, 49], ["glycosylation patterns", "PROBLEM", 111, 133], ["human plasma", "TEST", 166, 178], ["mammary gland", "ANATOMY", 67, 80]]], ["In general, the glycosylation found on human proteins secreted into transgenic animal milk has been generally similar to plasma protein glycosylation.", [["milk", "ANATOMY", 86, 90], ["plasma", "ANATOMY", 121, 127], ["human", "ORGANISM", 39, 44], ["milk", "ORGANISM_SUBSTANCE", 86, 90], ["plasma", "ORGANISM_SUBSTANCE", 121, 127], ["human proteins", "PROTEIN", 39, 53], ["human", "SPECIES", 39, 44], ["milk", "SPECIES", 86, 90], ["human", "SPECIES", 39, 44], ["the glycosylation", "TREATMENT", 12, 29], ["human proteins", "TREATMENT", 39, 53], ["plasma protein glycosylation", "TREATMENT", 121, 149]]], ["Sites are mainly biantennary complex oligosaccharides with some variations consistent with the tissue and species of origin.", [["tissue", "ANATOMY", 95, 101], ["tissue", "TISSUE", 95, 101], ["mainly biantennary complex oligosaccharides", "PROBLEM", 10, 53], ["some variations", "PROBLEM", 59, 74], ["mainly", "OBSERVATION_MODIFIER", 10, 16], ["biantennary", "OBSERVATION_MODIFIER", 17, 28], ["complex", "OBSERVATION_MODIFIER", 29, 36], ["oligosaccharides", "OBSERVATION", 37, 53], ["consistent with", "UNCERTAINTY", 75, 90], ["tissue", "OBSERVATION", 95, 101], ["origin", "ANATOMY_MODIFIER", 117, 123]]], ["Cole et al. (1994) have shown that human an-tithrombin III (AT III) and a long-acting form of htPA expressed in goat milk had some GalNAc replacing galactose on complex Nlinked oligosaccharides.", [["milk", "ANATOMY", 117, 121], ["htPA", "CHEMICAL", 94, 98], ["galactose", "CHEMICAL", 148, 157], ["GalNAc", "CHEMICAL", 131, 137], ["galactose", "CHEMICAL", 148, 157], ["human", "ORGANISM", 35, 40], ["an-tithrombin III", "GENE_OR_GENE_PRODUCT", 41, 58], ["AT III", "GENE_OR_GENE_PRODUCT", 60, 66], ["htPA", "GENE_OR_GENE_PRODUCT", 94, 98], ["goat", "ORGANISM", 112, 116], ["milk", "ORGANISM_SUBSTANCE", 117, 121], ["GalNAc", "GENE_OR_GENE_PRODUCT", 131, 137], ["galactose", "SIMPLE_CHEMICAL", 148, 157], ["Nlinked oligosaccharides", "SIMPLE_CHEMICAL", 169, 193], ["human an-tithrombin III", "PROTEIN", 35, 58], ["AT III", "PROTEIN", 60, 66], ["htPA", "PROTEIN", 94, 98], ["human", "SPECIES", 35, 40], ["goat", "SPECIES", 112, 116], ["milk", "SPECIES", 117, 121], ["human", "SPECIES", 35, 40], ["goat", "SPECIES", 112, 116], ["htPA", "TREATMENT", 94, 98], ["galactose on complex Nlinked oligosaccharides", "TREATMENT", 148, 193]]], ["Both LAtPA and AT III were shown to be more fucosylated than their recombinant or plasma counterparts.", [["plasma", "ANATOMY", 82, 88], ["LAtPA", "GENE_OR_GENE_PRODUCT", 5, 10], ["AT III", "GENE_OR_GENE_PRODUCT", 15, 21], ["plasma", "ORGANISM_SUBSTANCE", 82, 88], ["LAtPA", "PROTEIN", 5, 10], ["AT III", "PROTEIN", 15, 21]]], ["Goat plasma AT III contains N-glycolylneuraminic acid and Nacetylneuraminic acid, as do transgenically expressed AT III and LAtPA.", [["plasma", "ANATOMY", 5, 11], ["N-glycolylneuraminic acid", "CHEMICAL", 28, 53], ["Nacetylneuraminic acid", "CHEMICAL", 58, 80], ["N-glycolylneuraminic acid", "CHEMICAL", 28, 53], ["Nacetylneuraminic acid", "CHEMICAL", 58, 80], ["plasma", "ORGANISM_SUBSTANCE", 5, 11], ["AT III", "GENE_OR_GENE_PRODUCT", 12, 18], ["N-glycolylneuraminic acid", "SIMPLE_CHEMICAL", 28, 53], ["Nacetylneuraminic acid", "SIMPLE_CHEMICAL", 58, 80], ["AT III", "GENE_OR_GENE_PRODUCT", 113, 119], ["LAtPA", "GENE_OR_GENE_PRODUCT", 124, 129], ["AT III", "PROTEIN", 113, 119], ["LAtPA", "PROTEIN", 124, 129], ["N-glycolylneuraminic acid", "TREATMENT", 28, 53], ["Nacetylneuraminic acid", "TREATMENT", 58, 80]]], ["An additional difference observed between plasma and transgenic goat AT III is in the degree of sialylation , with the transgenic protein less sialylated than plasma AT III.", [["plasma", "ANATOMY", 42, 48], ["plasma", "ANATOMY", 159, 165], ["plasma", "ORGANISM_SUBSTANCE", 42, 48], ["goat AT III", "GENE_OR_GENE_PRODUCT", 64, 75], ["plasma", "ORGANISM_SUBSTANCE", 159, 165], ["AT III", "GENE_OR_GENE_PRODUCT", 166, 172], ["transgenic goat AT III", "PROTEIN", 53, 75], ["transgenic protein", "PROTEIN", 119, 137], ["plasma AT III", "PROTEIN", 159, 172], ["goat", "SPECIES", 64, 68], ["goat", "SPECIES", 64, 68], ["plasma", "TEST", 42, 48], ["the transgenic protein", "TEST", 115, 137], ["transgenic goat", "OBSERVATION", 53, 68], ["sialylation", "OBSERVATION", 96, 107]]], ["Denman et al., (1991) have also noted that significantly lower levels of galactose, N-acetylglucosamine, and sialic acid are present in goat transgenic LAtPA compared to the murine C 127 cell line and Chinese hamster ovary (CHO) cell-derived LAtPA.Biosynthesis of Milk ProteinsThe glycosylation of interferon-~ at asparagine 25 and 97 is influenced dramatically by CHO cell culture conditions (Curling et al., 1990) ; considerable variations in site occupancy are seen.", [["C 127 cell line", "ANATOMY", 181, 196], ["hamster ovary (CHO) cell", "ANATOMY", 209, 233], ["LAtPA", "ANATOMY", 242, 247], ["CHO cell", "ANATOMY", 365, 373], ["galactose", "CHEMICAL", 73, 82], ["N-acetylglucosamine", "CHEMICAL", 84, 103], ["sialic acid", "CHEMICAL", 109, 120], ["asparagine", "CHEMICAL", 314, 324], ["galactose", "CHEMICAL", 73, 82], ["N-acetylglucosamine", "CHEMICAL", 84, 103], ["sialic acid", "CHEMICAL", 109, 120], ["asparagine", "CHEMICAL", 314, 324], ["galactose", "SIMPLE_CHEMICAL", 73, 82], ["N-acetylglucosamine", "SIMPLE_CHEMICAL", 84, 103], ["sialic acid", "SIMPLE_CHEMICAL", 109, 120], ["goat transgenic LAtPA", "ORGANISM", 136, 157], ["murine", "ORGANISM", 174, 180], ["C 127 cell line", "CELL", 181, 196], ["Chinese hamster ovary (CHO) cell", "CELL", 201, 233], ["LAtPA", "CELL", 242, 247], ["interferon", "GENE_OR_GENE_PRODUCT", 298, 308], ["asparagine", "AMINO_ACID", 314, 324], ["25", "AMINO_ACID", 325, 327], ["CHO cell", "CELL", 365, 373], ["goat transgenic LAtPA", "CELL_LINE", 136, 157], ["murine C 127 cell line", "CELL_LINE", 174, 196], ["Chinese hamster ovary (CHO) cell-derived LAtPA", "CELL_LINE", 201, 247], ["Milk Proteins", "PROTEIN", 264, 277], ["interferon", "PROTEIN", 298, 308], ["goat", "SPECIES", 136, 140], ["murine", "SPECIES", 174, 180], ["goat", "SPECIES", 136, 140], ["Chinese hamster", "SPECIES", 201, 216], ["galactose", "TREATMENT", 73, 82], ["acetylglucosamine", "TREATMENT", 86, 103], ["sialic acid", "TREATMENT", 109, 120], ["the murine C 127 cell line", "TREATMENT", 170, 196], ["Chinese hamster ovary", "TREATMENT", 201, 222], ["LAtPA", "TREATMENT", 242, 247], ["Biosynthesis of Milk Proteins", "TREATMENT", 248, 277], ["The glycosylation of interferon-~ at asparagine", "TREATMENT", 277, 324], ["considerable variations in site occupancy", "PROBLEM", 418, 459], ["cell line", "OBSERVATION", 187, 196], ["ovary", "ANATOMY", 217, 222], ["site occupancy", "OBSERVATION", 445, 459]]], ["Transgenic mouse-derived interferon-~ has predominantly complex sialated biantennary N-glycans at asparagine 25, and oligosaccharides are ~ 1-6 core fucosylated similar to the Asn2s of CHO cellderived interferon-~ (James et al., 1995) .", [["asparagine 25", "CHEMICAL", 98, 111], ["asparagine", "CHEMICAL", 98, 108], ["mouse", "ORGANISM", 11, 16], ["interferon", "GENE_OR_GENE_PRODUCT", 25, 35], ["asparagine 25", "SIMPLE_CHEMICAL", 98, 111], ["Asn2s", "GENE_OR_GENE_PRODUCT", 176, 181], ["interferon", "PROTEIN", 25, 35], ["Asn2s", "PROTEIN", 176, 181], ["interferon", "PROTEIN", 201, 211], ["mouse", "SPECIES", 11, 16], ["mouse", "SPECIES", 11, 16], ["interferon", "TREATMENT", 25, 35], ["glycans at asparagine", "TREATMENT", 87, 108], ["oligosaccharides", "TEST", 117, 133], ["CHO cellderived interferon", "TREATMENT", 185, 211]]], ["There is an increased incidence of oligomannose at Asn97 compared to the CHO-derived counterpart, suggesting that murine mammary epithelial cells may be deficient in the ~ 1-2 mannosidase I and GlcNAc transferase I activities in the endoplasmic reticulum.Biosynthesis of Milk ProteinsAlthough an ultimate goal may be to produce proteins with authentic human glycosylation patterns, a more realistic and possibly more desirable objective is the production of proteins with defined, engineered glycosylation characteristics and therefore predictable pharmacokinetics.", [["CHO", "ANATOMY", 73, 76], ["mammary epithelial cells", "ANATOMY", 121, 145], ["endoplasmic reticulum", "ANATOMY", 233, 254], ["GlcNAc", "CHEMICAL", 194, 200], ["oligomannose", "GENE_OR_GENE_PRODUCT", 35, 47], ["Asn97", "GENE_OR_GENE_PRODUCT", 51, 56], ["CHO", "CELL", 73, 76], ["murine", "ORGANISM", 114, 120], ["mammary epithelial cells", "CELL", 121, 145], ["mannosidase I", "GENE_OR_GENE_PRODUCT", 176, 189], ["GlcNAc transferase I", "GENE_OR_GENE_PRODUCT", 194, 214], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 233, 254], ["human", "ORGANISM", 352, 357], ["Asn97", "PROTEIN", 51, 56], ["CHO-derived counterpart", "CELL_LINE", 73, 96], ["murine mammary epithelial cells", "CELL_TYPE", 114, 145], ["mannosidase I", "PROTEIN", 176, 189], ["GlcNAc transferase I", "PROTEIN", 194, 214], ["Milk Proteins", "PROTEIN", 271, 284], ["murine", "SPECIES", 114, 120], ["human", "SPECIES", 352, 357], ["human", "SPECIES", 352, 357], ["an increased incidence of oligomannose", "PROBLEM", 9, 47], ["murine mammary epithelial cells", "PROBLEM", 114, 145], ["GlcNAc transferase I activities in the endoplasmic reticulum", "PROBLEM", 194, 254], ["Biosynthesis of Milk Proteins", "TREATMENT", 255, 284], ["predictable pharmacokinetics", "PROBLEM", 536, 564], ["increased", "OBSERVATION_MODIFIER", 12, 21], ["incidence", "OBSERVATION_MODIFIER", 22, 31], ["mammary", "ANATOMY", 121, 128], ["epithelial cells", "OBSERVATION", 129, 145], ["GlcNAc transferase", "OBSERVATION", 194, 212], ["endoplasmic reticulum", "ANATOMY", 233, 254]]], ["Glycoproteins can be remodeled in situ by the transgenic coexpression of human glycosyltransferase.", [["human", "ORGANISM", 73, 78], ["glycosyltransferase", "GENE_OR_GENE_PRODUCT", 79, 98], ["human glycosyltransferase", "PROTEIN", 73, 98], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["Glycoproteins", "TREATMENT", 0, 13], ["human glycosyltransferase", "TREATMENT", 73, 98]]], ["Prieto et al. (1995) have demonstrated that the heterologous, transgenic expression of human ~l,2-fucosyltransferase results in expression of both transgene and secondary gene products.", [["human", "ORGANISM", 87, 92], ["~l,2-fucosyltransferase", "GENE_OR_GENE_PRODUCT", 93, 116], ["human ~l,2", "PROTEIN", 87, 97], ["fucosyltransferase", "PROTEIN", 98, 116], ["secondary gene products", "PROTEIN", 161, 184], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["secondary gene products", "TREATMENT", 161, 184], ["secondary gene products", "OBSERVATION", 161, 184]]], ["Their work also suggests that the mammary gland may be a unique bioreactor for the production of biologically active oligosaccharides and glycoconjugates.Biosynthesis of Milk ProteinsIn studies of the expression of rh protein C in transgenic pigs, Subramanian et al. (1996) have shown that there are rate limitations of ~-carboxylation in mice and pigs, partly dependent on the transgene.", [["mammary gland", "ANATOMY", 34, 47], ["mammary gland", "ORGAN", 34, 47], ["glycoconjugates", "SIMPLE_CHEMICAL", 138, 153], ["rh protein C", "GENE_OR_GENE_PRODUCT", 215, 227], ["transgenic pigs", "ORGANISM", 231, 246], ["mice", "ORGANISM", 339, 343], ["pigs", "ORGANISM", 348, 352], ["Milk Proteins", "PROTEIN", 170, 183], ["rh protein C", "PROTEIN", 215, 227], ["pigs", "SPECIES", 242, 246], ["mice", "SPECIES", 339, 343], ["pigs", "SPECIES", 348, 352], ["pigs", "SPECIES", 242, 246], ["mice", "SPECIES", 339, 343], ["a unique bioreactor", "TREATMENT", 55, 74], ["Biosynthesis of Milk Proteins", "TREATMENT", 154, 183], ["rh protein C", "PROBLEM", 215, 227], ["~-carboxylation in mice", "TREATMENT", 320, 343], ["mammary gland", "ANATOMY", 34, 47]]], ["Their study indicates that a rate limitation of ~-carboxylation in mammary epithelial cells occurs at expression levels of >20 ~g/ml in mice and at >500 ~g/ml milk in pigs.Milk Secretion from the Mammary GlandMammary glands are skin glands that have no counterpart in nonmammals and are located in the inguinal region of cows, sheep, and goats.", [["mammary epithelial cells", "ANATOMY", 67, 91], ["Mammary GlandMammary glands", "ANATOMY", 196, 223], ["skin glands", "ANATOMY", 228, 239], ["nonmammals", "ANATOMY", 268, 278], ["inguinal region", "ANATOMY", 302, 317], ["cows", "ANATOMY", 321, 325], ["mammary epithelial cells", "CELL", 67, 91], ["mice", "ORGANISM", 136, 140], ["milk", "ORGANISM_SUBSTANCE", 159, 163], ["pigs", "ORGANISM", 167, 171], ["Milk", "ORGANISM_SUBSTANCE", 172, 176], ["Mammary GlandMammary glands", "ORGAN", 196, 223], ["skin glands", "ORGAN", 228, 239], ["nonmammals", "CANCER", 268, 278], ["inguinal region", "MULTI-TISSUE_STRUCTURE", 302, 317], ["cows", "ORGANISM_SUBDIVISION", 321, 325], ["sheep", "ORGANISM_SUBDIVISION", 327, 332], ["goats", "ORGANISM", 338, 343], ["mammary epithelial cells", "CELL_TYPE", 67, 91], ["mice", "SPECIES", 136, 140], ["pigs", "SPECIES", 167, 171], ["cows", "SPECIES", 321, 325], ["sheep", "SPECIES", 327, 332], ["goats", "SPECIES", 338, 343], ["mice", "SPECIES", 136, 140], ["pigs", "SPECIES", 167, 171], ["sheep", "SPECIES", 327, 332], ["goats", "SPECIES", 338, 343], ["Their study", "TEST", 0, 11], ["a rate limitation", "PROBLEM", 27, 44], ["~-carboxylation in mammary epithelial cells", "PROBLEM", 48, 91], ["expression levels", "TEST", 102, 119], ["mammary", "ANATOMY", 67, 74], ["epithelial cells", "OBSERVATION", 75, 91], ["Mammary", "ANATOMY", 196, 203], ["GlandMammary", "ANATOMY_MODIFIER", 204, 216], ["glands", "ANATOMY", 217, 223], ["skin glands", "ANATOMY", 228, 239], ["nonmammals", "OBSERVATION", 268, 278], ["inguinal", "ANATOMY", 302, 310], ["region", "ANATOMY_MODIFIER", 311, 317], ["cows", "OBSERVATION", 321, 325], ["goats", "ANATOMY", 338, 343]]], ["In the sow they are located along the thoracic, abdominal, and inguinal walls.", [["thoracic", "ANATOMY", 38, 46], ["abdominal", "ANATOMY", 48, 57], ["inguinal walls", "ANATOMY", 63, 77], ["thoracic", "ORGAN", 38, 46], ["abdominal", "ORGAN", 48, 57], ["inguinal walls", "MULTI-TISSUE_STRUCTURE", 63, 77], ["thoracic", "ANATOMY", 38, 46], ["abdominal", "ANATOMY", 48, 57], ["inguinal", "ANATOMY", 63, 71], ["walls", "ANATOMY_MODIFIER", 72, 77]]], ["Streak canals link the internal milk secretory system with the external environment.", [["milk secretory system", "ANATOMY", 32, 53], ["Streak canals", "MULTI-TISSUE_STRUCTURE", 0, 13], ["milk", "ORGANISM_SUBSTANCE", 32, 36], ["internal", "ANATOMY_MODIFIER", 23, 31], ["external environment", "OBSERVATION", 63, 83]]], ["The number of teats, teat orientation, and length of the let-down reflex affect the ease and periodicity of milking.", [["teats", "ANATOMY", 14, 19], ["teat", "ANATOMY", 21, 25], ["teats", "ORGANISM_SUBDIVISION", 14, 19], ["teat", "ORGANISM_SUBDIVISION", 21, 25]]], ["Milk is released as a result of a neuroendocrine reflex of the nervous system to tactile, auditory, and visual stimuli.", [["neuroendocrine", "ANATOMY", 34, 48], ["nervous system", "ANATOMY", 63, 77], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["nervous system", "ANATOMICAL_SYSTEM", 63, 77], ["visual stimuli", "TEST", 104, 118], ["nervous", "ANATOMY", 63, 70]]], ["Negative psychological and environmental disturbances have a detrimental effect on milk production.", [["milk", "ANATOMY", 83, 87], ["milk", "ORGANISM_SUBSTANCE", 83, 87], ["psychological and environmental disturbances", "PROBLEM", 9, 53]]], ["Milk let-down is a response to the release of oxytocin, synthesized in the hypothalamus, by the posterior pituitary gland.", [["hypothalamus", "ANATOMY", 75, 87], ["posterior pituitary gland", "ANATOMY", 96, 121], ["oxytocin", "CHEMICAL", 46, 54], ["oxytocin", "CHEMICAL", 46, 54], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["oxytocin", "GENE_OR_GENE_PRODUCT", 46, 54], ["hypothalamus", "ORGAN", 75, 87], ["posterior pituitary gland", "ORGAN", 96, 121], ["oxytocin", "TREATMENT", 46, 54], ["hypothalamus", "ANATOMY", 75, 87], ["posterior", "ANATOMY_MODIFIER", 96, 105], ["pituitary gland", "ANATOMY", 106, 121]]], ["Oxytocin is transported to the mammary gland in the arterial blood and binds to myoepithelial cells that contract, causing a release or let-down of the milk.", [["mammary gland", "ANATOMY", 31, 44], ["arterial blood", "ANATOMY", 52, 66], ["myoepithelial cells", "ANATOMY", 80, 99], ["milk", "ANATOMY", 152, 156], ["Oxytocin", "CHEMICAL", 0, 8], ["Oxytocin", "CHEMICAL", 0, 8], ["Oxytocin", "GENE_OR_GENE_PRODUCT", 0, 8], ["mammary gland", "ORGAN", 31, 44], ["arterial blood", "ORGANISM_SUBSTANCE", 52, 66], ["myoepithelial cells", "CELL", 80, 99], ["milk", "ORGANISM_SUBSTANCE", 152, 156], ["myoepithelial cells", "CELL_TYPE", 80, 99], ["Oxytocin", "TREATMENT", 0, 8], ["mammary gland", "ANATOMY", 31, 44], ["arterial", "ANATOMY", 52, 60], ["myoepithelial cells", "OBSERVATION", 80, 99]]], ["Sheep and goats have let-down periods of 1-2 and 2-4 min, respectively.", [["Sheep", "ORGANISM", 0, 5], ["goats", "ORGANISM", 10, 15], ["Sheep", "SPECIES", 0, 5], ["goats", "SPECIES", 10, 15], ["Sheep", "SPECIES", 0, 5], ["goats", "SPECIES", 10, 15]]], ["The let-down reflex in the cow lasts for 5-8 min.", [["cow", "ORGANISM", 27, 30], ["cow", "SPECIES", 27, 30], ["cow", "SPECIES", 27, 30], ["The let-down reflex", "TEST", 0, 19]]], ["In the sow, however, the reflex is extremely short, of the order of 10-20 sec, with a frequency of 1 hr or less.Milk Secretion from the Mammary GlandFrom the point of view of primary milk production, goats and cows are preferred animals because of the relatively long let-down reflexes, vertical teat orientation, milk volume, and duration of lactation.", [["Mammary GlandFrom", "ANATOMY", 136, 153], ["milk", "ANATOMY", 183, 187], ["teat", "ANATOMY", 296, 300], ["milk", "ANATOMY", 314, 318], ["Milk", "ORGANISM_SUBSTANCE", 112, 116], ["milk", "ORGANISM_SUBSTANCE", 183, 187], ["cows", "ORGANISM_SUBDIVISION", 210, 214], ["teat", "ORGANISM_SUBDIVISION", 296, 300], ["milk", "ORGANISM_SUBDIVISION", 314, 318], ["goats", "SPECIES", 200, 205], ["cows", "SPECIES", 210, 214], ["goats", "SPECIES", 200, 205], ["the reflex", "TEST", 21, 31], ["Milk Secretion", "PROBLEM", 112, 126], ["reflex", "OBSERVATION", 25, 31], ["Mammary", "ANATOMY", 136, 143]]], ["However, other factors, such as protein concentration, may favor a choice of sheep.", [["sheep", "ORGANISM", 77, 82], ["sheep", "SPECIES", 77, 82], ["sheep", "SPECIES", 77, 82]]], ["Goats, sheep, and cows respond to familiar signals, such as the sound of a milking machine, whereas lactating, nonsuckling sows require injections of oxytocin to elicit the let-down response.Lactation and Milk OutputAt parturition, a series of programmed hormonal changes take place that transform the mammary cells to the fully secretory state.", [["mammary cells", "ANATOMY", 302, 315], ["oxytocin", "CHEMICAL", 150, 158], ["oxytocin", "CHEMICAL", 150, 158], ["Goats", "ORGANISM", 0, 5], ["sheep", "ORGANISM", 7, 12], ["cows", "ORGANISM", 18, 22], ["sows", "ORGANISM", 123, 127], ["oxytocin", "SIMPLE_CHEMICAL", 150, 158], ["mammary cells", "CELL", 302, 315], ["mammary cells", "CELL_TYPE", 302, 315], ["Goats", "SPECIES", 0, 5], ["sheep", "SPECIES", 7, 12], ["cows", "SPECIES", 18, 22], ["sheep", "SPECIES", 7, 12], ["a milking machine", "TREATMENT", 73, 90], ["oxytocin", "TREATMENT", 150, 158], ["programmed hormonal changes", "TREATMENT", 244, 271], ["mammary", "ANATOMY", 302, 309]]], ["Stage 2 lactogenesis, or the copious production of milk, is brought about by a synchronous drop in progesterone, an increase in estrogen, and the release of prolactin from the anterior pituitary and follows the immediate postpartum production of colostrum.Lactation and Milk OutputIn the cow, milk production increases in the first 3-6 weeks of lactation and then slowly declines.", [["milk", "ANATOMY", 51, 55], ["anterior pituitary", "ANATOMY", 176, 194], ["colostrum", "ANATOMY", 246, 255], ["milk", "ANATOMY", 293, 297], ["lactogenesis", "DISEASE", 8, 20], ["progesterone", "CHEMICAL", 99, 111], ["estrogen", "CHEMICAL", 128, 136], ["progesterone", "CHEMICAL", 99, 111], ["estrogen", "CHEMICAL", 128, 136], ["milk", "ORGANISM_SUBSTANCE", 51, 55], ["progesterone", "SIMPLE_CHEMICAL", 99, 111], ["estrogen", "SIMPLE_CHEMICAL", 128, 136], ["prolactin", "GENE_OR_GENE_PRODUCT", 157, 166], ["anterior pituitary", "ORGAN", 176, 194], ["colostrum", "ORGANISM_SUBSTANCE", 246, 255], ["cow", "ORGANISM", 288, 291], ["milk", "ORGANISM_SUBSTANCE", 293, 297], ["cow", "SPECIES", 288, 291], ["cow", "SPECIES", 288, 291], ["Stage 2 lactogenesis", "PROBLEM", 0, 20], ["the copious production of milk", "PROBLEM", 25, 55], ["progesterone", "TREATMENT", 99, 111], ["an increase in estrogen", "TREATMENT", 113, 136], ["prolactin", "TREATMENT", 157, 166], ["Lactation", "TREATMENT", 256, 265], ["lactogenesis", "OBSERVATION", 8, 20], ["increase", "OBSERVATION_MODIFIER", 116, 124], ["anterior", "ANATOMY_MODIFIER", 176, 184], ["pituitary", "ANATOMY", 185, 194]]], ["A similar pattern is seen in goats, sheep, and pigs.", [["goats", "ORGANISM_SUBDIVISION", 29, 34], ["sheep", "ORGANISM", 36, 41], ["pigs", "ORGANISM", 47, 51], ["goats", "SPECIES", 29, 34], ["sheep", "SPECIES", 36, 41], ["pigs", "SPECIES", 47, 51], ["goats", "SPECIES", 29, 34], ["sheep", "SPECIES", 36, 41], ["pigs", "SPECIES", 47, 51], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["pattern", "OBSERVATION_MODIFIER", 10, 17]]], ["Milk secretion continues as long as milk is regularly withdrawn, although production declines during lactation.", [["Milk", "ANATOMY", 0, 4], ["milk", "ANATOMY", 36, 40], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["milk", "ORGANISM_SUBSTANCE", 36, 40], ["Milk secretion", "PROBLEM", 0, 14]]], ["Dairy animals are capable of undergoing estrus and pregnancy while maintaining their lactation.", [["estrus and pregnancy", "PROBLEM", 40, 60]]], ["This enables dairy management to breed the animal such that it will give birth and begin lactation on a yearly basis.", [["dairy management", "TREATMENT", 13, 29]]], ["In order to maximize production, the animals are allowed to lactate until 2 months before they are due to give birth.", [["lactate", "CHEMICAL", 60, 67], ["lactate", "CHEMICAL", 60, 67], ["animals", "ORGANISM", 37, 44], ["lactate", "TEST", 60, 67]]], ["The 2-month rest before the restart of lactation allows the animal to rebuild her energy reserves for the coming birth and lactation.", [["lactation", "TREATMENT", 39, 48]]], ["In all species, yield and energy content are related to body size.Lactation and Milk OutputThe expression level of exogenous protein tends to follow the normal milk output as can be seen from the plots in Fig. 1 which shows (a) the production of a recombinant monoclonal antibody over a 220-day lactation of a transgenic goat and (b) the levels of antithrombin III in the milk of a transgenic goat during a 300-day lactation.Lactation and Milk OutputIt has been noted that \"considering the yearly milk output of dairy cattle (6000-8000 liters)and the milk content of as 1-casein (10 g/liter), one cow carrying a transgene under the control of as 1casein promoter would theoretically produce 60-80 kg/year of the transgene-derived protein\" (J~inne et al., 1992) .", [["body", "ANATOMY", 56, 60], ["milk", "ANATOMY", 160, 164], ["milk", "ANATOMY", 372, 376], ["milk", "ANATOMY", 497, 501], ["milk", "ANATOMY", 551, 555], ["1-casein", "CHEMICAL", 570, 578], ["body", "ORGANISM_SUBDIVISION", 56, 60], ["milk", "ORGANISM_SUBSTANCE", 160, 164], ["goat", "ORGANISM", 321, 325], ["antithrombin III", "GENE_OR_GENE_PRODUCT", 348, 364], ["milk", "ORGANISM_SUBSTANCE", 372, 376], ["goat", "ORGANISM", 393, 397], ["milk", "ORGANISM_SUBDIVISION", 497, 501], ["milk", "ORGANISM_SUBSTANCE", 551, 555], ["1-casein", "GENE_OR_GENE_PRODUCT", 570, 578], ["cow", "ORGANISM", 597, 600], ["1casein", "GENE_OR_GENE_PRODUCT", 646, 653], ["exogenous protein", "PROTEIN", 115, 132], ["recombinant monoclonal antibody", "PROTEIN", 248, 279], ["transgenic goat", "PROTEIN", 310, 325], ["antithrombin III", "PROTEIN", 348, 364], ["1casein promoter", "DNA", 646, 662], ["goat", "SPECIES", 321, 325], ["goat", "SPECIES", 393, 397], ["cattle", "SPECIES", 518, 524], ["cow", "SPECIES", 597, 600], ["goat", "SPECIES", 321, 325], ["goat", "SPECIES", 393, 397], ["cattle", "SPECIES", 518, 524], ["cow", "SPECIES", 597, 600], ["Lactation", "TREATMENT", 66, 75], ["Milk Output", "TEST", 80, 91], ["exogenous protein", "PROBLEM", 115, 132], ["a recombinant monoclonal antibody", "PROBLEM", 246, 279], ["a transgenic goat", "TREATMENT", 308, 325], ["antithrombin III", "TREATMENT", 348, 364], ["a transgenic goat", "TREATMENT", 380, 397], ["Lactation", "TREATMENT", 425, 434], ["Milk Output", "TEST", 439, 450], ["energy content", "OBSERVATION", 26, 40], ["size", "OBSERVATION_MODIFIER", 61, 65], ["exogenous protein", "OBSERVATION", 115, 132]]], ["At an expression level of 5 g/liter a transgenic goat is capable of producing about 4 kg of target protein per year; at 20 g/liter the output is 16 kg.", [["goat", "ORGANISM", 49, 53], ["transgenic goat", "PROTEIN", 38, 53], ["goat", "SPECIES", 49, 53], ["goat", "SPECIES", 49, 53], ["the output", "TEST", 131, 141], ["16 kg", "OBSERVATION_MODIFIER", 145, 150]]], ["It is, therefore, quite conceivable to produce 100-kg quantities of target protein in small goat herds or sheep flocks.Milk Composition and Purification of the Target ProteinMilk is a multiphasic fluid composed of a fat emulsion, a micellular casein dispersion, a colloidal suspension of lipoproteins, and a solution of proteins, mineral salts, vitamins, organic acids, and minor components.", [["fat", "ANATOMY", 216, 219], ["mineral salts", "CHEMICAL", 330, 343], ["vitamins, organic acids", "CHEMICAL", 345, 368], ["vitamins", "CHEMICAL", 345, 353], ["goat", "ORGANISM", 92, 96], ["sheep", "ORGANISM", 106, 111], ["Milk", "ORGANISM_SUBSTANCE", 119, 123], ["fat", "TISSUE", 216, 219], ["mineral salts", "SIMPLE_CHEMICAL", 330, 343], ["vitamins", "SIMPLE_CHEMICAL", 345, 353], ["organic acids", "SIMPLE_CHEMICAL", 355, 368], ["target protein", "PROTEIN", 68, 82], ["lipoproteins", "PROTEIN", 288, 300], ["goat", "SPECIES", 92, 96], ["sheep", "SPECIES", 106, 111], ["goat", "SPECIES", 92, 96], ["sheep", "SPECIES", 106, 111], ["target protein", "PROBLEM", 68, 82], ["Milk Composition", "TREATMENT", 119, 135], ["a multiphasic fluid", "PROBLEM", 182, 201], ["a fat emulsion", "TREATMENT", 214, 228], ["a micellular casein dispersion", "TREATMENT", 230, 260], ["a colloidal suspension of lipoproteins", "TREATMENT", 262, 300], ["a solution of proteins, mineral salts", "TREATMENT", 306, 343], ["vitamins", "TREATMENT", 345, 353], ["organic acids", "TREATMENT", 355, 368], ["minor components", "TREATMENT", 374, 390], ["small", "OBSERVATION_MODIFIER", 86, 91], ["goat herds", "OBSERVATION", 92, 102], ["sheep flocks", "OBSERVATION", 106, 118], ["minor components", "OBSERVATION_MODIFIER", 374, 390]]], ["When collected, milk is not sterile and containsI-<bacteria derived from the teat as well as somatic cells derived mostly from the lymphatic ducts of the udder.", [["milk", "ANATOMY", 16, 20], ["teat", "ANATOMY", 77, 81], ["somatic cells", "ANATOMY", 93, 106], ["lymphatic ducts", "ANATOMY", 131, 146], ["udder", "ANATOMY", 154, 159], ["milk", "ORGANISM_SUBSTANCE", 16, 20], ["teat", "ORGANISM_SUBDIVISION", 77, 81], ["somatic cells", "CELL", 93, 106], ["lymphatic ducts", "MULTI-TISSUE_STRUCTURE", 131, 146], ["udder", "ORGANISM_SUBDIVISION", 154, 159], ["somatic cells", "CELL_TYPE", 93, 106], ["sterile and containsI-<bacteria", "PROBLEM", 28, 59], ["somatic cells", "PROBLEM", 93, 106], ["lymphatic ducts", "ANATOMY", 131, 146]]], ["According to the Pasteurized Milk Ordinance (U.S. Department of Health and Human Services, 1993) , the bacterial plate count should be less than 100,000 per milliliter.", [["Human", "ORGANISM", 75, 80], ["Human", "SPECIES", 75, 80], ["the bacterial plate count", "TEST", 99, 124]]], ["Milk composition is species specific; major differences are seen between human and ruminant milk.", [["milk", "ANATOMY", 92, 96], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["human", "ORGANISM", 73, 78], ["milk", "ORGANISM_SUBSTANCE", 92, 96], ["human", "SPECIES", 73, 78], ["milk", "SPECIES", 92, 96], ["human", "SPECIES", 73, 78]]], ["Table 3 gives the average percentage compositions of livestock milk.", [["milk", "ANATOMY", 63, 67], ["milk", "ORGANISM_SUBSTANCE", 63, 67], ["livestock milk", "OBSERVATION", 53, 67]]], ["Milk is approximately 85-90% water; the pH is 6.5-6.7 and as high as pH 6.8 in ewe's milk.I-<It is important from a purification point of view that the fat is present in globular form in the size range of 0.1-10 ~m and with a density higher than the other constituents.", [["milk", "ANATOMY", 85, 89], ["fat", "ANATOMY", 152, 155], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["ewe", "ORGANISM_SUBDIVISION", 79, 82], ["milk", "ORGANISM_SUBSTANCE", 85, 89], ["fat", "TISSUE", 152, 155], ["the pH", "TEST", 36, 42], ["pH", "TEST", 69, 71], ["fat", "OBSERVATION", 152, 155], ["globular", "OBSERVATION_MODIFIER", 170, 178], ["size", "OBSERVATION_MODIFIER", 191, 195], ["density", "OBSERVATION", 226, 233], ["higher", "OBSERVATION_MODIFIER", 234, 240]]], ["The fat globule is enclosed in a membrane of polar lipids and proteins.", [["fat globule", "ANATOMY", 4, 15], ["membrane", "ANATOMY", 33, 41], ["polar lipids", "ANATOMY", 45, 57], ["fat globule", "TISSUE", 4, 15], ["membrane", "CELLULAR_COMPONENT", 33, 41], ["polar lipids", "CELLULAR_COMPONENT", 45, 57], ["fat globule", "OBSERVATION", 4, 15]]], ["Triglycerides make up 97% of the fat.I-<The three subgroups of casein, as-, 13-, and K-casein, display genetic polymorphism and consist of two to eight variants.", [["fat", "ANATOMY", 33, 36], ["Triglycerides", "CHEMICAL", 0, 13], ["Triglycerides", "SIMPLE_CHEMICAL", 0, 13], ["fat", "TISSUE", 33, 36], ["casein", "GENE_OR_GENE_PRODUCT", 63, 69], ["as-", "GENE_OR_GENE_PRODUCT", 71, 74], ["K-casein", "GENE_OR_GENE_PRODUCT", 85, 93], ["casein", "PROTEIN", 63, 69], ["K-casein", "PROTEIN", 85, 93], ["Triglycerides", "TEST", 0, 13], ["as-", "TEST", 71, 74], ["genetic polymorphism", "PROBLEM", 103, 123], ["fat", "ANATOMY", 33, 36], ["genetic polymorphism", "OBSERVATION", 103, 123]]], ["Casein is present as 10 to 300-nm micelles formed of submicelles held together by phosphate and hydrophobic bonding.", [["submicelles", "ANATOMY", 53, 64], ["phosphate", "CHEMICAL", 82, 91], ["phosphate", "CHEMICAL", 82, 91], ["Casein", "GENE_OR_GENE_PRODUCT", 0, 6], ["submicelles", "SIMPLE_CHEMICAL", 53, 64], ["phosphate", "SIMPLE_CHEMICAL", 82, 91]]], ["Each submicelle has a polar core and a heterogeneous distribution of ~s-and ~-casein with surface K-casein, ~s-and ~-caseins are almost insoluble, whereas the glycoprotein, ~-casein is highly soluble in water.", [["submicelle", "ANATOMY", 5, 15], ["surface", "ANATOMY", 90, 97], ["~-casein", "CHEMICAL", 173, 181], ["K-casein", "CHEMICAL", 98, 106], ["submicelle", "CANCER", 5, 15], ["~-casein", "SIMPLE_CHEMICAL", 76, 84], ["surface K-casein", "SIMPLE_CHEMICAL", 90, 106], ["~-caseins", "SIMPLE_CHEMICAL", 115, 124], ["~-casein", "SIMPLE_CHEMICAL", 173, 181], ["water", "SIMPLE_CHEMICAL", 203, 208], ["glycoprotein", "PROTEIN", 159, 171], ["~-casein", "PROTEIN", 173, 181], ["surface K-casein", "TREATMENT", 90, 106], ["the glycoprotein", "TREATMENT", 155, 171], ["polar core", "OBSERVATION_MODIFIER", 22, 32], ["heterogeneous", "OBSERVATION_MODIFIER", 39, 52], ["distribution", "OBSERVATION_MODIFIER", 53, 65], ["insoluble", "OBSERVATION", 136, 145]]], ["Casein may be precipitated somewhat below the isoelectric point range (pH 5.1-5.", [["Casein", "GENE_OR_GENE_PRODUCT", 0, 6], ["pH", "TEST", 71, 73]]], ["3) at about pH 4.6-4.7 by acidification or by the addition of chymosin, which attacks the 105 (phenylalanine)and 106 (methionine) peptide bond of the K-casein.", [["chymosin", "CHEMICAL", 62, 70], ["phenylalanine", "CHEMICAL", 95, 108], ["methionine", "CHEMICAL", 118, 128], ["K-casein", "CHEMICAL", 150, 158], ["chymosin", "CHEMICAL", 62, 70], ["phenylalanine", "CHEMICAL", 95, 108], ["methionine", "CHEMICAL", 118, 128], ["K-casein", "CHEMICAL", 150, 158], ["chymosin", "SIMPLE_CHEMICAL", 62, 70], ["phenylalanine", "AMINO_ACID", 95, 108], ["methionine", "AMINO_ACID", 118, 128], ["K-casein", "SIMPLE_CHEMICAL", 150, 158], ["pH", "TEST", 12, 14], ["chymosin", "TREATMENT", 62, 70], ["methionine) peptide bond of the K-casein", "TREATMENT", 118, 158]]], ["The hydrophilic amino acid terminal peptide (106-169)of K-casein solubilizes in the whey fraction and all other caseins precipitate.", [["amino acid", "CHEMICAL", 16, 26], ["K-casein", "CHEMICAL", 56, 64], ["amino acid", "CHEMICAL", 16, 26], ["K-casein", "CHEMICAL", 56, 64], ["amino acid", "AMINO_ACID", 16, 26], ["K-casein", "SIMPLE_CHEMICAL", 56, 64], ["whey", "ORGANISM_SUBSTANCE", 84, 88], ["caseins", "GENE_OR_GENE_PRODUCT", 112, 119], ["The hydrophilic amino acid terminal peptide", "TEST", 0, 43], ["K-casein solubilizes", "TREATMENT", 56, 76], ["the whey fraction", "TREATMENT", 80, 97], ["all other caseins", "TREATMENT", 102, 119]]], ["The soluble whey proteins consist primarily of ~-lactalbumin and f~-lactoglobulin with serum albumin and immunoglobulins being derived from the bloodstream. ~-Lactoglobulin is the major protein, accounting for 50% or more of the total whey protein in ruminants and pigs. ~-Lactalbumin accounts for approximately 25 % of the whey protein fraction and is essential for lactose synthesis and the control of milk secretion: ~-lactalbumin binds calcium and zinc.", [["serum", "ANATOMY", 87, 92], ["bloodstream", "ANATOMY", 144, 155], ["milk", "ANATOMY", 404, 408], ["Lactalbumin", "CHEMICAL", 273, 284], ["lactose", "CHEMICAL", 367, 374], ["~-lactalbumin", "CHEMICAL", 420, 433], ["calcium", "CHEMICAL", 440, 447], ["zinc", "CHEMICAL", 452, 456], ["Lactalbumin", "CHEMICAL", 273, 284], ["lactose", "CHEMICAL", 367, 374], ["calcium", "CHEMICAL", 440, 447], ["zinc", "CHEMICAL", 452, 456], ["~-lactalbumin", "SIMPLE_CHEMICAL", 47, 60], ["f~-lactoglobulin", "SIMPLE_CHEMICAL", 65, 81], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["albumin", "GENE_OR_GENE_PRODUCT", 93, 100], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 105, 120], ["Lactoglobulin", "GENE_OR_GENE_PRODUCT", 159, 172], ["pigs", "ORGANISM", 265, 269], ["~-Lactalbumin", "SIMPLE_CHEMICAL", 271, 284], ["lactose", "SIMPLE_CHEMICAL", 367, 374], ["milk", "ORGANISM_SUBSTANCE", 404, 408], ["~-lactalbumin", "SIMPLE_CHEMICAL", 420, 433], ["calcium", "SIMPLE_CHEMICAL", 440, 447], ["zinc", "SIMPLE_CHEMICAL", 452, 456], ["soluble whey proteins", "PROTEIN", 4, 25], ["~-lactalbumin", "PROTEIN", 47, 60], ["f~-lactoglobulin", "PROTEIN", 65, 81], ["serum albumin", "PROTEIN", 87, 100], ["immunoglobulins", "PROTEIN", 105, 120], ["Lactoglobulin", "PROTEIN", 159, 172], ["whey protein", "PROTEIN", 235, 247], ["pigs", "SPECIES", 265, 269], ["pigs", "SPECIES", 265, 269], ["The soluble whey proteins", "TEST", 0, 25], ["~-lactalbumin", "TEST", 47, 60], ["f~-lactoglobulin", "TREATMENT", 65, 81], ["serum albumin", "TEST", 87, 100], ["immunoglobulins", "TREATMENT", 105, 120], ["Lactoglobulin", "TREATMENT", 159, 172], ["Lactalbumin", "TREATMENT", 273, 284], ["the whey protein fraction", "TEST", 320, 345], ["lactose synthesis", "TREATMENT", 367, 384], ["~-lactalbumin binds calcium", "TREATMENT", 420, 447], ["zinc", "TREATMENT", 452, 456], ["bloodstream", "ANATOMY", 144, 155]]], ["Both ~-lactalbumin and ~-lactoglobulin have an amino acid composition close to the nutritional optimum and provide amino acids that are essential for the neonate.", [["~-lactalbumin", "CHEMICAL", 5, 18], ["~-lactoglobulin", "CHEMICAL", 23, 38], ["amino acid", "CHEMICAL", 47, 57], ["amino acids", "CHEMICAL", 115, 126], ["~-lactalbumin", "CHEMICAL", 5, 18], ["~-lactoglobulin", "CHEMICAL", 23, 38], ["amino acid", "CHEMICAL", 47, 57], ["amino acids", "CHEMICAL", 115, 126], ["~-lactalbumin", "SIMPLE_CHEMICAL", 5, 18], ["~-lactoglobulin", "SIMPLE_CHEMICAL", 23, 38], ["amino acid", "AMINO_ACID", 47, 57], ["amino acids", "AMINO_ACID", 115, 126], ["Both ~-lactalbumin", "TREATMENT", 0, 18], ["~-lactoglobulin", "TREATMENT", 23, 38], ["an amino acid composition", "TREATMENT", 44, 69], ["amino acids", "TREATMENT", 115, 126]]], ["Whey acid protein is present only in rodent milk.I-<The temperatures of raw milk at collection is about 3 7~ To prevent bacterial growth, oxidation, and proteolysis, milk should be chilled immediately to 4~ and processed within 48 hr unless it is frozen and stored.", [["milk", "ANATOMY", 44, 48], ["milk", "ANATOMY", 76, 80], ["milk", "ANATOMY", 166, 170], ["Whey acid", "CHEMICAL", 0, 9], ["Whey acid", "SIMPLE_CHEMICAL", 0, 9], ["milk", "ORGANISM_SUBSTANCE", 44, 48], ["milk", "ORGANISM_SUBSTANCE", 76, 80], ["milk", "ORGANISM_SUBSTANCE", 166, 170], ["Whey acid protein", "PROTEIN", 0, 17], ["rodent", "SPECIES", 37, 43], ["Whey acid protein", "TEST", 0, 17], ["bacterial growth", "PROBLEM", 120, 136], ["proteolysis", "PROBLEM", 153, 164], ["milk", "TREATMENT", 166, 170], ["acid protein", "OBSERVATION", 5, 17], ["prevent", "UNCERTAINTY", 112, 119], ["bacterial", "OBSERVATION_MODIFIER", 120, 129], ["growth", "OBSERVATION_MODIFIER", 130, 136]]], ["In the dairy, milk is standardized with regard to the fat content by the centrifugal separation of cream and skim milk: 100 kg of 4% (fat)bovine milk yields 90.35 kg of 0.05% fat skim milk and 9.65 kg of 40% fat cream.", [["milk", "ANATOMY", 14, 18], ["fat", "ANATOMY", 54, 57], ["milk", "ANATOMY", 114, 118], ["milk", "ANATOMY", 145, 149], ["milk", "ANATOMY", 184, 188], ["fat", "ANATOMY", 208, 211], ["milk", "ORGANISM_SUBSTANCE", 14, 18], ["fat", "TISSUE", 54, 57], ["cream", "SIMPLE_CHEMICAL", 99, 104], ["skim milk", "ORGANISM_SUBSTANCE", 109, 118], ["fat", "ORGANISM_SUBDIVISION", 134, 137], ["bovine", "ORGANISM", 138, 144], ["milk", "ORGANISM_SUBSTANCE", 145, 149], ["milk", "ORGANISM_SUBSTANCE", 184, 188], ["fat", "TISSUE", 208, 211], ["bovine", "SPECIES", 138, 144], ["bovine", "SPECIES", 138, 144], ["the centrifugal separation of cream", "TREATMENT", 69, 104], ["0.05% fat skim milk", "TREATMENT", 169, 188], ["40% fat cream", "TREATMENT", 204, 217]]], ["The cream fraction is remixed with the skim milk to the required fat content.", [["skim milk", "ANATOMY", 39, 48], ["fat", "ANATOMY", 65, 68], ["skim milk", "ORGANISM_SUBSTANCE", 39, 48], ["fat", "TISSUE", 65, 68], ["The cream fraction", "TREATMENT", 0, 18], ["the skim milk", "TREATMENT", 35, 48]]], ["In processing for a target protein in the whey it is clear that the bulk of the fat can be removed using this standard procedure.", [["fat", "ANATOMY", 80, 83], ["fat", "TISSUE", 80, 83], ["a target protein in the whey", "TREATMENT", 18, 46], ["this standard procedure", "TREATMENT", 105, 128]]], ["However, other standard dairy procedures, particularly microfiltration, may be used to remove fat, casein, and cellular components in a single step.", [["fat", "ANATOMY", 94, 97], ["cellular", "ANATOMY", 111, 119], ["fat", "TISSUE", 94, 97], ["casein", "GENE_OR_GENE_PRODUCT", 99, 105], ["cellular", "CELL", 111, 119], ["other standard dairy procedures", "TREATMENT", 9, 40], ["microfiltration", "TREATMENT", 55, 70]]], ["The high lactose and salt content may also be reduced by ultrafiltration.", [["lactose", "CHEMICAL", 9, 16], ["salt", "CHEMICAL", 21, 25], ["lactose", "CHEMICAL", 9, 16], ["lactose", "SIMPLE_CHEMICAL", 9, 16], ["salt", "SIMPLE_CHEMICAL", 21, 25], ["The high lactose and salt content", "TREATMENT", 0, 33], ["ultrafiltration", "TREATMENT", 57, 72], ["salt content", "OBSERVATION", 21, 33], ["may also be", "UNCERTAINTY", 34, 45], ["reduced", "OBSERVATION_MODIFIER", 46, 53], ["ultrafiltration", "OBSERVATION", 57, 72]]], ["Membrane techniques are generally the initial recovery methods of choice and, when correctly used, may yield a 60% pure protein in a single or a tandem microultrafiltration step, thus providing a clarified whey concentrate for further processing.", [["Membrane", "ANATOMY", 0, 8], ["Membrane techniques", "TREATMENT", 0, 19], ["a tandem microultrafiltration step", "TREATMENT", 143, 177], ["further processing", "TREATMENT", 227, 245]]], ["The use of such techniques also provides a barrier to the entry of adventitious viruses, bacteria, and other microorganisms into the final product.I-<An alternative pathway is to apply expanded bed technology.", [["such techniques", "TREATMENT", 11, 26], ["a barrier", "TREATMENT", 41, 50], ["adventitious viruses", "PROBLEM", 67, 87], ["bacteria", "PROBLEM", 89, 97], ["other microorganisms", "PROBLEM", 103, 123], ["expanded bed technology", "TREATMENT", 185, 208], ["viruses", "OBSERVATION", 80, 87]]], ["After initial processing to remove fat, skim milk may be passed through an adsorbent for the target, allowing the casein, lactose, and the bulk of the whey proteins to pass through the bed.", [["fat", "ANATOMY", 35, 38], ["skim milk", "ANATOMY", 40, 49], ["lactose", "CHEMICAL", 122, 129], ["lactose", "CHEMICAL", 122, 129], ["fat", "TISSUE", 35, 38], ["skim", "ORGANISM_SUBSTANCE", 40, 44], ["milk", "ORGANISM_SUBSTANCE", 45, 49], ["casein", "GENE_OR_GENE_PRODUCT", 114, 120], ["lactose", "SIMPLE_CHEMICAL", 122, 129], ["whey proteins", "PROTEIN", 151, 164], ["fat, skim milk", "TREATMENT", 35, 49], ["an adsorbent", "TREATMENT", 72, 84], ["the casein, lactose", "TREATMENT", 110, 129]]], ["Partially purified target protein may be recovered by desorbtion from the matrix in a fixed bed mode.", [["matrix", "ANATOMY", 74, 80], ["matrix", "CELLULAR_COMPONENT", 74, 80], ["Partially purified target protein", "PROBLEM", 0, 33], ["a fixed bed mode", "TREATMENT", 84, 100], ["target protein", "OBSERVATION", 19, 33], ["may be", "UNCERTAINTY", 34, 40]]], ["This type of separation or direct feed capture may be used in a totally fixed bed mode applied to the whey fraction after tangential flow filtration.", [["direct feed capture", "TREATMENT", 27, 46], ["a totally fixed bed mode", "TREATMENT", 62, 86], ["tangential flow filtration", "TREATMENT", 122, 148], ["flow filtration", "OBSERVATION", 133, 148]]], ["Subsequent processing by various chromatographic techniques, including affinity, hydrophobic interaction, ion exchange, and metal chelate chromatography, is applicable to achieve a protein of required purity.", [["metal chelate", "SIMPLE_CHEMICAL", 124, 137], ["various chromatographic techniques", "TREATMENT", 25, 59], ["ion exchange", "TREATMENT", 106, 118], ["metal chelate chromatography", "TREATMENT", 124, 152]]], ["The number of steps should be kept to a minimum as even small step losses can lead to a low yield over an extensive process.I-<A procedure for the purification of human recombinant protein C expressed in porcine milk has been described (Degener et al., 1996) .", [["milk", "ANATOMY", 212, 216], ["human", "ORGANISM", 163, 168], ["recombinant protein C", "GENE_OR_GENE_PRODUCT", 169, 190], ["porcine", "ORGANISM", 204, 211], ["milk", "ORGANISM_SUBSTANCE", 212, 216], ["human recombinant protein C", "PROTEIN", 163, 190], ["human", "SPECIES", 163, 168], ["porcine", "SPECIES", 204, 211], ["human", "SPECIES", 163, 168], ["porcine", "SPECIES", 204, 211], ["small step losses", "PROBLEM", 56, 73], ["a low yield", "PROBLEM", 86, 97], ["A procedure", "TREATMENT", 127, 138], ["the purification", "TREATMENT", 143, 159], ["human recombinant protein C expressed in porcine milk", "TREATMENT", 163, 216], ["extensive", "OBSERVATION", 106, 115]]], ["Milk fat was removed by centrifugation, and casein was precipitated in the presence of zinc.", [["Milk fat", "ANATOMY", 0, 8], ["zinc", "CHEMICAL", 87, 91], ["zinc", "CHEMICAL", 87, 91], ["Milk fat", "ORGANISM_SUBSTANCE", 0, 8], ["casein", "GENE_OR_GENE_PRODUCT", 44, 50], ["zinc", "SIMPLE_CHEMICAL", 87, 91], ["Milk fat", "TREATMENT", 0, 8]]], ["Direct feed capture was performed using an expanded bed, and the protein was purified by hydrophobic interaction and anion-exchange chromatography.Quality Issues in Transgenic ProductionFarm activities associated with transgenic production include founder development, progeny testing, and dairying.", [["anion", "CHEMICAL", 117, 122], ["anion", "SIMPLE_CHEMICAL", 117, 122], ["Direct feed capture", "TREATMENT", 0, 19], ["an expanded bed", "TREATMENT", 40, 55], ["anion-exchange chromatography", "TEST", 117, 146], ["transgenic production", "PROBLEM", 218, 239], ["progeny testing", "TEST", 269, 284]]], ["To minimize production risks and achieve validatable procedures, \"good agricultural practices\" (GAPs), which are in the spirit of good manufacturing practices and good laboratory practice, should be used.", [["validatable procedures", "TREATMENT", 41, 63]]], ["GAPs are based on high standards of animal husbandry, adherence to standard operating procedures, on-site veterinary care, rigorous animal health monitoring programs, and state-of-the-art milking practices to maximize product quality.", [["GAPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["GAPs", "PROTEIN", 0, 4], ["standard operating procedures", "TREATMENT", 67, 96], ["rigorous animal health monitoring programs", "TEST", 123, 165], ["the-art milking practices", "TREATMENT", 180, 205]]], ["Standard operating procedures should cover areas such as generating founder animals, herd maintenance, herd health, breeding, milk production, and other special procedures.", [["milk", "ANATOMY", 126, 130], ["milk", "ORGANISM_SUBSTANCE", 126, 130], ["Standard operating procedures", "TREATMENT", 0, 29], ["other special procedures", "TREATMENT", 147, 171]]], ["Master and working transgenic banks should be kept under strictly controlled conditions.", [["working transgenic banks", "TREATMENT", 11, 35]]], ["Animal feeds should be specially blended free of animal fat and protein.", [["fat", "ANATOMY", 56, 59], ["fat", "TISSUE", 56, 59], ["Animal feeds", "TREATMENT", 0, 12]]], ["Hay for transgenic production animals should be screened for residual chemicals that may have been used in the growing process.", [["transgenic production animals", "PROBLEM", 8, 37], ["residual chemicals", "PROBLEM", 61, 79]]], ["Both written and computerized records should be kept to track animal lineages, health, and performance records.Quality Issues in Transgenic ProductionCareful attention should be paid to milk facilities and personnel sanitation.", [["milk", "ORGANISM_SUBSTANCE", 186, 190], ["personnel sanitation", "TREATMENT", 206, 226]]], ["Production animals should be observed on a daily basis, and animal side testing of milk can be used to detect early indications of mastitis and other animal illnesses.", [["milk", "ANATOMY", 83, 87], ["mastitis", "DISEASE", 131, 139], ["milk", "ORGANISM_SUBSTANCE", 83, 87], ["animal side testing", "TEST", 60, 79], ["mastitis", "PROBLEM", 131, 139], ["other animal illnesses", "PROBLEM", 144, 166], ["mastitis", "OBSERVATION", 131, 139]]], ["Milk collection and processing areas should be physically separated, and state-of-the-art pharmaceutical grade milking equipment and practices should be used in dedicated milking parlors.Regulatory Considerations\"Points to Consider in the Manufacture and Testing of Therapeutic Products for Human Use Derived from Transgenic Animals\" [Food and Drug Administration (FDA), 1995] is the result of an iterative process between the FDA and the biopharmaceutical industry, and the FDA is supportive of transgenic production.", [["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["Human", "ORGANISM", 291, 296], ["Human", "SPECIES", 291, 296], ["Milk collection", "TREATMENT", 0, 15], ["the-art pharmaceutical grade milking equipment", "TREATMENT", 82, 128], ["Therapeutic Products", "TREATMENT", 266, 286], ["Human Use", "TREATMENT", 291, 300], ["an iterative process", "PROBLEM", 394, 414], ["transgenic production", "PROBLEM", 496, 517]]], ["The European Union's Committee on Proprietary Medicinal Products (CPMP) is similarly positive to the use of transgenic animals, stating in its guidance document: \"Transgenic animals may produce higher quantities of material in more concentrated form than existing culture methods, and therefore have considerable advantages in both the cost of producing the starting material and in its downstream processing.", [["Proprietary Medicinal Products", "TREATMENT", 34, 64], ["transgenic animals", "TREATMENT", 108, 126], ["higher quantities of material", "PROBLEM", 194, 223], ["existing culture methods", "TEST", 255, 279]]], ["In some instances where very large amounts of material are required for therapy the use of transgenic animals may be one of the few viable production strategies\" (CPMP, 1995) .Regulatory ConsiderationsThe FDA has addressed topics such as the structure of the transgene, creation, characterization, and maintenance of the transgenic herd, fidelity of transgenic inheritance, consistency of transgene expression, analysis of product identity and purity, and the avoidance of contamination by drugs, chemicals, and adventitious agents.", [["very large amounts of material", "PROBLEM", 24, 54], ["therapy", "TREATMENT", 72, 79], ["transgenic animals", "TREATMENT", 91, 109], ["transgenic inheritance", "PROBLEM", 350, 372], ["drugs", "TREATMENT", 490, 495], ["chemicals", "TREATMENT", 497, 506], ["adventitious agents", "TREATMENT", 512, 531], ["very", "OBSERVATION_MODIFIER", 24, 28], ["large", "OBSERVATION_MODIFIER", 29, 34], ["amounts", "OBSERVATION_MODIFIER", 35, 42]]], ["Many issues of purity, consistency, safety, and potency of transgenically produced therapeutic proteins overlap with various CBER points to consider for monoclonal antibodies and other biologicals produced by recombinant DNA technology.", [["DNA", "CELLULAR_COMPONENT", 221, 224], ["monoclonal antibodies", "PROTEIN", 153, 174], ["therapeutic proteins overlap", "PROBLEM", 83, 111], ["various CBER points", "TREATMENT", 117, 136], ["monoclonal antibodies", "TREATMENT", 153, 174], ["purity", "OBSERVATION", 15, 21]]], ["To quote the FDA: \"The considerations that apply are therefore a blend of those relevant to recombinant DNA derived materials and materials from less defined sources\" (FDA, 1995) .Regulatory ConsiderationsDespite the fact that goats and other farm animals are susceptible to species-specific viral and prion infections, viruses may be more of a concern for animal health than they are a human risk.", [["prion infections", "DISEASE", 302, 318], ["DNA", "CELLULAR_COMPONENT", 104, 107], ["goats", "ORGANISM", 227, 232], ["farm animals", "ORGANISM", 243, 255], ["human", "ORGANISM", 387, 392], ["goats", "SPECIES", 227, 232], ["human", "SPECIES", 387, 392], ["goats", "SPECIES", 227, 232], ["human", "SPECIES", 387, 392], ["recombinant DNA derived materials", "TREATMENT", 92, 125], ["species", "PROBLEM", 275, 282], ["specific viral and prion infections", "PROBLEM", 283, 318], ["viruses", "PROBLEM", 320, 327]]], ["A CBER official has pointed out that prions, such as those responsible for bovine spongiform encephalitis and scrapie, have \"less than a theoretical\" risk of transmission via milk because they do not occur in the mammary gland and, if introduced, they do not persist (Rudolph, 1995) .", [["milk", "ANATOMY", 175, 179], ["mammary gland", "ANATOMY", 213, 226], ["bovine spongiform encephalitis", "DISEASE", 75, 105], ["scrapie", "DISEASE", 110, 117], ["bovine spongiform encephalitis", "ORGANISM", 75, 105], ["milk", "ORGANISM_SUBSTANCE", 175, 179], ["mammary gland", "ORGAN", 213, 226], ["bovine", "SPECIES", 75, 81], ["bovine spongiform encephalitis", "SPECIES", 75, 105], ["scrapie", "SPECIES", 110, 117], ["prions", "PROBLEM", 37, 43], ["bovine spongiform encephalitis", "PROBLEM", 75, 105], ["scrapie", "PROBLEM", 110, 117], ["spongiform", "OBSERVATION_MODIFIER", 82, 92], ["encephalitis", "OBSERVATION", 93, 105], ["mammary gland", "ANATOMY", 213, 226]]], ["No transmission of scrapie has ever been reported in humans.", [["scrapie", "DISEASE", 19, 26], ["humans", "ORGANISM", 53, 59], ["humans", "SPECIES", 53, 59], ["scrapie", "SPECIES", 19, 26], ["humans", "SPECIES", 53, 59], ["transmission of scrapie", "PROBLEM", 3, 26], ["scrapie", "OBSERVATION", 19, 26]]], ["Milk and semen are noninfectious for scrapie according to the World Health Organization (1996) .", [["Milk", "ANATOMY", 0, 4], ["semen", "ANATOMY", 9, 14], ["scrapie", "DISEASE", 37, 44], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["semen", "ORGANISM_SUBSTANCE", 9, 14], ["scrapie", "SPECIES", 37, 44], ["noninfectious", "PROBLEM", 19, 32], ["scrapie", "PROBLEM", 37, 44], ["noninfectious", "OBSERVATION", 19, 32]]], ["Although scrapie has been detected in significant numbers of sheep in the United States, only five goat scrapie cases have occurred in goats, all comingled with scrapie-infected sheep.", [["scrapie", "DISEASE", 9, 16], ["scrapie-infected", "DISEASE", 161, 177], ["sheep", "ORGANISM", 61, 66], ["goat", "ORGANISM", 99, 103], ["goats", "ORGANISM", 135, 140], ["sheep", "ORGANISM", 178, 183], ["sheep", "SPECIES", 61, 66], ["goat", "SPECIES", 99, 103], ["goats", "SPECIES", 135, 140], ["sheep", "SPECIES", 178, 183], ["scrapie", "SPECIES", 9, 16], ["sheep", "SPECIES", 61, 66], ["goat", "SPECIES", 99, 103], ["goats", "SPECIES", 135, 140], ["scrapie", "SPECIES", 161, 168], ["sheep", "SPECIES", 178, 183], ["scrapie", "PROBLEM", 9, 16], ["scrapie", "OBSERVATION", 9, 16], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["numbers", "OBSERVATION_MODIFIER", 50, 57], ["infected", "OBSERVATION", 169, 177]]], ["Goat viruses relevant in North America are shown in Table 4 .Regulatory ConsiderationsThe risk of viral and bacterial contamination of human biopharmaceutical products expressed in the milk of transgenic goats can be minimized by a multistage or combinatorial approach at three levels: the goat, the milk, and the final product (Ziomek, 1996) .", [["milk", "ANATOMY", 185, 189], ["milk", "ANATOMY", 300, 304], ["Goat viruses", "ORGANISM", 0, 12], ["human", "ORGANISM", 135, 140], ["milk", "ORGANISM_SUBSTANCE", 185, 189], ["goats", "ORGANISM", 204, 209], ["goat", "ORGANISM", 290, 294], ["milk", "ORGANISM_SUBSTANCE", 300, 304], ["human biopharmaceutical products", "PROTEIN", 135, 167], ["Goat", "SPECIES", 0, 4], ["human", "SPECIES", 135, 140], ["goats", "SPECIES", 204, 209], ["goat", "SPECIES", 290, 294], ["human", "SPECIES", 135, 140], ["goats", "SPECIES", 204, 209], ["goat", "SPECIES", 290, 294], ["viral and bacterial contamination", "PROBLEM", 98, 131], ["human biopharmaceutical products", "TREATMENT", 135, 167], ["transgenic goats", "TREATMENT", 193, 209], ["a multistage or combinatorial approach", "TREATMENT", 230, 268], ["viruses", "OBSERVATION", 5, 12], ["viral", "OBSERVATION", 98, 103], ["bacterial contamination", "OBSERVATION", 108, 131]]], ["Minimization of the risk of contamination of the goat production herd can be accomplished by strict selection, animal husbandry, and adherence to GAPs.", [["goat", "ORGANISM", 49, 53], ["GAPs", "GENE_OR_GENE_PRODUCT", 146, 150], ["GAPs", "PROTEIN", 146, 150], ["goat", "SPECIES", 49, 53], ["goat", "SPECIES", 49, 53]]], ["Bacterial contamination can be minimized by careful, state-of-the-art milking procedures and rapid GMP processing.", [["GMP", "CHEMICAL", 99, 102], ["GMP", "CHEMICAL", 99, 102], ["GMP", "SIMPLE_CHEMICAL", 99, 102], ["Bacterial contamination", "PROBLEM", 0, 23], ["the-art milking procedures", "TREATMENT", 62, 88], ["rapid GMP processing", "TREATMENT", 93, 113], ["contamination", "OBSERVATION", 10, 23]]], ["Purification processes from raw milk are designed in a manner similar to the manufacturing schemes for recombinant therapeutics from fermentation and cell culture with the inclusion of steps to remove and/or inactivate adventitious agents, microbial contaminants, and pyrogens.Regulatory ConsiderationsFor advantages and disadvantages of transgenic expression in the milk of dairy animals, see Table 5 . aFrom Ziomek (1996) . bz, zoonotic: ss, single stranded; ds, double stranded.AdvantagesHigh level expression at multigram/liter level Expression directed to and located in mammary gland Expression can be tested in rodents Genetic and lactation-to-lactation stability Animal-to-animal consistency Mammary epithelial cells carry out post-translational modification Product recovered at high concentration in milk Aseptic milk processing technology well proven Bulk impurities removed easily Low cost of pre-purification product Low investment costs Capability of combining transgenics with nuclear transfer (cloning)DisadvantagesPossible adventitious virus and prion issues in dairy animals Control of animal environment and feed Microinjection required as a technology for species where cloning is not yet available Time to clinical product slower than cell culture (without process development)Current Status and Future DirectionsExpression of therapeutically beneficial proteins in the milk of transgenic dairy animals present an unparalleled opportunity for the large-scale production of monoclonal antibodies, plasma, and other proteins.Current Status and Future DirectionsMammary gland epithelia have a cell density that is 100-to 1000-fold greater than the cell densities used, for example, in mammalian cell culture using CHO cells.", [["milk", "ANATOMY", 32, 36], ["cell", "ANATOMY", 150, 154], ["milk", "ANATOMY", 367, 371], ["mammary gland", "ANATOMY", 576, 589], ["Mammary epithelial cells", "ANATOMY", 700, 724], ["milk", "ANATOMY", 823, 827], ["nuclear", "ANATOMY", 992, 999], ["cell", "ANATOMY", 1256, 1260], ["milk", "ANATOMY", 1391, 1395], ["plasma", "ANATOMY", 1517, 1523], ["Mammary gland epithelia", "ANATOMY", 1580, 1603], ["cell", "ANATOMY", 1611, 1615], ["cell", "ANATOMY", 1666, 1670], ["cell culture", "ANATOMY", 1713, 1725], ["CHO cells", "ANATOMY", 1732, 1741], ["bz", "CHEMICAL", 426, 428], ["milk", "ORGANISM_SUBSTANCE", 32, 36], ["cell", "CELL", 150, 154], ["pyrogens", "SIMPLE_CHEMICAL", 268, 276], ["milk", "ORGANISM_SUBSTANCE", 367, 371], ["mammary gland", "ORGAN", 576, 589], ["Mammary epithelial cells", "CELL", 700, 724], ["milk", "ORGANISM_SUBSTANCE", 810, 814], ["milk", "ORGANISM_SUBSTANCE", 823, 827], ["cell culture", "CELL", 1256, 1268], ["milk", "ORGANISM_SUBSTANCE", 1391, 1395], ["plasma", "ORGANISM_SUBSTANCE", 1517, 1523], ["Mammary gland epithelia", "TISSUE", 1580, 1603], ["cell", "CELL", 1611, 1615], ["cell", "CELL", 1666, 1670], ["mammalian cell culture", "CELL", 1703, 1725], ["CHO cells", "CELL", 1732, 1741], ["zoonotic: ss, single stranded; ds, double stranded", "DNA", 430, 480], ["Mammary epithelial cells", "CELL_TYPE", 700, 724], ["monoclonal antibodies", "PROTEIN", 1494, 1515], ["mammalian cell culture", "CELL_LINE", 1703, 1725], ["CHO cells", "CELL_LINE", 1732, 1741], ["Purification processes", "PROBLEM", 0, 22], ["the manufacturing schemes", "TREATMENT", 73, 98], ["recombinant therapeutics", "TREATMENT", 103, 127], ["cell culture", "TEST", 150, 162], ["adventitious agents", "TREATMENT", 219, 238], ["microbial contaminants", "TREATMENT", 240, 262], ["transgenic expression", "TREATMENT", 338, 359], ["High level expression at multigram/liter level", "TREATMENT", 491, 537], ["Mammary epithelial cells", "TREATMENT", 700, 724], ["post-translational modification Product", "TREATMENT", 735, 774], ["high concentration in milk Aseptic milk processing technology", "TREATMENT", 788, 849], ["pre-purification product", "TREATMENT", 905, 929], ["combining transgenics", "TREATMENT", 965, 986], ["nuclear transfer (cloning)", "TREATMENT", 992, 1018], ["adventitious virus", "PROBLEM", 1040, 1058], ["prion issues", "PROBLEM", 1063, 1075], ["feed Microinjection", "TREATMENT", 1127, 1146], ["cell culture", "TEST", 1256, 1268], ["therapeutically beneficial proteins", "TREATMENT", 1348, 1383], ["transgenic dairy animals", "TREATMENT", 1399, 1423], ["monoclonal antibodies", "TEST", 1494, 1515], ["a cell density", "TEST", 1609, 1623], ["the cell densities", "TEST", 1662, 1680], ["mammalian cell culture", "TEST", 1703, 1725], ["mammary gland", "ANATOMY", 576, 589], ["epithelial cells", "OBSERVATION", 708, 724], ["virus", "OBSERVATION", 1053, 1058], ["gland", "ANATOMY", 1588, 1593], ["epithelia", "ANATOMY_MODIFIER", 1594, 1603], ["cell density", "OBSERVATION", 1611, 1623], ["cell densities", "OBSERVATION", 1666, 1680], ["mammalian cell", "OBSERVATION", 1703, 1717], ["CHO cells", "OBSERVATION", 1732, 1741]]], ["The cells are some of the most productive protein synthesis sources designed by nature to produce large amounts of correctly processed protein and which are switched on and off by hormonal changes.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["the most productive protein synthesis sources", "PROBLEM", 22, 67], ["cells", "OBSERVATION", 4, 9], ["large", "OBSERVATION_MODIFIER", 98, 103], ["amounts", "OBSERVATION_MODIFIER", 104, 111]]], ["Thirty-five transgenic goats expressing a monoclonal antibody at 8 g/liter in their milk are equivalent to a 8500-liter batch CHO cell culture running 200 days/year with a 1-g/liter final expression level (Young et al., 1997) .", [["milk", "ANATOMY", 84, 88], ["cell", "ANATOMY", 130, 134], ["goats", "ORGANISM", 23, 28], ["milk", "ORGANISM_SUBSTANCE", 84, 88], ["CHO cell", "CELL", 126, 134], ["monoclonal antibody", "PROTEIN", 42, 61], ["CHO cell culture", "CELL_LINE", 126, 142], ["goats", "SPECIES", 23, 28], ["goats", "SPECIES", 23, 28], ["a monoclonal antibody", "TREATMENT", 40, 61]]], ["In production terms, 170,000 liters of culture is equivalent to 21,000 liters of milk; with the expression levels noted earlier and process yields of 60%, both of these systems would produce 100 kg of purified monoclonal antibody.Current Status and Future DirectionsIt has also been discussed that the mammary bioreactor is capable of most posttranslational modifications and protein folding and can, therefore, be used to produce complex proteins.Current Status and Future DirectionsA current limitation of the technology is the low rate (5-10%) of transgenesis.", [["milk", "ANATOMY", 81, 85], ["mammary bioreactor", "ANATOMY", 302, 320], ["milk", "ORGANISM_SUBSTANCE", 81, 85], ["purified monoclonal antibody", "PROTEIN", 201, 229], ["complex proteins", "PROTEIN", 431, 447], ["culture", "TEST", 39, 46], ["the expression levels", "TEST", 92, 113], ["purified monoclonal antibody", "PROBLEM", 201, 229], ["the mammary bioreactor", "TREATMENT", 298, 320], ["most posttranslational modifications", "PROBLEM", 335, 371], ["protein folding", "PROBLEM", 376, 391], ["complex proteins", "PROBLEM", 431, 447], ["transgenesis", "TREATMENT", 550, 562], ["monoclonal antibody", "OBSERVATION", 210, 229], ["mammary", "ANATOMY", 302, 309], ["bioreactor", "OBSERVATION", 310, 320]]], ["Nuclear transfer techniques, in which embryonic or adult cells are engineered and cultured to produce a master cell bank from which nuclei are transferred to recipient oocytes, are under development; these methods hold great promise for improved rates of transgenesis.Current Status and Future DirectionsBecause of concerns of transmissible spongiform encephalopathies, animal sourced proteins and amino acids are currently under scrutiny.", [["Nuclear", "ANATOMY", 0, 7], ["embryonic", "ANATOMY", 38, 47], ["adult cells", "ANATOMY", 51, 62], ["cell", "ANATOMY", 111, 115], ["nuclei", "ANATOMY", 132, 138], ["oocytes", "ANATOMY", 168, 175], ["transmissible spongiform encephalopathies", "DISEASE", 327, 368], ["amino acids", "CHEMICAL", 398, 409], ["amino acids", "CHEMICAL", 398, 409], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 38, 47], ["adult cells", "CELL", 51, 62], ["cell", "CELL", 111, 115], ["nuclei", "CELLULAR_COMPONENT", 132, 138], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 168, 175], ["amino acids", "AMINO_ACID", 398, 409], ["embryonic or adult cells", "CELL_TYPE", 38, 62], ["animal sourced proteins", "PROTEIN", 370, 393], ["Nuclear transfer techniques", "TEST", 0, 27], ["adult cells", "PROBLEM", 51, 62], ["transmissible spongiform encephalopathies", "PROBLEM", 327, 368], ["animal sourced proteins", "PROBLEM", 370, 393], ["amino acids", "TREATMENT", 398, 409], ["transmissible", "OBSERVATION_MODIFIER", 327, 340], ["spongiform encephalopathies", "OBSERVATION", 341, 368]]], ["However, it should be kept in mind that the expression system described in this chapter is the mammary gland.", [["mammary gland", "ANATOMY", 95, 108], ["mammary gland", "ORGAN", 95, 108], ["the expression system", "PROBLEM", 40, 61], ["mammary gland", "ANATOMY", 95, 108]]], ["Given the safety of milk and milk products in combination with the quality and regulatory precautions described, there is every reason to consider that proteins derived from transgenic animals should be safe with respect to possible virus and prion transmission.", [["milk", "ANATOMY", 20, 24], ["milk", "ANATOMY", 29, 33], ["milk", "ORGANISM_SUBSTANCE", 20, 24], ["milk", "ORGANISM_SUBSTANCE", 29, 33], ["transgenic animals", "ORGANISM", 174, 192], ["milk and milk products", "TREATMENT", 20, 42], ["regulatory precautions", "TREATMENT", 79, 101], ["virus", "PROBLEM", 233, 238]]], ["Many of the proteins that are expression targets today are currently available as human plasma derivatives, which have a measurable degree of risk for the transmission of HIV, hepatitis, parvo-, and other viruses, and Creutzfeld-Jakob disease.Current Status and Future DirectionsAs indicated, several proteins are in phase I and II clinical trials.", [["plasma", "ANATOMY", 88, 94], ["HIV, hepatitis, parvo-, and other viruses", "DISEASE", 171, 212], ["Creutzfeld-Jakob disease", "DISEASE", 218, 242], ["human", "ORGANISM", 82, 87], ["plasma", "ORGANISM_SUBSTANCE", 88, 94], ["HIV", "ORGANISM", 171, 174], ["Creutzfeld-Jakob", "ORGANISM", 218, 234], ["human", "SPECIES", 82, 87], ["HIV", "SPECIES", 171, 174], ["human", "SPECIES", 82, 87], ["HIV", "SPECIES", 171, 174], ["human plasma derivatives", "TREATMENT", 82, 106], ["HIV", "PROBLEM", 171, 174], ["hepatitis", "PROBLEM", 176, 185], ["parvo", "TEST", 187, 192], ["other viruses", "PROBLEM", 199, 212], ["Jakob disease", "PROBLEM", 229, 242], ["hepatitis", "OBSERVATION", 176, 185], ["viruses", "OBSERVATION", 205, 212], ["Jakob disease", "OBSERVATION", 229, 242]]], ["This number can be expected to increase dramatically in the near future.", [["increase", "OBSERVATION_MODIFIER", 31, 39], ["dramatically", "OBSERVATION_MODIFIER", 40, 52]]], ["Transgenic dairy animals provide a bulk protein production system that is capable of making proteins available that are either not available today or are only recoverable from other sources at very low yields.", [["a bulk protein production system", "TREATMENT", 33, 65]]], ["Transgenic production may thus enable a move from \"on-demand\" patient treatment to prophylaxis and far wider indications and use of many proteins.", [["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69], ["Transgenic production", "PROBLEM", 0, 21], ["on-demand\" patient treatment", "TREATMENT", 51, 79], ["prophylaxis", "TREATMENT", 83, 94], ["many proteins", "TREATMENT", 132, 145]]], ["In addition, the production of proteins in the milk of transgenic dairy animals is highly cost effective (Young et al., 1997) , opening up real possibilities for nutraceutical product development.", [["milk", "ANATOMY", 47, 51], ["milk", "ORGANISM_SUBSTANCE", 47, 51], ["nutraceutical product development", "TREATMENT", 162, 195]]]]}